<SEC-DOCUMENT>0001104659-21-138190.txt : 20211112
<SEC-HEADER>0001104659-21-138190.hdr.sgml : 20211112
<ACCEPTANCE-DATETIME>20211112170115
ACCESSION NUMBER:		0001104659-21-138190
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		50
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211112
DATE AS OF CHANGE:		20211112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synaptogenix, Inc.
		CENTRAL INDEX KEY:			0001571934
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461585656
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40458
		FILM NUMBER:		211404625

	BUSINESS ADDRESS:	
		STREET 1:		1185 AVENUE OF THE AMERICAS, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		9732420005

	MAIL ADDRESS:	
		STREET 1:		1185 AVENUE OF THE AMERICAS, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NEUROTROPE BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20130312
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>snpx-20210930x10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7908.23199 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/12/2021 8:48:39 PM -->
      <!-- iXBRL Library version: 1.0.7908.23207 -->
      <!-- iXBRL Service Job ID: 46c81730-11e8-4278-bfa1-fccc8326eca7 -->

  <html xmlns:snpx="http://www.synaptogen.com/20210930" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" xs:nil="true" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_fDe3O408nEi2jvo1RD6swg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" xs:nil="true" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_krI9so5-9UmPdmXWn2WopA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_RTBDhhCuuUSgoHhaqOJfsg">6196600</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_LQNAkKpYxkq1OAhEu1AgZg">4755100</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_yRosEYzqSk2WjudLy-nn_Q">4420200</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_Afr5_7NwrEq-7_cOBF_X4Q">4274200</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityCentralIndexKey" id="Tc_jeQBIGecd0eQP68qWnru4w_1_1">0001571934</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:CurrentFiscalYearEndDate" id="Tc_rT0uwQRkpk2R8Qy4I6q7tA_2_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:DocumentFiscalYearFocus" id="Tc_8j3lqvyKkECtadz2ud_0cw_3_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:DocumentFiscalPeriodFocus" id="Tc_g5JPgH181k-Zgzew8nuDBQ_4_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:AmendmentFlag" id="Tc_yRKWE0rs8Um5dO1O-lKGxA_5_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_sezuUeTn10uo_a0fcUf5bg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_NxZR55ns0U21CNNDyARbLw">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityRegistrantName" id="Hidden_bLlD-sqth0-4iiDJqsKpmA">Synaptogenix, Inc.</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityFilerCategory" id="Hidden_HNBE-7UQ-EqvhG0jvd0ytg">Non-accelerated Filer</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_toyVA6bUkEiJ-JBvLSf_Pg">6136967</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_GzA5X_D0D06IlZ-X3HzHwQ">1257579</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_r9plw0qNOECAE0OiFEJRZQ">0.47</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_uJrZsluMHkihC8HIIwYSHg">0.90</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_LQmeZvVOEka8eEiD5e9XgQ">1.89</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_8WgOmX6PPUy5f6-S6IlyLw">2.28</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_5JNwmAqnxEi_l_f3YHC7-w" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_lr9X8jg5jUiA4B9EE7n2ZA">P3Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g" contextRef="Duration_7_23_2020_To_7_23_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_CN7r02Xyn0ydRSaKF-TAyQ" decimals="0" name="snpx:TargetEnrollmentOfStudySubjects" id="Hidden_zKPmU54jT0W3JjwS4wGcXw">100</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_nGWTvPqSrUWNdtWgmidJhQ" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_hGoeBKVmBU20RQRV2PAyfQ">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1ZxjK4Ju5UaJMzlhxHko5g" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_G8xXS6bLZUG7c6GZDPjMxQ">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_snpx_ShareBasedPaymentArrangementTrancheFourMember_8TQ3g1npeESE9PjcWoOF6g" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_YpLSh0QAWUSUkURr5jx6fw">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_7m4RE_sc4ku1rRSLUCwYWA" decimals="INF" name="snpx:NumberOfMonthsBaseSalaryPayableUponSeparation" id="Hidden_jgZLIHXGVkmWEP_qt_Shbw">12</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow" decimals="0" name="us-gaap:CommonStockSharesIssued" id="Hidden_2WjS9OcCE0OUM5kOWGUAdg">1257579</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g" decimals="0" name="us-gaap:CommonStockSharesIssued" id="Hidden_dSJYuuGr1UaWnhcxWt0JcA">1257579</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_5_19_2021_To_5_19_2021_EXMdTsz2BUaSS0bnxBggtw" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_a2wS05qZI0qbkELASHqfgA">0.25</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_jsE_CQrzZ0az5CCzW8NilA" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Hidden_Ran0Cu55WEO7SIeyEo9upQ">P0Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="snpx-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_B-Ol5sPKMEmSFSQmzxOz7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_C14DO597P0mvWWCy-BLV8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eLQU0iW2-kKPmLdZRgP3_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_cABB2dwDnkidrh1FDqutMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_16_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_wMyE8rhAOUa-rFk2SZC6uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_16_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_SVTnUQyCqkSlwAQiGiSQ2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_16_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_x7uB4f4XkkixVNeVpg4H_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesHWarrantsMember_6isVxzRL6UqO5BOyR_DEnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesHWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Bv7Emv5esUO_DuRCzz0CPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_19_2021_To_5_19_2021_EXMdTsz2BUaSS0bnxBggtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-19</xbrli:startDate><xbrli:endDate>2021-05-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jaPCkYCkeUON4gyi4G8yUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_5M6N4BgC0U-FB5io86IYSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__GkfWAubpE6DJAYWPvj1gA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5Je_ZI8c30mq5LUNLv-5Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_Ucphx9av20iHwREQym4HHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ypXLoCBb2ki0jyO4ErlUFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tJKcPCyeyUWqkuie4MqZSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_f4snRmZeDkO06xUTfzJ97w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mydigcM49UWnKRDBJI3xHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zZH3ckIIi0qEdvdPW_U0Uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iE0Gc6ADH0GlOfrRzcSuFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cPmmOsgAh0WB3a-cIX_Kmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_HthvWJobo0OzesTLSZPLwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YSISzRr0bky6jJiuWUvVbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_UQQvJk6FaUucAss2ojsT9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2LGNFezF1EW4idiVG3QiZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_FMu0KxA6Dk2LDplFkct4jA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_P7zGDC_-hEeO9i5oMGGuig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_7_2020_To_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_ARQKCYx9ckaXd0ahx6smkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpinoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ugoS2seriU2HHmwKq25Lyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w2D7T-YOaEup8wjSL_aSZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_EAh8LLeUbUiQqs-4hpkvgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WtmrZrtb2E-vIIoDu3xIMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Kh-IvwB8kUufVGx_81DRzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TQgurJPz3022iUU8jDNU7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_f4-Im_6b00Ktvk63-6KZww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0KTSxMliRU68--TLFjCX-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Z8OFwl7EbUOJULDl_93Hrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-8SoERMK70Sy1smuFNcHUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_firc-Dmg-0eR-8Hv8fLQyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JxAib4ryK0Og6uxEH2c6Qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_jsE_CQrzZ0az5CCzW8NilA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_TIqQYJV7CE6L3nRKPgyfzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-13</xbrli:startDate><xbrli:endDate>2021-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_6QohAsIzTk-vhW1SAPewPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-13</xbrli:startDate><xbrli:endDate>2021-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_srt_ChiefFinancialOfficerMember_8D5SdWMw5U6irlsB96168A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-13</xbrli:startDate><xbrli:endDate>2021-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2021_To_1_13_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_9WmgNIy7zkuk1nx7ZlVGaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-13</xbrli:startDate><xbrli:endDate>2021-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_7_2020_To_12_7_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_QAtyG63Ml0iGUPsG62eDkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2021_X8xLB1j8lkOI3Ju5ytfjTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_6_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_fx1ygIKoY02ITh98bpD4mQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_GxaNy02f7U-vVY71VeBA5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">snpx:ShareBasedPaymentArrangementNonemployeeDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:DirectorCompensationPolicyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_snpx_SixMonthAnniversaryOfGrantDateMember_-sX3SPAv7ECVADMCMnxDhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">snpx:SixMonthAnniversaryOfGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-13</xbrli:startDate><xbrli:endDate>2021-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_snpx_FirstAnniversaryOfGrantDateMember_ATxH9vpPDUaonf7pLjCDXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">snpx:FirstAnniversaryOfGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-13</xbrli:startDate><xbrli:endDate>2021-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_12_2021_To_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_MbYQXmYqxEe7PlJNeR4iPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">snpx:ShareBasedPaymentArrangementNewlyAppointedDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:DirectorCompensationPolicyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-12</xbrli:startDate><xbrli:endDate>2021-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_12_2021_To_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_9fTB0b96S0mwgdrtIFJHkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">snpx:ShareBasedPaymentArrangementNewlyAppointedDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:DirectorCompensationPolicyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-12</xbrli:startDate><xbrli:endDate>2021-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_12_2021_To_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember__FUNeXcc1U2KnJsXyWj-rQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">snpx:ShareBasedPaymentArrangementNewlyAppointedDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:DirectorCompensationPolicyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-12</xbrli:startDate><xbrli:endDate>2021-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_brWXOs9rvk-CL2mnnpvfcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-13</xbrli:startDate><xbrli:endDate>2021-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0nx63wQyWkygtYDUEq138Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-13</xbrli:startDate><xbrli:endDate>2021-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_O8lsXfv060q08M33KwFJoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-13</xbrli:startDate><xbrli:endDate>2021-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_snpx_DateOfGrantMember_CoXoxGX9_kGVwzm95w2HWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">snpx:DateOfGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-13</xbrli:startDate><xbrli:endDate>2021-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_nGWTvPqSrUWNdtWgmidJhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:EmploymentAgreementWithAlanJ.TuchmanM.dMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1ZxjK4Ju5UaJMzlhxHko5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:EmploymentAgreementWithAlanJ.TuchmanM.dMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_q7uNiiIzykOY--M3GXitdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:EmploymentAgreementWithAlanJ.TuchmanM.dMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_snpx_ShareBasedPaymentArrangementTrancheFourMember_8TQ3g1npeESE9PjcWoOF6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:EmploymentAgreementWithAlanJ.TuchmanM.dMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">snpx:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_GxGMgiomqkCkvB744Sb2wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_21_2021_DeloaH3epUmWvrrrKTfurQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_a4h_NxjSXky22JFgrPHDSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_5JNwmAqnxEi_l_f3YHC7-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_Qj_fG9oUqUuK8DNTHXfAoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_RightsAgreementMember_4x3-7JV2VESTTUvsqOn7Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:RightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_AgreementsWithBryologyxMember_avDjLw3FK0-K01yBV8psnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:AgreementsWithBryologyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_HYkNCxHRy02mLmJWCc8lbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_lvIlGvc4GUestVJZO6CW1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:AdvisoryAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_19_2017_To_1_19_2017_srt_ProductOrServiceAxis_us-gaap_LicenseMember_QAFY1ZmrLkORAEkzbODSjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-19</xbrli:startDate><xbrli:endDate>2017-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2020_us-gaap_RelatedPartyTransactionAxis_snpx_CurrentShareholdersOfCompanyMember_XXkmy-IesU2Cqs0foH1_cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">snpx:CurrentShareholdersOfCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesHWarrantsMember_Po7eMRWnyk627VgjFVaEXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesHWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_tkPkOaqtJUqYc0v8c4QvAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_c7G1rxSzNE2F1m4rqz2OEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hBfQpmlzBEiZWBUIw5oRgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_26_2020_Wvo7So2luU-dbvH6dz-R9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_NE8e4JpcsUy1zfWK6UBJew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_5_2019_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_AWIKoH8MRU-5fF4wYndp6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EUnVc5n1yE-8V5lSC_clxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_DeGjeBcBwEGnc13gbozhlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Mqocl8Q9OUW-zNTHh7tZ4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_cufB87OPd0uxPv8DnNgAwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_PT7hcM8umEeDTrhm4UVpkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_OIdTKpqZekCiObLbbJPl8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_fU78qKLlQUeUn6turqsGfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_FH717EVLtkqn-fpPWhn4rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:AdvisoryAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Fr0ZwcPdYUak8BJTwsJziA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_snpx_PlacementAgentAgreementMember_iBkmenKfkESMsfPkSD7zrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:PlacementAgentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_Xii_2FmPcky3sXIraY0ypg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_qFNn0PiONUWj2D4Fv2tSVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_PrefundedWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_Y9y3VTtvt0-HBEjwyQXlZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_zUGNKTUDa0uRvG6Lbuctbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snpx:PlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_W8rULN8LVU2iFXd7lTqq6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_GFeDDnIUDEeDxbNQIpRbmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember__pHwfWJFzkixGuEnVWDzJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:AdvisoryAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_4Hb6Y7xE0kyrvRnId9g4PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_5eSvOe54PkCVmjdVxgbZig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:AdvisoryAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_SDRsv452YEy1QbPpr3-H7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_CU6eHywSfU2jd_Ogr83-kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2021_e--_NbHbEE6MXeRdEtUWUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_GlLZteV0L0Sp_5QqZ3bkiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_21_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_njgrU71ChUuuukDv39OPww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snpx:PlacementAgentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_16_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_B7CPRdhRrUi03pd8HH2WHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_GzKIkZ8knECSIuc2D4qCoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_97X_EvVSLEObXZUCOmP-LA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_sQgKmUmCo0SOmBKWdTYsrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_FYkHNg0eDkqsEfsyfLe89Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_hF3BfbuxTkaBt64WDXedaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_l191m19UVk-g-tWdcIuAvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_ZcuRlFcZlk6RzU5e00C74w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_lqTTCdUJv0Gbk8pPOgt1Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_9otCxOcf30aqj9YleMKvAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_QhnfmLSW0k2hAwylpTMIlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_eXAu7kGsKUqqwxXMjOEi5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_5hwgduBRaEOxiMvk-glrAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_ghqdfvGBdUyTpIbQr-dO0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_0euqztFk-UWqNJ-EMYldhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_mKADfe9OGEuXe9ZYlIg4Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2020_To_2_1_2020_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_aEnOkbRtSEKBDafsd3izUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CF3yESI8t0-Cw7te7xhxbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_dPVmqepTmE6hEYumSC7-NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2GQFAY6UeEqXkOLT4ajRHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_aqSGqF3d9EOAW-vdRB2T0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_aqF2KklEf0u18kWTm7BHtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_7ynEJUOgpEaTJWjy14CbxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_IAPUN0sCQ0SOUwKfGoet8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_WrGK0uDCmUGfS8ag_ejX5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_s2nrkv1GlUOqLv_ow-biXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_NsMIo03fS0GvupLoZPxqNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_AlB4qWeQFkGYL40ag-oXkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_sv5TfcxykECMI_R-TDkDOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">snpx:ShareBasedPaymentArrangementNewlyAppointedDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:DirectorCompensationPolicyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_31_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_wwIsJnRvikGynuEld8gG7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:CharlesRyanSeparationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_31_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember__tepL3mKh0iXiuyC48F1pQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:CharlesRyanSeparationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-31</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_19_2017_To_1_19_2017_srt_RangeAxis_srt_MinimumMember_byQy3JDAGkCSL09nDP4uAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-19</xbrli:startDate><xbrli:endDate>2017-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_19_2017_To_1_19_2017_srt_RangeAxis_srt_MaximumMember_9oZ5nMAmCE-LtGzgYi_y-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-19</xbrli:startDate><xbrli:endDate>2017-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_14_2014_To_7_14_2014_srt_StatementScenarioAxis_snpx_NetSalesUpToDollars250MillionMember_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_ttgHcX6d-ESz6q6J8dXSbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">snpx:NetSalesUpToDollars250MillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:Mt.SinaiLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-07-14</xbrli:startDate><xbrli:endDate>2014-07-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_14_2014_To_7_14_2014_srt_StatementScenarioAxis_snpx_NetSalesOverDollarsMillionMember_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_yH6gk0Ukj0ORfCWsxOM59A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">snpx:NetSalesOverDollarsMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:Mt.SinaiLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-07-14</xbrli:startDate><xbrli:endDate>2014-07-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_11_30_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eDY3684nJE-p7S0A8UmC-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_v3U1szDl4k2j8DFDpZYu8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_YVddo9k3xUe1Mty-SsrZWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_AgreementsWithBryologyxMember_l1G14r9qTki6SweRFMEsIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:AgreementsWithBryologyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2021_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_TxVysG0320uYChAcxvCRyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:EmploymentAgreementWithAlanJ.TuchmanM.dMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kLgOmbRun06NqMMcX7EhDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Cr2IzRTXakm82Stu4mohyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_lR04OAC-tUOnEiZFv4wu8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember__q6Kouwx7ka5jQwWeyinOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_NgyqTk38w0WSX-vTVG_Qfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_gbBWD2FtDki4KkvEusVG5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_aMs2yxkpWEe7tYMJ_xTFLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_RightsAgreementMember_cbGd3CdlBUqQ_qyF1XZXPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:RightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-13</xbrli:startDate><xbrli:endDate>2021-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_7_2020_To_12_7_2020_srt_StatementScenarioAxis_snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_yvpkUlirp0a1bWJ5z_hbhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">snpx:IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:EmploymentAgreementWithAlanJ.TuchmanM.dMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_7m4RE_sc4ku1rRSLUCwYWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:CharlesRyanSeparationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_XOhWuqO7-UmxW3rdr5h8WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-13</xbrli:startDate><xbrli:endDate>2021-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_jhrqwDH5JUKGX1yjRe_zDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-13</xbrli:startDate><xbrli:endDate>2021-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_6_2021_To_4_6_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_iOYMLdM_qUSnnsL4WR4G2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-06</xbrli:startDate><xbrli:endDate>2021-04-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-13</xbrli:startDate><xbrli:endDate>2021-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uOzUNq5PSE2XqZhY7SoRMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_qmdvRA7HJkGJm9mM-_iwZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QG8rYYtb-Uy4gyffTC5Lcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WekrDXrYzUSxTXRQk2RDxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_sBHxntfERUS1cbWvgfagyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ECz7Je18oEu9fwUB7c6eqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_StandFordLicenseAgreementMember_LrA02ttJr0Skelb_psotsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:StandFordLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_Jj8qpfoArUmBLAPesOXY6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:Mt.SinaiLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_14_2014_To_7_14_2014_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_grnTBMjygUGvo-rt4z7rsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:Mt.SinaiLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-07-14</xbrli:startDate><xbrli:endDate>2014-07-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_7_2020_To_12_7_2020_sjyc_Q4Tz0y82heiYi_stA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_30_2020_To_11_30_2020_us-gaap_RelatedPartyTransactionAxis_snpx_CurrentShareholdersOfCompanyMember_M1g-SpCvMkOthGYObm_VUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">snpx:CurrentShareholdersOfCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpinoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_8kjX07DyaE-HzdlEbheL3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">snpx:NationalInstitutesOfHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_TIkglklIoUO2Ye16Man1yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_ShareholderRightsPlanMember_BeWp9EwyLU-Pw2i4t19P6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ShareholderRightsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-13</xbrli:startDate><xbrli:endDate>2021-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_5_2021_To_8_5_2021_us-gaap_TypeOfArrangementAxis_snpx_NemoursAgreementMember_duKRD6ZZp0unUKaBSODNWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:NemoursAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2020_To_7_23_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_CN7r02Xyn0ydRSaKF-TAyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-23</xbrli:startDate><xbrli:endDate>2020-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_R-FJ60uA10ybeZXoxwgloA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_YeeVT1VLT0GCoyCiHtvk3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_6GCBoefDCEis5MNeRLe2Dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2020_To_2_1_2020_nGp21D17LkONtLS4Ybajpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_5_2019_To_6_5_2019_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_mhXWMvG4xk6I8_Dt9Z6IgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-05</xbrli:startDate><xbrli:endDate>2019-06-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_Bfz_1syvz0adg3VenxJYAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithSmCapitalManagementLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_izoFKLvbS0qca5XE_8MiDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_rB9I5A7GXUOkubGYNYktVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_MqIvc6D6ak-bP_Ls5cIdEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithSmCapitalManagementLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_ZdwykQQjnki7EjxvNtEUvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_T6M0FiL3YEiY7TJp-0yjrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_21_2021_To_1_21_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_fZfc3Q0FgUaqAHKikZxANA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-21</xbrli:startDate><xbrli:endDate>2021-01-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesHWarrantsMember_t0GYiy1420idJAGM8em5Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesHWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_2k34O0Id4kWZX644U9EfIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_yUgO0gWhX0Kj3WzQ05UBjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesWarrantsMember_55AWN-0IQEiKtuL0SJcHtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesDWarrantsMember_TqviIe44M0KRUuCnfF8Jsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesCWarrantsMember_z_WS3P03W02KA988MbJQRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesBWarrantsMember_7SQ3AypUt0SSMTahwvnMAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_14_2021_To_6_14_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_Hw9nxWYRIEOMqSut960Tzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-14</xbrli:startDate><xbrli:endDate>2021-06-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_14_2021_To_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_Q4EJ6pY3MEGvIljDamjqvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snpx:PlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-14</xbrli:startDate><xbrli:endDate>2021-06-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_21_2021_To_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_L_BlpkHz3kyav_r8wtOz5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-21</xbrli:startDate><xbrli:endDate>2021-01-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_21_2021_To_1_21_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_o7nYuxzxoUywgFr4YqnBRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snpx:PlacementAgentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-21</xbrli:startDate><xbrli:endDate>2021-01-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_19_2017_To_1_19_2017_RyYqzdEgTkmLuudVtZapew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-19</xbrli:startDate><xbrli:endDate>2017-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_sdadKr2ZFUGPSuQk3FpIsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:EmploymentAgreementWithAlanJ.TuchmanM.dMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_AJnmojkQsECwB_nfR566Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:CharlesRyanSeparationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_4_2016_To_8_4_2016_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_ITeAjsMVWUKi59WUOf-Khg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithSmCapitalManagementLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-04</xbrli:startDate><xbrli:endDate>2016-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_11_30_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_exdHd3zzYkWzxHQw70jWQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">snpx:NationalInstitutesOfHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_rlr4KPaCbkyP11bzHs4H5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">snpx:NationalInstitutesOfHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_OpMJCHhLC0ywEnxoJd5pzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">snpx:NationalInstitutesOfHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_fxANfnDJfkq-DjAu241ovA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">snpx:NationalInstitutesOfHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2020_To_7_23_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_s1iUX1xsBUGU6nFszabgYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">snpx:NationalInstitutesOfHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-23</xbrli:startDate><xbrli:endDate>2020-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_14_2021_To_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_OrexfrNIiEKu4uzwmMWMwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-14</xbrli:startDate><xbrli:endDate>2021-06-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_14_2021_To_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_PrefundedWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_UTFOvvwdkkKSLwa22CdtEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-14</xbrli:startDate><xbrli:endDate>2021-06-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_21_2021_To_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_HmAmRGGq3UKNzSa-eZihpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-21</xbrli:startDate><xbrli:endDate>2021-01-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_21_2021_To_1_21_2021_HYTbWiKKQEKRtx7xP4_xwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-21</xbrli:startDate><xbrli:endDate>2021-01-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_14_2014_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_XWK_0a7heU6xMzkPuo_XLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:Mt.SinaiLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_fa_BU9Kh_0-JxvaVT_wQww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_10_2021_cI8-59YAKkquXUEgzeXqKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001571934</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_director_RA5R3TwOe0i9LByRRHbWMw"><xbrli:measure>snpx:director</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_employee_TK-gmXNo9Eqj4Kw_3BydmQ"><xbrli:measure>snpx:employee</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_DzbStCv5TEKWycjen-OBEA"><xbrli:measure>snpx:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g"><xbrli:measure>snpx:item</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_9ec239bd_034c_41ef_a91e_1df3232c9184"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:DocumentType" id="Narr_MoBDnb7tDkyUciWeu7RNXQ"><b style="font-size:9pt;font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_b21f8da6_1242_4d79_9ab1_1f8aefbd49e2"></a><a id="Tc_YmGc7nNnDki4sYP_0w2v9A_1_1"></a><a id="Tc_yZYoSiZWkkq4LhZclwID1Q_3_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:DocumentQuarterlyReport" id="Tc_ELTE9LcNP0m_f2kae9T1eA_1_0"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr style="height:9.9pt;"><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:96.67%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:96.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">For the quarterly period ended</span><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:DocumentPeriodEndDate" id="Narr_qPasKir-AUqOG09LcfUrSg"><span style="font-size:9pt;"> September&#160;30, 2021</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_bd6abe59_7299_402b_9af0_ed61154c87a3"></a><a id="Tc_JKN15CMj1kmzgRO9N5ra6g_1_1"></a><a id="Tc_Z09GMZzIY0C3S-PYU0u0fw_3_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:DocumentTransitionReport" id="Tc_GFx-ngOaV0G0quIZ5EgX6A_1_0"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:96.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">For the transition period from __________________ to __________________</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Commission File Number:&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityFileNumber" id="Narr_dkr1iJDMMUmVlT8jfICb6w"><b style="font-size:9pt;font-weight:bold;">001-40458</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_bLlD-sqth0-4iiDJqsKpmA;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:center;">SYNAPTOGENIX,&#160;INC.</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_51d57d8c_e60c_4003_a8ad_b207ad54367c"></a><a id="Tc_anQQiMWx10-QU8UJdTlBkg_2_0"></a><a id="Tc_yhLHItuZtU-xv-rRlt1j0Q_2_1"></a><a id="Tc_hmTuFqOvOU-owz8pj9x09Q_3_0"></a><a id="Tc_fIpH0g_sNUmCP7rVtsWy5A_3_1"></a><a id="Tc_w9BVUG9zVkW1HPbVOUyiEQ_5_0"></a><a id="Tc_3ASfaYHEcUKcgAmPNlKCxw_6_0"></a><a id="Tc_bL8P4lqIv0S_t77te-jouw_7_0"></a><a id="Tc_PArwUelqa0WG1cw62XmdZQ_7_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityIncorporationStateCountryCode" id="Tc_vHDXokeU3kSsLMbDJuManw_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityTaxIdentificationNumber" id="Tc_OWff4myXBUm0jqqWNng63g_1_1"><b style="font-size:9pt;font-weight:bold;">46-1585656</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or </p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(I.R.S. Employer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">organization)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityAddressAddressLine1" id="Narr_OpuInyVXckmVj4bLEMoLUA"><b style="font-size:9pt;font-weight:bold;">1185 Avenue of the Americas</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityAddressAddressLine2" id="Narr_O9MKWHno6k23SPrAW5h5nA"><b style="font-size:9pt;font-weight:bold;">3</b><sup style="font-size:6.75pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">rd</sup><b style="font-size:9pt;font-weight:bold;"> Floor</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityAddressCityOrTown" id="Narr_FelFinBmk0mStHZaM0xVhg"><b style="font-size:9pt;font-weight:bold;">New York</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityAddressStateOrProvince" id="Narr_SAY-Ty6llUGNk56IHdSsqA"><b style="font-size:9pt;font-weight:bold;">New York</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityAddressPostalZipCode" id="Tc_tDpSyBFR30yxCldy3DifnQ_6_1"><b style="font-size:9pt;font-weight:bold;">10036</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:CityAreaCode" id="Narr_jfPIup3UQ0aKEKLRwmGZLw"><b style="font-size:9pt;font-weight:bold;">973</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:LocalPhoneNumber" id="Narr_-JN6ZM6sBE2H3p6-VniLYg"><b style="font-size:9pt;font-weight:bold;">242-0005</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former name, former address and former fiscal&#160;year, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:32.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:30.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:31.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on <br />which registered</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_daabb458_3d19_488c_a571_b402456207cc"></a><a id="Tc_jE-JB__lzEWYMCbYVPMXGg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:30.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:32.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:Security12bTitle" id="Tc_fYUFd3Do_EOIdOD-sFzTMw_1_0"><span style="font-size:8pt;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:30.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:TradingSymbol" id="Tc_GirBFDrL-kWNm4YwkqcGnA_1_2"><span style="font-size:8pt;">SNPX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:31.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:SecurityExchangeName" id="Narr_Q-qAoUFP1kSVCFqpaGxgug"><span style="font-size:8pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:8pt;"> Stock Market LLC</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityCurrentReportingStatus" id="Narr_lTKD1h9GekOOUdHbrSTKLA"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;No&#160;</span><span style="color:#212529;font-family:'Wingdings';">&#168;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityInteractiveDataCurrent" id="Narr_Xw2aOwpxgUC-DpdyGGrO9w"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;No&#160;</span><span style="color:#212529;font-family:'Wingdings';">&#168;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_cbc24406_d18a_47f2_98f9_9d01069fbb2e"></a><a id="Tc_GZN-CtzLF0u0FizAoeVmNQ_0_0"></a><a id="Tc_8UwCwixnjEqyr05nwWsUAg_0_1"></a><a id="Tc__xIuR2uokEizVvwidccdWg_0_2"></a><a id="Tc_XTBJD9Kgx0667RHiiB3a5Q_0_3"></a><a id="Tc_AJPQOTDu9UmE-5f0LqDSaw_1_1"></a><a id="Tc_Ee6oxguvDUqngBv14aMAaA_1_2"></a><a id="Tc_nTjxFAvCxEKLCHAPLMSrTg_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:37.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:6.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;font-family:'Wingdings';">&#168;</span></p></td><td style="vertical-align:top;width:47.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;font-family:'Wingdings';">&#168;</span></p></td></tr><tr><td style="vertical-align:top;width:37.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_HNBE-7UQ-EqvhG0jvd0ytg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Non-accelerated filer</span></span></p></td><td style="vertical-align:top;width:6.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:47.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntitySmallBusiness" id="Tc_H8lNI4mtbE6Csj61-LSVrw_1_3"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:37.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:6.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:47.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityEmergingGrowthCompany" id="Tc_3fUK3L3jnUSfF6qA3svigA_2_3"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#160;</span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityExTransitionPeriod" id="Narr_KoUic7r6sEiczIbbwPWzdw"><span style="color:#212529;font-family:'Wingdings';">&#168;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act) Yes&#160;</span><span style="color:#212529;font-family:'Wingdings';">&#168;</span><span style="font-size:9pt;">&#160;No&#160;</span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="dei:EntityShellCompany" id="Narr_2dRUUydVn0iS4MXiS3CN-A"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:36pt;margin:0pt;">As of November&#160;10, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_11_10_2021_cI8-59YAKkquXUEgzeXqKg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_TAOmAOEEqUOhzUD1S2k6JA">6,674,472</ix:nonFraction> shares of the registrant&#8217;s common stock, $0.0001 par value per share, issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0f08dac9_88b6_405f_a731_67f1618bf15a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain statements in this report contain or may contain forward-looking statements. These statements, identified by words such as &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;expect&#8221; and similar expressions, include our expectations and objectives regarding our future financial position, operating results and business strategy. These statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause our actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, our patent portfolio, our inability to expand our business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of our raw materials, existing or increased competition, stock volatility and illiquidity, and the our failure to implement our business plans or strategies. Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Readers should carefully review this report in its entirety, including but not limited to our financial statements and the notes thereto and the risks described in Annual Report on Form&#160;10-K for the fiscal&#160;year ended December&#160;31, 2020, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March&#160;30, 2021. We advise you to carefully review the reports and documents we file from time to time with the SEC including our current reports on Form&#160;8-K. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to publicly release any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_da8d09b9_1a39_482a_947d_2a39988e683a"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_954603"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Part&#160;I&#160;&#8211; FINANCIAL INFORMATION</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_86564"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1. Financial Statements (Unaudited)</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BalanceSheets_561547"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Balance Sheets as of September 30, 2021 and December&#160;31, 2020</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofOperations_75318"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed and Combined Statements of Operations for the three&#160;and nine months ended September 30, 2021 and 2020</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Equity_94231"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed and Combined Statements of Changes in Stockholders&#8217; Equity and Parent Company Investment for the three&#160;and nine months ended September 30, 2021 and 2020</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CashFlows_386858"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed and Combined Statements of Cash Flows for the three&#160;and nine months ended September 30, 2021 and 2020</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONDENSEDFINANCIALSTATEMENTS_3081"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes&#160;to Condensed Financial Statements</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">24</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_303380"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4. Controls and Procedures</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_864559"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Part&#160;II&#160;&#8211; OTHER INFORMATION</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_969762"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1. Legal Proceedings</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_894724"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1A. Risk Factors</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsuponSeniorSecurities_455084"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3. Defaults upon Senior Securities</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_328331"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4. Mine Safety Disclosures</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_865222"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;5. Other Information</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_669068"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;6. Exhibits</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:middle;width:95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_975732"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Signatures</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">36</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_79619cbf_5fa3_4f08_a0d8_fb0a126e07c9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I</p><a id="PARTIFINANCIALINFORMATION_954603"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_86564"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;1. Financial Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Synaptogenix,&#160;Inc.</b></p><a id="BalanceSheets_561547"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Condensed Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5cbc64de_b0b2_46ec_b85e_45447b1f9358"></a><a id="Tc_UhGi65a_DkKWq95K0d_2qw_1_2"></a><a id="Tc_eI6q3MKv6EOG1Dtg2qva6g_1_5"></a><a id="Tc_4rv1kSoa5UePB7vLTH08bw_2_2"></a><a id="Tc_AqQOs4UjIEqXbBVUz2IuLg_2_5"></a><a id="Tc_D-IpuJ0n3k67rALPtT_aNw_3_0"></a><a id="Tc_oGtMUNxjtUm_VmSEABbI7A_5_0"></a><a id="Tc_f26XmzR52kSTScejuGxkgw_6_0"></a><a id="Tc_tAkGY4hHQE-COGVwOyw40g_6_2"></a><a id="Tc_cvd_jnXq-UWDigH6e_vSyQ_6_5"></a><a id="Tc_UHr7nXuJY0adfyaw9rgsrA_7_0"></a><a id="Tc_dTy2vynzEUmiBTLbzk3k-Q_7_3"></a><a id="Tc_UXf4krqg2kiqJpuJnoHtGg_8_0"></a><a id="Tc_wve_KDS7GEWU8xNqTcoG7A_10_0"></a><a id="Tc_KwB2N1JPLE2IerwbV91AwQ_12_0"></a><a id="Tc_1FZCEpTli0i-PopyysTlzA_14_0"></a><a id="Tc_pdYw-hWbWE2HVrX0Y8OexA_14_2"></a><a id="Tc_4W-M-oFswUm8gSXiFb-B6Q_14_5"></a><a id="Tc_NtIxhqwJyEusEuzf8lqchw_17_0"></a><a id="Tc_iDmfN8DQv0W5XgdqINQyYw_19_0"></a><a id="Tc_oVZa7KtZcU-yoKYHEMLcag_20_0"></a><a id="Tc_TeCdFOobuk28H6xK1OZTJQ_20_2"></a><a id="Tc_va0v45cVGU6Nu1ZrPWXRLg_20_5"></a><a id="Tc_nmxgDhO8tkqv9HN7DZ5-Vg_21_0"></a><a id="Tc_CidavTgllU6kRuV2dogX9Q_23_0"></a><a id="Tc_fgY5LKPSZUGlL5cdOaEjsQ_25_0"></a><a id="Tc_p9Nqwmh4k0ODX3oTJDBrKA_27_0"></a><a id="Tc_TQLS8sMx0EeWSj3d8S2OCA_28_0"></a><a id="_8e73964e_d73f_4faa_b755_d9a295c863f9"></a><a id="_8e73964e_d73f_4faa_b755_d9a295c863f9_2"></a><a id="_8e73964e_d73f_4faa_b755_d9a295c863f9_3"></a><a id="Tc_S82_yDk1tE6YwkbwatHWIw_28_3"></a><a id="Tc_WX5SSw3MLUe4ihpdu1kR9A_28_6"></a><a id="Tc_QiVG-yRenk-4T16UJS2D5A_29_0"></a><a id="Tc_s4N3lazx6EylmO55iG2r9w_30_0"></a><a id="Tc_XVjil0smAUWydrjwdyTL9w_31_0"></a><a id="Tc_fYsIW_tv50GaqBnLjeyzcQ_33_0"></a><a id="Tc_rr3NJWK81k-QMjF_S1EuHw_35_0"></a><a id="Tc_hHlrPl4ue0q_pEUgje829Q_35_2"></a><a id="Tc_GAecJ_xeUES2JbUeoKmbjg_35_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CURRENT ASSETS</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_EBAoNvM73U23Nz9OZr_pRw_6_3">31,294,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_FOMN-HoYo0m4K8qrT-aKlA_6_6">5,795,055</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_LqizdvTeO0q3m0r8GdDcJg_7_6">127,445</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_9A609DxFnUyzBk46vV5WHw_8_3">1,045,512</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_byxVyAtmXka7uS5TceoKZg_8_6">806,289</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">TOTAL CURRENT ASSETS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_BFaD2EOa70yXWGdAfIXoCQ_10_3">32,340,157</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_ZXy1HLq4PUmMy18QAyrPiA_10_6">6,728,789</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fixed assets, net of accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_OpA1xdjwkEyqksR9rXHjOA_12_3">18,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_3smxkm4YE0CEdPidY3j3qA_12_6">22,212</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">TOTAL ASSETS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_u1624y99jk-JOZnNfMyPuw_14_3">32,358,642</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_McpDmLtLVkGsuI47Ll3aig_14_6">6,751,001</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LIABILITIES AND SHAREHOLDERS&#39; EQUITY</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CURRENT LIABILITIES</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_sKZWcI28i0y4MjgaWFLUNQ_20_3">935,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_3EKbmFHuwUyiXKxcEoKQVA_20_6">1,260,335</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_BisW7JSiZUeRhIddQeQcXg_21_3">71,953</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_JmGfPlcvAE2eF0Ok8Bd27w_21_6">352,154</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">TOTAL CURRENT LIABILITIES</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_HUYld_oYHU-xYI0xu6dWYg_23_3">1,007,329</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_n5vS9oZwPEiRXPh7dYDWAg_23_6">1,612,489</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SHAREHOLDERS&#39; EQUITY</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Preferred stock - <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_l6smMuIlVke0ejZ5Dgh4OQ"><ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_Ncz9zoGPT0661Ca0rOzl_A">1,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of September 30, 2021, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_vRzASsWAFk6Wt8f_KH2afw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Zg-DZZfoY0uZ4N_YqyhJ2A">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_nuwcUBGfQECyRvT4R1vfbg"><ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_1BKAj8-cmEW5mnq_Mcc5xQ">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2021 and December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common stock - <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_bZ2webyeLEqjk-XIiC2QWA"><ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_DAhN0BhtM024wRO_txC7Fg">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of September 30, 2021, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_EIFh0o14X0q1EaoHDsoiww"><ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_R2FyUJ4dSUSEWooHKFYK-g">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_IytvC-zf50OgOSrsUdjiCQ">6,136,967</ix:nonFraction> shares issued and <span style="-sec-ix-hidden:Hidden_toyVA6bUkEiJ-JBvLSf_Pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span> as of September 30, 2021 and <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_4PCZFjRCk0OOo945Og2fVg">1,257,579</ix:nonFraction> <span style="-sec-ix-hidden:Hidden_GzA5X_D0D06IlZ-X3HzHwQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">shares</span></span> as of December 31, 2020.</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_1MnJB7bElkql3jU_NpaJuQ_29_3">615</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_RPZHVE-vUkmLKHiuaN2kig_29_6">126</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_1sOaWM7ynUGDr5XyK5UyCw_30_3">41,256,323</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_PCWG_JrKc0GHBI-ozSt_aA_30_6">6,668,859</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_ECq8QBD090Gykm6vaEWMIg_31_3">9,905,625</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_ej7S6pw6l0CeVg914qLHSw_31_6">1,530,473</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">TOTAL SHAREHOLDERS&#39; EQUITY</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_bqTl-NyuhEauqIRKPMkX-w_33_3">31,351,313</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ATYAlDmoP0a_HhOM2NIwpg_33_6">5,138,512</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">TOTAL LIABILITIES AND SHAREHOLDERS&#39; EQUITY</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_CXnycghzjUyKGWQAm0R19g_35_3">32,358,642</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_lRqiZar8AUmkllQk_74OWA_35_6">6,751,001</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">See accompanying notes to condensed financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cc895689_bebe_4cbf_a658_0e42f38795e3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Synaptogenix,&#160;Inc.</b></p><a id="StatementsofOperations_75318"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">Condensed Statements of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_8f5ab6be_88b2_4d72_8977_914f384d8515"></a><a id="Tc_6A3nIWSXj063fqfrXZO8Qg_1_2"></a><a id="Tc__-KLl9mMqUiBD3P5zlpGVg_1_5"></a><a id="Tc_ZfX72BD7akquHnBF278t4w_1_8"></a><a id="Tc_yAQUD1tdRk6a4bvjflMF3g_1_11"></a><a id="Tc_NUHmiKlBQkeOkGQn_gV_3g_2_2"></a><a id="Tc_XwXHn4SZY0Gv6hjtDnOwkw_2_5"></a><a id="Tc_UrfoLqzomE2s3KS_Cc9kSQ_2_8"></a><a id="Tc_BojYe07NIEigsOUYFIVwnA_2_11"></a><a id="Tc_PnSL7d0JxUaCdUfRyg2DFA_3_2"></a><a id="Tc_wlFWXk6mBU2NkUirhy4Qdw_3_5"></a><a id="Tc_-MDQ1gUsUEqUWw5KSGefMQ_3_8"></a><a id="Tc_pgY34Rp1_UGiytpG1YvQnQ_3_11"></a><a id="Tc_GwSk5jLuVkOTOd6-eDa1og_4_0"></a><a id="Tc_n9ZRNq11mEGNPgTAkKXnCg_5_0"></a><a id="Tc_sm7rX3HmGEaaj7dwwseKtw_5_2"></a><a id="Tc_QFLnflRW-U6oA3G7FSh6GA_5_5"></a><a id="Tc_Xr7rK2wumkWiIhAMEzFmvQ_5_8"></a><a id="Tc_-usbNmXFRU6SJN56oWociw_5_11"></a><a id="Tc_5t8ra0dulEmBV1yUZtZIjw_6_0"></a><a id="Tc_mPmeO_-r4EO6qPCVQxrRNA_8_0"></a><a id="Tc_ecR68qmmk0ShT89ggH7NVQ_10_0"></a><a id="Tc_IsbKzRSYiEWyZ4BA_oPUrw_11_0"></a><a id="Tc_lz06oDYXQU-nxlTaEzO_vw_12_0"></a><a id="Tc_K3db2nrifke4BE3MG-D2rg_14_0"></a><a id="Tc_ZR3evYFPSEy4bFRW5dkaiQ_16_0"></a><a id="Tc_9tdsZivXtUiXMIKFBudwtw_18_0"></a><a id="Tc_l0n8X9XiCEyGcoXX3kN5pQ_18_2"></a><a id="Tc_X6FL3b4wGEe0arqhb7eopg_18_5"></a><a id="Tc_r-k8GNBalEuIKiSFa3CpbA_18_8"></a><a id="Tc_XSYrdwVXgkKbqjT7wmaAMQ_18_11"></a><a id="Tc_rw0yCb3AMkyDfWa3UwciQA_20_0"></a><a id="Tc_LSaHOIC90UO-W0IKaqpCNw_22_0"></a><a id="Tc_irWO0UFYUUWdPh-deTKqjg_24_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">OPERATING EXPENSES:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_ZLvcbNbzhkSyPK9wne4z2Q_5_3">836,716</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_u97BRnxmtU2kqQGa_cPbcQ_5_6">563,317</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_bJLOTCHaVkeZLy3N1_jcmg_5_9">2,974,776</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_A132qjtMiEiPVxYc9LhCbQ_5_12">1,556,627</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_U3hc0D4Qc0-heJT5h_EEzQ_6_3">2,092,662</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_C8b-IPr8O0qU0jHs9CkZUg_6_6">2,013,089</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_bFP1XnX4xkioC5cDAXfGNQ_6_9">5,404,968</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_uJRo1E9xHUSNgiPJBt-eHQ_6_12">6,635,757</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">TOTAL OPERATING EXPENSES</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_c1gqM1NYJ0ON5dqLWH0xyw_8_3">2,929,378</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_M9JTZDHXukOJUt5nxJqmtw_8_6">2,576,406</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_U7chm0biPU20y4ozr_6yhw_8_9">8,379,744</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_bfGDWwOVbEGTokaL6C4HcQ_8_12">8,192,384</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">OTHER INCOME (EXPENSE):</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant amendment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_KgCfW7rxXEONhtVQFETQCw_11_6">1,700,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_NH_ihVAErkSxBnyxuNFMqQ_11_12">1,700,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="0" id="Tc_DAnYw3xWk0W41kg2dPPSbQ_12_3">2,445</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="0" id="Tc_EHFSHfDoy0O7PnwWf4QL2g_12_6">6,797</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="0" id="Tc_u5x8EBR5HkeGNAst6aYyRA_12_9">4,592</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="0" id="Tc_D6s-oPVKgEiTsPurbHffUA_12_12">153,305</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss before income taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_f7QBRs8K90SCocJo6rTjOg_14_3">2,926,933</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_-KkTQ7x5GkKEemxJfaX-fg_14_6">4,269,609</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_ZKV2DniF80WbTJQBkFfZZQ_14_9">8,375,152</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_G7FDlOIsWkWLRZr2TMtQBA_14_12">9,739,079</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Provision for income taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_prEoVeN2Z0WB_izUridRTw_16_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_CrLvzpueE0ibxwaDtBe55Q_16_6">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_sJvJXn0-6EGvJSEmqSbxtQ_16_9">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_840tP0Yij0yZzWSBUWULSQ_16_12">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_8N9pHWPWkUCjsSMSNCF_lA_18_3">2,926,933</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_2M-LDwwWwECb5VG6bxKhUw_18_6">4,269,609</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_MV5Fdgo6Qk2ONQkRam_68A_18_9">8,375,152</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_sf8PH1KA5kiwP31OWBx2-g_18_12">9,739,079</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PER SHARE DATA:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic and diluted loss per common share</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_r9plw0qNOECAE0OiFEJRZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_KCag5r0BmkiTQIzfP5bzIw_22_3">0.47</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_uJrZsluMHkihC8HIIwYSHg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_d83ypAzhV0-gWX13RnmgYQ_22_6">0.90</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_LQmeZvVOEka8eEiD5e9XgQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_J6USy4GtskWS_IcbvxdiYA_22_9">1.89</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_8WgOmX6PPUy5f6-S6IlyLw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_j4fYnL9tWkeRoxGr3R4TiA_22_12">2.28</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic and diluted weighted average common shares outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_gI9hbm1oeUepqUIYyp_c9w_24_3">6,196,600</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc__gpi0mu_y0uiMLaduiMDpQ_24_6">4,755,100</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_h-WLuam5H0uwIB0NE5gUZQ_24_9">4,420,200</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_JqpMx3ihZUeZFKWX6KHd5Q_24_12">4,274,200</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">See accompanying notes to condensed financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_14f8ffce_af91_40aa_8840_3b7dd4b16906"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">Synaptogenix, Inc.</b></p><a id="Equity_94231"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">Condensed Statements of Changes in Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#212529;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_970d8586_393a_4940_8a66_86c72275e30d"></a><a id="Tc_Eac5xUcrNkaNKUzTpmYzEA_1_2"></a><a id="Tc_gxYckDxGl020WvN8jpLv-A_2_13"></a><a id="Tc_mLD-4kS2HUiqWRapl8jc8Q_2_16"></a><a id="Tc_GuIlwMmY5UiUcXcn0SBJfA_3_2"></a><a id="Tc_c3_-IHizh0ujUlyyuZ5Epg_3_7"></a><a id="Tc_JcozmmXYDESmAY3jpH2nGw_3_13"></a><a id="Tc_3exM9YmIokaHvOe96Cq0SQ_3_16"></a><a id="Tc_1f656gITO0CoIzlTPDC5eg_3_19"></a><a id="Tc_GtHWaDgOKk6liCf0y4V3QQ_4_2"></a><a id="Tc_vwy8vno5x0C7XocnGFnDFg_4_4"></a><a id="Tc_N-rKDORIg0a0nSjFYOe1Ig_4_7"></a><a id="Tc_gWUQGlnyi0isPiiu9sVefg_4_10"></a><a id="Tc_-2-k0UBbNUKMw9Jx2D7RYg_4_13"></a><a id="Tc_dOrrBRVh20uueyG_Pjtz7Q_4_16"></a><a id="Tc_00VeVWxFc0WmMKnroGCYPg_4_19"></a><a id="Tc_RpOM1ATvXkGCibCBpI7Usg_4_22"></a><a id="Tc_T39PEc-48E2PpdIiO0RIjA_6_0"></a><a id="Tc_wGXmtw-lTEuRvciZCVo09g_6_4"></a><a id="Tc_k0Od1r3FNUO5Fhk9X3PxLA_6_7"></a><a id="Tc_j4Llj6kI60q21KaN2Et4ag_6_10"></a><a id="Tc_AUVH_GN5TUCygOItKQIJnQ_6_13"></a><a id="Tc_bxfXIUzxaEqK7Z2EbquY6A_6_16"></a><a id="Tc_NrZavI9ES0Gs_tz9wLwQng_6_19"></a><a id="Tc_gJxEOkNpQUGqRHzDrpQdZA_6_22"></a><a id="Tc_-mOvM8JqsUujyuJv54yIcA_8_0"></a><a id="Tc_yskdnzdpIUWRm3FGc8gE2Q_10_0"></a><a id="Tc_Ozg5fBACykSFvLuZtnAzFg_12_0"></a><a id="Tc_TGnAcbApTkKqGZcD27JkYQ_14_0"></a><a id="Tc_GS2mmkNI9UiMYf_TfcSIjw_16_0"></a><a id="Tc_2mqI5dj23kG3kj1qJpMcmg_18_0"></a><a id="Tc_HpJN0kznR0-1LRFIw9ijKg_20_0"></a><a id="Tc_0rkJ4e97u0i1btD3ewiIOw_20_4"></a><a id="Tc_vM3MYORG20qZq9spbEUrag_20_7"></a><a id="Tc_a4qxGqVmq0OO2vx1IiFoCg_20_10"></a><a id="Tc_ZoAjuQgBFU2L3s9b4E7F7A_20_13"></a><a id="Tc_WAljMEXOZkuss0uKoSO0pw_20_16"></a><a id="Tc_ORCn9STbhEitgsGcB5gX4Q_20_17"></a><a id="Tc_1i_2hL5-KkuJh5264oG-xw_20_19"></a><a id="Tc_AQC7pwiaQkmBQm0FGXGD1w_20_22"></a><a id="Tc_G1FIg9AZh0u8_sbgcKIVbQ_20_23"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="22" style="vertical-align:bottom;white-space:nowrap;width:71.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Additional</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Parent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common&#160;Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Preferred&#160;Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Paid-In</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Company</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Accumulated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Balance July 1, 2020 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-8SoERMK70Sy1smuFNcHUw" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="Tc_LyCQ8-PgSkqq-Bp0Upym4w_6_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-8SoERMK70Sy1smuFNcHUw" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_jIpTuFPxukunpZCwG8Mpmw_6_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Z8OFwl7EbUOJULDl_93Hrg" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="Tc_pE1C_mXarUqqyxeYTh1t2A_6_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Z8OFwl7EbUOJULDl_93Hrg" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ZEuR2wHnIUC7sU-BbY7yiw_6_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YSISzRr0bky6jJiuWUvVbQ" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_yC0uqa02Yk2PtQ0UhGM3zA_6_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_HthvWJobo0OzesTLSZPLwg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_D-9N_D3oiUKDeGlz5bGw8Q_6_17">29,797,838</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cPmmOsgAh0WB3a-cIX_Kmw" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_VBrJkNBwUU2eCcCGRJOdcw_6_20">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_6_30_2020_UQQvJk6FaUucAss2ojsT9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_sabgXWHRkEOP2cKnbnJ6-Q_6_23">29,797,838</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Net change in Parent company investment </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg" decimals="INF" format="ixt:zerodash" name="snpx:NetChangeInInvestment" scale="0" id="Tc_8NO-GLHAGUyqlRj2BkBdmQ_8_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg" decimals="0" format="ixt:zerodash" name="snpx:NetChangeInInvestment" scale="0" id="Tc_ZzuUpOfMykehC5sna2A95w_8_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA" decimals="INF" format="ixt:zerodash" name="snpx:NetChangeInInvestment" scale="0" id="Tc_VrqzLntr0k2YJALTvaCEuA_8_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA" decimals="0" format="ixt:zerodash" name="snpx:NetChangeInInvestment" scale="0" id="Tc_PoXrvJWE_UerHFWCeV-trw_8_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QG8rYYtb-Uy4gyffTC5Lcw" decimals="0" format="ixt:zerodash" name="snpx:NetChangeInInvestment" scale="0" id="Tc_zABFg_XeV0OBCW9uL2CeSw_8_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_qmdvRA7HJkGJm9mM-_iwZQ" decimals="0" format="ixt:zerodash" name="snpx:NetChangeInInvestment" scale="0" id="Tc_fCIh3TX1Tk2g8YXVWvEC8w_8_17">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uOzUNq5PSE2XqZhY7SoRMQ" decimals="0" format="ixt:zerodash" name="snpx:NetChangeInInvestment" scale="0" id="Tc_Dj4tKNhiYUONFlo1Gvf5Kg_8_20">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q" decimals="0" format="ixt:zerodash" name="snpx:NetChangeInInvestment" scale="0" id="Tc_WhRvvPTnLUSWhaMl_AtBiQ_8_23">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Parent company stock based compensation </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg" decimals="INF" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_pxyf9L3lOUCXNiYBJWnzMw_10_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_eBnJcupqnUWvGWd73k4_8Q_10_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA" decimals="INF" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_u4rUQOo9TkKVvsCLrxLDxQ_10_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_l8k8YYHSA0OTKa-6FGcBWA_10_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QG8rYYtb-Uy4gyffTC5Lcw" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_nMpukiXKYk-HRck6QoPg_w_10_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_qmdvRA7HJkGJm9mM-_iwZQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_zzPYlBbugUe0stcehidodA_10_17">387,927</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uOzUNq5PSE2XqZhY7SoRMQ" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_3d-c0yNKd0y0B_AJKt48zA_10_20">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_JFGW0snsxUuOBGpBcelAlw_10_23">387,927</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Consulting services paid by issuance of Parant company common stock </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_jF_OoyBLhkOpnqsuFWO_Ew_12_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_jQkIZYxmJU6QkCSBXpqrYg_12_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_uzZXK_Ebake_dm6XwW-w4Q_12_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_qYFdwXXD_UyG2r4nHKbfFw_12_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QG8rYYtb-Uy4gyffTC5Lcw" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_pB-66gnCxku6L9G28Zmy9Q_12_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_qmdvRA7HJkGJm9mM-_iwZQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_27XV1cvU9UugdYuC7SHjBw_12_17">120,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uOzUNq5PSE2XqZhY7SoRMQ" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_BQ3dJIA7fUKCE6zbkgXIvw_12_20">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_lEHAElXt9EquioaF1UJzhg_12_23">120,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Consulting services paid by issuance of Parant company common stock warrants </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg" decimals="INF" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_xIK20gcJvk2QWJJ43c_sIQ_14_2">&#8212;</ix:nonFraction></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg" decimals="0" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_VOHgao3K80mITK4gJnvaaA_14_5">&#8212;</ix:nonFraction></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA" decimals="INF" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_GI54_YnY8EKUtUdcrtUJsA_14_8">&#8212;</ix:nonFraction></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA" decimals="0" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_ThB-QFzxJUODDF0yOEvDRw_14_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QG8rYYtb-Uy4gyffTC5Lcw" decimals="0" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_k5ofYsBBRUekmnk0Bgae8g_14_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_qmdvRA7HJkGJm9mM-_iwZQ" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_Wun0PjJgBkCW5e3fxV87jA_14_17">113,281</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uOzUNq5PSE2XqZhY7SoRMQ" decimals="0" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_P5B9rHpa3UGFon8OAWP4Tg_14_20">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_ZxtuNeQK-kutPQrHMrtglA_14_23">113,281</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Warrant amendment expense </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg" decimals="INF" format="ixt:zerodash" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_vbW5iSm5ok-TXznBoQ9bPw_16_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg" decimals="0" format="ixt:zerodash" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_XBqJsxa5U0yIVzPg2g6hbg_16_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA" decimals="INF" format="ixt:zerodash" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_SbFBpy_hV0OpRI8dVDBT5Q_16_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA" decimals="0" format="ixt:zerodash" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_PzlVDhTIdE6uihCsHMOqjw_16_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QG8rYYtb-Uy4gyffTC5Lcw" decimals="0" format="ixt:zerodash" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_nZXNDfQ1KES2PpSVuuCOKg_16_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_qmdvRA7HJkGJm9mM-_iwZQ" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_2XfJVjgHoE6XqsspBsvWNQ_16_17">1,700,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uOzUNq5PSE2XqZhY7SoRMQ" decimals="0" format="ixt:zerodash" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_jZHTqToyjEqj-3AbDckRAQ_16_20">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_umT_HGTRZkyGNssQ6NaXyw_16_23">1,700,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Net loss </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg" decimals="INF" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_2BQo0DkucEKc-6uaxCW8Lw_18_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_WrwysUs-5UWYSKlRjbmduQ_18_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA" decimals="INF" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_Cz66UO7Y-kmzWk4QWP1g3Q_18_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_plfdnbtoSkuHeStD5gNY0w_18_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QG8rYYtb-Uy4gyffTC5Lcw" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_1ih3v4blf02rXsqc30N-Kw_18_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_qmdvRA7HJkGJm9mM-_iwZQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_8I4d-EGggUuN0reY1ZXcfQ_18_17">4,269,609</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uOzUNq5PSE2XqZhY7SoRMQ" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_PvLhkvIMCkid6T-024FbMA_18_20">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_72zeCgZIEUy5T-HF_FKRQA_18_23">4,269,609</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Balance September 30, 2020 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0KTSxMliRU68--TLFjCX-Q" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="Tc_MS7apbAHrUmK5a2k5xSDww_20_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0KTSxMliRU68--TLFjCX-Q" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_cBqifXU5_Ua5uinhIk9wcA_20_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_f4-Im_6b00Ktvk63-6KZww" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="Tc_mVi1dfUhz0iXSRc67FEgfA_20_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_f4-Im_6b00Ktvk63-6KZww" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_XCAV5_F8cECzidMYNKhDDg_20_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iE0Gc6ADH0GlOfrRzcSuFQ" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_0XAtFerqpkun5K6LmTJ3Ow_20_14">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,849,337</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zZH3ckIIi0qEdvdPW_U0Uw" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_NskbM4RgpEOgtqhz78_0oQ_20_20">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,849,337</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7f7d846b_2392_4e75_936a_4e243409ac9b"></a><a id="Tc_eJa1kmNaO06bxs17qKrcBQ_1_2"></a><a id="Tc_ejvFTEJ8aki89o09wtlxeg_2_12"></a><a id="Tc_UsNdQsLlYkSe33Ugk7TpTA_2_15"></a><a id="Tc_NDlCZ56imkCF1FlTrTStPw_3_2"></a><a id="Tc_pmVpgtxp1kSzoGklkA9qBw_3_7"></a><a id="Tc_ky3Kkzhew0yJWHIH2DZT7w_3_12"></a><a id="Tc_hdvuH5BLZ0aWCs4j2aA3GA_3_15"></a><a id="Tc_dzuXHl8xTky2-Ybt4QAwpg_3_18"></a><a id="Tc_ohPEHV0h9E2qQLfp1ywO7g_4_2"></a><a id="Tc_mH5x-kS9nU-0GEYcdrewvQ_4_4"></a><a id="Tc_3feSf4RCdkO-_SePnLaAoQ_4_7"></a><a id="Tc_zzcsn_wv8EOQoH7ozwitXw_4_9"></a><a id="Tc_J1sBk0hgxUGgFs7BL3ZHRA_4_12"></a><a id="Tc_n0DqNOl-gEimXAx_jIHQbA_4_15"></a><a id="Tc_6eE5nqhIWkCfTX0E9F5jDQ_4_18"></a><a id="Tc_l71qDFyb-k-FIajNN4cggw_4_21"></a><a id="Tc_TYk2X9QrPkWWFnuBUha3VA_6_0"></a><a id="Tc_kOpmA0oQ10qm_ioidKBpFA_6_4"></a><a id="Tc_ndmUz7-UsU-JI-9G0hLR7g_6_9"></a><a id="Tc_537MjU0b5UKHYvczp2VPYw_6_12"></a><a id="Tc_x4pwL5MUtkKO9pTly-E4kA_6_15"></a><a id="Tc_5cYB09g40UaLkuklylzfUw_6_18"></a><a id="Tc_n50oNaERKUOtyxEqCFek7g_6_21"></a><a id="Tc_jRfut7GitUmCBheBO22PPA_8_0"></a><a id="Tc_GqAWHisoEUq-k4AP6UzoGg_10_0"></a><a id="Tc_u-2u7t1V_UyFuxeBbmbEtg_12_0"></a><a id="Tc_vkHgibfUfUeuvdqeAhlbTA_14_0"></a><a id="Tc_F4dmiqGlfUGzfjrSYJHbYQ_16_0"></a><a id="Tc_IK6feDii0k6vplftwr-FBQ_18_0"></a><a id="Tc_yiHhPZhG6Uiy1qmOnDuq7A_20_0"></a><a id="Tc_LNQk5NSO8k6YBLDPXUSdTw_20_4"></a><a id="Tc_mUtPxaFaVU2ZvHGmINMxKw_20_9"></a><a id="Tc_pBifZHSoKEazVOXIodxM3Q_20_12"></a><a id="Tc_v1rqf-cv70K18QSuEPOLtg_20_15"></a><a id="Tc_wHwcC31dxUmKBMLzcCcb6g_20_16"></a><a id="Tc_m2GYHZNY_0-cZfXevHFUdg_20_18"></a><a id="Tc_8nrL0htHmU-LlWZ7_wey7Q_20_21"></a><a id="Tc_uMZZsF7pnkKERb765ZNsfA_20_22"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="21" style="vertical-align:bottom;white-space:nowrap;width:71.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, 2020 </b></p></td></tr><tr><td style="vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Additional</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Parent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common&#160;Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Preferred&#160;Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Paid-In</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Company</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Accumulated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Balance January 1, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JxAib4ryK0Og6uxEH2c6Qw" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="Tc__CYoN20Xt0a2SH-zm8Plkw_6_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JxAib4ryK0Og6uxEH2c6Qw" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ZkTfhmN4L02dpjCKcz7lIQ_6_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_firc-Dmg-0eR-8Hv8fLQyw" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="Tc_JdGkH7kAt0qv61JT94tSWA_6_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_firc-Dmg-0eR-8Hv8fLQyw" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Wmf3F_zpfUGDBukyI6fgJg_6_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_P7zGDC_-hEeO9i5oMGGuig" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_EWo_avD0kU2WDxmg30_vHg_6_13">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_FMu0KxA6Dk2LDplFkct4jA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_e_wYX3NXAk-DD6GnYmI9rA_6_16">17,418,765</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2LGNFezF1EW4idiVG3QiZA" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_EUhKQKsIL0Oqc1n664hMaA_6_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2019_97X_EvVSLEObXZUCOmP-LA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ehd2PDBfd0ClYf655gJRiA_6_22">17,418,765</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net change in Parent company investment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw" decimals="INF" format="ixt:zerodash" name="snpx:NetChangeInInvestment" scale="0" id="Tc_qpkmOUk6IUiL_RWFURsmxw_8_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw" decimals="0" format="ixt:zerodash" name="snpx:NetChangeInInvestment" scale="0" id="Tc_AJDycpnNx0OnlUCaVr8wmg_8_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw" decimals="INF" format="ixt:zerodash" name="snpx:NetChangeInInvestment" scale="0" id="Tc_RVgUh5knA0-INjtYMnxjJQ_8_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw" decimals="0" format="ixt:zerodash" name="snpx:NetChangeInInvestment" scale="0" id="Tc_s2UlEfJItESlsyLyOxhVfw_8_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ECz7Je18oEu9fwUB7c6eqw" decimals="0" format="ixt:zerodash" name="snpx:NetChangeInInvestment" scale="0" id="Tc_2q10OMjsRkOq4n6SMOjK8Q_8_13">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_sBHxntfERUS1cbWvgfagyw" decimals="0" format="ixt:numdotdecimal" name="snpx:NetChangeInInvestment" scale="0" id="Tc_q2pOgRmZK0Oew9A3IjTF9Q_8_16">16,519,988</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WekrDXrYzUSxTXRQk2RDxA" decimals="0" format="ixt:zerodash" name="snpx:NetChangeInInvestment" scale="0" id="Tc_eoDMUGLC40-C0k-1JAVOhQ_8_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="snpx:NetChangeInInvestment" scale="0" id="Tc_JmcVg8kvFUmz3d3dZ9Qv9Q_8_22">16,519,988</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Parent company stock based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw" decimals="INF" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_X3N6gGoSGUOXyeOCqw-erQ_10_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_78hG9Wxx_EWUUHPg-DY7wA_10_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw" decimals="INF" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_pK4Wv_sMV0O16iI3g-rcFQ_10_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_S1JThOwB7UqHnVojTejodg_10_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ECz7Je18oEu9fwUB7c6eqw" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_dAm8HYv5g024l6z1tJllsw_10_13">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_sBHxntfERUS1cbWvgfagyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_GLB8QuH7jkODR7giCAiK-A_10_16">1,449,023</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WekrDXrYzUSxTXRQk2RDxA" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_L3pffyA1ekyaKCI2eOCjww_10_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_zY_rpa7y402KObiNpoJZ8w_10_22">1,449,023</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Consulting services paid by issuance of Parant company common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_YArJb2-Zg0Gw-Po2rBzV_w_12_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_lkUfqI4aTUS3Ynt4_-_Qrw_12_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_L4Jok3WOzEy_z8AEkT9DQA_12_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_-vk43zivGUKhCwT40K3QLA_12_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ECz7Je18oEu9fwUB7c6eqw" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_MVvi3Bs3nkWMltxQURNhcg_12_13">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_sBHxntfERUS1cbWvgfagyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_ldu7q5xRFkSwTh-fQ5m7gA_12_16">120,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WekrDXrYzUSxTXRQk2RDxA" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_4xL7X2VhVE-wKxySiBMhqQ_12_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_118-Kuj8nk6LSEzoCH71UA_12_22">120,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Consulting services paid by issuance of Parant company common stock warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw" decimals="INF" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_vKidzLfEN0udCIYiS7NF-Q_14_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw" decimals="0" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_TKxjHZERgkG34X6VrytxGA_14_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw" decimals="INF" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_jz4TEX4JJkS11Ky-_IdzSw_14_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw" decimals="0" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_KnvFCz3Likq4LiWQjdkyZA_14_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ECz7Je18oEu9fwUB7c6eqw" decimals="0" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_BMrx4iCQ8UOLFU9Q1hStSg_14_13">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_sBHxntfERUS1cbWvgfagyw" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_RUW_BzE9gEu1lZSB6RQKsA_14_16">380,740</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WekrDXrYzUSxTXRQk2RDxA" decimals="0" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_gLKjf0vGQEWxovhxfZPzzg_14_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_R5eU4VnDqkS5YVLSwjAHAQ_14_22">380,740</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Warrant amendment expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw" decimals="INF" format="ixt:zerodash" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_TmvGVX9KNUayYirciUZI9w_16_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw" decimals="0" format="ixt:zerodash" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_hyz4IxKkuEe8BQKL0SkxIg_16_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw" decimals="INF" format="ixt:zerodash" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_H33aFv0__0mNmLAQBK9B1Q_16_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw" decimals="0" format="ixt:zerodash" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_p1PWcKfnX0-olBXdISFCjw_16_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ECz7Je18oEu9fwUB7c6eqw" decimals="0" format="ixt:zerodash" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_Bhb_mxH1QUaMIqfP5u5Y4w_16_13">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_sBHxntfERUS1cbWvgfagyw" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_CdfIcW0_OkmmE9_hc1zMew_16_16">1,700,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WekrDXrYzUSxTXRQk2RDxA" decimals="0" format="ixt:zerodash" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_z5AG_HYUMUaRfBlnv8Q5wA_16_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_BsqN9eHgUk-XGPYVKCakUw_16_22">1,700,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw" decimals="INF" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_4n3dBmkmUUybQGZV5GQD4Q_18_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_MbAYhYDQR0yYSanYL2HGvg_18_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw" decimals="INF" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_kzw1uNO6F0yyx9YxPm0tmA_18_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_iPKNUJYiV0KmZdf-ZkBiQg_18_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ECz7Je18oEu9fwUB7c6eqw" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_pjxiPT2sqEOrXFVHbtCT8A_18_13">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_sBHxntfERUS1cbWvgfagyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_Gm4QdwwhrkC0B8IPPlh8Sg_18_16">9,739,079</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WekrDXrYzUSxTXRQk2RDxA" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_KYpQVQTWb0CfC3BN1NT4Uw_18_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_sZrNFprDR0CCKiNzipcoSA_18_22">9,739,079</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Balance September 30, 2020 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0KTSxMliRU68--TLFjCX-Q" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="Tc_L5VthP6mbk6a8INP8-IiXQ_20_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0KTSxMliRU68--TLFjCX-Q" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_DvcyuWgbW0K_6fU_XhShqA_20_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_f4-Im_6b00Ktvk63-6KZww" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="Tc_9m8M1HK-XEmRYvzwdQJX9Q_20_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_f4-Im_6b00Ktvk63-6KZww" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_IdxaILE2OECROwtmQTS6Kg_20_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iE0Gc6ADH0GlOfrRzcSuFQ" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_43Q4JgSahUmJmQSwvBzggg_20_13">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,849,437</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zZH3ckIIi0qEdvdPW_U0Uw" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_9LiJ6wc1YUmEM8iClw-1jA_20_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,849,437</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ae4f0657_6436_4ed5_98ed_6896981e153b"></a><a id="Tc_2Zpi-uia00-hi832BiX5HA_1_2"></a><a id="Tc_VgVTrvY3-ESBfWiwf7Vcsg_2_12"></a><a id="Tc_Ns020ym8vEiI3x2EaO3feA_2_15"></a><a id="Tc_89UGytMY50GWFp1o4ZiZZw_3_2"></a><a id="Tc_3R2KIHdP6kei76pdZuyYiQ_3_7"></a><a id="Tc_T3S5CGdoq0-T1qzTR0IjNw_3_12"></a><a id="Tc_uhj3aNBFfUq28e8naluJcw_3_15"></a><a id="Tc_oW4_xJhjF0aaYP6aXrWreQ_3_18"></a><a id="Tc_Ir6y5klMLkiHmMHCTzn_Kw_4_2"></a><a id="Tc_jd2upBsl6EqKK24rdO5mQQ_4_4"></a><a id="Tc_a7QSBUVcCEyiNC-W38j19g_4_7"></a><a id="Tc_SeokZvBDl0Wc6I84izqE5w_4_9"></a><a id="Tc_2qVMdqnFmUWjWhFAXTOJ5Q_4_12"></a><a id="Tc_vzkWoxEi1kuOjroVr6LYqA_4_15"></a><a id="Tc_UaabiO84PUa2aXms8QlTXA_4_18"></a><a id="Tc_Aa1L1NR19ESUf2814582WQ_4_21"></a><a id="Tc_YWjVo-OaKkKJ7B_PuDyy_Q_6_0"></a><a id="Tc_7z-VMrQduUe7JVhFcEUnfQ_6_4"></a><a id="Tc_gH_8758FBEOi2kTqtZEdKQ_6_9"></a><a id="Tc_xdtcpbTdAUKIJ6crmpz5Gg_6_12"></a><a id="Tc__njOMl_m4ESNw7-r9y3tLA_6_15"></a><a id="Tc_LrJ_XSz_bkuotOq1Kxnezg_6_18"></a><a id="Tc_5nmCMWv-UEGbY0H-HORsEg_6_21"></a><a id="Tc_Ks7yhWWkF0O_nPlTFdSbJg_8_0"></a><a id="Tc_1BYP-BwQ50uBTb17ywHRkA_10_0"></a><a id="Tc_zJF2YGIbeke0v2JWv4bG5w_12_0"></a><a id="Tc_73OAyDbYHU2MflLntGFNJw_14_0"></a><a id="Tc_4hY9mzr-5keT-wm381FcZA_16_0"></a><a id="Tc_mWHjZ9-lxk2wkBuW_oJL1A_18_0"></a><a id="Tc_cD01QXkkIk2_Xs_pBWBeZQ_18_4"></a><a id="Tc_FmQz2cHKbEiH63WfET6kHQ_18_9"></a><a id="Tc_gFDfX8GZZk-owYXtx8Q6LA_18_12"></a><a id="Tc_uvSKYheC5U6vdP81tXSpqQ_18_15"></a><a id="Tc_9EkWic1jzkao7y57NLb6Ag_18_18"></a><a id="Tc_NMaxKaIlvkmye1P84YFZlg_18_21"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="21" style="vertical-align:bottom;white-space:nowrap;width:71.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Additional</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Parent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common&#160;Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Preferred&#160;Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Paid-In</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Company</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Accumulated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance July 1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WtmrZrtb2E-vIIoDu3xIMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_41pDxNA3cUSQud2k1yjcqQ_6_2">6,038,798</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WtmrZrtb2E-vIIoDu3xIMQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_n34St8ECJkyZWRxqAizmRA_6_5">604</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_EAh8LLeUbUiQqs-4hpkvgQ" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Ieosu0duiEePoGhUb4mFzQ_6_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_EAh8LLeUbUiQqs-4hpkvgQ" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_L_AqIU3DAk6gFv4ussWYcg_6_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ypXLoCBb2ki0jyO4ErlUFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_K5to0qxuEUqMykB5f3nc3g_6_13">39,168,084</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_Ucphx9av20iHwREQym4HHQ" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_GED4r-frAkyp-R7vWQBxrA_6_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5Je_ZI8c30mq5LUNLv-5Aw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Uy_gEGR9kUKfxAfTxfkUAg_6_19">6,978,692</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_6_30_2021_Xii_2FmPcky3sXIraY0ypg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_f3nu-8ZbiUK84U40A7fjPg_6_22">32,189,996</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA" decimals="INF" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_ADu-hj03yUuyXuZnjesgww_8_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_BWX2TRYthkytngURvcavfg_8_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ" decimals="INF" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_VmAU7ywZsEKyZEHnMBIXZw_8_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_P0iBVTC100u4vIVGuO--2Q_8_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2GQFAY6UeEqXkOLT4ajRHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_o9JZoNI6tE-qyXM_8_OI2g_8_13">1,198,860</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_dPVmqepTmE6hEYumSC7-NA" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_JGm0m0FmukiyOj6_kbkBMQ_8_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CF3yESI8t0-Cw7te7xhxbA" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_OsB01o_HFU-glGSAsJFecw_8_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_UeFSHubWR0-gfstSw1eONw_8_22">1,198,860</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of warrants for consulting fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA" decimals="INF" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_8o4Z2mM-B0Cv-ZtXEA1eMw_10_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_IbCD42DC9UOZ74DAXLZn0A_10_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ" decimals="INF" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_rE8UNitYDkmoZKL3Zeu48A_10_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_YNvnFHUhPkWHgfjRLL6CVQ_10_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2GQFAY6UeEqXkOLT4ajRHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_JoHv1RwI-kmZ5aoGRU_apg_10_13">84,648</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_dPVmqepTmE6hEYumSC7-NA" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_RNdNO3PZmkK6xwmobIoGyQ_10_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CF3yESI8t0-Cw7te7xhxbA" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_M2XglFLA7EaXEjNOzi2u_g_10_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_t58oYTT_PEuKQXJdia8Ymw_10_22">84,648</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Issuance of common stock for consulting fees </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA" decimals="INF" format="ixt:numdotdecimal" name="snpx:WarrantsIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_YKfRk7WL3ECzRQltYL__7w_12_2">665</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_LK_Yxzu-fkGbaD31B1GTig_12_5">1</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ" decimals="INF" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_H0S2efcaHUG4Yyxh6sVTAQ_12_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ" decimals="0" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_mbkZT23xAUCl-xKBrcagyg_12_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2GQFAY6UeEqXkOLT4ajRHw" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_vjjLOvT2O0i3p4g4jIwYOQ_12_13">4,501</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_dPVmqepTmE6hEYumSC7-NA" decimals="0" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_fJvsY4BuFE2dJzUUursokQ_12_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CF3yESI8t0-Cw7te7xhxbA" decimals="0" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_09G5IAbo5EaeYxtERoVu1Q_12_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_ciQWe7r0hEyIyZr3ir-5Ng_12_22">4,502</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of common stock warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA" decimals="INF" format="ixt:numdotdecimal" name="snpx:StockIssuedDuringPeriodSharesWarrantExercises" scale="0" id="Tc_N55KddoH00S0WvxRQc5P3g_14_2">97,504</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA" decimals="0" format="ixt:numdotdecimal" name="snpx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_Hqj7MO7eEkOM0o3qCELXjg_14_5">10</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ" decimals="INF" format="ixt:zerodash" name="snpx:StockIssuedDuringPeriodSharesWarrantExercises" scale="0" id="Tc_z0NMhL4WokiofJuMXoAjCg_14_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ" decimals="0" format="ixt:zerodash" name="snpx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_kLbl23NxJUm25-Pbx3h-WA_14_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2GQFAY6UeEqXkOLT4ajRHw" decimals="0" format="ixt:numdotdecimal" name="snpx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_OSRqc9tva0i0Gn5iaI7tzQ_14_13">800,230</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_dPVmqepTmE6hEYumSC7-NA" decimals="0" format="ixt:zerodash" name="snpx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_S4kH-UToMkOnkU2Xkz_PRQ_14_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CF3yESI8t0-Cw7te7xhxbA" decimals="0" format="ixt:zerodash" name="snpx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_ak4hNrfP6USPcQrFRr41DQ_14_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw" decimals="0" format="ixt:numdotdecimal" name="snpx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_igW7fVZbAUqsVS7u35_hTg_14_22">800,240</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA" decimals="INF" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_We3AqDhEVU66-eFXiqblFA_16_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_7j7yVFxFSUmhuCVEEG1KqQ_16_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ" decimals="INF" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_JZQwo85k6EaGeu3ahdT4kA_16_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_eo0tV2k2iEy0RKVsfVvs8Q_16_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2GQFAY6UeEqXkOLT4ajRHw" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_ghnckDRUbE2xB0N1OWrmoA_16_13">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_dPVmqepTmE6hEYumSC7-NA" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_9YewsN5c0UOrW-L5Vqn61g_16_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CF3yESI8t0-Cw7te7xhxbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_R5sDs0URXUGH8cB2STpJbA_16_19">2,926,933</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_2dUktI9RPEiAi65MerGckg_16_22">2,926,933</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:26.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Balance September 30, 2021 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w2D7T-YOaEup8wjSL_aSZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_WTnH_7ozTEuZuE7MC4uQPg_18_2">6,136,967</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w2D7T-YOaEup8wjSL_aSZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_lLClw4GgcUyV9TCaKRFeyQ_18_5">615</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ugoS2seriU2HHmwKq25Lyg" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="Tc_aFF8c0DmI0C-SCuiXTG7Zg_18_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ugoS2seriU2HHmwKq25Lyg" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_sR3bBgMfTUe_SrW7ml17VQ_18_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__GkfWAubpE6DJAYWPvj1gA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_w14mmTfJaEaG8knY3a3BTA_18_13">41,256,323</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_5M6N4BgC0U-FB5io86IYSA" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_D9D8jUriREue4p-EXoMLvg_18_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jaPCkYCkeUON4gyi4G8yUw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_1b104nir0UO34e997wxwHA_18_19">9,905,625</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_-OaCv3neQ0uHU7QUIvQTDA_18_22">31,351,313</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ae1e8333_d17e_4d79_84c6_e298546b873c"></a><a id="Tc_BYWb3jKRS0OxHetCUIjLMw_1_2"></a><a id="Tc_efihVJnd1kOAq3ulHjEu5A_2_12"></a><a id="Tc_X-8b_Y40GUG5IzBmU6RWPw_2_15"></a><a id="Tc_D8xtPs_hm0CQu3fPgJSbWw_3_2"></a><a id="Tc__avf82sTBUCaQCiHvWasGQ_3_7"></a><a id="Tc_MKp-vjLijkm-U3k-aDZ4Kg_3_12"></a><a id="Tc_17dMLC_UPkeXUWaVCyyr6g_3_15"></a><a id="Tc_qB5eNKbg_E6gNOBqWEJT4A_3_18"></a><a id="Tc_BYu0v_YKEU6jMPAGkjlKAA_4_2"></a><a id="Tc_OaTyWf34JkS4fvphkZEP3w_4_4"></a><a id="Tc_zfraZG_HBES9zFL1XczCPA_4_7"></a><a id="Tc_zNSRFOEVDUGx_44xDiNBCA_4_9"></a><a id="Tc_c048VwSPGkeZ7LPjf4-Gsw_4_12"></a><a id="Tc_HFgAN_W6MEyFkduzSJVpgA_4_15"></a><a id="Tc_DMrX8EGJL0eMErxjRFtr3A_4_18"></a><a id="Tc_WktEVGNHdkCbx-ivE0xMVQ_4_21"></a><a id="Tc_VvqOSqxlGEK28PxyJc7OKQ_6_0"></a><a id="Tc_eS9A_TRPU0WQ1kL9SqIpZQ_6_4"></a><a id="Tc_cRBJjcqs3UyJrLSiP54OIg_6_9"></a><a id="Tc_c0lvGF7vh0KjhAm4hsZIyQ_6_12"></a><a id="Tc_tEBckIQxzE6RMri1cmDlmg_6_15"></a><a id="Tc_7_WnbWAkpEGnF73KInMBtQ_6_18"></a><a id="Tc_Sr9GzPadzEWRGdsiwlOzvw_6_21"></a><a id="Tc_kbcc31bEEU6sLZ8x89GyTA_8_0"></a><a id="Tc_nIOFpZ4EikKxz44j0pJoOQ_10_0"></a><a id="Tc_twqBa0D09Emq4HcIrnK7LA_12_0"></a><a id="Tc_lC3Iu_idAUq6pDk3wI8a0w_14_0"></a><a id="Tc_5s9REA6wLEuhvOejdUGs2w_16_0"></a><a id="Tc_so-z-6F7IkSO5fHfC8q3MA_18_0"></a><a id="Tc_k39YTviZAk6iQVXNlgvDaQ_20_0"></a><a id="Tc_SgXtemGlKE61kr8VlkMmTg_22_0"></a><a id="Tc_ZUbx0SpbfUO3jH0cDRkhAQ_22_4"></a><a id="Tc_Te1cp5kg5kGo_4sdhKoUeQ_22_9"></a><a id="Tc_DSl1PMc0bkSTNvCOEiLfGA_22_12"></a><a id="Tc_OshMKUEP6ku1BxxveIwzDw_22_15"></a><a id="Tc_SYjAcn_9z0KduPGFmbf5KA_22_18"></a><a id="Tc_EixnRjoo9EW0Y8jyDKdFLw_22_21"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="21" style="vertical-align:bottom;white-space:nowrap;width:71.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, 2021 </b></p></td></tr><tr><td style="vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Additional</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Parent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common&#160;Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Preferred&#160;Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Paid-In</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Company</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Accumulated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Balance January 1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TQgurJPz3022iUU8jDNU7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_4AalcYV8TESpdP92x2TFhw_6_2">1,257,579</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TQgurJPz3022iUU8jDNU7Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_paWnzDAPQEua76GCfO9foA_6_5">126</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Kh-IvwB8kUufVGx_81DRzg" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="Tc_y-uxyEaD3UmQrjXw9Uv8eA_6_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Kh-IvwB8kUufVGx_81DRzg" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_UPaex8gW9kqYCwAPx5F19w_6_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mydigcM49UWnKRDBJI3xHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_skck5aKq4kKHF9s3NVaLsw_6_13">6,668,859</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_f4snRmZeDkO06xUTfzJ97w" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ktzZ3kCh30epRqCdW4g9cg_6_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tJKcPCyeyUWqkuie4MqZSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_DrPeYdKcz0iE2tvFTaA3-A_6_19">1,530,473</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_yDLFcRzII0mTbC7Qh7NGtA_6_22">5,138,512</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Reverse stock split rounding </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" sign="-" scale="0" id="Tc_CbqqNPAYa0aeFhLHK7uYeQ_8_2">345</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="0" id="Tc_HV_1ThpbPE-l5-54QkCs2A_8_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" id="Tc_VZ2rp6PsME-Dz92WSeo0iQ_8_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="0" id="Tc_Y5c5ccPr6Eiu1fqd1hlN-g_8_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="0" id="Tc_LkY80XEI406ftxFeWe3GOw_8_13">1,529</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="0" id="Tc_ZWHCVbUdAEi3JCkYhtS0XQ_8_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="0" id="Tc_6O51UHSnzEmzHdnynoAlQA_8_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="0" id="Tc_BFV4RRqD7kKLXh2M0hwy3g_8_22">1,529</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Stock based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w" decimals="INF" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc__EDAMES0oUCX5pLtTCKJoQ_10_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_nGsTMIZkOkuxNcpF8G_WqQ_10_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw" decimals="INF" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_w6s-ycPvu0yNm-yyUl9qcQ_10_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_DTtdkSdhrUWFVkTeKwQxuQ_10_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_G62EIU4Eqkqh5F79vXg25w_10_13">1,918,651</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_WE2Tva0qKUuMScTUD9pHIw_10_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_0TZ0MNS1tEK2jLQp_f65_A_10_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_b-5W1wO7tUq-Z5enJBQYbg_10_22">1,918,651</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of warrants for consulting fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w" decimals="INF" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_w4XaFGKEpEKWysz1anNWxA_12_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_GE6heNvTekSmN_x8Rclc5w_12_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw" decimals="INF" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_YK42O5XUC0CrpoXWmdh6Cw_12_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_hyE-so0lbkWTq-UoB5tP-g_12_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_ovZVVcRwVkCkSX33-2aNhg_12_13">481,496</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_qm_CeRwh4Em1wQ2cvJbmaA_12_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_r216kGB2BUiKzaQNC6BNpg_12_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_xhtArfQf-0iroWSTYG_V3Q_12_22">481,496</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> Issuance of common stock for consulting fees </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w" decimals="INF" format="ixt:numdotdecimal" name="snpx:WarrantsIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_K14Cog78xk6rVSZb8qbTGw_14_2">3,255</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_RBBA_sqOik-lD9qn0Dx6mg_14_5">1</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw" decimals="INF" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_2wJHCbL2bEukjB_fNuVeJw_14_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw" decimals="0" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_gdX67HrnVUOMrbfK8E1Ywg_14_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_vsiw8t5KtEaP8U7zfbto9w_14_13">22,657</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ" decimals="0" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_CZ8FQ0MW9UWc6mNHW9YmTg_14_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q" decimals="0" format="ixt:zerodash" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_jVn9fjj8r0CtnrWH7UEVFA_14_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantsIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_pHNwHQORGkKC4vOsdxQONw_14_22">22,658</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> Private placements of common stock and warrants </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_ubcPDd3RUUminsfqVA-oCw_16_2">3,837,580</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_a_7sh4F98EyU6GEn0yj8VA_16_5">384</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_EGTr2HUezEi1PJHhSlGNlQ_16_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_ig_1EAs_GE6faRagk32W5A_16_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_-62bBfT5FEWUFROBlW4CDA_16_13">23,783,777</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_fggQF4E8vUuiC7WoXinz_g_16_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_EPykFfh5WE-JSyTNBaVVWQ_16_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_ssKHi25KNUemPbQ9L-tdKA_16_22">23,784,161</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> Exercise of common stock warrants </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w" decimals="INF" format="ixt:numdotdecimal" name="snpx:StockIssuedDuringPeriodSharesWarrantExercises" scale="0" id="Tc_22GLjS_qhE2iRtEhj8AF9g_18_2">1,038,898</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w" decimals="0" format="ixt:numdotdecimal" name="snpx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_gov4I1t4DUitQpTi801c6A_18_5">104</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw" decimals="INF" format="ixt:zerodash" name="snpx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_kIJziv4PeUO81VaBHShxew_18_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw" decimals="0" format="ixt:zerodash" name="snpx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_9FvzNymqpkKGeKmgE0T03w_18_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA" decimals="0" format="ixt:numdotdecimal" name="snpx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_yWcN8AkAYkqFkIPeDYM2wg_18_13">8,382,412</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ" decimals="0" format="ixt:zerodash" name="snpx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_fsorOJDlz0eni71eYq_d7g_18_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q" decimals="0" format="ixt:zerodash" name="snpx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_UuB5_DZ5v0SYZwvsF2qqZQ_18_19">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="snpx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_0vWuB1AGo0y1LBnphjk3GA_18_22">8,382,516</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w" decimals="INF" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_qxP3_DlGFEuvJtfGRy9DCg_20_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_-Ixmv0nMl0SXTvhJwKSPeg_20_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw" decimals="INF" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_eFUHbtm1UECZHTJ6TuOeJA_20_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_oIzHHnxD006h8_rB184l6A_20_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_I7A_vt5OKUao_JfT1vOPOA_20_13">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_ZLPAf1ZHfEaTKx_qG-dzHg_20_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_e_n5iX-pEkmLMDe0CKNeew_20_19">8,375,152</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_RDXuZaQS7UaUr4X2R_EWOw_20_22">8,375,152</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:27.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> Balance September 30, 2021 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w2D7T-YOaEup8wjSL_aSZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_WC-VdeEQ80WmlvaVOrRlDw_22_2">6,136,967</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w2D7T-YOaEup8wjSL_aSZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_IAtIuYAbl0G7VXoxAqVtSw_22_5">615</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ugoS2seriU2HHmwKq25Lyg" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="Tc_N4B4FR91CkCCMfU8e2H1gA_22_7">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ugoS2seriU2HHmwKq25Lyg" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_TFDH0L0dok2pu5FNdbb-yQ_22_10">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__GkfWAubpE6DJAYWPvj1gA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_HnN7R-nsuE20q0FsE3FnLA_22_13">41,256,323</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_5M6N4BgC0U-FB5io86IYSA" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_DXWgwEpfu06GlmtTTPkC3Q_22_16">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jaPCkYCkeUON4gyi4G8yUw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Ci9Q_c6Tn0eT74nKJh6MyA_22_19">9,905,625</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_f5fQmhp3wkahTo1FLV0eEQ_22_22">31,351,313</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><b style="color:#212529;font-weight:bold;">See accompanying notes to condensed financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_02f62da9_8792_4848_b4de_15e647ef1f96"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Synaptogenix,&#160;Inc.</b></p><a id="CashFlows_386858"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">Condensed Statements of Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><a id="_110043ba_882c_4ff7_8a16_66c4d3d3b529"></a><a id="Tc_rytWmdj6akKmrDrSxMDg9Q_1_2"></a><a id="Tc_ChFk0ZEvqECiQ0EpV_y9SQ_1_5"></a><a id="Tc_LpHMrcoGSUmkAF-qP58ZOg_2_2"></a><a id="Tc_8M1YF3gJZ0CRbJwzgeNL0A_2_5"></a><a id="Tc_z-r8oUhX-k-2dshIX3WJnw_3_0"></a><a id="Tc_UKWSJxas1kKnljQ5uBLLEg_4_0"></a><a id="Tc_Haj0yhlDWUqcP_UESd59hQ_4_2"></a><a id="Tc_Z7qx3F7PhEaISJHmhHr5DA_4_5"></a><a id="Tc_1nsuQCehEUySJoAhUUSD1Q_5_0"></a><a id="Tc_QcNNnd718EOohEnovnmLpw_6_0"></a><a id="Tc_pHxAP8E_ok29kQJRqnnzYw_7_0"></a><a id="Tc_yvNTy97iAkeiJ2Eyzk5wdg_7_3"></a><a id="Tc_-L45yIk8cESSOZIPAimu5A_8_0"></a><a id="Tc_FiXfUH1MHEST-kgJHhpsbQ_8_6"></a><a id="Tc_teQIYNbmD0GNHE5V_ms6vQ_9_0"></a><a id="Tc_dBy3W4YVvUWJh0j8veBHIg_9_6"></a><a id="Tc_g3Zads7APk-QIIv_UUWPUQ_10_0"></a><a id="Tc_W5Exj4lQ2EWD_AQOOfd2_w_10_6"></a><a id="Tc_DvvAQIQ34E-Gd6ntUYnjgw_11_0"></a><a id="Tc_Dd2nx3Wv3UCRMQY5ng3XGw_11_3"></a><a id="Tc_ncA2QuzsQEWtqG7_unRf1Q_12_0"></a><a id="Tc_l4onK-JvY0yPw9r1vh-zfA_12_3"></a><a id="Tc_RJ_zWrO0Dki8h41EzFGhjQ_13_0"></a><a id="Tc_VBj8vO0cH0GPB7niS28bVg_13_3"></a><a id="Tc_8wK8bVlK5UquiuSwkW2c3g_14_0"></a><a id="Tc_P-srrqJNyUeQxao62d00eg_15_0"></a><a id="Tc_V-47m6JMqk6Y4qstwjJoXw_16_0"></a><a id="Tc_5V4VRpbWBU-peGsQKdqdrg_17_0"></a><a id="Tc_w7ummsemUky41AT75KqiAg_18_0"></a><a id="Tc__H60Z8eoAUqC1GyJj__0og_19_0"></a><a id="Tc_5QoJryWJfEOecalMMfET5Q_20_0"></a><a id="Tc_vKL8NA81MUa-S7PegEkGDg_22_0"></a><a id="Tc_FH20gINIA0Krwz0A55ZrCQ_24_0"></a><a id="Tc_8K8v8X1am06NKRqflZ-grw_25_0"></a><a id="Tc_6tYMjnCPnkO_wbEyy8nfTA_25_3"></a><a id="Tc_L_iop8FXkki7koAN_9M73w_27_0"></a><a id="Tc_Ylsf4_yP-keKRW3rxA7Plg_27_3"></a><a id="Tc_y_OoibzJX0uXcxjdTd58rg_29_0"></a><a id="Tc_9pUdoiKj70GsJ9xgDV_qjg_30_0"></a><a id="Tc_yJoMX_UzZkSki8uaploONA_30_6"></a><a id="Tc_LsSisWNS2EaR_PidxwUe7Q_31_0"></a><a id="Tc_qZb72rF9XEuq4T2b0E-9JQ_31_6"></a><a id="Tc_LepBFx49ukSr3M0ZhH4udg_32_0"></a><a id="Tc_aCgIbsoDRkWkRdPQrFspLQ_32_6"></a><a id="Tc_ohGkpjwWu0eOSfozYAxZWQ_33_0"></a><a id="Tc_hDJFyPvCVEGBmioVC3EBuQ_33_3"></a><a id="Tc_lK5TrkqsfkG1kegYV50JYQ_35_0"></a><a id="Tc_Oovs4l11FkODMRteqEq1tg_37_0"></a><a id="Tc_Y2_qNI5yRUup78uduW9-uQ_39_0"></a><a id="Tc_pGZdY2-MI0K4OGIm3Npf6w_41_0"></a><a id="Tc_hwZ51_UuIE2gUAnd7qferQ_41_2"></a><a id="Tc_S9wAuwYgeEGnQXUPKEOfoA_41_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CASH FLOW USED IN OPERATING ACTIVITIES</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_a488sLG1GE-5Q62dI6jbbw_4_3">8,375,152</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_jF-rEqYWWECoMyZTlrAaxA_4_6">9,739,079</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Adjustments to reconcile net loss to net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">cash used by operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Parent company stock based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation" scale="0" id="Tc_6aEZk6HO2UWi_U7UMXqPYg_7_6">1,449,023</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" id="Tc_4ZV3GOA48EmHmaq9h-wcIg_8_3">1,918,651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Consulting services paid by issuance of common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" id="Tc_Hn4s3Hlf70-Umd0pCPaIaQ_9_3">22,657</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Consulting services paid by issuance of common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="snpx:IssuanceOfStockAndWarrantsForServices" scale="0" id="Tc_-ECRtGF-9E2OMJp3ePSSGA_10_3">481,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Consulting services paid by issuance of Parent company common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="snpx:ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock" scale="0" id="Tc_Witpuycq8kGweCstjoX1eg_11_6">120,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Consulting services paid by issuance of Parent company common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="snpx:ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants" scale="0" id="Tc_pc5UzZ8hv0ieQpWANYWNUQ_12_6">380,740</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Warrant amendment expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="snpx:WarrantAmendmentExpense" scale="0" id="Tc_KHTZUBV1GEmUSqSRPb7RIw_13_6">1,700,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_U11TJLVmxUaU1R3sOeFs3w_14_3">3,727</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_iCXeH3iMo02ypoN-b200yw_14_6">3,638</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Change in assets and liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30pt;">Decrease (Increase) in grant receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="snpx:IncreaseDecreaseInGrantReceivableCurrent" sign="-" scale="0" id="Tc_3E9XxZb40UGjCCoWTD6sow_16_3">127,445</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="snpx:IncreaseDecreaseInGrantReceivableCurrent" scale="0" id="Tc_Ou2SXqn5x0SEuAmycjVn5A_16_6">861,852</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30pt;">Increase in prepaid expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="Tc_GxlPsNYxuU-6xNJwKUW-7A_17_3">239,223</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="Tc_nMbW8kyRvEOEaaLXSAcflA_17_6">770,609</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30pt;">(Decrease) increase in accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="0" id="Tc_LipWqi2x60yUDo_qlhcQ_w_18_3">324,959</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_5zeNRfOxn0O_U0uo9vWErA_18_6">777,204</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30pt;">(Decrease) increase in accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_cBDPLhUIA0GnlcFSMahoiA_19_3">280,200</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_dsLn9N7s8EWBesQRFQr1vg_19_6">44,184</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Total adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="0" id="Tc_sfWFs2ASB0GUHbesOCPVng_20_3">1,709,594</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="0" id="Tc_8ob6nYJP4E6Vh4wEdnDw0g_20_6">2,842,328</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Net Cash Used in Operating Activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_tD7lOHQxlkO3nmDFPoZibg_22_3">6,665,558</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_srAqDwFqhUaMjFzNQwd5zA_22_6">6,896,751</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CASH FLOWS USED IN INVESTING ACTIVITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Purchase of fixed assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_FpMmoP42VkOM7r9t5ZpKBw_25_6">5,413</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 30pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Net Cash Used in Investing Activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_XFBcgPi91EmutLIwzPSBrg_27_6">5,413</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Private placements of common stock and warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" id="Tc_jWjUPeLgJESgHohP2aepNg_30_3">23,784,161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from exercise of investor warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Tc_H2aGDwePbkyzwqkTrQK6QQ_31_3">8,382,516</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash in lieu of shares for reverse stock split</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="snpx:PaymentsInLieuSharesForReverseStockSplit" scale="0" id="Tc_lGDkZpH5jUKucZpqd4qDLg_32_3">1,529</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net transfer from parent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="snpx:NetTransferFromToParent" scale="0" id="Tc_Qo0fzLYEY0iWGA-T4jk8iw_33_6">16,519,988</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Net Cash Provided by Financing Activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_tZy9rLtmCECMBxYdhYY76A_35_3">32,165,148</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_l56QaQEIpECeFWjC2wHaUA_35_6">16,519,988</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NET INCREASE IN CASH AND EQUIVALENTS</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" id="Tc_Y9CaAimmXUG48BeobS-x_g_37_3">25,499,590</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" id="Tc_vxJPIkDzsEGq0AvwzkZq0g_37_6">9,617,824</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CASH AND EQUIVALENTS AT BEGINNING OF PERIOD</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_fZ3Gzecq5kSOrSpmkJr46g_39_3">5,795,055</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2019_97X_EvVSLEObXZUCOmP-LA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_vb0MPnp_tEuQmFzthawJAA_39_6">17,382,038</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CASH AND EQUIVALENTS AT END OF PERIOD</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_w9GaA3DcUU2GZ_dpW4kCLA_41_3">31,294,645</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2020_GzKIkZ8knECSIuc2D4qCoQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_M_16orkZd0C3WLZ7wWCudA_41_6">26,999,862</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">See accompanying notes to condensed financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_63f7f396_3cac_4362_aebb_32f513a0295f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">SYNAPTOGENIX,&#160;INC.</p><a id="NOTESTOCONDENSEDFINANCIALSTATEMENTS_3081"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">NOTES&#160;TO CONDENSED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">(UNAUDITED)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Unless the context otherwise indicates, references in these Notes&#160;to the accompanying financial statements to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and &#8220;the Company&#8221; refer to Synaptogenix,&#160;Inc. (formerly known as Neurotrope Bioscience,&#160;Inc.), a Delaware corporation. References to &#8220;Neurotrope&#8221;, &#8220;Parent Company&#8221; or &#8220;Parent&#8221; refer to Neurotrope,&#160;Inc., a Nevada corporation.</i></p><a id="_2ee3f7b1_d67d_4fc4_9a82_a02110dacf74"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:NatureOfOperations" id="Tb_DiYzJCYk5USqadnHK4n1jA" continuedAt="Tb_DiYzJCYk5USqadnHK4n1jA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;1&#160;&#8211; Organization, Business, Risks and Uncertainties:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Organization and Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On May 17, 2020, Neurotrope, Inc. (&#8220;Neurotrope&#8221; or &#8220;the Parent&#8221;) announced plans for the complete legal and structural separation of its wholly owned subsidiary, Neurotrope Bioscience, Inc., from Neurotrope (the &#8220;Spin-Off&#8221;). Under the Separation and Distribution Agreement, Neurotrope planned to distribute all of its equity interest in this wholly owned subsidiary to Neurotrope&#8217;s stockholders. Following the Spin-Off, Neurotrope does not own any equity interest in the Company, and we operate independently from Neurotrope. On December 7, 2020 we became an independent company, Synaptogenix, Inc., a Delaware corporation (formerly known as Neurotrope Bioscience, Inc.) (the &#8220;Company&#8221; or &#8220;Synaptogenix&#8221;) as the Company amended and restated their certificate of incorporation which, among other things, changed its name to Synaptogenix, Inc. Our shares of common stock are listed on The Nasdaq Capital Market under the symbol &#8220;SNPX.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Neurotrope Bioscience,&#160;Inc. was incorporated in Delaware on October&#160;31, 2012 to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer&#8217;s disease (&#8220;AD&#8221;).&#160;The Company&#160;is collaborating with Cognitive Research Enterprises,&#160;Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (&#8220;CRE&#8221;), a related party, in this process. The exclusive rights to certain technology were licensed by CRE to the Company on February&#160;28, 2013 (see Note&#160;4 - Related Party Transactions and Licensing / Research Agreements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the separation from Neurotrope, we entered into a Separation and Distribution Agreement and several other ancillary agreements. These agreements govern the relationship between the parties after the separation and allocate between the parties various assets, liabilities, rights and obligations following the separation, including employee benefits, intellectual property, information technology, insurance and tax-related liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Spin-Off </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;1, 2020, Neurotrope, and Petros Pharmaceuticals,&#160;Inc., a Delaware corporation (&#8220;Petros&#8221;) and formerly Metuchen Pharmaceuticals LLC, consummated their reverse merger transactions (the &#8220;Mergers&#8221;) contemplated by a certain Agreement and Plan of Merger dated as of May&#160;17, 2020 (the &#8220; Merger Agreement&#8221;), as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As a condition to the Mergers, Neurotrope approved a transaction (the &#8220;Spin-Off&#8221;), which became effective on December&#160;7, 2020, whereby (i)&#160;any cash in excess of $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow" decimals="0" format="ixt:numdotdecimal" name="snpx:ExcessOfCashInOperatingAssetsAndLiabilities" scale="0" id="Narr_fGMw1Z8ETkCZ12cHQH13sw">20,000,000</ix:nonFraction>, subject to adjustment as provided in the Merger Agreement, and all of the operating assets and liabilities of Neurotrope not retained by Neurotrope in connection with the Mergers were contributed to Neurotrope Bioscience,&#160;Inc., and (ii)&#160;holders of record of Neurotrope common stock, Neurotrope preferred stock and certain warrants that were not amended and restated as of the Spin-Off Record Date received a pro rata distribution at the rate of (i)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfSharesForEveryFiveCommonSharesHeld" scale="0" id="Narr_PdQ6cR6PhkuoKxvhrwHxhA">one</ix:nonFraction> share of Synaptogenix,&#160;Inc. common stock for every five shares of Neurotrope common stock held, (ii)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld" scale="0" id="Narr_1b1n67WMS0ixILfEiKQp1Q">one</ix:nonFraction> share of Synaptogenix common stock for every five shares of Neurotrope common stock issuable upon conversion of Neurotrope preferred stock held and (iii)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld" scale="0" id="Narr_76nNby_W8UW7T-NJNkt1TQ">one</ix:nonFraction> share of Synaptogenix,&#160;Inc. common stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held that were entitled to participate in the Spin-Off pursuant to the terms thereof (collectively, the &#8220;Distribution&#8221;). Any fractional shares were paid in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The holders of Neurotrope&#8217;s amended and restated warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_TbAPyGkGaEeK9Oja__ggTA">4,889,158</ix:nonFraction> shares of Neurotrope common stock (the &#8220;A&amp;R Warrants&#8221;) received <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_12_7_2020_To_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_ARQKCYx9ckaXd0ahx6smkQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" id="Narr_iqQXvOeMIUaRYhF4ofz9yQ">977,831</ix:nonFraction> warrants to purchase shares of Synaptogenix common stock upon the exercise of such A&amp;R Warrants held as of the Spin-Off Record Date (collectively, the &#8220;Spin-Off Warrants&#8221;). All the warrants have <ix:nonNumeric contextRef="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_jd54OHmR_E6NThQk2tHrUQ">five year</ix:nonNumeric> terms from December&#160;2, 2020. See Note 8 &#8211; Common Stock Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_DiYzJCYk5USqadnHK4n1jA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of September&#160;30, 2021, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_1945ShTbYkudinhLhhk3FA">31.3</ix:nonFraction> million in cash and cash equivalents as compared to $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_lMOyledOJkSikrG53YidfA">5.8</ix:nonFraction> million at December&#160;31, 2020. The Company expects that its current cash and cash equivalents, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="-6" format="ixt:numdotdecimal" name="snpx:CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate" scale="6" id="Narr_YtB_y7KrFE29yr-TO8H_7A">35</ix:nonFraction> million as of the date of this quarterly report, which includes cash received during October and November, 2021 of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_10_1_2021_To_11_30_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eDY3684nJE-p7S0A8UmC-g" decimals="-6" format="ixt:numdotdecimal" name="snpx:ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses" scale="6" id="Narr_dbLoyapv5kSoXysU4JsblA">5</ix:nonFraction> million from the exercise of investor warrants of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_10_1_2021_To_11_30_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eDY3684nJE-p7S0A8UmC-g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_JNPqQ9s_l0KJcJzApNJo4Q">4.5</ix:nonFraction> million plus reimbursement of trial expenses of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_10_1_2021_To_11_30_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_exdHd3zzYkWzxHQw70jWQw" decimals="0" format="ixt:numdotdecimal" name="snpx:AmountOfFundingReceived" scale="0" id="Narr_BJr5kLtwZUKjRSS_PyaGKw">530,000</ix:nonFraction> from the NIH, will be sufficient to support its projected operating requirements for at least the next 12 months from this date. The operating requirements include the current development plan for Bryostatin-1, our novel drug targeting the activation of PKC epsilon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company expects to need additional capital in order to initiate and pursue potential additional development projects, including the continuing development beyond the current Phase 2 trial.&#160;Any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company&#8217;s current stockholders and debt financing, if available, may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its technologies or product candidates that the Company would otherwise seek to develop or commercialize on its own, on terms that are not favorable to the Company. The Company&#8217;s ability to access capital when needed is not assured and, if not achieved on a timely basis, will likely have a materially adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Other Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company operates in an industry that is subject to rapid technological change, intense competition, and significant government regulation. The Company&#8217;s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the limited supply of raw materials, the ability to obtain favorable licensing, manufacturing or other agreements, including risk associated with our CRE licensing agreement, and the ability to raise capital to achieve strategic objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">CRE has entered into a material transfer agreement with the National Cancer Institute of the National Institutes of Health (&#8220;NCI&#8221;), pursuant to which the NCI has agreed to supply bryostatin required for the Company&#8217;s pre-clinical research and clinical trials. This agreement does not provide for a sufficient amount of bryostatin to support the completion of all of the clinical trials that the Company is required to conduct in order to seek U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval. Therefore, CRE or the Company would have to enter into one or more subsequent agreements with the NCI for the supply of additional amounts of bryostatin. If CRE or the Company were unable to secure such additional agreements, or if the NCI otherwise discontinues the supply, the Company would have to either secure another source of bryostatin or discontinue its efforts to develop and commercialize bryostatin for the treatment of AD. In June&#160;2020, the Company entered into a supply agreement (the &#8220;Supply Agreement&#8221;) with BryoLogyx Inc. (&#8220;BryoLogyx&#8221;), pursuant to which BryoLogyx agreed to be the Company&#8217;s exclusive supplier of synthetic Bryostatin-1. Pursuant to the terms of the Supply Agreement, the Company received its initial order of one gram synthetic Bryostatin-1. See Note 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company also faces the ongoing risk that the coronavirus pandemic may slow, for an unforeseeable period, the conduct of the Company&#8217;s trial. In order to prioritize patient health and that of the investigators at clinical trial sites, we will monitor enrollment of new patients in our current Phase 2 clinical trial. In addition, some patients may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services. These and other factors outside of our control could delay our ability to conduct clinical trials or release clinical trial results. In addition, the effects of a pandemic resurgence may also increase non-trial costs such as insurance premiums, increase the demand for and cost of capital, increase loss of work time from key personnel, and negatively impact our key clinical trial vendors and suppliers.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb__awmc5riPkKxAxbzHT-xDQ" continuedAt="Tb__awmc5riPkKxAxbzHT-xDQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;2&#160;&#8211; Summary of Significant Accounting Policies:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_DLVV8MCOBk2D78CIRnf7Gg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Subsequent to the Spin-Off, the Company&#8217;s financial statements as of December 31, 2020 and for the period December 7, 2020 to December 31, 2020 are presented on a consolidated basis as the Company became a standalone public company on December 7, 2020. The Company&#8217;s combined financial statements for the period from January 1, 2020 through December 6, 2020 that is included in the results of operations for the three and nine months ending September 30, 2020 and the year ended December 31, 2020 were derived from the consolidated financial statements and accounting records of Neurotrope, the former Parent. These combined financial statements reflect the historical results of operations, financial position and cash flows of the former Parent&#8217;s Spin-Off business which was a wholly owned subsidiary of Neurotrope, Neurotrope Bioscience, Inc., and represented substantially all the business of Neurotrope. These financial statements reflect our financial position, results of operations and cash flows as we were historically managed, in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">All intercompany transactions between the Company and Neurotrope have been included in our financial statements and are considered to be effectively settled for cash at the time the Spin-Off was recorded. The total net effect of the settlement of these intercompany transactions is reflected in our statements of cash flow as a financing activity and in the balance sheets as &#8220;Parent company investment&#8221;. See Note 9.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the unaudited condensed financial statements included herein contain all adjustments necessary to present fairly the Company&#8217;s financial position and the results of its operations and cash flows for the interim periods presented. Such adjustments are of a normal recurring nature. The results of operations for the three and nine months ended September 30, 2021 may not be indicative of results for the full year. These unaudited condensed financial statements should be read in conjunction with the audited condensed financial statements and the notes to those statements for the year ended December 31, 2020 included in our Annual Report on Form 10-K.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:UseOfEstimates" id="Tb_OXKYknxGzEiHOkcAWNhEZQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make significant estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the general economic environment and actions it may take in the future. The Company adjusts such estimates when facts and circumstances dictate. However, these estimates may involve significant uncertainties and judgments and cannot be determined with precision. In addition, these estimates are based on management&#8217;s best judgment at a point in time and as such these estimates may ultimately differ from actual results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="snpx:CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock" id="Tb_z72IbDZdMEeurvtfizg2PA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents and Concentration of Credit Risk:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company considers all highly liquid cash investments with an original maturity of three months or less when purchased to be cash equivalents. At September 30, 2021, the Company&#8217;s cash balances that exceed the current insured amounts under the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashFDICInsuredAmount" scale="6" id="Narr_YBpzuDmG00ui3HnJlEaOIw">3.6</ix:nonFraction> million. In addition, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="6" id="Narr_F6iMTy_Ez0GH3b0hGk1erg">27.7</ix:nonFraction> million included in cash and cash equivalents were invested in a money market fund, which is not insured under the FDIC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_QmRr475FxkaBk7Lg-M-mVQ" continuedAt="Tb_QmRr475FxkaBk7Lg-M-mVQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fixed Assets and Leases:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">All leases with a lease term greater than 12 months, regardless of lease type classification, are recorded as an obligation on the balance sheet with a corresponding right-of-use asset. The Company does not have any leases greater than 12 months in duration during the respective reporting periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Fixed assets are stated at cost less accumulated depreciation. Depreciation is computed on a straight line basis over the estimated useful life of the asset, which is deemed to be between <span style="-sec-ix-hidden:Hidden_lr9X8jg5jUiA4B9EE7n2ZA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">three</span></span> and <ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_Qj_fG9oUqUuK8DNTHXfAoQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_TRQw-C0j8E-ilgXqrACY3A">ten years</ix:nonNumeric>.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb__awmc5riPkKxAxbzHT-xDQ_cont1" continuedAt="Tb__awmc5riPkKxAxbzHT-xDQ_cont2"><ix:continuation id="Tb_QmRr475FxkaBk7Lg-M-mVQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_hTc2KKjqdEalzO1iCq51SA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Research and Development Costs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">All research and development costs, including costs to maintain or expand the Company&#8217;s patent portfolio licensed from CRE are expensed when incurred. Non-refundable advance payments for research and development are capitalized because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt-sec:numwordsen" name="snpx:CapitalizedResearchAndDevelopmentServices" scale="0" id="Narr_ZyAdTJWEuEyNGXa-KVZnGw"><ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt-sec:numwordsen" name="snpx:CapitalizedResearchAndDevelopmentServices" scale="0" id="Narr_eMudoguEzEOj_VmbBs2tgA">no</ix:nonFraction></ix:nonFraction> capitalized research and development services at September&#160;30, 2021 and December&#160;31, 2020.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_KtxRf-zXyUON230bOfMh0w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss Per Share of Common Stock:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On the Spin Off date, <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_11_30_2020_To_11_30_2020_us-gaap_RelatedPartyTransactionAxis_snpx_CurrentShareholdersOfCompanyMember_M1g-SpCvMkOthGYObm_VUw" decimals="INF" format="ixt:numdotdecimal" name="snpx:IssueOfSharesOnSpinOff" scale="0" id="Narr_UYLnwKlhOEaYqxJKASXunQ">1,257,579</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_11_30_2020_us-gaap_RelatedPartyTransactionAxis_snpx_CurrentShareholdersOfCompanyMember_XXkmy-IesU2Cqs0foH1_cQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_zX4Lih5IkkyXetQLDFYrHQ">0.0001</ix:nonFraction> per share (the Common Stock&#8221;) were distributed to Neurotrope stockholders as of November 30, 2020 (the &#8220;Record Date&#8221;). This share amount was being utilized for the calculation of basic earnings (loss) per share (&#8220;EPS&#8221;) for the periods prior to the Spin-Off because the Company was a wholly-owned subsidiary of Neurotrope prior to the Spin Off date. For the periods after the Spin-Off Date, EPS attributable to the Company&#8217;s common stockholders is based upon net income (loss) attributable to the Company&#8217;s common stockholders divided by the weighted-average number of Common Stock outstanding during the period. Penny warrants were included in the calculation of outstanding shares for purposes of basic loss per share. For the periods when a net loss is reported, the computation of diluted EPS equals the basic EPS calculation since common stock equivalents were antidilutive due to losses from continuing operations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_s1n64ErT_kOB9JK5JgEfAA" continuedAt="Tb_s1n64ErT_kOB9JK5JgEfAA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Income Taxes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company accounts for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes under the &#8220;Separate return method.&#8221; Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company applies the provisions of FASB ASC 740-10, <i style="font-style:italic;">Accounting for Uncertain Tax Positions</i>, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also provides guidance on de-recognition, classification, interest and penalties, and accounting in interim periods, disclosure and transitions. The Company has determined that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is generally three&#160;years from the date of filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company (collectively with Neurotrope, Inc. / Petros Pharmaceuticals, Inc.) may be subject to significant U.S. federal income tax-related liabilities with respect to our prior distribution of all of the issued and outstanding shares of the common stock of Neurotrope Bioscience, Inc., the former subsidiary of Neurotrope, to our stockholders as of and on November 30, 2020 (the &#8220;Spin-Off&#8221;), if there is a determination that the Spin-Off is taxable for U.S. federal income tax purposes. In connection with the Spin-Off, the Company believes substantially to the effect that, among other things, the Spin-Off should qualify as a tax-free transaction for U.S. federal income tax purposes under Section 355 and Section 368(a)(1)(D) of the Code. If the conclusions of the tax opinions are not correct, or if the Spin-Off is otherwise ultimately determined to be a taxable transaction, the Company would be liable for U.S. federal income tax related liabilities. Pursuant to the Separation and Distribution Agreement and the Tax Matters Agreement, Neurotrope agreed to indemnify Synaptogenix for certain liabilities, and Synaptogenix agreed to indemnify Neurotrope for certain liabilities, in each case for uncapped amounts. Indemnities that Synaptogenix may be required to provide Neurotrope are not subject to any cap, may be significant and could negatively impact Synaptogenix&#8217;s business, particularly with respect to indemnities provided in the Tax Matters Agreement. Third parties could also seek to hold Synaptogenix responsible for any of the liabilities that Neurotrope has agreed to retain. Further, the indemnity from Neurotrope may not be sufficient to protect Synaptogenix against the full amount of such liabilities, and Neurotrope may not be able to fully satisfy its indemnification obligations. Moreover, even if Synaptogenix ultimately succeeds in recovering from Neurotrope any amounts for which Synaptogenix is held liable, Synaptogenix may be temporarily required to bear these losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb__awmc5riPkKxAxbzHT-xDQ_cont2"><ix:continuation id="Tb_s1n64ErT_kOB9JK5JgEfAA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under Section 382 of the Internal Revenue Code of 1986, as amended, changes in the Company&#8217;s ownership may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. In addition, the significant historical operating losses incurred by the Company may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. The Company believes that operating loss carryforwards are limited under Section 382 limitations although Section 382 studies have not been conducted to determine the actual limitations.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="snpx:ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock" id="Tb_26dSeUvvY0a8Fj7X3a0cRg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Expense Reimbursement for Grant Award:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company reduces its research and development expenses by funding received or receivable from an NIH grant during the period that the expenses are incurred. The Company recognized grant related expense reductions during the three and nine months ended September 30, 2021 of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="6" id="Narr_0UwtsiHtcUuyNHQZZfPSkA"><ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="6" id="Narr_cGOevsKOZEi0TK58j5XcjA">1.1</ix:nonFraction></ix:nonFraction> million. See Note 5, &#8220;<i style="font-style:italic;">Clinical Trial Services Agreements</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Of the total $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_fxANfnDJfkq-DjAu241ovA" decimals="-5" format="ixt:numdotdecimal" name="snpx:AmountOfAwardReceived" scale="6" id="Narr_LG7Cmrv7bEOXJDi-EixJlg">2.7</ix:nonFraction> million available from the NIH grant, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_rlr4KPaCbkyP11bzHs4H5A" decimals="-5" format="ixt:numdotdecimal" name="snpx:AmountOfFundingReceived" scale="6" id="Narr_bAwXXfu0EUCqwYFDZoUOaw">2.6</ix:nonFraction> million was received for trial-related expenses incurred since grant inception to October&#160;31, 2021 with the remaining $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_3_31_2022_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_OpMJCHhLC0ywEnxoJd5pzA" decimals="-5" format="ixt:numdotdecimal" name="snpx:AmountOfFundingReceivable" scale="6" id="Narr_onrRdGJYY0qnW4NMARwxow">0.1</ix:nonFraction> million available for reimbursement during the period November&#160;2021 to March&#160;2022. The Company believes it will receive the maximum reimbursements under the grant.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_AYR93thk1UCZqqfW778UXw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">&#160;In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, which reduces the number of accounting models for convertible instruments, amends diluted earnings per share calculations for convertible instruments and allows more contracts to qualify for equity classification. ASU 2020-06 will be effective for interim and annual periods beginning after December 15, 2021. Early adoption is permitted. The Company is evaluating the adoption of ASU 2020-06.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="snpx:CollaborativeAgreementsAndCommitmentsTextBlock" id="Tb_-tKUmADv806W1ShvibSV-w" continuedAt="Tb_-tKUmADv806W1ShvibSV-w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note&#160;3&#8211; Collaborative</b> <b style="font-weight:bold;">Agreements and Commitments:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:8pt;font-weight:normal;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stanford License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On May&#160;12, 2014, the Company entered into a license agreement (the &#8220;Stanford Agreement&#8221;) with The Board of Trustees of The Leland Stanford Junior University (&#8220;Stanford&#8221;), pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as &#8220;bryologs,&#8221; for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents. The Company is required to use commercially reasonable efforts to develop, manufacture and sell products (&#8220;Licensed Products&#8221;) in the Licensed Field of Use (as defined) during the term of the licensing agreement which expires upon the termination of the last valid claim of any licensed patent under this agreement. In addition, the Company must meet specific diligence milestones, and upon meeting such milestones, make specific milestone payments to Stanford. The Company must also pay Stanford royalties&#160;of <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_StandFordLicenseAgreementMember_LrA02ttJr0Skelb_psotsQ" decimals="2" format="ixt:numdotdecimal" name="snpx:RoyaltyPaymentPercentage" scale="-2" id="Narr_4CEQirHd_UKXCdKyw0oZRg">3</ix:nonFraction>% of net sales, if any, of Licensed Products (as defined) and milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_StandFordLicenseAgreementMember_LrA02ttJr0Skelb_psotsQ" decimals="-5" format="ixt:numdotdecimal" name="snpx:MilestonePaymentsPaid" scale="6" id="Narr_uhKUBjbJh0CvqJW67eykuQ">3.7</ix:nonFraction> million dependent upon stage of product development. As of September 30, 2021, <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_StandFordLicenseAgreementMember_LrA02ttJr0Skelb_psotsQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PaymentsForRoyalties" scale="0" id="Narr_1fVpqGa5N0CDbwPrBCaojQ">no</ix:nonFraction> royalties nor milestone payments have been required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On January&#160;19, 2017, the Company entered into an additional, second license agreement with Stanford, pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of &#8220;Bryostatin Compounds and Methods of Preparing the Same,&#8221; or synthesized bryostatin, for use in the treatment of neurological diseases, cognitive dysfunction and psychiatric disorders, for the life of the licensed patents. The Company paid Stanford $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_19_2017_To_1_19_2017_srt_ProductOrServiceAxis_us-gaap_LicenseMember_QAFY1ZmrLkORAEkzbODSjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="Narr_UOTOwpub80uzxWUzPXADUw">70,000</ix:nonFraction> upon executing the license and is obligated to pay an additional $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_19_2017_To_1_19_2017_RyYqzdEgTkmLuudVtZapew" decimals="0" format="ixt:numdotdecimal" name="snpx:AnnualLicenseMaintenanceFee" scale="0" id="Narr_KQ3Tvn5OUUm6ixx5Lg8dhg">10,000</ix:nonFraction> annually as a license maintenance fee. In addition, based upon certain milestones which include product development and commercialization, the Company is required to pay up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_19_2017_To_1_19_2017_RyYqzdEgTkmLuudVtZapew" decimals="-5" format="ixt:numdotdecimal" name="snpx:CommitmentToPayFees" scale="6" id="Narr_MWY55MrWaU6mrbJuNDZYnA">2.1</ix:nonFraction> million and between <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_19_2017_To_1_19_2017_srt_RangeAxis_srt_MinimumMember_byQy3JDAGkCSL09nDP4uAQ" decimals="3" format="ixt:numdotdecimal" name="snpx:RoyaltyPaymentPercentage" scale="-2" id="Narr_0IziVjvTg0Wtv6BSJhdBCg">1.5</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_19_2017_To_1_19_2017_srt_RangeAxis_srt_MaximumMember_9oZ5nMAmCE-LtGzgYi_y-A" decimals="3" format="ixt:numdotdecimal" name="snpx:RoyaltyPaymentPercentage" scale="-2" id="Narr_lhJZHbji5kyBEcMCJVENMA">4.5</ix:nonFraction>% royalty payments on certain revenues generated by the Company relating to the licensed technology. The Company has made all required annual maintenance payments. As of September 30, 2021, <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_StandFordLicenseAgreementMember_LrA02ttJr0Skelb_psotsQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PaymentsForRoyalties" scale="0" id="Narr_pdFIdOkY10uzNcgpMEgNig">no</ix:nonFraction> royalties nor milestone payments have been required.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-tKUmADv806W1ShvibSV-w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Mt. Sinai License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On July&#160;14, 2014, the Company entered into an Exclusive License Agreement (the &#8220;Mount Sinai Agreement&#8221;) with the Icahn School of Medicine at Mount Sinai (&#8220;Mount Sinai&#8221;). Pursuant to the Mount Sinai Agreement, Mount Sinai granted the Company (a)&#160;a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under Mount Sinai&#8217;s interest in certain joint patents held by the Company and Mount Sinai (the &#8220;Joint Patents&#8221;) as well as in certain results and data (the &#8220;Data Package&#8221;) and (b)&#160;a non-exclusive license, with the right to grant sublicenses on certain conditions, to certain technical information, both relating to the diagnostic, prophylactic or therapeutic use for treating diseases or disorders in humans relying on activation of Protein Kinase C Epsilon (&#8220;PKC&#949;&#8221;), which includes Niemann-Pick Disease (the &#8220;Mount Sinai Field of Use&#8221;). The Mount Sinai Agreement allows the Company to research, discover, develop, make, have made, use, have used, import, lease, sell, have sold and offer certain products, processes or methods that are covered by valid claims of Mount Sinai&#8217;s interest in the Joint Patents or an Orphan Drug Designation Application covering the Data Package (&#8220;Mount Sinai Licensed Products&#8221;) in the Mount Sinai Field of Use (as such terms are defined in the Mount Sinai Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company is required to pay Mt. Sinai milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_7_14_2014_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_XWK_0a7heU6xMzkPuo_XLw" decimals="-6" format="ixt:numdotdecimal" name="snpx:MilestonePaymentsPayable" scale="6" id="Narr_cF4V3DipKEyE8TPKXm-27g">2</ix:nonFraction> million upon approval of a new drug approval (&#8220;NDA&#8221;) in the United States and an additional $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_7_14_2014_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_XWK_0a7heU6xMzkPuo_XLw" decimals="-5" format="ixt:numdotdecimal" name="snpx:AdditionalMilestonePaymentsPayable" scale="6" id="Narr_DIEfwC_FukWIU3KcMgHRmw">1.5</ix:nonFraction> million for an NDA approval in the European Union or Japan. In addition, the Company is required to pay Mt. Sinai royalties on net sales of licensed product of <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_7_14_2014_To_7_14_2014_srt_StatementScenarioAxis_snpx_NetSalesUpToDollars250MillionMember_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_ttgHcX6d-ESz6q6J8dXSbA" decimals="3" format="ixt:numdotdecimal" name="snpx:RoyaltyPaymentPercentage" scale="-2" id="Narr_HZhTQhL41UyZKQYS5Xn6Uw">2.0</ix:nonFraction>% for up to $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_14_2014_To_7_14_2014_srt_StatementScenarioAxis_snpx_NetSalesUpToDollars250MillionMember_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_ttgHcX6d-ESz6q6J8dXSbA" decimals="-6" format="ixt:numdotdecimal" name="snpx:RoyaltyPaymentThresholdNetSales" scale="6" id="Narr_cvkVxXrlg0m2oV_DApoAZg">250</ix:nonFraction> million of net sales and <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_7_14_2014_To_7_14_2014_srt_StatementScenarioAxis_snpx_NetSalesOverDollarsMillionMember_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_yH6gk0Ukj0ORfCWsxOM59A" decimals="3" format="ixt:numdotdecimal" name="snpx:RoyaltyPaymentPercentage" scale="-2" id="Narr_Ejtda6ebFE2g7ewjLb0UAA">3.0</ix:nonFraction>% of net sales over $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_14_2014_To_7_14_2014_srt_StatementScenarioAxis_snpx_NetSalesOverDollarsMillionMember_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_yH6gk0Ukj0ORfCWsxOM59A" decimals="-6" format="ixt:numdotdecimal" name="snpx:RoyaltyPaymentThresholdNetSales" scale="6" id="Narr_l6Q-i1SHk0-YuONweKaljw">250</ix:nonFraction> million. Since inception, the Company has paid Mt. Sinai approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_7_14_2014_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_XWK_0a7heU6xMzkPuo_XLw" decimals="0" format="ixt:numdotdecimal" name="snpx:TotalSavings" scale="0" id="Narr_4bVLTUxAUk6aln2my3aQ2g">180,000</ix:nonFraction> consisting of licensing fees of $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_14_2014_To_7_14_2014_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_grnTBMjygUGvo-rt4z7rsw" decimals="0" format="ixt:numdotdecimal" name="snpx:LicenseAgreementsLicensingFees" scale="0" id="Narr_z45htwNrlUW4zNB3NvSjvA">105,000</ix:nonFraction> plus development costs and patent fees of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_14_2014_To_7_14_2014_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_grnTBMjygUGvo-rt4z7rsw" decimals="0" format="ixt:numdotdecimal" name="snpx:LicenseAgreementsDevelopmentCostsAndPatentFees" scale="0" id="Narr_-jBz1o9N9kKUzchhhmYzOw">75,000</ix:nonFraction>. As of September 30, 2021, <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_Jj8qpfoArUmBLAPesOXY6A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PaymentsForRoyalties" scale="0" id="Narr_h2_RvcwKAkmoPDnOjqIyYg">no</ix:nonFraction> royalties <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_Jj8qpfoArUmBLAPesOXY6A" decimals="0" format="ixt-sec:numwordsen" name="snpx:MilestonePaymentsPaid" scale="0" id="Narr_4EhNIvjB1kieYyW0GERc3g">no</ix:nonFraction>r milestone payments have been required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Agreements with BryoLogyx</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June&#160;9, 2020, the Company entered into a supply agreement (the &#8220;Supply Agreement&#8221;) with BryoLogyx&#160;Inc. (&#8220;BryoLogyx&#8221;), pursuant to which BryoLogyx agreed to serve as the Company&#8217;s exclusive supplier of synthetic Bryostatin-1. Pursuant to the terms of the Supply Agreement, the Company placed an initial order and subsequently received one gram of current good manufacturing practice (&#8220;cGMP&#8221;) synthetic Bryostatin-1 as an active pharmaceutical ingredient to be used in a drug product (&#8220;API&#8221;). The Company may place additional orders for API beyond the initial order by making a written request to BryoLogyx no later than six months prior to the requested delivery date. The Company is not currently using synthetic Bryostatin-1 for its current Phase 2 clinical trial and will determine when to incorporate the synthetic into the clinical trial process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the Supply Agreement, on June&#160;9, 2020, the Company entered into a transfer agreement (the &#8220;Transfer Agreement&#8221;) with BryoLogyx. Pursuant to the terms of the Transfer Agreement, the Company agreed to assign and transfer to BryoLogyx all of the Company&#8217;s right, title and interest in and to that certain Cooperative Research and Development Agreement, dated as of January&#160;29, 2019 (the &#8220;CRADA&#8221;), by and between the Company and the U.S. Department of Health and Human Services, as represented by the NCI, under which Bryostatin-1&#8217;s ability to modulate CD22 in patients with relapsed/refractory CD22+ disease has been evaluated to date. Pursuant to guidance provided by NCI, the Company CRADA has been cancelled and BryoLogyx has initiated a request for a new CRADA in its name. BryoLogyx will be filing its own investigational new drug application (&#8220;IND&#8221;) for CD22 with the FDA. As consideration for the transfer of rights to the CRADA, BryoLogyx has agreed to pay to the Company <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_AgreementsWithBryologyxMember_l1G14r9qTki6SweRFMEsIA" decimals="2" format="ixt:numdotdecimal" name="snpx:PercentageOfGrossRevenue" scale="-2" id="Narr_V6ExmjFZ_UinmYQRitBIRQ">2</ix:nonFraction>% of the gross revenue received in connection with the sale of bryostatin products, up to an aggregate payment amount of $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_AgreementsWithBryologyxMember_avDjLw3FK0-K01yBV8psnw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRoyalties" scale="6" id="Narr_GwI5Neum9UuetWRFdi8X8w">1</ix:nonFraction> million. <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_AgreementsWithBryologyxMember_avDjLw3FK0-K01yBV8psnw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:OtherIncome" scale="0" id="Narr_kGAKrHGcCU2PM_Q-vvoP3Q">No</ix:nonFraction> such revenues have been earned as of September&#160;30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nemours Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On September 5, 2018, we announced a collaboration with Nemours A.I. DuPont Hospital (&#8220;Nemours&#8221;), a premier U.S. children&#8217;s hospital, to initiate a clinical trial in children with Fragile X. In addition to the primary objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as anxiety, repetitive behavior, executive functioning, and social behavior. On August 5, 2021, the Company announced its memorandum of understanding with Nemours to initiate a clinical trial using bryostatin, under Orphan Drug Status, to treat Fragile X. The Company intends to provide the bryostatin drug product and obtain the investigational new drug documentation (&#8220;IND&#8221;) and Nemours intends to provide the clinical site and attendant support for the trial. The Company and Nemours, jointly, will develop the trial protocol. The Company estimates its total trial and IND cost to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_8_5_2021_To_8_5_2021_us-gaap_TypeOfArrangementAxis_snpx_NemoursAgreementMember_duKRD6ZZp0unUKaBSODNWw" decimals="0" format="ixt:numdotdecimal" name="snpx:CostOnTrailAndInvestigationNewDrugDocumentationExpenses" scale="0" id="Narr_mNZBkXVXSE2E5oclBa8sYg">700,000</ix:nonFraction>. To-date, the Company has not incurred any expenses associated with this agreement.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_a2qmY-WSt06QWPkmfy-8aQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;4&#8211; Related Party Transactions and Licensing / Research Agreements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cognitive Research Enterprises,&#160;Inc. (&#8220;CRE&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Effective October&#160;31, 2012, the Company executed a Technology License and Services Agreement (the &#8220;TLSA&#8221;) with CRE, a related party, and NRV II, LLC (&#8220;NRV II&#8221;), another affiliate of CRE, which was amended by Amendment No.&#160;1 to the TLSA as of August&#160;21, 2013. As of February&#160;4, 2015, the parties entered into an Amended and Restated Technology License and Services Agreement (the &#8220;CRE License Agreement&#8221;). The CRE License Agreement provides research services and has granted the Company the exclusive and nontransferable world-wide, royalty-bearing right, with a right to sublicense (in accordance with the terms and conditions described below), under CRE&#8217;s and NRV II&#8217;s respective right, title and interest in and to certain patents and technology owned by CRE or licensed to NRV II by CRE as of or subsequent to October&#160;31, 2012, to develop, use, manufacture, market, offer for sale, sell, distribute, import and export certain products or services for therapeutic applications for AD and other cognitive dysfunctions in humans or animals (the &#8220;Field of Use&#8221;). Additionally, the CRE License Agreement specifies that all patents that issue from a certain patent application shall constitute licensed patents and all trade secrets, know-how and other confidential information claimed by such patents constitute licensed technology under the CRE License. The CRE License Agreement terminates on the later of the date (a)&#160;the last of the licensed patent expires, is abandoned, or is declared unenforceable or invalid or (b)&#160;the last of the intellectual property enters the public domain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">After Neurotrope&#8217;s initial Series A Stock financing, the CRE License Agreement required the Company to enter into scope of work agreements with CRE as the preferred service provider for any research and development services or other related scientific assistance and support services. There were <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt-sec:numwordsen" name="snpx:NumberOfStatementsEnteredIntoAgreement" scale="0" id="Narr_-0aGty26bE20Sh9UBTbgfg"><ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q" decimals="0" format="ixt-sec:numwordsen" name="snpx:NumberOfStatementsEnteredIntoAgreement" scale="0" id="Narr_dnf5eQLN2kOe1yWPDHqQZg"><ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt-sec:numwordsen" name="snpx:NumberOfStatementsEnteredIntoAgreement" scale="0" id="Narr_IKy9rCTbkES6rwNEKI4ZiQ"><ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw" decimals="0" format="ixt-sec:numwordsen" name="snpx:NumberOfStatementsEnteredIntoAgreement" scale="0" id="Narr_wCtWfwAZ5UqtMv_a9SdszA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> such statements of work agreements required to be entered into during the three and nine months ended September 30, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, on November&#160;10, 2018, the Company and CRE entered into a second amendment (the &#8220;Second Amendment&#8221;) to the TLSA pursuant to which CRE granted certain patent prosecution and maintenance rights to the Company. Under the Second Amendment, the Company will have the sole and exclusive right and the obligation, to apply for, file, prosecute and maintain patents and applications for the intellectual property licensed to the Company, and pay all fees, costs and expenses related to the licensed intellectual property. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d7ae6a1d_a125_46a0_a7ee_f6a1df24f0ab"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_iBCQyRiED0S1C-qDQO69_w" continuedAt="Tb_iBCQyRiED0S1C-qDQO69_w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;5&#160;&#8211; Commitments and Contingencies:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Clinical Trial Services Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On July&#160;23, 2020, the Company entered into the 2020 Services Agreement with WCT. The 2020 Services Agreement relates to services for the current Phase 2 clinical trial assessing the safety, tolerability and long-term efficacy of bryostatin in the treatment of moderately severe AD subjects not receiving memantine treatment (the &#8220;2020 Study&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the terms of the 2020 Services Agreement, WCT is providing services to enroll approximately <span style="-sec-ix-hidden:Hidden_zKPmU54jT0W3JjwS4wGcXw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">one</span></span> hundred (100) 2020 Study subjects, which enrollment is currently underway. The&#160;first 2020 Study site was initiated during the third quarter of 2020. The total estimated budget for the services, including pass-through costs, is currently approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_7_23_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_TIkglklIoUO2Ye16Man1yQ" decimals="-5" format="ixt:numdotdecimal" name="snpx:EstimatedBudgetForServices" scale="6" id="Narr_BdplRAfmKkKVduueANAvhA">9.6</ix:nonFraction> million. The Company was awarded a $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_23_2020_To_7_23_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_s1iUX1xsBUGU6nFszabgYg" decimals="-5" format="ixt:numdotdecimal" name="snpx:AmountOfAwardReceived" scale="6" id="Narr_PGYvi1sNQ0WngYLZg_9UkQ">2.7</ix:nonFraction> million grant from the NIH, which will be used to support the 2020 Study, resulting in an estimated net budgeted cost of the 2020 Study to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_7_23_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_8kjX07DyaE-HzdlEbheL3A" decimals="-5" format="ixt:numdotdecimal" name="snpx:EstimatedBudgetForServices" scale="6" id="Narr_kCOuZ9GqGkGM8rgTSLg9Nw">6.9</ix:nonFraction> million. The NIH grant provides for funds in the first year, which began in April&#160;2020, of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_YVddo9k3xUe1Mty-SsrZWQ" decimals="-5" format="ixt:numdotdecimal" name="snpx:ProceedsFromGrants" scale="6" id="Narr_Bd_LS_gN5kyc0ELFpMk5OQ">1.0</ix:nonFraction> million and funding in year two, which begins April&#160;2021, of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_4_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_HYkNCxHRy02mLmJWCc8lbw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivableCurrent" scale="6" id="Narr_yZsIyLu42020r-k9GZ_RBg">1.7</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company may terminate the 2020 Services Agreement without cause upon sixty (<ix:nonNumeric contextRef="Duration_7_23_2020_To_7_23_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_CN7r02Xyn0ydRSaKF-TAyQ" format="ixt-sec:durday" name="snpx:ConsultingAgreementNoticeForCancellation" id="Narr_HVlYCiywSUWKGa9bn6sNEQ">60</ix:nonNumeric>)&#160;days prior written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30, 2021, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_fa_BU9Kh_0-JxvaVT_wQww" decimals="-5" format="ixt:numdotdecimal" name="snpx:AmountFundedAgainstTotalTrialCost" scale="6" id="Narr_Yt3CalO7gkWnlUTkIBjzfA">5.1</ix:nonFraction> million has been paid against the total trial cost. Of this total, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_v3U1szDl4k2j8DFDpZYu8A" decimals="-5" format="ixt:numdotdecimal" name="snpx:ProceedsFromGrants" scale="6" id="Narr_hEVxfMGSg0S2vMvxd9m4XQ">2.1</ix:nonFraction> million has been received from the NIH. The Company incurred approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_fxANfnDJfkq-DjAu241ovA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_1VFio2KZJEe65DXIf10pQw">5.9</ix:nonFraction> million of cumulative expenses associated with the current Phase 2 clinical trial as of September 30, 2021. Of the total $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_23_2020_To_7_23_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_CN7r02Xyn0ydRSaKF-TAyQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_2AaPsMPDckOMzEKdzHSdOw">5.9</ix:nonFraction> million incurred for the trial to-date, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_a4h_NxjSXky22JFgrPHDSQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_QNpbAzRG9k-C1tQyQIEJQg">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_v3U1szDl4k2j8DFDpZYu8A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_SlK2YsGBAkqSBayY6CeCGg">3.2</ix:nonFraction> million is reflected in the statement of operations for the three and nine months ended September 30, 2021, respectively. As of September 30, 2021, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_fa_BU9Kh_0-JxvaVT_wQww" decimals="0" format="ixt:numdotdecimal" name="snpx:PrepaymentsForServiceAgreementCurrent" scale="0" id="Narr_jOB77wfhgkG81tu-Kdikgg">460,000</ix:nonFraction> of WCT prepayments is included as a prepaid expense and other current assets and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_fa_BU9Kh_0-JxvaVT_wQww" decimals="0" format="ixt:numdotdecimal" name="snpx:AccountsPayableForServiceAgreementCurrent" scale="0" id="Narr__APJqNU_lkuAx_QaVNh22w">771,000</ix:nonFraction> which is included in accounts payable in the accompanying balance sheet.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_iBCQyRiED0S1C-qDQO69_w_cont1" continuedAt="Tb_iBCQyRiED0S1C-qDQO69_w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Related Party and Other Consulting Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On August&#160;4, 2016, Neurotrope,&#160;Inc. entered into a consulting agreement with SM Capital Management, LLC (&#8220;SMCM&#8221;), a limited liability company owned and controlled by the Company&#8217;s Chairman of the Board, Mr.&#160;Joshua N. Silverman (the &#8220;Consulting Agreement&#8221;). Pursuant to the Consulting Agreement, SMCM shall provide consulting services which shall include, but not be limited to, providing business development, financial communications and management transition services, for a <ix:nonNumeric contextRef="Duration_8_4_2016_To_8_4_2016_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_ITeAjsMVWUKi59WUOf-Khg" format="ixt-sec:durwordsen" name="snpx:ContractPaymentsTerm" id="Narr_I_cmzUli2EOOEPzbBmzJCw">one-year</ix:nonNumeric> period, subject to annual review thereafter. SMCM&#8217;s annual consulting fee is $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_8_4_2016_To_8_4_2016_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_ITeAjsMVWUKi59WUOf-Khg" decimals="0" format="ixt:numdotdecimal" name="snpx:AnnualConsultancyAgreementFees" scale="0" id="Narr_xwTQN7nYsk-ffKvk-LcE4A">120,000</ix:nonFraction>, payable by the Company in&#160;monthly installments of $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_8_4_2016_To_8_4_2016_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_ITeAjsMVWUKi59WUOf-Khg" decimals="0" format="ixt:numdotdecimal" name="snpx:ConsultingAgreementMonthlyInstallmentFee" scale="0" id="Narr_zA_h80tF1k-7tIdbKHJTpQ">10,000</ix:nonFraction>. This contract has been assigned to Synaptogenix,&#160;Inc. as of December&#160;1, 2020. For the three and nine months ended September 30, 2021, $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_Bfz_1syvz0adg3VenxJYAQ" decimals="0" format="ixt:numdotdecimal" name="snpx:ConsultancyFees" scale="0" id="Narr_Y_4U70Kno0m6LtBfGAEZsA">60,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_MqIvc6D6ak-bP_Ls5cIdEA" decimals="0" format="ixt:numdotdecimal" name="snpx:ConsultancyFees" scale="0" id="Narr_eEEt9_AJIUKG3QpgSGwNKA">180,000</ix:nonFraction> is reflected in the Company&#8217;s statements of operations, respectively, pursuant to the Consulting Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Effective as of January&#160;1, 2021, the Company entered into an amended consulting agreement with Katalyst Securities LLC (&#8220;Katalyst&#8221;) reducing the cash payment to $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_YeeVT1VLT0GCoyCiHtvk3A" decimals="0" format="ixt:numdotdecimal" name="snpx:ConsultingAgreementMonthlyInstallmentFee" scale="0" id="Narr_blAEQr-uHkecAl_wXcLnPg">20,000</ix:nonFraction> per month. In addition, on February&#160;16, 2021, Katalyst was granted warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_1_16_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_B7CPRdhRrUi03pd8HH2WHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_q715h8b4OU2sIcfugHzwCw">25,000</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_1_16_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_B7CPRdhRrUi03pd8HH2WHA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Y3pYtCj2AEKALUvbpbWe9g">11.46</ix:nonFraction> per share, on April 1, 2021, was granted warrants to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_W8rULN8LVU2iFXd7lTqq6A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_i5e6Z_txMUm-_PidHJ3CmQ">4,500</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_W8rULN8LVU2iFXd7lTqq6A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Xs6b27oCFkGjia30IeA5kA">8.80</ix:nonFraction> per share, on July 1, 2021, was granted warrants to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_OIdTKpqZekCiObLbbJPl8w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_xfNz8nY9v0i1Bkbdg5gLFw">4,500</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_OIdTKpqZekCiObLbbJPl8w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_-_5-hJ0ryk2E47ZrmC6NkQ">9.76</ix:nonFraction> per share, and, on October 1, 2021, was granted warrants to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_cufB87OPd0uxPv8DnNgAwQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_GLT7x23yl0KZ65RxcLQw_g">4,500</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_cufB87OPd0uxPv8DnNgAwQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_vKIJDsJaF0iL5tcW1H7qVw">9.30</ix:nonFraction> per share. All other terms and conditions of the Katalyst Agreement remain unchanged. For the three and nine months ended September 30, 2021, $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_izoFKLvbS0qca5XE_8MiDA" decimals="0" format="ixt:numdotdecimal" name="snpx:ConsultancyFees" scale="0" id="Narr_KbSvwow80EahIciWjET7Aw">96,982</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_ZdwykQQjnki7EjxvNtEUvg" decimals="0" format="ixt:numdotdecimal" name="snpx:ConsultancyFees" scale="0" id="Narr_Jed7cJc8QkWj09rnZ6pKjg">556,682</ix:nonFraction> is reflected in the Company&#8217;s statements of operations, respectively, pursuant to the consulting agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Effective as of June&#160;5, 2019, the Company entered into a consulting agreement with GP Nurmenkari,&#160;Inc. (&#8220;GPN&#8221;) (the &#8220;GPN Agreement&#8221;), pursuant to which GPN agreed to provide investment banking consulting services to the Company and Neurotrope. The term of the agreement continued until December 1, 2020. As consideration for its services under the GPN Agreement, the Company agreed to pay to GPN $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_6_5_2019_To_6_5_2019_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_mhXWMvG4xk6I8_Dt9Z6IgA" decimals="0" format="ixt:numdotdecimal" name="snpx:ConsultingAgreementMonthlyInstallmentFee" scale="0" id="Narr_ddWaoHRV9Ui1YA0biwlF_Q">8,000</ix:nonFraction> per&#160;month, plus <ix:nonNumeric contextRef="As_Of_6_5_2019_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_AWIKoH8MRU-5fF4wYndp6w" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_Rrf1B4jPNUerV7N2n3RZjg">five-year</ix:nonNumeric> warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_6_5_2019_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_AWIKoH8MRU-5fF4wYndp6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_NWUDq0YDgE2MjrYkVPp4Bw">1,200</ix:nonFraction> shares of Neurotrope&#8217;s common stock on the effective date and on each of the <ix:nonNumeric contextRef="Duration_6_5_2019_To_6_5_2019_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_mhXWMvG4xk6I8_Dt9Z6IgA" format="ixt-sec:durwordsen" name="snpx:WarrantsAndRightsOutstandingTermFollowingEffectiveDate" id="Narr_PFKEA2Cd90CxIMCX-cL2Cw">three-month</ix:nonNumeric> anniversaries following the effective date. The warrants have an exercise price equal to the closing price of Neurotrope&#8217;s stock on the dates of issuances. On February&#160;1, 2020, the Company amended the GPN Agreement, increasing the cash compensation to $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_2_1_2020_To_2_1_2020_nGp21D17LkONtLS4Ybajpg" decimals="0" format="ixt:numdotdecimal" name="snpx:ConsultingAgreementMonthlyInstallmentFee" scale="0" id="Narr_HlDVEJh5T0-vS-2OQ5EHpA">17,500</ix:nonFraction> per&#160;month thru November 30, 2020 and increasing the number of warrants issued each <ix:nonNumeric contextRef="Duration_2_1_2020_To_2_1_2020_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_aEnOkbRtSEKBDafsd3izUw" format="ixt-sec:durwordsen" name="snpx:WarrantsAndRightsOutstandingTermFollowingEffectiveDate" id="Narr_HHUOWWXjkk6iIxZHgqikdw">three-month</ix:nonNumeric> period to <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_1_31_2020_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_NE8e4JpcsUy1zfWK6UBJew" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_b1a4LxRo10GjACEjknD9-Q">2,500</ix:nonFraction>, with the last issuance on December 1, 2020. GPN&#8217;s cash and stock-based compensation is included as general and administrative expenses in the Company&#8217;s statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Effective as of January&#160;1, 2021, the Company entered into an amended consulting agreement with GPN reducing the cash payment to $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_6GCBoefDCEis5MNeRLe2Dw" decimals="0" format="ixt:numdotdecimal" name="snpx:ConsultingAgreementMonthlyInstallmentFee" scale="0" id="Narr_tJlj-1tGuk2GcnbKUQqdXQ">12,000</ix:nonFraction> per month. Effective as of July 1, 2021, the Company entered into a second amended consulting agreement with GPN increasing the cash payment to $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_R-FJ60uA10ybeZXoxwgloA" decimals="0" format="ixt:numdotdecimal" name="snpx:ConsultingAgreementMonthlyInstallmentFee" scale="0" id="Narr_S2t0OhHXlUG_Say29aoMng">20,000</ix:nonFraction> per month and increasing warrant issued for each three-month period beginning July 1, 2021 to <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_mKADfe9OGEuXe9ZYlIg4Sw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Narr_IMkYLPPphE2scms_1pQ9fw">5,800</ix:nonFraction>, with the last issuance on October 1, 2021. In addition, on February&#160;16, 2021, GPN was granted warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_4Hb6Y7xE0kyrvRnId9g4PQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_dDueCZhKoU-MpttEh399aw">10,000</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_4Hb6Y7xE0kyrvRnId9g4PQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_CyMWfFW6tEueEg0sDmgj-g">11.46</ix:nonFraction> per share, on April 1, 2021, was granted warrants to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_GFeDDnIUDEeDxbNQIpRbmQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_w4Jdn68fQUm1C9XMLEJ4jA">2,500</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_GFeDDnIUDEeDxbNQIpRbmQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr__sh3w6l_rEKrlVe0gmW0uA">8.80</ix:nonFraction> per share, on July 1, 2021, was granted warrants to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_fU78qKLlQUeUn6turqsGfg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_SGbz6W_hrEShL7kymVTidA">5,800</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_fU78qKLlQUeUn6turqsGfg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_y4wUdWVhaUGwd-ic7jYQ4w">9.76</ix:nonFraction> per share, and, on October 1, 2021, was granted warrants to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_PT7hcM8umEeDTrhm4UVpkQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_sjbpzWP5oU-Zh6YWwMPoWQ">5,800</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_PT7hcM8umEeDTrhm4UVpkQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_6reYuENOWk2eD_IJxp-RkA">9.30</ix:nonFraction> per share. All other terms and conditions of the GPN Agreement remain unchanged. For the three and nine months ended September 30, 2021, $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_rB9I5A7GXUOkubGYNYktVQ" decimals="0" format="ixt:numdotdecimal" name="snpx:ConsultancyFees" scale="0" id="Narr_0uG0t9drjEmDvifDm9E5mA">107,666</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_T6M0FiL3YEiY7TJp-0yjrw" decimals="0" format="ixt:numdotdecimal" name="snpx:ConsultancyFees" scale="0" id="Narr_d14BUt6cJ0ymL_gaDzFAGQ">296,814</ix:nonFraction> is reflected in the Company&#8217;s statements of operations, respectively, pursuant to the GPN Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Employment Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;7, 2020, the Company entered into an offer letter (the &#8220;Offer Letter&#8221;) with Alan J. Tuchman, M.D., pursuant to which Dr.&#160;Tuchman agreed to serve as the Company&#8217;s Chief Executive Officer, commencing on December&#160;7, 2020. In addition, in connection with his appointment as the Company&#8217;s Chief Executive Officer, Dr.&#160;Tuchman was appointed to the board of directors of the Company. Dr.&#160;Tuchman will receive an initial annual base salary of $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_sdadKr2ZFUGPSuQk3FpIsA" decimals="0" format="ixt:numdotdecimal" name="snpx:InitialAnnualBaseSalaryPayable" scale="0" id="Narr_jkv28W25NEKzaEHn6sfnEQ">222,000</ix:nonFraction>, with an annual discretionary bonus of up to <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_sdadKr2ZFUGPSuQk3FpIsA" decimals="INF" format="ixt:numdotdecimal" name="snpx:AnnualDiscretionaryBonusPayableMaximumPercent" scale="-2" id="Narr_q53SiPymFESmwMdjc5RVoA">50</ix:nonFraction>% of his base salary then in effect. Dr.&#160;Tuchman also received an initial equity grant (subject to Board approval which was received in January&#160;2021) of options to purchase a number of shares of Common Stock equal to at least <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_1_1_2021_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_TxVysG0320uYChAcxvCRyQ" decimals="INF" format="ixt:numdotdecimal" name="snpx:OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff" scale="-2" id="Narr_us2plWL_NUqzF8VdIyYBqw">1</ix:nonFraction>% of the Company&#8217;s outstanding shares of Common Stock immediately following the Spin-Off. The option will vest with respect to <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_q7uNiiIzykOY--M3GXitdQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_emjy6xLK60aFgf2UkfLQ9g">25</ix:nonFraction>% on each of the first, <span style="-sec-ix-hidden:Hidden_hGoeBKVmBU20RQRV2PAyfQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">second</span></span>, <span style="-sec-ix-hidden:Hidden_G8xXS6bLZUG7c6GZDPjMxQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">third</span></span> and <span style="-sec-ix-hidden:Hidden_YpLSh0QAWUSUkURr5jx6fw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">fourth</span></span> quarterly anniversaries from the Start Date, subject to Dr.&#160;Tuchman&#8217;s continued employment with the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_iBCQyRiED0S1C-qDQO69_w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The term of Dr.&#160;Tuchman&#8217;s employment pursuant to the Offer Letter is <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_12_7_2020_To_12_7_2020_srt_StatementScenarioAxis_snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_yvpkUlirp0a1bWJ5z_hbhg" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfMonthsBaseSalaryPayableUponTermination" scale="0" id="Narr_9jZJg8hffUiX5DTFsv0mnw">one</ix:nonFraction> year, which shall be extended automatically for six month periods unless either party gives timely written notice. Pursuant to the Offer Letter, if Dr.&#160;Tuchman is terminated during the period that is within six months from the Start Date, Dr.&#160;Tuchman will receive compensation totaling a minimum of <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_sdadKr2ZFUGPSuQk3FpIsA" decimals="INF" format="ixt:numdotdecimal" name="snpx:MinimumPercentageOfAnnualizedSalaryPayableUponTermination" scale="-2" id="Narr_-hqVxMGQTkWhBInWWZladQ">50</ix:nonFraction>% of his annualized salary. If Dr.&#160;Tuchman is terminated within the period which is after six months from the Start Date and before the one year anniversary of the Start Date, Dr.&#160;Tuchman will receive severance equal to one (1)&#160;month of his base salary. If Dr.&#160;Tuchman is terminated within the period which is after the one year anniversary of the Start Date, Dr.&#160;Tuchman will receive severance equal to two (2)&#160;months of his base salary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with Dr.&#160;Ryan&#8217;s termination on December 1, 2020, Synaptogenix and Dr.&#160;Ryan entered into a Separation Agreement, dated as of December&#160;7, 2020 (the &#8220;Charles Ryan Separation Agreement&#8221;). Pursuant to the Charles Ryan Separation Agreement, Dr.&#160;Ryan is entitled to receive the following separation benefits in consideration of, and subject to, Dr.&#160;Ryan&#8217;s compliance with his continuing obligations under the Charles Ryan Separation Agreement and all other agreements between Dr.&#160;Ryan and the Company, and provided that Dr.&#160;Ryan does not revoke the Charles Ryan Separation Agreement: (i)&#160;payment of <span style="-sec-ix-hidden:Hidden_jgZLIHXGVkmWEP_qt_Shbw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">twelve</span></span> (12) months of Dr.&#160;Ryan&#8217;s base salary as of the Separation Date of $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_AJnmojkQsECwB_nfR566Pg" decimals="0" format="ixt:numdotdecimal" name="snpx:TotalAmountOfBaseSalaryPayableUponSeparation" scale="0" id="Narr_T3yMNWdHC0aUKY__eR3GGw">425,000</ix:nonFraction>; (ii)&#160;a cash bonus in an amount equal to $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_AJnmojkQsECwB_nfR566Pg" decimals="0" format="ixt:numdotdecimal" name="snpx:CashBonusPayableUponSeparation" scale="0" id="Narr_lI51CPQOjkKcgdTXKDBxKg">225,000</ix:nonFraction>; and (iii)&#160;payment of Dr.&#160;Ryan&#8217;s COBRA premiums for the period starting on the Charles Ryan Separation Date and ending on the earliest to occur of (x)&#160;<ix:nonNumeric contextRef="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_7m4RE_sc4ku1rRSLUCwYWA" format="ixt-sec:durwordsen" name="snpx:PeriodFollowingSeparationDateToPayCobraPremiums" id="Narr_O70oJSCA-0Gsk5x4ThuSgg">12 months</ix:nonNumeric> following the Separation Date; (y)&#160;the date Dr.&#160;Ryan is no longer eligible under COBRA and (z)&#160;the date that Dr.&#160;Ryan obtains employment that offers group health benefits. Total commitment pursuant to the Charles Ryan Separation Agreement is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_AJnmojkQsECwB_nfR566Pg" decimals="0" format="ixt:numdotdecimal" name="snpx:TotalSeparationBenefitsPayable" scale="0" id="Narr_OqL0hbWGcESI6Xy7HnoiJQ">660,000</ix:nonFraction>. Pursuant to the employee leasing agreement as part of the Merger Agreement, <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_AJnmojkQsECwB_nfR566Pg" decimals="INF" format="ixt:numdotdecimal" name="snpx:AnnualDiscretionaryBonusPayableMaximumPercent" scale="-2" id="Narr_-cfLBS4OYkWTqV2OsP_2vQ">50</ix:nonFraction>% of any payments to Dr.&#160;Ryan will be reimbursed by Metuchen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2020 and September&#160;30, 2021, the severance obligation included in accrued expenses on the Company&#8217;s balance sheet was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_12_31_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember__tepL3mKh0iXiuyC48F1pQ" decimals="0" format="ixt:numdotdecimal" name="snpx:SeparationBenefitsReimbursed" scale="0" id="Narr_YPEn7nKgGU2eGlZWDfT_ow">332,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_3_31_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_wwIsJnRvikGynuEld8gG7w" decimals="0" format="ixt:numdotdecimal" name="snpx:SeparationBenefitsReimbursed" scale="0" id="Narr_HazuOEnnOEq9da_2xiW2mg">46,000</ix:nonFraction>, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">See Notes 3 and 4 for Collaboration and License Agreement related commitments.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the Separation Agreement and Tax Matters Agreement with Neurotrope, Neurotrope agreed to indemnify Synaptogenix for certain liabilities, and Synaptogenix agreed to indemnify Neurotrope for certain liabilities, in each case for uncapped amounts. Indemnities that Synaptogenix may be required to provide Neurotrope are not subject to any cap, may be significant and could negatively impact Synaptogenix&#8217;s business, particularly with respect to indemnities provided in the Tax Matters Agreement. Third parties could also seek to hold Synaptogenix responsible for any of the liabilities that Neurotrope has agreed to retain. Further, the indemnity from Neurotrope may not be sufficient to protect Synaptogenix against the full amount of such liabilities, and Neurotrope may not be able to fully satisfy its indemnification obligations. Moreover, even if Synaptogenix ultimately succeeds in recovering from Neurotrope any amounts for which Synaptogenix is held liable, Synaptogenix may be temporarily required to bear these losses ourselves. As of the reporting date, there are no claims relating to the indemnification agreement.&#160;</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_59noYseshUyDwVtRpxlEXA" continuedAt="Tb_59noYseshUyDwVtRpxlEXA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Note&#160;6&#160;&#8211;</b> <b style="font-weight:bold;">Stockholders&#8217; Equity:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;7, 2020, the Company completed its Spin-Off from Neurotrope and <span style="-sec-ix-hidden:Hidden_2WjS9OcCE0OUM5kOWGUAdg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">issued</span></span> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_12_7_2020_To_12_7_2020_sjyc_Q4Tz0y82heiYi_stA" decimals="0" format="ixt:numdotdecimal" name="snpx:IssueOfSharesOnSpinOff" scale="0" id="Narr_9u6OO6rrWUG8cyUwjTuJkQ">1,257,579</ix:nonFraction> of Common Stock to stakeholders of Neurotrope. The shares issues were determined by the number of Neurotrope shares held by each shareholder multiplied by the exchange rate of <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g" decimals="2" name="snpx:SpinOffRatio" scale="0" id="Narr_n_9xGi_PlUOrHlwZAR1C-Q">.20</ix:nonFraction> shares of Synaptogenix for each share of Neurotrope, held on November&#160;30, 2020, the record date of the Spin-Off. In addition, shares of Common Stock were <span style="-sec-ix-hidden:Hidden_dSJYuuGr1UaWnhcxWt0JcA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">issued</span></span> to Neurotrope. Warrant holders that chose not to amend their warrants pursuant to the amendments offered to all Series&#160;E, F, G and H warrant holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s certificate of incorporation authorizes it to issue <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_56Vw2-KVnUmus6eLgg8rEw">150,000,000</ix:nonFraction> shares of Common Stock and <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_YOTUAXY7ukybyNdwlGK-uw">1,000,000</ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_5P1NbU4wI0-EjhI0CU77Kw">0.0001</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_59noYseshUyDwVtRpxlEXA_cont1" continuedAt="Tb_59noYseshUyDwVtRpxlEXA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The holders of Common Stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends at such times and in such amounts as the Board from time to time may determine. To date, the Company has not paid dividends on its Common Stock. Holders of Common Stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_DzbStCv5TEKWycjen-OBEA" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfVotesPerShareOwned" scale="0" id="Narr_PMKJbXyU-Eef6lWSZgctgQ">one</ix:nonFraction> vote for each share held on all matters submitted to a vote of stockholders. There is no cumulative voting of the election of directors then standing for election. The Common Stock is not entitled to pre-emptive rights and is not subject to conversion or redemption. Upon liquidation, dissolution or winding up of the Company, the assets legally available for distribution to stockholders are distributable ratably among the holders of Common Stock after payment of liabilities, accrued dividends and liquidation preferences, if any. Each outstanding share of Common Stock is duly and validly issued, fully paid and non-assessable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">January&#160;2021 Private Placement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January&#160;21, 2021, the Company entered into Securities Purchase Agreements (the &#8220;Purchase Agreement&#8221;) with certain accredited investors (the &#8220;Purchasers&#8221;) to issue (a)&#160;an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_21_2021_To_1_21_2021_HYTbWiKKQEKRtx7xP4_xwQ" decimals="0" format="ixt:numdotdecimal" name="snpx:AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement" scale="0" id="Narr_RHZncO4HekaWo7Mj7wTyFw">2,333,884</ix:nonFraction> shares of Common Stock and/or prefunded warrants to purchase shares of Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_1_21_2021_DeloaH3epUmWvrrrKTfurQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_b1OY7jqK5kmvJ-Z1hdBP_A">0.01</ix:nonFraction> per share (the &#8220;Pre-Funded Warrants&#8221;), (b)&#160;Series&#160;E warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_GlLZteV0L0Sp_5QqZ3bkiQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_3yF5LvNexkecVyxRwiVbmg">2,333,908</ix:nonFraction> shares of Common Stock, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_GlLZteV0L0Sp_5QqZ3bkiQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_NNyK14O-9k2Mjjqw5hlXCA">8.51</ix:nonFraction> per share (subject to adjustment), for a period of <ix:nonNumeric contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_L_BlpkHz3kyav_r8wtOz5w" format="ixt-sec:durwordsen" name="snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights" id="Narr_n0LPV4WlmEKu27zYIZiuAA">twelve months</ix:nonNumeric> from the date of an effective registration statement (the &#8220;Series&#160;E Warrants&#8221;) and (c)&#160;Series&#160;F warrants to purchase up to an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_HmAmRGGq3UKNzSa-eZihpA" decimals="0" format="ixt:numdotdecimal" name="snpx:AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement" scale="0" id="Narr_OusaK_zYc0yzCafmvljvvA">2,333,908</ix:nonFraction> shares of Common stock, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_GxGMgiomqkCkvB744Sb2wg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_yLicx-9Zzk63Uijv_KLz5A">6.90</ix:nonFraction> per share (subject to adjustment), for a period of <ix:nonNumeric contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_HmAmRGGq3UKNzSa-eZihpA" format="ixt-sec:durwordsen" name="snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights" id="Narr_4tbhqrEAd0OAohOiokPQWg">five years</ix:nonNumeric> from the date of issuance (the &#8220;Series&#160;F Warrants&#8221; and together with the Series&#160;E Warrants, the &#8220;Warrants&#8221;) at a combined purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_fZfc3Q0FgUaqAHKikZxANA" decimals="2" format="ixt:numdotdecimal" name="snpx:CombinedPurchasePriceOfCommonStockAndWarrants" scale="0" id="Narr_N9Kflrc20EWsdLOzbBxBFg">6.00</ix:nonFraction> per share of Common Stock and Warrants (the &#8220;Offering&#8221;). The Company received total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_fZfc3Q0FgUaqAHKikZxANA" decimals="0" format="ixt:numdotdecimal" name="snpx:GrossProceedsFromSaleOfWarrantsAndCommonStock" scale="0" id="Narr_8pRrDGT4lkODNlKA4h37Ig">14,000,000</ix:nonFraction> and net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_fZfc3Q0FgUaqAHKikZxANA" decimals="-5" format="ixt:numdotdecimal" name="snpx:NetProceedsFromSaleOfWarrantsAndCommonStock" scale="6" id="Narr_itWFXbm620ySWCz403PbAg">12.5</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the Purchase Agreement, the Company and the Purchasers entered into a Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;) on January&#160;21, 2021. Under the terms of the Registration Rights Agreement, the Company agreed to register the shares of Common Stock and the shares of Common Stock issuable upon exercise of the Warrants and the Pre-Funded Warrants sold to the Buyers pursuant to the Purchase Agreement. The Company filed a registration statement on Form S-1 in connection with the Registration Rights Agreement on February 8, 2021. The Company also agreed to other customary obligations regarding registration, including indemnification and maintenance of the effectiveness of the registration statement. The Company&#8217;s registration statement on Form S-1 to register the shares of Common Stock and the shares of Common Stock issuable upon exercise of the Warrants and Pre-Funded Warrants went effective on April 29, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;border-bottom:1.0pt solid #ffffff;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;">In connection with the Offering, we paid our placement agents Katalyst and GPN (i)&#160;a cash fee equal to ten percent (<ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_21_2021_To_1_21_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_o7nYuxzxoUywgFr4YqnBRA" decimals="INF" format="ixt:numdotdecimal" name="snpx:PercentageOfOfferingFeesInCash" scale="-2" id="Narr_2I5KxSA0_0CGNl1h0aR0vA">10</ix:nonFraction>%) of the gross proceeds from any sale of securities in the Offering sold to Purchasers introduced by the Placement Agent and (ii)&#160;warrants to purchase shares of Common Stock equal to ten percent (<ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_21_2021_To_1_21_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_o7nYuxzxoUywgFr4YqnBRA" decimals="INF" format="ixt:numdotdecimal" name="snpx:PercentageOfOfferingFeesInWarrants" scale="-2" id="Narr_cmT26C4eQkSNeV-wA-_vsQ">10</ix:nonFraction>%) of the number of shares of Common Stock sold to Purchasers introduced by the placement agents, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_1_21_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_njgrU71ChUuuukDv39OPww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_RBz5c1r3UEi3pApbbqenkQ">6.90</ix:nonFraction> per share and a <ix:nonNumeric contextRef="Duration_1_21_2021_To_1_21_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_o7nYuxzxoUywgFr4YqnBRA" format="ixt-sec:durwordsen" name="snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights" id="Narr_yxZcsE0NZk2BisDikueQCQ">five-year</ix:nonNumeric> term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_59noYseshUyDwVtRpxlEXA_cont2" continuedAt="Tb_59noYseshUyDwVtRpxlEXA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">June 2021 Private Placement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On June 14, 2021, the Company entered into Securities Purchase Agreements (the &#8220;June Purchase Agreement&#8221;) with certain accredited investors (the &#8220;June Purchasers&#8221;) to issue (a) an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_6_14_2021_To_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_PrefundedWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_UTFOvvwdkkKSLwa22CdtEA" decimals="INF" format="ixt:numdotdecimal" name="snpx:AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement" scale="0" id="Narr_XCqft7He5kmHxmFHxJwXnw">1,653,281</ix:nonFraction> shares of the Company&#8217;s Common Stock and/or prefunded warrants to purchase shares of Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_PrefundedWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_Y9y3VTtvt0-HBEjwyQXlZw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_3IzOShSAj0OdzGEOXJ9JZw">0.01</ix:nonFraction> per share (the &#8220;June Pre-Funded Warrants&#8221;) and (b) Series G warrants to purchase up to an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_6_14_2021_To_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_OrexfrNIiEKu4uzwmMWMwQ" decimals="INF" format="ixt:numdotdecimal" name="snpx:AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement" scale="0" id="Narr_uiPnNYTI50aOay71n4lLCw">1,653,281</ix:nonFraction> shares of Common stock, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_qFNn0PiONUWj2D4Fv2tSVQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_dvY8uKH8mE-X4D3xD65J7g">8.51</ix:nonFraction> per share (subject to adjustment), for a period of <ix:nonNumeric contextRef="Duration_6_14_2021_To_6_14_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_Hw9nxWYRIEOMqSut960Tzw" format="ixt-sec:durwordsen" name="snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights" id="Narr_8dH4FeGdwEO4KxQPL1iNkQ">five years</ix:nonNumeric> from the date of issuance (the &#8220;June Warrants&#8221;) at a combined purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="Duration_6_14_2021_To_6_14_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_Hw9nxWYRIEOMqSut960Tzw" decimals="3" format="ixt:numdotdecimal" name="snpx:CombinedPurchasePriceOfCommonStockAndWarrants" scale="0" id="Narr_nQWM2I81BE2DXFXl8e-ALw">7.547</ix:nonFraction> per share of Common Stock and June Warrants (the &#8220;June Offering&#8221;). The Company received total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_6_14_2021_To_6_14_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_Hw9nxWYRIEOMqSut960Tzw" decimals="-5" format="ixt:numdotdecimal" name="snpx:GrossProceedsFromSaleOfWarrantsAndCommonStock" scale="6" id="Narr_Nb-AxKd0tkqvINeF3SprFA">12.5</ix:nonFraction> million and net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_6_14_2021_To_6_14_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_Hw9nxWYRIEOMqSut960Tzw" decimals="-5" format="ixt:numdotdecimal" name="snpx:NetProceedsFromSaleOfWarrantsAndCommonStock" scale="6" id="Narr_73IzhWlVzUe_8PUH6nYjWg">11.2</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In connection with the June Purchase Agreement, the Company and the June Purchasers entered into a Registration Rights Agreement (the &#8220;June Registration Rights Agreement&#8221;) on June 14, 2021. Under the terms of the June Registration Rights Agreement, the Company agreed to register the shares of Common Stock and the shares of Common Stock issuable upon exercise of the June Warrants and the June Pre-Funded Warrants sold to the Buyers pursuant to the June Purchase Agreement. The Company filed a registration statement for the resale of such securities on June 24, 2021, and it was declared effective by the SEC on July 6, 2021. The Company also agreed to other customary obligations regarding registration, including indemnification and maintenance of the effectiveness of the registration statement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In connection with the June Offering, pursuant to an Engagement Agreement, dated June 14, 2021 (the &#8220;June Engagement Agreement&#8221;), between the Company and Katalyst Securities LLC (the &#8220;June Placement Agent&#8221;), the Company paid the June Placement Agent (i) a cash fee equal to ten percent (<ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_6_14_2021_To_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_Q4EJ6pY3MEGvIljDamjqvg" decimals="2" format="ixt:numdotdecimal" name="snpx:PercentageOfOfferingFeesInCash" scale="-2" id="Narr_X7jW2Oweh0e9_gKi2aWe0w">10</ix:nonFraction>%) of the gross proceeds from the sale of securities in the June Offering sold to June Purchasers introduced by the June Placement Agent and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_zUGNKTUDa0uRvG6Lbuctbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_eZgvjAThO0e7vxh4TVNe5A">152,378</ix:nonFraction> warrants to purchase shares of Common Stock equal to ten percent (<ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_6_14_2021_To_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_Q4EJ6pY3MEGvIljDamjqvg" decimals="2" format="ixt:numdotdecimal" name="snpx:PercentageOfOfferingFeesInWarrants" scale="-2" id="Narr_Jl94lNJxC02tGEmSNJgsAg">10</ix:nonFraction>%) of the number of shares of Common Stock sold to June Purchasers introduced by the June Placement Agent, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_zUGNKTUDa0uRvG6Lbuctbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_7o9NY2jx2EG8tDp6Fy9xvQ">8.51</ix:nonFraction> per share and a <ix:nonNumeric contextRef="Duration_6_14_2021_To_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_Q4EJ6pY3MEGvIljDamjqvg" format="ixt-sec:durwordsen" name="snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights" id="Narr_1Eb9QXdGtkC0P4AW4sCIZQ">five-year</ix:nonNumeric> term (the &#8220;June Broker Warrants&#8221;). Furthermore, the Company agreed to pay the June Placement Agent a warrant exercise fee equal to ten percent (<ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_6_14_2021_To_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_Q4EJ6pY3MEGvIljDamjqvg" decimals="2" format="ixt:numdotdecimal" name="snpx:PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant" scale="-2" id="Narr_2ozU40XFWUiP3mvg0_QRow">10</ix:nonFraction>%) of the aggregate exercise price that is paid in connection with each exercise, if any, of the June Warrants initially held by June Purchasers introduced by the June Placement Agent. The June Placement Agent is also entitled to the foregoing fees with respect to any future financing or capital-raising transaction by the Company (a &#8220;Subsequent Financing&#8221;), to the extent such financing or capital is provided to the Company by investors whom the Placement Agent had introduced to the Company, in the event such Subsequent Financing is consummated within eighteen (<ix:nonNumeric contextRef="Duration_6_14_2021_To_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_Q4EJ6pY3MEGvIljDamjqvg" format="ixt-sec:durmonth" name="snpx:ThresholdPeriodForArrangingFutureFinancing" id="Narr_1TWFZIAU8Umic89-xsm4Ig">18</ix:nonNumeric>) months following the closing of the June Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Adoption of a Shareholder Rights Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January&#160;13, 2021, the Company adopted a shareholder rights plan (the &#8220;Rights Plan&#8221;). The Rights Plan is intended to protect the interests of the Company&#8217;s stockholders and enable them to realize the full potential value of their investment by reducing the likelihood that any person or group gains control of the Company, through open market accumulation or other tactics, without appropriately compensating all stockholders. Pursuant to the Rights Plan, the Company will issue, by means of a dividend, <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_ShareholderRightsPlanMember_BeWp9EwyLU-Pw2i4t19P6w" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend" scale="0" id="Narr_7dNUAzvfZ0uRpUjqtIGO4w">one</ix:nonFraction> preferred share purchase right for each outstanding share of our Common Stock to shareholders of record on the close of business on January&#160;25, 2021. Initially, these Rights will trade with, and be represented by, the shares of our Common Stock.&#160;The Rights&#160;will generally become exercisable only if any person (or any persons acting as a group) acquires <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_ShareholderRightsPlanMember_BeWp9EwyLU-Pw2i4t19P6w" decimals="INF" format="ixt:numdotdecimal" name="snpx:MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights" scale="0" id="Narr_WEEVte66h0ePvM6UckpHSg">15</ix:nonFraction>% or more of our outstanding Common Stock (the &#8220;Acquiring Person&#8221;) in a transaction not approved by the Board, subject to certain exceptions, as explained below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If the Rights become exercisable, all holders of Rights, other than the Acquiring Person, will be entitled to acquire shares of Common Stock at a <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_ShareholderRightsPlanMember_BeWp9EwyLU-Pw2i4t19P6w" decimals="INF" format="ixt:numdotdecimal" name="snpx:DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson" scale="-2" id="Narr_4xE4f5DCAEKu2yk2fL2Lvg">50</ix:nonFraction>% discount or the Company may exchange each Right held by such holders for <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_ShareholderRightsPlanMember_BeWp9EwyLU-Pw2i4t19P6w" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfCommonSharesForEachRight" scale="0" id="Narr_wseinrINH0-KjC0eaQBPfw">one</ix:nonFraction> share of Common Stock. In such situation, Rights held by the Acquiring Person would become void and will not be exercisable. If any person at the time of the first public announcement of the Rights Plan owns more than the triggering percentage, then that stockholder&#8217;s existing ownership percentage will be grandfathered, although, with certain exceptions, the Rights will become exercisable if at any time after the announcement of the Rights Plan such stockholder increases its ownership of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_59noYseshUyDwVtRpxlEXA_cont3"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January&#160;13, 2021, the board of directors of the Company (the &#8220;Board&#8221;)declared a dividend of one preferred share purchase right (a &#8220;Right&#8221;), payable on January&#160;25, 2021, for each share of Common Stock outstanding on January&#160;25, 2021 (the &#8220;Record Date&#8221;) to the stockholders of record on that date. In connection with the distribution of the Rights, the Company entered into a Rights Agreement (the &#8220;Rights Agreement&#8221;), dated as of January&#160;19, 2021, between the Company and Philadelphia Stock Transfer,&#160;Inc., as rights agent. Each Right entitles the registered holder to purchase from the Company one one-thousandth of a share of Series&#160;A Preferred Stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_RightsAgreementMember_4x3-7JV2VESTTUvsqOn7Yw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_DnEDJZuOU0-4LrloclvyWw">0.001</ix:nonFraction> per share (the &#8220;Preferred Shares&#8221;), of the Company at a price of $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_RightsAgreementMember_cbGd3CdlBUqQ_qyF1XZXPA" decimals="0" format="ixt:numdotdecimal" name="snpx:PurchasePriceOfRight" scale="0" id="Narr_I7FJMXz2LEGVXfMO_Hp25Q">20</ix:nonFraction> per <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_RightsAgreementMember_cbGd3CdlBUqQ_qyF1XZXPA" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight" scale="0" id="Narr_FzSNAz53b0ad5u-i1mEjKw">one</ix:nonFraction> one-thousandth of a Preferred Share represented by a Right (the &#8220;Purchase Price&#8221;), subject to adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Unless earlier redeemed, terminated or exchanged pursuant to the terms of the Rights Plan, the Rights will expire at the close of business on&#160;January&#160;13, 2023. The Board may terminate the Rights Plan before that date if the Board determines that there is no longer a threat to shareholder value.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At the Special Meeting, the stockholders approved our proposal to effect one reverse stock split of the Company&#8217;s outstanding shares of Common stock, at any ratio between 1-for-<ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_5JNwmAqnxEi_l_f3YHC7-w" decimals="1" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_5YwkeGw7xkKT5Y77YPv83g">1.5</ix:nonFraction> and 1-for-<ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_Qj_fG9oUqUuK8DNTHXfAoQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_vqXBLJotZ0CzUzvAoCY4vA">20</ix:nonFraction>, at such time as the Company&#8217;s Board of Directors shall determine, in its sole discretion, before December 31, 2022. On May 19, 2021, the Company effected a <span style="-sec-ix-hidden:Hidden_a2wS05qZI0qbkELASHqfgA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">1-for-4</span></span> reverse stock split of its Common Stock. As a result of the reverse stock split, every four (4) shares of the Company&#8217;s pre-reverse split Common Stock was combined and reclassified into one share of Common Stock. These financial statements have been adjusted to retrospectively reflect this reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_GSZYKI0qqUuSfqzaHGeC9g" continuedAt="Tb_GSZYKI0qqUuSfqzaHGeC9g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Note 7 &#8211; Stock Based Compensation:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">2020 Equity Incentive Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon completion of the Spin-Off, the Company&#8217;s 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) became effective on December&#160;7, 2020. The total number of securities available for grant under the 2020 Plan was <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_2fKv6c-MNkOS4fTpvlS39g">250,000</ix:nonFraction> shares of Common Stock, subject to adjustment. On April 7, 2021, the Company held a special meeting of stockholders (&#8220;Special Meeting&#8221;). At the Special Meeting, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s 2020 Plan to increase the total number of shares of Common Stock from <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr__mOBPLGGnEOs6lumwmGmGg">250,000</ix:nonFraction> to an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_4_7_2021_X8xLB1j8lkOI3Ju5ytfjTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_2dLGvcVtqEORyfgNDiWM0w">625,000</ix:nonFraction> shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Compensation Committee of the Company&#8217;s board of directors (the &#8220;Committee&#8221;) will administer the 2020 Plan and have full power to grant stock options and Common Stock, construe and interpret the 2020 Plan, establish rules&#160;and regulations and perform all other acts, including the delegation of administrative responsibilities, as it believes reasonable and proper. The Committee, in its absolute discretion, may award Common Stock to employees, consultants, and directors of the Company, and such other persons as the Committee may select, and permit holders of options to exercise such options prior to full vesting.<i style="font-style:italic;"> </i>Pursuant to the Spin-Off, all options issued and outstanding prior to this plan were assumed by Petros Pharmaceuticals,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Before the Spin-Off, Neurotrope was the sponsor of the Company&#8217;s 2017 stock option plan (&#8220;2017 Plan&#8221;). Upon the Spin-Off, the 2017 Plan was transferred to Petros Pharmaceuticals,&#160;Inc. Total expenses for 2020 was recognized as expense and attributable to the Company (See Note 9 &#8211; Parent Company Investment.) As of the Spin-Off date, no additional options expense will be reflected based upon the 2017 Plan.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Option Grants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a61e3024_f05e_484e_98e3_db4ead3b26eb"></a><a id="Tc_lwTCdA8xA0O2SJT1vJmQfg_1_7"></a><a id="Tc_MLMIEzT52E6s3-L_ewsruQ_2_7"></a><a id="Tc_LoAeNwoijEqH15386KKyzw_2_9"></a><a id="Tc_MDo40qfd8kGvGir84EhHaw_3_4"></a><a id="Tc_4KmEKB6rhkCQXqQmcfHS5w_3_7"></a><a id="Tc_P7tCmzrFVk2-S2wam5-Wbg_3_9"></a><a id="Tc_5Sx8LBIrQkavLF8VJChGkA_4_2"></a><a id="Tc_i6mH3IbVQ0iJGO5krZIDIw_4_4"></a><a id="Tc_rzCmCydM_0-UYfRbhNxKqg_4_7"></a><a id="Tc_VvWBcj1OJ0iBc_O9rb8Lxg_4_9"></a><a id="Tc_vDtIko4SJUO4SXfTAowRSw_5_2"></a><a id="Tc_kM-yIZZXTk-PIZjEjNkoLA_5_4"></a><a id="Tc_mIf2kaTqhUaAKCLQcAiljw_5_7"></a><a id="Tc_x5i-ug3clUekAXo-EwAJcQ_5_9"></a><a id="Tc_PgTcoz01bU6F1srTdo8wrA_6_2"></a><a id="Tc_9ccwGZcU5kOW6dxQRjhlRQ_6_4"></a><a id="Tc_6p-NLi8XrUKouM_85Y7JWw_6_7"></a><a id="Tc_lidEzxgUREWJBfxd22F7cw_6_9"></a><a id="Tc_JPrQteB3SEqACXP_pnqP_g_7_0"></a><a id="Tc_TV6bb_PZUEOyZ_oNJOCb2A_7_4"></a><a id="Tc_5derTaXtwUKSHxW0zL3gbg_7_9"></a><a id="Tc_zJ7wak5rSUicc7NrTtVmMQ_8_0"></a><a id="Tc_E8Th7sLMl0GwJYZkgjLLPA_8_4"></a><a id="Tc_xFS2hNtPlkmuzeC6CCzo1Q_9_0"></a><a id="Tc_8UMOT6L6-EeTeOtNCiM5Rw_9_2"></a><a id="Tc_P6_dARiIeE2pDoac4o1B1A_9_4"></a><a id="Tc_zSBrp5_9fUyoNCeb-Zp2mQ_9_5"></a><a id="Tc_VY0fBf1G10ar-amXcjP_bA_10_0"></a><a id="Tc_00yg1OqkAkuBI6LKs0IXRw_10_2"></a><a id="Tc_n2b9FXqAlkKHddqe97NhvQ_10_4"></a><a id="Tc_4HxiYM7aOECRj0oL5KTIrg_10_5"></a><a id="Tc_PD5QrShCGE2kycg6_nNMtg_11_0"></a><a id="Tc_DVXwzbQ8FEyIBoHZQ1UgRw_11_2"></a><a id="Tc_2JAxdOmqKkeRflF1fk7yzw_11_4"></a><a id="Tc_yMhMLoZpo06wKB0FIZDjQA_11_5"></a><a id="Tc_QOjigVhfQkul7_tB8bDd-w_12_0"></a><a id="Tc_rSPHc9534Ey-3LgavDXkNw_12_4"></a><a id="Tc_y1BVp2d8jkiEVsYXpc-avg_12_9"></a><a id="Tc_Icgqu6dYS0a7wJWPhIKhxA_13_0"></a><a id="Tc_QTwg-WBRe0K_WJaqJbEntA_13_4"></a><a id="Tc_76JGQawEXEWvY49Npxe3mw_13_9"></a><ix:continuation id="Tb_GSZYKI0qqUuSfqzaHGeC9g_cont1" continuedAt="Tb_GSZYKI0qqUuSfqzaHGeC9g_cont2"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="Tb_4A2X7Z08HUes-B20p8ovQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a summary of stock option activity under the stock option plans for the nine months ended September 30, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">millions)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Options outstanding at January&#160;1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_7YFL4cRXuUeOau145D_pTQ_7_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_SFCp17F6kk-4lNQJwec8AQ_7_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ran0Cu55WEO7SIeyEo9upQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="-6" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="Tc_c-2FVdUQFkm4rbFhSaj8xw_7_10">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_7o1leu8QQ022UdhSFqdDJw_8_2">123,850</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc__FAazdZ94EynoKIMh5skAA_8_5">9.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" format="ixt-sec:duryear" name="snpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="Tc_ZYEYZD-R1EakB7UEWlvyTw_8_7"> 9.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less options forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less options expired/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Options outstanding at September&#160;30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_bN6JvXe-UEShlFsKs3xHxw_12_2">123,850</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_Xpli6gUejkaIkIMfs6r2tg_12_5">9.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_pj7UKKWeGU2ZtScBn2xepw_12_7"> 9.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="-6" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="Tc_AxoiqKL-akuNQHDtJ02JIQ_12_10">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Options exercisable at September 30, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_5uG4UW2X4kejso8Xp6DmRw_13_2">89,613</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_WTBx9W-Fk0OjJpWl_helog_13_5">9.84</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_QMmXh9kkl0mAvMq732hcAw_13_7"> 9.2</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="-6" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="Tc_Pi-Nwibz4kqXMd3oGnyWOg_13_10">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January&#160;13, 2021, pursuant to its 2020 Plan, the Company granted stock options to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Juykt8FDIU2ic5Pf-lDtiw">116,350</ix:nonFraction> shares of Common Stock to <ix:nonFraction unitRef="Unit_Standard_director_RA5R3TwOe0i9LByRRHbWMw" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfDirectors" scale="0" id="Narr_77SAqEzaE06v2H1JbgirMQ">six</ix:nonFraction> members of the board of directors and <ix:nonFraction unitRef="Unit_Standard_employee_TK-gmXNo9Eqj4Kw_3BydmQ" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfEmployee" scale="0" id="Narr_QMpNZGaVwUKw6QbTDzW2sg">four</ix:nonFraction> employees, including <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_12_7_2020_To_12_7_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_QAtyG63Ml0iGUPsG62eDkw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_-pe2ZS2_TUmAN3H3r-ZXQw">12,575</ix:nonFraction> options granted to the Company&#8217;s Chief Executive Officer pursuant to his employment agreement with the Company dated December&#160;7, 2020. The stock options have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_Zdh6uuhWsk-t86FbJlf7Hg">9.84</ix:nonFraction> per share and an expiration date that is <ix:nonNumeric contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_qkIhNz_J3EavaZLn8zVtKA">ten years</ix:nonNumeric> from the date of issuance. <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Narr_8ulL3smMWUSDAvxUkHF58Q">103,775</ix:nonFraction> options vest <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_snpx_DateOfGrantMember_CoXoxGX9_kGVwzm95w2HWA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_bXTjTJY1zkS4ykHJ2gH74g">50</ix:nonFraction>% on the date of grant and <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_O8lsXfv060q08M33KwFJoQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_9SUe7fFIuk6QAtEV54HPmw">50</ix:nonFraction>% on the first anniversary of the grant date, the <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_13_2021_To_1_13_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_9WmgNIy7zkuk1nx7ZlVGaA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Xl9gvn8BxEqwYOUSE8iWYw">12,575</ix:nonFraction> options granted to the CEO vest <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_brWXOs9rvk-CL2mnnpvfcA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_bgETK-10c0Sq7aox0NS_tA">25</ix:nonFraction>% per quarter over one year, with the initial <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0nx63wQyWkygtYDUEq138Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_TdOD8gcX0E-gFHFunA9HiA">25</ix:nonFraction>% vesting on March&#160;7, 2021. On April 6, 2021, pursuant to the Company&#8217;s Director Compensation Policy (see below), the Company granted stock options to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_4_6_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_fx1ygIKoY02ITh98bpD4mQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_jPAHnXPWrUS0r3dnS4HCDQ">7,500</ix:nonFraction> shares of Common Stock to <ix:nonFraction unitRef="Unit_Standard_director_RA5R3TwOe0i9LByRRHbWMw" contextRef="Duration_4_6_2021_To_4_6_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_iOYMLdM_qUSnnsL4WR4G2g" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfDirectors" scale="0" id="Narr_KTaRipjA_EOVsYbV7VA24A">five</ix:nonFraction> members of the board of directors. &#160;The stock options have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="Duration_4_6_2021_To_4_6_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_iOYMLdM_qUSnnsL4WR4G2g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_bfGE6HDVz0qpEFFAb0OLEA">9.80</ix:nonFraction> per share and an expiration that is <ix:nonNumeric contextRef="Duration_4_6_2021_To_4_6_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_iOYMLdM_qUSnnsL4WR4G2g" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_HhHUA2DtnEqxSbwru_pUgg">ten years</ix:nonNumeric> from the date of issuance. All these options vest on the first anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Black-Scholes valuation model was used to calculate the fair value of these stock options issued pursuant to the 2020 Plan. The fair value of stock options issued was estimated at the grant date using the following weighted average assumptions: Dividend yield <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_FbxOIlI7skC81uqaZUmLDg">0</ix:nonFraction>%; Expected term <ix:nonNumeric contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_J0BCy0_ZKUCdjbjSwv0-VQ">5.2</ix:nonNumeric> years; an aggregate volatility based upon a blend of the former Parent Company&#8217;s historical volatility and guideline company historical volatility of <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_lqp3078JRUqwCsy90EboIg">129.9</ix:nonFraction>%; and Risk-free interest rate <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_CXorPI-LHU-lgoHLT21KXg">0.51</ix:nonFraction>%. The weighted average grant date fair value of options granted was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw" decimals="0" format="ixt:numdotdecimal" name="snpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue" scale="0" id="Narr_Yf8-RIhXTkCaz1naVXz5Fg">1,054,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March&#160;12, 2021, Synaptogenix adopted a new non-employee director compensation policy (the &#8220;Director Compensation Policy&#8221;). The Director Compensation Policy provides for the annual automatic grant of nonqualified stock options to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_GxaNy02f7U-vVY71VeBA5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_HPoRPVSp0Uq73O-SIxNX2Q">1,500</ix:nonFraction> shares of Synaptogenix&#8217;s Common Stock to each of Synaptogenix&#8217;s nonemployee directors. Such grants shall occur annually on the fifth business day after the filing of Synaptogenix&#8217;s Annual Report on Form&#160;10-K and shall vest on the one-year anniversary from the date of grant subject to the director&#8217;s continued service on the Board of Directors on the vesting date. The Director Compensation Policy also provides for the automatic grant of nonqualified stock options to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_sv5TfcxykECMI_R-TDkDOg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_YpfUBXW3XEOFD3xEyQC87Q">1,200</ix:nonFraction> shares of Synaptogenix&#8217;s Common Stock, plus options to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_sv5TfcxykECMI_R-TDkDOg" decimals="INF" format="ixt:numdotdecimal" name="snpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors" scale="0" id="Narr_O8J8_49-hkWd0sjShVJFBw">300</ix:nonFraction> shares of Common Stock for service on a committee of the Board of Directors, to each newly appointed director following the date of his or her appointment. Such options shall vest as follows: fifty percent (<ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_3_12_2021_To_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember__FUNeXcc1U2KnJsXyWj-rQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_NsphB43QMkutpl_mm-bnyw">50</ix:nonFraction>%) on the date of the grant, twenty-five percent (<ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_3_12_2021_To_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_MbYQXmYqxEe7PlJNeR4iPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_WhWuI9S5_EKliZnQ_bLxlA">25</ix:nonFraction>%) on the one year anniversary from the date of the grant, and twenty-five percent (<ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_3_12_2021_To_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_9fTB0b96S0mwgdrtIFJHkA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_ZPwxgt8yLkOQOBT7KKd4wA">25</ix:nonFraction>%) on the second year anniversary from the date of the grant, subject to the director&#8217;s continued service on the Board of Directors on the applicable vesting dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Grants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On July 13, 2021, the Company granted a total of <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_jhrqwDH5JUKGX1yjRe_zDQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_wTcugCGtUkSRlBxZBbVMNg">495,000</ix:nonFraction> restricted stock units (RSUs) of which <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_TIqQYJV7CE6L3nRKPgyfzA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_4A_NOL2wH0uocw1HE_VXGQ">425,000</ix:nonFraction> were granted to <ix:nonFraction unitRef="Unit_Standard_director_RA5R3TwOe0i9LByRRHbWMw" contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_jhrqwDH5JUKGX1yjRe_zDQ" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfDirectors" scale="0" id="Narr_f92C0nRGokSlI-SOZ8q17A">seven</ix:nonFraction> Board members (including <ix:nonFraction unitRef="Unit_Standard_director_RA5R3TwOe0i9LByRRHbWMw" contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_jhrqwDH5JUKGX1yjRe_zDQ" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfExecutiveDirectors" scale="0" id="Narr_2gILetGOvk2Kqdc_kHvsVQ">two</ix:nonFraction> executives), <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_srt_ChiefFinancialOfficerMember_8D5SdWMw5U6irlsB96168A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_LQa-22CfL0CtUifOXgvBMg">60,000</ix:nonFraction> to the Company&#8217;s CFO and <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_6QohAsIzTk-vhW1SAPewPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_7eCKAodTak6ifm0ZrzZgEA">10,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_employee_TK-gmXNo9Eqj4Kw_3BydmQ" contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_XOhWuqO7-UmxW3rdr5h8WQ" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfEmployee" scale="0" id="Narr_A4fxN6YBuU2fopbhAJP0bA">two</ix:nonFraction> employees. The RSUs vest <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_snpx_SixMonthAnniversaryOfGrantDateMember_-sX3SPAv7ECVADMCMnxDhg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_qcUeLGzp90aKKT1ZvlDVMQ">50</ix:nonFraction>% upon the six month anniversary of the grant with the remaining <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_snpx_FirstAnniversaryOfGrantDateMember_ATxH9vpPDUaonf7pLjCDXw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_vehzf-0K9k27cnzSn4RRdA">50</ix:nonFraction>% vesting upon the one year anniversary of the grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Total stock-based compensation for the nine months ended September 30, 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_lqTTCdUJv0Gbk8pPOgt1Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_RqB-dhIpzE-_Rps-7_aNPw">1,918,651</ix:nonFraction>, of which $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_l191m19UVk-g-tWdcIuAvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_kJk2bmJrT0WzAV7OCSMyUA">424,993</ix:nonFraction> was classified as research and development expense and $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_ZcuRlFcZlk6RzU5e00C74w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_0GjqdgxfZUaUIi5RpKR1Fg">1,493,658</ix:nonFraction> was classified as general and administrative expense. Total stock-based </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_GSZYKI0qqUuSfqzaHGeC9g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">compensation for the nine months ended September 30, 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_0euqztFk-UWqNJ-EMYldhw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_bcFeMD7P2UGgzykjwqwWQw">1,449,024</ix:nonFraction>, of which $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_5hwgduBRaEOxiMvk-glrAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_VUDNrQQTl0WnY5HMO7CDZg">551,865</ix:nonFraction> was classified as research and development expense and $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_ghqdfvGBdUyTpIbQr-dO0g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_vWp3M2lfL0qFPak66QD_uQ">897,159</ix:nonFraction> was classified as general and administrative expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For the three months ended September 30, 2021, total stock-based compensation was $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_hF3BfbuxTkaBt64WDXedaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_VZqsv4HaNkK6v0msYDM1WQ">1,198,860</ix:nonFraction>, of which $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_sQgKmUmCo0SOmBKWdTYsrw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_4ZjOqAloe0-QS9JCmPb4sQ">215,528</ix:nonFraction> was classified as research and development and $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_FYkHNg0eDkqsEfsyfLe89Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_LiKwztm-F0i_RjlgM1Ndxg">983,332</ix:nonFraction> was classified as general and administrative expense. Stock-based compensation for the three months ended September 30, 2020, was $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_eXAu7kGsKUqqwxXMjOEi5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_H6qQBygVZk27DVVXdnDs_g">387,928</ix:nonFraction>, of which $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_9otCxOcf30aqj9YleMKvAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_mEOiVcOHak6RqT0YC3gVoQ">153,025</ix:nonFraction> was classified as research and development and $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_QhnfmLSW0k2hAwylpTMIlg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_nGmlyGIWf0ajQgJGGSV_4g">234,903</ix:nonFraction> was classified as general and administrative expense.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="snpx:StockOptionNoteDisclosureTextBlock" id="Tb_28JAfnXPfkqUft-sx6Xx_w" continuedAt="Tb_28JAfnXPfkqUft-sx6Xx_w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Note 8 &#8211; Common Stock Warrants:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Beginning on September&#160;28, 2020, Neurotrope entered into separate warrant amendment agreements with certain existing holders of its warrants to purchase shares of the Neurotrope&#8217;s common stock. As of October&#160;26, 2020, holders of warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_10_26_2020_Wvo7So2luU-dbvH6dz-R9g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_e5AxAPUq3UmNl2HM-QjBVQ">978,077</ix:nonFraction> shares of Neurotrope Common Stock had entered into warrant amendment agreements, including holders of Series&#160;E Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hBfQpmlzBEiZWBUIw5oRgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_bkH3hpSNIEWjEsoBu9RUGA">39,535</ix:nonFraction> shares of common stock, Series&#160;F Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_c7G1rxSzNE2F1m4rqz2OEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_-Y3DCWYlbEaM_gfGM3WRbw">155,917</ix:nonFraction> shares of common stock, Series&#160;G Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_tkPkOaqtJUqYc0v8c4QvAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_jqNnVahEbUGM280871AC3g">227,163</ix:nonFraction> shares of common stock and Series&#160;H Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesHWarrantsMember_Po7eMRWnyk627VgjFVaEXg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_lC9uIxu0JESc_1iXJcBb9Q">555,462</ix:nonFraction> shares of Neurotrope&#8217;s Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the terms of the warrant amendment agreements, Neurotrope and the holders agreed to the following provisions with respect to the Company&#8217;s warrants:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The initial exercise price of the Spin-Off Warrants was determined as follows for each of the Original Warrants (all of which expire on December&#160;7, 2025):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">for the Neurotrope Series&#160;E Warrants (now the Company&#8217;s Series&#160;A Warrants), by dividing $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q" decimals="-6" format="ixt:numdotdecimal" name="snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants" scale="6" id="Narr_zPeyEcpPbUKwQhHZfxxnGQ">250</ix:nonFraction>&#160;million by <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_aMs2yxkpWEe7tYMJ_xTFLQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_M8pg75I3TUyDFIl_npOSNQ">1,257,604</ix:nonFraction> shares of common stock of the Spin-Off Company outstanding immediately after the Spin-Off. This resulted in an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesWarrantsMember_55AWN-0IQEiKtuL0SJcHtA" decimals="INF" format="ixt:numdotdecimal" name="snpx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment" scale="0" id="Narr_TLRPllRsmkaTVDtbiLg7Bw">198.80</ix:nonFraction> per warrant for <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesWarrantsMember_55AWN-0IQEiKtuL0SJcHtA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_StHVF6hSKE2rSakSh8zuuw">39,535</ix:nonFraction> Series&#160;A Warrants;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">for the Neurotrope Series&#160;F Warrants (now the Company&#8217;s Series&#160;B Warrants), by dividing $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_yUgO0gWhX0Kj3WzQ05UBjA" decimals="-6" format="ixt:numdotdecimal" name="snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants" scale="6" id="Narr__HhtoeJ8C02rtHvfcMWRPA">100</ix:nonFraction>&#160;million by <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_gbBWD2FtDki4KkvEusVG5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_XUL4QB1HI0yHlcPxMBtIPQ">1,257,604</ix:nonFraction> of shares of common stock of the Spin-Off Company outstanding immediately after the Spin-Off. This resulted in an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesBWarrantsMember_7SQ3AypUt0SSMTahwvnMAA" decimals="INF" format="ixt:numdotdecimal" name="snpx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment" scale="0" id="Narr_M8FNYinzSUCL44afoc7gqQ">79.52</ix:nonFraction> per warrant for <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesBWarrantsMember_7SQ3AypUt0SSMTahwvnMAA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_L_nx0ArEpU2FpYKo85Bp-A">155,917</ix:nonFraction> Series&#160;B Warrants;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">for the Neurotrope Series&#160;G Warrants (now the Company&#8217;s Series&#160;C Warrants), by dividing $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_2k34O0Id4kWZX644U9EfIQ" decimals="-6" format="ixt:numdotdecimal" name="snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants" scale="6" id="Narr__rz5yAqKTUCQEvNc29IrZQ">50</ix:nonFraction>&#160;million by <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Bv7Emv5esUO_DuRCzz0CPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_e9yIS9UXH0-tMcZN35KfuA">1,257,604</ix:nonFraction> shares of common stock of the Spin-Off Company outstanding immediately after the Spin-Off. This resulted in an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesCWarrantsMember_z_WS3P03W02KA988MbJQRw" decimals="INF" format="ixt:numdotdecimal" name="snpx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment" scale="0" id="Narr_sCwfFq3Wo0i5RStf5N65iw">39.76</ix:nonFraction> per warrant for <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesCWarrantsMember_z_WS3P03W02KA988MbJQRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_P08LrvPOlECiCCQw-STGPw">227,163</ix:nonFraction> Series&#160;C Warrants; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(iv)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">for the Neurotrope Series&#160;H Warrants (now the Company&#8217;s Series&#160;D Warrants), by dividing $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesHWarrantsMember_t0GYiy1420idJAGM8em5Jw" decimals="-6" format="ixt:numdotdecimal" name="snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants" scale="6" id="Narr_0vtyreXRSkmmM0COgbayuw">20</ix:nonFraction>&#160;million by <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesHWarrantsMember_6isVxzRL6UqO5BOyR_DEnQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_B-BuFYAFL0miv_41T1Qt_Q">1,257,604</ix:nonFraction> of shares of common stock of the Spin-Off Company outstanding immediately after the Spin-Off. This resulted in an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesDWarrantsMember_TqviIe44M0KRUuCnfF8Jsg" decimals="INF" format="ixt:numdotdecimal" name="snpx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment" scale="0" id="Narr_gbVJms2YBUOXYp5vq01zVg">15.92</ix:nonFraction> per warrant for <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesDWarrantsMember_TqviIe44M0KRUuCnfF8Jsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_3ngjUP7Xbkyj7Ne0cqx8WQ">555,462</ix:nonFraction> Series&#160;D Warrants.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company used the Black-Scholes valuation model to calculate the warrant amendment expense. The fair value of the warrants amended in connection with the Mergers was estimated at the date of the merger using the following weighted average assumptions: Dividend yield <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_9_30_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_WrGK0uDCmUGfS8ag_ejX5w" decimals="INF" format="ixt:numdotdecimal" name="snpx:SpinOffRatio" scale="0" id="Narr_6rM8f12GfEqKo44bJhDD9Q">0</ix:nonFraction>%; Expected terms ranging from <ix:nonNumeric contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_B-Ol5sPKMEmSFSQmzxOz7Q" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_tUm0N__pEkW3gKLDpDZ8RA">0.2</ix:nonNumeric> to <ix:nonNumeric contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_C14DO597P0mvWWCy-BLV8g" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_RHzM-kX_t0uzLKmHZ6xIAg">10</ix:nonNumeric> years; volatility based upon a blend of the Parent company&#8217;s and guideline company historical volatility ranging from <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_aqF2KklEf0u18kWTm7BHtQ" decimals="INF" format="ixt:numdotdecimal" name="snpx:SpinOffRatio" scale="0" id="Narr_0cuSNSjkdk68jsA9bMNHgQ">31.75</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_IAPUN0sCQ0SOUwKfGoet8Q" decimals="INF" format="ixt:numdotdecimal" name="snpx:SpinOffRatio" scale="0" id="Narr_cJ2y8Ep_X0aHdhvpW5SdgA">112.3</ix:nonFraction>%; and Risk-free interest rates ranging from <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_aqSGqF3d9EOAW-vdRB2T0w" decimals="2" format="ixt:numdotdecimal" name="snpx:SpinOffRatio" scale="0" id="Narr_vBFQd_p41UK1BOsAHnKsCw">0.11</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_7ynEJUOgpEaTJWjy14CbxQ" decimals="2" format="ixt:numdotdecimal" name="snpx:SpinOffRatio" scale="0" id="Narr_4wzyLSdAoU6KSlZsT8DvJw">0.42</ix:nonFraction>%. The total expense recorded in the third quarter of 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" id="Narr_AjEmOe2qJkqB1XWnrQdOiw">1.7</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Deemed Distribution</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;7, 2020, pursuant to the Merger , the Company issued a total of <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_QdVgTl0vo0yG_OL_6eRY7g">978,077</ix:nonFraction> warrants to investors that elected to amend their existing Neurotrope warrants (see above) and a total of <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_osxEMCeBtkmBHP2Q9bIx0g">52,983</ix:nonFraction> shares of Common Stock to those Neurotrope shareholders not electing to amend their existing warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_6l0XzDcHmEm7pmGHn_B7ew_1_2"></a><a id="Tc_6fnH2bxG_EmLeuj0ZW2nMA_2_2"></a><a id="Tc_yP4ID6MXn0m1s1bGHJ3Ftw_3_0"></a><a id="Tc_SOuYtqhKp0WnTdOf79yjYg_4_0"></a><a id="Tc_KAHlkbGrlE6-JpI9M30JgA_5_0"></a><a id="Tc_UmQ0TCHGXU2IrvNUfnp7QA_6_0"></a><ix:continuation id="Tb_28JAfnXPfkqUft-sx6Xx_w_cont1"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The distribution was treated as a deemed dividend, which increased the loss available to common stockholders in the calculation of loss per share by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g" decimals="-4" format="ixt:numdotdecimal" name="snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants" scale="6" id="Narr_p8CLJgVVxUGgdYTuYtcrMg">2.43</ix:nonFraction> million in the fourth quarter of 2020. The Company used the Black-Scholes valuation model to calculate the total charge to earnings per share. The fair value of the warrants and Common Stock issued in connection with the deemed distribution was estimated at the date of the Spin-Off using the following assumptions: Dividend yield <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_AlB4qWeQFkGYL40ag-oXkg" decimals="INF" format="ixt:numdotdecimal" name="snpx:SpinOffRatio" scale="0" id="Narr_-m6XCZJWZkaD8qv9Di0lSQ">0</ix:nonFraction>%; Expected term of warrants <ix:nonNumeric contextRef="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eLQU0iW2-kKPmLdZRgP3_A" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_ZUUr0KE0jk6DvNzxC5XvsA">5</ix:nonNumeric> years; volatility based upon a blend of Neurotrope&#8217;s and guideline company historical volatility of <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_NsMIo03fS0GvupLoZPxqNQ" decimals="1" format="ixt:numdotdecimal" name="snpx:SpinOffRatio" scale="0" id="Narr_6S3IVcdDWkKXmsWyejEGaw">115.0</ix:nonFraction>%; and a Risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_s2nrkv1GlUOqLv_ow-biXw" decimals="2" format="ixt:numdotdecimal" name="snpx:SpinOffRatio" scale="0" id="Narr_bfMubOy1hkaIX-XHMzpwMQ">0.40</ix:nonFraction>%.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Outstanding Warrants</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2021, the Company had warrants outstanding consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_Jn3x5JA2Lk68XsR7wQT93Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of&#160;shares</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding January&#160;1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_4NleRKmQI06NI7gc-WAFWA_3_2">978,077</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="Tc_EfWVvYl1uEK0A8cNtWBRKg_4_2">6,908,751</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" id="Tc_7ScGxa1FEUycvMM4yjqITQ_5_2">1,038,898</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_DT7ITOMgnECgapDnGBIzig_6_2">6,847,930</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the Offering, the Company issued to investors Series&#160;E Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_CU6eHywSfU2jd_Ogr83-kg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_RJT4wFQVZ0ejPMXGU_1EgQ">2,333,908</ix:nonFraction> shares of Common Stock, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_CU6eHywSfU2jd_Ogr83-kg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Uo_rqLd6fUaXSjAyk-I6hA">8.51</ix:nonFraction> per share (subject to adjustment), for a period of <ix:nonNumeric contextRef="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_CU6eHywSfU2jd_Ogr83-kg" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_wutJo2SOD0690kWBoxGAtA">twelve months</ix:nonNumeric> from the date of an effective registration statement, Series&#160;F Warrants to purchase up to an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_SDRsv452YEy1QbPpr3-H7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_ez9YcAaef0Sa61sF-377pA">2,567,299</ix:nonFraction> shares of Common stock, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_SDRsv452YEy1QbPpr3-H7A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_dUH6lACA2kWgwtSdik1uJw">6.90</ix:nonFraction> per share (subject to adjustment), for a period of <ix:nonNumeric contextRef="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_SDRsv452YEy1QbPpr3-H7A" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_1IfPwft3H0WfbGygbaVN8w">five years</ix:nonNumeric> from the date of issuance and pre-funded Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_1_31_2021_e--_NbHbEE6MXeRdEtUWUQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_f0WYTwvJC0eSUVWDjLKMsw">83,334</ix:nonFraction> shares of Common Stock, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_1_31_2021_e--_NbHbEE6MXeRdEtUWUQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Ls89nvBRhEiajJ4yHrvx-Q">0.01</ix:nonFraction> per share (subject to adjustment), for a period of <ix:nonNumeric contextRef="As_Of_1_31_2021_e--_NbHbEE6MXeRdEtUWUQ" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_X4aXLi0OI0CsovVbFn8e6A">five years</ix:nonNumeric> from the date of issuance. Of the total Series&#160;F Warrants, <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_SDRsv452YEy1QbPpr3-H7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_7rSCOJIhmU6eGEPyKqrOMQ">233,391</ix:nonFraction> were issued pursuant to the Company&#8217;s placement agent agreements for the private placement (See Note 6 &#8211; &#8220;January&#160;2021 Private Placement&#8221; above). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the June Offering, the Company issued to investors Series G Warrants to purchase up to an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_6_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Fr0ZwcPdYUak8BJTwsJziA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_i-Wh0u0_U0irWIbB344Qzg">1,653,281</ix:nonFraction> shares of Common stock, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_6_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Fr0ZwcPdYUak8BJTwsJziA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr__iOZQ7cobkGC0kONyDjBIA">8.51</ix:nonFraction> per share (subject to adjustment), for a period of <ix:nonNumeric contextRef="As_Of_6_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Fr0ZwcPdYUak8BJTwsJziA" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_GIGQBfTXE0ejO5nd2YGZxQ">five years</ix:nonNumeric> from the date of issuance and pre-funded June Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_6_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Fr0ZwcPdYUak8BJTwsJziA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_dwDHetMWQEeG6wp3nSKMAA">66,251</ix:nonFraction> shares of Common Stock, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_6_30_2021_Xii_2FmPcky3sXIraY0ypg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_8xWtvSIOck-t4N-EISUBxw">0.01</ix:nonFraction> per share (subject to customary adjustment for stock splits, dividends, other), for a period of <ix:nonNumeric contextRef="As_Of_6_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Fr0ZwcPdYUak8BJTwsJziA" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_TeNPOLN6jE2hgUFEgak6XQ">five years</ix:nonNumeric> from the date of issuance. In addition, <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_snpx_PlacementAgentAgreementMember_iBkmenKfkESMsfPkSD7zrQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_dcKM6J9W40ust4y2JN87Bg">152,378</ix:nonFraction> warrants were issued pursuant to the Company&#8217;s Placement Agent Agreement for the private placement with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_snpx_PlacementAgentAgreementMember_iBkmenKfkESMsfPkSD7zrQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_3BpLmnChE0uyhNx4FLosKQ">7.547</ix:nonFraction> per share (See Note 6 &#8211; &#8220;June 2021 Private Placement&#8221; above).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On February 16, 2021, pursuant to its advisory agreements, the Company issued warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_5eSvOe54PkCVmjdVxgbZig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_r603chrdtEuZIGABDH0kCA">35,000</ix:nonFraction> share of Common Stock, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_5eSvOe54PkCVmjdVxgbZig" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_1HvPYPhY2EGmDRh3kfGqPw">11.46</ix:nonFraction> per share, for a period of <ix:nonNumeric contextRef="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_5eSvOe54PkCVmjdVxgbZig" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_zU7z9p92b0Sjwpp5gjHxdA">five years</ix:nonNumeric> from the issuance date. On April 1, 2021, the Company issued warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember__pHwfWJFzkixGuEnVWDzJA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_fxEJek2B_kWL4JjZYUBH2A">7,000</ix:nonFraction> shares of Common Stock, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember__pHwfWJFzkixGuEnVWDzJA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_NXPQV1bL50WD3-g9epzLYQ">9.76</ix:nonFraction> per share, for a period of <ix:nonNumeric contextRef="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_5eSvOe54PkCVmjdVxgbZig" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_y99ltBQ0l0WCfIEbftN7Yg">five years</ix:nonNumeric> from the issuance date. On July 1, 2021, the Company issued warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_FH717EVLtkqn-fpPWhn4rA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_skwGVwf8I0GMVTt8EPUtSg">10,300</ix:nonFraction> shares of Common Stock, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_FH717EVLtkqn-fpPWhn4rA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_XBQkF_j05EudGYA7aT3DKg">9.30</ix:nonFraction> per share, for a period of <ix:nonNumeric contextRef="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_FH717EVLtkqn-fpPWhn4rA" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_R-NXyI0cYUCuyZtRgNjaeA">five years</ix:nonNumeric> from the issuance date. The Company used the Black-Scholes valuation model to calculate the value of these warrants issued to advisors during the nine months ended September 30, 2021. The fair value of the warrants was estimated at the date of issuance using the following weighted average assumptions: Dividend yield <ix:nonFraction unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g" contextRef="As_Of_2_16_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_x7uB4f4XkkixVNeVpg4H_w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_sKjKoKc560-w5FFX47ZdSw">0</ix:nonFraction>%; Expected term <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="As_Of_9_30_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_cABB2dwDnkidrh1FDqutMA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_kZjrN-YFjEiWiCRH3z_ejA">five</ix:nonFraction> years; volatility based upon a blend of the Parent company&#8217;s and guideline company historical volatility <ix:nonFraction unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g" contextRef="As_Of_2_16_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_SVTnUQyCqkSlwAQiGiSQ2w" decimals="1" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_6hiqwLwef0WC37jisxpScw">129.4</ix:nonFraction>%; and Risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g" contextRef="As_Of_2_16_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_wMyE8rhAOUa-rFk2SZC6uQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_5qFU0LD_CkGKR07Sw7V4-A">0.68</ix:nonFraction>%. The total expense recorded during the nine month period was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_lvIlGvc4GUestVJZO6CW1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="Narr_4c3LOaYpIE6F8YMnqWuDTw">482,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">During the three month period ended September 30, 2021, <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_NgyqTk38w0WSX-vTVG_Qfw" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfWarrantHoldersWhoExercisedWarrants" scale="0" id="Narr_iEXkKcpCqke-j3DORHLteg">five</ix:nonFraction> warrant holders exercised <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_fMguviqZT0-vf1vNCpbacg">79,169</ix:nonFraction> Series E Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_YQzxFfn_zUmxCJ_90cH1NQ">79,169</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr__wq73PVzQE62OSBvsbbFAQ">8.51</ix:nonFraction> per warrant and <ix:nonFraction unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember__q6Kouwx7ka5jQwWeyinOg" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfWarrantHoldersWhoExercisedWarrants" scale="0" id="Narr_M3n40ykw70W9Flbdzd6q_A">three</ix:nonFraction> warrant holders exercised <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_yUgO0gWhX0Kj3WzQ05UBjA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_iVa370gQIkWuVEo_VkrXuQ">18,335</ix:nonFraction> Series F Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_yUgO0gWhX0Kj3WzQ05UBjA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_b4Ih_dFL9EaKwGAs64WgQg">18,335</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_yUgO0gWhX0Kj3WzQ05UBjA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_o1ns_XTOyE-4yUtZ-Zuhfw">6.90</ix:nonFraction> per warrant. Total proceeds from these warrant exercises was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Narr_dhWulTzvgUmjlIqZEY6Byw">800,000</ix:nonFraction>. During the nine month period ended September 30, 2021, <ix:nonFraction unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_aMs2yxkpWEe7tYMJ_xTFLQ" decimals="INF" format="ixt:numdotdecimal" name="snpx:NumberOfWarrantHoldersWhoExercisedWarrants" scale="0" id="Narr_8i5NuZxV5EuZMQf9QSW_Ug">16</ix:nonFraction> warrant holders exercised <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q" decimals="INF" format="ixt:numdotdecimal" name="snpx:ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_p0TxDU6s70KA7HU5-bRNKg">754,170</ix:nonFraction> Series E Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q" decimals="INF" format="ixt:numdotdecimal" name="snpx:ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_-rcQDgpaRk-u23RRHaYXsw">754,170</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_w7Gs9CUw0Uew9GD9_o8p4w">8.51</ix:nonFraction> per warrant and <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_gbBWD2FtDki4KkvEusVG5A" decimals="INF" format="ixt:numdotdecimal" name="snpx:NumberOfWarrantHoldersWhoExercisedWarrants" scale="0" id="Narr_1ygcJ4t7wEKZMRD7Ciq6qA">14</ix:nonFraction> warrant holders exercised <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_yUgO0gWhX0Kj3WzQ05UBjA" decimals="INF" format="ixt:numdotdecimal" name="snpx:ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_1G_BwRIM_kKGNNa74zD5Pw">284,728</ix:nonFraction> Series F Warrants to purchase <ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_gbBWD2FtDki4KkvEusVG5A" decimals="INF" format="ixt:numdotdecimal" name="snpx:NumberOfWarrantHoldersWhoExercisedWarrants" scale="0" id="Narr_yanEgVCKtESXProJ0mwspQ">284,728</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_yUgO0gWhX0Kj3WzQ05UBjA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_EQYtLGQh60OWcBLf3AbYWA">6.90</ix:nonFraction> per warrant. Total proceeds from these warrant exercises was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_vJFU858LdEeYcpWu1AAhUg">8.4</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">Subsequent to period end, during October and November, 2021, <ix:nonFraction unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g" contextRef="Duration_10_1_2021_To_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_lR04OAC-tUOnEiZFv4wu8A" decimals="INF" format="ixt:numdotdecimal" name="snpx:NumberOfWarrantHoldersWhoExercisedWarrants" scale="0" id="Narr_Ntfz1UBbN06mP1PGm8iPLg">16</ix:nonFraction> warrant holders exercised <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Mqocl8Q9OUW-zNTHh7tZ4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_SjnLJD1Ha0SrBDNP93aLHw">425,170</ix:nonFraction> Series E Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Mqocl8Q9OUW-zNTHh7tZ4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_nU6mNp78oUeSDLoywp7q0A">425,170</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Mqocl8Q9OUW-zNTHh7tZ4Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_P3KuCAbyGk6apP4d_60VZw">8.51</ix:nonFraction> per share, <ix:nonFraction unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g" contextRef="Duration_10_1_2021_To_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Cr2IzRTXakm82Stu4mohyg" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfWarrantHoldersWhoExercisedWarrants" scale="0" id="Narr_IVVzUwRQr0yARS0OqKrEhQ">nine</ix:nonFraction> warrant holders exercised <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_DeGjeBcBwEGnc13gbozhlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_QNKjR1vdk0S2i2vKnp1-Tw">47,335</ix:nonFraction> Series F Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_DeGjeBcBwEGnc13gbozhlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_12sTMK7qdEyuhqd2k62hkw">47,335</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_DeGjeBcBwEGnc13gbozhlA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_R2LzWv7JfUeWjM_f6le02Q">6.90</ix:nonFraction> per share, and <ix:nonFraction unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g" contextRef="Duration_10_1_2021_To_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kLgOmbRun06NqMMcX7EhDg" decimals="INF" format="ixt-sec:numwordsen" name="snpx:NumberOfWarrantHoldersWhoExercisedWarrants" scale="0" id="Narr_49Ru4fu250ykfcyaZctxhg">one</ix:nonFraction> holder exercised <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EUnVc5n1yE-8V5lSC_clxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_XXaCwSIIiEGwJt5K0mvWOw">65,000</ix:nonFraction> Series G Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ" contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EUnVc5n1yE-8V5lSC_clxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_v9XO3CES0kKw7OHPtcCWxw">65,000</ix:nonFraction> shares of Common Stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A" contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EUnVc5n1yE-8V5lSC_clxw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_TGCm7tHgmkCbMrxHy9SyMA">8.51</ix:nonFraction> per share. Total cash proceeds from these warrant exercises was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_10_1_2021_To_11_30_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eDY3684nJE-p7S0A8UmC-g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_kLe08QzVZkuiQI-HhLNR5w">4.5</ix:nonFraction> million.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_IiBtlbpolUuibIDurw8IiQ_1_2"></a><a id="Tc_WYGOPLvAUkK4VeYnZ8_CKA_2_2"></a><a id="Tc_dfZ0Vvy8dUKL4HcG3OJnvA_3_2"></a><a id="Tc_p6DSOQWR6kGxCCsS-z1Tsg_3_5"></a><a id="Tc_jluNPUPvD0iliS-Wx4bLfQ_4_0"></a><a id="Tc_eHza7rnPyE2umQz45bhSCw_4_2"></a><a id="Tc_0BVYKDNoXkmHQBcQJx3b7w_4_5"></a><a id="Tc_ElGNDYkBZ0WdIdF1Cp1Htw_5_0"></a><a id="Tc_uzHdYjFGYUqT6rSqJKAytA_6_0"></a><a id="Tc_-4OcbWhfoE2Y5qc8nwj4YA_6_6"></a><a id="Tc_UkAIyXz5fky4qxAgF3sSVw_7_0"></a><a id="Tc_2WRWLuBkfU2BL--NCqNRAw_7_2"></a><a id="Tc_dPe5M7MJQUeyzHxXlrMymw_7_5"></a><a id="Tc_B8ffpWjYjU2pycnyEE09sw_1_2"></a><a id="Tc_gjDCod-i9UqWqT8MbzZr_g_2_2"></a><a id="Tc_9ASCAk_mvU6fstcptHcp8A_3_2"></a><a id="Tc_azn2gwjbKEGaJl8Lc-xWxw_3_5"></a><a id="Tc_QgcPWdSy_U6e3mvn1wSBPA_4_0"></a><a id="Tc_lb6hYDmUKEyu4hQTHppogw_4_2"></a><a id="Tc_KkfOrxarrk-f9gQbkrYR-g_4_5"></a><a id="Tc_njEPqmPXGkuUbVEBVq0vnw_5_0"></a><a id="Tc_BlSSNi-KNEaN-y9PkugB7g_6_0"></a><a id="Tc_q-f0TF7iFUyP2Dhk0iFR2Q_7_0"></a><a id="Tc_fbofsQlBQEmw1P3S8pYjVQ_7_2"></a><a id="Tc_CK41PMY5Fkmdt-ye7CAxtw_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock" id="Tb_8UyxllxUwUOnN-cRvJ77PQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 9 - Parent Company Investment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The components of the net transfers from parent for the three and nine months ended September 30, 2021 and 2020 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" id="Group_eRUu8wFrPkSg5tqFa41SDw" continuedAt="Group_eRUu8wFrPkSg5tqFa41SDw_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three&#160;months&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock based compensation from Parent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw" decimals="0" format="ixt:zerodash" name="snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation" scale="0" id="Tc_wbYiiO2WbkSRh1Rd7V0HIQ_4_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q" decimals="0" format="ixt:numdotdecimal" name="snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation" scale="0" id="Tc_257GytQpq0KQtjdOs1YGCg_4_6">387,927</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consultant compensation paid with Parent equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw" decimals="0" format="ixt:zerodash" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" scale="0" id="Tc_4KhyV-Q74EmrCh3vA-f8CA_5_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" scale="0" id="Tc_zKq43i8h60OuC1IgiqTaAQ_5_6">233,281</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Parent contributions</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw" decimals="0" format="ixt:zerodash" name="snpx:ContributionsFromParent" scale="0" id="Tc_o0PRQlpCeE6OEt-s8GNMXQ_6_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw" decimals="0" format="ixt:zerodash" name="us-gaap:LaborAndRelatedExpense" scale="0" id="Tc_ePpivtDIGEqRqvxUmugEpg_7_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="0" id="Tc_xJWi-EyAoEius7PSlm7jvg_7_6">621,208</ix:nonFraction></p></td></tr></table></ix:nonNumeric><ix:continuation id="Group_eRUu8wFrPkSg5tqFa41SDw_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine&#160;months&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock based compensation from Parent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:zerodash" name="snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation" scale="0" id="Tc_eY4mF6iPh0aih1mgBE5lag_4_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation" scale="0" id="Tc_2rFtFSL0XEmNrAFT5GC6-Q_4_6">1,449,023</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consultant compensation paid with Parent equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:zerodash" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" scale="0" id="Tc_oDbjrR0OUkabj18HDq_vpQ_5_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" scale="0" id="Tc_OITdzKRRnE6931-ATDpcsQ_5_6">500,740</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Parent contributions</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:zerodash" name="snpx:ContributionsFromParent" scale="0" id="Tc_bGX9fXW47kuTiXl7D2qAmA_6_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="snpx:ContributionsFromParent" scale="0" id="Tc_atcVtHA-ckex8I6biXAkVg_6_6">16,519,988</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" decimals="0" format="ixt:zerodash" name="us-gaap:LaborAndRelatedExpense" scale="0" id="Tc_Lpq9sD4n7kSaA12RUkjQ4w_7_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A" contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="0" id="Tc_TlRTyd71lkq0_bNgGxVmfA_7_6">18,469,751</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw" name="us-gaap:SubsequentEventsTextBlock" id="Tb_A9FOqOZp0kC-JpJuYyqkBA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#160;10&#160;&#8211; Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Refer to Notes 1, 5, 6, 7 and 8 for disclosure of applicable subsequent events.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e8083ca1_06e4_4657_851f_e58917d71373"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled &#8220;Risk Factors&#8221; included elsewhere in this report and our annual report on Form&#160;10-K for the&#160;year ended December&#160;31, 2020.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion highlights our results of operations and the principal factors that have affected our financial condition as well as our liquidity and capital resources for the periods described, and provides information that management believes is relevant for an assessment and understanding of the statements of financial condition and results of operations presented herein. The following discussion and analysis are based on the unaudited financial statements contained in this report, which we have prepared in accordance with United States generally accepted accounting principles. You should read the discussion and analysis together with such financial statements and the related notes thereto.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Explanatory Note</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May&#160;17, 2020, Neurotrope,&#160;Inc. (Neurotrope or Parent) announced plans for the complete legal and structural separation of us from Neurotrope, also known as the Spin-Off. Under the Separation and Distribution Agreement, Neurotrope planned to distribute all of its equity interest in us to Neurotrope&#8217;s stockholders. Following the Spin-Off, Neurotrope would not own any equity interest in us, and we would operate independently from Neurotrope. Neurotrope Bioscience,&#160;Inc. was a wholly-owned subsidiary of Neurotrope prior to the completion of the Spin-Off on December&#160;7, 2020 (see below for description of Spin-Off). Neurotrope Bioscience,&#160;Inc. represented substantially all the business of Neurotrope.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;6, 2020, Neurotrope approved the final distribution ratio and holders of record of Neurotrope common stock, Neurotrope preferred stock and certain warrants as of November&#160;30, 2020 received a pro rata distribution at the rate of (i)&#160;one share of our Common Stock for every five shares of Neurotrope common stock held, (ii)&#160;one share of our Common Stock for every five shares of Neurotrope common stock issuable upon conversion of Neurotrope preferred stock held and (iii)&#160;one share of our Common Stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held that were entitled to participate in the Spin-Off pursuant to the terms thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The unaudited financial statements for the fiscal nine months ended September 30, 2021 and 2020 include a summary of our significant accounting policies and should be read in conjunction with the discussion below and our financial statements and related notes included elsewhere in this quarterly report. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in the financial statements. All such adjustments are of a normal recurring nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subsequent to the Spin-Off, our financial statements as of December 31, 2020 and for the period December 7, 2020 to December 30, 2020 are presented on a consolidated basis as we became a standalone public company on December 7, 2020. Our combined financial statements as of September 30, 2020 were derived from the consolidated financial statements and accounting records of Neurotrope, the former Parent. These combined financial statements reflect the historical results of operations, financial position and cash flows of the former Parent&#8217;s Spin-Off business which was a wholly owned subsidiary of Neurotrope. Neurotrope Bioscience, Inc. represented substantially all the business of Neurotrope. As a result, the historical financial statements of Synaptogenix are virtually identical to those of Neurotrope, other than capitalization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a biopharmaceutical company with product candidates in pre-clinical and clinical development. We began operations in October&#160;2012. We are principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer&#8217;s disease, which is in the clinical testing stage. We are also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Neurotrope had been a party to a technology license and services agreement with the original Blanchette Rockefeller Neurosciences Institute (which has been known as Cognitive Research Enterprises,&#160;Inc. since October&#160;2016), and its affiliate NRV II, LLC, which we collectively refer to herein as &#8220;CRE,&#8221; pursuant to which we now have an exclusive non-transferable license to certain patents and technologies required to develop our proposed products. We were formed for the primary purpose of commercializing the technologies initially developed by BRNI for therapeutic applications for AD or other cognitive dysfunctions. These technologies have been under development by BRNI since 1999 and, until March&#160;2013, had been financed through funding from a variety of non-investor sources (which include not-for-profit foundations, the NIH, which is part of the U.S. Department of Health and Human Services, and individual philanthropists). From March&#160;2013 forward, development of the licensed technology has been funded principally through us in collaboration with CRE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Spin-Off from Neurotrope,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;1, 2020, Neurotrope, Petros Pharmaceuticals,&#160;Inc., a Delaware corporation (&#8220;Petros&#8221;), PM Merger Sub 1, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Petros (&#8220;Merger Sub 1&#8221;), PN Merger Sub 2,&#160;Inc., a Delaware corporation and a wholly-owned subsidiary of Petros (&#8220;Merger Sub 2&#8221;), and Metuchen Pharmaceuticals LLC, a Delaware limited liability company (&#8220;Metuchen&#8221;), consummated the transactions (the &#8220;Mergers&#8221;) contemplated by that certain Agreement and Plan of Merger by and among Neurotrope, Petros, Merger Sub 1, Merger Sub 2 and Metuchen, dated as of May&#160;17, 2020 (the &#8220;Original Merger Agreement&#8221;), as amended by the First Amendment to the Original Merger Agreement (the &#8220;First Amendment&#8221;), dated as of July&#160;23, 2020 and the Second Amendment to the Original Merger Agreement, dated as of September&#160;30, 2020 (the &#8220;Second Amendment&#8221; and, together with the Original Merger Agreement and the First Amendment, the &#8220;Merger Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a condition to the Mergers, Neurotrope approved the Spin-Off, which became effective on December&#160;7, 2020, whereby (i)&#160;any cash in excess of $20,000,000, subject to adjustment as provided in the Merger Agreement, and all of the operating assets and liabilities of Neurotrope not retained by Neurotrope in connection with the Mergers were contributed to Neurotrope Bioscience,&#160;Inc. (now known as Synaptogenix,&#160;Inc.), and (ii)&#160;holders of record of Neurotrope common stock, Neurotrope preferred stock and certain warrants as of the Spin-Off Record Date received a pro rata distribution at the rate of (i)&#160;one share of our Common Stock for every five shares of Neurotrope common stock held, (ii)&#160;one share of our Common Stock for every five shares of Neurotrope common stock issuable upon conversion of Neurotrope preferred stock held and (iii)&#160;one share of our Common Stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held that were entitled to participate in the Spin-Off pursuant to the terms thereof (collectively, the &#8220;Distribution&#8221;). Any fractional shares were paid in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in connection with the Spin-Off, the holders of Neurotrope&#8217;s amended and restated warrants to purchase shares of Neurotrope common stock (the &#8220;A&amp;R Warrants&#8221;) received warrants to purchase shares of our Common Stock at the ratio of one share of our Common Stock for every five shares of Neurotrope common stock issuable upon exercise of such A&amp;R Warrants held as of the Spin-Off Record Date (collectively, the &#8220;Spin-Off Warrants&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;6, 2020, we entered into the Separation and Distribution Agreement with Neurotrope that sets forth our agreements with Neurotrope regarding the principal transactions necessary to separate us from Neurotrope, including: (i)&#160;the contribution of cash in excess of $20,000,000, as adjusted pursuant to the Merger Agreement, and all of the operating assets and liabilities not retained by Neurotrope in connection with the Merger to us and (ii)&#160;the Distribution. The Separation and Distribution Agreement also sets forth the other provisions that govern certain aspects of Neurotrope&#8217;s relationship with us after the completion of the Spin-Off and provides for the allocation of assets, liabilities and obligations between us and Neurotrope in connection with the Spin-Off.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;6, 2020, we entered into a Tax Matters Agreement with Neurotrope (the &#8220;Tax Matters Agreement&#8221;) that generally governs the parties&#8217; respective rights, responsibilities and obligations after the Spin-Off with respect to taxes. Under the Tax Matters Agreement, Neurotrope will be liable for and shall indemnify us from all taxes of Neurotrope for any taxable period and any transfer taxes for which Neurotrope is responsible as a result of the Spin-Off. We will be liable for and shall indemnify Neurotrope from (i)&#160;all taxes, other than transfer taxes of Neurotrope for any pre-Spin-Off tax period to the extent they are attributable to us (ii)&#160;all taxes, other than transfer taxes, of us for any taxable period other than a pre-Spin-Off tax period, (iii)&#160;from all taxes, other than transfer taxes, of Neurotrope related to the recapture of any &#8220;dual consolidated loss&#8221; and (iv)&#160;any transfer taxes for which it is responsible as a result of the Spin-Off.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 7, 2020, we filed an amended and restated certificate of incorporation which, among other things, changed our name to Synaptogenix, Inc. Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;SNPX&#8221;.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">January&#160;2021 Private Placement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 21, 2021, we entered into Securities Purchase Agreements (the &#8220;Purchase Agreement&#8221;) with certain accredited investors (the &#8220;Purchasers&#8221;) to issue (a) an aggregate of 2,333,884 shares of our Common Stock and/or Pre-Funded Warrants to purchase shares of Common Stock, (b) Series E Warrants to purchase 2,333,908 shares of Common Stock, with an exercise price of $8.51 per share (subject to adjustment), for a period of twelve months from the date of an effective registration statement and (c) Series F Warrants to purchase up to an aggregate of 2,333,908 shares of Common Stock, with an exercise price of $6.90 per share (subject to adjustment), for a period of five years from the date of issuance at a combined purchase price of $6.00 per share of Common Stock and Warrants (the &#8220;Offering&#8221;). We received total gross proceeds of approximately $14,000,000 in Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Purchase Agreement, we entered into a Registration Rights Agreement with the Purchasers (the &#8220;Registration Rights Agreement&#8221;) on January 21, 2021. Under the terms of the Registration Rights Agreement, we agreed to register the shares of Common Stock and the shares of Common Stock issuable upon exercise of the Warrants and the Pre-Funded Warrants sold to the Purchasers pursuant to the Purchase Agreement. We filed a registration statement on Form S-1 in connection with the Registration Rights Agreement on February 8, 2021. We also agreed to other customary obligations regarding registration, including indemnification and maintenance of the effectiveness of the registration statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Offering, we paid our Placement Agents (i) a cash fee equal to ten percent (10%) of the gross proceeds from any sale of securities in the Offering sold to Purchasers introduced by the Placement Agent and (ii) warrants to purchase shares of Common Stock equal to ten percent (10%) of the number of shares of Common Stock sold to Purchasers introduced by the Placement Agent, with an exercise price of $6.90 per share and a five-year term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">June 2021 Private Placement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 14, 2021, we entered into Securities Purchase Agreements (the &#8220;June Purchase Agreement&#8221;) with certain accredited investors (the &#8220;June Purchasers&#8221;) to issue (a) an aggregate of 1,653,281 shares of Common Stock and/or prefunded warrants to purchase shares of Common Stock at an exercise price of $0.01 per share (the &#8220;June Pre-Funded Warrants&#8221;) and (b) Series G warrants to purchase up to an aggregate of 1,653,281 shares of Common stock, with an exercise price of $8.51 per share (subject to adjustment), for a period of five years from the date of issuance (the &#8220;June Warrants&#8221;) at a combined purchase price of $7.547 per share of Common Stock and Warrants (the &#8220;June Offering&#8221;). We received total gross proceeds of approximately $12.5 million and net proceeds of approximately $11.2 million from the June Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the June Purchase Agreement, we and the June Purchasers entered into a Registration Rights Agreement (the &#8220;June Registration Rights Agreement&#8221;) on June 14, 2021. Under the terms of the June Registration Rights Agreement, we agreed to register the shares of Common Stock and the shares of Common Stock issuable upon exercise of the June Warrants and the June Pre-Funded Warrants sold to the Buyers pursuant to the June Purchase Agreement. We filed a registration statement for the resale of such securities on June 24, 2021, and it was declared effective by the SEC on July 6, 2021. We also agreed to other customary obligations regarding registration, including indemnification and maintenance of the effectiveness of the registration statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the June Offering, pursuant to an Engagement Agreement, dated June 14, 2021 (the &#8220;June Engagement Agreement&#8221;), between the Company and Katalyst Securities LLC (the &#8220;June Placement Agent&#8221;), we paid the June Placement Agent (i) a cash fee equal to ten percent (10%) of the gross proceeds from the sale of securities in the June Offering sold to June Purchasers introduced by the June Placement Agent and (ii) 152,378 warrants to purchase shares of Common Stock equal to ten percent (10%) of the number of shares of Common Stock sold to June Purchasers introduced by the June Placement Agent, with an exercise price of $8.51 per share and a five-year term (the &#8220;June Broker Warrants&#8221;). Furthermore, we agreed to pay the June Placement Agent a warrant exercise fee equal to ten percent (10%) of the aggregate exercise price that is paid in connection with each exercise, if any, of the Warrants initially held by Purchasers introduced by the June Placement Agent. The June Placement Agent is also entitled to the foregoing fees with respect to any future financing or capital-raising transaction by us (a &#8220;Subsequent Financing&#8221;), to the extent such financing or capital is provided to us by investors whom the June Placement Agent had introduced to us, in the event such Subsequent Financing is consummated within eighteen (18) months following the closing of the June Offering.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Reverse Stock Split</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the Special Meeting, the stockholders approved our proposal to effect one reverse stock split of our outstanding shares of Common stock, at any ratio between 1-for-1.5 and 1-for-20, at such time as the Board shall determine, in its sole discretion, before December 31, 2022. On May 19, 2021, we effected a 1-for-4 reverse stock split of our shares of Common Stock. &#160;As a result of the reverse stock split, every four (4) shares of our pre-reverse split Common Stock was combined and reclassified into one share of Common Stock. The information herein has been adjusted to retrospectively reflect this reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Results of Most Recent Confirmatory Phase 2 Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;9, 2019, Neurotrope issued a press release announcing that the confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD did not achieve statistical significance on the primary endpoint, which was changed from baseline to Week 13 in the SIB total score.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An average increase in SIB total score of 1.3 points and 2.1 points was observed for the Bryostatin-1 and placebo groups, respectively, at Week 13. There were multiple secondary outcome measures in this trial, including the changes from baseline at Weeks 5, 9 and 15 in the SIB total score. No statistically significant difference was observed in the change from baseline in SIB total score between the Bryostatin&#160;-1 and placebo treatment groups.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The confirmatory Phase 2 multicenter trial was designed to assess the safety and efficacy of Bryostatin-1 as a treatment for cognitive deficits in patients with moderate to severe AD&#160;&#8212; defined as a MMSE-2 score of 4-15&#160;&#8211; who are not currently taking memantine. Patients were randomized 1:1 to be treated with either Bryostatin-1 20&#956;g or placebo, receiving 7 doses over 12 weeks. Patients on memantine, an NMDA receptor antagonist, were excluded unless they had been discontinued from memantine treatment for a 30-day washout period prior to study enrollment. The primary efficacy endpoint was the change in the SIB score between the baseline and week 13. Secondary endpoints included repeated SIB changes from baseline SIB at weeks 5, 9, 13 and&#160;15.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;22, 2020, we announced the completion of an additional analysis in connection with the confirmatory Phase 2 study, which examined moderately severe to severe AD patients treated with Byrostatin-1 in the absence of memantine. To adjust for the baseline imbalance observed in the study, a post-hoc analysis was conducted using paired data for individual patients, with each patient as his/her own control. For the pre-specified moderate stratum (i.e., MMSE-2 baseline scores 10-15), the baseline value and the week 13 value were used, resulting in pairs of observations for each patient. The changes from baseline for each patient were calculated and a paired t-test was used to compare the mean change from baseline to week 13 for each patient. A total of 65 patients had both baseline and week 13 values, from which there were 32 patients in the Bryostatin-1 treatment group and 33 patients in the placebo group. There was a statistically significant improvement over baseline (4.8 points) in the mean SIB at week 13 for subjects in the Bryostatin-1 treatment group (32 subjects), paired t-test p &lt; 0.0076, 2-tailed. In the placebo group (33 subjects), there was also a statistically significant increase from baseline in the mean SIB at week 13, for paired t-test p &lt; 0.0144, consistent with the placebo effect seen in the overall 203 study. Although there was a signal of Bryostatin-1&#8217;s benefit for the moderately severe stratum, the difference between the Bryostatin-1 and placebo treatment groups was not statistically significant (p=0.2727). As a further test of the robustness of this Moderate Stratum benefit signal, a pre-specified trend analysis (measuring increase of SIB improvement as a function of successive drug doses) was performed on the repeated SIB measures over time (Weeks 0, 5, 9, and 13). These trend analyses showed a significant positive slope of improvement for the treatment groups in the 203 study that was significantly greater than for the placebo group (p&lt;.01).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the additional analysis, we also announced the approval of a $2.7 million award from the NIH to support an additional Phase 2 clinical study focused on the moderate stratum for which we saw improvement in the 203 study. The grant provides for funds in the first&#160;year of approximately $1.0 million and funding in&#160;year two of approximately $1.7 million subject to satisfactory progress of the project. We are planning to meet with the FDA to present the totality of the clinical data for Bryostatin-1. We are continuing to determine how to proceed with respect to our current development programs for Bryostatin-1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 23, 2020, we entered into the 2020 Services Agreement with WCT. The 2020 Services Agreement relates to services for our Phase 2 clinical study assessing the safety, tolerability and long-term efficacy of bryostatin in the treatment of moderately severe AD subjects not receiving memantine treatment. The total estimated budget for the services, including pass-through costs, is approximately $9.6 million. As previously disclosed, on January 22, 2020, we have received a $2.7 million award from the NIH, which award will be used to support the 2020 Study, resulting in an estimated net budgeted cost of the 2020 Study to us of $6.9 million.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, we incurred cumulative expenses of approximately $5.1 million associated with services provided by WCT and certain pass thru expenses incurred by WCT, which was offset by NIH reimbursements recognized of $2.1 million. As of November 10, 2021, the NIH has reimbursed us a total of approximately $2.6 million for expenses incurred to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Other Development Projects</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent resources permit, we may pursue development of selected technology platforms with indications related to the treatment of various disorders, including neurodegenerative disorders such as AD, based on our currently licensed technology and/or technologies available from third party licensors or collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">Nemours Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 5, 2018, we announced a collaboration with Nemours, a premier U.S. children&#8217;s hospital, to initiate a clinical trial in children with Fragile X. In addition to the primary objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as anxiety, repetitive behavior, executive functioning, and social behavior. On August 5, 2021, the Company announced its memorandum of understanding with Nemours A.I. DuPont Hospital (&#8220;Nemours&#8221;) to initiate a clinical trial using bryostatin, under Orphan Drug Status, to treat Fragile X. The Company intends to provide the bryostatin drug product and obtain the investigational new drug documentation (&#8220;IND&#8221;) and Nemours intends to provide the clinical site and attendant support for the trial. The Company and Nemours, jointly, will develop the trial protocol. The Company estimates its total trial and IND cost to be approximately $700,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Impact of COVID-19</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face the ongoing risk that the coronavirus pandemic may slow the conduct of our current trial. In order to prioritize patient health and that of the investigators at clinical trial sites, we will monitor enrollment of new patients in our Phase 2 clinical trial of Bryostatin-1 for the treatment of patients with Alzheimer&#8217;s disease. In addition, some patients may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services. These and other factors outside of our control could delay our ability to conduct clinical trials or release clinical trial results. In addition, the effects of the ongoing coronavirus pandemic may also increase non-trial costs such as insurance premiums, increase the demand for and cost of capital, increase loss of work time from key personnel, and negatively impact our key clinical trial vendors and supplier of API.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In light of the COVID-19 outbreak, the FDA has issued a number of new guidance documents. Specifically, as a result of the potential effect of the COVID-19 outbreak on many clinical trial programs in the US and globally, the FDA issued guidance concerning potential impacts on clinical trial programs, changes that may be necessary to such programs if they proceed, considerations regarding trial suspensions and discontinuations, the potential need to consult with or make submissions to relevant ethics committees,&#160;Institutional Review Board (&#8220;IRBs&#8221;), and the FDA, the use of alternative drug delivery methods, and considerations with respect the outbreak&#8217;s impacts on endpoints, data collection, study procedures, and analysis. Such developments may result in delays in our development of Bryostatin-1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Comparison of the nine months ended September 30, 2021 and 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our results of operations for the nine months ended September 30, 2021 and 2020:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dollar</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating Expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,974,776</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,556,627</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,418,149</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 91.1</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,404,968</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,735,757</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,230,789)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (18.5)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other income (Expense), net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,592</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,546,695)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,551,287</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (100.3)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,375,152</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,739,079</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,363,927)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (14.0)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We did not generate any revenues for the nine months ended September 30, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">Overview</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total operating expenses for the nine months ended September 30, 2021 were $8,379,744 as compared to $8,192,384 for the nine months ended September 30, 2020, an increase of approximately 2.3%. The increase in total operating expenses is due primarily to the increase in research and development expenses mostly offset by the decrease in our general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the nine months ended September 30, 2021, we incurred $2,974,776 in research and development expenses as compared to $1,556,627 for the nine months ended September 30, 2020, an increase of approximately 91.1%. These expenses were incurred pursuant to developing the potential AD therapeutic product, specifically expenses relating to our ongoing Phase 2 clinical trial for AD. Of these expenses, for the nine months ended September 30, 2021, $2,265,285, which includes an expense offset of $1,121,629 reimbursed pursuant to our NIH grant, was incurred principally relating to our current confirmatory clinical trial and related storage of drug product, $222,853 for clinical consulting services, $22,438 of amortization of prepaid licensing fees relating to the Stanford and Mount Sinai license agreements, $39,207 for development of alternative drug supply with Stanford University and $424,993 of non-cash stock options compensation expense as compared to, for the nine months ended September 30, 2020, $616,851, which includes an expense offset of $861,852 reimbursed pursuant to our NIH grant, was incurred principally relating to our confirmatory clinical trial and related storage of drug product, $339,128 for clinical consulting services, $22,138 of amortization of prepaid licensing fees relating to the Stanford and Mount Sinai license agreements, $26,645 for development of alternative drug supply with Stanford University and $551,865 of non-cash stock options compensation expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect our research and development expenses to substantially increase, in the short term, as our current Phase 2 clinical trial for AD was initiated approximately one year ago. Other development expenses might increase, as our resources permit, in order to advance our potential products. We are continuing to determine how to proceed with respect to our other current development programs for Bryostatin-1.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incurred $5,404,968 and $6,635,757 of non-related party general and administrative expenses for the nine months ended September 30, 2021 and 2020, respectively, a decrease of approximately 18.5%. Of the amounts for the nine months ended September 30, 2021, as compared to the comparable 2020 period: $852,300 was incurred primarily for wages, bonuses, vacation pay, severance, taxes and insurance, versus $1,381,863 for the 2020 comparable period. The decrease is primarily attributable to the termination of our Chief Executive Officer at the end of 2020; $576,646 was incurred for legal expenses versus $1,799,735 for the 2020 comparable period. The decrease for 2021 is based upon one-time work associated with our strategic alternatives, planning, restructuring and spin-off of Synaptogenix, Inc. in 2020; $1,414,544 was incurred for outside operations consulting services, versus $1,235,761 for the 2020 comparable period as, for 2021, we incurred additional non-cash expenses associated with warrant issuances for investment banking consulting services; $43,754 was incurred for travel expenses, versus $53,448 for the 2020 comparable period, which decrease is primarily attributable to less travel due to the COVID-19 contagion; $232,098 was incurred for investor relations services versus $368,984 for the 2020 comparable period as, for 2020, we incurred additional non-cash expenses; $137,576 was incurred for professional fees associated with auditing, financial, accounting and tax advisory services, versus $236,163 for the 2020 comparable period, which additional expenses during the prior period were incurred for fees associated with our strategic transactions; $492,771 was incurred for insurance, versus $457,887 for the 2020 comparable period, which increase is primarily attributable to an increase in coverage; $161,621 was incurred for utilities, supplies, license fees, filing costs, rent, advertising and other versus $204,758 for the 2020 comparable period, and $1,493,658 was recorded as non-cash stock options compensation expense versus $897,158 for the 2020 comparable period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">Other Income / Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We earned $4,592 of interest income for the nine months ended September 30, 2021 as compared to $153,305 for the nine months ended September 30, 2020 on funds deposited in interest bearing money market accounts. The decrease is primarily attributable to the decrease in money market interest income rates partially offset by higher cash balances for the nine months ended September 30, 2021 versus 2020. In addition, during the third quarter 2020, the Company recorded a warrant amendment expense of $1.7 million associated with the spin-off transaction discussed above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">Net loss</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incurred losses of $8,375,152 and $9,739,079 for the nine months ended September 30, 2021 and 2020, respectively. The decreased loss was primarily attributable to the decrease in our general and administrative expenses and warrant amendment expense partially offset by an increase in net research and development expenses associated with our current Phase 2 confirmatory clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Comparison of the three months ended September 30, 2021 and 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes our results of operations for the three months ended September 30, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dollar</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating Expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 836,716</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 563,317</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 273,399</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 48.5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,092,662</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,013,089</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 79,573</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.045.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other income (expense), net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,445</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,693,203)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,695,648</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (100.1)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,926,933</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,269,609</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,342,676)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (31.4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We did not generate any revenues for the three months ended September 30, 2021 and 2020.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">Overview</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total operating expenses for the three months ended September 30, 2021 were $2,929,378 as compared to $2,576,406 for the three months ended September 30, 2020, an increase of approximately 13.7%. The increase in total operating expenses is due primarily to increases in our general and administrative and research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended September 30, 2021, we incurred $836,716 in research and development expenses as compared to $563,317 for the three months ended September 30, 2020. These expenses were incurred pursuant to developing the potential AD therapeutic product, specifically expenses relating to the ongoing Phase 2 clinical trial for AD. Of these expenses, for the three months ended September 30, 2021, $532,616, which includes an expense offset of $1,121,629 reimbursed pursuant to our NIH grant, was incurred principally relating to our current confirmatory clinical trial and related storage of drug product, $66,000 for clinical consulting services, $7,562 of amortization of prepaid licensing fees relating to the Stanford and Mount Sinai license agreements, $15,010 for development of alternative drug supply with Stanford University and $215,528 of non-cash stock options compensation expense as compared to, for the three months ended September 30, 2020, $259,729, which includes an expense offset of $861,852 reimbursed pursuant to our NIH grant, was incurred principally relating to our confirmatory clinical trial and related storage of drug product, $130,887 for clinical consulting services, $7,179 of amortization of prepaid licensing fees relating to the Stanford and Mount Sinai license agreements, $12,497 for development of alternative drug supply with Stanford University and $153,025 of non-cash stock options compensation expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect our research and development expenses to substantially increase, in the short term, as our current Phase 2 clinical trial for AD was initiated approximately one year ago. Other development expenses might increase, as our resources permit, in order to advance our potential products. We are continuing to determine how to proceed with respect to our other current development programs for Bryostatin-1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incurred $2,092,662 and $2,013,089 of general and administrative expenses for the three months ended September 30, 2021 and 2020, respectively, an increase of approximately 4.0%. Of the amounts for the three months ended September 30, 2021, as compared to the comparable 2020 period: $184,748 was incurred primarily for wages, bonuses, vacation pay, severance, taxes and insurance, versus $343,774 for the 2020 comparable period. The decrease is primarily attributable to the termination of our Chief Executive Officer at the end of 2020; $108,239 was incurred for legal expenses versus $529,855 for the 2020 comparable period. The decrease for 2021 is based upon one-time work associated with our strategic alternatives, planning, restructuring and spin-off of Synaptogenix, Inc. in 2020; $458,014 was incurred for outside operations consulting services, versus $437,180 for the 2020 comparable period; $15,586 was incurred for travel expenses, versus $7,792 for the 2020 comparable period, which increase is primarily attributable to increased travel due to the COVID-19 contagion vaccinations resulting in lower infection rates; $75,570 was incurred for investor relations services versus $146,593 for the 2020 comparable period, which additional expenses during 2020 were primarily attributable to additional advisors hired for anticipated strategic transaction and an increase in our market exposure; $49,413 was incurred for professional fees associated with auditing, financial, accounting and tax advisory services, versus $80,028 for the 2020 comparable period, which additional expenses during the 2020 period were incurred for fees associated with our strategic transactions; $165,225 was incurred for insurance, versus $149,490 for the 2020 comparable period, which increase is primarily attributable to an increase in coverage; $52,535 was incurred for utilities, supplies, license fees, filing costs, rent, advertising and other versus $83,474 for the 2020 comparable period, which additional expenses during the 2020 period were incurred for expenses associated with our strategic transactions; and $983,332 was recorded as non-cash stock options compensation expense versus $234,903 for the 2020 comparable period, which increase for the 2021 period was based upon initial restricted stock unit grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">Other Income / Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We earned $2,445 of interest income for the nine months ended September 30, 2021 as compared to $6,797 for the three months ended September 30, 2020 on funds deposited in interest bearing money market accounts. The decrease is primarily attributable to the decrease in money market interest income rates partially offset by higher cash balances for the nine months ended September 30, 2021 versus 2020. In addition, during the third quarter 2020, the Company recorded a warrant amendment expense of $1.7 million associated with the spin-off transaction discussed above.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">Net loss</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incurred losses of $2,926,933 and $4,269,609 for the three months ended September 30, 2021 and 2020, respectively. The decreased loss was primarily attributable to the decrease in our warrant amendment expense offset by the increase in research and development and general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The computation of diluted loss per share for the three months ended September 30, 2021 excludes 6,842,930 warrants and options and restricted stock units to purchase 495,000 shares of our Common Stock as they are anti-dilutive due to our net loss. For the three months ended September 30, 2020, the computation excludes 500 shares of convertible preferred stock convertible into 75,758 shares of Common Stock, 5,502,815 warrants and options to purchase 567,894 shares of our Common Stock, as they are anti-dilutive due to our net loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Financial Condition, Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Working Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since inception, we have incurred negative cash flows from operations. As of September 30, 2021, we had working capital of $31,332,828 as compared to working capital of $5,116,300 as of December 31, 2020. The $26,216,528 increase in working capital was primarily attributable to our January 2021 and June 2021 private placement offering resulting in net cash proceeds from our two private placement offerings of approximately $23.8 million, cash proceeds from warrant exercises of approximately $8.4 million, approximately $0.8 million from change in balance sheet current assets and liabilities, offset by a decrease in cash of approximately $6.8 million from operating expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that our current cash and cash equivalents of approximately $35 million will be sufficient to support our projected operating requirements for at least the next 12 months from the Form 10-Q filing date, which would include the continuing development and current Phase 2 clinical trial, of bryostatin, our novel drug targeting the activation of PKC epsilon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to require additional capital in order to initiate, pursue and complete all potential AD clinical trials and obtain regulatory approval of one or more therapeutic candidates. However, additional future funding may not be available to us on acceptable terms, or at all. If we are unable to access additional funds when needed, we may not be able to initiate, pursue and complete all planned clinical trials or continue the development of our product candidates or we could be required to delay, scale back or eliminate some or all of our development programs and operations. Any additional equity financing, if available, may not be available on favorable terms, would most likely be significantly dilutive to our current stockholders and debt financing, if available, and may involve restrictive covenants. If we are able to access funds through collaborative or licensing arrangements, we may be required to relinquish rights to some of our technologies or product candidates that we would otherwise seek to develop or commercialize on our own, on terms that are not favorable to us. Our ability to access capital when needed is not assured and, if not achieved on a timely basis, would likely materially harm our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Sources and Uses of Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Since inception, we have satisfied our operating cash requirements from transfers of cash from Neurotrope, which was raised by Neurotrope through the private placement of equity securities sold principally to outside investors. We expect to continue to incur expenses, resulting in losses and negative cash flows from operations, over at least the next several years as we may continue to develop AD and other therapeutic products. We anticipate that this development may include clinical trials in addition to our current ongoing clinical trial and additional research and development expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash used in operating activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,665,558</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,896,751</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,413</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash provided by financing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 32,165,148</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,519,988</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 9pt 0pt;">Net Cash Used in Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Cash used in operating activities was $6,665,558 for the nine months ended September 30, 2021, compared to $6,896,751 for the nine months ended September 30, 2020. The $103,748 decrease primarily resulted from a decrease in net loss of approximately 1.36 million, an increase in prepaid expenses of approximately $1.07 million, an increase in non-cash stock-based compensation expenses of approximately $473,000, offset by the decrease in payables of approximately $1.1 million and an increase in warrant amendment expense of $1.7 million for the nine months ended September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 9pt 0pt;">Net Cash Used in Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Net cash used in investing activities was $0 for the nine months ended September 30, 2021 compared to $5,413 for the nine months ended September 30, 2020. The cash used in investing activities for the nine months ended September 30, 2020 was for capital expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 9pt 0pt;">Net Cash Provided by Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Net cash provided by financing activities was $32,165,148 for the nine months ended September 30, 2021 compared to cash provided by financing activities of $16,519,988 for the nine months ended September 30, 2020. The change in net cash provided by financing activities for 2020 and 2021 were the result of net transfers from our Parent of approximately $16.5 million in 2020 and $23.7 million of net proceeds from our private placement offerings and $8.4 million from warrant exercises during the first nine months of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_972d7c98_2b13_4255_bf64_765ca39ae8de"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable to a smaller reporting company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ee2f483c_d45c_4225_bf8c_93c9d6b8864f"></a><a id="Item4ControlsandProcedures_303380"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;">Item&#160;4. Controls and Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 9pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">An evaluation was performed under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive officer and principal financial officer, respectively, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on their evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are not effective due to: inadequate segregation of duties consistent with control objectives in the areas over certain payroll and banking systems and user access controls; ineffective processes over period end financial disclosure and reporting including documentation of GAAP disclosure and reporting reviews supporting the financial reporting process and changes to chart of accounts; and ineffective information technology (IT) general computing controls including lack of risk and design assessments supporting IT security policies and procedures, user access, and IT controls within third party contracts. These weaknesses may affect management&#8217;s ability to determine if errors or inappropriate actions have taken place. Management is required to apply its judgment in evaluating the cost-benefit relationship of possible changes in our disclosure controls and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">We previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, that our management, including our Chairman of the Board, principal executive officer and principal financial officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in the 2013 Internal Control&#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) and SEC guidance on conducting such assessments. Based on that evaluation, they concluded that, during the period covered by the Annual Report on Form 10-K for the fiscal year ended December 31, 2020, such internal controls and procedures were not effective to detect the inappropriate application of US generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Notwithstanding the material weaknesses described above, our management, including the Chief Executive Officer and Chief Financial Officer, has concluded that financial statements, and other financial information included in this quarterly report, fairly present in all material respects our financial condition, results of operations, and cash flows as of and for the periods presented in this quarterly report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Changes in Internal Controls over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There was no change in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b2cb4a16_b5b2_4263_a118_39c775bc1951"></a><a id="PARTII_864559"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="OTHERINFORMATION_297110"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">OTHER INFORMATION</p><a id="Item1LegalProceedings_969762"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;1. Legal Proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_23a0e7bd_a85d_4460_adaf_08206d0c3f19"></a><a id="Item1ARiskFactors_894724"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;1A. Risk Factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">You should carefully review and consider the information regarding certain factors that could materially affect our business, consolidated financial condition or results of operations set forth under Item 1A. Risk Factors in our 2020 Annual Report on Form 10-K. There have been no material changes from the risk factors disclosed in our 2020 Annual Report on Form 10-K. We may disclose changes to risk factors from time to time in our future filings with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a9cd82d4_3c04_4c07_bf2a_9060de61a850"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 1, 2021, we issued warrants to purchase up to 10,300 shares of our common stock to Katalyst Securities LLC and up to 5,800 shares of our common stock to GP Nurmenkari, Inc., each at an exercise price of $9.76 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 1, 2021, we issued warrants to purchase up to 10,300 shares of our common stock to Katalyst Securities LLC and up to 5,800 shares of our common stock to GP Nurmenkari, Inc., each at an exercise price of $9.30 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The foregoing transaction did not involve any underwriters or any public offering. The sale of the above securities was deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act (and Regulation D promulgated thereunder) or Rule 701 promulgated under Section 3(b) of the Securities Act as transactions by an issuer not involving any public offering. The recipients of the securities in the transaction represented their intentions to acquire the securities for investment only and not with a view to, or for sale in connection with, any distribution thereof, and appropriate legends were affixed to the securities issued in these transactions. All recipients received or had, through their relationships with us, adequate access to information about us.</p><a id="_ceda5dd0_9548_4582_b32e_bb110fc9d6fa"></a><a id="Item3DefaultsuponSeniorSecurities_455084"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;3. Defaults upon Senior Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5c25a3e6_77bd_4036_8830_d99809678462"></a><a id="Item4MineSafetyDisclosures_328331"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;4. Mine Safety Disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2eb72082_97b4_4fce_8275_d2be86ea4002"></a><a id="Item5OtherInformation_865222"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;5. Other Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4127bb8b_3d0b_42f9_8dcf_3444e78a67dd"></a><a id="Item6Exhibits_669068"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Item&#160;6. Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Exhibit<br />Number</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="snpx-20210930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Certification of the President and Chief Executive Officer pursuant to Rule&#160;13a-14(a)&#160;under the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="snpx-20210930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Certification of the Chief Financial Officer pursuant to Rule&#160;13a-14(a)&#160;under the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="snpx-20210930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Certification of the President and Chief Executive Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.2*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="snpx-20210930xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following financial information from this Quarterly Report on Form&#160;10-Q for the period ended September 30, 2021, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Statements of Operations; (ii)&#160;the Condensed Balance Sheets; (iii)&#160;the Condensed Statements of Cash Flows; and (iv)&#160;the Notes&#160;to Financial Statements, tagged as blocks of text.</p></td></tr><tr><td style="vertical-align:top;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background-color:#ffffff;">Cover Page&#160;Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b7432d8a_dc21_4066_bbbb_29c2e174657a"></a><a id="SIGNATURES_975732"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Synaptogenix,&#160;Inc.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;12, 2021</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Alan J. Tuchman, M.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alan J. Tuchman, M.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(principal executive officer)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;12, 2021</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robert Weinstein</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert Weinstein</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer, Executive Vice President, Secretary and Treasurer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(principal financial officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>snpx-20210930xex31d1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/12/2021 08:48:20 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ALAN J. TUCHMAN, M.D.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CHIEF EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SYNAPTOGENIX, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I,&#160;Alan J. Tuchman, M.D., Chief Executive Officer of Synaptogenix, Inc., certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">1.&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Synaptogenix, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">a)&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">b)&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">c)&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">d)&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5.&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">a)&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">b)&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date:&#160;&#160;November 12, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Alan J. Tuchman, M.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alan J. Tuchman, M.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(principal executive officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>snpx-20210930xex31d2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/12/2021 08:48:24 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ROBERT WEINSTEIN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CHIEF FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SYNAPTOGENIX, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I,&#160;Robert Weinstein, Chief Financial Officer of Synaptogenix, Inc., certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">1.&#160;I have reviewed this quarterly report on Form 10-Q of Synaptogenix, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5.&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#39;s board of directors:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 12, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:57.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robert Weinstein</p></td></tr><tr><td style="vertical-align:top;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:57.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert Weinstein</p></td></tr><tr><td style="vertical-align:top;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:57.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer, Executive Vice President, Secretary and Treasurer</p></td></tr><tr><td style="vertical-align:top;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:57.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(principal financial officer and principal accounting officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>snpx-20210930xex32d1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/12/2021 08:48:27 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the Quarterly Report of Synaptogenix, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Alan J. Tuchman, M.D., Chief Executive Officer of the Company, state and certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">(1)&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">(2)&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 12, 2021</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Alan J. Tuchman, M.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alan J. Tuchman, M.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(principal executive officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>snpx-20210930xex32d2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/12/2021 08:48:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the Quarterly Report of Synaptogenix, Inc. (the &#8220;Company&#8221;) on Form 10-Q<b style="font-weight:bold;">&#160;</b>for the period ending September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Robert Weinstein, Chief Financial Officer of the Company, state and certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to<b style="font-weight:bold;">&#160;&#167;&#160;</b>906 of the Sarbanes-Oxley Act of 2002, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">(1)&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">(2)&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 12, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:56.65%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robert Weinstein</p></td></tr><tr><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert Weinstein</p></td></tr><tr><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer, Executive Vice President, Secretary and Treasurer</p></td></tr><tr><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(principal financial officer and principal accounting officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>snpx-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2021 8:48:53 PM-->
<!--Modified on: 11/12/2021 8:48:53 PM-->
<xsd:schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" targetNamespace="http://www.synaptogen.com/20210930" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:snpx="http://www.synaptogen.com/20210930" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/StatementCondensedBalanceSheets" id="StatementCondensedBalanceSheets">
        <link:definition>00100 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations" id="StatementCondensedStatementsOfOperations">
        <link:definition>00200 - Statement - Condensed Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows" id="StatementCondensedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails" id="DisclosureParentCompanyInvestmentDetails">
        <link:definition>40901 - Disclosure - Parent Company Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/StatementCondensedBalanceSheetsParenthetical" id="StatementCondensedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity" id="StatementCondensedStatementsOfChangesInShareholdersEquity">
        <link:definition>00300 - Statement - Condensed Statements of Changes in Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureCommonStockWarrants" id="DisclosureCommonStockWarrants">
        <link:definition>10801 - Disclosure - Common Stock Warrants:</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30703 - Disclosure - Stock Based Compensation: (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureCommonStockWarrantsTables" id="DisclosureCommonStockWarrantsTables">
        <link:definition>30803 - Disclosure - Common Stock Warrants: (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails" id="DisclosureOrganizationBusinessRisksAndUncertaintiesDetails">
        <link:definition>40101 - Disclosure - Organization, Business, Risks and Uncertainties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails" id="DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails">
        <link:definition>40102 - Disclosure - Organization, Business, Risks and Uncertainties - Liquidity Uncertainties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails" id="DisclosureCollaborativeAgreementsAndCommitmentsDetails">
        <link:definition>40301 - Disclosure - Collaborative Agreements and Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureRelatedPartyTransactionsAndLicensingResearchAgreementsDetails" id="DisclosureRelatedPartyTransactionsAndLicensingResearchAgreementsDetails">
        <link:definition>40401 - Disclosure - Related Party Transactions and Licensing / Research Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>40501 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>40601 - Disclosure - Stockholders' Equity: (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails" id="DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails">
        <link:definition>40602 - Disclosure - Stockholders' Equity: - January 2021 Private Placement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails" id="DisclosureStockBasedCompensationDetails">
        <link:definition>40701 - Disclosure - Stock Based Compensation: (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureCommonStockWarrantsCommonStockWarrantActivityDetails" id="DisclosureCommonStockWarrantsCommonStockWarrantActivityDetails">
        <link:definition>40801 - Disclosure - Common Stock Warrants: - Common stock warrant activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails" id="DisclosureCommonStockWarrantsAdditionalInformationDetails">
        <link:definition>40802 - Disclosure - Common Stock Warrants: - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertainties" id="DisclosureOrganizationBusinessRisksAndUncertainties">
        <link:definition>10101 - Disclosure - Organization, Business, Risks and Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitments" id="DisclosureCollaborativeAgreementsAndCommitments">
        <link:definition>10301 - Disclosure - Collaborative Agreements and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureRelatedPartyTransactionsAndLicensingResearchAgreements" id="DisclosureRelatedPartyTransactionsAndLicensingResearchAgreements">
        <link:definition>10401 - Disclosure - Related Party Transactions and Licensing / Research Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10501 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10601 - Disclosure - Stockholders' Equity:</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10701 - Disclosure - Stock Based Compensation:</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureParentCompanyInvestment" id="DisclosureParentCompanyInvestment">
        <link:definition>10901 - Disclosure - Parent Company Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11001 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentTables" id="DisclosureParentCompanyInvestmentTables">
        <link:definition>30903 - Disclosure - Parent Company Investment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails" id="DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails">
        <link:definition>40702 - Disclosure - Stock Based Compensation: - Stock option activity under the stock option plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="snpx-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="snpx-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="snpx-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="snpx-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="snpx_StockIssuedDuringPeriodValueWarrantsExercised" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantExercises" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="snpx_StockIssuedDuringPeriodSharesWarrantExercises" substitutionGroup="xbrli:item" />
  <xsd:element id="snpx_StockOptionNoteDisclosureTextBlock" name="StockOptionNoteDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock" name="CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="snpx_SummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="snpx_SummaryOfSignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element name="PeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="snpx_PeriodAxis" substitutionGroup="xbrldt:dimensionItem" />
  <xsd:element name="PeriodDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="snpx_PeriodDomain" substitutionGroup="xbrli:item" />
  <xsd:element id="snpx_AnnualLicenseMaintenanceFee" name="AnnualLicenseMaintenanceFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element name="CommitmentToPayFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="snpx_CommitmentToPayFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element id="snpx_EstimatedBudgetForServices" name="EstimatedBudgetForServices" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="snpx_RoyaltyPaymentPercentage" name="RoyaltyPaymentPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_CommonStockWarrants" name="CommonStockWarrants" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices" name="WarrantsIssuedDuringPeriodSharesIssuedForServices" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_IssuanceOfStockAndWarrantsForServices" name="IssuanceOfStockAndWarrantsForServices" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_CapitalizedResearchAndDevelopmentServices" name="CapitalizedResearchAndDevelopmentServices" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="snpx_ContractPaymentsTerm" name="ContractPaymentsTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_NumberOfDirectors" name="NumberOfDirectors" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_PlacementAgentAgreementMember" name="PlacementAgentAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_RightsAgreementMember" name="RightsAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_StandFordLicenseAgreementMember" name="StandFordLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_Mt.SinaiLicenseAgreementMember" name="Mt.SinaiLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_NetSalesUpToDollars250MillionMember" name="NetSalesUpToDollars250MillionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_NetSalesOverDollarsMillionMember" name="NetSalesOverDollarsMillionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_MilestonePaymentsPayable" name="MilestonePaymentsPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="snpx_AdditionalMilestonePaymentsPayable" name="AdditionalMilestonePaymentsPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="snpx_RoyaltyPaymentThresholdNetSales" name="RoyaltyPaymentThresholdNetSales" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="snpx_LicenseAgreementsLicensingFees" name="LicenseAgreementsLicensingFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_LicenseAgreementsDevelopmentCostsAndPatentFees" name="LicenseAgreementsDevelopmentCostsAndPatentFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_MilestonePaymentsPaid" name="MilestonePaymentsPaid" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="snpx_TotalSavings" name="TotalSavings" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="snpx_ConsultingAgreementWithSmCapitalManagementLlcMember" name="ConsultingAgreementWithSmCapitalManagementLlcMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember" name="ConsultingAgreementWithKatalystSecuritiesLlcMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_ConsultingAgreementMonthlyInstallmentFee" name="ConsultingAgreementMonthlyInstallmentFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_ConsultingAgreementNoticeForCancellation" name="ConsultingAgreementNoticeForCancellation" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate" name="WarrantsAndRightsOutstandingTermFollowingEffectiveDate" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_ConsultingAgreementWithGpNurmenkariIncMember" name="ConsultingAgreementWithGpNurmenkariIncMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_NationalInstitutesOfHealthMember" name="NationalInstitutesOfHealthMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_AmountOfAwardReceived" name="AmountOfAwardReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_CurrentShareholdersOfCompanyMember" name="CurrentShareholdersOfCompanyMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_PercentageOfGrossRevenue" name="PercentageOfGrossRevenue" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="snpx_AgreementsWithBryologyxMember" name="AgreementsWithBryologyxMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_ServicesAgreement2020Member" name="ServicesAgreement2020Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_TargetEnrollmentOfStudySubjects" name="TargetEnrollmentOfStudySubjects" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_AmountFundedAgainstTotalTrialCost" name="AmountFundedAgainstTotalTrialCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="snpx_ExcessOfCashInOperatingAssetsAndLiabilities" name="ExcessOfCashInOperatingAssetsAndLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="snpx_NumberOfWarrantHoldersWhoExercisedWarrants" name="NumberOfWarrantHoldersWhoExercisedWarrants" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_IncreaseDecreaseInGrantReceivableCurrent" name="IncreaseDecreaseInGrantReceivableCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="snpx_SeriesHWarrantsMember" name="SeriesHWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_SeriesGWarrantsMember" name="SeriesGWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_SeriesFWarrantsMember" name="SeriesFWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_SeriesEWarrantsMember" name="SeriesEWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants" name="ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="snpx_SpinOffRatio" name="SpinOffRatio" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="snpx_AccountsPayableForServiceAgreementCurrent" name="AccountsPayableForServiceAgreementCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock" name="ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_AmountOfFundingReceived" name="AmountOfFundingReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_AmountOfFundingReceivable" name="AmountOfFundingReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="snpx_PrepaymentsForServiceAgreementCurrent" name="PrepaymentsForServiceAgreementCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="snpx_NetTransferFromToParent" name="NetTransferFromToParent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate" name="CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="snpx_ContributionsFromParent" name="ContributionsFromParent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_NumberOfStatementsEnteredIntoAgreement" name="NumberOfStatementsEnteredIntoAgreement" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_NetChangeInInvestment" name="NetChangeInInvestment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="snpx_NumberOfSharesForEveryFiveCommonSharesHeld" name="NumberOfSharesForEveryFiveCommonSharesHeld" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld" name="NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld" name="NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="snpx_IssueOfSharesOnSpinOff" name="IssueOfSharesOnSpinOff" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember" name="EmploymentAgreementWithAlanJ.TuchmanM.dMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_CharlesRyanSeparationAgreementMember" name="CharlesRyanSeparationAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_ShareBasedPaymentArrangementTrancheFourMember" name="ShareBasedPaymentArrangementTrancheFourMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember" name="IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_ProceedsFromGrants" name="ProceedsFromGrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_InitialAnnualBaseSalaryPayable" name="InitialAnnualBaseSalaryPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="snpx_AnnualDiscretionaryBonusPayableMaximumPercent" name="AnnualDiscretionaryBonusPayableMaximumPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff" name="OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination" name="MinimumPercentageOfAnnualizedSalaryPayableUponTermination" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="snpx_NumberOfMonthsBaseSalaryPayableUponTermination" name="NumberOfMonthsBaseSalaryPayableUponTermination" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_NumberOfMonthsBaseSalaryPayableUponSeparation" name="NumberOfMonthsBaseSalaryPayableUponSeparation" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_TotalAmountOfBaseSalaryPayableUponSeparation" name="TotalAmountOfBaseSalaryPayableUponSeparation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="snpx_CashBonusPayableUponSeparation" name="CashBonusPayableUponSeparation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="snpx_PeriodFollowingSeparationDateToPayCobraPremiums" name="PeriodFollowingSeparationDateToPayCobraPremiums" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_TotalSeparationBenefitsPayable" name="TotalSeparationBenefitsPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="snpx_SeparationBenefitsReimbursed" name="SeparationBenefitsReimbursed" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_NumberOfVotesPerShareOwned" name="NumberOfVotesPerShareOwned" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_SecuritiesPurchaseAgreementsMember" name="SecuritiesPurchaseAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_ShareholderRightsPlanMember" name="ShareholderRightsPlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_PlacementAgentsMember" name="PlacementAgentsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights" name="ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_CombinedPurchasePriceOfCommonStockAndWarrants" name="CombinedPurchasePriceOfCommonStockAndWarrants" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock" name="GrossProceedsFromSaleOfWarrantsAndCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_PercentageOfOfferingFeesInCash" name="PercentageOfOfferingFeesInCash" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_PercentageOfOfferingFeesInWarrants" name="PercentageOfOfferingFeesInWarrants" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend" name="NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson" name="DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_NumberOfCommonSharesForEachRight" name="NumberOfCommonSharesForEachRight" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight" name="NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_PurchasePriceOfRight" name="PurchasePriceOfRight" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_EquityIncentivePlan2020Member" name="EquityIncentivePlan2020Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_DateOfGrantMember" name="DateOfGrantMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_FirstAnniversaryOfGrantDateMember" name="FirstAnniversaryOfGrantDateMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_NumberOfEmployee" name="NumberOfEmployee" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_CollaborativeAgreementsAndCommitmentsAbstract" name="CollaborativeAgreementsAndCommitmentsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_CollaborativeAgreementsAndCommitmentsTextBlock" name="CollaborativeAgreementsAndCommitmentsTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_WarrantsIssuedDuringPeriodValueIssuedForServices" name="WarrantsIssuedDuringPeriodValueIssuedForServices" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" abstract="false" />
  <xsd:element id="snpx_AggregateIntrinsicValueAbstract" name="AggregateIntrinsicValueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember" name="ShareBasedPaymentArrangementNonemployeeDirectorsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember" name="ShareBasedPaymentArrangementNewlyAppointedDirectorsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_DirectorCompensationPolicyMember" name="DirectorCompensationPolicyMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="snpx_AdvisoryAgreementsMember" name="AdvisoryAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_SeriesWarrantsMember" name="SeriesWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_SeriesCWarrantsMember" name="SeriesCWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_SeriesDWarrantsMember" name="SeriesDWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation" name="ParentCompanyEmployeeBenefitsAndShareBasedCompensation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_NetProceedsFromSaleOfWarrantsAndCommonStock" name="NetProceedsFromSaleOfWarrantsAndCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights" name="MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement" name="AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_PaymentsInLieuSharesForReverseStockSplit" name="PaymentsInLieuSharesForReverseStockSplit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses" name="ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_ConsultancyFees" name="ConsultancyFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_AnnualConsultancyAgreementFees" name="AnnualConsultancyAgreementFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant" name="PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_ThresholdPeriodForArrangingFutureFinancing" name="ThresholdPeriodForArrangingFutureFinancing" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_SixMonthAnniversaryOfGrantDateMember" name="SixMonthAnniversaryOfGrantDateMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="snpx_NumberOfExecutiveDirectors" name="NumberOfExecutiveDirectors" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses" name="CostOnTrailAndInvestigationNewDrugDocumentationExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="snpx_NemoursAgreementMember" name="NemoursAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantAmendmentExpense" id="snpx_WarrantAmendmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock" id="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants" id="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights" id="snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>snpx-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2021 8:48:53 PM-->
<!--Modified on: 11/12/2021 8:48:54 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#StatementCondensedBalanceSheets" roleURI="http://www.synaptogen.com/role/StatementCondensedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#StatementCondensedStatementsOfOperations" roleURI="http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#StatementCondensedStatementsOfCashFlows" roleURI="http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureParentCompanyInvestmentDetails" roleURI="http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails" />
  <calculationLink xlink:role="http://www.synaptogen.com/role/StatementCondensedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637723469320379178" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637723469320379178" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723469320389176" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637723469320379178" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723469320389176" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_637723469320389176" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637723469320379178" xlink:to="us-gaap_GrantsReceivableCurrent_637723469320389176" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637723469320389176" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637723469320379178" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637723469320389176" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637723469320389176" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637723469320389176" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637723469320389176" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent_637723469320389176" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637723469320389176" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637723469320389176" xlink:to="us-gaap_AccountsPayableCurrent_637723469320389176" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637723469320389176" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637723469320389176" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637723469320389176" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637723469320389176" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_637723469320389176" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637723469320399197" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637723469320399197" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637723469320399197" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637723469320399197" xlink:to="us-gaap_CommonStockValue_637723469320399197" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637723469320399197" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637723469320399197" xlink:to="us-gaap_AdditionalPaidInCapital_637723469320399197" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637723469320399197" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637723469320399197" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637723469320399197" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Statements of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637723469320399197" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss_637723469320399197" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637723469320399197" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637723469320399197" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637723469320399197" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637723469320399197" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637723469320399197" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637723469320399197" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther_637723469320399197" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637723469320399197" xlink:to="us-gaap_InterestIncomeOther_637723469320399197" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantAmendmentExpense" xlink:label="snpx_WarrantAmendmentExpense_637723469320399197" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637723469320399197" xlink:to="snpx_WarrantAmendmentExpense_637723469320399197" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637723469320499178" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637723469320399197" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637723469320499178" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637723469320499178" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637723469320399197" xlink:to="us-gaap_OperatingExpenses_637723469320499178" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637723469320499178" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637723469320499178" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637723469320499178" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637723469320499178" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637723469320499178" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637723469320499178" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723469320499178" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723469320499178" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637723469320499178" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723469320499178" xlink:to="us-gaap_ProceedsFromWarrantExercises_637723469320499178" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637723469320499178" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723469320499178" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637723469320499178" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PaymentsInLieuSharesForReverseStockSplit" xlink:label="snpx_PaymentsInLieuSharesForReverseStockSplit_637723469320499178" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723469320499178" xlink:to="snpx_PaymentsInLieuSharesForReverseStockSplit_637723469320499178" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetTransferFromToParent" xlink:label="snpx_NetTransferFromToParent_637723469320509186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723469320499178" xlink:to="snpx_NetTransferFromToParent_637723469320509186" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637723469320509186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637723469320509186" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637723469320509186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637723469320509186" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637723469320509186" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723469320509186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723469320509186" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_637723469320509186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_637723469320509186" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation" xlink:label="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation_637723469320509186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation_637723469320509186" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock" xlink:label="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock_637723469320509186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock_637723469320509186" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants" xlink:label="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants_637723469320519182" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants_637723469320519182" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantAmendmentExpense" xlink:label="snpx_WarrantAmendmentExpense_637723469320519182" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="snpx_WarrantAmendmentExpense_637723469320519182" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637723469320519182" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637723469320519182" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_IssuanceOfStockAndWarrantsForServices" xlink:label="snpx_IssuanceOfStockAndWarrantsForServices_637723469320519182" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="snpx_IssuanceOfStockAndWarrantsForServices_637723469320519182" order="7" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_637723469320519182" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_637723469320519182" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637723469320519182" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637723469320519182" order="9" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_IncreaseDecreaseInGrantReceivableCurrent" xlink:label="snpx_IncreaseDecreaseInGrantReceivableCurrent_637723469320519182" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="snpx_IncreaseDecreaseInGrantReceivableCurrent_637723469320519182" order="10" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_637723469320529206" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_637723469320529206" order="11" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637723469320529206" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637723469320529206" order="12" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637723469320529206" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637723469320529206" order="13" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637723469320529206" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723469320509186" xlink:to="us-gaap_NetIncomeLoss_637723469320529206" order="2" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Parent Company Investment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ContributionsFromParent" xlink:label="snpx_ContributionsFromParent_637723469320529206" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="snpx_ContributionsFromParent_637723469320529206" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_637723469320539189" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_637723469320539189" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation" xlink:label="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation_637723469320539189" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation_637723469320539189" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>snpx-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2021 8:48:53 PM-->
<!--Modified on: 11/12/2021 8:48:54 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#StatementCondensedStatementsOfChangesInShareholdersEquity" roleURI="http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureOrganizationBusinessRisksAndUncertaintiesDetails" roleURI="http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails" roleURI="http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureCollaborativeAgreementsAndCommitmentsDetails" roleURI="http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails" roleURI="http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureCommonStockWarrantsAdditionalInformationDetails" roleURI="http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.synaptogen.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="snpx-20210930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.synaptogen.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="us-gaap_OtherComprehensiveIncomeLocationAxis_1" xlink:title="us-gaap_OtherComprehensiveIncomeLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain_1" xlink:title="us-gaap_OtherComprehensiveIncomeLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OtherComprehensiveIncomeLocationAxis_1" xlink:to="us-gaap_OtherComprehensiveIncomeLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OtherComprehensiveIncomeLocationAxis_1 To us-gaap_OtherComprehensiveIncomeLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis_1" xlink:title="us-gaap_ExtinguishmentOfDebtAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_1" xlink:title="us-gaap_ExtinguishmentOfDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ExtinguishmentOfDebtAxis_1" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ExtinguishmentOfDebtAxis_1 To us-gaap_ExtinguishmentOfDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_1" xlink:title="us-gaap_DerivativeInstrumentRiskAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_1" xlink:title="us-gaap_DerivativeContractTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_1" xlink:to="us-gaap_DerivativeContractTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DerivativeInstrumentRiskAxis_1 To us-gaap_DerivativeContractTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_1" xlink:title="us-gaap_RestructuringCostAndReserveAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_1" xlink:title="us-gaap_TypeOfRestructuringDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestructuringCostAndReserveAxis_1" xlink:to="us-gaap_TypeOfRestructuringDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestructuringCostAndReserveAxis_1 To us-gaap_TypeOfRestructuringDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" xlink:title="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_1" xlink:title="us-gaap_ProjectMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" xlink:to="us-gaap_ProjectMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1 To us-gaap_ProjectMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BusinessAcquisitionAxis_1" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PeriodAxis" xlink:label="snpx_PeriodAxis_1" xlink:title="snpx_PeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PeriodDomain" xlink:label="snpx_PeriodDomain_1" xlink:title="snpx_PeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="snpx_PeriodAxis_1" xlink:to="snpx_PeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:snpx_PeriodAxis_1 To snpx_PeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis_1" xlink:title="us-gaap_TransactionTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain_1" xlink:title="us-gaap_TransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TransactionTypeAxis_1" xlink:to="us-gaap_TransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TransactionTypeAxis_1 To us-gaap_TransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis_1" xlink:title="us-gaap_NatureOfExpenseAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain_1" xlink:title="us-gaap_InterimPeriodCostsNotAllocableDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_NatureOfExpenseAxis_1" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_NatureOfExpenseAxis_1 To us-gaap_InterimPeriodCostsNotAllocableDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OptionIndexedToIssuersEquityTypeAxis_1 To us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_1" xlink:title="us-gaap_OtherCommitmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_1" xlink:title="us-gaap_OtherCommitmentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OtherCommitmentsAxis_1" xlink:to="us-gaap_OtherCommitmentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OtherCommitmentsAxis_1 To us-gaap_OtherCommitmentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" xlink:title="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1 To us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis_1" xlink:title="us-gaap_DisposalGroupClassificationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_1" xlink:title="us-gaap_DisposalGroupClassificationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DisposalGroupClassificationAxis_1" xlink:to="us-gaap_DisposalGroupClassificationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DisposalGroupClassificationAxis_1 To us-gaap_DisposalGroupClassificationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Condensed Statements of Changes in Shareholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetChangeInInvestment" xlink:label="snpx_NetChangeInInvestment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_NetChangeInInvestment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="snpx_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="snpx_StockIssuedDuringPeriodSharesWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_StockIssuedDuringPeriodSharesWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantsIssuedDuringPeriodValueIssuedForServices" xlink:label="snpx_WarrantsIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_WarrantsIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices" xlink:label="snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantAmendmentExpense" xlink:label="snpx_WarrantAmendmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_WarrantAmendmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization, Business, Risks and Uncertainties (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SpinoffMember" xlink:label="us-gaap_SpinoffMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_SpinoffMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfSharesForEveryFiveCommonSharesHeld" xlink:label="snpx_NumberOfSharesForEveryFiveCommonSharesHeld" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_NumberOfSharesForEveryFiveCommonSharesHeld" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld" xlink:label="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld" xlink:label="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ExcessOfCashInOperatingAssetsAndLiabilities" xlink:label="snpx_ExcessOfCashInOperatingAssetsAndLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_ExcessOfCashInOperatingAssetsAndLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails" xlink:type="extended" xlink:title="40102 - Disclosure - Organization, Business, Risks and Uncertainties - Liquidity Uncertainties (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ServicesAgreement2020Member" xlink:label="snpx_ServicesAgreement2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_ServicesAgreement2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NationalInstitutesOfHealthMember" xlink:label="snpx_NationalInstitutesOfHealthMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="snpx_NationalInstitutesOfHealthMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate" xlink:label="snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses" xlink:label="snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountOfFundingReceived" xlink:label="snpx_AmountOfFundingReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_AmountOfFundingReceived" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="snpx_SummaryOfSignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NationalInstitutesOfHealthMember" xlink:label="snpx_NationalInstitutesOfHealthMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="snpx_NationalInstitutesOfHealthMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ServicesAgreement2020Member" xlink:label="snpx_ServicesAgreement2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_ServicesAgreement2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CurrentShareholdersOfCompanyMember" xlink:label="snpx_CurrentShareholdersOfCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="snpx_CurrentShareholdersOfCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="snpx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="snpx_SummaryOfSignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashUninsuredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CapitalizedResearchAndDevelopmentServices" xlink:label="snpx_CapitalizedResearchAndDevelopmentServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="snpx_CapitalizedResearchAndDevelopmentServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_IssueOfSharesOnSpinOff" xlink:label="snpx_IssueOfSharesOnSpinOff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="snpx_IssueOfSharesOnSpinOff" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GrantsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountOfAwardReceived" xlink:label="snpx_AmountOfAwardReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="snpx_AmountOfAwardReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountOfFundingReceived" xlink:label="snpx_AmountOfFundingReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="snpx_AmountOfFundingReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountOfFundingReceivable" xlink:label="snpx_AmountOfFundingReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="snpx_AmountOfFundingReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Collaborative Agreements and Commitments (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_StandFordLicenseAgreementMember" xlink:label="snpx_StandFordLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_StandFordLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_Mt.SinaiLicenseAgreementMember" xlink:label="snpx_Mt.SinaiLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_Mt.SinaiLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AgreementsWithBryologyxMember" xlink:label="snpx_AgreementsWithBryologyxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_AgreementsWithBryologyxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NemoursAgreementMember" xlink:label="snpx_NemoursAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_NemoursAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetSalesUpToDollars250MillionMember" xlink:label="snpx_NetSalesUpToDollars250MillionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="snpx_NetSalesUpToDollars250MillionMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetSalesOverDollarsMillionMember" xlink:label="snpx_NetSalesOverDollarsMillionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="snpx_NetSalesOverDollarsMillionMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_RoyaltyPaymentPercentage" xlink:label="snpx_RoyaltyPaymentPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="snpx_RoyaltyPaymentPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_MilestonePaymentsPaid" xlink:label="snpx_MilestonePaymentsPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="snpx_MilestonePaymentsPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForRoyalties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AnnualLicenseMaintenanceFee" xlink:label="snpx_AnnualLicenseMaintenanceFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="snpx_AnnualLicenseMaintenanceFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CommitmentToPayFees" xlink:label="snpx_CommitmentToPayFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="snpx_CommitmentToPayFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_MilestonePaymentsPayable" xlink:label="snpx_MilestonePaymentsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="snpx_MilestonePaymentsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AdditionalMilestonePaymentsPayable" xlink:label="snpx_AdditionalMilestonePaymentsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="snpx_AdditionalMilestonePaymentsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_RoyaltyPaymentThresholdNetSales" xlink:label="snpx_RoyaltyPaymentThresholdNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="snpx_RoyaltyPaymentThresholdNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_TotalSavings" xlink:label="snpx_TotalSavings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="snpx_TotalSavings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_LicenseAgreementsLicensingFees" xlink:label="snpx_LicenseAgreementsLicensingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="snpx_LicenseAgreementsLicensingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_LicenseAgreementsDevelopmentCostsAndPatentFees" xlink:label="snpx_LicenseAgreementsDevelopmentCostsAndPatentFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="snpx_LicenseAgreementsDevelopmentCostsAndPatentFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PercentageOfGrossRevenue" xlink:label="snpx_PercentageOfGrossRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="snpx_PercentageOfGrossRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses" xlink:label="snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Commitments and Contingencies (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementWithSmCapitalManagementLlcMember" xlink:label="snpx_ConsultingAgreementWithSmCapitalManagementLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_ConsultingAgreementWithSmCapitalManagementLlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember" xlink:label="snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementWithGpNurmenkariIncMember" xlink:label="snpx_ConsultingAgreementWithGpNurmenkariIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_ConsultingAgreementWithGpNurmenkariIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ServicesAgreement2020Member" xlink:label="snpx_ServicesAgreement2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_ServicesAgreement2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember" xlink:label="snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CharlesRyanSeparationAgreementMember" xlink:label="snpx_CharlesRyanSeparationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_CharlesRyanSeparationAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="snpx_ShareBasedPaymentArrangementTrancheFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_VestingDomain" xlink:to="snpx_ShareBasedPaymentArrangementTrancheFourMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember" xlink:label="snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NationalInstitutesOfHealthMember" xlink:label="snpx_NationalInstitutesOfHealthMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="snpx_NationalInstitutesOfHealthMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ContractPaymentsTerm" xlink:label="snpx_ContractPaymentsTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_ContractPaymentsTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AnnualConsultancyAgreementFees" xlink:label="snpx_AnnualConsultancyAgreementFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_AnnualConsultancyAgreementFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultancyFees" xlink:label="snpx_ConsultancyFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_ConsultancyFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate" xlink:label="snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_TargetEnrollmentOfStudySubjects" xlink:label="snpx_TargetEnrollmentOfStudySubjects" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_TargetEnrollmentOfStudySubjects" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_EstimatedBudgetForServices" xlink:label="snpx_EstimatedBudgetForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_EstimatedBudgetForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountOfAwardReceived" xlink:label="snpx_AmountOfAwardReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_AmountOfAwardReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementNoticeForCancellation" xlink:label="snpx_ConsultingAgreementNoticeForCancellation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_ConsultingAgreementNoticeForCancellation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ProceedsFromGrants" xlink:label="snpx_ProceedsFromGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_ProceedsFromGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_GrantsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountFundedAgainstTotalTrialCost" xlink:label="snpx_AmountFundedAgainstTotalTrialCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_AmountFundedAgainstTotalTrialCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PrepaymentsForServiceAgreementCurrent" xlink:label="snpx_PrepaymentsForServiceAgreementCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_PrepaymentsForServiceAgreementCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementMonthlyInstallmentFee" xlink:label="snpx_ConsultingAgreementMonthlyInstallmentFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_ConsultingAgreementMonthlyInstallmentFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_InitialAnnualBaseSalaryPayable" xlink:label="snpx_InitialAnnualBaseSalaryPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_InitialAnnualBaseSalaryPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AnnualDiscretionaryBonusPayableMaximumPercent" xlink:label="snpx_AnnualDiscretionaryBonusPayableMaximumPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_AnnualDiscretionaryBonusPayableMaximumPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff" xlink:label="snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination" xlink:label="snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfMonthsBaseSalaryPayableUponTermination" xlink:label="snpx_NumberOfMonthsBaseSalaryPayableUponTermination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_NumberOfMonthsBaseSalaryPayableUponTermination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfMonthsBaseSalaryPayableUponSeparation" xlink:label="snpx_NumberOfMonthsBaseSalaryPayableUponSeparation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_NumberOfMonthsBaseSalaryPayableUponSeparation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_TotalAmountOfBaseSalaryPayableUponSeparation" xlink:label="snpx_TotalAmountOfBaseSalaryPayableUponSeparation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_TotalAmountOfBaseSalaryPayableUponSeparation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CashBonusPayableUponSeparation" xlink:label="snpx_CashBonusPayableUponSeparation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_CashBonusPayableUponSeparation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PeriodFollowingSeparationDateToPayCobraPremiums" xlink:label="snpx_PeriodFollowingSeparationDateToPayCobraPremiums" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_PeriodFollowingSeparationDateToPayCobraPremiums" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_TotalSeparationBenefitsPayable" xlink:label="snpx_TotalSeparationBenefitsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_TotalSeparationBenefitsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeparationBenefitsReimbursed" xlink:label="snpx_SeparationBenefitsReimbursed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_SeparationBenefitsReimbursed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AccountsPayableForServiceAgreementCurrent" xlink:label="snpx_AccountsPayableForServiceAgreementCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="snpx_AccountsPayableForServiceAgreementCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Stockholders' Equity: (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SpinoffMember" xlink:label="us-gaap_SpinoffMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_SpinoffMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_IssueOfSharesOnSpinOff" xlink:label="snpx_IssueOfSharesOnSpinOff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_IssueOfSharesOnSpinOff" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SpinOffRatio" xlink:label="snpx_SpinOffRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_SpinOffRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfVotesPerShareOwned" xlink:label="snpx_NumberOfVotesPerShareOwned" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_NumberOfVotesPerShareOwned" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Stockholders' Equity: - January 2021 Private Placement (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PrefundedWarrantsMember" xlink:label="snpx_PrefundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="snpx_PrefundedWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesEWarrantsMember" xlink:label="snpx_SeriesEWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="snpx_SeriesEWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesGWarrantsMember" xlink:label="snpx_SeriesGWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="snpx_SeriesGWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesFWarrantsMember" xlink:label="snpx_SeriesFWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="snpx_SeriesFWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SecuritiesPurchaseAgreementsMember" xlink:label="snpx_SecuritiesPurchaseAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_SecuritiesPurchaseAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareholderRightsPlanMember" xlink:label="snpx_ShareholderRightsPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_ShareholderRightsPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_RightsAgreementMember" xlink:label="snpx_RightsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_RightsAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PlacementAgentsMember" xlink:label="snpx_PlacementAgentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="snpx_PlacementAgentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement" xlink:label="snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant" xlink:label="snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ThresholdPeriodForArrangingFutureFinancing" xlink:label="snpx_ThresholdPeriodForArrangingFutureFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_ThresholdPeriodForArrangingFutureFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights" xlink:label="snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CombinedPurchasePriceOfCommonStockAndWarrants" xlink:label="snpx_CombinedPurchasePriceOfCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_CombinedPurchasePriceOfCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock" xlink:label="snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetProceedsFromSaleOfWarrantsAndCommonStock" xlink:label="snpx_NetProceedsFromSaleOfWarrantsAndCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_NetProceedsFromSaleOfWarrantsAndCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PercentageOfOfferingFeesInCash" xlink:label="snpx_PercentageOfOfferingFeesInCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_PercentageOfOfferingFeesInCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PercentageOfOfferingFeesInWarrants" xlink:label="snpx_PercentageOfOfferingFeesInWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_PercentageOfOfferingFeesInWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend" xlink:label="snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights" xlink:label="snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson" xlink:label="snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfCommonSharesForEachRight" xlink:label="snpx_NumberOfCommonSharesForEachRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_NumberOfCommonSharesForEachRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight" xlink:label="snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PurchasePriceOfRight" xlink:label="snpx_PurchasePriceOfRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="snpx_PurchasePriceOfRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stock Based Compensation: (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="snpx_ShareBasedPaymentArrangementTrancheFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_VestingDomain" xlink:to="snpx_ShareBasedPaymentArrangementTrancheFourMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_DateOfGrantMember" xlink:label="snpx_DateOfGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_VestingDomain" xlink:to="snpx_DateOfGrantMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_FirstAnniversaryOfGrantDateMember" xlink:label="snpx_FirstAnniversaryOfGrantDateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_VestingDomain" xlink:to="snpx_FirstAnniversaryOfGrantDateMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SixMonthAnniversaryOfGrantDateMember" xlink:label="snpx_SixMonthAnniversaryOfGrantDateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_VestingDomain" xlink:to="snpx_SixMonthAnniversaryOfGrantDateMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember" xlink:label="snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember" xlink:label="snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="srt_ChiefFinancialOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_EquityIncentivePlan2020Member" xlink:label="snpx_EquityIncentivePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="snpx_EquityIncentivePlan2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_DirectorCompensationPolicyMember" xlink:label="snpx_DirectorCompensationPolicyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="snpx_DirectorCompensationPolicyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfDirectors" xlink:label="snpx_NumberOfDirectors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="snpx_NumberOfDirectors" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfExecutiveDirectors" xlink:label="snpx_NumberOfExecutiveDirectors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="snpx_NumberOfExecutiveDirectors" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfEmployee" xlink:label="snpx_NumberOfEmployee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="snpx_NumberOfEmployee" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Common Stock Warrants: - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PlacementAgentAgreementMember" xlink:label="snpx_PlacementAgentAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_PlacementAgentAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AdvisoryAgreementsMember" xlink:label="snpx_AdvisoryAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="snpx_AdvisoryAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesWarrantsMember" xlink:label="snpx_SeriesWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="snpx_SeriesWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesBWarrantsMember" xlink:label="snpx_SeriesBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="snpx_SeriesBWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesCWarrantsMember" xlink:label="snpx_SeriesCWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="snpx_SeriesCWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesDWarrantsMember" xlink:label="snpx_SeriesDWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="snpx_SeriesDWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesHWarrantsMember" xlink:label="snpx_SeriesHWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="snpx_SeriesHWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesGWarrantsMember" xlink:label="snpx_SeriesGWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="snpx_SeriesGWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesFWarrantsMember" xlink:label="snpx_SeriesFWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="snpx_SeriesFWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesEWarrantsMember" xlink:label="snpx_SeriesEWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="snpx_SeriesEWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment" xlink:label="snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants" xlink:label="snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SpinOffRatio" xlink:label="snpx_SpinOffRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_SpinOffRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfWarrantHoldersWhoExercisedWarrants" xlink:label="snpx_NumberOfWarrantHoldersWhoExercisedWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="snpx_NumberOfWarrantHoldersWhoExercisedWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>snpx-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2021 8:48:53 PM-->
<!--Modified on: 11/12/2021 8:48:54 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US">Grants Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US">Grant receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US">Funding receivable in year two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net of accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - 150,000,000 shares authorized as of September 30, 2021, $0.0001 par value; 6,136,967 shares issued and outstanding as of September 30, 2021 and 1,257,579 shares as of December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, stated value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Condensed Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Clinical trial expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">TOTAL OPERATING EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Total expense</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantAmendmentExpense" xlink:label="snpx_WarrantAmendmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_WarrantAmendmentExpense" xlink:to="snpx_WarrantAmendmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_WarrantAmendmentExpense_lbl" xml:lang="en-US">The amount of warrant amendment expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_WarrantAmendmentExpense_lbl" xml:lang="en-US">Warrant amendment expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="snpx_WarrantAmendmentExpense_lbl" xml:lang="en-US">Warrant amendment expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest Income, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Federal and state net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common shareholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">PER SHARE DATA:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic loss per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted loss per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic weighted average common shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted weighted average common shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Condensed Statements of Changes in Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Parent Company Investment.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetChangeInInvestment" xlink:label="snpx_NetChangeInInvestment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NetChangeInInvestment" xlink:to="snpx_NetChangeInInvestment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NetChangeInInvestment_lbl" xml:lang="en-US">The amount of investment in equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NetChangeInInvestment_lbl" xml:lang="en-US">Net Change In Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NetChangeInInvestment_lbl" xml:lang="en-US">Net change in Parent company investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Parent company stock based compensation</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="snpx_StockIssuedDuringPeriodValueWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="snpx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Exercise of common stock warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="snpx_StockIssuedDuringPeriodSharesWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_StockIssuedDuringPeriodSharesWarrantExercises" xlink:to="snpx_StockIssuedDuringPeriodSharesWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_StockIssuedDuringPeriodSharesWarrantExercises_lbl" xml:lang="en-US">Number of shares of capital stock issued during the current period as a result of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_StockIssuedDuringPeriodSharesWarrantExercises_lbl" xml:lang="en-US">Stock Issued During Period Shares, Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_StockIssuedDuringPeriodSharesWarrantExercises_lbl" xml:lang="en-US">Exercise of common stock warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Consulting services paid by issuance of Parent company common stock</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantsIssuedDuringPeriodValueIssuedForServices" xlink:label="snpx_WarrantsIssuedDuringPeriodValueIssuedForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_WarrantsIssuedDuringPeriodValueIssuedForServices" xlink:to="snpx_WarrantsIssuedDuringPeriodValueIssuedForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_WarrantsIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Values of warrants issued for consulting service.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_WarrantsIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Warrants Issued During Period Value Issued For Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_WarrantsIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Consulting services paid by issuance of Parent company common stock warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices" xlink:label="snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices" xlink:to="snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Number of warrants issued for consulting service.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Warrants Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Consulting services paid by issuance of Parent company common stock warrants (in Shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US">Reverse stock split rounding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Shares issued for reverse stock split rounding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of warrants for consulting fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Private placement of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Private placement of common stock and warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOW USED IN OPERATING ACTIVITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used by operating activities</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation" xlink:label="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation" xlink:to="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Amount of expense for parent company employee benefit and equity-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Parent Company Employee Benefits and Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Parent company stock based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation from Parent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Employee Benefits and Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Consulting services paid by issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_IssuanceOfStockAndWarrantsForServices" xlink:label="snpx_IssuanceOfStockAndWarrantsForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_IssuanceOfStockAndWarrantsForServices" xlink:to="snpx_IssuanceOfStockAndWarrantsForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_IssuanceOfStockAndWarrantsForServices_lbl" xml:lang="en-US">Fair value of share-based compensation granted to nonemployees as payment for services rendered.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_IssuanceOfStockAndWarrantsForServices_lbl" xml:lang="en-US">Issuance Of Stock And Warrants For Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_IssuanceOfStockAndWarrantsForServices_lbl" xml:lang="en-US">Consulting services paid by issuance of common stock warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock" xlink:label="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock" xlink:to="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock_lbl" xml:lang="en-US">Consulting services paid by issuance of Parent company common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock_lbl" xml:lang="en-US">Consulting services paid by issuance of Parent company common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock_lbl" xml:lang="en-US">Consulting services paid by issuance of Parent company common stock</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants" xlink:label="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants" xlink:to="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants_lbl" xml:lang="en-US">Consulting services paid by issuance of Parent company common stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants_lbl" xml:lang="en-US">Consulting services paid by issuance of Parent company common stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants_lbl" xml:lang="en-US">Consulting services paid by issuance of Parent company common stock warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_IncreaseDecreaseInGrantReceivableCurrent" xlink:label="snpx_IncreaseDecreaseInGrantReceivableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_IncreaseDecreaseInGrantReceivableCurrent" xlink:to="snpx_IncreaseDecreaseInGrantReceivableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_IncreaseDecreaseInGrantReceivableCurrent_lbl" xml:lang="en-US">The increase (decrease) during the reporting period in grants receivable, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_IncreaseDecreaseInGrantReceivableCurrent_lbl" xml:lang="en-US">Increase (Decrease) In Grant Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="snpx_IncreaseDecreaseInGrantReceivableCurrent_lbl" xml:lang="en-US">Decrease (Increase) in grant receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Increase in prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">(Decrease) increase in accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">(Decrease) increase in accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Total adjustments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used in Operating Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS USED IN INVESTING ACTIVITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used in Investing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Private placements of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of investor warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PaymentsInLieuSharesForReverseStockSplit" xlink:label="snpx_PaymentsInLieuSharesForReverseStockSplit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_PaymentsInLieuSharesForReverseStockSplit" xlink:to="snpx_PaymentsInLieuSharesForReverseStockSplit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_PaymentsInLieuSharesForReverseStockSplit_lbl" xml:lang="en-US">Amount of cash outflow in lieu of shares for reverse stock split.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_PaymentsInLieuSharesForReverseStockSplit_lbl" xml:lang="en-US">Payments In Lieu Shares For Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="snpx_PaymentsInLieuSharesForReverseStockSplit_lbl" xml:lang="en-US">Cash in lieu of shares for reverse stock split</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetTransferFromToParent" xlink:label="snpx_NetTransferFromToParent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NetTransferFromToParent" xlink:to="snpx_NetTransferFromToParent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NetTransferFromToParent_lbl" xml:lang="en-US">.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NetTransferFromToParent_lbl" xml:lang="en-US">Net Transfer from (to) Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NetTransferFromToParent_lbl" xml:lang="en-US">Net transfer from parent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by Financing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE IN CASH AND EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH AND EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH AND EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Business, Risks and Uncertainties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Organization, Business, Risks and Uncertainties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CollaborativeAgreementsAndCommitmentsAbstract" xlink:label="snpx_CollaborativeAgreementsAndCommitmentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_CollaborativeAgreementsAndCommitmentsAbstract" xlink:to="snpx_CollaborativeAgreementsAndCommitmentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_CollaborativeAgreementsAndCommitmentsAbstract_lbl" xml:lang="en-US">Information about collaborative agreements and commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_CollaborativeAgreementsAndCommitmentsAbstract_lbl" xml:lang="en-US">Collaborative Agreements and Commitments</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CollaborativeAgreementsAndCommitmentsTextBlock" xlink:label="snpx_CollaborativeAgreementsAndCommitmentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_CollaborativeAgreementsAndCommitmentsTextBlock" xlink:to="snpx_CollaborativeAgreementsAndCommitmentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_CollaborativeAgreementsAndCommitmentsTextBlock_lbl" xml:lang="en-US">The entire disclosure for collaborative agreements and commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_CollaborativeAgreementsAndCommitmentsTextBlock_lbl" xml:lang="en-US">Collaborative Agreements and Commitments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_CollaborativeAgreementsAndCommitmentsTextBlock_lbl" xml:lang="en-US">Collaborative Agreements and Commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions and Licensing / Research Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions and Licensing / Research Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock Based Compensation:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock Based Compensation:</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CommonStockWarrants" xlink:label="snpx_CommonStockWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_CommonStockWarrants" xlink:to="snpx_CommonStockWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_CommonStockWarrants_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_CommonStockWarrants_lbl" xml:lang="en-US">Common Stock Warrants:</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_StockOptionNoteDisclosureTextBlock" xlink:label="snpx_StockOptionNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_StockOptionNoteDisclosureTextBlock" xlink:to="snpx_StockOptionNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_StockOptionNoteDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure for stock option note disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_StockOptionNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stock Option Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_StockOptionNoteDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock Warrants:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfInvestmentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract_lbl" xml:lang="en-US">Parent Company Investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock" xlink:label="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock" xlink:to="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock_lbl" xml:lang="en-US">Investment Holdings, Schedule of Investments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock_lbl" xml:lang="en-US">Parent Company Investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock" xlink:label="snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock" xlink:to="snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for Cash and Cash Equivalents and Concentration of Credit Risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents and Concentration Of credit Risk [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents and Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets and Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss Per Share of Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock" xlink:label="snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock" xlink:to="snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock_lbl" xml:lang="en-US">The disclosure of accounting policy for expense reimbursement for grant award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock_lbl" xml:lang="en-US">Expense Reimbursement For Grant Award, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock_lbl" xml:lang="en-US">Expense Reimbursement for Grant Award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock option activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Common stock warrant activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of stock outstanding under the plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:label="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:to="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_lbl" xml:lang="en-US">Investment Holdings, Schedule of Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_lbl" xml:lang="en-US">Schedule components of the net transfers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US">Restructuring Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US">Type of Restructuring [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SpinoffMember" xlink:label="us-gaap_SpinoffMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SpinoffMember" xlink:to="us-gaap_SpinoffMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SpinoffMember_lbl" xml:lang="en-US">Spin-Off from Neurotrope</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfSharesForEveryFiveCommonSharesHeld" xlink:label="snpx_NumberOfSharesForEveryFiveCommonSharesHeld" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NumberOfSharesForEveryFiveCommonSharesHeld" xlink:to="snpx_NumberOfSharesForEveryFiveCommonSharesHeld_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NumberOfSharesForEveryFiveCommonSharesHeld_lbl" xml:lang="en-US">Number of shares of Synaptogenix, Inc. . common stock for every five shares of Neurotrope common stock held.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NumberOfSharesForEveryFiveCommonSharesHeld_lbl" xml:lang="en-US">Number of Shares for Every Five Common Shares Held</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NumberOfSharesForEveryFiveCommonSharesHeld_lbl" xml:lang="en-US">Number of shares for every five shares held</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld" xlink:label="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld" xlink:to="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld_lbl" xml:lang="en-US">The number of shares of common stock for every five shares of Neurotrope common stock issuable upon conversion of Neurotrope preferred stock held.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld_lbl" xml:lang="en-US">Number of Shares For Every Five Shares of Common Stock Issuable Upon Conversion of Preferred Stock Held</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld_lbl" xml:lang="en-US">Number of shares for every five shares of Neurcommon stock issuable upon conversion of preferred stock held</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld" xlink:label="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld" xlink:to="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld_lbl" xml:lang="en-US">The number of common stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld_lbl" xml:lang="en-US">Number of Shares for Every Five Shares of Common Stock Issuable Upon Exercise of Warrants Held</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld_lbl" xml:lang="en-US">Number of common stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ExcessOfCashInOperatingAssetsAndLiabilities" xlink:label="snpx_ExcessOfCashInOperatingAssetsAndLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ExcessOfCashInOperatingAssetsAndLiabilities" xlink:to="snpx_ExcessOfCashInOperatingAssetsAndLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ExcessOfCashInOperatingAssetsAndLiabilities_lbl" xml:lang="en-US">The amount represents Excess Of Cash In Operating Assets And Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ExcessOfCashInOperatingAssetsAndLiabilities_lbl" xml:lang="en-US">Excess Of Cash In Operating Assets And Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_ExcessOfCashInOperatingAssetsAndLiabilities_lbl" xml:lang="en-US">Excess of cash in operating assets And liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Common share issuable upon exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of shares called for by warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Number of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ServicesAgreement2020Member" xlink:label="snpx_ServicesAgreement2020Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ServicesAgreement2020Member" xlink:to="snpx_ServicesAgreement2020Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ServicesAgreement2020Member_lbl" xml:lang="en-US">Represents information pertaining to 2020 Services Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ServicesAgreement2020Member_lbl" xml:lang="en-US">2020 Services Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NationalInstitutesOfHealthMember" xlink:label="snpx_NationalInstitutesOfHealthMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NationalInstitutesOfHealthMember" xlink:to="snpx_NationalInstitutesOfHealthMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NationalInstitutesOfHealthMember_lbl" xml:lang="en-US">Represents the information pertaining to National Institutes of Health.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NationalInstitutesOfHealthMember_lbl" xml:lang="en-US">National Institutes of Health</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate" xlink:label="snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate" xlink:to="snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate_lbl" xml:lang="en-US">Represents the expected amount of cash and cash equivalents at financial reporting date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate_lbl" xml:lang="en-US">Cash and Cash Equivalents, Expected Amount at Financial Reporting Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate_lbl" xml:lang="en-US">Cash and cash equivalents expected amount at financial reporting date</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses" xlink:label="snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses" xlink:to="snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses_lbl" xml:lang="en-US">Amount of cash inflow due to warrant exercise and reimbursement of trial expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses_lbl" xml:lang="en-US">Proceeds From Warrant Exercises And Reimbursement of Trial Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses_lbl" xml:lang="en-US">Inflow of cash due to warrant exercise and reimbursement of trial expense</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountOfFundingReceived" xlink:label="snpx_AmountOfFundingReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_AmountOfFundingReceived" xlink:to="snpx_AmountOfFundingReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_AmountOfFundingReceived_lbl" xml:lang="en-US">Amount of funding received by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_AmountOfFundingReceived_lbl" xml:lang="en-US">Amount Of Funding Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_AmountOfFundingReceived_lbl" xml:lang="en-US">Funding received in first year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_AmountOfFundingReceived_lbl" xml:lang="en-US">Reimbursement of trial expenses</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="snpx_SummaryOfSignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="snpx_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CurrentShareholdersOfCompanyMember" xlink:label="snpx_CurrentShareholdersOfCompanyMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_CurrentShareholdersOfCompanyMember" xlink:to="snpx_CurrentShareholdersOfCompanyMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_CurrentShareholdersOfCompanyMember_lbl" xml:lang="en-US">This member stands for current shareholders of the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_CurrentShareholdersOfCompanyMember_lbl" xml:lang="en-US">Current Neurotrope stockholders</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="snpx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="snpx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash balance of insured FDIC amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash balance of uninsured amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life (years)</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CapitalizedResearchAndDevelopmentServices" xlink:label="snpx_CapitalizedResearchAndDevelopmentServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_CapitalizedResearchAndDevelopmentServices" xlink:to="snpx_CapitalizedResearchAndDevelopmentServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_CapitalizedResearchAndDevelopmentServices_lbl" xml:lang="en-US">Capitalized non-refundable advance payments for research and development services pursuant to contractual agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_CapitalizedResearchAndDevelopmentServices_lbl" xml:lang="en-US">Capitalized Research and Development Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_CapitalizedResearchAndDevelopmentServices_lbl" xml:lang="en-US">Capitalized research and development services</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_IssueOfSharesOnSpinOff" xlink:label="snpx_IssueOfSharesOnSpinOff" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_IssueOfSharesOnSpinOff" xlink:to="snpx_IssueOfSharesOnSpinOff_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_IssueOfSharesOnSpinOff_lbl" xml:lang="en-US">The number of shares issued at spin off.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_IssueOfSharesOnSpinOff_lbl" xml:lang="en-US">Issue of Shares On Spin Off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_IssueOfSharesOnSpinOff_lbl" xml:lang="en-US">Issue of shares on spin off</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Grants Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Grants receivable</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountOfAwardReceived" xlink:label="snpx_AmountOfAwardReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_AmountOfAwardReceived" xlink:to="snpx_AmountOfAwardReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_AmountOfAwardReceived_lbl" xml:lang="en-US">The amount of award received to support an additional phase 2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_AmountOfAwardReceived_lbl" xml:lang="en-US">Amount of Award Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_AmountOfAwardReceived_lbl" xml:lang="en-US">Amount of award received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_AmountOfAwardReceived_lbl" xml:lang="en-US">Amount of award received</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountOfFundingReceivable" xlink:label="snpx_AmountOfFundingReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_AmountOfFundingReceivable" xlink:to="snpx_AmountOfFundingReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_AmountOfFundingReceivable_lbl" xml:lang="en-US">Amount of funding receivable by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_AmountOfFundingReceivable_lbl" xml:lang="en-US">Amount Of Funding Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_AmountOfFundingReceivable_lbl" xml:lang="en-US">Funding receivable in second year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License [Member]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_StandFordLicenseAgreementMember" xlink:label="snpx_StandFordLicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_StandFordLicenseAgreementMember" xlink:to="snpx_StandFordLicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_StandFordLicenseAgreementMember_lbl" xml:lang="en-US">Stand Ford License Agreement Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_StandFordLicenseAgreementMember_lbl" xml:lang="en-US">Stand Ford License Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_Mt.SinaiLicenseAgreementMember" xlink:label="snpx_Mt.SinaiLicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_Mt.SinaiLicenseAgreementMember" xlink:to="snpx_Mt.SinaiLicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_Mt.SinaiLicenseAgreementMember_lbl" xml:lang="en-US">This member stands for Mt. Sinai License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_Mt.SinaiLicenseAgreementMember_lbl" xml:lang="en-US">Mt. Sinai License Agreement</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AgreementsWithBryologyxMember" xlink:label="snpx_AgreementsWithBryologyxMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_AgreementsWithBryologyxMember" xlink:to="snpx_AgreementsWithBryologyxMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_AgreementsWithBryologyxMember_lbl" xml:lang="en-US">Represents information pertaining to agreements with BryoLogyx.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_AgreementsWithBryologyxMember_lbl" xml:lang="en-US">Agreements with BryoLogyx</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NemoursAgreementMember" xlink:label="snpx_NemoursAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NemoursAgreementMember" xlink:to="snpx_NemoursAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NemoursAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to Nemours Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NemoursAgreementMember_lbl" xml:lang="en-US">Nemours Agreement</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetSalesUpToDollars250MillionMember" xlink:label="snpx_NetSalesUpToDollars250MillionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NetSalesUpToDollars250MillionMember" xlink:to="snpx_NetSalesUpToDollars250MillionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NetSalesUpToDollars250MillionMember_lbl" xml:lang="en-US">This member stands for the scenario, net sales of up to $250 million.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NetSalesUpToDollars250MillionMember_lbl" xml:lang="en-US">Net sales up to $250 million</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetSalesOverDollarsMillionMember" xlink:label="snpx_NetSalesOverDollarsMillionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NetSalesOverDollarsMillionMember" xlink:to="snpx_NetSalesOverDollarsMillionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NetSalesOverDollarsMillionMember_lbl" xml:lang="en-US">This member stands for the scenario, net sales of over $250 million.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NetSalesOverDollarsMillionMember_lbl" xml:lang="en-US">Net sales over $250 million</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_RoyaltyPaymentPercentage" xlink:label="snpx_RoyaltyPaymentPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_RoyaltyPaymentPercentage" xlink:to="snpx_RoyaltyPaymentPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_RoyaltyPaymentPercentage_lbl" xml:lang="en-US">Royalty Payment Percentage .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_RoyaltyPaymentPercentage_lbl" xml:lang="en-US">Royalty Payment Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_RoyaltyPaymentPercentage_lbl" xml:lang="en-US">Royalty payment percentage</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_MilestonePaymentsPaid" xlink:label="snpx_MilestonePaymentsPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_MilestonePaymentsPaid" xlink:to="snpx_MilestonePaymentsPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_MilestonePaymentsPaid_lbl" xml:lang="en-US">The amount of cash paid for milestone payments during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_MilestonePaymentsPaid_lbl" xml:lang="en-US">Milestone Payments Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_MilestonePaymentsPaid_lbl" xml:lang="en-US">Milestone payments made</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Payments for Royalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Aggregate amount paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Aggregate amount paid</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AnnualLicenseMaintenanceFee" xlink:label="snpx_AnnualLicenseMaintenanceFee" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_AnnualLicenseMaintenanceFee" xlink:to="snpx_AnnualLicenseMaintenanceFee_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_AnnualLicenseMaintenanceFee_lbl" xml:lang="en-US">Represents the amount of annual license maintenance fee paid during reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_AnnualLicenseMaintenanceFee_lbl" xml:lang="en-US">Annual License Maintenance Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_AnnualLicenseMaintenanceFee_lbl" xml:lang="en-US">Annual license maintenance fee</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CommitmentToPayFees" xlink:label="snpx_CommitmentToPayFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_CommitmentToPayFees" xlink:to="snpx_CommitmentToPayFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_CommitmentToPayFees_lbl" xml:lang="en-US">Represents the amount of committed fees to be paid by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_CommitmentToPayFees_lbl" xml:lang="en-US">Commitment To Pay Fees</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_MilestonePaymentsPayable" xlink:label="snpx_MilestonePaymentsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_MilestonePaymentsPayable" xlink:to="snpx_MilestonePaymentsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_MilestonePaymentsPayable_lbl" xml:lang="en-US">The amount of milestone payments payable by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_MilestonePaymentsPayable_lbl" xml:lang="en-US">Milestone Payments Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_MilestonePaymentsPayable_lbl" xml:lang="en-US">Payable of milestone payments</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AdditionalMilestonePaymentsPayable" xlink:label="snpx_AdditionalMilestonePaymentsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_AdditionalMilestonePaymentsPayable" xlink:to="snpx_AdditionalMilestonePaymentsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_AdditionalMilestonePaymentsPayable_lbl" xml:lang="en-US">The amount of additional milestone payments payable by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_AdditionalMilestonePaymentsPayable_lbl" xml:lang="en-US">Additional Milestone Payments Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_AdditionalMilestonePaymentsPayable_lbl" xml:lang="en-US">Additional milestone payments</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_RoyaltyPaymentThresholdNetSales" xlink:label="snpx_RoyaltyPaymentThresholdNetSales" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_RoyaltyPaymentThresholdNetSales" xlink:to="snpx_RoyaltyPaymentThresholdNetSales_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_RoyaltyPaymentThresholdNetSales_lbl" xml:lang="en-US">The threshold amount of net sales to be considered for payment of royalty.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_RoyaltyPaymentThresholdNetSales_lbl" xml:lang="en-US">Royalty Payment, Threshold Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_RoyaltyPaymentThresholdNetSales_lbl" xml:lang="en-US">Threshold net sales</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_TotalSavings" xlink:label="snpx_TotalSavings" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_TotalSavings" xlink:to="snpx_TotalSavings_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_TotalSavings_lbl" xml:lang="en-US">The total amount of savings made by the company as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_TotalSavings_lbl" xml:lang="en-US">Total Savings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_TotalSavings_lbl" xml:lang="en-US">Total services fees</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_LicenseAgreementsLicensingFees" xlink:label="snpx_LicenseAgreementsLicensingFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_LicenseAgreementsLicensingFees" xlink:to="snpx_LicenseAgreementsLicensingFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_LicenseAgreementsLicensingFees_lbl" xml:lang="en-US">The amount of license fees paid by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_LicenseAgreementsLicensingFees_lbl" xml:lang="en-US">License Agreements, Licensing Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_LicenseAgreementsLicensingFees_lbl" xml:lang="en-US">Licensing fees</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_LicenseAgreementsDevelopmentCostsAndPatentFees" xlink:label="snpx_LicenseAgreementsDevelopmentCostsAndPatentFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_LicenseAgreementsDevelopmentCostsAndPatentFees" xlink:to="snpx_LicenseAgreementsDevelopmentCostsAndPatentFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_LicenseAgreementsDevelopmentCostsAndPatentFees_lbl" xml:lang="en-US">The amount of development costs and patent fees paid by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_LicenseAgreementsDevelopmentCostsAndPatentFees_lbl" xml:lang="en-US">License Agreements, Development Costs And Patent Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_LicenseAgreementsDevelopmentCostsAndPatentFees_lbl" xml:lang="en-US">Development costs and patent fees</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PercentageOfGrossRevenue" xlink:label="snpx_PercentageOfGrossRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_PercentageOfGrossRevenue" xlink:to="snpx_PercentageOfGrossRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_PercentageOfGrossRevenue_lbl" xml:lang="en-US">The value represents percentage of gross revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_PercentageOfGrossRevenue_lbl" xml:lang="en-US">Percentage of Gross Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other Income</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses" xlink:label="snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses" xlink:to="snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses_lbl" xml:lang="en-US">The amount relates to cost on Trail and investigation new drug documentation expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses_lbl" xml:lang="en-US">Cost on Trail and investigation new drug documentation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses_lbl" xml:lang="en-US">Cost on Trail and investigation new drug documentation expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfStatementsEnteredIntoAgreement" xlink:label="snpx_NumberOfStatementsEnteredIntoAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NumberOfStatementsEnteredIntoAgreement" xlink:to="snpx_NumberOfStatementsEnteredIntoAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NumberOfStatementsEnteredIntoAgreement_lbl" xml:lang="en-US">It represents number of statements entered into agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NumberOfStatementsEnteredIntoAgreement_lbl" xml:lang="en-US">Number of Statements Entered Into Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NumberOfStatementsEnteredIntoAgreement_lbl" xml:lang="en-US">Number of statements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US">Other Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementWithSmCapitalManagementLlcMember" xlink:label="snpx_ConsultingAgreementWithSmCapitalManagementLlcMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ConsultingAgreementWithSmCapitalManagementLlcMember" xlink:to="snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_lbl" xml:lang="en-US">This member stands for consulting agreement with SM Capital Management, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_lbl" xml:lang="en-US">Consulting Agreement with SM Capital Management, LLC [Member]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember" xlink:label="snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember" xlink:to="snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_lbl" xml:lang="en-US">This member stands for consulting agreement with Katalyst Securities LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_lbl" xml:lang="en-US">Consulting Agreement with Katalyst Securities LLC [Member]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementWithGpNurmenkariIncMember" xlink:label="snpx_ConsultingAgreementWithGpNurmenkariIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ConsultingAgreementWithGpNurmenkariIncMember" xlink:to="snpx_ConsultingAgreementWithGpNurmenkariIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ConsultingAgreementWithGpNurmenkariIncMember_lbl" xml:lang="en-US">This member stands for consulting agreement with GP Nurmenkari.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ConsultingAgreementWithGpNurmenkariIncMember_lbl" xml:lang="en-US">Consulting Agreement with GP Nurmenkari, Inc [Member]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember" xlink:label="snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember" xlink:to="snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_lbl" xml:lang="en-US">This member stands for employment agreement with Alan J. Tuchman, M.D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_lbl" xml:lang="en-US">Employment agreement with Alan J. Tuchman, M.D</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CharlesRyanSeparationAgreementMember" xlink:label="snpx_CharlesRyanSeparationAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_CharlesRyanSeparationAgreementMember" xlink:to="snpx_CharlesRyanSeparationAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_CharlesRyanSeparationAgreementMember_lbl" xml:lang="en-US">This member stands for Charles Ryan Separation Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_CharlesRyanSeparationAgreementMember_lbl" xml:lang="en-US">Charles Ryan Separation Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">First anniversary from Start Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Second anniversary from Start Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Third anniversary from Start Date</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="snpx_ShareBasedPaymentArrangementTrancheFourMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ShareBasedPaymentArrangementTrancheFourMember" xlink:to="snpx_ShareBasedPaymentArrangementTrancheFourMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ShareBasedPaymentArrangementTrancheFourMember_lbl" xml:lang="en-US">Fourth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ShareBasedPaymentArrangementTrancheFourMember_lbl" xml:lang="en-US">Fourth anniversary from Start Date</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember" xlink:label="snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember" xlink:to="snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember_lbl" xml:lang="en-US">This member stands for the scenario, if the employee is terminated after six months but within one year from Start Date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember_lbl" xml:lang="en-US">If employee is terminated after six months but within one year from Start Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Other Commitments [Line Items]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ContractPaymentsTerm" xlink:label="snpx_ContractPaymentsTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ContractPaymentsTerm" xlink:to="snpx_ContractPaymentsTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ContractPaymentsTerm_lbl" xml:lang="en-US">Period from commencement over which fixed contract payments are due per the terms of an agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ContractPaymentsTerm_lbl" xml:lang="en-US">Contract Payments, Term</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AnnualConsultancyAgreementFees" xlink:label="snpx_AnnualConsultancyAgreementFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_AnnualConsultancyAgreementFees" xlink:to="snpx_AnnualConsultancyAgreementFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_AnnualConsultancyAgreementFees_lbl" xml:lang="en-US">Represents the amount of annual consulting fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_AnnualConsultancyAgreementFees_lbl" xml:lang="en-US">Annual Consultancy Agreement Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_AnnualConsultancyAgreementFees_lbl" xml:lang="en-US">Annual consulting fee</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultancyFees" xlink:label="snpx_ConsultancyFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ConsultancyFees" xlink:to="snpx_ConsultancyFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ConsultancyFees_lbl" xml:lang="en-US">The amount of consulting fees incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ConsultancyFees_lbl" xml:lang="en-US">Consultancy Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ConsultancyFees_lbl" xml:lang="en-US">Consultancy fees</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate" xlink:label="snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate" xlink:to="snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate_lbl" xml:lang="en-US">Warrants term following the effective date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate_lbl" xml:lang="en-US">Warrants And Rights Outstanding, Term, Following Effective Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate_lbl" xml:lang="en-US">Warrants term following the effective date</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_TargetEnrollmentOfStudySubjects" xlink:label="snpx_TargetEnrollmentOfStudySubjects" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_TargetEnrollmentOfStudySubjects" xlink:to="snpx_TargetEnrollmentOfStudySubjects_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_TargetEnrollmentOfStudySubjects_lbl" xml:lang="en-US">Represents the target enrollment of study subjects.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_TargetEnrollmentOfStudySubjects_lbl" xml:lang="en-US">Target Enrollment Of Study Subjects</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_TargetEnrollmentOfStudySubjects_lbl" xml:lang="en-US">Target enrollment of study subjects</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_EstimatedBudgetForServices" xlink:label="snpx_EstimatedBudgetForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_EstimatedBudgetForServices" xlink:to="snpx_EstimatedBudgetForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_EstimatedBudgetForServices_lbl" xml:lang="en-US">Represents the estimated budget for services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_EstimatedBudgetForServices_lbl" xml:lang="en-US">Estimated Budget For Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="snpx_EstimatedBudgetForServices_lbl" xml:lang="en-US">Total estimated budget for the services</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementNoticeForCancellation" xlink:label="snpx_ConsultingAgreementNoticeForCancellation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ConsultingAgreementNoticeForCancellation" xlink:to="snpx_ConsultingAgreementNoticeForCancellation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ConsultingAgreementNoticeForCancellation_lbl" xml:lang="en-US">Represents the notice term for cancellation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ConsultingAgreementNoticeForCancellation_lbl" xml:lang="en-US">Consulting Agreement, Notice for Cancellation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_ConsultingAgreementNoticeForCancellation_lbl" xml:lang="en-US">Threshold period of prior written notice to terminate agreement</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ProceedsFromGrants" xlink:label="snpx_ProceedsFromGrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ProceedsFromGrants" xlink:to="snpx_ProceedsFromGrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ProceedsFromGrants_lbl" xml:lang="en-US">Amount of proceeds from grants during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ProceedsFromGrants_lbl" xml:lang="en-US">Proceeds From Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ProceedsFromGrants_lbl" xml:lang="en-US">Funding received</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountFundedAgainstTotalTrialCost" xlink:label="snpx_AmountFundedAgainstTotalTrialCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_AmountFundedAgainstTotalTrialCost" xlink:to="snpx_AmountFundedAgainstTotalTrialCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_AmountFundedAgainstTotalTrialCost_lbl" xml:lang="en-US">Amount stated the total trial cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_AmountFundedAgainstTotalTrialCost_lbl" xml:lang="en-US">Amount funded against the total trial cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_AmountFundedAgainstTotalTrialCost_lbl" xml:lang="en-US">Amount funded against the total trial cost</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PrepaymentsForServiceAgreementCurrent" xlink:label="snpx_PrepaymentsForServiceAgreementCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_PrepaymentsForServiceAgreementCurrent" xlink:to="snpx_PrepaymentsForServiceAgreementCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_PrepaymentsForServiceAgreementCurrent_lbl" xml:lang="en-US">Amount of prepayments under the service agreement, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_PrepaymentsForServiceAgreementCurrent_lbl" xml:lang="en-US">Prepayments For Service Agreement, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_PrepaymentsForServiceAgreementCurrent_lbl" xml:lang="en-US">WCT prepayments included as a prepaid expense and other current assets</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementMonthlyInstallmentFee" xlink:label="snpx_ConsultingAgreementMonthlyInstallmentFee" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ConsultingAgreementMonthlyInstallmentFee" xlink:to="snpx_ConsultingAgreementMonthlyInstallmentFee_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ConsultingAgreementMonthlyInstallmentFee_lbl" xml:lang="en-US">Represents the monthly installment of annual consulting fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ConsultingAgreementMonthlyInstallmentFee_lbl" xml:lang="en-US">Consulting Agreement, Monthly Installment, Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ConsultingAgreementMonthlyInstallmentFee_lbl" xml:lang="en-US">Monthly installment of annual consulting fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_InitialAnnualBaseSalaryPayable" xlink:label="snpx_InitialAnnualBaseSalaryPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_InitialAnnualBaseSalaryPayable" xlink:to="snpx_InitialAnnualBaseSalaryPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_InitialAnnualBaseSalaryPayable_lbl" xml:lang="en-US">Amount of initial annual base salary payable to the employee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_InitialAnnualBaseSalaryPayable_lbl" xml:lang="en-US">Initial Annual Base Salary Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_InitialAnnualBaseSalaryPayable_lbl" xml:lang="en-US">Initial annual base salary</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AnnualDiscretionaryBonusPayableMaximumPercent" xlink:label="snpx_AnnualDiscretionaryBonusPayableMaximumPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_AnnualDiscretionaryBonusPayableMaximumPercent" xlink:to="snpx_AnnualDiscretionaryBonusPayableMaximumPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_AnnualDiscretionaryBonusPayableMaximumPercent_lbl" xml:lang="en-US">Maximum percentage of base salary payable as annual discretionary bonus to the employee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_AnnualDiscretionaryBonusPayableMaximumPercent_lbl" xml:lang="en-US">Annual Discretionary Bonus Payable, Maximum Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_AnnualDiscretionaryBonusPayableMaximumPercent_lbl" xml:lang="en-US">Annual discretionary bonus payable (as a percent)</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff" xlink:label="snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff" xlink:to="snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff_lbl" xml:lang="en-US">Options granted to the employee to purchase shares of common stock as a minimum percent of Company's outstanding shares of common stock immediately following the Spin-Off.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff_lbl" xml:lang="en-US">Options Granted As A Minimum Percent Of Company's Outstanding Shares Of Common Stock Immediately Following Spin Off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff_lbl" xml:lang="en-US">Options granted to purchase shares of common stock as a percent of Company's outstanding shares of common stock immediately following the Spin-Off</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Options granted, vesting percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination" xlink:label="snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination" xlink:to="snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination_lbl" xml:lang="en-US">Minimum percentage of annualized salary payable as compensation upon termination of the employee within six months from Start Date of the employment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination_lbl" xml:lang="en-US">Minimum Percentage Of Annualized Salary Payable Upon Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination_lbl" xml:lang="en-US">Minimum percentage of annualized salary payable if the employee is termination within six months from start date</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfMonthsBaseSalaryPayableUponTermination" xlink:label="snpx_NumberOfMonthsBaseSalaryPayableUponTermination" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NumberOfMonthsBaseSalaryPayableUponTermination" xlink:to="snpx_NumberOfMonthsBaseSalaryPayableUponTermination_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NumberOfMonthsBaseSalaryPayableUponTermination_lbl" xml:lang="en-US">Number of months base salary payable to the employee upon his termination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NumberOfMonthsBaseSalaryPayableUponTermination_lbl" xml:lang="en-US">Number Of Months Base Salary Payable Upon Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NumberOfMonthsBaseSalaryPayableUponTermination_lbl" xml:lang="en-US">Number of months base salary payable if the employee is terminated</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfMonthsBaseSalaryPayableUponSeparation" xlink:label="snpx_NumberOfMonthsBaseSalaryPayableUponSeparation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NumberOfMonthsBaseSalaryPayableUponSeparation" xlink:to="snpx_NumberOfMonthsBaseSalaryPayableUponSeparation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NumberOfMonthsBaseSalaryPayableUponSeparation_lbl" xml:lang="en-US">Number of months base salary payable to the employee upon his separation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NumberOfMonthsBaseSalaryPayableUponSeparation_lbl" xml:lang="en-US">Number Of Months Base Salary Payable Upon Separation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NumberOfMonthsBaseSalaryPayableUponSeparation_lbl" xml:lang="en-US">Number of months base salary payable as of the Separation Date</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_TotalAmountOfBaseSalaryPayableUponSeparation" xlink:label="snpx_TotalAmountOfBaseSalaryPayableUponSeparation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_TotalAmountOfBaseSalaryPayableUponSeparation" xlink:to="snpx_TotalAmountOfBaseSalaryPayableUponSeparation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_TotalAmountOfBaseSalaryPayableUponSeparation_lbl" xml:lang="en-US">Total amounts of base salary payable to the employee upon his separation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_TotalAmountOfBaseSalaryPayableUponSeparation_lbl" xml:lang="en-US">Total Amount Of Base Salary Payable Upon Separation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_TotalAmountOfBaseSalaryPayableUponSeparation_lbl" xml:lang="en-US">Total base salary payable upon Separation</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CashBonusPayableUponSeparation" xlink:label="snpx_CashBonusPayableUponSeparation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_CashBonusPayableUponSeparation" xlink:to="snpx_CashBonusPayableUponSeparation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_CashBonusPayableUponSeparation_lbl" xml:lang="en-US">Cash bonus payable to the employee upon his separation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_CashBonusPayableUponSeparation_lbl" xml:lang="en-US">Cash Bonus Payable Upon Separation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_CashBonusPayableUponSeparation_lbl" xml:lang="en-US">Cash bonus payable upon Separation</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PeriodFollowingSeparationDateToPayCobraPremiums" xlink:label="snpx_PeriodFollowingSeparationDateToPayCobraPremiums" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_PeriodFollowingSeparationDateToPayCobraPremiums" xlink:to="snpx_PeriodFollowingSeparationDateToPayCobraPremiums_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_PeriodFollowingSeparationDateToPayCobraPremiums_lbl" xml:lang="en-US">Period following the Separation Date to pay COBRA premiums, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_PeriodFollowingSeparationDateToPayCobraPremiums_lbl" xml:lang="en-US">Period Following Separation Date To Pay COBRA Premiums</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_PeriodFollowingSeparationDateToPayCobraPremiums_lbl" xml:lang="en-US">Period following the Separation Date to pay COBRA premiums</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_TotalSeparationBenefitsPayable" xlink:label="snpx_TotalSeparationBenefitsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_TotalSeparationBenefitsPayable" xlink:to="snpx_TotalSeparationBenefitsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_TotalSeparationBenefitsPayable_lbl" xml:lang="en-US">Total benefits payable to the employee upon his separation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_TotalSeparationBenefitsPayable_lbl" xml:lang="en-US">Total Separation Benefits Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_TotalSeparationBenefitsPayable_lbl" xml:lang="en-US">Total commitment</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeparationBenefitsReimbursed" xlink:label="snpx_SeparationBenefitsReimbursed" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_SeparationBenefitsReimbursed" xlink:to="snpx_SeparationBenefitsReimbursed_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_SeparationBenefitsReimbursed_lbl" xml:lang="en-US">Amount of separation benefits paid by the company, which has been reimbursed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_SeparationBenefitsReimbursed_lbl" xml:lang="en-US">Separation Benefits Reimbursed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_SeparationBenefitsReimbursed_lbl" xml:lang="en-US">Separation benefits reimbursed by Metuchen pursuant to Merger</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AccountsPayableForServiceAgreementCurrent" xlink:label="snpx_AccountsPayableForServiceAgreementCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_AccountsPayableForServiceAgreementCurrent" xlink:to="snpx_AccountsPayableForServiceAgreementCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_AccountsPayableForServiceAgreementCurrent_lbl" xml:lang="en-US">Amount payable under the service agreement, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_AccountsPayableForServiceAgreementCurrent_lbl" xml:lang="en-US">Accounts Payable For Service Agreement, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_AccountsPayableForServiceAgreementCurrent_lbl" xml:lang="en-US">WCT payments included in accounts payable</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SpinOffRatio" xlink:label="snpx_SpinOffRatio" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_SpinOffRatio" xlink:to="snpx_SpinOffRatio_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_SpinOffRatio_lbl" xml:lang="en-US">Ratio of shares of spin-off company issued for shares of the Company's common stock owned by such stockholder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_SpinOffRatio_lbl" xml:lang="en-US">Spin Off Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_SpinOffRatio_lbl" xml:lang="en-US">Spin-Off Ratio</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfVotesPerShareOwned" xlink:label="snpx_NumberOfVotesPerShareOwned" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NumberOfVotesPerShareOwned" xlink:to="snpx_NumberOfVotesPerShareOwned_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NumberOfVotesPerShareOwned_lbl" xml:lang="en-US">Number of votes entitled for each common share held.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NumberOfVotesPerShareOwned_lbl" xml:lang="en-US">Number of Votes Per Share Owned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NumberOfVotesPerShareOwned_lbl" xml:lang="en-US">Votes per share of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PrefundedWarrantsMember" xlink:label="snpx_PrefundedWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_PrefundedWarrantsMember" xlink:to="snpx_PrefundedWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_PrefundedWarrantsMember_lbl" xml:lang="en-US">This represents prefunded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_PrefundedWarrantsMember_lbl" xml:lang="en-US">Prefunded warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesEWarrantsMember" xlink:label="snpx_SeriesEWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_SeriesEWarrantsMember" xlink:to="snpx_SeriesEWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_SeriesEWarrantsMember_lbl" xml:lang="en-US">This member stands for Series E Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_SeriesEWarrantsMember_lbl" xml:lang="en-US">Series E Warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesGWarrantsMember" xlink:label="snpx_SeriesGWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_SeriesGWarrantsMember" xlink:to="snpx_SeriesGWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_SeriesGWarrantsMember_lbl" xml:lang="en-US">This member stands for Series G Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_SeriesGWarrantsMember_lbl" xml:lang="en-US">Series G Warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesFWarrantsMember" xlink:label="snpx_SeriesFWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_SeriesFWarrantsMember" xlink:to="snpx_SeriesFWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_SeriesFWarrantsMember_lbl" xml:lang="en-US">This member stands for Series F Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_SeriesFWarrantsMember_lbl" xml:lang="en-US">Series F Warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SecuritiesPurchaseAgreementsMember" xlink:label="snpx_SecuritiesPurchaseAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_SecuritiesPurchaseAgreementsMember" xlink:to="snpx_SecuritiesPurchaseAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_SecuritiesPurchaseAgreementsMember_lbl" xml:lang="en-US">This represents Securities Purchase Agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_SecuritiesPurchaseAgreementsMember_lbl" xml:lang="en-US">Securities Purchase Agreements</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareholderRightsPlanMember" xlink:label="snpx_ShareholderRightsPlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ShareholderRightsPlanMember" xlink:to="snpx_ShareholderRightsPlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ShareholderRightsPlanMember_lbl" xml:lang="en-US">This represents shareholders rights plan member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ShareholderRightsPlanMember_lbl" xml:lang="en-US">Shareholder Rights Plan</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_RightsAgreementMember" xlink:label="snpx_RightsAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_RightsAgreementMember" xlink:to="snpx_RightsAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_RightsAgreementMember_lbl" xml:lang="en-US">This member stands for the Rights Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_RightsAgreementMember_lbl" xml:lang="en-US">Rights Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PlacementAgentsMember" xlink:label="snpx_PlacementAgentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_PlacementAgentsMember" xlink:to="snpx_PlacementAgentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_PlacementAgentsMember_lbl" xml:lang="en-US">Represents about placement agents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_PlacementAgentsMember_lbl" xml:lang="en-US">Placement Agents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement" xlink:label="snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement" xlink:to="snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement_lbl" xml:lang="en-US">Aggregate number of shares authorized to issue under purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement_lbl" xml:lang="en-US">Aggregate Number of Shares Authorized to Issue Under Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement_lbl" xml:lang="en-US">Aggregate number of shares authorized to issue under purchase agreement</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant" xlink:label="snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant" xlink:to="snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant_lbl" xml:lang="en-US">Percentage of fees on offering based on aggregate exercise price paid to placement agents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant_lbl" xml:lang="en-US">Percentage Of Offering Fees Based On Aggregate Exercise Price Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant_lbl" xml:lang="en-US">Percentage of offering fees on aggregate price of warrant exercise</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ThresholdPeriodForArrangingFutureFinancing" xlink:label="snpx_ThresholdPeriodForArrangingFutureFinancing" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ThresholdPeriodForArrangingFutureFinancing" xlink:to="snpx_ThresholdPeriodForArrangingFutureFinancing_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ThresholdPeriodForArrangingFutureFinancing_lbl" xml:lang="en-US">Period within which the future financing should be consummated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ThresholdPeriodForArrangingFutureFinancing_lbl" xml:lang="en-US">Threshold Period For Arranging Future Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ThresholdPeriodForArrangingFutureFinancing_lbl" xml:lang="en-US">Period within which future financing should be consummated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Share price</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights" xlink:label="snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights" xlink:to="snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights_lbl" xml:lang="en-US">Warrants exercise period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Period of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights_lbl" xml:lang="en-US">Warrants exercise period</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CombinedPurchasePriceOfCommonStockAndWarrants" xlink:label="snpx_CombinedPurchasePriceOfCommonStockAndWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_CombinedPurchasePriceOfCommonStockAndWarrants" xlink:to="snpx_CombinedPurchasePriceOfCommonStockAndWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_CombinedPurchasePriceOfCommonStockAndWarrants_lbl" xml:lang="en-US">Combined purchase price per share of Common Stock and Warrants (the "Offering").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_CombinedPurchasePriceOfCommonStockAndWarrants_lbl" xml:lang="en-US">Combined Purchase Price of Common Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_CombinedPurchasePriceOfCommonStockAndWarrants_lbl" xml:lang="en-US">Combined purchase price of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock" xlink:label="snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock" xlink:to="snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock_lbl" xml:lang="en-US">Amount of gross proceeds received from offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock_lbl" xml:lang="en-US">Gross Proceeds from Sale of Warrants and Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock_lbl" xml:lang="en-US">Gross proceeds in offering</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetProceedsFromSaleOfWarrantsAndCommonStock" xlink:label="snpx_NetProceedsFromSaleOfWarrantsAndCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NetProceedsFromSaleOfWarrantsAndCommonStock" xlink:to="snpx_NetProceedsFromSaleOfWarrantsAndCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NetProceedsFromSaleOfWarrantsAndCommonStock_lbl" xml:lang="en-US">Amount of net proceeds from sale of Warrants and Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NetProceedsFromSaleOfWarrantsAndCommonStock_lbl" xml:lang="en-US">Net Proceeds from Sale of Warrants and Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NetProceedsFromSaleOfWarrantsAndCommonStock_lbl" xml:lang="en-US">Net proceeds in offering</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PercentageOfOfferingFeesInCash" xlink:label="snpx_PercentageOfOfferingFeesInCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_PercentageOfOfferingFeesInCash" xlink:to="snpx_PercentageOfOfferingFeesInCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_PercentageOfOfferingFeesInCash_lbl" xml:lang="en-US">Percentage of fees on offering in cash to placement agents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_PercentageOfOfferingFeesInCash_lbl" xml:lang="en-US">Percentage of Offering Fees in Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_PercentageOfOfferingFeesInCash_lbl" xml:lang="en-US">Percentage of offering fees in cash</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PercentageOfOfferingFeesInWarrants" xlink:label="snpx_PercentageOfOfferingFeesInWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_PercentageOfOfferingFeesInWarrants" xlink:to="snpx_PercentageOfOfferingFeesInWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_PercentageOfOfferingFeesInWarrants_lbl" xml:lang="en-US">Percentage of fees on offering in warrants to placement agents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_PercentageOfOfferingFeesInWarrants_lbl" xml:lang="en-US">Percentage of Offering Fees in Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_PercentageOfOfferingFeesInWarrants_lbl" xml:lang="en-US">Percentage of offering fees in warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend" xlink:label="snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend" xlink:to="snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend_lbl" xml:lang="en-US">Number of preferred share purchase right for each outstanding share of Common Stock by means of dividend.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend_lbl" xml:lang="en-US">Number of Preferred Share Purchase Right for Each Outstanding Share of Common Stock, Dividend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend_lbl" xml:lang="en-US">Number of preferred share purchase right for each outstanding share of Common Stock by means of dividend</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights" xlink:label="snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights" xlink:to="snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights_lbl" xml:lang="en-US">Minimum acquisition percentage of outstanding common stock to exercise rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights_lbl" xml:lang="en-US">Minimum Acquisition Percentage of Outstanding Common Stock to Exercise Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights_lbl" xml:lang="en-US">Minimum acquisition percentage of outstanding common stock to exercise rights</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson" xlink:label="snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson" xlink:to="snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson_lbl" xml:lang="en-US">Discount available to right holders to purchase common stock upon acquisition of minimum shareholding by acquiring person.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson_lbl" xml:lang="en-US">Discount Available to Right Holders to Purchase Common Stock Upon Acquisition of Minimum Shareholding by Acquiring Person</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson_lbl" xml:lang="en-US">Discount available to right holders to purchase common stock upon acquisition of minimum shareholding by acquiring person</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfCommonSharesForEachRight" xlink:label="snpx_NumberOfCommonSharesForEachRight" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NumberOfCommonSharesForEachRight" xlink:to="snpx_NumberOfCommonSharesForEachRight_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NumberOfCommonSharesForEachRight_lbl" xml:lang="en-US">Number of common shares upon exercise of each right.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NumberOfCommonSharesForEachRight_lbl" xml:lang="en-US">Number of Common Shares for Each Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NumberOfCommonSharesForEachRight_lbl" xml:lang="en-US">Number of common shares for each right</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight" xlink:label="snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight" xlink:to="snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight_lbl" xml:lang="en-US">Number of One-Thousandth share of Series A Preferred stock Included In Right.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight_lbl" xml:lang="en-US">Number of One-Thousanth share of Series A Preferred stock Included In Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight_lbl" xml:lang="en-US">Number of One-Thousandth share of Series A Preferred stock Issued In Right</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PurchasePriceOfRight" xlink:label="snpx_PurchasePriceOfRight" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_PurchasePriceOfRight" xlink:to="snpx_PurchasePriceOfRight_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_PurchasePriceOfRight_lbl" xml:lang="en-US">Purchase price of right.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_PurchasePriceOfRight_lbl" xml:lang="en-US">Purchase Price of Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_PurchasePriceOfRight_lbl" xml:lang="en-US">Purchase price of right</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Reverse Stock Split, conversion ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_DateOfGrantMember" xlink:label="snpx_DateOfGrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_DateOfGrantMember" xlink:to="snpx_DateOfGrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_DateOfGrantMember_lbl" xml:lang="en-US">Represents the information pertaining to date of grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_DateOfGrantMember_lbl" xml:lang="en-US">Date of grant</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_FirstAnniversaryOfGrantDateMember" xlink:label="snpx_FirstAnniversaryOfGrantDateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_FirstAnniversaryOfGrantDateMember" xlink:to="snpx_FirstAnniversaryOfGrantDateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_FirstAnniversaryOfGrantDateMember_lbl" xml:lang="en-US">Represents the information pertaining to First anniversary of grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_FirstAnniversaryOfGrantDateMember_lbl" xml:lang="en-US">First anniversary of grant date</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SixMonthAnniversaryOfGrantDateMember" xlink:label="snpx_SixMonthAnniversaryOfGrantDateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_SixMonthAnniversaryOfGrantDateMember" xlink:to="snpx_SixMonthAnniversaryOfGrantDateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_SixMonthAnniversaryOfGrantDateMember_lbl" xml:lang="en-US">Represents the information pertaining to six month anniversary of grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_SixMonthAnniversaryOfGrantDateMember_lbl" xml:lang="en-US">Six month anniversary of grant date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US">Director</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember" xlink:label="snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember" xlink:to="snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember_lbl" xml:lang="en-US">Represents the information pertaining to nonemployee directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember_lbl" xml:lang="en-US">Nonemployee directors</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember" xlink:label="snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember" xlink:to="snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_lbl" xml:lang="en-US">Represents the information pertaining to newly appointed directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_lbl" xml:lang="en-US">Newly appointed director</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">CFO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">RSU's</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_EquityIncentivePlan2020Member" xlink:label="snpx_EquityIncentivePlan2020Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_EquityIncentivePlan2020Member" xlink:to="snpx_EquityIncentivePlan2020Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_EquityIncentivePlan2020Member_lbl" xml:lang="en-US">Represents the information pertaining to 2020 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_EquityIncentivePlan2020Member_lbl" xml:lang="en-US">2020 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_DirectorCompensationPolicyMember" xlink:label="snpx_DirectorCompensationPolicyMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_DirectorCompensationPolicyMember" xlink:to="snpx_DirectorCompensationPolicyMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_DirectorCompensationPolicyMember_lbl" xml:lang="en-US">Represents the information pertaining to director compensation policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_DirectorCompensationPolicyMember_lbl" xml:lang="en-US">Director Compensation Policy</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of securities available for grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock options expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors" xlink:to="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors_lbl" xml:lang="en-US">Number of shares authorized for issuance under share-based payment arrangement for service on a committee of the Board of Directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors_lbl" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized For Service On Committee Of The Board Of Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors_lbl" xml:lang="en-US">Stock option grant authorized for service on a committee of the Board of Directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue" xlink:to="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue_lbl" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue_lbl" xml:lang="en-US">Fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Less options exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of options vested</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfDirectors" xlink:label="snpx_NumberOfDirectors" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NumberOfDirectors" xlink:to="snpx_NumberOfDirectors_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NumberOfDirectors_lbl" xml:lang="en-US">Number of directors affected by the transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NumberOfDirectors_lbl" xml:lang="en-US">Number of Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="snpx_NumberOfDirectors_lbl" xml:lang="en-US">Number of director</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfExecutiveDirectors" xlink:label="snpx_NumberOfExecutiveDirectors" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NumberOfExecutiveDirectors" xlink:to="snpx_NumberOfExecutiveDirectors_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NumberOfExecutiveDirectors_lbl" xml:lang="en-US">Number of executive directors affected by the transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NumberOfExecutiveDirectors_lbl" xml:lang="en-US">Number Of Executive Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NumberOfExecutiveDirectors_lbl" xml:lang="en-US">Number of executive directors</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfEmployee" xlink:label="snpx_NumberOfEmployee" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NumberOfEmployee" xlink:to="snpx_NumberOfEmployee_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NumberOfEmployee_lbl" xml:lang="en-US">Represents the number of directors .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NumberOfEmployee_lbl" xml:lang="en-US">Number Of Employee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_NumberOfEmployee_lbl" xml:lang="en-US">Number of employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding at the beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable at the end</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted-Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options outstanding at the end (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options outstanding at the beginning (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable at the end (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Term (Years) and Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining contractual term for option awards in granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Options granted (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding at the end (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options exercisable at the end (in years)</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AggregateIntrinsicValueAbstract" xlink:label="snpx_AggregateIntrinsicValueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_AggregateIntrinsicValueAbstract" xlink:to="snpx_AggregateIntrinsicValueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">No definition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding at the end (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Options exercisable at the end (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants outstanding September 30, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants outstanding January 1, 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PlacementAgentAgreementMember" xlink:label="snpx_PlacementAgentAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_PlacementAgentAgreementMember" xlink:to="snpx_PlacementAgentAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_PlacementAgentAgreementMember_lbl" xml:lang="en-US">This member stands for placement agent agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_PlacementAgentAgreementMember_lbl" xml:lang="en-US">Placement Agent Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AdvisoryAgreementsMember" xlink:label="snpx_AdvisoryAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_AdvisoryAgreementsMember" xlink:to="snpx_AdvisoryAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_AdvisoryAgreementsMember_lbl" xml:lang="en-US">Represents the information pertaining to advisory agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_AdvisoryAgreementsMember_lbl" xml:lang="en-US">Advisory Agreements [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesWarrantsMember" xlink:label="snpx_SeriesWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_SeriesWarrantsMember" xlink:to="snpx_SeriesWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_SeriesWarrantsMember_lbl" xml:lang="en-US">This member stand for Series A Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_SeriesWarrantsMember_lbl" xml:lang="en-US">Series A Warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesBWarrantsMember" xlink:label="snpx_SeriesBWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_SeriesBWarrantsMember" xlink:to="snpx_SeriesBWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_SeriesBWarrantsMember_lbl" xml:lang="en-US">This member stands for Series H Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesCWarrantsMember" xlink:label="snpx_SeriesCWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_SeriesCWarrantsMember" xlink:to="snpx_SeriesCWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_SeriesCWarrantsMember_lbl" xml:lang="en-US">This member stands for Series C Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_SeriesCWarrantsMember_lbl" xml:lang="en-US">Series C Warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesDWarrantsMember" xlink:label="snpx_SeriesDWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_SeriesDWarrantsMember" xlink:to="snpx_SeriesDWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_SeriesDWarrantsMember_lbl" xml:lang="en-US">This member stands for Series D Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_SeriesDWarrantsMember_lbl" xml:lang="en-US">Series D Warrants</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesHWarrantsMember" xlink:label="snpx_SeriesHWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_SeriesHWarrantsMember" xlink:to="snpx_SeriesHWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_SeriesHWarrantsMember_lbl" xml:lang="en-US">This member stands for Series H Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_SeriesHWarrantsMember_lbl" xml:lang="en-US">Series H Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment" xlink:label="snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment" xlink:to="snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment_lbl" xml:lang="en-US">Exercise price per share or per unit of warrants or rights outstanding, before amendment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment_lbl" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Before Amendment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment_lbl" xml:lang="en-US">Exercise price of warrants before amendment</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants" xlink:label="snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants" xlink:to="snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants_lbl" xml:lang="en-US">Numerator used to determine the initial exercise price of warrants in the event of spin-off.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants_lbl" xml:lang="en-US">Class Of Warrant Or Right, Numerator Used To Determine Initial Exercise Price Of Spin-Off Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants_lbl" xml:lang="en-US">Exercise price to purchase shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants, measurement input</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Rights, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares of common stock</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfWarrantHoldersWhoExercisedWarrants" xlink:label="snpx_NumberOfWarrantHoldersWhoExercisedWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_NumberOfWarrantHoldersWhoExercisedWarrants" xlink:to="snpx_NumberOfWarrantHoldersWhoExercisedWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_NumberOfWarrantHoldersWhoExercisedWarrants_lbl" xml:lang="en-US">Number of warrant holders who exercised their warrants during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_NumberOfWarrantHoldersWhoExercisedWarrants_lbl" xml:lang="en-US">Number Of Warrant Holders Who Exercised Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_lbl" xml:lang="en-US">Compensation Expense, Excluding Cost of Good and Service Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_lbl" xml:lang="en-US">Consultant compensation paid with Parent equity</label>
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ContributionsFromParent" xlink:label="snpx_ContributionsFromParent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="snpx_ContributionsFromParent" xlink:to="snpx_ContributionsFromParent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="snpx_ContributionsFromParent_lbl" xml:lang="en-US">Represents the amount of contributions from Parent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="snpx_ContributionsFromParent_lbl" xml:lang="en-US">Contributions from Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="snpx_ContributionsFromParent_lbl" xml:lang="en-US">Parent contributions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Labor and Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Total</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>snpx-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2021 8:48:53 PM-->
<!--Modified on: 11/12/2021 8:48:53 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#StatementCondensedBalanceSheets" roleURI="http://www.synaptogen.com/role/StatementCondensedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#StatementCondensedBalanceSheetsParenthetical" roleURI="http://www.synaptogen.com/role/StatementCondensedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#StatementCondensedStatementsOfOperations" roleURI="http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#StatementCondensedStatementsOfChangesInShareholdersEquity" roleURI="http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#StatementCondensedStatementsOfCashFlows" roleURI="http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureOrganizationBusinessRisksAndUncertainties" roleURI="http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertainties" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureCollaborativeAgreementsAndCommitments" roleURI="http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitments" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureRelatedPartyTransactionsAndLicensingResearchAgreements" roleURI="http://www.synaptogen.com/role/DisclosureRelatedPartyTransactionsAndLicensingResearchAgreements" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.synaptogen.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureStockholdersEquity" roleURI="http://www.synaptogen.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureStockBasedCompensation" roleURI="http://www.synaptogen.com/role/DisclosureStockBasedCompensation" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureCommonStockWarrants" roleURI="http://www.synaptogen.com/role/DisclosureCommonStockWarrants" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureParentCompanyInvestment" roleURI="http://www.synaptogen.com/role/DisclosureParentCompanyInvestment" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureSubsequentEvents" roleURI="http://www.synaptogen.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.synaptogen.com/role/DisclosureStockBasedCompensationTables" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureCommonStockWarrantsTables" roleURI="http://www.synaptogen.com/role/DisclosureCommonStockWarrantsTables" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureParentCompanyInvestmentTables" roleURI="http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentTables" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureOrganizationBusinessRisksAndUncertaintiesDetails" roleURI="http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails" roleURI="http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureCollaborativeAgreementsAndCommitmentsDetails" roleURI="http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureRelatedPartyTransactionsAndLicensingResearchAgreementsDetails" roleURI="http://www.synaptogen.com/role/DisclosureRelatedPartyTransactionsAndLicensingResearchAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails" roleURI="http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails" roleURI="http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureCommonStockWarrantsCommonStockWarrantActivityDetails" roleURI="http://www.synaptogen.com/role/DisclosureCommonStockWarrantsCommonStockWarrantActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureCommonStockWarrantsAdditionalInformationDetails" roleURI="http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="snpx-20210930.xsd#DisclosureParentCompanyInvestmentDetails" roleURI="http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails" />
  <presentationLink xlink:role="http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637723469321279179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637723469321279179" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637723469321289188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637723469321289188" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637723469321289188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637723469321289188" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637723469321289188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637723469321289188" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637723469321289188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637723469321289188" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637723469321289188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637723469321289188" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637723469321289188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637723469321289188" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637723469321289188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637723469321289188" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637723469321289188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637723469321289188" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637723469321289188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637723469321289188" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637723469321289188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637723469321289188" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637723469321289188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637723469321289188" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637723469321289188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637723469321289188" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637723469321299185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637723469321299185" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637723469321299185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637723469321299185" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637723469321299185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637723469321299185" order="16" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637723469321299185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637723469321299185" order="17" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637723469321299185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637723469321299185" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637723469321299185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637723469321299185" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637723469321299185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637723469321299185" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637723469321299185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637723469321299185" order="21" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637723469321299185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637723469321299185" order="22" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637723469321299185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637723469321299185" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637723469321309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637723469321309182" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637723469321309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637723469321309182" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637723469321309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637723469321309182" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637723469321309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637723469321309182" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637723469321309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637723469321309182" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637723469321309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637723469321309182" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637723469321309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637723469321309182" order="30" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637723469321309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637723469321309182" order="31" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/StatementCondensedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_31" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637723469321319184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_31" xlink:to="us-gaap_AssetsAbstract_637723469321319184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637723469321319184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637723469321319184" xlink:to="us-gaap_AssetsCurrentAbstract_637723469321319184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723469321319184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637723469321319184" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723469321319184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_637723469321319184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637723469321319184" xlink:to="us-gaap_GrantsReceivableCurrent_637723469321319184" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637723469321319184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637723469321319184" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637723469321319184" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637723469321319184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637723469321319184" xlink:to="us-gaap_AssetsCurrent_637723469321319184" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637723469321319184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637723469321319184" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637723469321319184" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637723469321319184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637723469321319184" xlink:to="us-gaap_Assets_637723469321319184" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637723469321319184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_31" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637723469321319184" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637723469321319184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637723469321319184" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637723469321319184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637723469321329182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637723469321319184" xlink:to="us-gaap_AccountsPayableCurrent_637723469321329182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637723469321329182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637723469321319184" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637723469321329182" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637723469321329182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637723469321319184" xlink:to="us-gaap_LiabilitiesCurrent_637723469321329182" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637723469321329182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637723469321319184" xlink:to="us-gaap_CommitmentsAndContingencies_637723469321329182" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637723469321329182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637723469321319184" xlink:to="us-gaap_StockholdersEquityAbstract_637723469321329182" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637723469321329182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637723469321329182" xlink:to="us-gaap_CommonStockValue_637723469321329182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637723469321329182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637723469321329182" xlink:to="us-gaap_AdditionalPaidInCapital_637723469321329182" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637723469321329182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637723469321329182" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637723469321329182" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637723469321329182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637723469321329182" xlink:to="us-gaap_StockholdersEquity_637723469321329182" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637723469321339203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637723469321319184" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637723469321339203" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/StatementCondensedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Condensed Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_93" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637723469321339203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93" xlink:to="us-gaap_PreferredStockSharesAuthorized_637723469321339203" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637723469321339203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637723469321339203" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637723469321339203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93" xlink:to="us-gaap_PreferredStockSharesIssued_637723469321339203" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637723469321339203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93" xlink:to="us-gaap_PreferredStockSharesOutstanding_637723469321339203" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637723469321339203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93" xlink:to="us-gaap_CommonStockSharesAuthorized_637723469321339203" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637723469321339203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637723469321339203" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637723469321339203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93" xlink:to="us-gaap_CommonStockSharesIssued_637723469321339203" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637723469321339203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93" xlink:to="us-gaap_CommonStockSharesOutstanding_637723469321339203" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Statements of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_184" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_184" xlink:to="us-gaap_OperatingExpensesAbstract_637723469321349183" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637723469321349183" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637723469321349183" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637723469321349183" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637723469321349183" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637723469321349183" xlink:to="us-gaap_OperatingExpenses_637723469321349183" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_184" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_637723469321349183" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract_637723469321349183" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637723469321349183" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantAmendmentExpense" xlink:label="snpx_WarrantAmendmentExpense_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract_637723469321349183" xlink:to="snpx_WarrantAmendmentExpense_637723469321349183" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract_637723469321349183" xlink:to="us-gaap_InterestIncomeOther_637723469321349183" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_184" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637723469321349183" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_184" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637723469321349183" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_184" xlink:to="us-gaap_NetIncomeLoss_637723469321349183" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_184" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637723469321349183" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_184" xlink:to="us-gaap_EarningsPerShareAbstract_637723469321349183" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637723469321349183" xlink:to="us-gaap_EarningsPerShareBasic_637723469321349183" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637723469321349183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637723469321349183" xlink:to="us-gaap_EarningsPerShareDiluted_637723469321349183" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637723469321359247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637723469321349183" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637723469321359247" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637723469321359247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637723469321349183" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637723469321359247" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Condensed Statements of Changes in Shareholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_319" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723469321359247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_319" xlink:to="us-gaap_StatementTable_637723469321359247" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637723469321359247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321359247" xlink:to="us-gaap_StatementEquityComponentsAxis_637723469321359247" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember_637723469321359247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637723469321359247" xlink:to="us-gaap_ParentMember_637723469321359247" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637723469321359247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637723469321359247" xlink:to="us-gaap_CommonStockMember_637723469321359247" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_637723469321359247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637723469321359247" xlink:to="us-gaap_PreferredStockMember_637723469321359247" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637723469321359247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637723469321359247" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637723469321359247" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637723469321359247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637723469321359247" xlink:to="us-gaap_RetainedEarningsMember_637723469321359247" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637723469321359247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637723469321359247" xlink:to="us-gaap_EquityComponentDomain_637723469321359247" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723469321369181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321359247" xlink:to="us-gaap_StatementLineItems_637723469321369181" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637723469321369181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="us-gaap_StockholdersEquity_637723469321369181" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637723469321369181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="us-gaap_SharesOutstanding_637723469321369181" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetChangeInInvestment" xlink:label="snpx_NetChangeInInvestment_637723469321369181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="snpx_NetChangeInInvestment_637723469321369181" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637723469321369181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637723469321369181" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="snpx_StockIssuedDuringPeriodValueWarrantsExercised_637723469321369181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="snpx_StockIssuedDuringPeriodValueWarrantsExercised_637723469321369181" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="snpx_StockIssuedDuringPeriodSharesWarrantExercises_637723469321369181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="snpx_StockIssuedDuringPeriodSharesWarrantExercises_637723469321369181" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637723469321369181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637723469321369181" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantsIssuedDuringPeriodValueIssuedForServices" xlink:label="snpx_WarrantsIssuedDuringPeriodValueIssuedForServices_637723469321369181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="snpx_WarrantsIssuedDuringPeriodValueIssuedForServices_637723469321369181" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices" xlink:label="snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices_637723469321369181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices_637723469321369181" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_637723469321369181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_637723469321369181" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_637723469321379184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_637723469321379184" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637723469321379184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637723469321379184" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637723469321379184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637723469321379184" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantAmendmentExpense" xlink:label="snpx_WarrantAmendmentExpense_637723469321379184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="snpx_WarrantAmendmentExpense_637723469321379184" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637723469321379184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637723469321379184" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637723469321379184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="us-gaap_NetIncomeLoss_637723469321379184" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637723469321379184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="us-gaap_StockholdersEquity_637723469321379184" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637723469321389349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321369181" xlink:to="us-gaap_SharesOutstanding_637723469321389349" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_338" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_338" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637723469321389349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" xlink:to="us-gaap_NetIncomeLoss_637723469321389349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation" xlink:label="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation_637723469321389349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" xlink:to="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation_637723469321389349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_637723469321389349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_637723469321389349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_637723469321389349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_637723469321389349" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_IssuanceOfStockAndWarrantsForServices" xlink:label="snpx_IssuanceOfStockAndWarrantsForServices_637723469321389349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" xlink:to="snpx_IssuanceOfStockAndWarrantsForServices_637723469321389349" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock" xlink:label="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock_637723469321399321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" xlink:to="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock_637723469321399321" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants" xlink:label="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants_637723469321399321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" xlink:to="snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants_637723469321399321" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantAmendmentExpense" xlink:label="snpx_WarrantAmendmentExpense_637723469321399321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" xlink:to="snpx_WarrantAmendmentExpense_637723469321399321" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637723469321399321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637723469321399321" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637723469321399321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637723469321399321" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723469321399321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723469321399321" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_IncreaseDecreaseInGrantReceivableCurrent" xlink:label="snpx_IncreaseDecreaseInGrantReceivableCurrent_637723469321399321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723469321399321" xlink:to="snpx_IncreaseDecreaseInGrantReceivableCurrent_637723469321399321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_637723469321399321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723469321399321" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_637723469321399321" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637723469321399321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723469321399321" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637723469321399321" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637723469321399321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723469321399321" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637723469321399321" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469321399321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723469321399321" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_637723469321399321" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723469321409187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637723469321389349" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723469321409187" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637723469321409187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_338" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637723469321409187" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637723469321409187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637723469321409187" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637723469321409187" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637723469321409187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637723469321409187" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637723469321409187" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723469321409187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_338" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723469321409187" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637723469321409187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723469321409187" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637723469321409187" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637723469321409187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723469321409187" xlink:to="us-gaap_ProceedsFromWarrantExercises_637723469321409187" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PaymentsInLieuSharesForReverseStockSplit" xlink:label="snpx_PaymentsInLieuSharesForReverseStockSplit_637723469321409187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723469321409187" xlink:to="snpx_PaymentsInLieuSharesForReverseStockSplit_637723469321409187" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetTransferFromToParent" xlink:label="snpx_NetTransferFromToParent_637723469321409187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723469321409187" xlink:to="snpx_NetTransferFromToParent_637723469321409187" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723469321419186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723469321409187" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723469321419186" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637723469321419186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637723469321419186" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637723469321419186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637723469321419186" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6377234693214191861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6377234693214191861" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertainties" xlink:type="extended" xlink:title="10101 - Disclosure - Organization, Business, Risks and Uncertainties">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_373" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_637723469321429196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_373" xlink:to="us-gaap_NatureOfOperations_637723469321429196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_376" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637723469321429196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_376" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637723469321429196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitments" xlink:type="extended" xlink:title="10301 - Disclosure - Collaborative Agreements and Commitments">
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CollaborativeAgreementsAndCommitmentsAbstract" xlink:label="snpx_CollaborativeAgreementsAndCommitmentsAbstract" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CollaborativeAgreementsAndCommitmentsTextBlock" xlink:label="snpx_CollaborativeAgreementsAndCommitmentsTextBlock_637723469321429196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_CollaborativeAgreementsAndCommitmentsAbstract" xlink:to="snpx_CollaborativeAgreementsAndCommitmentsTextBlock_637723469321429196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureRelatedPartyTransactionsAndLicensingResearchAgreements" xlink:type="extended" xlink:title="10401 - Disclosure - Related Party Transactions and Licensing / Research Agreements">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637723469321429196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637723469321429196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10501 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637031338462027363" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637723469321439207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637031338462027363" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637723469321439207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10601 - Disclosure - Stockholders' Equity:">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637723469321439207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637723469321439207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10701 - Disclosure - Stock Based Compensation:">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637723469321439207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637723469321439207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureCommonStockWarrants" xlink:type="extended" xlink:title="10801 - Disclosure - Common Stock Warrants:">
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CommonStockWarrants" xlink:label="snpx_CommonStockWarrants" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_StockOptionNoteDisclosureTextBlock" xlink:label="snpx_StockOptionNoteDisclosureTextBlock_637723469321439207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_CommonStockWarrants" xlink:to="snpx_StockOptionNoteDisclosureTextBlock_637723469321439207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureParentCompanyInvestment" xlink:type="extended" xlink:title="10901 - Disclosure - Parent Company Investment">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock" xlink:label="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock_637723469321439207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock_637723469321439207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11001 - Disclosure - Subsequent Events">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_58" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637723469321449192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_58" xlink:to="us-gaap_SubsequentEventsTextBlock_637723469321449192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_61" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637723469321449192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637723469321449192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637723469321449192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61" xlink:to="us-gaap_UseOfEstimates_637723469321449192" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock" xlink:label="snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock_637723469321449192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61" xlink:to="snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock_637723469321449192" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637723469321449192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637723469321449192" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637723469321449192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637723469321449192" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637723469321449192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637723469321449192" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637723469321449192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637723469321449192" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock" xlink:label="snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock_637723469321449192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61" xlink:to="snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock_637723469321449192" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637723469321449192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637723469321449192" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stock Based Compensation: (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637723469321459189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637723469321459189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_637723469321459189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_637723469321459189" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureCommonStockWarrantsTables" xlink:type="extended" xlink:title="30803 - Disclosure - Common Stock Warrants: (Tables)">
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CommonStockWarrants" xlink:label="snpx_CommonStockWarrants" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637723469321459189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_CommonStockWarrants" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637723469321459189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentTables" xlink:type="extended" xlink:title="30903 - Disclosure - Parent Company Investment (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:label="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_637723469321459189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_637723469321459189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization, Business, Risks and Uncertainties (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723469321459189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable_637723469321459189" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637723469321459189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321459189" xlink:to="us-gaap_SubsequentEventTypeAxis_637723469321459189" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637723469321459189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637723469321459189" xlink:to="us-gaap_SubsequentEventTypeDomain_637723469321459189" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637723469321469190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637723469321459189" xlink:to="us-gaap_SubsequentEventMember_637723469321469190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_637723469321469190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321459189" xlink:to="us-gaap_RestructuringCostAndReserveAxis_637723469321469190" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_637723469321469190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis_637723469321469190" xlink:to="us-gaap_TypeOfRestructuringDomain_637723469321469190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SpinoffMember" xlink:label="us-gaap_SpinoffMember_637723469321469190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain_637723469321469190" xlink:to="us-gaap_SpinoffMember_637723469321469190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723469321469190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321459189" xlink:to="us-gaap_StatementLineItems_637723469321469190" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfSharesForEveryFiveCommonSharesHeld" xlink:label="snpx_NumberOfSharesForEveryFiveCommonSharesHeld_637723469321469190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321469190" xlink:to="snpx_NumberOfSharesForEveryFiveCommonSharesHeld_637723469321469190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld" xlink:label="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld_637723469321469190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321469190" xlink:to="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld_637723469321469190" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld" xlink:label="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld_637723469321469190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321469190" xlink:to="snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld_637723469321469190" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ExcessOfCashInOperatingAssetsAndLiabilities" xlink:label="snpx_ExcessOfCashInOperatingAssetsAndLiabilities_637723469321469190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321469190" xlink:to="snpx_ExcessOfCashInOperatingAssetsAndLiabilities_637723469321469190" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637723469321469190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321469190" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637723469321469190" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_637723469321469190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321469190" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_637723469321469190" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637723469321469190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321469190" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637723469321469190" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails" xlink:type="extended" xlink:title="40102 - Disclosure - Organization, Business, Risks and Uncertainties - Liquidity Uncertainties (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_637031338462057283" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723469321479187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_637031338462057283" xlink:to="us-gaap_StatementTable_637723469321479187" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637723469321479187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321479187" xlink:to="us-gaap_SubsequentEventTypeAxis_637723469321479187" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637723469321479187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637723469321479187" xlink:to="us-gaap_SubsequentEventTypeDomain_637723469321479187" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637723469321479187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637723469321479187" xlink:to="us-gaap_SubsequentEventMember_637723469321479187" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637723469321479187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321479187" xlink:to="us-gaap_TypeOfArrangementAxis_637723469321479187" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321479187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637723469321479187" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321479187" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ServicesAgreement2020Member" xlink:label="snpx_ServicesAgreement2020Member_637723469321479187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321479187" xlink:to="snpx_ServicesAgreement2020Member_637723469321479187" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637723469321479187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321479187" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637723469321479187" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637723469321479187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637723469321479187" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637723469321479187" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NationalInstitutesOfHealthMember" xlink:label="snpx_NationalInstitutesOfHealthMember_637723469321479187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637723469321479187" xlink:to="snpx_NationalInstitutesOfHealthMember_637723469321479187" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723469321479187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321479187" xlink:to="us-gaap_StatementLineItems_637723469321479187" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723469321479187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321479187" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723469321479187" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate" xlink:label="snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate_637723469321479187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321479187" xlink:to="snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate_637723469321479187" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses" xlink:label="snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses_637723469321489192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321479187" xlink:to="snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses_637723469321489192" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637723469321489192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321479187" xlink:to="us-gaap_ProceedsFromWarrantExercises_637723469321489192" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountOfFundingReceived" xlink:label="snpx_AmountOfFundingReceived_637723469321489192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321479187" xlink:to="snpx_AmountOfFundingReceived_637723469321489192" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637031338462117123" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="snpx_SummaryOfSignificantAccountingPoliciesTable_637723469321489192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637031338462117123" xlink:to="snpx_SummaryOfSignificantAccountingPoliciesTable_637723469321489192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637723469321489192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesTable_637723469321489192" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637723469321489192" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637723469321489192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637723469321489192" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637723469321489192" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NationalInstitutesOfHealthMember" xlink:label="snpx_NationalInstitutesOfHealthMember_637723469321489192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637723469321489192" xlink:to="snpx_NationalInstitutesOfHealthMember_637723469321489192" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637723469321489192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesTable_637723469321489192" xlink:to="srt_RangeAxis_637723469321489192" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637723469321489192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637723469321489192" xlink:to="srt_RangeMember_637723469321489192" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637723469321489192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723469321489192" xlink:to="srt_MaximumMember_637723469321489192" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637723469321499265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723469321489192" xlink:to="srt_MinimumMember_637723469321499265" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637723469321499265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesTable_637723469321489192" xlink:to="us-gaap_TypeOfArrangementAxis_637723469321499265" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321499265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637723469321499265" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321499265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ServicesAgreement2020Member" xlink:label="snpx_ServicesAgreement2020Member_637723469321499265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321499265" xlink:to="snpx_ServicesAgreement2020Member_637723469321499265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637723469321499265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesTable_637723469321489192" xlink:to="us-gaap_SubsequentEventTypeAxis_637723469321499265" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637723469321499265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637723469321499265" xlink:to="us-gaap_SubsequentEventTypeDomain_637723469321499265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637723469321499265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637723469321499265" xlink:to="us-gaap_SubsequentEventMember_637723469321499265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637723469321499265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesTable_637723469321489192" xlink:to="srt_StatementScenarioAxis_637723469321499265" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637723469321499265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637723469321499265" xlink:to="srt_ScenarioUnspecifiedDomain_637723469321499265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_637723469321499265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637723469321499265" xlink:to="srt_ScenarioForecastMember_637723469321499265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_637723469321509191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesTable_637723469321489192" xlink:to="us-gaap_RelatedPartyTransactionAxis_637723469321509191" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637723469321509191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_637723469321509191" xlink:to="us-gaap_RelatedPartyTransactionDomain_637723469321509191" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CurrentShareholdersOfCompanyMember" xlink:label="snpx_CurrentShareholdersOfCompanyMember_637723469321509191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637723469321509191" xlink:to="snpx_CurrentShareholdersOfCompanyMember_637723469321509191" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="snpx_SummaryOfSignificantAccountingPoliciesLineItems_637723469321509191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesTable_637723469321489192" xlink:to="snpx_SummaryOfSignificantAccountingPoliciesLineItems_637723469321509191" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount_637723469321509191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems_637723469321509191" xlink:to="us-gaap_CashFDICInsuredAmount_637723469321509191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount_637723469321509191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems_637723469321509191" xlink:to="us-gaap_CashUninsuredAmount_637723469321509191" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637723469321509191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems_637723469321509191" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637723469321509191" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CapitalizedResearchAndDevelopmentServices" xlink:label="snpx_CapitalizedResearchAndDevelopmentServices_637723469321509191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems_637723469321509191" xlink:to="snpx_CapitalizedResearchAndDevelopmentServices_637723469321509191" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_IssueOfSharesOnSpinOff" xlink:label="snpx_IssueOfSharesOnSpinOff_637723469321519190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems_637723469321509191" xlink:to="snpx_IssueOfSharesOnSpinOff_637723469321519190" order="5" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637723469321519190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems_637723469321509191" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637723469321519190" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable_637723469321519190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems_637723469321509191" xlink:to="us-gaap_GrantsReceivable_637723469321519190" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountOfAwardReceived" xlink:label="snpx_AmountOfAwardReceived_637723469321519190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems_637723469321509191" xlink:to="snpx_AmountOfAwardReceived_637723469321519190" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountOfFundingReceived" xlink:label="snpx_AmountOfFundingReceived_637723469321519190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems_637723469321509191" xlink:to="snpx_AmountOfFundingReceived_637723469321519190" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountOfFundingReceivable" xlink:label="snpx_AmountOfFundingReceivable_637723469321519190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems_637723469321509191" xlink:to="snpx_AmountOfFundingReceivable_637723469321519190" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637723469321519190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_SummaryOfSignificantAccountingPoliciesLineItems_637723469321509191" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637723469321519190" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Collaborative Agreements and Commitments (Details)">
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CollaborativeAgreementsAndCommitmentsAbstract" xlink:label="snpx_CollaborativeAgreementsAndCommitmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637723469321529189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_CollaborativeAgreementsAndCommitmentsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637723469321529189" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637723469321529189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637723469321529189" xlink:to="srt_RangeAxis_637723469321529189" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637723469321529189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637723469321529189" xlink:to="srt_RangeMember_637723469321529189" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637723469321529189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723469321529189" xlink:to="srt_MinimumMember_637723469321529189" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637723469321529189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723469321529189" xlink:to="srt_MaximumMember_637723469321529189" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637723469321529189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637723469321529189" xlink:to="srt_ProductOrServiceAxis_637723469321529189" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637723469321529189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637723469321529189" xlink:to="srt_ProductsAndServicesDomain_637723469321529189" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember_637723469321529189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637723469321529189" xlink:to="us-gaap_LicenseMember_637723469321529189" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637723469321529189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637723469321529189" xlink:to="us-gaap_TypeOfArrangementAxis_637723469321529189" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321539208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637723469321529189" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321539208" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_StandFordLicenseAgreementMember" xlink:label="snpx_StandFordLicenseAgreementMember_637723469321539208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321539208" xlink:to="snpx_StandFordLicenseAgreementMember_637723469321539208" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_Mt.SinaiLicenseAgreementMember" xlink:label="snpx_Mt.SinaiLicenseAgreementMember_637723469321539208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321539208" xlink:to="snpx_Mt.SinaiLicenseAgreementMember_637723469321539208" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AgreementsWithBryologyxMember" xlink:label="snpx_AgreementsWithBryologyxMember_637723469321539208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321539208" xlink:to="snpx_AgreementsWithBryologyxMember_637723469321539208" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NemoursAgreementMember" xlink:label="snpx_NemoursAgreementMember_637723469321539208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321539208" xlink:to="snpx_NemoursAgreementMember_637723469321539208" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637723469321539208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637723469321529189" xlink:to="srt_StatementScenarioAxis_637723469321539208" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637723469321539208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637723469321539208" xlink:to="srt_ScenarioUnspecifiedDomain_637723469321539208" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetSalesUpToDollars250MillionMember" xlink:label="snpx_NetSalesUpToDollars250MillionMember_637723469321539208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637723469321539208" xlink:to="snpx_NetSalesUpToDollars250MillionMember_637723469321539208" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetSalesOverDollarsMillionMember" xlink:label="snpx_NetSalesOverDollarsMillionMember_637723469321539208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637723469321539208" xlink:to="snpx_NetSalesOverDollarsMillionMember_637723469321539208" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637723469321529189" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_RoyaltyPaymentPercentage" xlink:label="snpx_RoyaltyPaymentPercentage_637723469321549349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="snpx_RoyaltyPaymentPercentage_637723469321549349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_MilestonePaymentsPaid" xlink:label="snpx_MilestonePaymentsPaid_637723469321549349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="snpx_MilestonePaymentsPaid_637723469321549349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties_637723469321549349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="us-gaap_PaymentsForRoyalties_637723469321549349" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_637723469321549349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="us-gaap_CostOfGoodsAndServicesSold_637723469321549349" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AnnualLicenseMaintenanceFee" xlink:label="snpx_AnnualLicenseMaintenanceFee_637723469321549349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="snpx_AnnualLicenseMaintenanceFee_637723469321549349" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CommitmentToPayFees" xlink:label="snpx_CommitmentToPayFees_637723469321549349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="snpx_CommitmentToPayFees_637723469321549349" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_MilestonePaymentsPayable" xlink:label="snpx_MilestonePaymentsPayable_637723469321549349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="snpx_MilestonePaymentsPayable_637723469321549349" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AdditionalMilestonePaymentsPayable" xlink:label="snpx_AdditionalMilestonePaymentsPayable_637723469321559211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="snpx_AdditionalMilestonePaymentsPayable_637723469321559211" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_RoyaltyPaymentThresholdNetSales" xlink:label="snpx_RoyaltyPaymentThresholdNetSales_637723469321559211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="snpx_RoyaltyPaymentThresholdNetSales_637723469321559211" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_TotalSavings" xlink:label="snpx_TotalSavings_637723469321559211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="snpx_TotalSavings_637723469321559211" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_LicenseAgreementsLicensingFees" xlink:label="snpx_LicenseAgreementsLicensingFees_637723469321559211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="snpx_LicenseAgreementsLicensingFees_637723469321559211" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_LicenseAgreementsDevelopmentCostsAndPatentFees" xlink:label="snpx_LicenseAgreementsDevelopmentCostsAndPatentFees_637723469321559211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="snpx_LicenseAgreementsDevelopmentCostsAndPatentFees_637723469321559211" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PercentageOfGrossRevenue" xlink:label="snpx_PercentageOfGrossRevenue_637723469321559211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="snpx_PercentageOfGrossRevenue_637723469321559211" order="13" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637723469321559211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="us-gaap_OtherIncome_637723469321559211" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses" xlink:label="snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses_637723469321569190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637723469321539208" xlink:to="snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses_637723469321569190" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureRelatedPartyTransactionsAndLicensingResearchAgreementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Related Party Transactions and Licensing / Research Agreements (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_149" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfStatementsEnteredIntoAgreement" xlink:label="snpx_NumberOfStatementsEnteredIntoAgreement_637723469321569190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_149" xlink:to="snpx_NumberOfStatementsEnteredIntoAgreement_637723469321569190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Commitments and Contingencies (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_637723469321569190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable_637723469321569190" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637723469321569190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637723469321569190" xlink:to="us-gaap_TypeOfArrangementAxis_637723469321569190" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321569190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637723469321569190" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321569190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementWithSmCapitalManagementLlcMember" xlink:label="snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_637723469321569190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321569190" xlink:to="snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_637723469321569190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember" xlink:label="snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_637723469321569190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321569190" xlink:to="snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_637723469321569190" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementWithGpNurmenkariIncMember" xlink:label="snpx_ConsultingAgreementWithGpNurmenkariIncMember_637723469321579187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321569190" xlink:to="snpx_ConsultingAgreementWithGpNurmenkariIncMember_637723469321579187" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ServicesAgreement2020Member" xlink:label="snpx_ServicesAgreement2020Member_637723469321579187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321569190" xlink:to="snpx_ServicesAgreement2020Member_637723469321579187" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember" xlink:label="snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_637723469321579187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321569190" xlink:to="snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_637723469321579187" order="5" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CharlesRyanSeparationAgreementMember" xlink:label="snpx_CharlesRyanSeparationAgreementMember_637723469321579187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321569190" xlink:to="snpx_CharlesRyanSeparationAgreementMember_637723469321579187" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637723469321579187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637723469321569190" xlink:to="us-gaap_VestingAxis_637723469321579187" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637723469321579187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637723469321579187" xlink:to="us-gaap_VestingDomain_637723469321579187" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637723469321579187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723469321579187" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637723469321579187" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637723469321579187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723469321579187" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637723469321579187" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_637723469321619190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723469321579187" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_637723469321619190" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="snpx_ShareBasedPaymentArrangementTrancheFourMember_637723469321619190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723469321579187" xlink:to="snpx_ShareBasedPaymentArrangementTrancheFourMember_637723469321619190" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637723469321619190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637723469321569190" xlink:to="us-gaap_SubsequentEventTypeAxis_637723469321619190" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637723469321619190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637723469321619190" xlink:to="us-gaap_SubsequentEventTypeDomain_637723469321619190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637723469321629196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637723469321619190" xlink:to="us-gaap_SubsequentEventMember_637723469321629196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637723469321629196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637723469321569190" xlink:to="srt_StatementScenarioAxis_637723469321629196" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637723469321629196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637723469321629196" xlink:to="srt_ScenarioUnspecifiedDomain_637723469321629196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember" xlink:label="snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember_637723469321629196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637723469321629196" xlink:to="snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember_637723469321629196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637723469321629196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637723469321569190" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637723469321629196" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637723469321629196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637723469321629196" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637723469321629196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NationalInstitutesOfHealthMember" xlink:label="snpx_NationalInstitutesOfHealthMember_637723469321629196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637723469321629196" xlink:to="snpx_NationalInstitutesOfHealthMember_637723469321629196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_637723469321629196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637723469321569190" xlink:to="us-gaap_OtherCommitmentsLineItems_637723469321629196" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ContractPaymentsTerm" xlink:label="snpx_ContractPaymentsTerm_637723469321639208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_ContractPaymentsTerm_637723469321639208" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AnnualConsultancyAgreementFees" xlink:label="snpx_AnnualConsultancyAgreementFees_637723469321639208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_AnnualConsultancyAgreementFees_637723469321639208" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637723469321639208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637723469321639208" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultancyFees" xlink:label="snpx_ConsultancyFees_637723469321639208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_ConsultancyFees_637723469321639208" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637723469321639208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637723469321639208" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate" xlink:label="snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate_637723469321639208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate_637723469321639208" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_TargetEnrollmentOfStudySubjects" xlink:label="snpx_TargetEnrollmentOfStudySubjects_637723469321639208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_TargetEnrollmentOfStudySubjects_637723469321639208" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_EstimatedBudgetForServices" xlink:label="snpx_EstimatedBudgetForServices_637723469321649197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_EstimatedBudgetForServices_637723469321649197" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountOfAwardReceived" xlink:label="snpx_AmountOfAwardReceived_637723469321649197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_AmountOfAwardReceived_637723469321649197" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementNoticeForCancellation" xlink:label="snpx_ConsultingAgreementNoticeForCancellation_637723469321649197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_ConsultingAgreementNoticeForCancellation_637723469321649197" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_637723469321649197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="us-gaap_CostOfGoodsAndServicesSold_637723469321649197" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ProceedsFromGrants" xlink:label="snpx_ProceedsFromGrants_637723469321649197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_ProceedsFromGrants_637723469321649197" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_637723469321649197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="us-gaap_GrantsReceivableCurrent_637723469321649197" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AmountFundedAgainstTotalTrialCost" xlink:label="snpx_AmountFundedAgainstTotalTrialCost_637723469321649197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_AmountFundedAgainstTotalTrialCost_637723469321649197" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637723469321659190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637723469321659190" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PrepaymentsForServiceAgreementCurrent" xlink:label="snpx_PrepaymentsForServiceAgreementCurrent_637723469321659190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_PrepaymentsForServiceAgreementCurrent_637723469321659190" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ConsultingAgreementMonthlyInstallmentFee" xlink:label="snpx_ConsultingAgreementMonthlyInstallmentFee_637723469321659190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_ConsultingAgreementMonthlyInstallmentFee_637723469321659190" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637723469321659190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637723469321659190" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637723469321659190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637723469321659190" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_InitialAnnualBaseSalaryPayable" xlink:label="snpx_InitialAnnualBaseSalaryPayable_637723469321659190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_InitialAnnualBaseSalaryPayable_637723469321659190" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AnnualDiscretionaryBonusPayableMaximumPercent" xlink:label="snpx_AnnualDiscretionaryBonusPayableMaximumPercent_637723469321669187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_AnnualDiscretionaryBonusPayableMaximumPercent_637723469321669187" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff" xlink:label="snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff_637723469321669187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff_637723469321669187" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637723469321669187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637723469321669187" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination" xlink:label="snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination_637723469321669187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination_637723469321669187" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfMonthsBaseSalaryPayableUponTermination" xlink:label="snpx_NumberOfMonthsBaseSalaryPayableUponTermination_637723469321669187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_NumberOfMonthsBaseSalaryPayableUponTermination_637723469321669187" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfMonthsBaseSalaryPayableUponSeparation" xlink:label="snpx_NumberOfMonthsBaseSalaryPayableUponSeparation_637723469321679187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_NumberOfMonthsBaseSalaryPayableUponSeparation_637723469321679187" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_TotalAmountOfBaseSalaryPayableUponSeparation" xlink:label="snpx_TotalAmountOfBaseSalaryPayableUponSeparation_637723469321679187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_TotalAmountOfBaseSalaryPayableUponSeparation_637723469321679187" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CashBonusPayableUponSeparation" xlink:label="snpx_CashBonusPayableUponSeparation_637723469321679187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_CashBonusPayableUponSeparation_637723469321679187" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PeriodFollowingSeparationDateToPayCobraPremiums" xlink:label="snpx_PeriodFollowingSeparationDateToPayCobraPremiums_637723469321679187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_PeriodFollowingSeparationDateToPayCobraPremiums_637723469321679187" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_TotalSeparationBenefitsPayable" xlink:label="snpx_TotalSeparationBenefitsPayable_637723469321679187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_TotalSeparationBenefitsPayable_637723469321679187" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeparationBenefitsReimbursed" xlink:label="snpx_SeparationBenefitsReimbursed_637723469321689186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_SeparationBenefitsReimbursed_637723469321689186" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AccountsPayableForServiceAgreementCurrent" xlink:label="snpx_AccountsPayableForServiceAgreementCurrent_637723469321689186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637723469321629196" xlink:to="snpx_AccountsPayableForServiceAgreementCurrent_637723469321689186" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Stockholders' Equity: (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723469321689186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StatementTable_637723469321689186" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_637723469321689186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321689186" xlink:to="us-gaap_RestructuringCostAndReserveAxis_637723469321689186" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_637723469321689186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis_637723469321689186" xlink:to="us-gaap_TypeOfRestructuringDomain_637723469321689186" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SpinoffMember" xlink:label="us-gaap_SpinoffMember_637723469321699187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain_637723469321689186" xlink:to="us-gaap_SpinoffMember_637723469321699187" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723469321699187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321689186" xlink:to="us-gaap_StatementLineItems_637723469321699187" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_IssueOfSharesOnSpinOff" xlink:label="snpx_IssueOfSharesOnSpinOff_637723469321699187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321699187" xlink:to="snpx_IssueOfSharesOnSpinOff_637723469321699187" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SpinOffRatio" xlink:label="snpx_SpinOffRatio_637723469321699187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321699187" xlink:to="snpx_SpinOffRatio_637723469321699187" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637723469321699187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321699187" xlink:to="us-gaap_CommonStockSharesAuthorized_637723469321699187" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637723469321699187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321699187" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637723469321699187" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637723469321699187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321699187" xlink:to="us-gaap_PreferredStockSharesAuthorized_637723469321699187" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637723469321699187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321699187" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637723469321699187" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfVotesPerShareOwned" xlink:label="snpx_NumberOfVotesPerShareOwned_637723469321699187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321699187" xlink:to="snpx_NumberOfVotesPerShareOwned_637723469321699187" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637723469321699187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321699187" xlink:to="us-gaap_CommonStockSharesIssued_637723469321699187" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637723469321699187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321699187" xlink:to="us-gaap_CommonStockSharesOutstanding_637723469321699187" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Stockholders' Equity: - January 2021 Private Placement (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637723469321709186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_637723469321709186" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637723469321709186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637723469321709186" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637723469321709186" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637723469321709186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637723469321709186" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637723469321709186" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PrefundedWarrantsMember" xlink:label="snpx_PrefundedWarrantsMember_637723469321709186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723469321709186" xlink:to="snpx_PrefundedWarrantsMember_637723469321709186" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesEWarrantsMember" xlink:label="snpx_SeriesEWarrantsMember_637723469321709186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723469321709186" xlink:to="snpx_SeriesEWarrantsMember_637723469321709186" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesGWarrantsMember" xlink:label="snpx_SeriesGWarrantsMember_637723469321709186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723469321709186" xlink:to="snpx_SeriesGWarrantsMember_637723469321709186" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesFWarrantsMember" xlink:label="snpx_SeriesFWarrantsMember_637723469321709186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723469321709186" xlink:to="snpx_SeriesFWarrantsMember_637723469321709186" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637723469321709186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637723469321709186" xlink:to="us-gaap_TypeOfArrangementAxis_637723469321709186" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321709186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637723469321709186" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321709186" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SecuritiesPurchaseAgreementsMember" xlink:label="snpx_SecuritiesPurchaseAgreementsMember_637723469321709186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321709186" xlink:to="snpx_SecuritiesPurchaseAgreementsMember_637723469321709186" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareholderRightsPlanMember" xlink:label="snpx_ShareholderRightsPlanMember_637723469321709186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321709186" xlink:to="snpx_ShareholderRightsPlanMember_637723469321709186" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_RightsAgreementMember" xlink:label="snpx_RightsAgreementMember_637723469321709186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321709186" xlink:to="snpx_RightsAgreementMember_637723469321709186" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637723469321709186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637723469321709186" xlink:to="us-gaap_SubsequentEventTypeAxis_637723469321709186" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637723469321719190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637723469321709186" xlink:to="us-gaap_SubsequentEventTypeDomain_637723469321719190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637723469321719190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637723469321719190" xlink:to="us-gaap_SubsequentEventMember_637723469321719190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637723469321719190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637723469321709186" xlink:to="srt_CounterpartyNameAxis_637723469321719190" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637723469321719190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637723469321719190" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637723469321719190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PlacementAgentsMember" xlink:label="snpx_PlacementAgentsMember_637723469321719190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637723469321719190" xlink:to="snpx_PlacementAgentsMember_637723469321719190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637723469321719190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637723469321709186" xlink:to="srt_RangeAxis_637723469321719190" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637723469321719190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637723469321719190" xlink:to="srt_RangeMember_637723469321719190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637723469321719190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723469321719190" xlink:to="srt_MinimumMember_637723469321719190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637723469321719190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723469321719190" xlink:to="srt_MaximumMember_637723469321719190" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637723469321719190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637723469321709186" xlink:to="us-gaap_ClassOfStockLineItems_637723469321719190" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement" xlink:label="snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement_637723469321719190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement_637723469321719190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637723469321729192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637723469321729192" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant" xlink:label="snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant_637723469321729192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant_637723469321729192" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ThresholdPeriodForArrangingFutureFinancing" xlink:label="snpx_ThresholdPeriodForArrangingFutureFinancing_637723469321729192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_ThresholdPeriodForArrangingFutureFinancing_637723469321729192" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_637723469321729192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="us-gaap_SaleOfStockPricePerShare_637723469321729192" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6377234693217291921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6377234693217291921" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637723469321729192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637723469321729192" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights" xlink:label="snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights_637723469321739206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights_637723469321739206" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637723469321739206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637723469321739206" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CombinedPurchasePriceOfCommonStockAndWarrants" xlink:label="snpx_CombinedPurchasePriceOfCommonStockAndWarrants_637723469321739206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_CombinedPurchasePriceOfCommonStockAndWarrants_637723469321739206" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock" xlink:label="snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock_637723469321739206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock_637723469321739206" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NetProceedsFromSaleOfWarrantsAndCommonStock" xlink:label="snpx_NetProceedsFromSaleOfWarrantsAndCommonStock_637723469321739206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_NetProceedsFromSaleOfWarrantsAndCommonStock_637723469321739206" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PercentageOfOfferingFeesInCash" xlink:label="snpx_PercentageOfOfferingFeesInCash_637723469321739206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_PercentageOfOfferingFeesInCash_637723469321739206" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PercentageOfOfferingFeesInWarrants" xlink:label="snpx_PercentageOfOfferingFeesInWarrants_637723469321739206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_PercentageOfOfferingFeesInWarrants_637723469321739206" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend" xlink:label="snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend_637723469321749199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend_637723469321749199" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights" xlink:label="snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights_637723469321749199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights_637723469321749199" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson" xlink:label="snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson_637723469321749199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson_637723469321749199" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfCommonSharesForEachRight" xlink:label="snpx_NumberOfCommonSharesForEachRight_637723469321749199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_NumberOfCommonSharesForEachRight_637723469321749199" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637723469321749199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637723469321749199" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight" xlink:label="snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight_637723469321749199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight_637723469321749199" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637723469321759193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637723469321759193" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PurchasePriceOfRight" xlink:label="snpx_PurchasePriceOfRight_637723469321759193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="snpx_PurchasePriceOfRight_637723469321759193" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637723469321759193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637723469321719190" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637723469321759193" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stock Based Compensation: (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637723469321769193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637723469321769193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637723469321769193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637723469321769193" xlink:to="us-gaap_VestingAxis_637723469321769193" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637723469321769193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637723469321769193" xlink:to="us-gaap_VestingDomain_637723469321769193" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637723469321769193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723469321769193" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637723469321769193" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637723469321769193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723469321769193" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637723469321769193" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_637723469321769193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723469321769193" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_637723469321769193" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="snpx_ShareBasedPaymentArrangementTrancheFourMember_637723469321769193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723469321769193" xlink:to="snpx_ShareBasedPaymentArrangementTrancheFourMember_637723469321769193" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_DateOfGrantMember" xlink:label="snpx_DateOfGrantMember_637723469321769193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723469321769193" xlink:to="snpx_DateOfGrantMember_637723469321769193" order="5" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_FirstAnniversaryOfGrantDateMember" xlink:label="snpx_FirstAnniversaryOfGrantDateMember_637723469321769193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723469321769193" xlink:to="snpx_FirstAnniversaryOfGrantDateMember_637723469321769193" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SixMonthAnniversaryOfGrantDateMember" xlink:label="snpx_SixMonthAnniversaryOfGrantDateMember_637723469321769193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723469321769193" xlink:to="snpx_SixMonthAnniversaryOfGrantDateMember_637723469321769193" order="7" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_637723469321769193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637723469321769193" xlink:to="us-gaap_GranteeStatusAxis_637723469321769193" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637723469321769193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_637723469321769193" xlink:to="us-gaap_GranteeStatusDomain_637723469321769193" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637723469321769193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637723469321769193" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637723469321769193" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember" xlink:label="snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember_637723469321769193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637723469321769193" xlink:to="snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember_637723469321769193" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember" xlink:label="snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_637723469321779190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637723469321769193" xlink:to="snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_637723469321779190" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637723469321779190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637723469321769193" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637723469321779190" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember_637723469321779190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637723469321769193" xlink:to="srt_ChiefFinancialOfficerMember_637723469321779190" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637723469321779190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637723469321769193" xlink:to="us-gaap_AwardTypeAxis_637723469321779190" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637723469321779190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637723469321779190" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637723469321779190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637723469321779190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637723469321779190" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637723469321779190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637723469321789186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637723469321769193" xlink:to="us-gaap_PlanNameAxis_637723469321789186" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637723469321789186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637723469321789186" xlink:to="us-gaap_PlanNameDomain_637723469321789186" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_EquityIncentivePlan2020Member" xlink:label="snpx_EquityIncentivePlan2020Member_637723469321789186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637723469321789186" xlink:to="snpx_EquityIncentivePlan2020Member_637723469321789186" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_DirectorCompensationPolicyMember" xlink:label="snpx_DirectorCompensationPolicyMember_637723469321789186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637723469321789186" xlink:to="snpx_DirectorCompensationPolicyMember_637723469321789186" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637723469321789186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637723469321769193" xlink:to="srt_TitleOfIndividualAxis_637723469321789186" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637723469321789186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637723469321789186" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637723469321789186" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_637723469321789186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637723469321789186" xlink:to="srt_ChiefExecutiveOfficerMember_637723469321789186" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637723469321789186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637723469321769193" xlink:to="us-gaap_IncomeStatementLocationAxis_637723469321789186" order="6" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637723469321799191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637723469321789186" xlink:to="us-gaap_IncomeStatementLocationDomain_637723469321799191" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637723469321799191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637723469321799191" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637723469321799191" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637723469321799191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637723469321799191" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637723469321799191" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637723469321769193" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637723469321799191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637723469321799191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637723469321799191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637723469321799191" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637723469321799191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637723469321799191" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637723469321799191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637723469321799191" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637723469321809188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637723469321809188" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637723469321809188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637723469321809188" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637723469321809188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637723469321809188" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors_637723469321809188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors_637723469321809188" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637723469321809188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637723469321809188" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue_637723469321809188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue_637723469321809188" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637723469321809188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637723469321809188" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637723469321819188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637723469321819188" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_637723469321819188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_637723469321819188" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637723469321819188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637723469321819188" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfDirectors" xlink:label="snpx_NumberOfDirectors_637723469321819188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="snpx_NumberOfDirectors_637723469321819188" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfExecutiveDirectors" xlink:label="snpx_NumberOfExecutiveDirectors_637723469321819188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="snpx_NumberOfExecutiveDirectors_637723469321819188" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfEmployee" xlink:label="snpx_NumberOfEmployee_637723469321819188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637723469321799191" xlink:to="snpx_NumberOfEmployee_637723469321819188" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stock Based Compensation: - Stock option activity under the stock option plans (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637723469321829189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637723469321829189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637723469321829189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637723469321829189" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637723469321829189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637723469321829189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637723469321829189" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637723469321829189" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6377234693218291891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637723469321829189" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6377234693218291891" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637723469321829189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637723469321829189" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637723469321829189" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637723469321869190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637723469321869190" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637723469321869190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637723469321869190" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637723469321869190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637723469321869190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637723469321869190" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637723469321869190" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637723469321869190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637723469321869190" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637723469321869190" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6377234693218691901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637723469321869190" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6377234693218691901" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637723469321869190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637723469321869190" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637723469321869190" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637723469321869190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637723469321869190" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_637723469321879188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637723469321869190" xlink:to="snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_637723469321879188" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637723469321879188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637723469321869190" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637723469321879188" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637723469321879188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637723469321869190" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637723469321879188" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AggregateIntrinsicValueAbstract" xlink:label="snpx_AggregateIntrinsicValueAbstract_637723469321879188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="snpx_AggregateIntrinsicValueAbstract_637723469321879188" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637723469321879188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_AggregateIntrinsicValueAbstract_637723469321879188" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637723469321879188" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637723469321879188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_AggregateIntrinsicValueAbstract_637723469321879188" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637723469321879188" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureCommonStockWarrantsCommonStockWarrantActivityDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Common Stock Warrants: - Common stock warrant activity (Details)">
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CommonStockWarrants" xlink:label="snpx_CommonStockWarrants" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_637723469321889191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_CommonStockWarrants" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_637723469321889191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_637723469321889191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_CommonStockWarrants" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_637723469321889191" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_637723469321889191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_CommonStockWarrants" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_637723469321889191" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_6377234693218891911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_CommonStockWarrants" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_6377234693218891911" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Common Stock Warrants: - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_CommonStockWarrants" xlink:label="snpx_CommonStockWarrants" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723469321889191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="snpx_CommonStockWarrants" xlink:to="us-gaap_StatementTable_637723469321889191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637723469321889191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321889191" xlink:to="us-gaap_TypeOfArrangementAxis_637723469321889191" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321889191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637723469321889191" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321889191" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_PlacementAgentAgreementMember" xlink:label="snpx_PlacementAgentAgreementMember_637723469321889191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321889191" xlink:to="snpx_PlacementAgentAgreementMember_637723469321889191" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_AdvisoryAgreementsMember" xlink:label="snpx_AdvisoryAgreementsMember_637723469321889191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723469321889191" xlink:to="snpx_AdvisoryAgreementsMember_637723469321889191" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637723469321889191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321889191" xlink:to="us-gaap_MeasurementInputTypeAxis_637723469321889191" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637723469321889191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637723469321889191" xlink:to="us-gaap_MeasurementInputTypeDomain_637723469321889191" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_637723469321889191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637723469321889191" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_637723469321889191" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637723469321899190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637723469321889191" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637723469321899190" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637723469321899190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637723469321889191" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637723469321899190" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637723469321899190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637723469321889191" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637723469321899190" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637723469321899190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321889191" xlink:to="srt_RangeAxis_637723469321899190" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637723469321899190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637723469321899190" xlink:to="srt_RangeMember_637723469321899190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637723469321899190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723469321899190" xlink:to="srt_MinimumMember_637723469321899190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637723469321899190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723469321899190" xlink:to="srt_MaximumMember_637723469321899190" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637723469321899190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321889191" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637723469321899190" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637723469321899190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637723469321899190" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637723469321899190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesWarrantsMember" xlink:label="snpx_SeriesWarrantsMember_637723469321899190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723469321899190" xlink:to="snpx_SeriesWarrantsMember_637723469321899190" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesBWarrantsMember" xlink:label="snpx_SeriesBWarrantsMember_637723469321899190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723469321899190" xlink:to="snpx_SeriesBWarrantsMember_637723469321899190" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesCWarrantsMember" xlink:label="snpx_SeriesCWarrantsMember_637723469321899190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723469321899190" xlink:to="snpx_SeriesCWarrantsMember_637723469321899190" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesDWarrantsMember" xlink:label="snpx_SeriesDWarrantsMember_637723469321909195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723469321899190" xlink:to="snpx_SeriesDWarrantsMember_637723469321909195" order="4" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesHWarrantsMember" xlink:label="snpx_SeriesHWarrantsMember_637723469321909195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723469321899190" xlink:to="snpx_SeriesHWarrantsMember_637723469321909195" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesGWarrantsMember" xlink:label="snpx_SeriesGWarrantsMember_637723469321909195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723469321899190" xlink:to="snpx_SeriesGWarrantsMember_637723469321909195" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesFWarrantsMember" xlink:label="snpx_SeriesFWarrantsMember_637723469321909195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723469321899190" xlink:to="snpx_SeriesFWarrantsMember_637723469321909195" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SeriesEWarrantsMember" xlink:label="snpx_SeriesEWarrantsMember_637723469321909195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723469321899190" xlink:to="snpx_SeriesEWarrantsMember_637723469321909195" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637723469321909195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321889191" xlink:to="us-gaap_SubsequentEventTypeAxis_637723469321909195" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637723469321909195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637723469321909195" xlink:to="us-gaap_SubsequentEventTypeDomain_637723469321909195" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637723469321909195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637723469321909195" xlink:to="us-gaap_SubsequentEventMember_637723469321909195" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723469321919190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723469321889191" xlink:to="us-gaap_StatementLineItems_637723469321919190" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637723469321919190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321919190" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637723469321919190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637723469321919190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321919190" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637723469321919190" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_637723469321919190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321919190" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_637723469321919190" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637723469321919190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321919190" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637723469321919190" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637723469321919190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321919190" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637723469321919190" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment" xlink:label="snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment_637723469321919190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321919190" xlink:to="snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment_637723469321919190" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants" xlink:label="snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants_637723469321919190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321919190" xlink:to="snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants_637723469321919190" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_SpinOffRatio" xlink:label="snpx_SpinOffRatio_637723469321929215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321919190" xlink:to="snpx_SpinOffRatio_637723469321929215" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_637723469321929215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321919190" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_637723469321929215" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637723469321929215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321919190" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637723469321929215" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637723469321929215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321919190" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637723469321929215" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights_637723469321929215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321919190" xlink:to="snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights_637723469321929215" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_NumberOfWarrantHoldersWhoExercisedWarrants" xlink:label="snpx_NumberOfWarrantHoldersWhoExercisedWarrants_637723469321929215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321919190" xlink:to="snpx_NumberOfWarrantHoldersWhoExercisedWarrants_637723469321929215" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637723469321939692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723469321919190" xlink:to="us-gaap_ProceedsFromWarrantExercises_637723469321939692" order="14" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Parent Company Investment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation" xlink:label="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation_637723469321939692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation_637723469321939692" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_637723469321939692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_637723469321939692" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="snpx-20210930.xsd#snpx_ContributionsFromParent" xlink:label="snpx_ContributionsFromParent_637723469321939692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="snpx_ContributionsFromParent_637723469321939692" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_637723469321939692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_LaborAndRelatedExpense_637723469321939692" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>snpx-20210930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:snpx="http://www.synaptogen.com/20210930"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="snpx-20210930.xsd" xlink:type="simple"/>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_B-Ol5sPKMEmSFSQmzxOz7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_C14DO597P0mvWWCy-BLV8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eLQU0iW2-kKPmLdZRgP3_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_cABB2dwDnkidrh1FDqutMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_2_16_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_wMyE8rhAOUa-rFk2SZC6uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="As_Of_2_16_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_SVTnUQyCqkSlwAQiGiSQ2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="As_Of_2_16_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_x7uB4f4XkkixVNeVpg4H_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesHWarrantsMember_6isVxzRL6UqO5BOyR_DEnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesHWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Bv7Emv5esUO_DuRCzz0CPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_19_2021_To_5_19_2021_EXMdTsz2BUaSS0bnxBggtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <startDate>2021-05-19</startDate>
            <endDate>2021-05-19</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jaPCkYCkeUON4gyi4G8yUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_5M6N4BgC0U-FB5io86IYSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__GkfWAubpE6DJAYWPvj1gA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5Je_ZI8c30mq5LUNLv-5Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_Ucphx9av20iHwREQym4HHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ypXLoCBb2ki0jyO4ErlUFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tJKcPCyeyUWqkuie4MqZSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_f4snRmZeDkO06xUTfzJ97w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mydigcM49UWnKRDBJI3xHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zZH3ckIIi0qEdvdPW_U0Uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iE0Gc6ADH0GlOfrRzcSuFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cPmmOsgAh0WB3a-cIX_Kmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_HthvWJobo0OzesTLSZPLwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YSISzRr0bky6jJiuWUvVbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_UQQvJk6FaUucAss2ojsT9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2LGNFezF1EW4idiVG3QiZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_FMu0KxA6Dk2LDplFkct4jA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_P7zGDC_-hEeO9i5oMGGuig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_7_2020_To_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_ARQKCYx9ckaXd0ahx6smkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpinoffMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ugoS2seriU2HHmwKq25Lyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w2D7T-YOaEup8wjSL_aSZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_EAh8LLeUbUiQqs-4hpkvgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WtmrZrtb2E-vIIoDu3xIMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Kh-IvwB8kUufVGx_81DRzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TQgurJPz3022iUU8jDNU7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_f4-Im_6b00Ktvk63-6KZww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0KTSxMliRU68--TLFjCX-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Z8OFwl7EbUOJULDl_93Hrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-8SoERMK70Sy1smuFNcHUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_firc-Dmg-0eR-8Hv8fLQyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JxAib4ryK0Og6uxEH2c6Qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_jsE_CQrzZ0az5CCzW8NilA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_TIqQYJV7CE6L3nRKPgyfzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-13</startDate>
            <endDate>2021-07-13</endDate>
        </period>
    </context>
    <context id="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_6QohAsIzTk-vhW1SAPewPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-13</startDate>
            <endDate>2021-07-13</endDate>
        </period>
    </context>
    <context id="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_srt_ChiefFinancialOfficerMember_8D5SdWMw5U6irlsB96168A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-13</startDate>
            <endDate>2021-07-13</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2021_To_1_13_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_9WmgNIy7zkuk1nx7ZlVGaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-13</startDate>
            <endDate>2021-01-13</endDate>
        </period>
    </context>
    <context id="Duration_12_7_2020_To_12_7_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_QAtyG63Ml0iGUPsG62eDkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="As_Of_4_7_2021_X8xLB1j8lkOI3Ju5ytfjTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <instant>2021-04-07</instant>
        </period>
    </context>
    <context id="As_Of_4_6_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_fx1ygIKoY02ITh98bpD4mQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-06</instant>
        </period>
    </context>
    <context id="As_Of_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_GxaNy02f7U-vVY71VeBA5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">snpx:ShareBasedPaymentArrangementNonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:DirectorCompensationPolicyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-12</instant>
        </period>
    </context>
    <context id="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_snpx_SixMonthAnniversaryOfGrantDateMember_-sX3SPAv7ECVADMCMnxDhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">snpx:SixMonthAnniversaryOfGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-13</startDate>
            <endDate>2021-07-13</endDate>
        </period>
    </context>
    <context id="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_snpx_FirstAnniversaryOfGrantDateMember_ATxH9vpPDUaonf7pLjCDXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">snpx:FirstAnniversaryOfGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-13</startDate>
            <endDate>2021-07-13</endDate>
        </period>
    </context>
    <context id="Duration_3_12_2021_To_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_MbYQXmYqxEe7PlJNeR4iPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">snpx:ShareBasedPaymentArrangementNewlyAppointedDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:DirectorCompensationPolicyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-12</startDate>
            <endDate>2021-03-12</endDate>
        </period>
    </context>
    <context id="Duration_3_12_2021_To_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_9fTB0b96S0mwgdrtIFJHkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">snpx:ShareBasedPaymentArrangementNewlyAppointedDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:DirectorCompensationPolicyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-12</startDate>
            <endDate>2021-03-12</endDate>
        </period>
    </context>
    <context id="Duration_3_12_2021_To_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember__FUNeXcc1U2KnJsXyWj-rQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">snpx:ShareBasedPaymentArrangementNewlyAppointedDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:DirectorCompensationPolicyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-12</startDate>
            <endDate>2021-03-12</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_brWXOs9rvk-CL2mnnpvfcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-13</startDate>
            <endDate>2021-01-13</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0nx63wQyWkygtYDUEq138Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-13</startDate>
            <endDate>2021-01-13</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_O8lsXfv060q08M33KwFJoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-13</startDate>
            <endDate>2021-01-13</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_snpx_DateOfGrantMember_CoXoxGX9_kGVwzm95w2HWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">snpx:DateOfGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-13</startDate>
            <endDate>2021-01-13</endDate>
        </period>
    </context>
    <context id="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_nGWTvPqSrUWNdtWgmidJhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:EmploymentAgreementWithAlanJ.TuchmanM.dMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1ZxjK4Ju5UaJMzlhxHko5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:EmploymentAgreementWithAlanJ.TuchmanM.dMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_q7uNiiIzykOY--M3GXitdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:EmploymentAgreementWithAlanJ.TuchmanM.dMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_snpx_ShareBasedPaymentArrangementTrancheFourMember_8TQ3g1npeESE9PjcWoOF6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:EmploymentAgreementWithAlanJ.TuchmanM.dMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">snpx:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="As_Of_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_GxGMgiomqkCkvB744Sb2wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-21</instant>
        </period>
    </context>
    <context id="As_Of_1_21_2021_DeloaH3epUmWvrrrKTfurQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <instant>2021-01-21</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_a4h_NxjSXky22JFgrPHDSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_5JNwmAqnxEi_l_f3YHC7-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_Qj_fG9oUqUuK8DNTHXfAoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_RightsAgreementMember_4x3-7JV2VESTTUvsqOn7Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:RightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-13</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_AgreementsWithBryologyxMember_avDjLw3FK0-K01yBV8psnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:AgreementsWithBryologyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_HYkNCxHRy02mLmJWCc8lbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_lvIlGvc4GUestVJZO6CW1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:AdvisoryAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_19_2017_To_1_19_2017_srt_ProductOrServiceAxis_us-gaap_LicenseMember_QAFY1ZmrLkORAEkzbODSjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-19</startDate>
            <endDate>2017-01-19</endDate>
        </period>
    </context>
    <context id="As_Of_11_30_2020_us-gaap_RelatedPartyTransactionAxis_snpx_CurrentShareholdersOfCompanyMember_XXkmy-IesU2Cqs0foH1_cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">snpx:CurrentShareholdersOfCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesHWarrantsMember_Po7eMRWnyk627VgjFVaEXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesHWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-26</instant>
        </period>
    </context>
    <context id="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_tkPkOaqtJUqYc0v8c4QvAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-26</instant>
        </period>
    </context>
    <context id="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_c7G1rxSzNE2F1m4rqz2OEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-26</instant>
        </period>
    </context>
    <context id="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hBfQpmlzBEiZWBUIw5oRgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-26</instant>
        </period>
    </context>
    <context id="As_Of_10_26_2020_Wvo7So2luU-dbvH6dz-R9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <instant>2020-10-26</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2020_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_NE8e4JpcsUy1zfWK6UBJew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="As_Of_6_5_2019_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_AWIKoH8MRU-5fF4wYndp6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-05</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EUnVc5n1yE-8V5lSC_clxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_DeGjeBcBwEGnc13gbozhlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Mqocl8Q9OUW-zNTHh7tZ4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="As_Of_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_cufB87OPd0uxPv8DnNgAwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="As_Of_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_PT7hcM8umEeDTrhm4UVpkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_OIdTKpqZekCiObLbbJPl8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_fU78qKLlQUeUn6turqsGfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_FH717EVLtkqn-fpPWhn4rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:AdvisoryAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Fr0ZwcPdYUak8BJTwsJziA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_snpx_PlacementAgentAgreementMember_iBkmenKfkESMsfPkSD7zrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:PlacementAgentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_Xii_2FmPcky3sXIraY0ypg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_qFNn0PiONUWj2D4Fv2tSVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-14</instant>
        </period>
    </context>
    <context id="As_Of_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_PrefundedWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_Y9y3VTtvt0-HBEjwyQXlZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-14</instant>
        </period>
    </context>
    <context id="As_Of_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_zUGNKTUDa0uRvG6Lbuctbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snpx:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-14</instant>
        </period>
    </context>
    <context id="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_W8rULN8LVU2iFXd7lTqq6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_GFeDDnIUDEeDxbNQIpRbmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember__pHwfWJFzkixGuEnVWDzJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:AdvisoryAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_4Hb6Y7xE0kyrvRnId9g4PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_5eSvOe54PkCVmjdVxgbZig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:AdvisoryAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_SDRsv452YEy1QbPpr3-H7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_CU6eHywSfU2jd_Ogr83-kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2021_e--_NbHbEE6MXeRdEtUWUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_GlLZteV0L0Sp_5QqZ3bkiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-21</instant>
        </period>
    </context>
    <context id="As_Of_1_21_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_njgrU71ChUuuukDv39OPww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snpx:PlacementAgentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-21</instant>
        </period>
    </context>
    <context id="As_Of_1_16_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_B7CPRdhRrUi03pd8HH2WHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-16</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_GzKIkZ8knECSIuc2D4qCoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_97X_EvVSLEObXZUCOmP-LA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_sQgKmUmCo0SOmBKWdTYsrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_FYkHNg0eDkqsEfsyfLe89Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_hF3BfbuxTkaBt64WDXedaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_l191m19UVk-g-tWdcIuAvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_ZcuRlFcZlk6RzU5e00C74w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_lqTTCdUJv0Gbk8pPOgt1Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_9otCxOcf30aqj9YleMKvAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_QhnfmLSW0k2hAwylpTMIlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_eXAu7kGsKUqqwxXMjOEi5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_5hwgduBRaEOxiMvk-glrAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_ghqdfvGBdUyTpIbQr-dO0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_0euqztFk-UWqNJ-EMYldhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_mKADfe9OGEuXe9ZYlIg4Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2020_To_2_1_2020_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_aEnOkbRtSEKBDafsd3izUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-01</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CF3yESI8t0-Cw7te7xhxbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_dPVmqepTmE6hEYumSC7-NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2GQFAY6UeEqXkOLT4ajRHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_aqSGqF3d9EOAW-vdRB2T0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_aqF2KklEf0u18kWTm7BHtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_7ynEJUOgpEaTJWjy14CbxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_IAPUN0sCQ0SOUwKfGoet8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_WrGK0uDCmUGfS8ag_ejX5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_s2nrkv1GlUOqLv_ow-biXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_NsMIo03fS0GvupLoZPxqNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_AlB4qWeQFkGYL40ag-oXkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="As_Of_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_sv5TfcxykECMI_R-TDkDOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">snpx:ShareBasedPaymentArrangementNewlyAppointedDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:DirectorCompensationPolicyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-12</instant>
        </period>
    </context>
    <context id="Duration_3_31_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_wwIsJnRvikGynuEld8gG7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:CharlesRyanSeparationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_12_31_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember__tepL3mKh0iXiuyC48F1pQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:CharlesRyanSeparationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_19_2017_To_1_19_2017_srt_RangeAxis_srt_MinimumMember_byQy3JDAGkCSL09nDP4uAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-19</startDate>
            <endDate>2017-01-19</endDate>
        </period>
    </context>
    <context id="Duration_1_19_2017_To_1_19_2017_srt_RangeAxis_srt_MaximumMember_9oZ5nMAmCE-LtGzgYi_y-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-19</startDate>
            <endDate>2017-01-19</endDate>
        </period>
    </context>
    <context id="Duration_7_14_2014_To_7_14_2014_srt_StatementScenarioAxis_snpx_NetSalesUpToDollars250MillionMember_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_ttgHcX6d-ESz6q6J8dXSbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">snpx:NetSalesUpToDollars250MillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:Mt.SinaiLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-14</startDate>
            <endDate>2014-07-14</endDate>
        </period>
    </context>
    <context id="Duration_7_14_2014_To_7_14_2014_srt_StatementScenarioAxis_snpx_NetSalesOverDollarsMillionMember_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_yH6gk0Ukj0ORfCWsxOM59A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">snpx:NetSalesOverDollarsMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:Mt.SinaiLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-14</startDate>
            <endDate>2014-07-14</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_11_30_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eDY3684nJE-p7S0A8UmC-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_v3U1szDl4k2j8DFDpZYu8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_YVddo9k3xUe1Mty-SsrZWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_AgreementsWithBryologyxMember_l1G14r9qTki6SweRFMEsIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:AgreementsWithBryologyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2021_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_TxVysG0320uYChAcxvCRyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:EmploymentAgreementWithAlanJ.TuchmanM.dMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kLgOmbRun06NqMMcX7EhDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Cr2IzRTXakm82Stu4mohyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_lR04OAC-tUOnEiZFv4wu8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember__q6Kouwx7ka5jQwWeyinOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_NgyqTk38w0WSX-vTVG_Qfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_gbBWD2FtDki4KkvEusVG5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_aMs2yxkpWEe7tYMJ_xTFLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_RightsAgreementMember_cbGd3CdlBUqQ_qyF1XZXPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:RightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-13</startDate>
            <endDate>2021-01-13</endDate>
        </period>
    </context>
    <context id="Duration_12_7_2020_To_12_7_2020_srt_StatementScenarioAxis_snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_yvpkUlirp0a1bWJ5z_hbhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">snpx:IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:EmploymentAgreementWithAlanJ.TuchmanM.dMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_7m4RE_sc4ku1rRSLUCwYWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:CharlesRyanSeparationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_XOhWuqO7-UmxW3rdr5h8WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-13</startDate>
            <endDate>2021-07-13</endDate>
        </period>
    </context>
    <context id="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_jhrqwDH5JUKGX1yjRe_zDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-13</startDate>
            <endDate>2021-07-13</endDate>
        </period>
    </context>
    <context id="Duration_4_6_2021_To_4_6_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_iOYMLdM_qUSnnsL4WR4G2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-06</startDate>
            <endDate>2021-04-06</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snpx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-13</startDate>
            <endDate>2021-01-13</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uOzUNq5PSE2XqZhY7SoRMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_qmdvRA7HJkGJm9mM-_iwZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QG8rYYtb-Uy4gyffTC5Lcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WekrDXrYzUSxTXRQk2RDxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_sBHxntfERUS1cbWvgfagyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ECz7Je18oEu9fwUB7c6eqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_StandFordLicenseAgreementMember_LrA02ttJr0Skelb_psotsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:StandFordLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_Jj8qpfoArUmBLAPesOXY6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:Mt.SinaiLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_14_2014_To_7_14_2014_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_grnTBMjygUGvo-rt4z7rsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:Mt.SinaiLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-14</startDate>
            <endDate>2014-07-14</endDate>
        </period>
    </context>
    <context id="Duration_12_7_2020_To_12_7_2020_sjyc_Q4Tz0y82heiYi_stA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="Duration_11_30_2020_To_11_30_2020_us-gaap_RelatedPartyTransactionAxis_snpx_CurrentShareholdersOfCompanyMember_M1g-SpCvMkOthGYObm_VUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">snpx:CurrentShareholdersOfCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpinoffMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_8kjX07DyaE-HzdlEbheL3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">snpx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-23</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_TIkglklIoUO2Ye16Man1yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-23</instant>
        </period>
    </context>
    <context id="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_ShareholderRightsPlanMember_BeWp9EwyLU-Pw2i4t19P6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ShareholderRightsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-13</startDate>
            <endDate>2021-01-13</endDate>
        </period>
    </context>
    <context id="Duration_8_5_2021_To_8_5_2021_us-gaap_TypeOfArrangementAxis_snpx_NemoursAgreementMember_duKRD6ZZp0unUKaBSODNWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:NemoursAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2020_To_7_23_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_CN7r02Xyn0ydRSaKF-TAyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-23</startDate>
            <endDate>2020-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_R-FJ60uA10ybeZXoxwgloA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_YeeVT1VLT0GCoyCiHtvk3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_6GCBoefDCEis5MNeRLe2Dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2020_To_2_1_2020_nGp21D17LkONtLS4Ybajpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-01</endDate>
        </period>
    </context>
    <context id="Duration_6_5_2019_To_6_5_2019_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_mhXWMvG4xk6I8_Dt9Z6IgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-05</startDate>
            <endDate>2019-06-05</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_Bfz_1syvz0adg3VenxJYAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithSmCapitalManagementLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_izoFKLvbS0qca5XE_8MiDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_rB9I5A7GXUOkubGYNYktVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_MqIvc6D6ak-bP_Ls5cIdEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithSmCapitalManagementLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_ZdwykQQjnki7EjxvNtEUvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_T6M0FiL3YEiY7TJp-0yjrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithGpNurmenkariIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_21_2021_To_1_21_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_fZfc3Q0FgUaqAHKikZxANA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-21</startDate>
            <endDate>2021-01-21</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesHWarrantsMember_t0GYiy1420idJAGM8em5Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesHWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_2k34O0Id4kWZX644U9EfIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_yUgO0gWhX0Kj3WzQ05UBjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesWarrantsMember_55AWN-0IQEiKtuL0SJcHtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesDWarrantsMember_TqviIe44M0KRUuCnfF8Jsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesCWarrantsMember_z_WS3P03W02KA988MbJQRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesBWarrantsMember_7SQ3AypUt0SSMTahwvnMAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_6_14_2021_To_6_14_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_Hw9nxWYRIEOMqSut960Tzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-14</startDate>
            <endDate>2021-06-14</endDate>
        </period>
    </context>
    <context id="Duration_6_14_2021_To_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_Q4EJ6pY3MEGvIljDamjqvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snpx:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-14</startDate>
            <endDate>2021-06-14</endDate>
        </period>
    </context>
    <context id="Duration_1_21_2021_To_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_L_BlpkHz3kyav_r8wtOz5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-21</startDate>
            <endDate>2021-01-21</endDate>
        </period>
    </context>
    <context id="Duration_1_21_2021_To_1_21_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_o7nYuxzxoUywgFr4YqnBRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snpx:PlacementAgentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-21</startDate>
            <endDate>2021-01-21</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_19_2017_To_1_19_2017_RyYqzdEgTkmLuudVtZapew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <startDate>2017-01-19</startDate>
            <endDate>2017-01-19</endDate>
        </period>
    </context>
    <context id="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_sdadKr2ZFUGPSuQk3FpIsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:EmploymentAgreementWithAlanJ.TuchmanM.dMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_AJnmojkQsECwB_nfR566Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:CharlesRyanSeparationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="Duration_8_4_2016_To_8_4_2016_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_ITeAjsMVWUKi59WUOf-Khg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ConsultingAgreementWithSmCapitalManagementLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-04</startDate>
            <endDate>2016-08-04</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_11_30_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_exdHd3zzYkWzxHQw70jWQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">snpx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_rlr4KPaCbkyP11bzHs4H5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">snpx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2022_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_OpMJCHhLC0ywEnxoJd5pzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">snpx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_fxANfnDJfkq-DjAu241ovA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">snpx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2020_To_7_23_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_s1iUX1xsBUGU6nFszabgYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">snpx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-23</startDate>
            <endDate>2020-07-23</endDate>
        </period>
    </context>
    <context id="Duration_6_14_2021_To_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_OrexfrNIiEKu4uzwmMWMwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesGWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-14</startDate>
            <endDate>2021-06-14</endDate>
        </period>
    </context>
    <context id="Duration_6_14_2021_To_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_PrefundedWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_UTFOvvwdkkKSLwa22CdtEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-14</startDate>
            <endDate>2021-06-14</endDate>
        </period>
    </context>
    <context id="Duration_1_21_2021_To_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_HmAmRGGq3UKNzSa-eZihpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">snpx:SeriesFWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-21</startDate>
            <endDate>2021-01-21</endDate>
        </period>
    </context>
    <context id="Duration_1_21_2021_To_1_21_2021_HYTbWiKKQEKRtx7xP4_xwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <startDate>2021-01-21</startDate>
            <endDate>2021-01-21</endDate>
        </period>
    </context>
    <context id="As_Of_7_14_2014_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_XWK_0a7heU6xMzkPuo_XLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:Mt.SinaiLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-07-14</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_fa_BU9Kh_0-JxvaVT_wQww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">snpx:ServicesAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_11_10_2021_cI8-59YAKkquXUEgzeXqKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <instant>2021-11-10</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001571934</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_director_RA5R3TwOe0i9LByRRHbWMw">
        <measure>snpx:director</measure>
    </unit>
    <unit id="Unit_Standard_employee_TK-gmXNo9Eqj4Kw_3BydmQ">
        <measure>snpx:employee</measure>
    </unit>
    <unit id="Unit_Standard_Vote_DzbStCv5TEKWycjen-OBEA">
        <measure>snpx:Vote</measure>
    </unit>
    <unit id="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g">
        <measure>snpx:item</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      id="Hidden_fDe3O408nEi2jvo1RD6swg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      id="Hidden_krI9so5-9UmPdmXWn2WopA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww"
      decimals="0"
      id="Hidden_RTBDhhCuuUSgoHhaqOJfsg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">6196600</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ"
      decimals="0"
      id="Hidden_LQNAkKpYxkq1OAhEu1AgZg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">4755100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Hidden_yRosEYzqSk2WjudLy-nn_Q"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">4420200</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Hidden_Afr5_7NwrEq-7_cOBF_X4Q"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">4274200</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_jeQBIGecd0eQP68qWnru4w_1_1">0001571934</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_rT0uwQRkpk2R8Qy4I6q7tA_2_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_8j3lqvyKkECtadz2ud_0cw_3_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_g5JPgH181k-Zgzew8nuDBQ_4_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_yRKWE0rs8Um5dO1O-lKGxA_5_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="INF"
      id="Hidden_sezuUeTn10uo_a0fcUf5bg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="INF"
      id="Hidden_NxZR55ns0U21CNNDyARbLw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:PreferredStockSharesOutstanding>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Hidden_bLlD-sqth0-4iiDJqsKpmA">Synaptogenix, Inc.</dei:EntityRegistrantName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Hidden_HNBE-7UQ-EqvhG0jvd0ytg">Non-accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="INF"
      id="Hidden_toyVA6bUkEiJ-JBvLSf_Pg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">6136967</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="INF"
      id="Hidden_GzA5X_D0D06IlZ-X3HzHwQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1257579</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww"
      decimals="2"
      id="Hidden_r9plw0qNOECAE0OiFEJRZQ"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ"
      decimals="2"
      id="Hidden_uJrZsluMHkihC8HIIwYSHg"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="2"
      id="Hidden_LQmeZvVOEka8eEiD5e9XgQ"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">1.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="2"
      id="Hidden_8WgOmX6PPUy5f6-S6IlyLw"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">2.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_5JNwmAqnxEi_l_f3YHC7-w"
      id="Hidden_lr9X8jg5jUiA4B9EE7n2ZA">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <snpx:TargetEnrollmentOfStudySubjects
      contextRef="Duration_7_23_2020_To_7_23_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_CN7r02Xyn0ydRSaKF-TAyQ"
      decimals="0"
      id="Hidden_zKPmU54jT0W3JjwS4wGcXw"
      unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g">100</snpx:TargetEnrollmentOfStudySubjects>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_nGWTvPqSrUWNdtWgmidJhQ"
      decimals="INF"
      id="Hidden_hGoeBKVmBU20RQRV2PAyfQ"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1ZxjK4Ju5UaJMzlhxHko5g"
      decimals="INF"
      id="Hidden_G8xXS6bLZUG7c6GZDPjMxQ"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_snpx_ShareBasedPaymentArrangementTrancheFourMember_8TQ3g1npeESE9PjcWoOF6g"
      decimals="INF"
      id="Hidden_YpLSh0QAWUSUkURr5jx6fw"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <snpx:NumberOfMonthsBaseSalaryPayableUponSeparation
      contextRef="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_7m4RE_sc4ku1rRSLUCwYWA"
      decimals="INF"
      id="Hidden_jgZLIHXGVkmWEP_qt_Shbw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">12</snpx:NumberOfMonthsBaseSalaryPayableUponSeparation>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow"
      decimals="0"
      id="Hidden_2WjS9OcCE0OUM5kOWGUAdg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1257579</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g"
      decimals="0"
      id="Hidden_dSJYuuGr1UaWnhcxWt0JcA"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1257579</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_5_19_2021_To_5_19_2021_EXMdTsz2BUaSS0bnxBggtw"
      decimals="2"
      id="Hidden_a2wS05qZI0qbkELASHqfgA"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.25</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_jsE_CQrzZ0az5CCzW8NilA"
      id="Hidden_Ran0Cu55WEO7SIeyEo9upQ">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Narr_MoBDnb7tDkyUciWeu7RNXQ">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_ELTE9LcNP0m_f2kae9T1eA_1_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Narr_qPasKir-AUqOG09LcfUrSg">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_GFx-ngOaV0G0quIZ5EgX6A_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Narr_dkr1iJDMMUmVlT8jfICb6w">001-40458</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_vHDXokeU3kSsLMbDJuManw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_OWff4myXBUm0jqqWNng63g_1_1">46-1585656</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Narr_OpuInyVXckmVj4bLEMoLUA">1185 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Narr_O9MKWHno6k23SPrAW5h5nA">3rd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Narr_FelFinBmk0mStHZaM0xVhg">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Narr_SAY-Ty6llUGNk56IHdSsqA">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_tDpSyBFR30yxCldy3DifnQ_6_1">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Narr_jfPIup3UQ0aKEKLRwmGZLw">973</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Narr_-JN6ZM6sBE2H3p6-VniLYg">242-0005</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_fYUFd3Do_EOIdOD-sFzTMw_1_0">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_GirBFDrL-kWNm4YwkqcGnA_1_2">SNPX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Narr_Q-qAoUFP1kSVCFqpaGxgug">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Narr_lTKD1h9GekOOUdHbrSTKLA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Narr_Xw2aOwpxgUC-DpdyGGrO9w">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_H8lNI4mtbE6Csj61-LSVrw_1_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_3fUK3L3jnUSfF6qA3svigA_2_3">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Narr_KoUic7r6sEiczIbbwPWzdw">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Narr_2dRUUydVn0iS4MXiS3CN-A">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_10_2021_cI8-59YAKkquXUEgzeXqKg"
      decimals="INF"
      id="Narr_TAOmAOEEqUOhzUD1S2k6JA"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">6674472</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_EBAoNvM73U23Nz9OZr_pRw_6_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">31294645</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_FOMN-HoYo0m4K8qrT-aKlA_6_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">5795055</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_LqizdvTeO0q3m0r8GdDcJg_7_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">127445</us-gaap:GrantsReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_9A609DxFnUyzBk46vV5WHw_8_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1045512</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_byxVyAtmXka7uS5TceoKZg_8_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">806289</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_BFaD2EOa70yXWGdAfIXoCQ_10_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">32340157</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_ZXy1HLq4PUmMy18QAyrPiA_10_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">6728789</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_OpA1xdjwkEyqksR9rXHjOA_12_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">18485</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_3smxkm4YE0CEdPidY3j3qA_12_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">22212</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_u1624y99jk-JOZnNfMyPuw_14_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">32358642</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_McpDmLtLVkGsuI47Ll3aig_14_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">6751001</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_sKZWcI28i0y4MjgaWFLUNQ_20_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">935376</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_3EKbmFHuwUyiXKxcEoKQVA_20_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1260335</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_BisW7JSiZUeRhIddQeQcXg_21_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">71953</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_JmGfPlcvAE2eF0Ok8Bd27w_21_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">352154</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_HUYld_oYHU-xYI0xu6dWYg_23_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1007329</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_n5vS9oZwPEiRXPh7dYDWAg_23_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1612489</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Narr_l6smMuIlVke0ejZ5Dgh4OQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Narr_Ncz9zoGPT0661Ca0rOzl_A"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="4"
      id="Narr_vRzASsWAFk6Wt8f_KH2afw"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="4"
      id="Narr_Zg-DZZfoY0uZ4N_YqyhJ2A"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="INF"
      id="Narr_nuwcUBGfQECyRvT4R1vfbg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="INF"
      id="Narr_1BKAj8-cmEW5mnq_Mcc5xQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Narr_bZ2webyeLEqjk-XIiC2QWA"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Narr_DAhN0BhtM024wRO_txC7Fg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="4"
      id="Narr_EIFh0o14X0q1EaoHDsoiww"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="4"
      id="Narr_R2FyUJ4dSUSEWooHKFYK-g"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="INF"
      id="Narr_IytvC-zf50OgOSrsUdjiCQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">6136967</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="INF"
      id="Narr_4PCZFjRCk0OOo945Og2fVg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1257579</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_1MnJB7bElkql3jU_NpaJuQ_29_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">615</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_RPZHVE-vUkmLKHiuaN2kig_29_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">126</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_1sOaWM7ynUGDr5XyK5UyCw_30_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">41256323</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_PCWG_JrKc0GHBI-ozSt_aA_30_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">6668859</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_ECq8QBD090Gykm6vaEWMIg_31_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-9905625</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_ej7S6pw6l0CeVg914qLHSw_31_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-1530473</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_bqTl-NyuhEauqIRKPMkX-w_33_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">31351313</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_ATYAlDmoP0a_HhOM2NIwpg_33_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">5138512</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_CXnycghzjUyKGWQAm0R19g_35_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">32358642</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_lRqiZar8AUmkllQk_74OWA_35_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">6751001</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww"
      decimals="0"
      id="Tc_ZLvcbNbzhkSyPK9wne4z2Q_5_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">836716</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ"
      decimals="0"
      id="Tc_u97BRnxmtU2kqQGa_cPbcQ_5_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">563317</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_bJLOTCHaVkeZLy3N1_jcmg_5_9"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">2974776</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_A132qjtMiEiPVxYc9LhCbQ_5_12"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1556627</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww"
      decimals="0"
      id="Tc_U3hc0D4Qc0-heJT5h_EEzQ_6_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">2092662</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ"
      decimals="0"
      id="Tc_C8b-IPr8O0qU0jHs9CkZUg_6_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">2013089</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_bFP1XnX4xkioC5cDAXfGNQ_6_9"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">5404968</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_uJRo1E9xHUSNgiPJBt-eHQ_6_12"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">6635757</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww"
      decimals="0"
      id="Tc_c1gqM1NYJ0ON5dqLWH0xyw_8_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">2929378</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ"
      decimals="0"
      id="Tc_M9JTZDHXukOJUt5nxJqmtw_8_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">2576406</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_U7chm0biPU20y4ozr_6yhw_8_9"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">8379744</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_bfGDWwOVbEGTokaL6C4HcQ_8_12"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">8192384</us-gaap:OperatingExpenses>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ"
      decimals="0"
      id="Tc_KgCfW7rxXEONhtVQFETQCw_11_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1700000</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_NH_ihVAErkSxBnyxuNFMqQ_11_12"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1700000</snpx:WarrantAmendmentExpense>
    <us-gaap:InterestIncomeOther
      contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww"
      decimals="0"
      id="Tc_DAnYw3xWk0W41kg2dPPSbQ_12_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">2445</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ"
      decimals="0"
      id="Tc_EHFSHfDoy0O7PnwWf4QL2g_12_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">6797</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_u5x8EBR5HkeGNAst6aYyRA_12_9"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">4592</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_D6s-oPVKgEiTsPurbHffUA_12_12"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">153305</us-gaap:InterestIncomeOther>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww"
      decimals="0"
      id="Tc_f7QBRs8K90SCocJo6rTjOg_14_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-2926933</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ"
      decimals="0"
      id="Tc_-KkTQ7x5GkKEemxJfaX-fg_14_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-4269609</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_ZKV2DniF80WbTJQBkFfZZQ_14_9"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-8375152</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_G7FDlOIsWkWLRZr2TMtQBA_14_12"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-9739079</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww"
      decimals="0"
      id="Tc_prEoVeN2Z0WB_izUridRTw_16_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ"
      decimals="0"
      id="Tc_CrLvzpueE0ibxwaDtBe55Q_16_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_sJvJXn0-6EGvJSEmqSbxtQ_16_9"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_840tP0Yij0yZzWSBUWULSQ_16_12"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww"
      decimals="0"
      id="Tc_8N9pHWPWkUCjsSMSNCF_lA_18_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-2926933</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ"
      decimals="0"
      id="Tc_2M-LDwwWwECb5VG6bxKhUw_18_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-4269609</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_MV5Fdgo6Qk2ONQkRam_68A_18_9"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-8375152</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_sf8PH1KA5kiwP31OWBx2-g_18_12"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-9739079</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww"
      decimals="2"
      id="Tc_KCag5r0BmkiTQIzfP5bzIw_22_3"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ"
      decimals="2"
      id="Tc_d83ypAzhV0-gWX13RnmgYQ_22_6"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="2"
      id="Tc_J6USy4GtskWS_IcbvxdiYA_22_9"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">1.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="2"
      id="Tc_j4fYnL9tWkeRoxGr3R4TiA_22_12"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">2.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww"
      decimals="0"
      id="Tc_gI9hbm1oeUepqUIYyp_c9w_24_3"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">6196600</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2020_To_6_30_2020_q49Mri-P70ylkVwSWZ_8JQ"
      decimals="0"
      id="Tc__gpi0mu_y0uiMLaduiMDpQ_24_6"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">4755100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_h-WLuam5H0uwIB0NE5gUZQ_24_9"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">4420200</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_JqpMx3ihZUeZFKWX6KHd5Q_24_12"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">4274200</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-8SoERMK70Sy1smuFNcHUw"
      decimals="INF"
      id="Tc_LyCQ8-PgSkqq-Bp0Upym4w_6_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-8SoERMK70Sy1smuFNcHUw"
      decimals="0"
      id="Tc_jIpTuFPxukunpZCwG8Mpmw_6_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Z8OFwl7EbUOJULDl_93Hrg"
      decimals="INF"
      id="Tc_pE1C_mXarUqqyxeYTh1t2A_6_8"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Z8OFwl7EbUOJULDl_93Hrg"
      decimals="0"
      id="Tc_ZEuR2wHnIUC7sU-BbY7yiw_6_11"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YSISzRr0bky6jJiuWUvVbQ"
      decimals="0"
      id="Tc_yC0uqa02Yk2PtQ0UhGM3zA_6_14"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_HthvWJobo0OzesTLSZPLwg"
      decimals="0"
      id="Tc_D-9N_D3oiUKDeGlz5bGw8Q_6_17"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">29797838</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cPmmOsgAh0WB3a-cIX_Kmw"
      decimals="0"
      id="Tc_VBrJkNBwUU2eCcCGRJOdcw_6_20"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_UQQvJk6FaUucAss2ojsT9g"
      decimals="0"
      id="Tc_sabgXWHRkEOP2cKnbnJ6-Q_6_23"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">29797838</us-gaap:StockholdersEquity>
    <snpx:NetChangeInInvestment
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg"
      decimals="INF"
      id="Tc_8NO-GLHAGUyqlRj2BkBdmQ_8_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NetChangeInInvestment>
    <snpx:NetChangeInInvestment
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg"
      decimals="0"
      id="Tc_ZzuUpOfMykehC5sna2A95w_8_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NetChangeInInvestment>
    <snpx:NetChangeInInvestment
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA"
      decimals="INF"
      id="Tc_VrqzLntr0k2YJALTvaCEuA_8_8"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NetChangeInInvestment>
    <snpx:NetChangeInInvestment
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA"
      decimals="0"
      id="Tc_PoXrvJWE_UerHFWCeV-trw_8_11"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NetChangeInInvestment>
    <snpx:NetChangeInInvestment
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QG8rYYtb-Uy4gyffTC5Lcw"
      decimals="0"
      id="Tc_zABFg_XeV0OBCW9uL2CeSw_8_14"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NetChangeInInvestment>
    <snpx:NetChangeInInvestment
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_qmdvRA7HJkGJm9mM-_iwZQ"
      decimals="0"
      id="Tc_fCIh3TX1Tk2g8YXVWvEC8w_8_17"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NetChangeInInvestment>
    <snpx:NetChangeInInvestment
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uOzUNq5PSE2XqZhY7SoRMQ"
      decimals="0"
      id="Tc_Dj4tKNhiYUONFlo1Gvf5Kg_8_20"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NetChangeInInvestment>
    <snpx:NetChangeInInvestment
      contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q"
      decimals="0"
      id="Tc_WhRvvPTnLUSWhaMl_AtBiQ_8_23"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NetChangeInInvestment>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg"
      decimals="INF"
      id="Tc_pxyf9L3lOUCXNiYBJWnzMw_10_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg"
      decimals="0"
      id="Tc_eBnJcupqnUWvGWd73k4_8Q_10_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA"
      decimals="INF"
      id="Tc_u4rUQOo9TkKVvsCLrxLDxQ_10_8"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA"
      decimals="0"
      id="Tc_l8k8YYHSA0OTKa-6FGcBWA_10_11"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QG8rYYtb-Uy4gyffTC5Lcw"
      decimals="0"
      id="Tc_nMpukiXKYk-HRck6QoPg_w_10_14"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_qmdvRA7HJkGJm9mM-_iwZQ"
      decimals="0"
      id="Tc_zzPYlBbugUe0stcehidodA_10_17"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">387927</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uOzUNq5PSE2XqZhY7SoRMQ"
      decimals="0"
      id="Tc_3d-c0yNKd0y0B_AJKt48zA_10_20"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q"
      decimals="0"
      id="Tc_JFGW0snsxUuOBGpBcelAlw_10_23"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">387927</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg"
      decimals="INF"
      id="Tc_jF_OoyBLhkOpnqsuFWO_Ew_12_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg"
      decimals="0"
      id="Tc_jQkIZYxmJU6QkCSBXpqrYg_12_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA"
      decimals="INF"
      id="Tc_uzZXK_Ebake_dm6XwW-w4Q_12_8"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA"
      decimals="0"
      id="Tc_qYFdwXXD_UyG2r4nHKbfFw_12_11"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QG8rYYtb-Uy4gyffTC5Lcw"
      decimals="0"
      id="Tc_pB-66gnCxku6L9G28Zmy9Q_12_14"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_qmdvRA7HJkGJm9mM-_iwZQ"
      decimals="0"
      id="Tc_27XV1cvU9UugdYuC7SHjBw_12_17"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">120000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uOzUNq5PSE2XqZhY7SoRMQ"
      decimals="0"
      id="Tc_BQ3dJIA7fUKCE6zbkgXIvw_12_20"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q"
      decimals="0"
      id="Tc_lEHAElXt9EquioaF1UJzhg_12_23"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">120000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg"
      decimals="INF"
      id="Tc_xIK20gcJvk2QWJJ43c_sIQ_14_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg"
      decimals="0"
      id="Tc_VOHgao3K80mITK4gJnvaaA_14_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA"
      decimals="INF"
      id="Tc_GI54_YnY8EKUtUdcrtUJsA_14_8"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA"
      decimals="0"
      id="Tc_ThB-QFzxJUODDF0yOEvDRw_14_11"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QG8rYYtb-Uy4gyffTC5Lcw"
      decimals="0"
      id="Tc_k5ofYsBBRUekmnk0Bgae8g_14_14"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_qmdvRA7HJkGJm9mM-_iwZQ"
      decimals="0"
      id="Tc_Wun0PjJgBkCW5e3fxV87jA_14_17"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">113281</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uOzUNq5PSE2XqZhY7SoRMQ"
      decimals="0"
      id="Tc_P5B9rHpa3UGFon8OAWP4Tg_14_20"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q"
      decimals="0"
      id="Tc_ZxtuNeQK-kutPQrHMrtglA_14_23"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">113281</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg"
      decimals="INF"
      id="Tc_vbW5iSm5ok-TXznBoQ9bPw_16_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg"
      decimals="0"
      id="Tc_XBqJsxa5U0yIVzPg2g6hbg_16_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA"
      decimals="INF"
      id="Tc_SbFBpy_hV0OpRI8dVDBT5Q_16_8"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA"
      decimals="0"
      id="Tc_PzlVDhTIdE6uihCsHMOqjw_16_11"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QG8rYYtb-Uy4gyffTC5Lcw"
      decimals="0"
      id="Tc_nZXNDfQ1KES2PpSVuuCOKg_16_14"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_qmdvRA7HJkGJm9mM-_iwZQ"
      decimals="0"
      id="Tc_2XfJVjgHoE6XqsspBsvWNQ_16_17"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1700000</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uOzUNq5PSE2XqZhY7SoRMQ"
      decimals="0"
      id="Tc_jZHTqToyjEqj-3AbDckRAQ_16_20"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q"
      decimals="0"
      id="Tc_umT_HGTRZkyGNssQ6NaXyw_16_23"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1700000</snpx:WarrantAmendmentExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg"
      decimals="INF"
      id="Tc_2BQo0DkucEKc-6uaxCW8Lw_18_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rzGnQopRHk63GwF_hWPQNg"
      decimals="0"
      id="Tc_WrwysUs-5UWYSKlRjbmduQ_18_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA"
      decimals="INF"
      id="Tc_Cz66UO7Y-kmzWk4QWP1g3Q_18_8"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fkV23d6K-UO5GdVnAqY4yA"
      decimals="0"
      id="Tc_plfdnbtoSkuHeStD5gNY0w_18_11"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QG8rYYtb-Uy4gyffTC5Lcw"
      decimals="0"
      id="Tc_1ih3v4blf02rXsqc30N-Kw_18_14"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_qmdvRA7HJkGJm9mM-_iwZQ"
      decimals="0"
      id="Tc_8I4d-EGggUuN0reY1ZXcfQ_18_17"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-4269609</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uOzUNq5PSE2XqZhY7SoRMQ"
      decimals="0"
      id="Tc_PvLhkvIMCkid6T-024FbMA_18_20"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q"
      decimals="0"
      id="Tc_72zeCgZIEUy5T-HF_FKRQA_18_23"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-4269609</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0KTSxMliRU68--TLFjCX-Q"
      decimals="INF"
      id="Tc_MS7apbAHrUmK5a2k5xSDww_20_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0KTSxMliRU68--TLFjCX-Q"
      decimals="0"
      id="Tc_cBqifXU5_Ua5uinhIk9wcA_20_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_f4-Im_6b00Ktvk63-6KZww"
      decimals="INF"
      id="Tc_mVi1dfUhz0iXSRc67FEgfA_20_8"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_f4-Im_6b00Ktvk63-6KZww"
      decimals="0"
      id="Tc_XCAV5_F8cECzidMYNKhDDg_20_11"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iE0Gc6ADH0GlOfrRzcSuFQ"
      decimals="0"
      id="Tc_0XAtFerqpkun5K6LmTJ3Ow_20_14"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zZH3ckIIi0qEdvdPW_U0Uw"
      decimals="0"
      id="Tc_NskbM4RgpEOgtqhz78_0oQ_20_20"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JxAib4ryK0Og6uxEH2c6Qw"
      decimals="INF"
      id="Tc__CYoN20Xt0a2SH-zm8Plkw_6_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JxAib4ryK0Og6uxEH2c6Qw"
      decimals="0"
      id="Tc_ZkTfhmN4L02dpjCKcz7lIQ_6_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_firc-Dmg-0eR-8Hv8fLQyw"
      decimals="INF"
      id="Tc_JdGkH7kAt0qv61JT94tSWA_6_7"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_firc-Dmg-0eR-8Hv8fLQyw"
      decimals="0"
      id="Tc_Wmf3F_zpfUGDBukyI6fgJg_6_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_P7zGDC_-hEeO9i5oMGGuig"
      decimals="0"
      id="Tc_EWo_avD0kU2WDxmg30_vHg_6_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_FMu0KxA6Dk2LDplFkct4jA"
      decimals="0"
      id="Tc_e_wYX3NXAk-DD6GnYmI9rA_6_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">17418765</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2LGNFezF1EW4idiVG3QiZA"
      decimals="0"
      id="Tc_EUhKQKsIL0Oqc1n664hMaA_6_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_97X_EvVSLEObXZUCOmP-LA"
      decimals="0"
      id="Tc_ehd2PDBfd0ClYf655gJRiA_6_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">17418765</us-gaap:StockholdersEquity>
    <snpx:NetChangeInInvestment
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw"
      decimals="INF"
      id="Tc_qpkmOUk6IUiL_RWFURsmxw_8_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NetChangeInInvestment>
    <snpx:NetChangeInInvestment
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw"
      decimals="0"
      id="Tc_AJDycpnNx0OnlUCaVr8wmg_8_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NetChangeInInvestment>
    <snpx:NetChangeInInvestment
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw"
      decimals="INF"
      id="Tc_RVgUh5knA0-INjtYMnxjJQ_8_7"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NetChangeInInvestment>
    <snpx:NetChangeInInvestment
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw"
      decimals="0"
      id="Tc_s2UlEfJItESlsyLyOxhVfw_8_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NetChangeInInvestment>
    <snpx:NetChangeInInvestment
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ECz7Je18oEu9fwUB7c6eqw"
      decimals="0"
      id="Tc_2q10OMjsRkOq4n6SMOjK8Q_8_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NetChangeInInvestment>
    <snpx:NetChangeInInvestment
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_sBHxntfERUS1cbWvgfagyw"
      decimals="0"
      id="Tc_q2pOgRmZK0Oew9A3IjTF9Q_8_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">16519988</snpx:NetChangeInInvestment>
    <snpx:NetChangeInInvestment
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WekrDXrYzUSxTXRQk2RDxA"
      decimals="0"
      id="Tc_eoDMUGLC40-C0k-1JAVOhQ_8_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NetChangeInInvestment>
    <snpx:NetChangeInInvestment
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_JmcVg8kvFUmz3d3dZ9Qv9Q_8_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">16519988</snpx:NetChangeInInvestment>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw"
      decimals="INF"
      id="Tc_X3N6gGoSGUOXyeOCqw-erQ_10_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw"
      decimals="0"
      id="Tc_78hG9Wxx_EWUUHPg-DY7wA_10_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw"
      decimals="INF"
      id="Tc_pK4Wv_sMV0O16iI3g-rcFQ_10_7"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw"
      decimals="0"
      id="Tc_S1JThOwB7UqHnVojTejodg_10_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ECz7Je18oEu9fwUB7c6eqw"
      decimals="0"
      id="Tc_dAm8HYv5g024l6z1tJllsw_10_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_sBHxntfERUS1cbWvgfagyw"
      decimals="0"
      id="Tc_GLB8QuH7jkODR7giCAiK-A_10_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1449023</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WekrDXrYzUSxTXRQk2RDxA"
      decimals="0"
      id="Tc_L3pffyA1ekyaKCI2eOCjww_10_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_zY_rpa7y402KObiNpoJZ8w_10_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1449023</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw"
      decimals="INF"
      id="Tc_YArJb2-Zg0Gw-Po2rBzV_w_12_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw"
      decimals="0"
      id="Tc_lkUfqI4aTUS3Ynt4_-_Qrw_12_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw"
      decimals="INF"
      id="Tc_L4Jok3WOzEy_z8AEkT9DQA_12_7"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw"
      decimals="0"
      id="Tc_-vk43zivGUKhCwT40K3QLA_12_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ECz7Je18oEu9fwUB7c6eqw"
      decimals="0"
      id="Tc_MVvi3Bs3nkWMltxQURNhcg_12_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_sBHxntfERUS1cbWvgfagyw"
      decimals="0"
      id="Tc_ldu7q5xRFkSwTh-fQ5m7gA_12_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">120000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WekrDXrYzUSxTXRQk2RDxA"
      decimals="0"
      id="Tc_4xL7X2VhVE-wKxySiBMhqQ_12_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_118-Kuj8nk6LSEzoCH71UA_12_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">120000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw"
      decimals="INF"
      id="Tc_vKidzLfEN0udCIYiS7NF-Q_14_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw"
      decimals="0"
      id="Tc_TKxjHZERgkG34X6VrytxGA_14_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw"
      decimals="INF"
      id="Tc_jz4TEX4JJkS11Ky-_IdzSw_14_7"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw"
      decimals="0"
      id="Tc_KnvFCz3Likq4LiWQjdkyZA_14_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ECz7Je18oEu9fwUB7c6eqw"
      decimals="0"
      id="Tc_BMrx4iCQ8UOLFU9Q1hStSg_14_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_sBHxntfERUS1cbWvgfagyw"
      decimals="0"
      id="Tc_RUW_BzE9gEu1lZSB6RQKsA_14_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">380740</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WekrDXrYzUSxTXRQk2RDxA"
      decimals="0"
      id="Tc_gLKjf0vGQEWxovhxfZPzzg_14_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_R5eU4VnDqkS5YVLSwjAHAQ_14_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">380740</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw"
      decimals="INF"
      id="Tc_TmvGVX9KNUayYirciUZI9w_16_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw"
      decimals="0"
      id="Tc_hyz4IxKkuEe8BQKL0SkxIg_16_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw"
      decimals="INF"
      id="Tc_H33aFv0__0mNmLAQBK9B1Q_16_7"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw"
      decimals="0"
      id="Tc_p1PWcKfnX0-olBXdISFCjw_16_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ECz7Je18oEu9fwUB7c6eqw"
      decimals="0"
      id="Tc_Bhb_mxH1QUaMIqfP5u5Y4w_16_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_sBHxntfERUS1cbWvgfagyw"
      decimals="0"
      id="Tc_CdfIcW0_OkmmE9_hc1zMew_16_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1700000</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WekrDXrYzUSxTXRQk2RDxA"
      decimals="0"
      id="Tc_z5AG_HYUMUaRfBlnv8Q5wA_16_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantAmendmentExpense>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_BsqN9eHgUk-XGPYVKCakUw_16_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1700000</snpx:WarrantAmendmentExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw"
      decimals="INF"
      id="Tc_4n3dBmkmUUybQGZV5GQD4Q_18_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TLJnMwF330OWhOsKDpqSLw"
      decimals="0"
      id="Tc_MbAYhYDQR0yYSanYL2HGvg_18_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw"
      decimals="INF"
      id="Tc_kzw1uNO6F0yyx9YxPm0tmA_18_7"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pVVApefzx0qBtZ0nbUjEfw"
      decimals="0"
      id="Tc_iPKNUJYiV0KmZdf-ZkBiQg_18_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ECz7Je18oEu9fwUB7c6eqw"
      decimals="0"
      id="Tc_pjxiPT2sqEOrXFVHbtCT8A_18_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_sBHxntfERUS1cbWvgfagyw"
      decimals="0"
      id="Tc_Gm4QdwwhrkC0B8IPPlh8Sg_18_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-9739079</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WekrDXrYzUSxTXRQk2RDxA"
      decimals="0"
      id="Tc_KYpQVQTWb0CfC3BN1NT4Uw_18_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_sZrNFprDR0CCKiNzipcoSA_18_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-9739079</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0KTSxMliRU68--TLFjCX-Q"
      decimals="INF"
      id="Tc_L5VthP6mbk6a8INP8-IiXQ_20_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0KTSxMliRU68--TLFjCX-Q"
      decimals="0"
      id="Tc_DvcyuWgbW0K_6fU_XhShqA_20_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_f4-Im_6b00Ktvk63-6KZww"
      decimals="INF"
      id="Tc_9m8M1HK-XEmRYvzwdQJX9Q_20_7"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_f4-Im_6b00Ktvk63-6KZww"
      decimals="0"
      id="Tc_IdxaILE2OECROwtmQTS6Kg_20_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iE0Gc6ADH0GlOfrRzcSuFQ"
      decimals="0"
      id="Tc_43Q4JgSahUmJmQSwvBzggg_20_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zZH3ckIIi0qEdvdPW_U0Uw"
      decimals="0"
      id="Tc_9LiJ6wc1YUmEM8iClw-1jA_20_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WtmrZrtb2E-vIIoDu3xIMQ"
      decimals="INF"
      id="Tc_41pDxNA3cUSQud2k1yjcqQ_6_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">6038798</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WtmrZrtb2E-vIIoDu3xIMQ"
      decimals="0"
      id="Tc_n34St8ECJkyZWRxqAizmRA_6_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">604</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_EAh8LLeUbUiQqs-4hpkvgQ"
      decimals="INF"
      id="Tc_Ieosu0duiEePoGhUb4mFzQ_6_7"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_EAh8LLeUbUiQqs-4hpkvgQ"
      decimals="0"
      id="Tc_L_AqIU3DAk6gFv4ussWYcg_6_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ypXLoCBb2ki0jyO4ErlUFA"
      decimals="0"
      id="Tc_K5to0qxuEUqMykB5f3nc3g_6_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">39168084</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_Ucphx9av20iHwREQym4HHQ"
      decimals="0"
      id="Tc_GED4r-frAkyp-R7vWQBxrA_6_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5Je_ZI8c30mq5LUNLv-5Aw"
      decimals="0"
      id="Tc_Uy_gEGR9kUKfxAfTxfkUAg_6_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-6978692</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_Xii_2FmPcky3sXIraY0ypg"
      decimals="0"
      id="Tc_f3nu-8ZbiUK84U40A7fjPg_6_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">32189996</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA"
      decimals="INF"
      id="Tc_ADu-hj03yUuyXuZnjesgww_8_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA"
      decimals="0"
      id="Tc_BWX2TRYthkytngURvcavfg_8_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ"
      decimals="INF"
      id="Tc_VmAU7ywZsEKyZEHnMBIXZw_8_7"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ"
      decimals="0"
      id="Tc_P0iBVTC100u4vIVGuO--2Q_8_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2GQFAY6UeEqXkOLT4ajRHw"
      decimals="0"
      id="Tc_o9JZoNI6tE-qyXM_8_OI2g_8_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1198860</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_dPVmqepTmE6hEYumSC7-NA"
      decimals="0"
      id="Tc_JGm0m0FmukiyOj6_kbkBMQ_8_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CF3yESI8t0-Cw7te7xhxbA"
      decimals="0"
      id="Tc_OsB01o_HFU-glGSAsJFecw_8_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw"
      decimals="0"
      id="Tc_UeFSHubWR0-gfstSw1eONw_8_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1198860</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA"
      decimals="INF"
      id="Tc_8o4Z2mM-B0Cv-ZtXEA1eMw_10_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA"
      decimals="0"
      id="Tc_IbCD42DC9UOZ74DAXLZn0A_10_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ"
      decimals="INF"
      id="Tc_rE8UNitYDkmoZKL3Zeu48A_10_7"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ"
      decimals="0"
      id="Tc_YNvnFHUhPkWHgfjRLL6CVQ_10_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2GQFAY6UeEqXkOLT4ajRHw"
      decimals="0"
      id="Tc_JoHv1RwI-kmZ5aoGRU_apg_10_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">84648</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_dPVmqepTmE6hEYumSC7-NA"
      decimals="0"
      id="Tc_RNdNO3PZmkK6xwmobIoGyQ_10_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CF3yESI8t0-Cw7te7xhxbA"
      decimals="0"
      id="Tc_M2XglFLA7EaXEjNOzi2u_g_10_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw"
      decimals="0"
      id="Tc_t58oYTT_PEuKQXJdia8Ymw_10_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">84648</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <snpx:WarrantsIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA"
      decimals="INF"
      id="Tc_YKfRk7WL3ECzRQltYL__7w_12_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">665</snpx:WarrantsIssuedDuringPeriodSharesIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA"
      decimals="0"
      id="Tc_LK_Yxzu-fkGbaD31B1GTig_12_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ"
      decimals="INF"
      id="Tc_H0S2efcaHUG4Yyxh6sVTAQ_12_7"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</snpx:WarrantsIssuedDuringPeriodSharesIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ"
      decimals="0"
      id="Tc_mbkZT23xAUCl-xKBrcagyg_12_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2GQFAY6UeEqXkOLT4ajRHw"
      decimals="0"
      id="Tc_vjjLOvT2O0i3p4g4jIwYOQ_12_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">4501</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_dPVmqepTmE6hEYumSC7-NA"
      decimals="0"
      id="Tc_fJvsY4BuFE2dJzUUursokQ_12_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CF3yESI8t0-Cw7te7xhxbA"
      decimals="0"
      id="Tc_09G5IAbo5EaeYxtERoVu1Q_12_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw"
      decimals="0"
      id="Tc_ciQWe7r0hEyIyZr3ir-5Ng_12_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">4502</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA"
      decimals="INF"
      id="Tc_N55KddoH00S0WvxRQc5P3g_14_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">97504</snpx:StockIssuedDuringPeriodSharesWarrantExercises>
    <snpx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA"
      decimals="0"
      id="Tc_Hqj7MO7eEkOM0o3qCELXjg_14_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">10</snpx:StockIssuedDuringPeriodValueWarrantsExercised>
    <snpx:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ"
      decimals="INF"
      id="Tc_z0NMhL4WokiofJuMXoAjCg_14_7"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</snpx:StockIssuedDuringPeriodSharesWarrantExercises>
    <snpx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ"
      decimals="0"
      id="Tc_kLbl23NxJUm25-Pbx3h-WA_14_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:StockIssuedDuringPeriodValueWarrantsExercised>
    <snpx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2GQFAY6UeEqXkOLT4ajRHw"
      decimals="0"
      id="Tc_OSRqc9tva0i0Gn5iaI7tzQ_14_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">800230</snpx:StockIssuedDuringPeriodValueWarrantsExercised>
    <snpx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_dPVmqepTmE6hEYumSC7-NA"
      decimals="0"
      id="Tc_S4kH-UToMkOnkU2Xkz_PRQ_14_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:StockIssuedDuringPeriodValueWarrantsExercised>
    <snpx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CF3yESI8t0-Cw7te7xhxbA"
      decimals="0"
      id="Tc_ak4hNrfP6USPcQrFRr41DQ_14_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:StockIssuedDuringPeriodValueWarrantsExercised>
    <snpx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw"
      decimals="0"
      id="Tc_igW7fVZbAUqsVS7u35_hTg_14_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">800240</snpx:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA"
      decimals="INF"
      id="Tc_We3AqDhEVU66-eFXiqblFA_16_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjucnGoBTkeBThcdXLFIJA"
      decimals="0"
      id="Tc_7j7yVFxFSUmhuCVEEG1KqQ_16_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ"
      decimals="INF"
      id="Tc_JZQwo85k6EaGeu3ahdT4kA_16_7"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YEArPhhMKkmwXmKRtIx1EQ"
      decimals="0"
      id="Tc_eo0tV2k2iEy0RKVsfVvs8Q_16_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2GQFAY6UeEqXkOLT4ajRHw"
      decimals="0"
      id="Tc_ghnckDRUbE2xB0N1OWrmoA_16_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_dPVmqepTmE6hEYumSC7-NA"
      decimals="0"
      id="Tc_9YewsN5c0UOrW-L5Vqn61g_16_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CF3yESI8t0-Cw7te7xhxbA"
      decimals="0"
      id="Tc_R5sDs0URXUGH8cB2STpJbA_16_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-2926933</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw"
      decimals="0"
      id="Tc_2dUktI9RPEiAi65MerGckg_16_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-2926933</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w2D7T-YOaEup8wjSL_aSZA"
      decimals="INF"
      id="Tc_WTnH_7ozTEuZuE7MC4uQPg_18_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">6136967</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w2D7T-YOaEup8wjSL_aSZA"
      decimals="0"
      id="Tc_lLClw4GgcUyV9TCaKRFeyQ_18_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">615</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ugoS2seriU2HHmwKq25Lyg"
      decimals="INF"
      id="Tc_aFF8c0DmI0C-SCuiXTG7Zg_18_7"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ugoS2seriU2HHmwKq25Lyg"
      decimals="0"
      id="Tc_sR3bBgMfTUe_SrW7ml17VQ_18_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__GkfWAubpE6DJAYWPvj1gA"
      decimals="0"
      id="Tc_w14mmTfJaEaG8knY3a3BTA_18_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">41256323</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_5M6N4BgC0U-FB5io86IYSA"
      decimals="0"
      id="Tc_D9D8jUriREue4p-EXoMLvg_18_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jaPCkYCkeUON4gyi4G8yUw"
      decimals="0"
      id="Tc_1b104nir0UO34e997wxwHA_18_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-9905625</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_-OaCv3neQ0uHU7QUIvQTDA_18_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">31351313</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TQgurJPz3022iUU8jDNU7Q"
      decimals="INF"
      id="Tc_4AalcYV8TESpdP92x2TFhw_6_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1257579</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TQgurJPz3022iUU8jDNU7Q"
      decimals="0"
      id="Tc_paWnzDAPQEua76GCfO9foA_6_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">126</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Kh-IvwB8kUufVGx_81DRzg"
      decimals="INF"
      id="Tc_y-uxyEaD3UmQrjXw9Uv8eA_6_7"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Kh-IvwB8kUufVGx_81DRzg"
      decimals="0"
      id="Tc_UPaex8gW9kqYCwAPx5F19w_6_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mydigcM49UWnKRDBJI3xHA"
      decimals="0"
      id="Tc_skck5aKq4kKHF9s3NVaLsw_6_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">6668859</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_f4snRmZeDkO06xUTfzJ97w"
      decimals="0"
      id="Tc_ktzZ3kCh30epRqCdW4g9cg_6_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tJKcPCyeyUWqkuie4MqZSA"
      decimals="0"
      id="Tc_DrPeYdKcz0iE2tvFTaA3-A_6_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-1530473</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_yDLFcRzII0mTbC7Qh7NGtA_6_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">5138512</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"
      decimals="INF"
      id="Tc_CbqqNPAYa0aeFhLHK7uYeQ_8_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">-345</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"
      decimals="0"
      id="Tc_HV_1ThpbPE-l5-54QkCs2A_8_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"
      decimals="INF"
      id="Tc_VZ2rp6PsME-Dz92WSeo0iQ_8_7"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"
      decimals="0"
      id="Tc_Y5c5ccPr6Eiu1fqd1hlN-g_8_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA"
      decimals="0"
      id="Tc_LkY80XEI406ftxFeWe3GOw_8_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1529</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ"
      decimals="0"
      id="Tc_ZWHCVbUdAEi3JCkYhtS0XQ_8_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q"
      decimals="0"
      id="Tc_6O51UHSnzEmzHdnynoAlQA_8_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_BFV4RRqD7kKLXh2M0hwy3g_8_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1529</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"
      decimals="INF"
      id="Tc__EDAMES0oUCX5pLtTCKJoQ_10_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"
      decimals="0"
      id="Tc_nGsTMIZkOkuxNcpF8G_WqQ_10_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"
      decimals="INF"
      id="Tc_w6s-ycPvu0yNm-yyUl9qcQ_10_7"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"
      decimals="0"
      id="Tc_DTtdkSdhrUWFVkTeKwQxuQ_10_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA"
      decimals="0"
      id="Tc_G62EIU4Eqkqh5F79vXg25w_10_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1918651</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ"
      decimals="0"
      id="Tc_WE2Tva0qKUuMScTUD9pHIw_10_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q"
      decimals="0"
      id="Tc_0TZ0MNS1tEK2jLQp_f65_A_10_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_b-5W1wO7tUq-Z5enJBQYbg_10_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1918651</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"
      decimals="INF"
      id="Tc_w4XaFGKEpEKWysz1anNWxA_12_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"
      decimals="0"
      id="Tc_GE6heNvTekSmN_x8Rclc5w_12_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"
      decimals="INF"
      id="Tc_YK42O5XUC0CrpoXWmdh6Cw_12_7"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"
      decimals="0"
      id="Tc_hyE-so0lbkWTq-UoB5tP-g_12_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA"
      decimals="0"
      id="Tc_ovZVVcRwVkCkSX33-2aNhg_12_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">481496</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ"
      decimals="0"
      id="Tc_qm_CeRwh4Em1wQ2cvJbmaA_12_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q"
      decimals="0"
      id="Tc_r216kGB2BUiKzaQNC6BNpg_12_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_xhtArfQf-0iroWSTYG_V3Q_12_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">481496</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <snpx:WarrantsIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"
      decimals="INF"
      id="Tc_K14Cog78xk6rVSZb8qbTGw_14_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">3255</snpx:WarrantsIssuedDuringPeriodSharesIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"
      decimals="0"
      id="Tc_RBBA_sqOik-lD9qn0Dx6mg_14_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"
      decimals="INF"
      id="Tc_2wJHCbL2bEukjB_fNuVeJw_14_7"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"
      decimals="0"
      id="Tc_gdX67HrnVUOMrbfK8E1Ywg_14_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA"
      decimals="0"
      id="Tc_vsiw8t5KtEaP8U7zfbto9w_14_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">22657</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ"
      decimals="0"
      id="Tc_CZ8FQ0MW9UWc6mNHW9YmTg_14_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q"
      decimals="0"
      id="Tc_jVn9fjj8r0CtnrWH7UEVFA_14_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <snpx:WarrantsIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_pHNwHQORGkKC4vOsdxQONw_14_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">22658</snpx:WarrantsIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"
      decimals="INF"
      id="Tc_ubcPDd3RUUminsfqVA-oCw_16_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">3837580</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"
      decimals="0"
      id="Tc_a_7sh4F98EyU6GEn0yj8VA_16_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">384</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"
      decimals="INF"
      id="Tc_EGTr2HUezEi1PJHhSlGNlQ_16_7"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"
      decimals="0"
      id="Tc_ig_1EAs_GE6faRagk32W5A_16_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA"
      decimals="0"
      id="Tc_-62bBfT5FEWUFROBlW4CDA_16_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">23783777</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ"
      decimals="0"
      id="Tc_fggQF4E8vUuiC7WoXinz_g_16_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q"
      decimals="0"
      id="Tc_EPykFfh5WE-JSyTNBaVVWQ_16_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_ssKHi25KNUemPbQ9L-tdKA_16_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">23784161</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <snpx:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"
      decimals="INF"
      id="Tc_22GLjS_qhE2iRtEhj8AF9g_18_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1038898</snpx:StockIssuedDuringPeriodSharesWarrantExercises>
    <snpx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"
      decimals="0"
      id="Tc_gov4I1t4DUitQpTi801c6A_18_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">104</snpx:StockIssuedDuringPeriodValueWarrantsExercised>
    <snpx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"
      decimals="INF"
      id="Tc_kIJziv4PeUO81VaBHShxew_18_7"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:StockIssuedDuringPeriodValueWarrantsExercised>
    <snpx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"
      decimals="0"
      id="Tc_9FvzNymqpkKGeKmgE0T03w_18_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:StockIssuedDuringPeriodValueWarrantsExercised>
    <snpx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA"
      decimals="0"
      id="Tc_yWcN8AkAYkqFkIPeDYM2wg_18_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">8382412</snpx:StockIssuedDuringPeriodValueWarrantsExercised>
    <snpx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ"
      decimals="0"
      id="Tc_fsorOJDlz0eni71eYq_d7g_18_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:StockIssuedDuringPeriodValueWarrantsExercised>
    <snpx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q"
      decimals="0"
      id="Tc_UuB5_DZ5v0SYZwvsF2qqZQ_18_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:StockIssuedDuringPeriodValueWarrantsExercised>
    <snpx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_0vWuB1AGo0y1LBnphjk3GA_18_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">8382516</snpx:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"
      decimals="INF"
      id="Tc_qxP3_DlGFEuvJtfGRy9DCg_20_2"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zT-HDGBV50SVj9rSJssA8w"
      decimals="0"
      id="Tc_-Ixmv0nMl0SXTvhJwKSPeg_20_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"
      decimals="INF"
      id="Tc_eFUHbtm1UECZHTJ6TuOeJA_20_7"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_yDJFUKjdLEqdQdpJfDOPMw"
      decimals="0"
      id="Tc_oIzHHnxD006h8_rB184l6A_20_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ma7LAiBQZkKO09J7KtdRwA"
      decimals="0"
      id="Tc_I7A_vt5OKUao_JfT1vOPOA_20_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_8A4s1EXWck6c73xy9ZDmrQ"
      decimals="0"
      id="Tc_ZLPAf1ZHfEaTKx_qG-dzHg_20_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__OoW6TGgCUilBszH2f993Q"
      decimals="0"
      id="Tc_e_n5iX-pEkmLMDe0CKNeew_20_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-8375152</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_RDXuZaQS7UaUr4X2R_EWOw_20_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-8375152</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w2D7T-YOaEup8wjSL_aSZA"
      decimals="INF"
      id="Tc_WC-VdeEQ80WmlvaVOrRlDw_22_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">6136967</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w2D7T-YOaEup8wjSL_aSZA"
      decimals="0"
      id="Tc_IAtIuYAbl0G7VXoxAqVtSw_22_5"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">615</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ugoS2seriU2HHmwKq25Lyg"
      decimals="INF"
      id="Tc_N4B4FR91CkCCMfU8e2H1gA_22_7"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ugoS2seriU2HHmwKq25Lyg"
      decimals="0"
      id="Tc_TFDH0L0dok2pu5FNdbb-yQ_22_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__GkfWAubpE6DJAYWPvj1gA"
      decimals="0"
      id="Tc_HnN7R-nsuE20q0FsE3FnLA_22_13"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">41256323</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_5M6N4BgC0U-FB5io86IYSA"
      decimals="0"
      id="Tc_DXWgwEpfu06GlmtTTPkC3Q_22_16"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jaPCkYCkeUON4gyi4G8yUw"
      decimals="0"
      id="Tc_Ci9Q_c6Tn0eT74nKJh6MyA_22_19"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-9905625</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_f5fQmhp3wkahTo1FLV0eEQ_22_22"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">31351313</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_a488sLG1GE-5Q62dI6jbbw_4_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-8375152</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_jF-rEqYWWECoMyZTlrAaxA_4_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-9739079</us-gaap:NetIncomeLoss>
    <snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_6aEZk6HO2UWi_U7UMXqPYg_7_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1449023</snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_4ZV3GOA48EmHmaq9h-wcIg_8_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1918651</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_Hn4s3Hlf70-Umd0pCPaIaQ_9_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">22657</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <snpx:IssuanceOfStockAndWarrantsForServices
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_-ECRtGF-9E2OMJp3ePSSGA_10_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">481496</snpx:IssuanceOfStockAndWarrantsForServices>
    <snpx:ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_Witpuycq8kGweCstjoX1eg_11_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">120000</snpx:ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock>
    <snpx:ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_pc5UzZ8hv0ieQpWANYWNUQ_12_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">380740</snpx:ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants>
    <snpx:WarrantAmendmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_KHTZUBV1GEmUSqSRPb7RIw_13_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1700000</snpx:WarrantAmendmentExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_U11TJLVmxUaU1R3sOeFs3w_14_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">3727</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_iCXeH3iMo02ypoN-b200yw_14_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">3638</us-gaap:DepreciationDepletionAndAmortization>
    <snpx:IncreaseDecreaseInGrantReceivableCurrent
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_3E9XxZb40UGjCCoWTD6sow_16_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-127445</snpx:IncreaseDecreaseInGrantReceivableCurrent>
    <snpx:IncreaseDecreaseInGrantReceivableCurrent
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_Ou2SXqn5x0SEuAmycjVn5A_16_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">861852</snpx:IncreaseDecreaseInGrantReceivableCurrent>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_GxlPsNYxuU-6xNJwKUW-7A_17_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">239223</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_nMbW8kyRvEOEaaLXSAcflA_17_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">770609</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_LipWqi2x60yUDo_qlhcQ_w_18_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-324959</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_5zeNRfOxn0O_U0uo9vWErA_18_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">777204</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_cBDPLhUIA0GnlcFSMahoiA_19_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-280200</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_dsLn9N7s8EWBesQRFQr1vg_19_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">44184</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_sfWFs2ASB0GUHbesOCPVng_20_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1709594</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_8ob6nYJP4E6Vh4wEdnDw0g_20_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">2842328</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_tD7lOHQxlkO3nmDFPoZibg_22_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-6665558</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_srAqDwFqhUaMjFzNQwd5zA_22_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-6896751</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_FpMmoP42VkOM7r9t5ZpKBw_25_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">5413</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_XFBcgPi91EmutLIwzPSBrg_27_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">-5413</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_jWjUPeLgJESgHohP2aepNg_30_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">23784161</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_H2aGDwePbkyzwqkTrQK6QQ_31_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">8382516</us-gaap:ProceedsFromWarrantExercises>
    <snpx:PaymentsInLieuSharesForReverseStockSplit
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_lGDkZpH5jUKucZpqd4qDLg_32_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1529</snpx:PaymentsInLieuSharesForReverseStockSplit>
    <snpx:NetTransferFromToParent
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_Qo0fzLYEY0iWGA-T4jk8iw_33_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">16519988</snpx:NetTransferFromToParent>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_tZy9rLtmCECMBxYdhYY76A_35_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">32165148</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_l56QaQEIpECeFWjC2wHaUA_35_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">16519988</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_Y9CaAimmXUG48BeobS-x_g_37_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">25499590</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_vxJPIkDzsEGq0AvwzkZq0g_37_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">9617824</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_fZ3Gzecq5kSOrSpmkJr46g_39_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">5795055</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_97X_EvVSLEObXZUCOmP-LA"
      decimals="0"
      id="Tc_vb0MPnp_tEuQmFzthawJAA_39_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">17382038</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_w9GaA3DcUU2GZ_dpW4kCLA_41_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">31294645</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2020_GzKIkZ8knECSIuc2D4qCoQ"
      decimals="0"
      id="Tc_M_16orkZd0C3WLZ7wWCudA_41_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">26999862</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_DiYzJCYk5USqadnHK4n1jA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;1&#160;&#x2013; Organization, Business, Risks and Uncertainties:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Organization and Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On May 17, 2020, Neurotrope, Inc. (&#x201c;Neurotrope&#x201d; or &#x201c;the Parent&#x201d;) announced plans for the complete legal and structural separation of its wholly owned subsidiary, Neurotrope Bioscience, Inc., from Neurotrope (the &#x201c;Spin-Off&#x201d;). Under the Separation and Distribution Agreement, Neurotrope planned to distribute all of its equity interest in this wholly owned subsidiary to Neurotrope&#x2019;s stockholders. Following the Spin-Off, Neurotrope does not own any equity interest in the Company, and we operate independently from Neurotrope. On December 7, 2020 we became an independent company, Synaptogenix, Inc., a Delaware corporation (formerly known as Neurotrope Bioscience, Inc.) (the &#x201c;Company&#x201d; or &#x201c;Synaptogenix&#x201d;) as the Company amended and restated their certificate of incorporation which, among other things, changed its name to Synaptogenix, Inc. Our shares of common stock are listed on The Nasdaq Capital Market under the symbol &#x201c;SNPX.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Neurotrope Bioscience,&#160;Inc. was incorporated in Delaware on October&#160;31, 2012 to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer&#x2019;s disease (&#x201c;AD&#x201d;).&#160;The Company&#160;is collaborating with Cognitive Research Enterprises,&#160;Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (&#x201c;CRE&#x201d;), a related party, in this process. The exclusive rights to certain technology were licensed by CRE to the Company on February&#160;28, 2013 (see Note&#160;4 - Related Party Transactions and Licensing / Research Agreements).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In connection with the separation from Neurotrope, we entered into a Separation and Distribution Agreement and several other ancillary agreements. These agreements govern the relationship between the parties after the separation and allocate between the parties various assets, liabilities, rights and obligations following the separation, including employee benefits, intellectual property, information technology, insurance and tax-related liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Spin-Off &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On December&#160;1, 2020, Neurotrope, and Petros Pharmaceuticals,&#160;Inc., a Delaware corporation (&#x201c;Petros&#x201d;) and formerly Metuchen Pharmaceuticals LLC, consummated their reverse merger transactions (the &#x201c;Mergers&#x201d;) contemplated by a certain Agreement and Plan of Merger dated as of May&#160;17, 2020 (the &#x201c; Merger Agreement&#x201d;), as amended.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As a condition to the Mergers, Neurotrope approved a transaction (the &#x201c;Spin-Off&#x201d;), which became effective on December&#160;7, 2020, whereby (i)&#160;any cash in excess of $20,000,000, subject to adjustment as provided in the Merger Agreement, and all of the operating assets and liabilities of Neurotrope not retained by Neurotrope in connection with the Mergers were contributed to Neurotrope Bioscience,&#160;Inc., and (ii)&#160;holders of record of Neurotrope common stock, Neurotrope preferred stock and certain warrants that were not amended and restated as of the Spin-Off Record Date received a pro rata distribution at the rate of (i)&#160;one share of Synaptogenix,&#160;Inc. common stock for every five shares of Neurotrope common stock held, (ii)&#160;one share of Synaptogenix common stock for every five shares of Neurotrope common stock issuable upon conversion of Neurotrope preferred stock held and (iii)&#160;one share of Synaptogenix,&#160;Inc. common stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held that were entitled to participate in the Spin-Off pursuant to the terms thereof (collectively, the &#x201c;Distribution&#x201d;). Any fractional shares were paid in cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The holders of Neurotrope&#x2019;s amended and restated warrants to purchase 4,889,158 shares of Neurotrope common stock (the &#x201c;A&amp;amp;R Warrants&#x201d;) received 977,831 warrants to purchase shares of Synaptogenix common stock upon the exercise of such A&amp;amp;R Warrants held as of the Spin-Off Record Date (collectively, the &#x201c;Spin-Off Warrants&#x201d;). All the warrants have five year terms from December&#160;2, 2020. See Note 8 &#x2013; Common Stock Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As of September&#160;30, 2021, the Company had approximately $31.3 million in cash and cash equivalents as compared to $5.8 million at December&#160;31, 2020. The Company expects that its current cash and cash equivalents, approximately $35 million as of the date of this quarterly report, which includes cash received during October and November, 2021 of approximately $5 million from the exercise of investor warrants of approximately $4.5 million plus reimbursement of trial expenses of approximately $530,000 from the NIH, will be sufficient to support its projected operating requirements for at least the next 12 months from this date. The operating requirements include the current development plan for Bryostatin-1, our novel drug targeting the activation of PKC epsilon.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company expects to need additional capital in order to initiate and pursue potential additional development projects, including the continuing development beyond the current Phase 2 trial.&#160;Any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company&#x2019;s current stockholders and debt financing, if available, may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its technologies or product candidates that the Company would otherwise seek to develop or commercialize on its own, on terms that are not favorable to the Company. The Company&#x2019;s ability to access capital when needed is not assured and, if not achieved on a timely basis, will likely have a materially adverse effect on our business, financial condition and results of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company operates in an industry that is subject to rapid technological change, intense competition, and significant government regulation. The Company&#x2019;s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the limited supply of raw materials, the ability to obtain favorable licensing, manufacturing or other agreements, including risk associated with our CRE licensing agreement, and the ability to raise capital to achieve strategic objectives.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;CRE has entered into a material transfer agreement with the National Cancer Institute of the National Institutes of Health (&#x201c;NCI&#x201d;), pursuant to which the NCI has agreed to supply bryostatin required for the Company&#x2019;s pre-clinical research and clinical trials. This agreement does not provide for a sufficient amount of bryostatin to support the completion of all of the clinical trials that the Company is required to conduct in order to seek U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval. Therefore, CRE or the Company would have to enter into one or more subsequent agreements with the NCI for the supply of additional amounts of bryostatin. If CRE or the Company were unable to secure such additional agreements, or if the NCI otherwise discontinues the supply, the Company would have to either secure another source of bryostatin or discontinue its efforts to develop and commercialize bryostatin for the treatment of AD. In June&#160;2020, the Company entered into a supply agreement (the &#x201c;Supply Agreement&#x201d;) with BryoLogyx Inc. (&#x201c;BryoLogyx&#x201d;), pursuant to which BryoLogyx agreed to be the Company&#x2019;s exclusive supplier of synthetic Bryostatin-1. Pursuant to the terms of the Supply Agreement, the Company received its initial order of one gram synthetic Bryostatin-1. See Note 3.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company also faces the ongoing risk that the coronavirus pandemic may slow, for an unforeseeable period, the conduct of the Company&#x2019;s trial. In order to prioritize patient health and that of the investigators at clinical trial sites, we will monitor enrollment of new patients in our current Phase 2 clinical trial. In addition, some patients may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services. These and other factors outside of our control could delay our ability to conduct clinical trials or release clinical trial results. In addition, the effects of a pandemic resurgence may also increase non-trial costs such as insurance premiums, increase the demand for and cost of capital, increase loss of work time from key personnel, and negatively impact our key clinical trial vendors and suppliers.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <snpx:ExcessOfCashInOperatingAssetsAndLiabilities
      contextRef="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow"
      decimals="0"
      id="Narr_fGMw1Z8ETkCZ12cHQH13sw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">20000000</snpx:ExcessOfCashInOperatingAssetsAndLiabilities>
    <snpx:NumberOfSharesForEveryFiveCommonSharesHeld
      contextRef="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow"
      decimals="INF"
      id="Narr_PdQ6cR6PhkuoKxvhrwHxhA"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1</snpx:NumberOfSharesForEveryFiveCommonSharesHeld>
    <snpx:NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld
      contextRef="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow"
      decimals="INF"
      id="Narr_1b1n67WMS0ixILfEiKQp1Q"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1</snpx:NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld>
    <snpx:NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld
      contextRef="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow"
      decimals="INF"
      id="Narr_76nNby_W8UW7T-NJNkt1TQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1</snpx:NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow"
      decimals="INF"
      id="Narr_TbAPyGkGaEeK9Oja__ggTA"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">4889158</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="Duration_12_7_2020_To_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_ARQKCYx9ckaXd0ahx6smkQ"
      decimals="0"
      id="Narr_iqQXvOeMIUaRYhF4ofz9yQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">977831</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow"
      id="Narr_jd54OHmR_E6NThQk2tHrUQ">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="-5"
      id="Narr_1945ShTbYkudinhLhhk3FA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">31300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="-5"
      id="Narr_lMOyledOJkSikrG53YidfA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">5800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <snpx:CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="-6"
      id="Narr_YtB_y7KrFE29yr-TO8H_7A"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">35000000</snpx:CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate>
    <snpx:ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses
      contextRef="Duration_10_1_2021_To_11_30_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eDY3684nJE-p7S0A8UmC-g"
      decimals="-6"
      id="Narr_dbLoyapv5kSoXysU4JsblA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">5000000</snpx:ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_10_1_2021_To_11_30_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eDY3684nJE-p7S0A8UmC-g"
      decimals="-5"
      id="Narr_JNPqQ9s_l0KJcJzApNJo4Q"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">4500000</us-gaap:ProceedsFromWarrantExercises>
    <snpx:AmountOfFundingReceived
      contextRef="Duration_10_1_2021_To_11_30_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_exdHd3zzYkWzxHQw70jWQw"
      decimals="0"
      id="Narr_BJr5kLtwZUKjRSS_PyaGKw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">530000</snpx:AmountOfFundingReceived>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb__awmc5riPkKxAxbzHT-xDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;2&#160;&#x2013; Summary of Significant Accounting Policies:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Basis of Presentation:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Subsequent to the Spin-Off, the Company&#x2019;s financial statements as of December 31, 2020 and for the period December 7, 2020 to December 31, 2020 are presented on a consolidated basis as the Company became a standalone public company on December 7, 2020. The Company&#x2019;s combined financial statements for the period from January 1, 2020 through December 6, 2020 that is included in the results of operations for the three and nine months ending September 30, 2020 and the year ended December 31, 2020 were derived from the consolidated financial statements and accounting records of Neurotrope, the former Parent. These combined financial statements reflect the historical results of operations, financial position and cash flows of the former Parent&#x2019;s Spin-Off business which was a wholly owned subsidiary of Neurotrope, Neurotrope Bioscience, Inc., and represented substantially all the business of Neurotrope. These financial statements reflect our financial position, results of operations and cash flows as we were historically managed, in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;All intercompany transactions between the Company and Neurotrope have been included in our financial statements and are considered to be effectively settled for cash at the time the Spin-Off was recorded. The total net effect of the settlement of these intercompany transactions is reflected in our statements of cash flow as a financing activity and in the balance sheets as &#x201c;Parent company investment&#x201d;. See Note 9.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the unaudited condensed financial statements included herein contain all adjustments necessary to present fairly the Company&#x2019;s financial position and the results of its operations and cash flows for the interim periods presented. Such adjustments are of a normal recurring nature. The results of operations for the three and nine months ended September 30, 2021 may not be indicative of results for the full year. These unaudited condensed financial statements should be read in conjunction with the audited condensed financial statements and the notes to those statements for the year ended December 31, 2020 included in our Annual Report on Form 10-K.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make significant estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the general economic environment and actions it may take in the future. The Company adjusts such estimates when facts and circumstances dictate. However, these estimates may involve significant uncertainties and judgments and cannot be determined with precision. In addition, these estimates are based on management&#x2019;s best judgment at a point in time and as such these estimates may ultimately differ from actual results.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Cash and Cash Equivalents and Concentration of Credit Risk:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company considers all highly liquid cash investments with an original maturity of three months or less when purchased to be cash equivalents. At September 30, 2021, the Company&#x2019;s cash balances that exceed the current insured amounts under the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) were approximately $3.6 million. In addition, approximately $27.7 million included in cash and cash equivalents were invested in a money market fund, which is not insured under the FDIC. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fixed Assets and Leases:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;All leases with a lease term greater than 12 months, regardless of lease type classification, are recorded as an obligation on the balance sheet with a corresponding right-of-use asset. The Company does not have any leases greater than 12 months in duration during the respective reporting periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Fixed assets are stated at cost less accumulated depreciation. Depreciation is computed on a straight line basis over the estimated useful life of the asset, which is deemed to be between &lt;span style="-sec-ix-hidden:Hidden_lr9X8jg5jUiA4B9EE7n2ZA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;three&lt;/span&gt;&lt;/span&gt; and ten years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development Costs:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;All research and development costs, including costs to maintain or expand the Company&#x2019;s patent portfolio licensed from CRE are expensed when incurred. Non-refundable advance payments for research and development are capitalized because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at September&#160;30, 2021 and December&#160;31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loss Per Share of Common Stock:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On the Spin Off date, 1,257,579 shares of the Company&#x2019;s common stock, par value $0.0001 per share (the Common Stock&#x201d;) were distributed to Neurotrope stockholders as of November 30, 2020 (the &#x201c;Record Date&#x201d;). This share amount was being utilized for the calculation of basic earnings (loss) per share (&#x201c;EPS&#x201d;) for the periods prior to the Spin-Off because the Company was a wholly-owned subsidiary of Neurotrope prior to the Spin Off date. For the periods after the Spin-Off Date, EPS attributable to the Company&#x2019;s common stockholders is based upon net income (loss) attributable to the Company&#x2019;s common stockholders divided by the weighted-average number of Common Stock outstanding during the period. Penny warrants were included in the calculation of outstanding shares for purposes of basic loss per share. For the periods when a net loss is reported, the computation of diluted EPS equals the basic EPS calculation since common stock equivalents were antidilutive due to losses from continuing operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Income Taxes:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes under the &#x201c;Separate return method.&#x201d; Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company applies the provisions of FASB ASC 740-10, &lt;i style="font-style:italic;"&gt;Accounting for Uncertain Tax Positions&lt;/i&gt;, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also provides guidance on de-recognition, classification, interest and penalties, and accounting in interim periods, disclosure and transitions. The Company has determined that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is generally three&#160;years from the date of filing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company (collectively with Neurotrope, Inc. / Petros Pharmaceuticals, Inc.) may be subject to significant U.S. federal income tax-related liabilities with respect to our prior distribution of all of the issued and outstanding shares of the common stock of Neurotrope Bioscience, Inc., the former subsidiary of Neurotrope, to our stockholders as of and on November 30, 2020 (the &#x201c;Spin-Off&#x201d;), if there is a determination that the Spin-Off is taxable for U.S. federal income tax purposes. In connection with the Spin-Off, the Company believes substantially to the effect that, among other things, the Spin-Off should qualify as a tax-free transaction for U.S. federal income tax purposes under Section 355 and Section 368(a)(1)(D) of the Code. If the conclusions of the tax opinions are not correct, or if the Spin-Off is otherwise ultimately determined to be a taxable transaction, the Company would be liable for U.S. federal income tax related liabilities. Pursuant to the Separation and Distribution Agreement and the Tax Matters Agreement, Neurotrope agreed to indemnify Synaptogenix for certain liabilities, and Synaptogenix agreed to indemnify Neurotrope for certain liabilities, in each case for uncapped amounts. Indemnities that Synaptogenix may be required to provide Neurotrope are not subject to any cap, may be significant and could negatively impact Synaptogenix&#x2019;s business, particularly with respect to indemnities provided in the Tax Matters Agreement. Third parties could also seek to hold Synaptogenix responsible for any of the liabilities that Neurotrope has agreed to retain. Further, the indemnity from Neurotrope may not be sufficient to protect Synaptogenix against the full amount of such liabilities, and Neurotrope may not be able to fully satisfy its indemnification obligations. Moreover, even if Synaptogenix ultimately succeeds in recovering from Neurotrope any amounts for which Synaptogenix is held liable, Synaptogenix may be temporarily required to bear these losses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Under Section 382 of the Internal Revenue Code of 1986, as amended, changes in the Company&#x2019;s ownership may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. In addition, the significant historical operating losses incurred by the Company may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. The Company believes that operating loss carryforwards are limited under Section 382 limitations although Section 382 studies have not been conducted to determine the actual limitations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Expense Reimbursement for Grant Award:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company reduces its research and development expenses by funding received or receivable from an NIH grant during the period that the expenses are incurred. The Company recognized grant related expense reductions during the three and nine months ended September 30, 2021 of approximately $1.1 million. See Note 5, &#x201c;&lt;i style="font-style:italic;"&gt;Clinical Trial Services Agreements&lt;/i&gt;.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Of the total $2.7 million available from the NIH grant, approximately $2.6 million was received for trial-related expenses incurred since grant inception to October&#160;31, 2021 with the remaining $0.1 million available for reimbursement during the period November&#160;2021 to March&#160;2022. The Company believes it will receive the maximum reimbursements under the grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Recent Accounting Pronouncements:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&#160;In August 2020, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, which reduces the number of accounting models for convertible instruments, amends diluted earnings per share calculations for convertible instruments and allows more contracts to qualify for equity classification. ASU 2020-06 will be effective for interim and annual periods beginning after December 15, 2021. Early adoption is permitted. The Company is evaluating the adoption of ASU 2020-06.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_DLVV8MCOBk2D78CIRnf7Gg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Basis of Presentation:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Subsequent to the Spin-Off, the Company&#x2019;s financial statements as of December 31, 2020 and for the period December 7, 2020 to December 31, 2020 are presented on a consolidated basis as the Company became a standalone public company on December 7, 2020. The Company&#x2019;s combined financial statements for the period from January 1, 2020 through December 6, 2020 that is included in the results of operations for the three and nine months ending September 30, 2020 and the year ended December 31, 2020 were derived from the consolidated financial statements and accounting records of Neurotrope, the former Parent. These combined financial statements reflect the historical results of operations, financial position and cash flows of the former Parent&#x2019;s Spin-Off business which was a wholly owned subsidiary of Neurotrope, Neurotrope Bioscience, Inc., and represented substantially all the business of Neurotrope. These financial statements reflect our financial position, results of operations and cash flows as we were historically managed, in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;All intercompany transactions between the Company and Neurotrope have been included in our financial statements and are considered to be effectively settled for cash at the time the Spin-Off was recorded. The total net effect of the settlement of these intercompany transactions is reflected in our statements of cash flow as a financing activity and in the balance sheets as &#x201c;Parent company investment&#x201d;. See Note 9.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the unaudited condensed financial statements included herein contain all adjustments necessary to present fairly the Company&#x2019;s financial position and the results of its operations and cash flows for the interim periods presented. Such adjustments are of a normal recurring nature. The results of operations for the three and nine months ended September 30, 2021 may not be indicative of results for the full year. These unaudited condensed financial statements should be read in conjunction with the audited condensed financial statements and the notes to those statements for the year ended December 31, 2020 included in our Annual Report on Form 10-K.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_OXKYknxGzEiHOkcAWNhEZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make significant estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the general economic environment and actions it may take in the future. The Company adjusts such estimates when facts and circumstances dictate. However, these estimates may involve significant uncertainties and judgments and cannot be determined with precision. In addition, these estimates are based on management&#x2019;s best judgment at a point in time and as such these estimates may ultimately differ from actual results.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <snpx:CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_z72IbDZdMEeurvtfizg2PA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Cash and Cash Equivalents and Concentration of Credit Risk:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company considers all highly liquid cash investments with an original maturity of three months or less when purchased to be cash equivalents. At September 30, 2021, the Company&#x2019;s cash balances that exceed the current insured amounts under the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) were approximately $3.6 million. In addition, approximately $27.7 million included in cash and cash equivalents were invested in a money market fund, which is not insured under the FDIC. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</snpx:CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="-5"
      id="Narr_YBpzuDmG00ui3HnJlEaOIw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">3600000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="-5"
      id="Narr_F6iMTy_Ez0GH3b0hGk1erg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">27700000</us-gaap:CashUninsuredAmount>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_QmRr475FxkaBk7Lg-M-mVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fixed Assets and Leases:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;All leases with a lease term greater than 12 months, regardless of lease type classification, are recorded as an obligation on the balance sheet with a corresponding right-of-use asset. The Company does not have any leases greater than 12 months in duration during the respective reporting periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Fixed assets are stated at cost less accumulated depreciation. Depreciation is computed on a straight line basis over the estimated useful life of the asset, which is deemed to be between &lt;span style="-sec-ix-hidden:Hidden_lr9X8jg5jUiA4B9EE7n2ZA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;three&lt;/span&gt;&lt;/span&gt; and ten years.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_Qj_fG9oUqUuK8DNTHXfAoQ"
      id="Narr_TRQw-C0j8E-ilgXqrACY3A">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_hTc2KKjqdEalzO1iCq51SA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development Costs:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;All research and development costs, including costs to maintain or expand the Company&#x2019;s patent portfolio licensed from CRE are expensed when incurred. Non-refundable advance payments for research and development are capitalized because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at September&#160;30, 2021 and December&#160;31, 2020.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <snpx:CapitalizedResearchAndDevelopmentServices
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Narr_ZyAdTJWEuEyNGXa-KVZnGw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:CapitalizedResearchAndDevelopmentServices>
    <snpx:CapitalizedResearchAndDevelopmentServices
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Narr_eMudoguEzEOj_VmbBs2tgA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:CapitalizedResearchAndDevelopmentServices>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_KtxRf-zXyUON230bOfMh0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loss Per Share of Common Stock:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On the Spin Off date, 1,257,579 shares of the Company&#x2019;s common stock, par value $0.0001 per share (the Common Stock&#x201d;) were distributed to Neurotrope stockholders as of November 30, 2020 (the &#x201c;Record Date&#x201d;). This share amount was being utilized for the calculation of basic earnings (loss) per share (&#x201c;EPS&#x201d;) for the periods prior to the Spin-Off because the Company was a wholly-owned subsidiary of Neurotrope prior to the Spin Off date. For the periods after the Spin-Off Date, EPS attributable to the Company&#x2019;s common stockholders is based upon net income (loss) attributable to the Company&#x2019;s common stockholders divided by the weighted-average number of Common Stock outstanding during the period. Penny warrants were included in the calculation of outstanding shares for purposes of basic loss per share. For the periods when a net loss is reported, the computation of diluted EPS equals the basic EPS calculation since common stock equivalents were antidilutive due to losses from continuing operations.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <snpx:IssueOfSharesOnSpinOff
      contextRef="Duration_11_30_2020_To_11_30_2020_us-gaap_RelatedPartyTransactionAxis_snpx_CurrentShareholdersOfCompanyMember_M1g-SpCvMkOthGYObm_VUw"
      decimals="INF"
      id="Narr_UYLnwKlhOEaYqxJKASXunQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1257579</snpx:IssueOfSharesOnSpinOff>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_11_30_2020_us-gaap_RelatedPartyTransactionAxis_snpx_CurrentShareholdersOfCompanyMember_XXkmy-IesU2Cqs0foH1_cQ"
      decimals="INF"
      id="Narr_zX4Lih5IkkyXetQLDFYrHQ"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_s1n64ErT_kOB9JK5JgEfAA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Income Taxes:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes under the &#x201c;Separate return method.&#x201d; Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company applies the provisions of FASB ASC 740-10, &lt;i style="font-style:italic;"&gt;Accounting for Uncertain Tax Positions&lt;/i&gt;, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also provides guidance on de-recognition, classification, interest and penalties, and accounting in interim periods, disclosure and transitions. The Company has determined that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is generally three&#160;years from the date of filing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company (collectively with Neurotrope, Inc. / Petros Pharmaceuticals, Inc.) may be subject to significant U.S. federal income tax-related liabilities with respect to our prior distribution of all of the issued and outstanding shares of the common stock of Neurotrope Bioscience, Inc., the former subsidiary of Neurotrope, to our stockholders as of and on November 30, 2020 (the &#x201c;Spin-Off&#x201d;), if there is a determination that the Spin-Off is taxable for U.S. federal income tax purposes. In connection with the Spin-Off, the Company believes substantially to the effect that, among other things, the Spin-Off should qualify as a tax-free transaction for U.S. federal income tax purposes under Section 355 and Section 368(a)(1)(D) of the Code. If the conclusions of the tax opinions are not correct, or if the Spin-Off is otherwise ultimately determined to be a taxable transaction, the Company would be liable for U.S. federal income tax related liabilities. Pursuant to the Separation and Distribution Agreement and the Tax Matters Agreement, Neurotrope agreed to indemnify Synaptogenix for certain liabilities, and Synaptogenix agreed to indemnify Neurotrope for certain liabilities, in each case for uncapped amounts. Indemnities that Synaptogenix may be required to provide Neurotrope are not subject to any cap, may be significant and could negatively impact Synaptogenix&#x2019;s business, particularly with respect to indemnities provided in the Tax Matters Agreement. Third parties could also seek to hold Synaptogenix responsible for any of the liabilities that Neurotrope has agreed to retain. Further, the indemnity from Neurotrope may not be sufficient to protect Synaptogenix against the full amount of such liabilities, and Neurotrope may not be able to fully satisfy its indemnification obligations. Moreover, even if Synaptogenix ultimately succeeds in recovering from Neurotrope any amounts for which Synaptogenix is held liable, Synaptogenix may be temporarily required to bear these losses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Under Section 382 of the Internal Revenue Code of 1986, as amended, changes in the Company&#x2019;s ownership may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. In addition, the significant historical operating losses incurred by the Company may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. The Company believes that operating loss carryforwards are limited under Section 382 limitations although Section 382 studies have not been conducted to determine the actual limitations.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <snpx:ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_26dSeUvvY0a8Fj7X3a0cRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Expense Reimbursement for Grant Award:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company reduces its research and development expenses by funding received or receivable from an NIH grant during the period that the expenses are incurred. The Company recognized grant related expense reductions during the three and nine months ended September 30, 2021 of approximately $1.1 million. See Note 5, &#x201c;&lt;i style="font-style:italic;"&gt;Clinical Trial Services Agreements&lt;/i&gt;.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Of the total $2.7 million available from the NIH grant, approximately $2.6 million was received for trial-related expenses incurred since grant inception to October&#160;31, 2021 with the remaining $0.1 million available for reimbursement during the period November&#160;2021 to March&#160;2022. The Company believes it will receive the maximum reimbursements under the grant.&lt;/p&gt;</snpx:ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="-5"
      id="Narr_0UwtsiHtcUuyNHQZZfPSkA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1100000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="-5"
      id="Narr_cGOevsKOZEi0TK58j5XcjA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1100000</us-gaap:GrantsReceivable>
    <snpx:AmountOfAwardReceived
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_fxANfnDJfkq-DjAu241ovA"
      decimals="-5"
      id="Narr_LG7Cmrv7bEOXJDi-EixJlg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">2700000</snpx:AmountOfAwardReceived>
    <snpx:AmountOfFundingReceived
      contextRef="Duration_1_1_2020_To_9_30_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_rlr4KPaCbkyP11bzHs4H5A"
      decimals="-5"
      id="Narr_bAwXXfu0EUCqwYFDZoUOaw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">2600000</snpx:AmountOfFundingReceived>
    <snpx:AmountOfFundingReceivable
      contextRef="As_Of_3_31_2022_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_OpMJCHhLC0ywEnxoJd5pzA"
      decimals="-5"
      id="Narr_onrRdGJYY0qnW4NMARwxow"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">100000</snpx:AmountOfFundingReceivable>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_AYR93thk1UCZqqfW778UXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Recent Accounting Pronouncements:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&#160;In August 2020, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, which reduces the number of accounting models for convertible instruments, amends diluted earnings per share calculations for convertible instruments and allows more contracts to qualify for equity classification. ASU 2020-06 will be effective for interim and annual periods beginning after December 15, 2021. Early adoption is permitted. The Company is evaluating the adoption of ASU 2020-06.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <snpx:CollaborativeAgreementsAndCommitmentsTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_-tKUmADv806W1ShvibSV-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;3&#x2013; Collaborative&lt;/b&gt; &lt;b style="font-weight:bold;"&gt;Agreements and Commitments:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:normal;margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Stanford License Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;On May&#160;12, 2014, the Company entered into a license agreement (the &#x201c;Stanford Agreement&#x201d;) with The Board of Trustees of The Leland Stanford Junior University (&#x201c;Stanford&#x201d;), pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as &#x201c;bryologs,&#x201d; for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents. The Company is required to use commercially reasonable efforts to develop, manufacture and sell products (&#x201c;Licensed Products&#x201d;) in the Licensed Field of Use (as defined) during the term of the licensing agreement which expires upon the termination of the last valid claim of any licensed patent under this agreement. In addition, the Company must meet specific diligence milestones, and upon meeting such milestones, make specific milestone payments to Stanford. The Company must also pay Stanford royalties&#160;of 3% of net sales, if any, of Licensed Products (as defined) and milestone payments of up to $3.7 million dependent upon stage of product development. As of September 30, 2021, no royalties nor milestone payments have been required.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;On January&#160;19, 2017, the Company entered into an additional, second license agreement with Stanford, pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of &#x201c;Bryostatin Compounds and Methods of Preparing the Same,&#x201d; or synthesized bryostatin, for use in the treatment of neurological diseases, cognitive dysfunction and psychiatric disorders, for the life of the licensed patents. The Company paid Stanford $70,000 upon executing the license and is obligated to pay an additional $10,000 annually as a license maintenance fee. In addition, based upon certain milestones which include product development and commercialization, the Company is required to pay up to an additional $2.1 million and between 1.5% and 4.5% royalty payments on certain revenues generated by the Company relating to the licensed technology. The Company has made all required annual maintenance payments. As of September 30, 2021, no royalties nor milestone payments have been required.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Mt. Sinai License Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;On July&#160;14, 2014, the Company entered into an Exclusive License Agreement (the &#x201c;Mount Sinai Agreement&#x201d;) with the Icahn School of Medicine at Mount Sinai (&#x201c;Mount Sinai&#x201d;). Pursuant to the Mount Sinai Agreement, Mount Sinai granted the Company (a)&#160;a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under Mount Sinai&#x2019;s interest in certain joint patents held by the Company and Mount Sinai (the &#x201c;Joint Patents&#x201d;) as well as in certain results and data (the &#x201c;Data Package&#x201d;) and (b)&#160;a non-exclusive license, with the right to grant sublicenses on certain conditions, to certain technical information, both relating to the diagnostic, prophylactic or therapeutic use for treating diseases or disorders in humans relying on activation of Protein Kinase C Epsilon (&#x201c;PKC&#x3b5;&#x201d;), which includes Niemann-Pick Disease (the &#x201c;Mount Sinai Field of Use&#x201d;). The Mount Sinai Agreement allows the Company to research, discover, develop, make, have made, use, have used, import, lease, sell, have sold and offer certain products, processes or methods that are covered by valid claims of Mount Sinai&#x2019;s interest in the Joint Patents or an Orphan Drug Designation Application covering the Data Package (&#x201c;Mount Sinai Licensed Products&#x201d;) in the Mount Sinai Field of Use (as such terms are defined in the Mount Sinai Agreement).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company is required to pay Mt. Sinai milestone payments of $2 million upon approval of a new drug approval (&#x201c;NDA&#x201d;) in the United States and an additional $1.5 million for an NDA approval in the European Union or Japan. In addition, the Company is required to pay Mt. Sinai royalties on net sales of licensed product of 2.0% for up to $250 million of net sales and 3.0% of net sales over $250 million. Since inception, the Company has paid Mt. Sinai approximately $180,000 consisting of licensing fees of $105,000 plus development costs and patent fees of approximately $75,000. As of September 30, 2021, no royalties nor milestone payments have been required.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Agreements with BryoLogyx&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On June&#160;9, 2020, the Company entered into a supply agreement (the &#x201c;Supply Agreement&#x201d;) with BryoLogyx&#160;Inc. (&#x201c;BryoLogyx&#x201d;), pursuant to which BryoLogyx agreed to serve as the Company&#x2019;s exclusive supplier of synthetic Bryostatin-1. Pursuant to the terms of the Supply Agreement, the Company placed an initial order and subsequently received one gram of current good manufacturing practice (&#x201c;cGMP&#x201d;) synthetic Bryostatin-1 as an active pharmaceutical ingredient to be used in a drug product (&#x201c;API&#x201d;). The Company may place additional orders for API beyond the initial order by making a written request to BryoLogyx no later than six months prior to the requested delivery date. The Company is not currently using synthetic Bryostatin-1 for its current Phase 2 clinical trial and will determine when to incorporate the synthetic into the clinical trial process.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In connection with the Supply Agreement, on June&#160;9, 2020, the Company entered into a transfer agreement (the &#x201c;Transfer Agreement&#x201d;) with BryoLogyx. Pursuant to the terms of the Transfer Agreement, the Company agreed to assign and transfer to BryoLogyx all of the Company&#x2019;s right, title and interest in and to that certain Cooperative Research and Development Agreement, dated as of January&#160;29, 2019 (the &#x201c;CRADA&#x201d;), by and between the Company and the U.S. Department of Health and Human Services, as represented by the NCI, under which Bryostatin-1&#x2019;s ability to modulate CD22 in patients with relapsed/refractory CD22+ disease has been evaluated to date. Pursuant to guidance provided by NCI, the Company CRADA has been cancelled and BryoLogyx has initiated a request for a new CRADA in its name. BryoLogyx will be filing its own investigational new drug application (&#x201c;IND&#x201d;) for CD22 with the FDA. As consideration for the transfer of rights to the CRADA, BryoLogyx has agreed to pay to the Company 2% of the gross revenue received in connection with the sale of bryostatin products, up to an aggregate payment amount of $1 million. No such revenues have been earned as of September&#160;30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Nemours Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On September 5, 2018, we announced a collaboration with Nemours A.I. DuPont Hospital (&#x201c;Nemours&#x201d;), a premier U.S. children&#x2019;s hospital, to initiate a clinical trial in children with Fragile X. In addition to the primary objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as anxiety, repetitive behavior, executive functioning, and social behavior. On August 5, 2021, the Company announced its memorandum of understanding with Nemours to initiate a clinical trial using bryostatin, under Orphan Drug Status, to treat Fragile X. The Company intends to provide the bryostatin drug product and obtain the investigational new drug documentation (&#x201c;IND&#x201d;) and Nemours intends to provide the clinical site and attendant support for the trial. The Company and Nemours, jointly, will develop the trial protocol. The Company estimates its total trial and IND cost to be approximately $700,000. To-date, the Company has not incurred any expenses associated with this agreement.&lt;/p&gt;</snpx:CollaborativeAgreementsAndCommitmentsTextBlock>
    <snpx:RoyaltyPaymentPercentage
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_StandFordLicenseAgreementMember_LrA02ttJr0Skelb_psotsQ"
      decimals="2"
      id="Narr_4CEQirHd_UKXCdKyw0oZRg"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.03</snpx:RoyaltyPaymentPercentage>
    <snpx:MilestonePaymentsPaid
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_StandFordLicenseAgreementMember_LrA02ttJr0Skelb_psotsQ"
      decimals="-5"
      id="Narr_uhKUBjbJh0CvqJW67eykuQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">3700000</snpx:MilestonePaymentsPaid>
    <us-gaap:PaymentsForRoyalties
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_StandFordLicenseAgreementMember_LrA02ttJr0Skelb_psotsQ"
      decimals="0"
      id="Narr_1fVpqGa5N0CDbwPrBCaojQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:PaymentsForRoyalties>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_19_2017_To_1_19_2017_srt_ProductOrServiceAxis_us-gaap_LicenseMember_QAFY1ZmrLkORAEkzbODSjA"
      decimals="0"
      id="Narr_UOTOwpub80uzxWUzPXADUw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">70000</us-gaap:CostOfGoodsAndServicesSold>
    <snpx:AnnualLicenseMaintenanceFee
      contextRef="Duration_1_19_2017_To_1_19_2017_RyYqzdEgTkmLuudVtZapew"
      decimals="0"
      id="Narr_KQ3Tvn5OUUm6ixx5Lg8dhg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">10000</snpx:AnnualLicenseMaintenanceFee>
    <snpx:CommitmentToPayFees
      contextRef="Duration_1_19_2017_To_1_19_2017_RyYqzdEgTkmLuudVtZapew"
      decimals="-5"
      id="Narr_MWY55MrWaU6mrbJuNDZYnA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">2100000</snpx:CommitmentToPayFees>
    <snpx:RoyaltyPaymentPercentage
      contextRef="Duration_1_19_2017_To_1_19_2017_srt_RangeAxis_srt_MinimumMember_byQy3JDAGkCSL09nDP4uAQ"
      decimals="3"
      id="Narr_0IziVjvTg0Wtv6BSJhdBCg"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.015</snpx:RoyaltyPaymentPercentage>
    <snpx:RoyaltyPaymentPercentage
      contextRef="Duration_1_19_2017_To_1_19_2017_srt_RangeAxis_srt_MaximumMember_9oZ5nMAmCE-LtGzgYi_y-A"
      decimals="3"
      id="Narr_lhJZHbji5kyBEcMCJVENMA"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.045</snpx:RoyaltyPaymentPercentage>
    <us-gaap:PaymentsForRoyalties
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_StandFordLicenseAgreementMember_LrA02ttJr0Skelb_psotsQ"
      decimals="0"
      id="Narr_pdFIdOkY10uzNcgpMEgNig"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:PaymentsForRoyalties>
    <snpx:MilestonePaymentsPayable
      contextRef="As_Of_7_14_2014_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_XWK_0a7heU6xMzkPuo_XLw"
      decimals="-6"
      id="Narr_cF4V3DipKEyE8TPKXm-27g"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">2000000</snpx:MilestonePaymentsPayable>
    <snpx:AdditionalMilestonePaymentsPayable
      contextRef="As_Of_7_14_2014_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_XWK_0a7heU6xMzkPuo_XLw"
      decimals="-5"
      id="Narr_DIEfwC_FukWIU3KcMgHRmw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1500000</snpx:AdditionalMilestonePaymentsPayable>
    <snpx:RoyaltyPaymentPercentage
      contextRef="Duration_7_14_2014_To_7_14_2014_srt_StatementScenarioAxis_snpx_NetSalesUpToDollars250MillionMember_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_ttgHcX6d-ESz6q6J8dXSbA"
      decimals="3"
      id="Narr_HZhTQhL41UyZKQYS5Xn6Uw"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.020</snpx:RoyaltyPaymentPercentage>
    <snpx:RoyaltyPaymentThresholdNetSales
      contextRef="Duration_7_14_2014_To_7_14_2014_srt_StatementScenarioAxis_snpx_NetSalesUpToDollars250MillionMember_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_ttgHcX6d-ESz6q6J8dXSbA"
      decimals="-6"
      id="Narr_cvkVxXrlg0m2oV_DApoAZg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">250000000</snpx:RoyaltyPaymentThresholdNetSales>
    <snpx:RoyaltyPaymentPercentage
      contextRef="Duration_7_14_2014_To_7_14_2014_srt_StatementScenarioAxis_snpx_NetSalesOverDollarsMillionMember_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_yH6gk0Ukj0ORfCWsxOM59A"
      decimals="3"
      id="Narr_Ejtda6ebFE2g7ewjLb0UAA"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.030</snpx:RoyaltyPaymentPercentage>
    <snpx:RoyaltyPaymentThresholdNetSales
      contextRef="Duration_7_14_2014_To_7_14_2014_srt_StatementScenarioAxis_snpx_NetSalesOverDollarsMillionMember_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_yH6gk0Ukj0ORfCWsxOM59A"
      decimals="-6"
      id="Narr_l6Q-i1SHk0-YuONweKaljw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">250000000</snpx:RoyaltyPaymentThresholdNetSales>
    <snpx:TotalSavings
      contextRef="As_Of_7_14_2014_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_XWK_0a7heU6xMzkPuo_XLw"
      decimals="0"
      id="Narr_4bVLTUxAUk6aln2my3aQ2g"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">180000</snpx:TotalSavings>
    <snpx:LicenseAgreementsLicensingFees
      contextRef="Duration_7_14_2014_To_7_14_2014_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_grnTBMjygUGvo-rt4z7rsw"
      decimals="0"
      id="Narr_z45htwNrlUW4zNB3NvSjvA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">105000</snpx:LicenseAgreementsLicensingFees>
    <snpx:LicenseAgreementsDevelopmentCostsAndPatentFees
      contextRef="Duration_7_14_2014_To_7_14_2014_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_grnTBMjygUGvo-rt4z7rsw"
      decimals="0"
      id="Narr_-jBz1o9N9kKUzchhhmYzOw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">75000</snpx:LicenseAgreementsDevelopmentCostsAndPatentFees>
    <us-gaap:PaymentsForRoyalties
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_Jj8qpfoArUmBLAPesOXY6A"
      decimals="0"
      id="Narr_h2_RvcwKAkmoPDnOjqIyYg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:PaymentsForRoyalties>
    <snpx:MilestonePaymentsPaid
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_Mt.SinaiLicenseAgreementMember_Jj8qpfoArUmBLAPesOXY6A"
      decimals="0"
      id="Narr_4EhNIvjB1kieYyW0GERc3g"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:MilestonePaymentsPaid>
    <snpx:PercentageOfGrossRevenue
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_AgreementsWithBryologyxMember_l1G14r9qTki6SweRFMEsIA"
      decimals="2"
      id="Narr_V6ExmjFZ_UinmYQRitBIRQ"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.02</snpx:PercentageOfGrossRevenue>
    <us-gaap:PaymentsForRoyalties
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_AgreementsWithBryologyxMember_avDjLw3FK0-K01yBV8psnw"
      decimals="-6"
      id="Narr_GwI5Neum9UuetWRFdi8X8w"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1000000</us-gaap:PaymentsForRoyalties>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_AgreementsWithBryologyxMember_avDjLw3FK0-K01yBV8psnw"
      decimals="0"
      id="Narr_kGAKrHGcCU2PM_Q-vvoP3Q"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:OtherIncome>
    <snpx:CostOnTrailAndInvestigationNewDrugDocumentationExpenses
      contextRef="Duration_8_5_2021_To_8_5_2021_us-gaap_TypeOfArrangementAxis_snpx_NemoursAgreementMember_duKRD6ZZp0unUKaBSODNWw"
      decimals="0"
      id="Narr_mNZBkXVXSE2E5oclBa8sYg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">700000</snpx:CostOnTrailAndInvestigationNewDrugDocumentationExpenses>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_a2qmY-WSt06QWPkmfy-8aQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;4&#x2013; Related Party Transactions and Licensing / Research Agreements:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Cognitive Research Enterprises,&#160;Inc. (&#x201c;CRE&#x201d;)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Effective October&#160;31, 2012, the Company executed a Technology License and Services Agreement (the &#x201c;TLSA&#x201d;) with CRE, a related party, and NRV II, LLC (&#x201c;NRV II&#x201d;), another affiliate of CRE, which was amended by Amendment No.&#160;1 to the TLSA as of August&#160;21, 2013. As of February&#160;4, 2015, the parties entered into an Amended and Restated Technology License and Services Agreement (the &#x201c;CRE License Agreement&#x201d;). The CRE License Agreement provides research services and has granted the Company the exclusive and nontransferable world-wide, royalty-bearing right, with a right to sublicense (in accordance with the terms and conditions described below), under CRE&#x2019;s and NRV II&#x2019;s respective right, title and interest in and to certain patents and technology owned by CRE or licensed to NRV II by CRE as of or subsequent to October&#160;31, 2012, to develop, use, manufacture, market, offer for sale, sell, distribute, import and export certain products or services for therapeutic applications for AD and other cognitive dysfunctions in humans or animals (the &#x201c;Field of Use&#x201d;). Additionally, the CRE License Agreement specifies that all patents that issue from a certain patent application shall constitute licensed patents and all trade secrets, know-how and other confidential information claimed by such patents constitute licensed technology under the CRE License. The CRE License Agreement terminates on the later of the date (a)&#160;the last of the licensed patent expires, is abandoned, or is declared unenforceable or invalid or (b)&#160;the last of the intellectual property enters the public domain.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;After Neurotrope&#x2019;s initial Series A Stock financing, the CRE License Agreement required the Company to enter into scope of work agreements with CRE as the preferred service provider for any research and development services or other related scientific assistance and support services. There were no such statements of work agreements required to be entered into during the three and nine months ended September 30, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In addition, on November&#160;10, 2018, the Company and CRE entered into a second amendment (the &#x201c;Second Amendment&#x201d;) to the TLSA pursuant to which CRE granted certain patent prosecution and maintenance rights to the Company. Under the Second Amendment, the Company will have the sole and exclusive right and the obligation, to apply for, file, prosecute and maintain patents and applications for the intellectual property licensed to the Company, and pay all fees, costs and expenses related to the licensed intellectual property. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <snpx:NumberOfStatementsEnteredIntoAgreement
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Narr_-0aGty26bE20Sh9UBTbgfg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NumberOfStatementsEnteredIntoAgreement>
    <snpx:NumberOfStatementsEnteredIntoAgreement
      contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q"
      decimals="0"
      id="Narr_dnf5eQLN2kOe1yWPDHqQZg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NumberOfStatementsEnteredIntoAgreement>
    <snpx:NumberOfStatementsEnteredIntoAgreement
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Narr_IKy9rCTbkES6rwNEKI4ZiQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NumberOfStatementsEnteredIntoAgreement>
    <snpx:NumberOfStatementsEnteredIntoAgreement
      contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw"
      decimals="0"
      id="Narr_wCtWfwAZ5UqtMv_a9SdszA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:NumberOfStatementsEnteredIntoAgreement>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_iBCQyRiED0S1C-qDQO69_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;5&#160;&#x2013; Commitments and Contingencies:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Clinical Trial Services Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;On July&#160;23, 2020, the Company entered into the 2020 Services Agreement with WCT. The 2020 Services Agreement relates to services for the current Phase 2 clinical trial assessing the safety, tolerability and long-term efficacy of bryostatin in the treatment of moderately severe AD subjects not receiving memantine treatment (the &#x201c;2020 Study&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Pursuant to the terms of the 2020 Services Agreement, WCT is providing services to enroll approximately &lt;span style="-sec-ix-hidden:Hidden_zKPmU54jT0W3JjwS4wGcXw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;one&lt;/span&gt;&lt;/span&gt; hundred (100) 2020 Study subjects, which enrollment is currently underway. The&#160;first 2020 Study site was initiated during the third quarter of 2020. The total estimated budget for the services, including pass-through costs, is currently approximately $9.6 million. The Company was awarded a $2.7 million grant from the NIH, which will be used to support the 2020 Study, resulting in an estimated net budgeted cost of the 2020 Study to the Company of $6.9 million. The NIH grant provides for funds in the first year, which began in April&#160;2020, of approximately $1.0 million and funding in year two, which begins April&#160;2021, of approximately $1.7 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company may terminate the 2020 Services Agreement without cause upon sixty (60)&#160;days prior written notice.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September&#160;30, 2021, approximately $5.1 million has been paid against the total trial cost. Of this total, approximately $2.1 million has been received from the NIH. The Company incurred approximately $5.9 million of cumulative expenses associated with the current Phase 2 clinical trial as of September 30, 2021. Of the total $5.9 million incurred for the trial to-date, approximately $1.6 million and $3.2 million is reflected in the statement of operations for the three and nine months ended September 30, 2021, respectively. As of September 30, 2021, approximately $460,000 of WCT prepayments is included as a prepaid expense and other current assets and approximately $771,000 which is included in accounts payable in the accompanying balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Related Party and Other Consulting Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;On August&#160;4, 2016, Neurotrope,&#160;Inc. entered into a consulting agreement with SM Capital Management, LLC (&#x201c;SMCM&#x201d;), a limited liability company owned and controlled by the Company&#x2019;s Chairman of the Board, Mr.&#160;Joshua N. Silverman (the &#x201c;Consulting Agreement&#x201d;). Pursuant to the Consulting Agreement, SMCM shall provide consulting services which shall include, but not be limited to, providing business development, financial communications and management transition services, for a one-year period, subject to annual review thereafter. SMCM&#x2019;s annual consulting fee is $120,000, payable by the Company in&#160;monthly installments of $10,000. This contract has been assigned to Synaptogenix,&#160;Inc. as of December&#160;1, 2020. For the three and nine months ended September 30, 2021, $60,000 and $180,000 is reflected in the Company&#x2019;s statements of operations, respectively, pursuant to the Consulting Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Effective as of January&#160;1, 2021, the Company entered into an amended consulting agreement with Katalyst Securities LLC (&#x201c;Katalyst&#x201d;) reducing the cash payment to $20,000 per month. In addition, on February&#160;16, 2021, Katalyst was granted warrants to purchase 25,000 shares of Common Stock at $11.46 per share, on April 1, 2021, was granted warrants to purchase an additional 4,500 shares of Common Stock at $8.80 per share, on July 1, 2021, was granted warrants to purchase an additional 4,500 shares of Common Stock at $9.76 per share, and, on October 1, 2021, was granted warrants to purchase an additional 4,500 shares of Common Stock at $9.30 per share. All other terms and conditions of the Katalyst Agreement remain unchanged. For the three and nine months ended September 30, 2021, $96,982 and $556,682 is reflected in the Company&#x2019;s statements of operations, respectively, pursuant to the consulting agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Effective as of June&#160;5, 2019, the Company entered into a consulting agreement with GP Nurmenkari,&#160;Inc. (&#x201c;GPN&#x201d;) (the &#x201c;GPN Agreement&#x201d;), pursuant to which GPN agreed to provide investment banking consulting services to the Company and Neurotrope. The term of the agreement continued until December 1, 2020. As consideration for its services under the GPN Agreement, the Company agreed to pay to GPN $8,000 per&#160;month, plus five-year warrants to purchase 1,200 shares of Neurotrope&#x2019;s common stock on the effective date and on each of the three-month anniversaries following the effective date. The warrants have an exercise price equal to the closing price of Neurotrope&#x2019;s stock on the dates of issuances. On February&#160;1, 2020, the Company amended the GPN Agreement, increasing the cash compensation to $17,500 per&#160;month thru November 30, 2020 and increasing the number of warrants issued each three-month period to 2,500, with the last issuance on December 1, 2020. GPN&#x2019;s cash and stock-based compensation is included as general and administrative expenses in the Company&#x2019;s statement of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Effective as of January&#160;1, 2021, the Company entered into an amended consulting agreement with GPN reducing the cash payment to $12,000 per month. Effective as of July 1, 2021, the Company entered into a second amended consulting agreement with GPN increasing the cash payment to $20,000 per month and increasing warrant issued for each three-month period beginning July 1, 2021 to 5,800, with the last issuance on October 1, 2021. In addition, on February&#160;16, 2021, GPN was granted warrants to purchase 10,000 shares of Common Stock at $11.46 per share, on April 1, 2021, was granted warrants to purchase an additional 2,500 shares of Common Stock at $8.80 per share, on July 1, 2021, was granted warrants to purchase an additional 5,800 shares of Common Stock at $9.76 per share, and, on October 1, 2021, was granted warrants to purchase an additional 5,800 shares of Common Stock at $9.30 per share. All other terms and conditions of the GPN Agreement remain unchanged. For the three and nine months ended September 30, 2021, $107,666 and $296,814 is reflected in the Company&#x2019;s statements of operations, respectively, pursuant to the GPN Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Employment Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On December&#160;7, 2020, the Company entered into an offer letter (the &#x201c;Offer Letter&#x201d;) with Alan J. Tuchman, M.D., pursuant to which Dr.&#160;Tuchman agreed to serve as the Company&#x2019;s Chief Executive Officer, commencing on December&#160;7, 2020. In addition, in connection with his appointment as the Company&#x2019;s Chief Executive Officer, Dr.&#160;Tuchman was appointed to the board of directors of the Company. Dr.&#160;Tuchman will receive an initial annual base salary of $222,000, with an annual discretionary bonus of up to 50% of his base salary then in effect. Dr.&#160;Tuchman also received an initial equity grant (subject to Board approval which was received in January&#160;2021) of options to purchase a number of shares of Common Stock equal to at least 1% of the Company&#x2019;s outstanding shares of Common Stock immediately following the Spin-Off. The option will vest with respect to 25% on each of the first, &lt;span style="-sec-ix-hidden:Hidden_hGoeBKVmBU20RQRV2PAyfQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;second&lt;/span&gt;&lt;/span&gt;, &lt;span style="-sec-ix-hidden:Hidden_G8xXS6bLZUG7c6GZDPjMxQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;third&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_YpLSh0QAWUSUkURr5jx6fw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;fourth&lt;/span&gt;&lt;/span&gt; quarterly anniversaries from the Start Date, subject to Dr.&#160;Tuchman&#x2019;s continued employment with the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The term of Dr.&#160;Tuchman&#x2019;s employment pursuant to the Offer Letter is one year, which shall be extended automatically for six month periods unless either party gives timely written notice. Pursuant to the Offer Letter, if Dr.&#160;Tuchman is terminated during the period that is within six months from the Start Date, Dr.&#160;Tuchman will receive compensation totaling a minimum of 50% of his annualized salary. If Dr.&#160;Tuchman is terminated within the period which is after six months from the Start Date and before the one year anniversary of the Start Date, Dr.&#160;Tuchman will receive severance equal to one (1)&#160;month of his base salary. If Dr.&#160;Tuchman is terminated within the period which is after the one year anniversary of the Start Date, Dr.&#160;Tuchman will receive severance equal to two (2)&#160;months of his base salary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with Dr.&#160;Ryan&#x2019;s termination on December 1, 2020, Synaptogenix and Dr.&#160;Ryan entered into a Separation Agreement, dated as of December&#160;7, 2020 (the &#x201c;Charles Ryan Separation Agreement&#x201d;). Pursuant to the Charles Ryan Separation Agreement, Dr.&#160;Ryan is entitled to receive the following separation benefits in consideration of, and subject to, Dr.&#160;Ryan&#x2019;s compliance with his continuing obligations under the Charles Ryan Separation Agreement and all other agreements between Dr.&#160;Ryan and the Company, and provided that Dr.&#160;Ryan does not revoke the Charles Ryan Separation Agreement: (i)&#160;payment of &lt;span style="-sec-ix-hidden:Hidden_jgZLIHXGVkmWEP_qt_Shbw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;twelve&lt;/span&gt;&lt;/span&gt; (12) months of Dr.&#160;Ryan&#x2019;s base salary as of the Separation Date of $425,000; (ii)&#160;a cash bonus in an amount equal to $225,000; and (iii)&#160;payment of Dr.&#160;Ryan&#x2019;s COBRA premiums for the period starting on the Charles Ryan Separation Date and ending on the earliest to occur of (x)&#160;12 months following the Separation Date; (y)&#160;the date Dr.&#160;Ryan is no longer eligible under COBRA and (z)&#160;the date that Dr.&#160;Ryan obtains employment that offers group health benefits. Total commitment pursuant to the Charles Ryan Separation Agreement is approximately $660,000. Pursuant to the employee leasing agreement as part of the Merger Agreement, 50% of any payments to Dr.&#160;Ryan will be reimbursed by Metuchen.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2020 and September&#160;30, 2021, the severance obligation included in accrued expenses on the Company&#x2019;s balance sheet was approximately $332,000 and $46,000, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;See Notes 3 and 4 for Collaboration and License Agreement related commitments.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Pursuant to the Separation Agreement and Tax Matters Agreement with Neurotrope, Neurotrope agreed to indemnify Synaptogenix for certain liabilities, and Synaptogenix agreed to indemnify Neurotrope for certain liabilities, in each case for uncapped amounts. Indemnities that Synaptogenix may be required to provide Neurotrope are not subject to any cap, may be significant and could negatively impact Synaptogenix&#x2019;s business, particularly with respect to indemnities provided in the Tax Matters Agreement. Third parties could also seek to hold Synaptogenix responsible for any of the liabilities that Neurotrope has agreed to retain. Further, the indemnity from Neurotrope may not be sufficient to protect Synaptogenix against the full amount of such liabilities, and Neurotrope may not be able to fully satisfy its indemnification obligations. Moreover, even if Synaptogenix ultimately succeeds in recovering from Neurotrope any amounts for which Synaptogenix is held liable, Synaptogenix may be temporarily required to bear these losses ourselves. As of the reporting date, there are no claims relating to the indemnification agreement.&#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <snpx:EstimatedBudgetForServices
      contextRef="As_Of_7_23_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_TIkglklIoUO2Ye16Man1yQ"
      decimals="-5"
      id="Narr_BdplRAfmKkKVduueANAvhA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">9600000</snpx:EstimatedBudgetForServices>
    <snpx:AmountOfAwardReceived
      contextRef="Duration_7_23_2020_To_7_23_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_s1iUX1xsBUGU6nFszabgYg"
      decimals="-5"
      id="Narr_PGYvi1sNQ0WngYLZg_9UkQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">2700000</snpx:AmountOfAwardReceived>
    <snpx:EstimatedBudgetForServices
      contextRef="As_Of_7_23_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_8kjX07DyaE-HzdlEbheL3A"
      decimals="-5"
      id="Narr_kCOuZ9GqGkGM8rgTSLg9Nw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">6900000</snpx:EstimatedBudgetForServices>
    <snpx:ProceedsFromGrants
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_YVddo9k3xUe1Mty-SsrZWQ"
      decimals="-5"
      id="Narr_Bd_LS_gN5kyc0ELFpMk5OQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1000000.0</snpx:ProceedsFromGrants>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_4_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_HYkNCxHRy02mLmJWCc8lbw"
      decimals="-5"
      id="Narr_yZsIyLu42020r-k9GZ_RBg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1700000</us-gaap:GrantsReceivableCurrent>
    <snpx:ConsultingAgreementNoticeForCancellation
      contextRef="Duration_7_23_2020_To_7_23_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_CN7r02Xyn0ydRSaKF-TAyQ"
      id="Narr_HVlYCiywSUWKGa9bn6sNEQ">P60D</snpx:ConsultingAgreementNoticeForCancellation>
    <snpx:AmountFundedAgainstTotalTrialCost
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_fa_BU9Kh_0-JxvaVT_wQww"
      decimals="-5"
      id="Narr_Yt3CalO7gkWnlUTkIBjzfA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">5100000</snpx:AmountFundedAgainstTotalTrialCost>
    <snpx:ProceedsFromGrants
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_v3U1szDl4k2j8DFDpZYu8A"
      decimals="-5"
      id="Narr_hEVxfMGSg0S2vMvxd9m4XQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">2100000</snpx:ProceedsFromGrants>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_snpx_NationalInstitutesOfHealthMember_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_fxANfnDJfkq-DjAu241ovA"
      decimals="-5"
      id="Narr_1VFio2KZJEe65DXIf10pQw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">5900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_23_2020_To_7_23_2020_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_CN7r02Xyn0ydRSaKF-TAyQ"
      decimals="-5"
      id="Narr_2AaPsMPDckOMzEKdzHSdOw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">5900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_a4h_NxjSXky22JFgrPHDSQ"
      decimals="-5"
      id="Narr_QNpbAzRG9k-C1tQyQIEJQg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_v3U1szDl4k2j8DFDpZYu8A"
      decimals="-5"
      id="Narr_SlK2YsGBAkqSBayY6CeCGg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">3200000</us-gaap:ResearchAndDevelopmentExpense>
    <snpx:PrepaymentsForServiceAgreementCurrent
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_fa_BU9Kh_0-JxvaVT_wQww"
      decimals="0"
      id="Narr_jOB77wfhgkG81tu-Kdikgg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">460000</snpx:PrepaymentsForServiceAgreementCurrent>
    <snpx:AccountsPayableForServiceAgreementCurrent
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ServicesAgreement2020Member_fa_BU9Kh_0-JxvaVT_wQww"
      decimals="0"
      id="Narr__APJqNU_lkuAx_QaVNh22w"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">771000</snpx:AccountsPayableForServiceAgreementCurrent>
    <snpx:ContractPaymentsTerm
      contextRef="Duration_8_4_2016_To_8_4_2016_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_ITeAjsMVWUKi59WUOf-Khg"
      id="Narr_I_cmzUli2EOOEPzbBmzJCw">P1Y</snpx:ContractPaymentsTerm>
    <snpx:AnnualConsultancyAgreementFees
      contextRef="Duration_8_4_2016_To_8_4_2016_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_ITeAjsMVWUKi59WUOf-Khg"
      decimals="0"
      id="Narr_xwTQN7nYsk-ffKvk-LcE4A"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">120000</snpx:AnnualConsultancyAgreementFees>
    <snpx:ConsultingAgreementMonthlyInstallmentFee
      contextRef="Duration_8_4_2016_To_8_4_2016_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_ITeAjsMVWUKi59WUOf-Khg"
      decimals="0"
      id="Narr_zA_h80tF1k-7tIdbKHJTpQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">10000</snpx:ConsultingAgreementMonthlyInstallmentFee>
    <snpx:ConsultancyFees
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_Bfz_1syvz0adg3VenxJYAQ"
      decimals="0"
      id="Narr_Y_4U70Kno0m6LtBfGAEZsA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">60000</snpx:ConsultancyFees>
    <snpx:ConsultancyFees
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithSmCapitalManagementLlcMember_MqIvc6D6ak-bP_Ls5cIdEA"
      decimals="0"
      id="Narr_eEEt9_AJIUKG3QpgSGwNKA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">180000</snpx:ConsultancyFees>
    <snpx:ConsultingAgreementMonthlyInstallmentFee
      contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_YeeVT1VLT0GCoyCiHtvk3A"
      decimals="0"
      id="Narr_blAEQr-uHkecAl_wXcLnPg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">20000</snpx:ConsultingAgreementMonthlyInstallmentFee>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_16_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_B7CPRdhRrUi03pd8HH2WHA"
      decimals="0"
      id="Narr_q715h8b4OU2sIcfugHzwCw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">25000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_16_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_B7CPRdhRrUi03pd8HH2WHA"
      decimals="3"
      id="Narr_Y3pYtCj2AEKALUvbpbWe9g"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">11.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_W8rULN8LVU2iFXd7lTqq6A"
      decimals="0"
      id="Narr_i5e6Z_txMUm-_PidHJ3CmQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">4500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_W8rULN8LVU2iFXd7lTqq6A"
      decimals="2"
      id="Narr_Xs6b27oCFkGjia30IeA5kA"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">8.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_OIdTKpqZekCiObLbbJPl8w"
      decimals="INF"
      id="Narr_xfNz8nY9v0i1Bkbdg5gLFw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">4500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_OIdTKpqZekCiObLbbJPl8w"
      decimals="2"
      id="Narr_-_5-hJ0ryk2E47ZrmC6NkQ"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">9.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_cufB87OPd0uxPv8DnNgAwQ"
      decimals="INF"
      id="Narr_GLT7x23yl0KZ65RxcLQw_g"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">4500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_cufB87OPd0uxPv8DnNgAwQ"
      decimals="2"
      id="Narr_vKIJDsJaF0iL5tcW1H7qVw"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">9.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <snpx:ConsultancyFees
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_izoFKLvbS0qca5XE_8MiDA"
      decimals="0"
      id="Narr_KbSvwow80EahIciWjET7Aw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">96982</snpx:ConsultancyFees>
    <snpx:ConsultancyFees
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember_ZdwykQQjnki7EjxvNtEUvg"
      decimals="0"
      id="Narr_Jed7cJc8QkWj09rnZ6pKjg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">556682</snpx:ConsultancyFees>
    <snpx:ConsultingAgreementMonthlyInstallmentFee
      contextRef="Duration_6_5_2019_To_6_5_2019_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_mhXWMvG4xk6I8_Dt9Z6IgA"
      decimals="0"
      id="Narr_ddWaoHRV9Ui1YA0biwlF_Q"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">8000</snpx:ConsultingAgreementMonthlyInstallmentFee>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_6_5_2019_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_AWIKoH8MRU-5fF4wYndp6w"
      id="Narr_Rrf1B4jPNUerV7N2n3RZjg">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_5_2019_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_AWIKoH8MRU-5fF4wYndp6w"
      decimals="0"
      id="Narr_NWUDq0YDgE2MjrYkVPp4Bw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1200</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <snpx:WarrantsAndRightsOutstandingTermFollowingEffectiveDate
      contextRef="Duration_6_5_2019_To_6_5_2019_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_mhXWMvG4xk6I8_Dt9Z6IgA"
      id="Narr_PFKEA2Cd90CxIMCX-cL2Cw">P3M</snpx:WarrantsAndRightsOutstandingTermFollowingEffectiveDate>
    <snpx:ConsultingAgreementMonthlyInstallmentFee
      contextRef="Duration_2_1_2020_To_2_1_2020_nGp21D17LkONtLS4Ybajpg"
      decimals="0"
      id="Narr_HlDVEJh5T0-vS-2OQ5EHpA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">17500</snpx:ConsultingAgreementMonthlyInstallmentFee>
    <snpx:WarrantsAndRightsOutstandingTermFollowingEffectiveDate
      contextRef="Duration_2_1_2020_To_2_1_2020_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_aEnOkbRtSEKBDafsd3izUw"
      id="Narr_HHUOWWXjkk6iIxZHgqikdw">P3M</snpx:WarrantsAndRightsOutstandingTermFollowingEffectiveDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_31_2020_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_NE8e4JpcsUy1zfWK6UBJew"
      decimals="0"
      id="Narr_b1a4LxRo10GjACEjknD9-Q"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">2500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <snpx:ConsultingAgreementMonthlyInstallmentFee
      contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_6GCBoefDCEis5MNeRLe2Dw"
      decimals="0"
      id="Narr_tJlj-1tGuk2GcnbKUQqdXQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">12000</snpx:ConsultingAgreementMonthlyInstallmentFee>
    <snpx:ConsultingAgreementMonthlyInstallmentFee
      contextRef="Duration_7_1_2021_To_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_R-FJ60uA10ybeZXoxwgloA"
      decimals="0"
      id="Narr_S2t0OhHXlUG_Say29aoMng"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">20000</snpx:ConsultingAgreementMonthlyInstallmentFee>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_mKADfe9OGEuXe9ZYlIg4Sw"
      decimals="0"
      id="Narr_IMkYLPPphE2scms_1pQ9fw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">5800</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_4Hb6Y7xE0kyrvRnId9g4PQ"
      decimals="0"
      id="Narr_dDueCZhKoU-MpttEh399aw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">10000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_4Hb6Y7xE0kyrvRnId9g4PQ"
      decimals="3"
      id="Narr_CyMWfFW6tEueEg0sDmgj-g"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">11.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_GFeDDnIUDEeDxbNQIpRbmQ"
      decimals="0"
      id="Narr_w4Jdn68fQUm1C9XMLEJ4jA"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">2500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_GFeDDnIUDEeDxbNQIpRbmQ"
      decimals="2"
      id="Narr__sh3w6l_rEKrlVe0gmW0uA"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">8.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_fU78qKLlQUeUn6turqsGfg"
      decimals="INF"
      id="Narr_SGbz6W_hrEShL7kymVTidA"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">5800</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_fU78qKLlQUeUn6turqsGfg"
      decimals="2"
      id="Narr_y4wUdWVhaUGwd-ic7jYQ4w"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">9.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_PT7hcM8umEeDTrhm4UVpkQ"
      decimals="INF"
      id="Narr_sjbpzWP5oU-Zh6YWwMPoWQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">5800</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_1_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_PT7hcM8umEeDTrhm4UVpkQ"
      decimals="2"
      id="Narr_6reYuENOWk2eD_IJxp-RkA"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">9.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <snpx:ConsultancyFees
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_rB9I5A7GXUOkubGYNYktVQ"
      decimals="0"
      id="Narr_0uG0t9drjEmDvifDm9E5mA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">107666</snpx:ConsultancyFees>
    <snpx:ConsultancyFees
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_ConsultingAgreementWithGpNurmenkariIncMember_T6M0FiL3YEiY7TJp-0yjrw"
      decimals="0"
      id="Narr_d14BUt6cJ0ymL_gaDzFAGQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">296814</snpx:ConsultancyFees>
    <snpx:InitialAnnualBaseSalaryPayable
      contextRef="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_sdadKr2ZFUGPSuQk3FpIsA"
      decimals="0"
      id="Narr_jkv28W25NEKzaEHn6sfnEQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">222000</snpx:InitialAnnualBaseSalaryPayable>
    <snpx:AnnualDiscretionaryBonusPayableMaximumPercent
      contextRef="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_sdadKr2ZFUGPSuQk3FpIsA"
      decimals="INF"
      id="Narr_q53SiPymFESmwMdjc5RVoA"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.50</snpx:AnnualDiscretionaryBonusPayableMaximumPercent>
    <snpx:OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff
      contextRef="As_Of_1_1_2021_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_TxVysG0320uYChAcxvCRyQ"
      decimals="INF"
      id="Narr_us2plWL_NUqzF8VdIyYBqw"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.01</snpx:OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_q7uNiiIzykOY--M3GXitdQ"
      decimals="INF"
      id="Narr_emjy6xLK60aFgf2UkfLQ9g"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <snpx:NumberOfMonthsBaseSalaryPayableUponTermination
      contextRef="Duration_12_7_2020_To_12_7_2020_srt_StatementScenarioAxis_snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_yvpkUlirp0a1bWJ5z_hbhg"
      decimals="INF"
      id="Narr_9jZJg8hffUiX5DTFsv0mnw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1</snpx:NumberOfMonthsBaseSalaryPayableUponTermination>
    <snpx:MinimumPercentageOfAnnualizedSalaryPayableUponTermination
      contextRef="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember_sdadKr2ZFUGPSuQk3FpIsA"
      decimals="INF"
      id="Narr_-hqVxMGQTkWhBInWWZladQ"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.50</snpx:MinimumPercentageOfAnnualizedSalaryPayableUponTermination>
    <snpx:TotalAmountOfBaseSalaryPayableUponSeparation
      contextRef="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_AJnmojkQsECwB_nfR566Pg"
      decimals="0"
      id="Narr_T3yMNWdHC0aUKY__eR3GGw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">425000</snpx:TotalAmountOfBaseSalaryPayableUponSeparation>
    <snpx:CashBonusPayableUponSeparation
      contextRef="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_AJnmojkQsECwB_nfR566Pg"
      decimals="0"
      id="Narr_lI51CPQOjkKcgdTXKDBxKg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">225000</snpx:CashBonusPayableUponSeparation>
    <snpx:PeriodFollowingSeparationDateToPayCobraPremiums
      contextRef="Duration_12_7_2020_To_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_7m4RE_sc4ku1rRSLUCwYWA"
      id="Narr_O70oJSCA-0Gsk5x4ThuSgg">P12M</snpx:PeriodFollowingSeparationDateToPayCobraPremiums>
    <snpx:TotalSeparationBenefitsPayable
      contextRef="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_AJnmojkQsECwB_nfR566Pg"
      decimals="0"
      id="Narr_OqL0hbWGcESI6Xy7HnoiJQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">660000</snpx:TotalSeparationBenefitsPayable>
    <snpx:AnnualDiscretionaryBonusPayableMaximumPercent
      contextRef="As_Of_12_7_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_AJnmojkQsECwB_nfR566Pg"
      decimals="INF"
      id="Narr_-cfLBS4OYkWTqV2OsP_2vQ"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.50</snpx:AnnualDiscretionaryBonusPayableMaximumPercent>
    <snpx:SeparationBenefitsReimbursed
      contextRef="Duration_12_31_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember__tepL3mKh0iXiuyC48F1pQ"
      decimals="0"
      id="Narr_YPEn7nKgGU2eGlZWDfT_ow"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">332000</snpx:SeparationBenefitsReimbursed>
    <snpx:SeparationBenefitsReimbursed
      contextRef="Duration_3_31_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_snpx_CharlesRyanSeparationAgreementMember_wwIsJnRvikGynuEld8gG7w"
      decimals="0"
      id="Narr_HazuOEnnOEq9da_2xiW2mg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">46000</snpx:SeparationBenefitsReimbursed>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_59noYseshUyDwVtRpxlEXA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;6&#160;&#x2013;&lt;/b&gt; &lt;b style="font-weight:bold;"&gt;Stockholders&#x2019; Equity:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On December&#160;7, 2020, the Company completed its Spin-Off from Neurotrope and &lt;span style="-sec-ix-hidden:Hidden_2WjS9OcCE0OUM5kOWGUAdg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;issued&lt;/span&gt;&lt;/span&gt; 1,257,579 of Common Stock to stakeholders of Neurotrope. The shares issues were determined by the number of Neurotrope shares held by each shareholder multiplied by the exchange rate of .20 shares of Synaptogenix for each share of Neurotrope, held on November&#160;30, 2020, the record date of the Spin-Off. In addition, shares of Common Stock were &lt;span style="-sec-ix-hidden:Hidden_dSJYuuGr1UaWnhcxWt0JcA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;issued&lt;/span&gt;&lt;/span&gt; to Neurotrope. Warrant holders that chose not to amend their warrants pursuant to the amendments offered to all Series&#160;E, F, G and H warrant holders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s certificate of incorporation authorizes it to issue 150,000,000 shares of Common Stock and 1,000,000 shares of preferred stock, par value $0.0001 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The holders of Common Stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends at such times and in such amounts as the Board from time to time may determine. To date, the Company has not paid dividends on its Common Stock. Holders of Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. There is no cumulative voting of the election of directors then standing for election. The Common Stock is not entitled to pre-emptive rights and is not subject to conversion or redemption. Upon liquidation, dissolution or winding up of the Company, the assets legally available for distribution to stockholders are distributable ratably among the holders of Common Stock after payment of liabilities, accrued dividends and liquidation preferences, if any. Each outstanding share of Common Stock is duly and validly issued, fully paid and non-assessable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;January&#160;2021 Private Placement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On January&#160;21, 2021, the Company entered into Securities Purchase Agreements (the &#x201c;Purchase Agreement&#x201d;) with certain accredited investors (the &#x201c;Purchasers&#x201d;) to issue (a)&#160;an aggregate of 2,333,884 shares of Common Stock and/or prefunded warrants to purchase shares of Common Stock at an exercise price of $0.01 per share (the &#x201c;Pre-Funded Warrants&#x201d;), (b)&#160;Series&#160;E warrants to purchase 2,333,908 shares of Common Stock, with an exercise price of $8.51 per share (subject to adjustment), for a period of twelve months from the date of an effective registration statement (the &#x201c;Series&#160;E Warrants&#x201d;) and (c)&#160;Series&#160;F warrants to purchase up to an aggregate of 2,333,908 shares of Common stock, with an exercise price of $6.90 per share (subject to adjustment), for a period of five years from the date of issuance (the &#x201c;Series&#160;F Warrants&#x201d; and together with the Series&#160;E Warrants, the &#x201c;Warrants&#x201d;) at a combined purchase price of $6.00 per share of Common Stock and Warrants (the &#x201c;Offering&#x201d;). The Company received total gross proceeds of approximately $14,000,000 and net proceeds of approximately $12.5 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In connection with the Purchase Agreement, the Company and the Purchasers entered into a Registration Rights Agreement (the &#x201c;Registration Rights Agreement&#x201d;) on January&#160;21, 2021. Under the terms of the Registration Rights Agreement, the Company agreed to register the shares of Common Stock and the shares of Common Stock issuable upon exercise of the Warrants and the Pre-Funded Warrants sold to the Buyers pursuant to the Purchase Agreement. The Company filed a registration statement on Form S-1 in connection with the Registration Rights Agreement on February 8, 2021. The Company also agreed to other customary obligations regarding registration, including indemnification and maintenance of the effectiveness of the registration statement. The Company&#x2019;s registration statement on Form S-1 to register the shares of Common Stock and the shares of Common Stock issuable upon exercise of the Warrants and Pre-Funded Warrants went effective on April 29, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;border-bottom:1.0pt solid #ffffff;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;"&gt;In connection with the Offering, we paid our placement agents Katalyst and GPN (i)&#160;a cash fee equal to ten percent (10%) of the gross proceeds from any sale of securities in the Offering sold to Purchasers introduced by the Placement Agent and (ii)&#160;warrants to purchase shares of Common Stock equal to ten percent (10%) of the number of shares of Common Stock sold to Purchasers introduced by the placement agents, with an exercise price of $6.90 per share and a five-year term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;June 2021 Private Placement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;On June 14, 2021, the Company entered into Securities Purchase Agreements (the &#x201c;June Purchase Agreement&#x201d;) with certain accredited investors (the &#x201c;June Purchasers&#x201d;) to issue (a) an aggregate of 1,653,281 shares of the Company&#x2019;s Common Stock and/or prefunded warrants to purchase shares of Common Stock at an exercise price of $0.01 per share (the &#x201c;June Pre-Funded Warrants&#x201d;) and (b) Series G warrants to purchase up to an aggregate of 1,653,281 shares of Common stock, with an exercise price of $8.51 per share (subject to adjustment), for a period of five years from the date of issuance (the &#x201c;June Warrants&#x201d;) at a combined purchase price of $7.547 per share of Common Stock and June Warrants (the &#x201c;June Offering&#x201d;). The Company received total gross proceeds of approximately $12.5 million and net proceeds of approximately $11.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the June Purchase Agreement, the Company and the June Purchasers entered into a Registration Rights Agreement (the &#x201c;June Registration Rights Agreement&#x201d;) on June 14, 2021. Under the terms of the June Registration Rights Agreement, the Company agreed to register the shares of Common Stock and the shares of Common Stock issuable upon exercise of the June Warrants and the June Pre-Funded Warrants sold to the Buyers pursuant to the June Purchase Agreement. The Company filed a registration statement for the resale of such securities on June 24, 2021, and it was declared effective by the SEC on July 6, 2021. The Company also agreed to other customary obligations regarding registration, including indemnification and maintenance of the effectiveness of the registration statement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the June Offering, pursuant to an Engagement Agreement, dated June 14, 2021 (the &#x201c;June Engagement Agreement&#x201d;), between the Company and Katalyst Securities LLC (the &#x201c;June Placement Agent&#x201d;), the Company paid the June Placement Agent (i) a cash fee equal to ten percent (10%) of the gross proceeds from the sale of securities in the June Offering sold to June Purchasers introduced by the June Placement Agent and (ii) 152,378 warrants to purchase shares of Common Stock equal to ten percent (10%) of the number of shares of Common Stock sold to June Purchasers introduced by the June Placement Agent, with an exercise price of $8.51 per share and a five-year term (the &#x201c;June Broker Warrants&#x201d;). Furthermore, the Company agreed to pay the June Placement Agent a warrant exercise fee equal to ten percent (10%) of the aggregate exercise price that is paid in connection with each exercise, if any, of the June Warrants initially held by June Purchasers introduced by the June Placement Agent. The June Placement Agent is also entitled to the foregoing fees with respect to any future financing or capital-raising transaction by the Company (a &#x201c;Subsequent Financing&#x201d;), to the extent such financing or capital is provided to the Company by investors whom the Placement Agent had introduced to the Company, in the event such Subsequent Financing is consummated within eighteen (18) months following the closing of the June Offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Adoption of a Shareholder Rights Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On January&#160;13, 2021, the Company adopted a shareholder rights plan (the &#x201c;Rights Plan&#x201d;). The Rights Plan is intended to protect the interests of the Company&#x2019;s stockholders and enable them to realize the full potential value of their investment by reducing the likelihood that any person or group gains control of the Company, through open market accumulation or other tactics, without appropriately compensating all stockholders. Pursuant to the Rights Plan, the Company will issue, by means of a dividend, one preferred share purchase right for each outstanding share of our Common Stock to shareholders of record on the close of business on January&#160;25, 2021. Initially, these Rights will trade with, and be represented by, the shares of our Common Stock.&#160;The Rights&#160;will generally become exercisable only if any person (or any persons acting as a group) acquires 15% or more of our outstanding Common Stock (the &#x201c;Acquiring Person&#x201d;) in a transaction not approved by the Board, subject to certain exceptions, as explained below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;If the Rights become exercisable, all holders of Rights, other than the Acquiring Person, will be entitled to acquire shares of Common Stock at a 50% discount or the Company may exchange each Right held by such holders for one share of Common Stock. In such situation, Rights held by the Acquiring Person would become void and will not be exercisable. If any person at the time of the first public announcement of the Rights Plan owns more than the triggering percentage, then that stockholder&#x2019;s existing ownership percentage will be grandfathered, although, with certain exceptions, the Rights will become exercisable if at any time after the announcement of the Rights Plan such stockholder increases its ownership of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On January&#160;13, 2021, the board of directors of the Company (the &#x201c;Board&#x201d;)declared a dividend of one preferred share purchase right (a &#x201c;Right&#x201d;), payable on January&#160;25, 2021, for each share of Common Stock outstanding on January&#160;25, 2021 (the &#x201c;Record Date&#x201d;) to the stockholders of record on that date. In connection with the distribution of the Rights, the Company entered into a Rights Agreement (the &#x201c;Rights Agreement&#x201d;), dated as of January&#160;19, 2021, between the Company and Philadelphia Stock Transfer,&#160;Inc., as rights agent. Each Right entitles the registered holder to purchase from the Company one one-thousandth of a share of Series&#160;A Preferred Stock, par value $0.001 per share (the &#x201c;Preferred Shares&#x201d;), of the Company at a price of $20 per one one-thousandth of a Preferred Share represented by a Right (the &#x201c;Purchase Price&#x201d;), subject to adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Unless earlier redeemed, terminated or exchanged pursuant to the terms of the Rights Plan, the Rights will expire at the close of business on&#160;January&#160;13, 2023. The Board may terminate the Rights Plan before that date if the Board determines that there is no longer a threat to shareholder value.&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;At the Special Meeting, the stockholders approved our proposal to effect one reverse stock split of the Company&#x2019;s outstanding shares of Common stock, at any ratio between 1-for-1.5 and 1-for-20, at such time as the Company&#x2019;s Board of Directors shall determine, in its sole discretion, before December 31, 2022. On May 19, 2021, the Company effected a &lt;span style="-sec-ix-hidden:Hidden_a2wS05qZI0qbkELASHqfgA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;1-for-4&lt;/span&gt;&lt;/span&gt; reverse stock split of its Common Stock. As a result of the reverse stock split, every four (4) shares of the Company&#x2019;s pre-reverse split Common Stock was combined and reclassified into one share of Common Stock. These financial statements have been adjusted to retrospectively reflect this reverse stock split.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <snpx:IssueOfSharesOnSpinOff
      contextRef="Duration_12_7_2020_To_12_7_2020_sjyc_Q4Tz0y82heiYi_stA"
      decimals="0"
      id="Narr_9u6OO6rrWUG8cyUwjTuJkQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1257579</snpx:IssueOfSharesOnSpinOff>
    <snpx:SpinOffRatio
      contextRef="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g"
      decimals="2"
      id="Narr_n_9xGi_PlUOrHlwZAR1C-Q"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.20</snpx:SpinOffRatio>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Narr_56Vw2-KVnUmus6eLgg8rEw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Narr_YOTUAXY7ukybyNdwlGK-uw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="INF"
      id="Narr_5P1NbU4wI0-EjhI0CU77Kw"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <snpx:NumberOfVotesPerShareOwned
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="INF"
      id="Narr_PMKJbXyU-Eef6lWSZgctgQ"
      unitRef="Unit_Standard_Vote_DzbStCv5TEKWycjen-OBEA">1</snpx:NumberOfVotesPerShareOwned>
    <snpx:AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement
      contextRef="Duration_1_21_2021_To_1_21_2021_HYTbWiKKQEKRtx7xP4_xwQ"
      decimals="0"
      id="Narr_RHZncO4HekaWo7Mj7wTyFw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">2333884</snpx:AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_1_21_2021_DeloaH3epUmWvrrrKTfurQ"
      decimals="2"
      id="Narr_b1OY7jqK5kmvJ-Z1hdBP_A"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.01</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_GlLZteV0L0Sp_5QqZ3bkiQ"
      decimals="0"
      id="Narr_3yF5LvNexkecVyxRwiVbmg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">2333908</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_GlLZteV0L0Sp_5QqZ3bkiQ"
      decimals="2"
      id="Narr_NNyK14O-9k2Mjjqw5hlXCA"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">8.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_L_BlpkHz3kyav_r8wtOz5w"
      id="Narr_n0LPV4WlmEKu27zYIZiuAA">P12M</snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights>
    <snpx:AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_HmAmRGGq3UKNzSa-eZihpA"
      decimals="0"
      id="Narr_OusaK_zYc0yzCafmvljvvA"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">2333908</snpx:AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_GxGMgiomqkCkvB744Sb2wg"
      decimals="3"
      id="Narr_yLicx-9Zzk63Uijv_KLz5A"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">6.90</us-gaap:SaleOfStockPricePerShare>
    <snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_HmAmRGGq3UKNzSa-eZihpA"
      id="Narr_4tbhqrEAd0OAohOiokPQWg">P5Y</snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights>
    <snpx:CombinedPurchasePriceOfCommonStockAndWarrants
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_fZfc3Q0FgUaqAHKikZxANA"
      decimals="2"
      id="Narr_N9Kflrc20EWsdLOzbBxBFg"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">6.00</snpx:CombinedPurchasePriceOfCommonStockAndWarrants>
    <snpx:GrossProceedsFromSaleOfWarrantsAndCommonStock
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_fZfc3Q0FgUaqAHKikZxANA"
      decimals="0"
      id="Narr_8pRrDGT4lkODNlKA4h37Ig"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">14000000</snpx:GrossProceedsFromSaleOfWarrantsAndCommonStock>
    <snpx:NetProceedsFromSaleOfWarrantsAndCommonStock
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_fZfc3Q0FgUaqAHKikZxANA"
      decimals="-5"
      id="Narr_itWFXbm620ySWCz403PbAg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">12500000</snpx:NetProceedsFromSaleOfWarrantsAndCommonStock>
    <snpx:PercentageOfOfferingFeesInCash
      contextRef="Duration_1_21_2021_To_1_21_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_o7nYuxzxoUywgFr4YqnBRA"
      decimals="INF"
      id="Narr_2I5KxSA0_0CGNl1h0aR0vA"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.10</snpx:PercentageOfOfferingFeesInCash>
    <snpx:PercentageOfOfferingFeesInWarrants
      contextRef="Duration_1_21_2021_To_1_21_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_o7nYuxzxoUywgFr4YqnBRA"
      decimals="INF"
      id="Narr_cmT26C4eQkSNeV-wA-_vsQ"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.10</snpx:PercentageOfOfferingFeesInWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_21_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_njgrU71ChUuuukDv39OPww"
      decimals="2"
      id="Narr_RBz5c1r3UEi3pApbbqenkQ"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">6.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights
      contextRef="Duration_1_21_2021_To_1_21_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_o7nYuxzxoUywgFr4YqnBRA"
      id="Narr_yxZcsE0NZk2BisDikueQCQ">P5Y</snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights>
    <snpx:AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement
      contextRef="Duration_6_14_2021_To_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_PrefundedWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_UTFOvvwdkkKSLwa22CdtEA"
      decimals="INF"
      id="Narr_XCqft7He5kmHxmFHxJwXnw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1653281</snpx:AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_PrefundedWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_Y9y3VTtvt0-HBEjwyQXlZw"
      decimals="2"
      id="Narr_3IzOShSAj0OdzGEOXJ9JZw"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <snpx:AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement
      contextRef="Duration_6_14_2021_To_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_OrexfrNIiEKu4uzwmMWMwQ"
      decimals="INF"
      id="Narr_uiPnNYTI50aOay71n4lLCw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1653281</snpx:AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_14_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_qFNn0PiONUWj2D4Fv2tSVQ"
      decimals="2"
      id="Narr_dvY8uKH8mE-X4D3xD65J7g"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">8.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights
      contextRef="Duration_6_14_2021_To_6_14_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_Hw9nxWYRIEOMqSut960Tzw"
      id="Narr_8dH4FeGdwEO4KxQPL1iNkQ">P5Y</snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights>
    <snpx:CombinedPurchasePriceOfCommonStockAndWarrants
      contextRef="Duration_6_14_2021_To_6_14_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_Hw9nxWYRIEOMqSut960Tzw"
      decimals="3"
      id="Narr_nQWM2I81BE2DXFXl8e-ALw"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">7.547</snpx:CombinedPurchasePriceOfCommonStockAndWarrants>
    <snpx:GrossProceedsFromSaleOfWarrantsAndCommonStock
      contextRef="Duration_6_14_2021_To_6_14_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_Hw9nxWYRIEOMqSut960Tzw"
      decimals="-5"
      id="Narr_Nb-AxKd0tkqvINeF3SprFA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">12500000</snpx:GrossProceedsFromSaleOfWarrantsAndCommonStock>
    <snpx:NetProceedsFromSaleOfWarrantsAndCommonStock
      contextRef="Duration_6_14_2021_To_6_14_2021_us-gaap_TypeOfArrangementAxis_snpx_SecuritiesPurchaseAgreementsMember_Hw9nxWYRIEOMqSut960Tzw"
      decimals="-5"
      id="Narr_73IzhWlVzUe_8PUH6nYjWg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">11200000</snpx:NetProceedsFromSaleOfWarrantsAndCommonStock>
    <snpx:PercentageOfOfferingFeesInCash
      contextRef="Duration_6_14_2021_To_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_Q4EJ6pY3MEGvIljDamjqvg"
      decimals="2"
      id="Narr_X7jW2Oweh0e9_gKi2aWe0w"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.10</snpx:PercentageOfOfferingFeesInCash>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_zUGNKTUDa0uRvG6Lbuctbg"
      decimals="INF"
      id="Narr_eZgvjAThO0e7vxh4TVNe5A"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">152378</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <snpx:PercentageOfOfferingFeesInWarrants
      contextRef="Duration_6_14_2021_To_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_Q4EJ6pY3MEGvIljDamjqvg"
      decimals="2"
      id="Narr_Jl94lNJxC02tGEmSNJgsAg"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.10</snpx:PercentageOfOfferingFeesInWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_zUGNKTUDa0uRvG6Lbuctbg"
      decimals="2"
      id="Narr_7o9NY2jx2EG8tDp6Fy9xvQ"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">8.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights
      contextRef="Duration_6_14_2021_To_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_Q4EJ6pY3MEGvIljDamjqvg"
      id="Narr_1Eb9QXdGtkC0P4AW4sCIZQ">P5Y</snpx:ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights>
    <snpx:PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant
      contextRef="Duration_6_14_2021_To_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_Q4EJ6pY3MEGvIljDamjqvg"
      decimals="2"
      id="Narr_2ozU40XFWUiP3mvg0_QRow"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.10</snpx:PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant>
    <snpx:ThresholdPeriodForArrangingFutureFinancing
      contextRef="Duration_6_14_2021_To_6_14_2021_srt_CounterpartyNameAxis_snpx_PlacementAgentsMember_Q4EJ6pY3MEGvIljDamjqvg"
      id="Narr_1TWFZIAU8Umic89-xsm4Ig">P18M</snpx:ThresholdPeriodForArrangingFutureFinancing>
    <snpx:NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_ShareholderRightsPlanMember_BeWp9EwyLU-Pw2i4t19P6w"
      decimals="INF"
      id="Narr_7dNUAzvfZ0uRpUjqtIGO4w"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1</snpx:NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend>
    <snpx:MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_ShareholderRightsPlanMember_BeWp9EwyLU-Pw2i4t19P6w"
      decimals="INF"
      id="Narr_WEEVte66h0ePvM6UckpHSg"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">15</snpx:MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights>
    <snpx:DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_ShareholderRightsPlanMember_BeWp9EwyLU-Pw2i4t19P6w"
      decimals="INF"
      id="Narr_4xE4f5DCAEKu2yk2fL2Lvg"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.50</snpx:DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson>
    <snpx:NumberOfCommonSharesForEachRight
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_ShareholderRightsPlanMember_BeWp9EwyLU-Pw2i4t19P6w"
      decimals="INF"
      id="Narr_wseinrINH0-KjC0eaQBPfw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1</snpx:NumberOfCommonSharesForEachRight>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_RightsAgreementMember_4x3-7JV2VESTTUvsqOn7Yw"
      decimals="INF"
      id="Narr_DnEDJZuOU0-4LrloclvyWw"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <snpx:PurchasePriceOfRight
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_RightsAgreementMember_cbGd3CdlBUqQ_qyF1XZXPA"
      decimals="0"
      id="Narr_I7FJMXz2LEGVXfMO_Hp25Q"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">20</snpx:PurchasePriceOfRight>
    <snpx:NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_TypeOfArrangementAxis_snpx_RightsAgreementMember_cbGd3CdlBUqQ_qyF1XZXPA"
      decimals="INF"
      id="Narr_FzSNAz53b0ad5u-i1mEjKw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1</snpx:NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_5JNwmAqnxEi_l_f3YHC7-w"
      decimals="1"
      id="Narr_5YwkeGw7xkKT5Y77YPv83g"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">1.5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_Qj_fG9oUqUuK8DNTHXfAoQ"
      decimals="0"
      id="Narr_vqXBLJotZ0CzUzvAoCY4vA"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">20</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_GSZYKI0qqUuSfqzaHGeC9g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 7 &#x2013; Stock Based Compensation:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;2020 Equity Incentive Plan&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon completion of the Spin-Off, the Company&#x2019;s 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) became effective on December&#160;7, 2020. The total number of securities available for grant under the 2020 Plan was 250,000 shares of Common Stock, subject to adjustment. On April 7, 2021, the Company held a special meeting of stockholders (&#x201c;Special Meeting&#x201d;). At the Special Meeting, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s 2020 Plan to increase the total number of shares of Common Stock from 250,000 to an aggregate of 625,000 shares of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Compensation Committee of the Company&#x2019;s board of directors (the &#x201c;Committee&#x201d;) will administer the 2020 Plan and have full power to grant stock options and Common Stock, construe and interpret the 2020 Plan, establish rules&#160;and regulations and perform all other acts, including the delegation of administrative responsibilities, as it believes reasonable and proper. The Committee, in its absolute discretion, may award Common Stock to employees, consultants, and directors of the Company, and such other persons as the Committee may select, and permit holders of options to exercise such options prior to full vesting.&lt;i style="font-style:italic;"&gt; &lt;/i&gt;Pursuant to the Spin-Off, all options issued and outstanding prior to this plan were assumed by Petros Pharmaceuticals,&#160;Inc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Before the Spin-Off, Neurotrope was the sponsor of the Company&#x2019;s 2017 stock option plan (&#x201c;2017 Plan&#x201d;). Upon the Spin-Off, the 2017 Plan was transferred to Petros Pharmaceuticals,&#160;Inc. Total expenses for 2020 was recognized as expense and attributable to the Company (See Note 9 &#x2013; Parent Company Investment.) As of the Spin-Off date, no additional options expense will be reflected based upon the 2017 Plan.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Option Grants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following is a summary of stock option activity under the stock option plans for the nine months ended September 30, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;millions)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Options outstanding at January&#160;1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Ran0Cu55WEO7SIeyEo9upQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 123,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less options expired/cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Options outstanding at September&#160;30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 123,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Options exercisable at September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 89,613&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.84&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On January&#160;13, 2021, pursuant to its 2020 Plan, the Company granted stock options to purchase an aggregate of 116,350 shares of Common Stock to six members of the board of directors and four employees, including 12,575 options granted to the Company&#x2019;s Chief Executive Officer pursuant to his employment agreement with the Company dated December&#160;7, 2020. The stock options have an exercise price of $9.84 per share and an expiration date that is ten years from the date of issuance. 103,775 options vest 50% on the date of grant and 50% on the first anniversary of the grant date, the 12,575 options granted to the CEO vest 25% per quarter over one year, with the initial 25% vesting on March&#160;7, 2021. On April 6, 2021, pursuant to the Company&#x2019;s Director Compensation Policy (see below), the Company granted stock options to purchase an aggregate of 7,500 shares of Common Stock to five members of the board of directors. &#160;The stock options have an exercise price of $9.80 per share and an expiration that is ten years from the date of issuance. All these options vest on the first anniversary of the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Black-Scholes valuation model was used to calculate the fair value of these stock options issued pursuant to the 2020 Plan. The fair value of stock options issued was estimated at the grant date using the following weighted average assumptions: Dividend yield 0%; Expected term 5.2 years; an aggregate volatility based upon a blend of the former Parent Company&#x2019;s historical volatility and guideline company historical volatility of 129.9%; and Risk-free interest rate 0.51%. The weighted average grant date fair value of options granted was approximately $1,054,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On March&#160;12, 2021, Synaptogenix adopted a new non-employee director compensation policy (the &#x201c;Director Compensation Policy&#x201d;). The Director Compensation Policy provides for the annual automatic grant of nonqualified stock options to purchase up to 1,500 shares of Synaptogenix&#x2019;s Common Stock to each of Synaptogenix&#x2019;s nonemployee directors. Such grants shall occur annually on the fifth business day after the filing of Synaptogenix&#x2019;s Annual Report on Form&#160;10-K and shall vest on the one-year anniversary from the date of grant subject to the director&#x2019;s continued service on the Board of Directors on the vesting date. The Director Compensation Policy also provides for the automatic grant of nonqualified stock options to purchase up to 1,200 shares of Synaptogenix&#x2019;s Common Stock, plus options to purchase an additional 300 shares of Common Stock for service on a committee of the Board of Directors, to each newly appointed director following the date of his or her appointment. Such options shall vest as follows: fifty percent (50%) on the date of the grant, twenty-five percent (25%) on the one year anniversary from the date of the grant, and twenty-five percent (25%) on the second year anniversary from the date of the grant, subject to the director&#x2019;s continued service on the Board of Directors on the applicable vesting dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restricted Stock Grants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On July 13, 2021, the Company granted a total of 495,000 restricted stock units (RSUs) of which 425,000 were granted to seven Board members (including two executives), 60,000 to the Company&#x2019;s CFO and 10,000 to two employees. The RSUs vest 50% upon the six month anniversary of the grant with the remaining 50% vesting upon the one year anniversary of the grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Total stock-based compensation for the nine months ended September 30, 2021 was $1,918,651, of which $424,993 was classified as research and development expense and $1,493,658 was classified as general and administrative expense. Total stock-based &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;compensation for the nine months ended September 30, 2020 was $1,449,024, of which $551,865 was classified as research and development expense and $897,159 was classified as general and administrative expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;For the three months ended September 30, 2021, total stock-based compensation was $1,198,860, of which $215,528 was classified as research and development and $983,332 was classified as general and administrative expense. Stock-based compensation for the three months ended September 30, 2020, was $387,928, of which $153,025 was classified as research and development and $234,903 was classified as general and administrative expense.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g"
      decimals="INF"
      id="Narr_2fKv6c-MNkOS4fTpvlS39g"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g"
      decimals="INF"
      id="Narr__mOBPLGGnEOs6lumwmGmGg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_4_7_2021_X8xLB1j8lkOI3Ju5ytfjTw"
      decimals="INF"
      id="Narr_2dLGvcVtqEORyfgNDiWM0w"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">625000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_4A2X7Z08HUes-B20p8ovQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following is a summary of stock option activity under the stock option plans for the nine months ended September 30, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;millions)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Options outstanding at January&#160;1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Ran0Cu55WEO7SIeyEo9upQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 123,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less options expired/cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Options outstanding at September&#160;30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 123,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Options exercisable at September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 89,613&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.84&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="0"
      id="Tc_7YFL4cRXuUeOau145D_pTQ_7_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="2"
      id="Tc_SFCp17F6kk-4lNQJwec8AQ_7_5"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="-6"
      id="Tc_c-2FVdUQFkm4rbFhSaj8xw_7_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_7o1leu8QQ022UdhSFqdDJw_8_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">123850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="2"
      id="Tc__FAazdZ94EynoKIMh5skAA_8_5"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">9.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <snpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_ZYEYZD-R1EakB7UEWlvyTw_8_7">P9Y2M12D</snpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_bN6JvXe-UEShlFsKs3xHxw_12_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">123850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="2"
      id="Tc_Xpli6gUejkaIkIMfs6r2tg_12_5"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">9.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_pj7UKKWeGU2ZtScBn2xepw_12_7">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="-6"
      id="Tc_AxoiqKL-akuNQHDtJ02JIQ_12_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="0"
      id="Tc_5uG4UW2X4kejso8Xp6DmRw_13_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">89613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="2"
      id="Tc_WTBx9W-Fk0OjJpWl_helog_13_5"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">9.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tc_QMmXh9kkl0mAvMq732hcAw_13_7">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="-6"
      id="Tc_Pi-Nwibz4kqXMd3oGnyWOg_13_10"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw"
      decimals="0"
      id="Narr_Juykt8FDIU2ic5Pf-lDtiw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">116350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <snpx:NumberOfDirectors
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw"
      decimals="INF"
      id="Narr_77SAqEzaE06v2H1JbgirMQ"
      unitRef="Unit_Standard_director_RA5R3TwOe0i9LByRRHbWMw">6</snpx:NumberOfDirectors>
    <snpx:NumberOfEmployee
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw"
      decimals="INF"
      id="Narr_QMpNZGaVwUKw6QbTDzW2sg"
      unitRef="Unit_Standard_employee_TK-gmXNo9Eqj4Kw_3BydmQ">4</snpx:NumberOfEmployee>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_12_7_2020_To_12_7_2020_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_QAtyG63Ml0iGUPsG62eDkw"
      decimals="0"
      id="Narr_-pe2ZS2_TUmAN3H3r-ZXQw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">12575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw"
      decimals="2"
      id="Narr_Zdh6uuhWsk-t86FbJlf7Hg"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">9.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw"
      id="Narr_qkIhNz_J3EavaZLn8zVtKA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw"
      decimals="0"
      id="Narr_8ulL3smMWUSDAvxUkHF58Q"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">103775</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_snpx_DateOfGrantMember_CoXoxGX9_kGVwzm95w2HWA"
      decimals="2"
      id="Narr_bXTjTJY1zkS4ykHJ2gH74g"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_O8lsXfv060q08M33KwFJoQ"
      decimals="2"
      id="Narr_9SUe7fFIuk6QAtEV54HPmw"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_13_2021_To_1_13_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_9WmgNIy7zkuk1nx7ZlVGaA"
      decimals="0"
      id="Narr_Xl9gvn8BxEqwYOUSE8iWYw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">12575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_brWXOs9rvk-CL2mnnpvfcA"
      decimals="2"
      id="Narr_bgETK-10c0Sq7aox0NS_tA"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0nx63wQyWkygtYDUEq138Q"
      decimals="2"
      id="Narr_TdOD8gcX0E-gFHFunA9HiA"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_4_6_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_fx1ygIKoY02ITh98bpD4mQ"
      decimals="INF"
      id="Narr_jPAHnXPWrUS0r3dnS4HCDQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <snpx:NumberOfDirectors
      contextRef="Duration_4_6_2021_To_4_6_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_iOYMLdM_qUSnnsL4WR4G2g"
      decimals="INF"
      id="Narr_KTaRipjA_EOVsYbV7VA24A"
      unitRef="Unit_Standard_director_RA5R3TwOe0i9LByRRHbWMw">5</snpx:NumberOfDirectors>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_4_6_2021_To_4_6_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_iOYMLdM_qUSnnsL4WR4G2g"
      decimals="2"
      id="Narr_bfGE6HDVz0qpEFFAb0OLEA"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">9.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_4_6_2021_To_4_6_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_iOYMLdM_qUSnnsL4WR4G2g"
      id="Narr_HhHUA2DtnEqxSbwru_pUgg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw"
      decimals="4"
      id="Narr_FbxOIlI7skC81uqaZUmLDg"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw"
      id="Narr_J0BCy0_ZKUCdjbjSwv0-VQ">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw"
      decimals="3"
      id="Narr_lqp3078JRUqwCsy90EboIg"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">1.299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw"
      decimals="4"
      id="Narr_CXorPI-LHU-lgoHLT21KXg"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.0051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <snpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue
      contextRef="Duration_1_13_2021_To_1_13_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_oMkW1S0kWk-awqjOLdNYAw"
      decimals="0"
      id="Narr_Yf8-RIhXTkCaz1naVXz5Fg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1054000</snpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_GxaNy02f7U-vVY71VeBA5A"
      decimals="INF"
      id="Narr_HPoRPVSp0Uq73O-SIxNX2Q"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_sv5TfcxykECMI_R-TDkDOg"
      decimals="INF"
      id="Narr_YpfUBXW3XEOFD3xEyQC87Q"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <snpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors
      contextRef="As_Of_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_sv5TfcxykECMI_R-TDkDOg"
      decimals="INF"
      id="Narr_O8J8_49-hkWd0sjShVJFBw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">300</snpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_3_12_2021_To_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember__FUNeXcc1U2KnJsXyWj-rQ"
      decimals="2"
      id="Narr_NsphB43QMkutpl_mm-bnyw"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_3_12_2021_To_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_MbYQXmYqxEe7PlJNeR4iPA"
      decimals="2"
      id="Narr_WhWuI9S5_EKliZnQ_bLxlA"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_3_12_2021_To_3_12_2021_us-gaap_GranteeStatusAxis_snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember_us-gaap_PlanNameAxis_snpx_DirectorCompensationPolicyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_9fTB0b96S0mwgdrtIFJHkA"
      decimals="2"
      id="Narr_ZPwxgt8yLkOQOBT7KKd4wA"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_jhrqwDH5JUKGX1yjRe_zDQ"
      decimals="INF"
      id="Narr_wTcugCGtUkSRlBxZBbVMNg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">495000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_TIqQYJV7CE6L3nRKPgyfzA"
      decimals="INF"
      id="Narr_4A_NOL2wH0uocw1HE_VXGQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">425000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <snpx:NumberOfDirectors
      contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_jhrqwDH5JUKGX1yjRe_zDQ"
      decimals="INF"
      id="Narr_f92C0nRGokSlI-SOZ8q17A"
      unitRef="Unit_Standard_director_RA5R3TwOe0i9LByRRHbWMw">7</snpx:NumberOfDirectors>
    <snpx:NumberOfExecutiveDirectors
      contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_jhrqwDH5JUKGX1yjRe_zDQ"
      decimals="INF"
      id="Narr_2gILetGOvk2Kqdc_kHvsVQ"
      unitRef="Unit_Standard_director_RA5R3TwOe0i9LByRRHbWMw">2</snpx:NumberOfExecutiveDirectors>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_srt_ChiefFinancialOfficerMember_8D5SdWMw5U6irlsB96168A"
      decimals="INF"
      id="Narr_LQa-22CfL0CtUifOXgvBMg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_6QohAsIzTk-vhW1SAPewPw"
      decimals="INF"
      id="Narr_7eCKAodTak6ifm0ZrzZgEA"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <snpx:NumberOfEmployee
      contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_XOhWuqO7-UmxW3rdr5h8WQ"
      decimals="INF"
      id="Narr_A4fxN6YBuU2fopbhAJP0bA"
      unitRef="Unit_Standard_employee_TK-gmXNo9Eqj4Kw_3BydmQ">2</snpx:NumberOfEmployee>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_snpx_SixMonthAnniversaryOfGrantDateMember_-sX3SPAv7ECVADMCMnxDhg"
      decimals="2"
      id="Narr_qcUeLGzp90aKKT1ZvlDVMQ"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_13_2021_To_7_13_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_snpx_FirstAnniversaryOfGrantDateMember_ATxH9vpPDUaonf7pLjCDXw"
      decimals="2"
      id="Narr_vehzf-0K9k27cnzSn4RRdA"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_lqTTCdUJv0Gbk8pPOgt1Wg"
      decimals="0"
      id="Narr_RqB-dhIpzE-_Rps-7_aNPw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1918651</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_l191m19UVk-g-tWdcIuAvA"
      decimals="0"
      id="Narr_kJk2bmJrT0WzAV7OCSMyUA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">424993</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_ZcuRlFcZlk6RzU5e00C74w"
      decimals="0"
      id="Narr_0GjqdgxfZUaUIi5RpKR1Fg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1493658</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_0euqztFk-UWqNJ-EMYldhw"
      decimals="0"
      id="Narr_bcFeMD7P2UGgzykjwqwWQw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1449024</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_5hwgduBRaEOxiMvk-glrAA"
      decimals="0"
      id="Narr_VUDNrQQTl0WnY5HMO7CDZg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">551865</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_ghqdfvGBdUyTpIbQr-dO0g"
      decimals="0"
      id="Narr_vWp3M2lfL0qFPak66QD_uQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">897159</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_hF3BfbuxTkaBt64WDXedaQ"
      decimals="0"
      id="Narr_VZqsv4HaNkK6v0msYDM1WQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1198860</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_sQgKmUmCo0SOmBKWdTYsrw"
      decimals="0"
      id="Narr_4ZjOqAloe0-QS9JCmPb4sQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">215528</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_FYkHNg0eDkqsEfsyfLe89Q"
      decimals="0"
      id="Narr_LiKwztm-F0i_RjlgM1Ndxg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">983332</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_eXAu7kGsKUqqwxXMjOEi5Q"
      decimals="0"
      id="Narr_H6qQBygVZk27DVVXdnDs_g"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">387928</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_9otCxOcf30aqj9YleMKvAQ"
      decimals="0"
      id="Narr_mEOiVcOHak6RqT0YC3gVoQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">153025</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_snpx_EquityIncentivePlan2020Member_QhnfmLSW0k2hAwylpTMIlg"
      decimals="0"
      id="Narr_nGmlyGIWf0ajQgJGGSV_4g"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">234903</us-gaap:AllocatedShareBasedCompensationExpense>
    <snpx:StockOptionNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_28JAfnXPfkqUft-sx6Xx_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 8 &#x2013; Common Stock Warrants:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrant Amendment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Beginning on September&#160;28, 2020, Neurotrope entered into separate warrant amendment agreements with certain existing holders of its warrants to purchase shares of the Neurotrope&#x2019;s common stock. As of October&#160;26, 2020, holders of warrants to purchase 978,077 shares of Neurotrope Common Stock had entered into warrant amendment agreements, including holders of Series&#160;E Warrants to purchase 39,535 shares of common stock, Series&#160;F Warrants to purchase 155,917 shares of common stock, Series&#160;G Warrants to purchase 227,163 shares of common stock and Series&#160;H Warrants to purchase 555,462 shares of Neurotrope&#x2019;s Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Pursuant to the terms of the warrant amendment agreements, Neurotrope and the holders agreed to the following provisions with respect to the Company&#x2019;s warrants:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The initial exercise price of the Spin-Off Warrants was determined as follows for each of the Original Warrants (all of which expire on December&#160;7, 2025):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;(i)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;for the Neurotrope Series&#160;E Warrants (now the Company&#x2019;s Series&#160;A Warrants), by dividing $250&#160;million by 1,257,604 shares of common stock of the Spin-Off Company outstanding immediately after the Spin-Off. This resulted in an exercise price of $198.80 per warrant for 39,535 Series&#160;A Warrants;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;(ii)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;for the Neurotrope Series&#160;F Warrants (now the Company&#x2019;s Series&#160;B Warrants), by dividing $100&#160;million by 1,257,604 of shares of common stock of the Spin-Off Company outstanding immediately after the Spin-Off. This resulted in an exercise price of $79.52 per warrant for 155,917 Series&#160;B Warrants;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;(iii)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;for the Neurotrope Series&#160;G Warrants (now the Company&#x2019;s Series&#160;C Warrants), by dividing $50&#160;million by 1,257,604 shares of common stock of the Spin-Off Company outstanding immediately after the Spin-Off. This resulted in an exercise price of $39.76 per warrant for 227,163 Series&#160;C Warrants; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;(iv)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;for the Neurotrope Series&#160;H Warrants (now the Company&#x2019;s Series&#160;D Warrants), by dividing $20&#160;million by 1,257,604 of shares of common stock of the Spin-Off Company outstanding immediately after the Spin-Off. This resulted in an exercise price of $15.92 per warrant for 555,462 Series&#160;D Warrants.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company used the Black-Scholes valuation model to calculate the warrant amendment expense. The fair value of the warrants amended in connection with the Mergers was estimated at the date of the merger using the following weighted average assumptions: Dividend yield 0%; Expected terms ranging from 0.2 to 10 years; volatility based upon a blend of the Parent company&#x2019;s and guideline company historical volatility ranging from 31.75% to 112.3%; and Risk-free interest rates ranging from 0.11% to 0.42%. The total expense recorded in the third quarter of 2020 was $1.7 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Deemed Distribution&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On December&#160;7, 2020, pursuant to the Merger , the Company issued a total of 978,077 warrants to investors that elected to amend their existing Neurotrope warrants (see above) and a total of 52,983 shares of Common Stock to those Neurotrope shareholders not electing to amend their existing warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The distribution was treated as a deemed dividend, which increased the loss available to common stockholders in the calculation of loss per share by approximately $2.43 million in the fourth quarter of 2020. The Company used the Black-Scholes valuation model to calculate the total charge to earnings per share. The fair value of the warrants and Common Stock issued in connection with the deemed distribution was estimated at the date of the Spin-Off using the following assumptions: Dividend yield 0%; Expected term of warrants 5 years; volatility based upon a blend of Neurotrope&#x2019;s and guideline company historical volatility of 115.0%; and a Risk-free interest rate of 0.40%.&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Outstanding Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;As of September 30, 2021, the Company had warrants outstanding consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&#160;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants outstanding January&#160;1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 978,077&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,908,751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,038,898)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants outstanding September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,847,930&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Pursuant to the Offering, the Company issued to investors Series&#160;E Warrants to purchase 2,333,908 shares of Common Stock, with an exercise price of $8.51 per share (subject to adjustment), for a period of twelve months from the date of an effective registration statement, Series&#160;F Warrants to purchase up to an aggregate of 2,567,299 shares of Common stock, with an exercise price of $6.90 per share (subject to adjustment), for a period of five years from the date of issuance and pre-funded Warrants to purchase 83,334 shares of Common Stock, with an exercise price of $0.01 per share (subject to adjustment), for a period of five years from the date of issuance. Of the total Series&#160;F Warrants, 233,391 were issued pursuant to the Company&#x2019;s placement agent agreements for the private placement (See Note 6 &#x2013; &#x201c;January&#160;2021 Private Placement&#x201d; above). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Pursuant to the June Offering, the Company issued to investors Series G Warrants to purchase up to an aggregate of 1,653,281 shares of Common stock, with an exercise price of $8.51 per share (subject to adjustment), for a period of five years from the date of issuance and pre-funded June Warrants to purchase 66,251 shares of Common Stock, with an exercise price of $0.01 per share (subject to customary adjustment for stock splits, dividends, other), for a period of five years from the date of issuance. In addition, 152,378 warrants were issued pursuant to the Company&#x2019;s Placement Agent Agreement for the private placement with an exercise price of $7.547 per share (See Note 6 &#x2013; &#x201c;June 2021 Private Placement&#x201d; above).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On February 16, 2021, pursuant to its advisory agreements, the Company issued warrants to purchase 35,000 share of Common Stock, with an exercise price of $11.46 per share, for a period of five years from the issuance date. On April 1, 2021, the Company issued warrants to purchase 7,000 shares of Common Stock, with an exercise price of $9.76 per share, for a period of five years from the issuance date. On July 1, 2021, the Company issued warrants to purchase 10,300 shares of Common Stock, with an exercise price of $9.30 per share, for a period of five years from the issuance date. The Company used the Black-Scholes valuation model to calculate the value of these warrants issued to advisors during the nine months ended September 30, 2021. The fair value of the warrants was estimated at the date of issuance using the following weighted average assumptions: Dividend yield 0%; Expected term five years; volatility based upon a blend of the Parent company&#x2019;s and guideline company historical volatility 129.4%; and Risk-free interest rate of 0.68%. The total expense recorded during the nine month period was approximately $482,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:10pt 0pt 0pt 0pt;"&gt;During the three month period ended September 30, 2021, five warrant holders exercised 79,169 Series E Warrants to purchase 79,169 shares of Common Stock at $8.51 per warrant and three warrant holders exercised 18,335 Series F Warrants to purchase 18,335 shares of Common Stock at $6.90 per warrant. Total proceeds from these warrant exercises was approximately $800,000. During the nine month period ended September 30, 2021, 16 warrant holders exercised 754,170 Series E Warrants to purchase 754,170 shares of Common Stock at $8.51 per warrant and 14 warrant holders exercised 284,728 Series F Warrants to purchase 284,728 shares of Common Stock at $6.90 per warrant. Total proceeds from these warrant exercises was approximately $8.4 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:10pt 0pt 0pt 0pt;"&gt;Subsequent to period end, during October and November, 2021, 16 warrant holders exercised 425,170 Series E Warrants to purchase 425,170 shares of Common Stock at $8.51 per share, nine warrant holders exercised 47,335 Series F Warrants to purchase 47,335 shares of Common Stock at $6.90 per share, and one holder exercised 65,000 Series G Warrants to purchase 65,000 shares of Common Stock at $8.51 per share. Total cash proceeds from these warrant exercises was approximately $4.5 million.&lt;/p&gt;</snpx:StockOptionNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_10_26_2020_Wvo7So2luU-dbvH6dz-R9g"
      decimals="INF"
      id="Narr_e5AxAPUq3UmNl2HM-QjBVQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">978077</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hBfQpmlzBEiZWBUIw5oRgw"
      decimals="INF"
      id="Narr_bkH3hpSNIEWjEsoBu9RUGA"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">39535</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_c7G1rxSzNE2F1m4rqz2OEA"
      decimals="INF"
      id="Narr_-Y3DCWYlbEaM_gfGM3WRbw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">155917</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_tkPkOaqtJUqYc0v8c4QvAg"
      decimals="INF"
      id="Narr_jqNnVahEbUGM280871AC3g"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">227163</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_10_26_2020_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesHWarrantsMember_Po7eMRWnyk627VgjFVaEXg"
      decimals="INF"
      id="Narr_lC9uIxu0JESc_1iXJcBb9Q"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">555462</us-gaap:ClassOfWarrantOrRightOutstanding>
    <snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q"
      decimals="-6"
      id="Narr_zPeyEcpPbUKwQhHZfxxnGQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">250000000</snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_aMs2yxkpWEe7tYMJ_xTFLQ"
      decimals="INF"
      id="Narr_M8pg75I3TUyDFIl_npOSNQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1257604</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <snpx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesWarrantsMember_55AWN-0IQEiKtuL0SJcHtA"
      decimals="INF"
      id="Narr_TLRPllRsmkaTVDtbiLg7Bw"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">198.80</snpx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesWarrantsMember_55AWN-0IQEiKtuL0SJcHtA"
      decimals="INF"
      id="Narr_StHVF6hSKE2rSakSh8zuuw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">39535</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_yUgO0gWhX0Kj3WzQ05UBjA"
      decimals="-6"
      id="Narr__HhtoeJ8C02rtHvfcMWRPA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">100000000</snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_gbBWD2FtDki4KkvEusVG5A"
      decimals="INF"
      id="Narr_XUL4QB1HI0yHlcPxMBtIPQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1257604</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <snpx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesBWarrantsMember_7SQ3AypUt0SSMTahwvnMAA"
      decimals="INF"
      id="Narr_M8FNYinzSUCL44afoc7gqQ"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">79.52</snpx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesBWarrantsMember_7SQ3AypUt0SSMTahwvnMAA"
      decimals="INF"
      id="Narr_L_nx0ArEpU2FpYKo85Bp-A"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">155917</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_2k34O0Id4kWZX644U9EfIQ"
      decimals="-6"
      id="Narr__rz5yAqKTUCQEvNc29IrZQ"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">50000000</snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Bv7Emv5esUO_DuRCzz0CPw"
      decimals="INF"
      id="Narr_e9yIS9UXH0-tMcZN35KfuA"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1257604</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <snpx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesCWarrantsMember_z_WS3P03W02KA988MbJQRw"
      decimals="INF"
      id="Narr_sCwfFq3Wo0i5RStf5N65iw"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">39.76</snpx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesCWarrantsMember_z_WS3P03W02KA988MbJQRw"
      decimals="INF"
      id="Narr_P08LrvPOlECiCCQw-STGPw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">227163</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesHWarrantsMember_t0GYiy1420idJAGM8em5Jw"
      decimals="-6"
      id="Narr_0vtyreXRSkmmM0COgbayuw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">20000000</snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesHWarrantsMember_6isVxzRL6UqO5BOyR_DEnQ"
      decimals="INF"
      id="Narr_B-BuFYAFL0miv_41T1Qt_Q"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1257604</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <snpx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesDWarrantsMember_TqviIe44M0KRUuCnfF8Jsg"
      decimals="INF"
      id="Narr_gbVJms2YBUOXYp5vq01zVg"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">15.92</snpx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesDWarrantsMember_TqviIe44M0KRUuCnfF8Jsg"
      decimals="INF"
      id="Narr_3ngjUP7Xbkyj7Ne0cqx8WQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">555462</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <snpx:SpinOffRatio
      contextRef="As_Of_9_30_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_WrGK0uDCmUGfS8ag_ejX5w"
      decimals="INF"
      id="Narr_6rM8f12GfEqKo44bJhDD9Q"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0</snpx:SpinOffRatio>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_B-Ol5sPKMEmSFSQmzxOz7Q"
      id="Narr_tUm0N__pEkW3gKLDpDZ8RA">P0Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_C14DO597P0mvWWCy-BLV8g"
      id="Narr_RHzM-kX_t0uzLKmHZ6xIAg">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <snpx:SpinOffRatio
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_aqF2KklEf0u18kWTm7BHtQ"
      decimals="INF"
      id="Narr_0cuSNSjkdk68jsA9bMNHgQ"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">31.75</snpx:SpinOffRatio>
    <snpx:SpinOffRatio
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_IAPUN0sCQ0SOUwKfGoet8Q"
      decimals="INF"
      id="Narr_cJ2y8Ep_X0aHdhvpW5SdgA"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">112.3</snpx:SpinOffRatio>
    <snpx:SpinOffRatio
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_aqSGqF3d9EOAW-vdRB2T0w"
      decimals="2"
      id="Narr_vBFQd_p41UK1BOsAHnKsCw"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.11</snpx:SpinOffRatio>
    <snpx:SpinOffRatio
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_7ynEJUOgpEaTJWjy14CbxQ"
      decimals="2"
      id="Narr_4wzyLSdAoU6KSlZsT8DvJw"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.42</snpx:SpinOffRatio>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q"
      decimals="-5"
      id="Narr_AjEmOe2qJkqB1XWnrQdOiw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1700000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g"
      decimals="INF"
      id="Narr_QdVgTl0vo0yG_OL_6eRY7g"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">978077</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g"
      decimals="INF"
      id="Narr_osxEMCeBtkmBHP2Q9bIx0g"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">52983</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants
      contextRef="As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g"
      decimals="-4"
      id="Narr_p8CLJgVVxUGgdYTuYtcrMg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">2430000</snpx:ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants>
    <snpx:SpinOffRatio
      contextRef="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_AlB4qWeQFkGYL40ag-oXkg"
      decimals="INF"
      id="Narr_-m6XCZJWZkaD8qv9Di0lSQ"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0</snpx:SpinOffRatio>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eLQU0iW2-kKPmLdZRgP3_A"
      id="Narr_ZUUr0KE0jk6DvNzxC5XvsA">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <snpx:SpinOffRatio
      contextRef="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_NsMIo03fS0GvupLoZPxqNQ"
      decimals="1"
      id="Narr_6S3IVcdDWkKXmsWyejEGaw"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">115.0</snpx:SpinOffRatio>
    <snpx:SpinOffRatio
      contextRef="As_Of_12_7_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_s2nrkv1GlUOqLv_ow-biXw"
      decimals="2"
      id="Narr_bfMubOy1hkaIX-XHMzpwMQ"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">0.40</snpx:SpinOffRatio>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_Jn3x5JA2Lk68XsR7wQT93Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&#160;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants outstanding January&#160;1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 978,077&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,908,751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,038,898)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants outstanding September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,847,930&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ"
      decimals="INF"
      id="Tc_4NleRKmQI06NI7gc-WAFWA_3_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">978077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="INF"
      id="Tc_EfWVvYl1uEK0A8cNtWBRKg_4_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">6908751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="INF"
      id="Tc_7ScGxa1FEUycvMM4yjqITQ_5_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1038898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ"
      decimals="INF"
      id="Tc_DT7ITOMgnECgapDnGBIzig_6_2"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">6847930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_CU6eHywSfU2jd_Ogr83-kg"
      decimals="INF"
      id="Narr_RJT4wFQVZ0ejPMXGU_1EgQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">2333908</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_CU6eHywSfU2jd_Ogr83-kg"
      decimals="2"
      id="Narr_Uo_rqLd6fUaXSjAyk-I6hA"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">8.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_CU6eHywSfU2jd_Ogr83-kg"
      id="Narr_wutJo2SOD0690kWBoxGAtA">P12M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_SDRsv452YEy1QbPpr3-H7A"
      decimals="INF"
      id="Narr_ez9YcAaef0Sa61sF-377pA"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">2567299</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_SDRsv452YEy1QbPpr3-H7A"
      decimals="2"
      id="Narr_dUH6lACA2kWgwtSdik1uJw"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">6.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_SDRsv452YEy1QbPpr3-H7A"
      id="Narr_1IfPwft3H0WfbGygbaVN8w">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_1_31_2021_e--_NbHbEE6MXeRdEtUWUQ"
      decimals="INF"
      id="Narr_f0WYTwvJC0eSUVWDjLKMsw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">83334</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_31_2021_e--_NbHbEE6MXeRdEtUWUQ"
      decimals="2"
      id="Narr_Ls89nvBRhEiajJ4yHrvx-Q"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2021_e--_NbHbEE6MXeRdEtUWUQ"
      id="Narr_X4aXLi0OI0CsovVbFn8e6A">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_1_31_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_SDRsv452YEy1QbPpr3-H7A"
      decimals="INF"
      id="Narr_7rSCOJIhmU6eGEPyKqrOMQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">233391</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Fr0ZwcPdYUak8BJTwsJziA"
      decimals="INF"
      id="Narr_i-Wh0u0_U0irWIbB344Qzg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">1653281</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Fr0ZwcPdYUak8BJTwsJziA"
      decimals="2"
      id="Narr__iOZQ7cobkGC0kONyDjBIA"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">8.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_6_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Fr0ZwcPdYUak8BJTwsJziA"
      id="Narr_GIGQBfTXE0ejO5nd2YGZxQ">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Fr0ZwcPdYUak8BJTwsJziA"
      decimals="INF"
      id="Narr_dwDHetMWQEeG6wp3nSKMAA"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">66251</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2021_Xii_2FmPcky3sXIraY0ypg"
      decimals="2"
      id="Narr_8xWtvSIOck-t4N-EISUBxw"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_6_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_Fr0ZwcPdYUak8BJTwsJziA"
      id="Narr_TeNPOLN6jE2hgUFEgak6XQ">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_snpx_PlacementAgentAgreementMember_iBkmenKfkESMsfPkSD7zrQ"
      decimals="INF"
      id="Narr_dcKM6J9W40ust4y2JN87Bg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">152378</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_snpx_PlacementAgentAgreementMember_iBkmenKfkESMsfPkSD7zrQ"
      decimals="3"
      id="Narr_3BpLmnChE0uyhNx4FLosKQ"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">7.547</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_5eSvOe54PkCVmjdVxgbZig"
      decimals="INF"
      id="Narr_r603chrdtEuZIGABDH0kCA"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">35000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_5eSvOe54PkCVmjdVxgbZig"
      decimals="2"
      id="Narr_1HvPYPhY2EGmDRh3kfGqPw"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">11.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_5eSvOe54PkCVmjdVxgbZig"
      id="Narr_zU7z9p92b0Sjwpp5gjHxdA">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember__pHwfWJFzkixGuEnVWDzJA"
      decimals="0"
      id="Narr_fxEJek2B_kWL4JjZYUBH2A"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">7000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_4_1_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember__pHwfWJFzkixGuEnVWDzJA"
      decimals="2"
      id="Narr_NXPQV1bL50WD3-g9epzLYQ"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">9.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_2_16_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_5eSvOe54PkCVmjdVxgbZig"
      id="Narr_y99ltBQ0l0WCfIEbftN7Yg">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_FH717EVLtkqn-fpPWhn4rA"
      decimals="0"
      id="Narr_skwGVwf8I0GMVTt8EPUtSg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">10300</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_FH717EVLtkqn-fpPWhn4rA"
      decimals="2"
      id="Narr_XBQkF_j05EudGYA7aT3DKg"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">9.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_7_1_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_FH717EVLtkqn-fpPWhn4rA"
      id="Narr_R-NXyI0cYUCuyZtRgNjaeA">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_2_16_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_x7uB4f4XkkixVNeVpg4H_w"
      decimals="0"
      id="Narr_sKjKoKc560-w5FFX47ZdSw"
      unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_30_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_cABB2dwDnkidrh1FDqutMA"
      decimals="INF"
      id="Narr_kZjrN-YFjEiWiCRH3z_ejA"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_2_16_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_SVTnUQyCqkSlwAQiGiSQ2w"
      decimals="1"
      id="Narr_6hiqwLwef0WC37jisxpScw"
      unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g">129.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_2_16_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_wMyE8rhAOUa-rFk2SZC6uQ"
      decimals="2"
      id="Narr_5qFU0LD_CkGKR07Sw7V4-A"
      unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g">0.68</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_snpx_AdvisoryAgreementsMember_lvIlGvc4GUestVJZO6CW1Q"
      decimals="INF"
      id="Narr_4c3LOaYpIE6F8YMnqWuDTw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">482000</us-gaap:FairValueAdjustmentOfWarrants>
    <snpx:NumberOfWarrantHoldersWhoExercisedWarrants
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_NgyqTk38w0WSX-vTVG_Qfw"
      decimals="INF"
      id="Narr_iEXkKcpCqke-j3DORHLteg"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">5</snpx:NumberOfWarrantHoldersWhoExercisedWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q"
      decimals="INF"
      id="Narr_fMguviqZT0-vf1vNCpbacg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">79169</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q"
      decimals="INF"
      id="Narr_YQzxFfn_zUmxCJ_90cH1NQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">79169</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q"
      decimals="2"
      id="Narr__wq73PVzQE62OSBvsbbFAQ"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">8.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <snpx:NumberOfWarrantHoldersWhoExercisedWarrants
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember__q6Kouwx7ka5jQwWeyinOg"
      decimals="INF"
      id="Narr_M3n40ykw70W9Flbdzd6q_A"
      unitRef="Unit_Standard_pure_W3ByCsfUeUOP3zYnQ97W6g">3</snpx:NumberOfWarrantHoldersWhoExercisedWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_yUgO0gWhX0Kj3WzQ05UBjA"
      decimals="INF"
      id="Narr_iVa370gQIkWuVEo_VkrXuQ"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">18335</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_yUgO0gWhX0Kj3WzQ05UBjA"
      decimals="INF"
      id="Narr_b4Ih_dFL9EaKwGAs64WgQg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">18335</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_yUgO0gWhX0Kj3WzQ05UBjA"
      decimals="2"
      id="Narr_o1ns_XTOyE-4yUtZ-Zuhfw"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">6.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw"
      decimals="0"
      id="Narr_dhWulTzvgUmjlIqZEY6Byw"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">800000</us-gaap:ProceedsFromWarrantExercises>
    <snpx:NumberOfWarrantHoldersWhoExercisedWarrants
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_aMs2yxkpWEe7tYMJ_xTFLQ"
      decimals="INF"
      id="Narr_8i5NuZxV5EuZMQf9QSW_Ug"
      unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g">16</snpx:NumberOfWarrantHoldersWhoExercisedWarrants>
    <snpx:ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q"
      decimals="INF"
      id="Narr_p0TxDU6s70KA7HU5-bRNKg"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">754170</snpx:ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights>
    <snpx:ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q"
      decimals="INF"
      id="Narr_-rcQDgpaRk-u23RRHaYXsw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">754170</snpx:ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_hgjaH9GgGUCJ0wyObHv38Q"
      decimals="2"
      id="Narr_w7Gs9CUw0Uew9GD9_o8p4w"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">8.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <snpx:NumberOfWarrantHoldersWhoExercisedWarrants
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_gbBWD2FtDki4KkvEusVG5A"
      decimals="INF"
      id="Narr_1ygcJ4t7wEKZMRD7Ciq6qA"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">14</snpx:NumberOfWarrantHoldersWhoExercisedWarrants>
    <snpx:ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_yUgO0gWhX0Kj3WzQ05UBjA"
      decimals="INF"
      id="Narr_1G_BwRIM_kKGNNa74zD5Pw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">284728</snpx:ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights>
    <snpx:NumberOfWarrantHoldersWhoExercisedWarrants
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_gbBWD2FtDki4KkvEusVG5A"
      decimals="INF"
      id="Narr_yanEgVCKtESXProJ0mwspQ"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">284728</snpx:NumberOfWarrantHoldersWhoExercisedWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_yUgO0gWhX0Kj3WzQ05UBjA"
      decimals="2"
      id="Narr_EQYtLGQh60OWcBLf3AbYWA"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">6.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="-5"
      id="Narr_vJFU858LdEeYcpWu1AAhUg"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">8400000</us-gaap:ProceedsFromWarrantExercises>
    <snpx:NumberOfWarrantHoldersWhoExercisedWarrants
      contextRef="Duration_10_1_2021_To_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_lR04OAC-tUOnEiZFv4wu8A"
      decimals="INF"
      id="Narr_Ntfz1UBbN06mP1PGm8iPLg"
      unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g">16</snpx:NumberOfWarrantHoldersWhoExercisedWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Mqocl8Q9OUW-zNTHh7tZ4Q"
      decimals="INF"
      id="Narr_SjnLJD1Ha0SrBDNP93aLHw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">425170</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Mqocl8Q9OUW-zNTHh7tZ4Q"
      decimals="INF"
      id="Narr_nU6mNp78oUeSDLoywp7q0A"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">425170</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesEWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Mqocl8Q9OUW-zNTHh7tZ4Q"
      decimals="2"
      id="Narr_P3KuCAbyGk6apP4d_60VZw"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">8.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <snpx:NumberOfWarrantHoldersWhoExercisedWarrants
      contextRef="Duration_10_1_2021_To_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Cr2IzRTXakm82Stu4mohyg"
      decimals="INF"
      id="Narr_IVVzUwRQr0yARS0OqKrEhQ"
      unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g">9</snpx:NumberOfWarrantHoldersWhoExercisedWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_DeGjeBcBwEGnc13gbozhlA"
      decimals="INF"
      id="Narr_QNKjR1vdk0S2i2vKnp1-Tw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">47335</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_DeGjeBcBwEGnc13gbozhlA"
      decimals="INF"
      id="Narr_12sTMK7qdEyuhqd2k62hkw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">47335</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesFWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_DeGjeBcBwEGnc13gbozhlA"
      decimals="2"
      id="Narr_R2LzWv7JfUeWjM_f6le02Q"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">6.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <snpx:NumberOfWarrantHoldersWhoExercisedWarrants
      contextRef="Duration_10_1_2021_To_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kLgOmbRun06NqMMcX7EhDg"
      decimals="INF"
      id="Narr_49Ru4fu250ykfcyaZctxhg"
      unitRef="Unit_Standard_item_vM2k1N4WBkyzN8Y7o7Ih_g">1</snpx:NumberOfWarrantHoldersWhoExercisedWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EUnVc5n1yE-8V5lSC_clxw"
      decimals="INF"
      id="Narr_XXaCwSIIiEGwJt5K0mvWOw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">65000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EUnVc5n1yE-8V5lSC_clxw"
      decimals="INF"
      id="Narr_v9XO3CES0kKw7OHPtcCWxw"
      unitRef="Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ">65000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_30_2021_us-gaap_ClassOfWarrantOrRightAxis_snpx_SeriesGWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EUnVc5n1yE-8V5lSC_clxw"
      decimals="2"
      id="Narr_TGCm7tHgmkCbMrxHy9SyMA"
      unitRef="Unit_Divide_USD_shares_4vzuLJCgfUe-nFdxGnQl3A">8.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_10_1_2021_To_11_30_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eDY3684nJE-p7S0A8UmC-g"
      decimals="-5"
      id="Narr_kLe08QzVZkuiQI-HhLNR5w"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">4500000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_8UyxllxUwUOnN-cRvJ77PQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 9 - Parent Company Investment&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The components of the net transfers from parent for the three and nine months ended September 30, 2021 and 2020 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;months&#160;ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock based compensation from Parent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 387,927&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Consultant compensation paid with Parent equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 233,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Parent contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 621,208&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine&#160;months&#160;ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock based compensation from Parent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,449,023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Consultant compensation paid with Parent equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 500,740&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Parent contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,519,988&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,469,751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock>
    <us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Group_eRUu8wFrPkSg5tqFa41SDw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;months&#160;ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock based compensation from Parent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 387,927&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Consultant compensation paid with Parent equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 233,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Parent contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 621,208&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine&#160;months&#160;ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock based compensation from Parent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,449,023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Consultant compensation paid with Parent equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 500,740&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Parent contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,519,988&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,469,751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock>
    <snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation
      contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw"
      decimals="0"
      id="Tc_wbYiiO2WbkSRh1Rd7V0HIQ_4_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation>
    <snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation
      contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q"
      decimals="0"
      id="Tc_257GytQpq0KQtjdOs1YGCg_4_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">387927</snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold
      contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw"
      decimals="0"
      id="Tc_4KhyV-Q74EmrCh3vA-f8CA_5_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold
      contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q"
      decimals="0"
      id="Tc_zKq43i8h60OuC1IgiqTaAQ_5_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">233281</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <snpx:ContributionsFromParent
      contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw"
      decimals="0"
      id="Tc_o0PRQlpCeE6OEt-s8GNMXQ_6_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:ContributionsFromParent>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw"
      decimals="0"
      id="Tc_ePpivtDIGEqRqvxUmugEpg_7_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_Q32vffaEN0-ppVlZ1pCs6Q"
      decimals="0"
      id="Tc_xJWi-EyAoEius7PSlm7jvg_7_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">621208</us-gaap:LaborAndRelatedExpense>
    <snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_eY4mF6iPh0aih1mgBE5lag_4_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation>
    <snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_2rFtFSL0XEmNrAFT5GC6-Q_4_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">1449023</snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_oDbjrR0OUkabj18HDq_vpQ_5_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_OITdzKRRnE6931-ATDpcsQ_5_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">500740</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <snpx:ContributionsFromParent
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_bGX9fXW47kuTiXl7D2qAmA_6_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</snpx:ContributionsFromParent>
    <snpx:ContributionsFromParent
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_atcVtHA-ckex8I6biXAkVg_6_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">16519988</snpx:ContributionsFromParent>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      decimals="0"
      id="Tc_Lpq9sD4n7kSaA12RUkjQ4w_7_3"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">0</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_DJy4PCOZikykbV8rWTkK5w"
      decimals="0"
      id="Tc_TlRTyd71lkq0_bNgGxVmfA_7_6"
      unitRef="Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A">18469751</us-gaap:LaborAndRelatedExpense>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw"
      id="Tb_A9FOqOZp0kC-JpJuYyqkBA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Note&#160;10&#160;&#x2013; Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Refer to Notes 1, 5, 6, 7 and 8 for disclosure of applicable subsequent events.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342568833368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Synaptogenix, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1585656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1185 Avenue of the Americas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">3rd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">242-0005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,674,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001571934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SNPX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342655701256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,294,645<span></span>
</td>
<td class="nump">$ 5,795,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,045,512<span></span>
</td>
<td class="nump">806,289<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">32,340,157<span></span>
</td>
<td class="nump">6,728,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="nump">18,485<span></span>
</td>
<td class="nump">22,212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">32,358,642<span></span>
</td>
<td class="nump">6,751,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">935,376<span></span>
</td>
<td class="nump">1,260,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">71,953<span></span>
</td>
<td class="nump">352,154<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">1,007,329<span></span>
</td>
<td class="nump">1,612,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - 150,000,000 shares authorized as of September 30, 2021, $0.0001 par value; 6,136,967 shares issued and outstanding as of September 30, 2021 and 1,257,579 shares as of December 31, 2020</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">41,256,323<span></span>
</td>
<td class="nump">6,668,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(9,905,625)<span></span>
</td>
<td class="num">(1,530,473)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">31,351,313<span></span>
</td>
<td class="nump">5,138,512<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 32,358,642<span></span>
</td>
<td class="nump">$ 6,751,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342573949592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,136,967<span></span>
</td>
<td class="nump">1,257,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">6,136,967<span></span>
</td>
<td class="nump">1,257,579<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342569610968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 836,716<span></span>
</td>
<td class="nump">$ 563,317<span></span>
</td>
<td class="nump">$ 2,974,776<span></span>
</td>
<td class="nump">$ 1,556,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,092,662<span></span>
</td>
<td class="nump">2,013,089<span></span>
</td>
<td class="nump">5,404,968<span></span>
</td>
<td class="nump">6,635,757<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">2,929,378<span></span>
</td>
<td class="nump">2,576,406<span></span>
</td>
<td class="nump">8,379,744<span></span>
</td>
<td class="nump">8,192,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_WarrantAmendmentExpense', window );">Warrant amendment expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,700,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">2,445<span></span>
</td>
<td class="nump">6,797<span></span>
</td>
<td class="nump">4,592<span></span>
</td>
<td class="nump">153,305<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="nump">2,926,933<span></span>
</td>
<td class="nump">4,269,609<span></span>
</td>
<td class="nump">8,375,152<span></span>
</td>
<td class="nump">9,739,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 2,926,933<span></span>
</td>
<td class="nump">$ 4,269,609<span></span>
</td>
<td class="nump">$ 8,375,152<span></span>
</td>
<td class="nump">$ 9,739,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>PER SHARE DATA:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per common share</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per common share</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding</a></td>
<td class="nump">6,196,600<span></span>
</td>
<td class="nump">4,755,100<span></span>
</td>
<td class="nump">4,420,200<span></span>
</td>
<td class="nump">4,274,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding</a></td>
<td class="nump">6,196,600<span></span>
</td>
<td class="nump">4,755,100<span></span>
</td>
<td class="nump">4,420,200<span></span>
</td>
<td class="nump">4,274,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_WarrantAmendmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant amendment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_WarrantAmendmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342648419288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Changes in Shareholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Parent Company Investment.</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 17,418,765<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17,418,765<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NetChangeInInvestment', window );">Net change in Parent company investment</a></td>
<td class="nump">16,519,988<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,519,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Parent company stock based compensation</a></td>
<td class="nump">1,449,023<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,449,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Consulting services paid by issuance of Parent company common stock</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_WarrantsIssuedDuringPeriodValueIssuedForServices', window );">Consulting services paid by issuance of Parent company common stock warrants</a></td>
<td class="nump">380,740<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">380,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_WarrantAmendmentExpense', window );">Warrant amendment expense</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,739,079)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,739,079)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">29,797,838<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,797,838<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NetChangeInInvestment', window );">Net change in Parent company investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Parent company stock based compensation</a></td>
<td class="nump">387,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">387,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Consulting services paid by issuance of Parent company common stock</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_WarrantsIssuedDuringPeriodValueIssuedForServices', window );">Consulting services paid by issuance of Parent company common stock warrants</a></td>
<td class="nump">113,281<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">113,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_WarrantAmendmentExpense', window );">Warrant amendment expense</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,269,609)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,269,609)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,668,859<span></span>
</td>
<td class="num">(1,530,473)<span></span>
</td>
<td class="nump">5,138,512<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257,579<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Parent company stock based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,918,651<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,918,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,382,412<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,382,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_StockIssuedDuringPeriodSharesWarrantExercises', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,038,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_WarrantsIssuedDuringPeriodValueIssuedForServices', window );">Consulting services paid by issuance of Parent company common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,657<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices', window );">Consulting services paid by issuance of Parent company common stock warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Reverse stock split rounding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(1,529)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Shares issued for reverse stock split rounding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(345)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants for consulting fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">481,496<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">481,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Private placement of common stock and warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 384<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">23,783,777<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,784,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Private placement of common stock and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,837,580<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,375,152)<span></span>
</td>
<td class="num">(8,375,152)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">41,256,323<span></span>
</td>
<td class="num">(9,905,625)<span></span>
</td>
<td class="nump">31,351,313<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,136,967<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 604<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">39,168,084<span></span>
</td>
<td class="num">(6,978,692)<span></span>
</td>
<td class="nump">32,189,996<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,038,798<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Parent company stock based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,198,860<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,198,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">800,230<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">800,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_StockIssuedDuringPeriodSharesWarrantExercises', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,504<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_WarrantsIssuedDuringPeriodValueIssuedForServices', window );">Consulting services paid by issuance of Parent company common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,501<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices', window );">Consulting services paid by issuance of Parent company common stock warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">665<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants for consulting fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">84,648<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,926,933)<span></span>
</td>
<td class="num">(2,926,933)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 41,256,323<span></span>
</td>
<td class="num">$ (9,905,625)<span></span>
</td>
<td class="nump">$ 31,351,313<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,136,967<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NetChangeInInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investment in equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NetChangeInInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_StockIssuedDuringPeriodSharesWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued during the current period as a result of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_StockIssuedDuringPeriodSharesWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_WarrantAmendmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant amendment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_WarrantAmendmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued for consulting service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_WarrantsIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Values of warrants issued for consulting service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_WarrantsIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342569003992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOW USED IN OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,926,933)<span></span>
</td>
<td class="num">$ (4,269,609)<span></span>
</td>
<td class="num">$ (8,375,152)<span></span>
</td>
<td class="num">$ (9,739,079)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation', window );">Parent company stock based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">387,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,449,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,918,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Consulting services paid by issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_IssuanceOfStockAndWarrantsForServices', window );">Consulting services paid by issuance of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock', window );">Consulting services paid by issuance of Parent company common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants', window );">Consulting services paid by issuance of Parent company common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_WarrantAmendmentExpense', window );">Warrant amendment expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,727<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_IncreaseDecreaseInGrantReceivableCurrent', window );">Decrease (Increase) in grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,445<span></span>
</td>
<td class="num">(861,852)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Increase in prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(239,223)<span></span>
</td>
<td class="num">(770,609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">(Decrease) increase in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(324,959)<span></span>
</td>
<td class="nump">777,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">(Decrease) increase in accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(280,200)<span></span>
</td>
<td class="nump">44,184<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709,594<span></span>
</td>
<td class="nump">2,842,328<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,665,558)<span></span>
</td>
<td class="num">(6,896,751)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS USED IN INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,413)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,413)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Private placements of common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,784,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of investor warrants</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,382,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_PaymentsInLieuSharesForReverseStockSplit', window );">Cash in lieu of shares for reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,529)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NetTransferFromToParent', window );">Net transfer from parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,519,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,165,148<span></span>
</td>
<td class="nump">16,519,988<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET INCREASE IN CASH AND EQUIVALENTS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,499,590<span></span>
</td>
<td class="nump">9,617,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,795,055<span></span>
</td>
<td class="nump">17,382,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">$ 31,294,645<span></span>
</td>
<td class="nump">$ 26,999,862<span></span>
</td>
<td class="nump">$ 31,294,645<span></span>
</td>
<td class="nump">$ 26,999,862<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consulting services paid by issuance of Parent company common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consulting services paid by issuance of Parent company common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_IncreaseDecreaseInGrantReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in grants receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_IncreaseDecreaseInGrantReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_IssuanceOfStockAndWarrantsForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_IssuanceOfStockAndWarrantsForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NetTransferFromToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NetTransferFromToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for parent company employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_PaymentsInLieuSharesForReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in lieu of shares for reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_PaymentsInLieuSharesForReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_WarrantAmendmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant amendment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_WarrantAmendmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342568015144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Business, Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Business, Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization, Business, Risks and Uncertainties</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;1&#160;&#8211; Organization, Business, Risks and Uncertainties:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Organization and Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On May 17, 2020, Neurotrope, Inc. (&#8220;Neurotrope&#8221; or &#8220;the Parent&#8221;) announced plans for the complete legal and structural separation of its wholly owned subsidiary, Neurotrope Bioscience, Inc., from Neurotrope (the &#8220;Spin-Off&#8221;). Under the Separation and Distribution Agreement, Neurotrope planned to distribute all of its equity interest in this wholly owned subsidiary to Neurotrope&#8217;s stockholders. Following the Spin-Off, Neurotrope does not own any equity interest in the Company, and we operate independently from Neurotrope. On December 7, 2020 we became an independent company, Synaptogenix, Inc., a Delaware corporation (formerly known as Neurotrope Bioscience, Inc.) (the &#8220;Company&#8221; or &#8220;Synaptogenix&#8221;) as the Company amended and restated their certificate of incorporation which, among other things, changed its name to Synaptogenix, Inc. Our shares of common stock are listed on The Nasdaq Capital Market under the symbol &#8220;SNPX.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Neurotrope Bioscience,&#160;Inc. was incorporated in Delaware on October&#160;31, 2012 to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer&#8217;s disease (&#8220;AD&#8221;).&#160;The Company&#160;is collaborating with Cognitive Research Enterprises,&#160;Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (&#8220;CRE&#8221;), a related party, in this process. The exclusive rights to certain technology were licensed by CRE to the Company on February&#160;28, 2013 (see Note&#160;4 - Related Party Transactions and Licensing / Research Agreements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the separation from Neurotrope, we entered into a Separation and Distribution Agreement and several other ancillary agreements. These agreements govern the relationship between the parties after the separation and allocate between the parties various assets, liabilities, rights and obligations following the separation, including employee benefits, intellectual property, information technology, insurance and tax-related liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Spin-Off </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;1, 2020, Neurotrope, and Petros Pharmaceuticals,&#160;Inc., a Delaware corporation (&#8220;Petros&#8221;) and formerly Metuchen Pharmaceuticals LLC, consummated their reverse merger transactions (the &#8220;Mergers&#8221;) contemplated by a certain Agreement and Plan of Merger dated as of May&#160;17, 2020 (the &#8220; Merger Agreement&#8221;), as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As a condition to the Mergers, Neurotrope approved a transaction (the &#8220;Spin-Off&#8221;), which became effective on December&#160;7, 2020, whereby (i)&#160;any cash in excess of $20,000,000, subject to adjustment as provided in the Merger Agreement, and all of the operating assets and liabilities of Neurotrope not retained by Neurotrope in connection with the Mergers were contributed to Neurotrope Bioscience,&#160;Inc., and (ii)&#160;holders of record of Neurotrope common stock, Neurotrope preferred stock and certain warrants that were not amended and restated as of the Spin-Off Record Date received a pro rata distribution at the rate of (i)&#160;one share of Synaptogenix,&#160;Inc. common stock for every five shares of Neurotrope common stock held, (ii)&#160;one share of Synaptogenix common stock for every five shares of Neurotrope common stock issuable upon conversion of Neurotrope preferred stock held and (iii)&#160;one share of Synaptogenix,&#160;Inc. common stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held that were entitled to participate in the Spin-Off pursuant to the terms thereof (collectively, the &#8220;Distribution&#8221;). Any fractional shares were paid in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The holders of Neurotrope&#8217;s amended and restated warrants to purchase 4,889,158 shares of Neurotrope common stock (the &#8220;A&amp;R Warrants&#8221;) received 977,831 warrants to purchase shares of Synaptogenix common stock upon the exercise of such A&amp;R Warrants held as of the Spin-Off Record Date (collectively, the &#8220;Spin-Off Warrants&#8221;). All the warrants have five year terms from December&#160;2, 2020. See Note 8 &#8211; Common Stock Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of September&#160;30, 2021, the Company had approximately $31.3 million in cash and cash equivalents as compared to $5.8 million at December&#160;31, 2020. The Company expects that its current cash and cash equivalents, approximately $35 million as of the date of this quarterly report, which includes cash received during October and November, 2021 of approximately $5 million from the exercise of investor warrants of approximately $4.5 million plus reimbursement of trial expenses of approximately $530,000 from the NIH, will be sufficient to support its projected operating requirements for at least the next 12 months from this date. The operating requirements include the current development plan for Bryostatin-1, our novel drug targeting the activation of PKC epsilon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company expects to need additional capital in order to initiate and pursue potential additional development projects, including the continuing development beyond the current Phase 2 trial.&#160;Any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company&#8217;s current stockholders and debt financing, if available, may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its technologies or product candidates that the Company would otherwise seek to develop or commercialize on its own, on terms that are not favorable to the Company. The Company&#8217;s ability to access capital when needed is not assured and, if not achieved on a timely basis, will likely have a materially adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Other Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company operates in an industry that is subject to rapid technological change, intense competition, and significant government regulation. The Company&#8217;s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the limited supply of raw materials, the ability to obtain favorable licensing, manufacturing or other agreements, including risk associated with our CRE licensing agreement, and the ability to raise capital to achieve strategic objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">CRE has entered into a material transfer agreement with the National Cancer Institute of the National Institutes of Health (&#8220;NCI&#8221;), pursuant to which the NCI has agreed to supply bryostatin required for the Company&#8217;s pre-clinical research and clinical trials. This agreement does not provide for a sufficient amount of bryostatin to support the completion of all of the clinical trials that the Company is required to conduct in order to seek U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval. Therefore, CRE or the Company would have to enter into one or more subsequent agreements with the NCI for the supply of additional amounts of bryostatin. If CRE or the Company were unable to secure such additional agreements, or if the NCI otherwise discontinues the supply, the Company would have to either secure another source of bryostatin or discontinue its efforts to develop and commercialize bryostatin for the treatment of AD. In June&#160;2020, the Company entered into a supply agreement (the &#8220;Supply Agreement&#8221;) with BryoLogyx Inc. (&#8220;BryoLogyx&#8221;), pursuant to which BryoLogyx agreed to be the Company&#8217;s exclusive supplier of synthetic Bryostatin-1. Pursuant to the terms of the Supply Agreement, the Company received its initial order of one gram synthetic Bryostatin-1. See Note 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company also faces the ongoing risk that the coronavirus pandemic may slow, for an unforeseeable period, the conduct of the Company&#8217;s trial. In order to prioritize patient health and that of the investigators at clinical trial sites, we will monitor enrollment of new patients in our current Phase 2 clinical trial. In addition, some patients may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services. These and other factors outside of our control could delay our ability to conduct clinical trials or release clinical trial results. In addition, the effects of a pandemic resurgence may also increase non-trial costs such as insurance premiums, increase the demand for and cost of capital, increase loss of work time from key personnel, and negatively impact our key clinical trial vendors and suppliers.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342568111144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;2&#160;&#8211; Summary of Significant Accounting Policies:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Subsequent to the Spin-Off, the Company&#8217;s financial statements as of December 31, 2020 and for the period December 7, 2020 to December 31, 2020 are presented on a consolidated basis as the Company became a standalone public company on December 7, 2020. The Company&#8217;s combined financial statements for the period from January 1, 2020 through December 6, 2020 that is included in the results of operations for the three and nine months ending September 30, 2020 and the year ended December 31, 2020 were derived from the consolidated financial statements and accounting records of Neurotrope, the former Parent. These combined financial statements reflect the historical results of operations, financial position and cash flows of the former Parent&#8217;s Spin-Off business which was a wholly owned subsidiary of Neurotrope, Neurotrope Bioscience, Inc., and represented substantially all the business of Neurotrope. These financial statements reflect our financial position, results of operations and cash flows as we were historically managed, in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">All intercompany transactions between the Company and Neurotrope have been included in our financial statements and are considered to be effectively settled for cash at the time the Spin-Off was recorded. The total net effect of the settlement of these intercompany transactions is reflected in our statements of cash flow as a financing activity and in the balance sheets as &#8220;Parent company investment&#8221;. See Note 9.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the unaudited condensed financial statements included herein contain all adjustments necessary to present fairly the Company&#8217;s financial position and the results of its operations and cash flows for the interim periods presented. Such adjustments are of a normal recurring nature. The results of operations for the three and nine months ended September 30, 2021 may not be indicative of results for the full year. These unaudited condensed financial statements should be read in conjunction with the audited condensed financial statements and the notes to those statements for the year ended December 31, 2020 included in our Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make significant estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the general economic environment and actions it may take in the future. The Company adjusts such estimates when facts and circumstances dictate. However, these estimates may involve significant uncertainties and judgments and cannot be determined with precision. In addition, these estimates are based on management&#8217;s best judgment at a point in time and as such these estimates may ultimately differ from actual results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents and Concentration of Credit Risk:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company considers all highly liquid cash investments with an original maturity of three months or less when purchased to be cash equivalents. At September 30, 2021, the Company&#8217;s cash balances that exceed the current insured amounts under the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) were approximately $3.6 million. In addition, approximately $27.7 million included in cash and cash equivalents were invested in a money market fund, which is not insured under the FDIC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fixed Assets and Leases:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">All leases with a lease term greater than 12 months, regardless of lease type classification, are recorded as an obligation on the balance sheet with a corresponding right-of-use asset. The Company does not have any leases greater than 12 months in duration during the respective reporting periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Fixed assets are stated at cost less accumulated depreciation. Depreciation is computed on a straight line basis over the estimated useful life of the asset, which is deemed to be between <span style="-sec-ix-hidden:Hidden_lr9X8jg5jUiA4B9EE7n2ZA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">three</span></span> and ten years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Research and Development Costs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">All research and development costs, including costs to maintain or expand the Company&#8217;s patent portfolio licensed from CRE are expensed when incurred. Non-refundable advance payments for research and development are capitalized because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at September&#160;30, 2021 and December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss Per Share of Common Stock:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On the Spin Off date, 1,257,579 shares of the Company&#8217;s common stock, par value $0.0001 per share (the Common Stock&#8221;) were distributed to Neurotrope stockholders as of November 30, 2020 (the &#8220;Record Date&#8221;). This share amount was being utilized for the calculation of basic earnings (loss) per share (&#8220;EPS&#8221;) for the periods prior to the Spin-Off because the Company was a wholly-owned subsidiary of Neurotrope prior to the Spin Off date. For the periods after the Spin-Off Date, EPS attributable to the Company&#8217;s common stockholders is based upon net income (loss) attributable to the Company&#8217;s common stockholders divided by the weighted-average number of Common Stock outstanding during the period. Penny warrants were included in the calculation of outstanding shares for purposes of basic loss per share. For the periods when a net loss is reported, the computation of diluted EPS equals the basic EPS calculation since common stock equivalents were antidilutive due to losses from continuing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Income Taxes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company accounts for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes under the &#8220;Separate return method.&#8221; Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company applies the provisions of FASB ASC 740-10, <i style="font-style:italic;">Accounting for Uncertain Tax Positions</i>, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also provides guidance on de-recognition, classification, interest and penalties, and accounting in interim periods, disclosure and transitions. The Company has determined that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is generally three&#160;years from the date of filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company (collectively with Neurotrope, Inc. / Petros Pharmaceuticals, Inc.) may be subject to significant U.S. federal income tax-related liabilities with respect to our prior distribution of all of the issued and outstanding shares of the common stock of Neurotrope Bioscience, Inc., the former subsidiary of Neurotrope, to our stockholders as of and on November 30, 2020 (the &#8220;Spin-Off&#8221;), if there is a determination that the Spin-Off is taxable for U.S. federal income tax purposes. In connection with the Spin-Off, the Company believes substantially to the effect that, among other things, the Spin-Off should qualify as a tax-free transaction for U.S. federal income tax purposes under Section 355 and Section 368(a)(1)(D) of the Code. If the conclusions of the tax opinions are not correct, or if the Spin-Off is otherwise ultimately determined to be a taxable transaction, the Company would be liable for U.S. federal income tax related liabilities. Pursuant to the Separation and Distribution Agreement and the Tax Matters Agreement, Neurotrope agreed to indemnify Synaptogenix for certain liabilities, and Synaptogenix agreed to indemnify Neurotrope for certain liabilities, in each case for uncapped amounts. Indemnities that Synaptogenix may be required to provide Neurotrope are not subject to any cap, may be significant and could negatively impact Synaptogenix&#8217;s business, particularly with respect to indemnities provided in the Tax Matters Agreement. Third parties could also seek to hold Synaptogenix responsible for any of the liabilities that Neurotrope has agreed to retain. Further, the indemnity from Neurotrope may not be sufficient to protect Synaptogenix against the full amount of such liabilities, and Neurotrope may not be able to fully satisfy its indemnification obligations. Moreover, even if Synaptogenix ultimately succeeds in recovering from Neurotrope any amounts for which Synaptogenix is held liable, Synaptogenix may be temporarily required to bear these losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under Section 382 of the Internal Revenue Code of 1986, as amended, changes in the Company&#8217;s ownership may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. In addition, the significant historical operating losses incurred by the Company may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. The Company believes that operating loss carryforwards are limited under Section 382 limitations although Section 382 studies have not been conducted to determine the actual limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Expense Reimbursement for Grant Award:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company reduces its research and development expenses by funding received or receivable from an NIH grant during the period that the expenses are incurred. The Company recognized grant related expense reductions during the three and nine months ended September 30, 2021 of approximately $1.1 million. See Note 5, &#8220;<i style="font-style:italic;">Clinical Trial Services Agreements</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Of the total $2.7 million available from the NIH grant, approximately $2.6 million was received for trial-related expenses incurred since grant inception to October&#160;31, 2021 with the remaining $0.1 million available for reimbursement during the period November&#160;2021 to March&#160;2022. The Company believes it will receive the maximum reimbursements under the grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">&#160;In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, which reduces the number of accounting models for convertible instruments, amends diluted earnings per share calculations for convertible instruments and allows more contracts to qualify for equity classification. ASU 2020-06 will be effective for interim and annual periods beginning after December 15, 2021. Early adoption is permitted. The Company is evaluating the adoption of ASU 2020-06.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342568059880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements and Commitments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_CollaborativeAgreementsAndCommitmentsAbstract', window );"><strong>Collaborative Agreements and Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_CollaborativeAgreementsAndCommitmentsTextBlock', window );">Collaborative Agreements and Commitments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note&#160;3&#8211; Collaborative</b> <b style="font-weight:bold;">Agreements and Commitments:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:8pt;font-weight:normal;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stanford License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On May&#160;12, 2014, the Company entered into a license agreement (the &#8220;Stanford Agreement&#8221;) with The Board of Trustees of The Leland Stanford Junior University (&#8220;Stanford&#8221;), pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as &#8220;bryologs,&#8221; for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents. The Company is required to use commercially reasonable efforts to develop, manufacture and sell products (&#8220;Licensed Products&#8221;) in the Licensed Field of Use (as defined) during the term of the licensing agreement which expires upon the termination of the last valid claim of any licensed patent under this agreement. In addition, the Company must meet specific diligence milestones, and upon meeting such milestones, make specific milestone payments to Stanford. The Company must also pay Stanford royalties&#160;of 3% of net sales, if any, of Licensed Products (as defined) and milestone payments of up to $3.7 million dependent upon stage of product development. As of September 30, 2021, no royalties nor milestone payments have been required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On January&#160;19, 2017, the Company entered into an additional, second license agreement with Stanford, pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of &#8220;Bryostatin Compounds and Methods of Preparing the Same,&#8221; or synthesized bryostatin, for use in the treatment of neurological diseases, cognitive dysfunction and psychiatric disorders, for the life of the licensed patents. The Company paid Stanford $70,000 upon executing the license and is obligated to pay an additional $10,000 annually as a license maintenance fee. In addition, based upon certain milestones which include product development and commercialization, the Company is required to pay up to an additional $2.1 million and between 1.5% and 4.5% royalty payments on certain revenues generated by the Company relating to the licensed technology. The Company has made all required annual maintenance payments. As of September 30, 2021, no royalties nor milestone payments have been required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Mt. Sinai License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On July&#160;14, 2014, the Company entered into an Exclusive License Agreement (the &#8220;Mount Sinai Agreement&#8221;) with the Icahn School of Medicine at Mount Sinai (&#8220;Mount Sinai&#8221;). Pursuant to the Mount Sinai Agreement, Mount Sinai granted the Company (a)&#160;a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under Mount Sinai&#8217;s interest in certain joint patents held by the Company and Mount Sinai (the &#8220;Joint Patents&#8221;) as well as in certain results and data (the &#8220;Data Package&#8221;) and (b)&#160;a non-exclusive license, with the right to grant sublicenses on certain conditions, to certain technical information, both relating to the diagnostic, prophylactic or therapeutic use for treating diseases or disorders in humans relying on activation of Protein Kinase C Epsilon (&#8220;PKC&#949;&#8221;), which includes Niemann-Pick Disease (the &#8220;Mount Sinai Field of Use&#8221;). The Mount Sinai Agreement allows the Company to research, discover, develop, make, have made, use, have used, import, lease, sell, have sold and offer certain products, processes or methods that are covered by valid claims of Mount Sinai&#8217;s interest in the Joint Patents or an Orphan Drug Designation Application covering the Data Package (&#8220;Mount Sinai Licensed Products&#8221;) in the Mount Sinai Field of Use (as such terms are defined in the Mount Sinai Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company is required to pay Mt. Sinai milestone payments of $2 million upon approval of a new drug approval (&#8220;NDA&#8221;) in the United States and an additional $1.5 million for an NDA approval in the European Union or Japan. In addition, the Company is required to pay Mt. Sinai royalties on net sales of licensed product of 2.0% for up to $250 million of net sales and 3.0% of net sales over $250 million. Since inception, the Company has paid Mt. Sinai approximately $180,000 consisting of licensing fees of $105,000 plus development costs and patent fees of approximately $75,000. As of September 30, 2021, no royalties nor milestone payments have been required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Agreements with BryoLogyx</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June&#160;9, 2020, the Company entered into a supply agreement (the &#8220;Supply Agreement&#8221;) with BryoLogyx&#160;Inc. (&#8220;BryoLogyx&#8221;), pursuant to which BryoLogyx agreed to serve as the Company&#8217;s exclusive supplier of synthetic Bryostatin-1. Pursuant to the terms of the Supply Agreement, the Company placed an initial order and subsequently received one gram of current good manufacturing practice (&#8220;cGMP&#8221;) synthetic Bryostatin-1 as an active pharmaceutical ingredient to be used in a drug product (&#8220;API&#8221;). The Company may place additional orders for API beyond the initial order by making a written request to BryoLogyx no later than six months prior to the requested delivery date. The Company is not currently using synthetic Bryostatin-1 for its current Phase 2 clinical trial and will determine when to incorporate the synthetic into the clinical trial process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the Supply Agreement, on June&#160;9, 2020, the Company entered into a transfer agreement (the &#8220;Transfer Agreement&#8221;) with BryoLogyx. Pursuant to the terms of the Transfer Agreement, the Company agreed to assign and transfer to BryoLogyx all of the Company&#8217;s right, title and interest in and to that certain Cooperative Research and Development Agreement, dated as of January&#160;29, 2019 (the &#8220;CRADA&#8221;), by and between the Company and the U.S. Department of Health and Human Services, as represented by the NCI, under which Bryostatin-1&#8217;s ability to modulate CD22 in patients with relapsed/refractory CD22+ disease has been evaluated to date. Pursuant to guidance provided by NCI, the Company CRADA has been cancelled and BryoLogyx has initiated a request for a new CRADA in its name. BryoLogyx will be filing its own investigational new drug application (&#8220;IND&#8221;) for CD22 with the FDA. As consideration for the transfer of rights to the CRADA, BryoLogyx has agreed to pay to the Company 2% of the gross revenue received in connection with the sale of bryostatin products, up to an aggregate payment amount of $1 million. No such revenues have been earned as of September&#160;30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nemours Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On September 5, 2018, we announced a collaboration with Nemours A.I. DuPont Hospital (&#8220;Nemours&#8221;), a premier U.S. children&#8217;s hospital, to initiate a clinical trial in children with Fragile X. In addition to the primary objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as anxiety, repetitive behavior, executive functioning, and social behavior. On August 5, 2021, the Company announced its memorandum of understanding with Nemours to initiate a clinical trial using bryostatin, under Orphan Drug Status, to treat Fragile X. The Company intends to provide the bryostatin drug product and obtain the investigational new drug documentation (&#8220;IND&#8221;) and Nemours intends to provide the clinical site and attendant support for the trial. The Company and Nemours, jointly, will develop the trial protocol. The Company estimates its total trial and IND cost to be approximately $700,000. To-date, the Company has not incurred any expenses associated with this agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_CollaborativeAgreementsAndCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about collaborative agreements and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_CollaborativeAgreementsAndCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_CollaborativeAgreementsAndCommitmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative agreements and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_CollaborativeAgreementsAndCommitmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342568745064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions and Licensing / Research Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions and Licensing / Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions and Licensing / Research Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;4&#8211; Related Party Transactions and Licensing / Research Agreements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cognitive Research Enterprises,&#160;Inc. (&#8220;CRE&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Effective October&#160;31, 2012, the Company executed a Technology License and Services Agreement (the &#8220;TLSA&#8221;) with CRE, a related party, and NRV II, LLC (&#8220;NRV II&#8221;), another affiliate of CRE, which was amended by Amendment No.&#160;1 to the TLSA as of August&#160;21, 2013. As of February&#160;4, 2015, the parties entered into an Amended and Restated Technology License and Services Agreement (the &#8220;CRE License Agreement&#8221;). The CRE License Agreement provides research services and has granted the Company the exclusive and nontransferable world-wide, royalty-bearing right, with a right to sublicense (in accordance with the terms and conditions described below), under CRE&#8217;s and NRV II&#8217;s respective right, title and interest in and to certain patents and technology owned by CRE or licensed to NRV II by CRE as of or subsequent to October&#160;31, 2012, to develop, use, manufacture, market, offer for sale, sell, distribute, import and export certain products or services for therapeutic applications for AD and other cognitive dysfunctions in humans or animals (the &#8220;Field of Use&#8221;). Additionally, the CRE License Agreement specifies that all patents that issue from a certain patent application shall constitute licensed patents and all trade secrets, know-how and other confidential information claimed by such patents constitute licensed technology under the CRE License. The CRE License Agreement terminates on the later of the date (a)&#160;the last of the licensed patent expires, is abandoned, or is declared unenforceable or invalid or (b)&#160;the last of the intellectual property enters the public domain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">After Neurotrope&#8217;s initial Series A Stock financing, the CRE License Agreement required the Company to enter into scope of work agreements with CRE as the preferred service provider for any research and development services or other related scientific assistance and support services. There were no such statements of work agreements required to be entered into during the three and nine months ended September 30, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, on November&#160;10, 2018, the Company and CRE entered into a second amendment (the &#8220;Second Amendment&#8221;) to the TLSA pursuant to which CRE granted certain patent prosecution and maintenance rights to the Company. Under the Second Amendment, the Company will have the sole and exclusive right and the obligation, to apply for, file, prosecute and maintain patents and applications for the intellectual property licensed to the Company, and pay all fees, costs and expenses related to the licensed intellectual property. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342568031288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;5&#160;&#8211; Commitments and Contingencies:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Clinical Trial Services Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On July&#160;23, 2020, the Company entered into the 2020 Services Agreement with WCT. The 2020 Services Agreement relates to services for the current Phase 2 clinical trial assessing the safety, tolerability and long-term efficacy of bryostatin in the treatment of moderately severe AD subjects not receiving memantine treatment (the &#8220;2020 Study&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the terms of the 2020 Services Agreement, WCT is providing services to enroll approximately <span style="-sec-ix-hidden:Hidden_zKPmU54jT0W3JjwS4wGcXw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">one</span></span> hundred (100) 2020 Study subjects, which enrollment is currently underway. The&#160;first 2020 Study site was initiated during the third quarter of 2020. The total estimated budget for the services, including pass-through costs, is currently approximately $9.6 million. The Company was awarded a $2.7 million grant from the NIH, which will be used to support the 2020 Study, resulting in an estimated net budgeted cost of the 2020 Study to the Company of $6.9 million. The NIH grant provides for funds in the first year, which began in April&#160;2020, of approximately $1.0 million and funding in year two, which begins April&#160;2021, of approximately $1.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company may terminate the 2020 Services Agreement without cause upon sixty (60)&#160;days prior written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30, 2021, approximately $5.1 million has been paid against the total trial cost. Of this total, approximately $2.1 million has been received from the NIH. The Company incurred approximately $5.9 million of cumulative expenses associated with the current Phase 2 clinical trial as of September 30, 2021. Of the total $5.9 million incurred for the trial to-date, approximately $1.6 million and $3.2 million is reflected in the statement of operations for the three and nine months ended September 30, 2021, respectively. As of September 30, 2021, approximately $460,000 of WCT prepayments is included as a prepaid expense and other current assets and approximately $771,000 which is included in accounts payable in the accompanying balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Related Party and Other Consulting Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On August&#160;4, 2016, Neurotrope,&#160;Inc. entered into a consulting agreement with SM Capital Management, LLC (&#8220;SMCM&#8221;), a limited liability company owned and controlled by the Company&#8217;s Chairman of the Board, Mr.&#160;Joshua N. Silverman (the &#8220;Consulting Agreement&#8221;). Pursuant to the Consulting Agreement, SMCM shall provide consulting services which shall include, but not be limited to, providing business development, financial communications and management transition services, for a one-year period, subject to annual review thereafter. SMCM&#8217;s annual consulting fee is $120,000, payable by the Company in&#160;monthly installments of $10,000. This contract has been assigned to Synaptogenix,&#160;Inc. as of December&#160;1, 2020. For the three and nine months ended September 30, 2021, $60,000 and $180,000 is reflected in the Company&#8217;s statements of operations, respectively, pursuant to the Consulting Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Effective as of January&#160;1, 2021, the Company entered into an amended consulting agreement with Katalyst Securities LLC (&#8220;Katalyst&#8221;) reducing the cash payment to $20,000 per month. In addition, on February&#160;16, 2021, Katalyst was granted warrants to purchase 25,000 shares of Common Stock at $11.46 per share, on April 1, 2021, was granted warrants to purchase an additional 4,500 shares of Common Stock at $8.80 per share, on July 1, 2021, was granted warrants to purchase an additional 4,500 shares of Common Stock at $9.76 per share, and, on October 1, 2021, was granted warrants to purchase an additional 4,500 shares of Common Stock at $9.30 per share. All other terms and conditions of the Katalyst Agreement remain unchanged. For the three and nine months ended September 30, 2021, $96,982 and $556,682 is reflected in the Company&#8217;s statements of operations, respectively, pursuant to the consulting agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Effective as of June&#160;5, 2019, the Company entered into a consulting agreement with GP Nurmenkari,&#160;Inc. (&#8220;GPN&#8221;) (the &#8220;GPN Agreement&#8221;), pursuant to which GPN agreed to provide investment banking consulting services to the Company and Neurotrope. The term of the agreement continued until December 1, 2020. As consideration for its services under the GPN Agreement, the Company agreed to pay to GPN $8,000 per&#160;month, plus five-year warrants to purchase 1,200 shares of Neurotrope&#8217;s common stock on the effective date and on each of the three-month anniversaries following the effective date. The warrants have an exercise price equal to the closing price of Neurotrope&#8217;s stock on the dates of issuances. On February&#160;1, 2020, the Company amended the GPN Agreement, increasing the cash compensation to $17,500 per&#160;month thru November 30, 2020 and increasing the number of warrants issued each three-month period to 2,500, with the last issuance on December 1, 2020. GPN&#8217;s cash and stock-based compensation is included as general and administrative expenses in the Company&#8217;s statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Effective as of January&#160;1, 2021, the Company entered into an amended consulting agreement with GPN reducing the cash payment to $12,000 per month. Effective as of July 1, 2021, the Company entered into a second amended consulting agreement with GPN increasing the cash payment to $20,000 per month and increasing warrant issued for each three-month period beginning July 1, 2021 to 5,800, with the last issuance on October 1, 2021. In addition, on February&#160;16, 2021, GPN was granted warrants to purchase 10,000 shares of Common Stock at $11.46 per share, on April 1, 2021, was granted warrants to purchase an additional 2,500 shares of Common Stock at $8.80 per share, on July 1, 2021, was granted warrants to purchase an additional 5,800 shares of Common Stock at $9.76 per share, and, on October 1, 2021, was granted warrants to purchase an additional 5,800 shares of Common Stock at $9.30 per share. All other terms and conditions of the GPN Agreement remain unchanged. For the three and nine months ended September 30, 2021, $107,666 and $296,814 is reflected in the Company&#8217;s statements of operations, respectively, pursuant to the GPN Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Employment Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;7, 2020, the Company entered into an offer letter (the &#8220;Offer Letter&#8221;) with Alan J. Tuchman, M.D., pursuant to which Dr.&#160;Tuchman agreed to serve as the Company&#8217;s Chief Executive Officer, commencing on December&#160;7, 2020. In addition, in connection with his appointment as the Company&#8217;s Chief Executive Officer, Dr.&#160;Tuchman was appointed to the board of directors of the Company. Dr.&#160;Tuchman will receive an initial annual base salary of $222,000, with an annual discretionary bonus of up to 50% of his base salary then in effect. Dr.&#160;Tuchman also received an initial equity grant (subject to Board approval which was received in January&#160;2021) of options to purchase a number of shares of Common Stock equal to at least 1% of the Company&#8217;s outstanding shares of Common Stock immediately following the Spin-Off. The option will vest with respect to 25% on each of the first, <span style="-sec-ix-hidden:Hidden_hGoeBKVmBU20RQRV2PAyfQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">second</span></span>, <span style="-sec-ix-hidden:Hidden_G8xXS6bLZUG7c6GZDPjMxQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">third</span></span> and <span style="-sec-ix-hidden:Hidden_YpLSh0QAWUSUkURr5jx6fw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">fourth</span></span> quarterly anniversaries from the Start Date, subject to Dr.&#160;Tuchman&#8217;s continued employment with the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The term of Dr.&#160;Tuchman&#8217;s employment pursuant to the Offer Letter is one year, which shall be extended automatically for six month periods unless either party gives timely written notice. Pursuant to the Offer Letter, if Dr.&#160;Tuchman is terminated during the period that is within six months from the Start Date, Dr.&#160;Tuchman will receive compensation totaling a minimum of 50% of his annualized salary. If Dr.&#160;Tuchman is terminated within the period which is after six months from the Start Date and before the one year anniversary of the Start Date, Dr.&#160;Tuchman will receive severance equal to one (1)&#160;month of his base salary. If Dr.&#160;Tuchman is terminated within the period which is after the one year anniversary of the Start Date, Dr.&#160;Tuchman will receive severance equal to two (2)&#160;months of his base salary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with Dr.&#160;Ryan&#8217;s termination on December 1, 2020, Synaptogenix and Dr.&#160;Ryan entered into a Separation Agreement, dated as of December&#160;7, 2020 (the &#8220;Charles Ryan Separation Agreement&#8221;). Pursuant to the Charles Ryan Separation Agreement, Dr.&#160;Ryan is entitled to receive the following separation benefits in consideration of, and subject to, Dr.&#160;Ryan&#8217;s compliance with his continuing obligations under the Charles Ryan Separation Agreement and all other agreements between Dr.&#160;Ryan and the Company, and provided that Dr.&#160;Ryan does not revoke the Charles Ryan Separation Agreement: (i)&#160;payment of <span style="-sec-ix-hidden:Hidden_jgZLIHXGVkmWEP_qt_Shbw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">twelve</span></span> (12) months of Dr.&#160;Ryan&#8217;s base salary as of the Separation Date of $425,000; (ii)&#160;a cash bonus in an amount equal to $225,000; and (iii)&#160;payment of Dr.&#160;Ryan&#8217;s COBRA premiums for the period starting on the Charles Ryan Separation Date and ending on the earliest to occur of (x)&#160;12 months following the Separation Date; (y)&#160;the date Dr.&#160;Ryan is no longer eligible under COBRA and (z)&#160;the date that Dr.&#160;Ryan obtains employment that offers group health benefits. Total commitment pursuant to the Charles Ryan Separation Agreement is approximately $660,000. Pursuant to the employee leasing agreement as part of the Merger Agreement, 50% of any payments to Dr.&#160;Ryan will be reimbursed by Metuchen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2020 and September&#160;30, 2021, the severance obligation included in accrued expenses on the Company&#8217;s balance sheet was approximately $332,000 and $46,000, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">See Notes 3 and 4 for Collaboration and License Agreement related commitments.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the Separation Agreement and Tax Matters Agreement with Neurotrope, Neurotrope agreed to indemnify Synaptogenix for certain liabilities, and Synaptogenix agreed to indemnify Neurotrope for certain liabilities, in each case for uncapped amounts. Indemnities that Synaptogenix may be required to provide Neurotrope are not subject to any cap, may be significant and could negatively impact Synaptogenix&#8217;s business, particularly with respect to indemnities provided in the Tax Matters Agreement. Third parties could also seek to hold Synaptogenix responsible for any of the liabilities that Neurotrope has agreed to retain. Further, the indemnity from Neurotrope may not be sufficient to protect Synaptogenix against the full amount of such liabilities, and Neurotrope may not be able to fully satisfy its indemnification obligations. Moreover, even if Synaptogenix ultimately succeeds in recovering from Neurotrope any amounts for which Synaptogenix is held liable, Synaptogenix may be temporarily required to bear these losses ourselves. As of the reporting date, there are no claims relating to the indemnification agreement.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342568057128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity:<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity:</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Note&#160;6&#160;&#8211;</b> <b style="font-weight:bold;">Stockholders&#8217; Equity:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;7, 2020, the Company completed its Spin-Off from Neurotrope and <span style="-sec-ix-hidden:Hidden_2WjS9OcCE0OUM5kOWGUAdg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">issued</span></span> 1,257,579 of Common Stock to stakeholders of Neurotrope. The shares issues were determined by the number of Neurotrope shares held by each shareholder multiplied by the exchange rate of .20 shares of Synaptogenix for each share of Neurotrope, held on November&#160;30, 2020, the record date of the Spin-Off. In addition, shares of Common Stock were <span style="-sec-ix-hidden:Hidden_dSJYuuGr1UaWnhcxWt0JcA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">issued</span></span> to Neurotrope. Warrant holders that chose not to amend their warrants pursuant to the amendments offered to all Series&#160;E, F, G and H warrant holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s certificate of incorporation authorizes it to issue 150,000,000 shares of Common Stock and 1,000,000 shares of preferred stock, par value $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The holders of Common Stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends at such times and in such amounts as the Board from time to time may determine. To date, the Company has not paid dividends on its Common Stock. Holders of Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. There is no cumulative voting of the election of directors then standing for election. The Common Stock is not entitled to pre-emptive rights and is not subject to conversion or redemption. Upon liquidation, dissolution or winding up of the Company, the assets legally available for distribution to stockholders are distributable ratably among the holders of Common Stock after payment of liabilities, accrued dividends and liquidation preferences, if any. Each outstanding share of Common Stock is duly and validly issued, fully paid and non-assessable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">January&#160;2021 Private Placement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January&#160;21, 2021, the Company entered into Securities Purchase Agreements (the &#8220;Purchase Agreement&#8221;) with certain accredited investors (the &#8220;Purchasers&#8221;) to issue (a)&#160;an aggregate of 2,333,884 shares of Common Stock and/or prefunded warrants to purchase shares of Common Stock at an exercise price of $0.01 per share (the &#8220;Pre-Funded Warrants&#8221;), (b)&#160;Series&#160;E warrants to purchase 2,333,908 shares of Common Stock, with an exercise price of $8.51 per share (subject to adjustment), for a period of twelve months from the date of an effective registration statement (the &#8220;Series&#160;E Warrants&#8221;) and (c)&#160;Series&#160;F warrants to purchase up to an aggregate of 2,333,908 shares of Common stock, with an exercise price of $6.90 per share (subject to adjustment), for a period of five years from the date of issuance (the &#8220;Series&#160;F Warrants&#8221; and together with the Series&#160;E Warrants, the &#8220;Warrants&#8221;) at a combined purchase price of $6.00 per share of Common Stock and Warrants (the &#8220;Offering&#8221;). The Company received total gross proceeds of approximately $14,000,000 and net proceeds of approximately $12.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the Purchase Agreement, the Company and the Purchasers entered into a Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;) on January&#160;21, 2021. Under the terms of the Registration Rights Agreement, the Company agreed to register the shares of Common Stock and the shares of Common Stock issuable upon exercise of the Warrants and the Pre-Funded Warrants sold to the Buyers pursuant to the Purchase Agreement. The Company filed a registration statement on Form S-1 in connection with the Registration Rights Agreement on February 8, 2021. The Company also agreed to other customary obligations regarding registration, including indemnification and maintenance of the effectiveness of the registration statement. The Company&#8217;s registration statement on Form S-1 to register the shares of Common Stock and the shares of Common Stock issuable upon exercise of the Warrants and Pre-Funded Warrants went effective on April 29, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;border-bottom:1.0pt solid #ffffff;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;">In connection with the Offering, we paid our placement agents Katalyst and GPN (i)&#160;a cash fee equal to ten percent (10%) of the gross proceeds from any sale of securities in the Offering sold to Purchasers introduced by the Placement Agent and (ii)&#160;warrants to purchase shares of Common Stock equal to ten percent (10%) of the number of shares of Common Stock sold to Purchasers introduced by the placement agents, with an exercise price of $6.90 per share and a five-year term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">June 2021 Private Placement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On June 14, 2021, the Company entered into Securities Purchase Agreements (the &#8220;June Purchase Agreement&#8221;) with certain accredited investors (the &#8220;June Purchasers&#8221;) to issue (a) an aggregate of 1,653,281 shares of the Company&#8217;s Common Stock and/or prefunded warrants to purchase shares of Common Stock at an exercise price of $0.01 per share (the &#8220;June Pre-Funded Warrants&#8221;) and (b) Series G warrants to purchase up to an aggregate of 1,653,281 shares of Common stock, with an exercise price of $8.51 per share (subject to adjustment), for a period of five years from the date of issuance (the &#8220;June Warrants&#8221;) at a combined purchase price of $7.547 per share of Common Stock and June Warrants (the &#8220;June Offering&#8221;). The Company received total gross proceeds of approximately $12.5 million and net proceeds of approximately $11.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In connection with the June Purchase Agreement, the Company and the June Purchasers entered into a Registration Rights Agreement (the &#8220;June Registration Rights Agreement&#8221;) on June 14, 2021. Under the terms of the June Registration Rights Agreement, the Company agreed to register the shares of Common Stock and the shares of Common Stock issuable upon exercise of the June Warrants and the June Pre-Funded Warrants sold to the Buyers pursuant to the June Purchase Agreement. The Company filed a registration statement for the resale of such securities on June 24, 2021, and it was declared effective by the SEC on July 6, 2021. The Company also agreed to other customary obligations regarding registration, including indemnification and maintenance of the effectiveness of the registration statement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In connection with the June Offering, pursuant to an Engagement Agreement, dated June 14, 2021 (the &#8220;June Engagement Agreement&#8221;), between the Company and Katalyst Securities LLC (the &#8220;June Placement Agent&#8221;), the Company paid the June Placement Agent (i) a cash fee equal to ten percent (10%) of the gross proceeds from the sale of securities in the June Offering sold to June Purchasers introduced by the June Placement Agent and (ii) 152,378 warrants to purchase shares of Common Stock equal to ten percent (10%) of the number of shares of Common Stock sold to June Purchasers introduced by the June Placement Agent, with an exercise price of $8.51 per share and a five-year term (the &#8220;June Broker Warrants&#8221;). Furthermore, the Company agreed to pay the June Placement Agent a warrant exercise fee equal to ten percent (10%) of the aggregate exercise price that is paid in connection with each exercise, if any, of the June Warrants initially held by June Purchasers introduced by the June Placement Agent. The June Placement Agent is also entitled to the foregoing fees with respect to any future financing or capital-raising transaction by the Company (a &#8220;Subsequent Financing&#8221;), to the extent such financing or capital is provided to the Company by investors whom the Placement Agent had introduced to the Company, in the event such Subsequent Financing is consummated within eighteen (18) months following the closing of the June Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Adoption of a Shareholder Rights Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January&#160;13, 2021, the Company adopted a shareholder rights plan (the &#8220;Rights Plan&#8221;). The Rights Plan is intended to protect the interests of the Company&#8217;s stockholders and enable them to realize the full potential value of their investment by reducing the likelihood that any person or group gains control of the Company, through open market accumulation or other tactics, without appropriately compensating all stockholders. Pursuant to the Rights Plan, the Company will issue, by means of a dividend, one preferred share purchase right for each outstanding share of our Common Stock to shareholders of record on the close of business on January&#160;25, 2021. Initially, these Rights will trade with, and be represented by, the shares of our Common Stock.&#160;The Rights&#160;will generally become exercisable only if any person (or any persons acting as a group) acquires 15% or more of our outstanding Common Stock (the &#8220;Acquiring Person&#8221;) in a transaction not approved by the Board, subject to certain exceptions, as explained below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If the Rights become exercisable, all holders of Rights, other than the Acquiring Person, will be entitled to acquire shares of Common Stock at a 50% discount or the Company may exchange each Right held by such holders for one share of Common Stock. In such situation, Rights held by the Acquiring Person would become void and will not be exercisable. If any person at the time of the first public announcement of the Rights Plan owns more than the triggering percentage, then that stockholder&#8217;s existing ownership percentage will be grandfathered, although, with certain exceptions, the Rights will become exercisable if at any time after the announcement of the Rights Plan such stockholder increases its ownership of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January&#160;13, 2021, the board of directors of the Company (the &#8220;Board&#8221;)declared a dividend of one preferred share purchase right (a &#8220;Right&#8221;), payable on January&#160;25, 2021, for each share of Common Stock outstanding on January&#160;25, 2021 (the &#8220;Record Date&#8221;) to the stockholders of record on that date. In connection with the distribution of the Rights, the Company entered into a Rights Agreement (the &#8220;Rights Agreement&#8221;), dated as of January&#160;19, 2021, between the Company and Philadelphia Stock Transfer,&#160;Inc., as rights agent. Each Right entitles the registered holder to purchase from the Company one one-thousandth of a share of Series&#160;A Preferred Stock, par value $0.001 per share (the &#8220;Preferred Shares&#8221;), of the Company at a price of $20 per one one-thousandth of a Preferred Share represented by a Right (the &#8220;Purchase Price&#8221;), subject to adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Unless earlier redeemed, terminated or exchanged pursuant to the terms of the Rights Plan, the Rights will expire at the close of business on&#160;January&#160;13, 2023. The Board may terminate the Rights Plan before that date if the Board determines that there is no longer a threat to shareholder value.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At the Special Meeting, the stockholders approved our proposal to effect one reverse stock split of the Company&#8217;s outstanding shares of Common stock, at any ratio between 1-for-1.5 and 1-for-20, at such time as the Company&#8217;s Board of Directors shall determine, in its sole discretion, before December 31, 2022. On May 19, 2021, the Company effected a <span style="-sec-ix-hidden:Hidden_a2wS05qZI0qbkELASHqfgA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">1-for-4</span></span> reverse stock split of its Common Stock. As a result of the reverse stock split, every four (4) shares of the Company&#8217;s pre-reverse split Common Stock was combined and reclassified into one share of Common Stock. These financial statements have been adjusted to retrospectively reflect this reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342568094808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation:<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock Based Compensation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation:</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Note 7 &#8211; Stock Based Compensation:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">2020 Equity Incentive Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon completion of the Spin-Off, the Company&#8217;s 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) became effective on December&#160;7, 2020. The total number of securities available for grant under the 2020 Plan was 250,000 shares of Common Stock, subject to adjustment. On April 7, 2021, the Company held a special meeting of stockholders (&#8220;Special Meeting&#8221;). At the Special Meeting, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s 2020 Plan to increase the total number of shares of Common Stock from 250,000 to an aggregate of 625,000 shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Compensation Committee of the Company&#8217;s board of directors (the &#8220;Committee&#8221;) will administer the 2020 Plan and have full power to grant stock options and Common Stock, construe and interpret the 2020 Plan, establish rules&#160;and regulations and perform all other acts, including the delegation of administrative responsibilities, as it believes reasonable and proper. The Committee, in its absolute discretion, may award Common Stock to employees, consultants, and directors of the Company, and such other persons as the Committee may select, and permit holders of options to exercise such options prior to full vesting.<i style="font-style:italic;"> </i>Pursuant to the Spin-Off, all options issued and outstanding prior to this plan were assumed by Petros Pharmaceuticals,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Before the Spin-Off, Neurotrope was the sponsor of the Company&#8217;s 2017 stock option plan (&#8220;2017 Plan&#8221;). Upon the Spin-Off, the 2017 Plan was transferred to Petros Pharmaceuticals,&#160;Inc. Total expenses for 2020 was recognized as expense and attributable to the Company (See Note 9 &#8211; Parent Company Investment.) As of the Spin-Off date, no additional options expense will be reflected based upon the 2017 Plan.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Option Grants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a summary of stock option activity under the stock option plans for the nine months ended September 30, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">millions)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Options outstanding at January&#160;1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ran0Cu55WEO7SIeyEo9upQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 123,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less options forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less options expired/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Options outstanding at September&#160;30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 123,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Options exercisable at September 30, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89,613</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.84</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January&#160;13, 2021, pursuant to its 2020 Plan, the Company granted stock options to purchase an aggregate of 116,350 shares of Common Stock to six members of the board of directors and four employees, including 12,575 options granted to the Company&#8217;s Chief Executive Officer pursuant to his employment agreement with the Company dated December&#160;7, 2020. The stock options have an exercise price of $9.84 per share and an expiration date that is ten years from the date of issuance. 103,775 options vest 50% on the date of grant and 50% on the first anniversary of the grant date, the 12,575 options granted to the CEO vest 25% per quarter over one year, with the initial 25% vesting on March&#160;7, 2021. On April 6, 2021, pursuant to the Company&#8217;s Director Compensation Policy (see below), the Company granted stock options to purchase an aggregate of 7,500 shares of Common Stock to five members of the board of directors. &#160;The stock options have an exercise price of $9.80 per share and an expiration that is ten years from the date of issuance. All these options vest on the first anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Black-Scholes valuation model was used to calculate the fair value of these stock options issued pursuant to the 2020 Plan. The fair value of stock options issued was estimated at the grant date using the following weighted average assumptions: Dividend yield 0%; Expected term 5.2 years; an aggregate volatility based upon a blend of the former Parent Company&#8217;s historical volatility and guideline company historical volatility of 129.9%; and Risk-free interest rate 0.51%. The weighted average grant date fair value of options granted was approximately $1,054,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March&#160;12, 2021, Synaptogenix adopted a new non-employee director compensation policy (the &#8220;Director Compensation Policy&#8221;). The Director Compensation Policy provides for the annual automatic grant of nonqualified stock options to purchase up to 1,500 shares of Synaptogenix&#8217;s Common Stock to each of Synaptogenix&#8217;s nonemployee directors. Such grants shall occur annually on the fifth business day after the filing of Synaptogenix&#8217;s Annual Report on Form&#160;10-K and shall vest on the one-year anniversary from the date of grant subject to the director&#8217;s continued service on the Board of Directors on the vesting date. The Director Compensation Policy also provides for the automatic grant of nonqualified stock options to purchase up to 1,200 shares of Synaptogenix&#8217;s Common Stock, plus options to purchase an additional 300 shares of Common Stock for service on a committee of the Board of Directors, to each newly appointed director following the date of his or her appointment. Such options shall vest as follows: fifty percent (50%) on the date of the grant, twenty-five percent (25%) on the one year anniversary from the date of the grant, and twenty-five percent (25%) on the second year anniversary from the date of the grant, subject to the director&#8217;s continued service on the Board of Directors on the applicable vesting dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Grants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On July 13, 2021, the Company granted a total of 495,000 restricted stock units (RSUs) of which 425,000 were granted to seven Board members (including two executives), 60,000 to the Company&#8217;s CFO and 10,000 to two employees. The RSUs vest 50% upon the six month anniversary of the grant with the remaining 50% vesting upon the one year anniversary of the grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Total stock-based compensation for the nine months ended September 30, 2021 was $1,918,651, of which $424,993 was classified as research and development expense and $1,493,658 was classified as general and administrative expense. Total stock-based </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">compensation for the nine months ended September 30, 2020 was $1,449,024, of which $551,865 was classified as research and development expense and $897,159 was classified as general and administrative expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For the three months ended September 30, 2021, total stock-based compensation was $1,198,860, of which $215,528 was classified as research and development and $983,332 was classified as general and administrative expense. Stock-based compensation for the three months ended September 30, 2020, was $387,928, of which $153,025 was classified as research and development and $234,903 was classified as general and administrative expense.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342569334840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants:<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_CommonStockWarrants', window );"><strong>Common Stock Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_StockOptionNoteDisclosureTextBlock', window );">Common Stock Warrants:</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Note 8 &#8211; Common Stock Warrants:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Beginning on September&#160;28, 2020, Neurotrope entered into separate warrant amendment agreements with certain existing holders of its warrants to purchase shares of the Neurotrope&#8217;s common stock. As of October&#160;26, 2020, holders of warrants to purchase 978,077 shares of Neurotrope Common Stock had entered into warrant amendment agreements, including holders of Series&#160;E Warrants to purchase 39,535 shares of common stock, Series&#160;F Warrants to purchase 155,917 shares of common stock, Series&#160;G Warrants to purchase 227,163 shares of common stock and Series&#160;H Warrants to purchase 555,462 shares of Neurotrope&#8217;s Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the terms of the warrant amendment agreements, Neurotrope and the holders agreed to the following provisions with respect to the Company&#8217;s warrants:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The initial exercise price of the Spin-Off Warrants was determined as follows for each of the Original Warrants (all of which expire on December&#160;7, 2025):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">for the Neurotrope Series&#160;E Warrants (now the Company&#8217;s Series&#160;A Warrants), by dividing $250&#160;million by 1,257,604 shares of common stock of the Spin-Off Company outstanding immediately after the Spin-Off. This resulted in an exercise price of $198.80 per warrant for 39,535 Series&#160;A Warrants;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">for the Neurotrope Series&#160;F Warrants (now the Company&#8217;s Series&#160;B Warrants), by dividing $100&#160;million by 1,257,604 of shares of common stock of the Spin-Off Company outstanding immediately after the Spin-Off. This resulted in an exercise price of $79.52 per warrant for 155,917 Series&#160;B Warrants;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">for the Neurotrope Series&#160;G Warrants (now the Company&#8217;s Series&#160;C Warrants), by dividing $50&#160;million by 1,257,604 shares of common stock of the Spin-Off Company outstanding immediately after the Spin-Off. This resulted in an exercise price of $39.76 per warrant for 227,163 Series&#160;C Warrants; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(iv)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;text-align:justify;">for the Neurotrope Series&#160;H Warrants (now the Company&#8217;s Series&#160;D Warrants), by dividing $20&#160;million by 1,257,604 of shares of common stock of the Spin-Off Company outstanding immediately after the Spin-Off. This resulted in an exercise price of $15.92 per warrant for 555,462 Series&#160;D Warrants.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company used the Black-Scholes valuation model to calculate the warrant amendment expense. The fair value of the warrants amended in connection with the Mergers was estimated at the date of the merger using the following weighted average assumptions: Dividend yield 0%; Expected terms ranging from 0.2 to 10 years; volatility based upon a blend of the Parent company&#8217;s and guideline company historical volatility ranging from 31.75% to 112.3%; and Risk-free interest rates ranging from 0.11% to 0.42%. The total expense recorded in the third quarter of 2020 was $1.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Deemed Distribution</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;7, 2020, pursuant to the Merger , the Company issued a total of 978,077 warrants to investors that elected to amend their existing Neurotrope warrants (see above) and a total of 52,983 shares of Common Stock to those Neurotrope shareholders not electing to amend their existing warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The distribution was treated as a deemed dividend, which increased the loss available to common stockholders in the calculation of loss per share by approximately $2.43 million in the fourth quarter of 2020. The Company used the Black-Scholes valuation model to calculate the total charge to earnings per share. The fair value of the warrants and Common Stock issued in connection with the deemed distribution was estimated at the date of the Spin-Off using the following assumptions: Dividend yield 0%; Expected term of warrants 5 years; volatility based upon a blend of Neurotrope&#8217;s and guideline company historical volatility of 115.0%; and a Risk-free interest rate of 0.40%.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Outstanding Warrants</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2021, the Company had warrants outstanding consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of&#160;shares</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding January&#160;1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 978,077</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,908,751</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,038,898)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,847,930</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the Offering, the Company issued to investors Series&#160;E Warrants to purchase 2,333,908 shares of Common Stock, with an exercise price of $8.51 per share (subject to adjustment), for a period of twelve months from the date of an effective registration statement, Series&#160;F Warrants to purchase up to an aggregate of 2,567,299 shares of Common stock, with an exercise price of $6.90 per share (subject to adjustment), for a period of five years from the date of issuance and pre-funded Warrants to purchase 83,334 shares of Common Stock, with an exercise price of $0.01 per share (subject to adjustment), for a period of five years from the date of issuance. Of the total Series&#160;F Warrants, 233,391 were issued pursuant to the Company&#8217;s placement agent agreements for the private placement (See Note 6 &#8211; &#8220;January&#160;2021 Private Placement&#8221; above). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the June Offering, the Company issued to investors Series G Warrants to purchase up to an aggregate of 1,653,281 shares of Common stock, with an exercise price of $8.51 per share (subject to adjustment), for a period of five years from the date of issuance and pre-funded June Warrants to purchase 66,251 shares of Common Stock, with an exercise price of $0.01 per share (subject to customary adjustment for stock splits, dividends, other), for a period of five years from the date of issuance. In addition, 152,378 warrants were issued pursuant to the Company&#8217;s Placement Agent Agreement for the private placement with an exercise price of $7.547 per share (See Note 6 &#8211; &#8220;June 2021 Private Placement&#8221; above).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On February 16, 2021, pursuant to its advisory agreements, the Company issued warrants to purchase 35,000 share of Common Stock, with an exercise price of $11.46 per share, for a period of five years from the issuance date. On April 1, 2021, the Company issued warrants to purchase 7,000 shares of Common Stock, with an exercise price of $9.76 per share, for a period of five years from the issuance date. On July 1, 2021, the Company issued warrants to purchase 10,300 shares of Common Stock, with an exercise price of $9.30 per share, for a period of five years from the issuance date. The Company used the Black-Scholes valuation model to calculate the value of these warrants issued to advisors during the nine months ended September 30, 2021. The fair value of the warrants was estimated at the date of issuance using the following weighted average assumptions: Dividend yield 0%; Expected term five years; volatility based upon a blend of the Parent company&#8217;s and guideline company historical volatility 129.4%; and Risk-free interest rate of 0.68%. The total expense recorded during the nine month period was approximately $482,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">During the three month period ended September 30, 2021, five warrant holders exercised 79,169 Series E Warrants to purchase 79,169 shares of Common Stock at $8.51 per warrant and three warrant holders exercised 18,335 Series F Warrants to purchase 18,335 shares of Common Stock at $6.90 per warrant. Total proceeds from these warrant exercises was approximately $800,000. During the nine month period ended September 30, 2021, 16 warrant holders exercised 754,170 Series E Warrants to purchase 754,170 shares of Common Stock at $8.51 per warrant and 14 warrant holders exercised 284,728 Series F Warrants to purchase 284,728 shares of Common Stock at $6.90 per warrant. Total proceeds from these warrant exercises was approximately $8.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">Subsequent to period end, during October and November, 2021, 16 warrant holders exercised 425,170 Series E Warrants to purchase 425,170 shares of Common Stock at $8.51 per share, nine warrant holders exercised 47,335 Series F Warrants to purchase 47,335 shares of Common Stock at $6.90 per share, and one holder exercised 65,000 Series G Warrants to purchase 65,000 shares of Common Stock at $8.51 per share. Total cash proceeds from these warrant exercises was approximately $4.5 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_CommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_CommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_StockOptionNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for stock option note disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_StockOptionNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342568138728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Parent Company Investment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsAbstract', window );"><strong>Parent Company Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock', window );">Parent Company Investment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 9 - Parent Company Investment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The components of the net transfers from parent for the three and nine months ended September 30, 2021 and 2020 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three&#160;months&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock based compensation from Parent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 387,927</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consultant compensation paid with Parent equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 233,281</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Parent contributions</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 621,208</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine&#160;months&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock based compensation from Parent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,449,023</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consultant compensation paid with Parent equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500,740</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Parent contributions</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,519,988</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,469,751</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment holdings.  This includes the information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342566613432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#160;10&#160;&#8211; Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Refer to Notes 1, 5, 6, 7 and 8 for disclosure of applicable subsequent events.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342565296792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Subsequent to the Spin-Off, the Company&#8217;s financial statements as of December 31, 2020 and for the period December 7, 2020 to December 31, 2020 are presented on a consolidated basis as the Company became a standalone public company on December 7, 2020. The Company&#8217;s combined financial statements for the period from January 1, 2020 through December 6, 2020 that is included in the results of operations for the three and nine months ending September 30, 2020 and the year ended December 31, 2020 were derived from the consolidated financial statements and accounting records of Neurotrope, the former Parent. These combined financial statements reflect the historical results of operations, financial position and cash flows of the former Parent&#8217;s Spin-Off business which was a wholly owned subsidiary of Neurotrope, Neurotrope Bioscience, Inc., and represented substantially all the business of Neurotrope. These financial statements reflect our financial position, results of operations and cash flows as we were historically managed, in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">All intercompany transactions between the Company and Neurotrope have been included in our financial statements and are considered to be effectively settled for cash at the time the Spin-Off was recorded. The total net effect of the settlement of these intercompany transactions is reflected in our statements of cash flow as a financing activity and in the balance sheets as &#8220;Parent company investment&#8221;. See Note 9.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the unaudited condensed financial statements included herein contain all adjustments necessary to present fairly the Company&#8217;s financial position and the results of its operations and cash flows for the interim periods presented. Such adjustments are of a normal recurring nature. The results of operations for the three and nine months ended September 30, 2021 may not be indicative of results for the full year. These unaudited condensed financial statements should be read in conjunction with the audited condensed financial statements and the notes to those statements for the year ended December 31, 2020 included in our Annual Report on Form 10-K.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make significant estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the general economic environment and actions it may take in the future. The Company adjusts such estimates when facts and circumstances dictate. However, these estimates may involve significant uncertainties and judgments and cannot be determined with precision. In addition, these estimates are based on management&#8217;s best judgment at a point in time and as such these estimates may ultimately differ from actual results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock', window );">Cash and Cash Equivalents and Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents and Concentration of Credit Risk:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company considers all highly liquid cash investments with an original maturity of three months or less when purchased to be cash equivalents. At September 30, 2021, the Company&#8217;s cash balances that exceed the current insured amounts under the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) were approximately $3.6 million. In addition, approximately $27.7 million included in cash and cash equivalents were invested in a money market fund, which is not insured under the FDIC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets and Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fixed Assets and Leases:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">All leases with a lease term greater than 12 months, regardless of lease type classification, are recorded as an obligation on the balance sheet with a corresponding right-of-use asset. The Company does not have any leases greater than 12 months in duration during the respective reporting periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Fixed assets are stated at cost less accumulated depreciation. Depreciation is computed on a straight line basis over the estimated useful life of the asset, which is deemed to be between <span style="-sec-ix-hidden:Hidden_lr9X8jg5jUiA4B9EE7n2ZA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">three</span></span> and ten years.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Research and Development Costs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">All research and development costs, including costs to maintain or expand the Company&#8217;s patent portfolio licensed from CRE are expensed when incurred. Non-refundable advance payments for research and development are capitalized because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at September&#160;30, 2021 and December&#160;31, 2020.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share of Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss Per Share of Common Stock:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On the Spin Off date, 1,257,579 shares of the Company&#8217;s common stock, par value $0.0001 per share (the Common Stock&#8221;) were distributed to Neurotrope stockholders as of November 30, 2020 (the &#8220;Record Date&#8221;). This share amount was being utilized for the calculation of basic earnings (loss) per share (&#8220;EPS&#8221;) for the periods prior to the Spin-Off because the Company was a wholly-owned subsidiary of Neurotrope prior to the Spin Off date. For the periods after the Spin-Off Date, EPS attributable to the Company&#8217;s common stockholders is based upon net income (loss) attributable to the Company&#8217;s common stockholders divided by the weighted-average number of Common Stock outstanding during the period. Penny warrants were included in the calculation of outstanding shares for purposes of basic loss per share. For the periods when a net loss is reported, the computation of diluted EPS equals the basic EPS calculation since common stock equivalents were antidilutive due to losses from continuing operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Income Taxes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company accounts for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes under the &#8220;Separate return method.&#8221; Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company applies the provisions of FASB ASC 740-10, <i style="font-style:italic;">Accounting for Uncertain Tax Positions</i>, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also provides guidance on de-recognition, classification, interest and penalties, and accounting in interim periods, disclosure and transitions. The Company has determined that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is generally three&#160;years from the date of filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company (collectively with Neurotrope, Inc. / Petros Pharmaceuticals, Inc.) may be subject to significant U.S. federal income tax-related liabilities with respect to our prior distribution of all of the issued and outstanding shares of the common stock of Neurotrope Bioscience, Inc., the former subsidiary of Neurotrope, to our stockholders as of and on November 30, 2020 (the &#8220;Spin-Off&#8221;), if there is a determination that the Spin-Off is taxable for U.S. federal income tax purposes. In connection with the Spin-Off, the Company believes substantially to the effect that, among other things, the Spin-Off should qualify as a tax-free transaction for U.S. federal income tax purposes under Section 355 and Section 368(a)(1)(D) of the Code. If the conclusions of the tax opinions are not correct, or if the Spin-Off is otherwise ultimately determined to be a taxable transaction, the Company would be liable for U.S. federal income tax related liabilities. Pursuant to the Separation and Distribution Agreement and the Tax Matters Agreement, Neurotrope agreed to indemnify Synaptogenix for certain liabilities, and Synaptogenix agreed to indemnify Neurotrope for certain liabilities, in each case for uncapped amounts. Indemnities that Synaptogenix may be required to provide Neurotrope are not subject to any cap, may be significant and could negatively impact Synaptogenix&#8217;s business, particularly with respect to indemnities provided in the Tax Matters Agreement. Third parties could also seek to hold Synaptogenix responsible for any of the liabilities that Neurotrope has agreed to retain. Further, the indemnity from Neurotrope may not be sufficient to protect Synaptogenix against the full amount of such liabilities, and Neurotrope may not be able to fully satisfy its indemnification obligations. Moreover, even if Synaptogenix ultimately succeeds in recovering from Neurotrope any amounts for which Synaptogenix is held liable, Synaptogenix may be temporarily required to bear these losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under Section 382 of the Internal Revenue Code of 1986, as amended, changes in the Company&#8217;s ownership may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. In addition, the significant historical operating losses incurred by the Company may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. The Company believes that operating loss carryforwards are limited under Section 382 limitations although Section 382 studies have not been conducted to determine the actual limitations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock', window );">Expense Reimbursement for Grant Award</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Expense Reimbursement for Grant Award:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company reduces its research and development expenses by funding received or receivable from an NIH grant during the period that the expenses are incurred. The Company recognized grant related expense reductions during the three and nine months ended September 30, 2021 of approximately $1.1 million. See Note 5, &#8220;<i style="font-style:italic;">Clinical Trial Services Agreements</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Of the total $2.7 million available from the NIH grant, approximately $2.6 million was received for trial-related expenses incurred since grant inception to October&#160;31, 2021 with the remaining $0.1 million available for reimbursement during the period November&#160;2021 to March&#160;2022. The Company believes it will receive the maximum reimbursements under the grant.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">&#160;In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, which reduces the number of accounting models for convertible instruments, amends diluted earnings per share calculations for convertible instruments and allows more contracts to qualify for equity classification. ASU 2020-06 will be effective for interim and annual periods beginning after December 15, 2021. Early adoption is permitted. The Company is evaluating the adoption of ASU 2020-06.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Cash and Cash Equivalents and Concentration of Credit Risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting policy for expense reimbursement for grant award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342566758008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation: (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock Based Compensation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of&#160;shares</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding January&#160;1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 978,077</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,908,751</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,038,898)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,847,930</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of stock outstanding under the plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a summary of stock option activity under the stock option plans for the nine months ended September 30, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">millions)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Options outstanding at January&#160;1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ran0Cu55WEO7SIeyEo9upQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 123,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less options forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less options expired/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Options outstanding at September&#160;30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 123,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Options exercisable at September 30, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89,613</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.84</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342566708856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants: (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_CommonStockWarrants', window );"><strong>Common Stock Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Common stock warrant activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of&#160;shares</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding January&#160;1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 978,077</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,908,751</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,038,898)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,847,930</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_CommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_CommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342568703720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Parent Company Investment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsAbstract', window );"><strong>Parent Company Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock', window );">Schedule components of the net transfers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three&#160;months&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock based compensation from Parent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 387,927</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consultant compensation paid with Parent equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 233,281</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Parent contributions</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 621,208</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine&#160;months&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock based compensation from Parent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,449,023</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consultant compensation paid with Parent equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500,740</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Parent contributions</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,519,988</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,469,751</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342648841160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization, Business, Risks and Uncertainties (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 07, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called for by warrants</a></td>
<td class="nump">52,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_SpinoffMember', window );">Spin-Off from Neurotrope</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfSharesForEveryFiveCommonSharesHeld', window );">Number of shares for every five shares held</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld', window );">Number of shares for every five shares of Neurcommon stock issuable upon conversion of preferred stock held</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld', window );">Number of common stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ExcessOfCashInOperatingAssetsAndLiabilities', window );">Excess of cash in operating assets And liabilities</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called for by warrants</a></td>
<td class="nump">4,889,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Number of warrants</a></td>
<td class="nump">$ 977,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ExcessOfCashInOperatingAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents Excess Of Cash In Operating Assets And Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ExcessOfCashInOperatingAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NumberOfSharesForEveryFiveCommonSharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of Synaptogenix, Inc. . common stock for every five shares of Neurotrope common stock held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NumberOfSharesForEveryFiveCommonSharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares of common stock for every five shares of Neurotrope common stock issuable upon conversion of Neurotrope preferred stock held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_SpinoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_SpinoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342570147528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Business, Risks and Uncertainties - Liquidity Uncertainties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,294,645<span></span>
</td>
<td class="nump">$ 31,294,645<span></span>
</td>
<td class="nump">$ 31,294,645<span></span>
</td>
<td class="nump">$ 5,795,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate', window );">Cash and cash equivalents expected amount at financial reporting date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of investor warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 8,382,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_ServicesAgreement2020Member', window );">2020 Services Agreement | National Institutes of Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AmountOfFundingReceived', window );">Reimbursement of trial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses', window );">Inflow of cash due to warrant exercise and reimbursement of trial expense</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of investor warrants</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | 2020 Services Agreement | National Institutes of Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AmountOfFundingReceived', window );">Reimbursement of trial expenses</a></td>
<td class="nump">$ 530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_AmountOfFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funding received by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_AmountOfFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expected amount of cash and cash equivalents at financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow due to warrant exercise and reimbursement of trial expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_ServicesAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_ServicesAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=snpx_NationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=snpx_NationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342574008904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 07, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jul. 23, 2020</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash balance of insured FDIC amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash balance of uninsured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_CapitalizedResearchAndDevelopmentServices', window );">Capitalized research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_IssueOfSharesOnSpinOff', window );">Issue of Shares On Spin Off</a></td>
<td class="nump">1,257,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Federal and state net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,926,933)<span></span>
</td>
<td class="num">$ (4,269,609)<span></span>
</td>
<td class="num">(8,375,152)<span></span>
</td>
<td class="num">$ (9,739,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=snpx_CurrentShareholdersOfCompanyMember', window );">Current Neurotrope stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_IssueOfSharesOnSpinOff', window );">Issue of Shares On Spin Off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=snpx_NationalInstitutesOfHealthMember', window );">National Institutes of Health | 2020 Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AmountOfAwardReceived', window );">Amount of award received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AmountOfFundingReceived', window );">Funding received in first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=snpx_NationalInstitutesOfHealthMember', window );">National Institutes of Health | 2020 Services Agreement | Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AmountOfFundingReceived', window );">Funding received in first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=snpx_NationalInstitutesOfHealthMember', window );">National Institutes of Health | 2020 Services Agreement | Subsequent events | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AmountOfFundingReceivable', window );">Funding receivable in second year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_AmountOfAwardReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of award received to support an additional phase 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_AmountOfAwardReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_AmountOfFundingReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funding receivable by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_AmountOfFundingReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_AmountOfFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funding received by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_AmountOfFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_CapitalizedResearchAndDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized non-refundable advance payments for research and development services pursuant to contractual agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_CapitalizedResearchAndDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_IssueOfSharesOnSpinOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued at spin off.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_IssueOfSharesOnSpinOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=snpx_CurrentShareholdersOfCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=snpx_CurrentShareholdersOfCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=snpx_NationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=snpx_NationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_ServicesAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_ServicesAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342648696648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements and Commitments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 05, 2021</div></th>
<th class="th"><div>Jan. 19, 2017</div></th>
<th class="th"><div>Jul. 14, 2014</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_CommitmentToPayFees', window );">Commitment To Pay Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_StandFordLicenseAgreementMember', window );">Stand Ford License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_RoyaltyPaymentPercentage', window );">Royalty payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_MilestonePaymentsPaid', window );">Milestone payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_Mt.SinaiLicenseAgreementMember', window );">Mt. Sinai License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_MilestonePaymentsPaid', window );">Milestone payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_MilestonePaymentsPayable', window );">Payable of milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AdditionalMilestonePaymentsPayable', window );">Additional milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_TotalSavings', window );">Total services fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_LicenseAgreementsLicensingFees', window );">Licensing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_LicenseAgreementsDevelopmentCostsAndPatentFees', window );">Development costs and patent fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_Mt.SinaiLicenseAgreementMember', window );">Mt. Sinai License Agreement | Net sales up to $250 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_RoyaltyPaymentPercentage', window );">Royalty payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_RoyaltyPaymentThresholdNetSales', window );">Threshold net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_Mt.SinaiLicenseAgreementMember', window );">Mt. Sinai License Agreement | Net sales over $250 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_RoyaltyPaymentPercentage', window );">Royalty payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_RoyaltyPaymentThresholdNetSales', window );">Threshold net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_AgreementsWithBryologyxMember', window );">Agreements with BryoLogyx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_PercentageOfGrossRevenue', window );">Percentage of Gross Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_NemoursAgreementMember', window );">Nemours Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses', window );">Cost on Trail and investigation new drug documentation expenses</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Aggregate amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_RoyaltyPaymentPercentage', window );">Royalty payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_RoyaltyPaymentPercentage', window );">Royalty payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_AdditionalMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional milestone payments payable by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_AdditionalMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_AnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of annual license maintenance fee paid during reporting period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_AnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_CommitmentToPayFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of committed fees to be paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_CommitmentToPayFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount relates to cost on Trail and investigation new drug documentation expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_LicenseAgreementsDevelopmentCostsAndPatentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of development costs and patent fees paid by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_LicenseAgreementsDevelopmentCostsAndPatentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_LicenseAgreementsLicensingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of license fees paid by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_LicenseAgreementsLicensingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_MilestonePaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for milestone payments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_MilestonePaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_MilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments payable by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_MilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_PercentageOfGrossRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents percentage of gross revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_PercentageOfGrossRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_RoyaltyPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Percentage .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_RoyaltyPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_RoyaltyPaymentThresholdNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The threshold amount of net sales to be considered for payment of royalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_RoyaltyPaymentThresholdNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_TotalSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of savings made by the company as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_TotalSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_StandFordLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_StandFordLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_Mt.SinaiLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_Mt.SinaiLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=snpx_NetSalesUpToDollars250MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=snpx_NetSalesUpToDollars250MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=snpx_NetSalesOverDollarsMillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=snpx_NetSalesOverDollarsMillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_AgreementsWithBryologyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_AgreementsWithBryologyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_NemoursAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_NemoursAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342566633256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions and Licensing / Research Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions and Licensing / Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfStatementsEnteredIntoAgreement', window );">Number of statements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NumberOfStatementsEnteredIntoAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents number of statements entered into agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NumberOfStatementsEnteredIntoAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342555744232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 07, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 23, 2020 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Feb. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 05, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 04, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 16, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 16, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants for consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Funding receivable in year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Clinical trial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 836,716<span></span>
</td>
<td class="nump">$ 563,317<span></span>
</td>
<td class="nump">2,974,776<span></span>
</td>
<td class="nump">$ 1,556,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ConsultingAgreementMonthlyInstallmentFee', window );">Monthly installment of annual consulting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_ConsultingAgreementWithSmCapitalManagementLlcMember', window );">Consulting Agreement with SM Capital Management, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ContractPaymentsTerm', window );">Contract Payments, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AnnualConsultancyAgreementFees', window );">Annual consulting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ConsultancyFees', window );">Consultancy fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ConsultingAgreementMonthlyInstallmentFee', window );">Monthly installment of annual consulting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember', window );">Consulting Agreement with Katalyst Securities LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ConsultancyFees', window );">Consultancy fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ConsultingAgreementMonthlyInstallmentFee', window );">Monthly installment of annual consulting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember', window );">Consulting Agreement with Katalyst Securities LLC [Member] | Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock | shares</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_ConsultingAgreementWithGpNurmenkariIncMember', window );">Consulting Agreement with GP Nurmenkari, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ConsultancyFees', window );">Consultancy fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate', window );">Warrants term following the effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ConsultingAgreementMonthlyInstallmentFee', window );">Monthly installment of annual consulting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
<td class="nump">$ 11.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_ConsultingAgreementWithGpNurmenkariIncMember', window );">Consulting Agreement with GP Nurmenkari, Inc [Member] | Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants for consulting fees</a></td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock | shares</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_ServicesAgreement2020Member', window );">2020 Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_TargetEnrollmentOfStudySubjects', window );">Target enrollment of study subjects | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_EstimatedBudgetForServices', window );">Total estimated budget for the services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ConsultingAgreementNoticeForCancellation', window );">Threshold period of prior written notice to terminate agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ProceedsFromGrants', window );">Funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Funding receivable in year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AmountFundedAgainstTotalTrialCost', window );">Amount funded against the total trial cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Clinical trial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_PrepaymentsForServiceAgreementCurrent', window );">WCT prepayments included as a prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AccountsPayableForServiceAgreementCurrent', window );">WCT payments included in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 771,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_ServicesAgreement2020Member', window );">2020 Services Agreement | National Institutes of Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_EstimatedBudgetForServices', window );">Total estimated budget for the services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AmountOfAwardReceived', window );">Amount of award received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Clinical trial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember', window );">Employment agreement with Alan J. Tuchman, M.D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_InitialAnnualBaseSalaryPayable', window );">Initial annual base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AnnualDiscretionaryBonusPayableMaximumPercent', window );">Annual discretionary bonus payable (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff', window );">Options granted to purchase shares of common stock as a percent of Company's outstanding shares of common stock immediately following the Spin-Off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination', window );">Minimum percentage of annualized salary payable if the employee is termination within six months from start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember', window );">Employment agreement with Alan J. Tuchman, M.D | If employee is terminated after six months but within one year from Start Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfMonthsBaseSalaryPayableUponTermination', window );">Number of months base salary payable if the employee is terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember', window );">Employment agreement with Alan J. Tuchman, M.D | First anniversary from Start Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Options granted, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember', window );">Employment agreement with Alan J. Tuchman, M.D | Second anniversary from Start Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Options granted, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember', window );">Employment agreement with Alan J. Tuchman, M.D | Third anniversary from Start Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Options granted, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember', window );">Employment agreement with Alan J. Tuchman, M.D | Fourth anniversary from Start Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Options granted, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_CharlesRyanSeparationAgreementMember', window );">Charles Ryan Separation Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AnnualDiscretionaryBonusPayableMaximumPercent', window );">Annual discretionary bonus payable (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfMonthsBaseSalaryPayableUponSeparation', window );">Number of months base salary payable as of the Separation Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_TotalAmountOfBaseSalaryPayableUponSeparation', window );">Total base salary payable upon Separation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_CashBonusPayableUponSeparation', window );">Cash bonus payable upon Separation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_PeriodFollowingSeparationDateToPayCobraPremiums', window );">Period following the Separation Date to pay COBRA premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_TotalSeparationBenefitsPayable', window );">Total commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SeparationBenefitsReimbursed', window );">Separation benefits reimbursed by Metuchen pursuant to Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_AccountsPayableForServiceAgreementCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount payable under the service agreement, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_AccountsPayableForServiceAgreementCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_AmountFundedAgainstTotalTrialCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount stated the total trial cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_AmountFundedAgainstTotalTrialCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_AmountOfAwardReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of award received to support an additional phase 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_AmountOfAwardReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_AnnualConsultancyAgreementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of annual consulting fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_AnnualConsultancyAgreementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_AnnualDiscretionaryBonusPayableMaximumPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of base salary payable as annual discretionary bonus to the employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_AnnualDiscretionaryBonusPayableMaximumPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_CashBonusPayableUponSeparation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash bonus payable to the employee upon his separation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_CashBonusPayableUponSeparation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ConsultancyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consulting fees incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ConsultancyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ConsultingAgreementMonthlyInstallmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the monthly installment of annual consulting fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ConsultingAgreementMonthlyInstallmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ConsultingAgreementNoticeForCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the notice term for cancellation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ConsultingAgreementNoticeForCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ContractPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from commencement over which fixed contract payments are due per the terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ContractPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_EstimatedBudgetForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated budget for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_EstimatedBudgetForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_InitialAnnualBaseSalaryPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of initial annual base salary payable to the employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_InitialAnnualBaseSalaryPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of annualized salary payable as compensation upon termination of the employee within six months from Start Date of the employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NumberOfMonthsBaseSalaryPayableUponSeparation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of months base salary payable to the employee upon his separation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NumberOfMonthsBaseSalaryPayableUponSeparation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NumberOfMonthsBaseSalaryPayableUponTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of months base salary payable to the employee upon his termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NumberOfMonthsBaseSalaryPayableUponTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options granted to the employee to purchase shares of common stock as a minimum percent of Company's outstanding shares of common stock immediately following the Spin-Off.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_PeriodFollowingSeparationDateToPayCobraPremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period following the Separation Date to pay COBRA premiums, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_PeriodFollowingSeparationDateToPayCobraPremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_PrepaymentsForServiceAgreementCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayments under the service agreement, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_PrepaymentsForServiceAgreementCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ProceedsFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of proceeds from grants during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ProceedsFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_SeparationBenefitsReimbursed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of separation benefits paid by the company, which has been reimbursed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_SeparationBenefitsReimbursed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_TargetEnrollmentOfStudySubjects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the target enrollment of study subjects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_TargetEnrollmentOfStudySubjects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_TotalAmountOfBaseSalaryPayableUponSeparation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amounts of base salary payable to the employee upon his separation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_TotalAmountOfBaseSalaryPayableUponSeparation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_TotalSeparationBenefitsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total benefits payable to the employee upon his separation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_TotalSeparationBenefitsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants term following the effective date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_ConsultingAgreementWithSmCapitalManagementLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_ConsultingAgreementWithSmCapitalManagementLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_ConsultingAgreementWithGpNurmenkariIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_ConsultingAgreementWithGpNurmenkariIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_ServicesAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_ServicesAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=snpx_NationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=snpx_NationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=snpx_ShareBasedPaymentArrangementTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=snpx_ShareBasedPaymentArrangementTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_CharlesRyanSeparationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_CharlesRyanSeparationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342570224584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity: (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 07, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_IssueOfSharesOnSpinOff', window );">Issue of shares on spin off</a></td>
<td class="nump">1,257,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SpinOffRatio', window );">Spin Off Ratio</a></td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfVotesPerShareOwned', window );">Votes per share of common stock | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,257,579<span></span>
</td>
<td class="nump">6,136,967<span></span>
</td>
<td class="nump">1,257,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,136,967<span></span>
</td>
<td class="nump">1,257,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_SpinoffMember', window );">Spin-Off from Neurotrope</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,257,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_IssueOfSharesOnSpinOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued at spin off.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_IssueOfSharesOnSpinOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NumberOfVotesPerShareOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of votes entitled for each common share held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NumberOfVotesPerShareOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_SpinOffRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of shares of spin-off company issued for shares of the Company's common stock owned by such stockholder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_SpinOffRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_SpinoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_SpinoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342558848088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity: - January 2021 Private Placement (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 14, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>May 19, 2021</div></th>
<th class="th">
<div>Jan. 21, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 13, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 07, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement', window );">Aggregate number of shares authorized to issue under purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,333,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common share issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, stated value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse Stock Split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse Stock Split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse Stock Split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=snpx_PlacementAgentsMember', window );">Placement Agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">152,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant', window );">Percentage of offering fees on aggregate price of warrant exercise</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ThresholdPeriodForArrangingFutureFinancing', window );">Period within which future financing should be consummated</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common share issuable upon exercise of warrants</a></td>
<td class="nump">152,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights', window );">Warrants exercise period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_PercentageOfOfferingFeesInCash', window );">Percentage of offering fees in cash</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_PercentageOfOfferingFeesInWarrants', window );">Percentage of offering fees in warrants</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_SecuritiesPurchaseAgreementsMember', window );">Securities Purchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights', window );">Warrants exercise period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_CombinedPurchasePriceOfCommonStockAndWarrants', window );">Combined purchase price of common stock and warrants | $ / shares</a></td>
<td class="nump">$ 7.547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock', window );">Gross proceeds in offering | $</a></td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NetProceedsFromSaleOfWarrantsAndCommonStock', window );">Net proceeds in offering | $</a></td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_SecuritiesPurchaseAgreementsMember', window );">Securities Purchase Agreements | Placement Agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights', window );">Warrants exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_PercentageOfOfferingFeesInCash', window );">Percentage of offering fees in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_PercentageOfOfferingFeesInWarrants', window );">Percentage of offering fees in warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_ShareholderRightsPlanMember', window );">Shareholder Rights Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend', window );">Number of preferred share purchase right for each outstanding share of Common Stock by means of dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights', window );">Minimum acquisition percentage of outstanding common stock to exercise rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson', window );">Discount available to right holders to purchase common stock upon acquisition of minimum shareholding by acquiring person</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfCommonSharesForEachRight', window );">Number of common shares for each right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_RightsAgreementMember', window );">Rights Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight', window );">Number of One-Thousandth share of Series A Preferred stock Issued In Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_PurchasePriceOfRight', window );">Purchase price of right | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_PrefundedWarrantsMember', window );">Prefunded warrants | Securities Purchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement', window );">Aggregate number of shares authorized to issue under purchase agreement</a></td>
<td class="nump">1,653,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesEWarrantsMember', window );">Series E Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common share issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesEWarrantsMember', window );">Series E Warrants | Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common share issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesEWarrantsMember', window );">Series E Warrants | Securities Purchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,333,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common share issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,333,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights', window );">Warrants exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesGWarrantsMember', window );">Series G Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common share issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesGWarrantsMember', window );">Series G Warrants | Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common share issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesGWarrantsMember', window );">Series G Warrants | Securities Purchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement', window );">Aggregate number of shares authorized to issue under purchase agreement</a></td>
<td class="nump">1,653,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesFWarrantsMember', window );">Series F Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,567,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common share issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,567,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesFWarrantsMember', window );">Series F Warrants | Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common share issuable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesFWarrantsMember', window );">Series F Warrants | Securities Purchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement', window );">Aggregate number of shares authorized to issue under purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,333,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights', window );">Warrants exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of shares authorized to issue under purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercise period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_CombinedPurchasePriceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Combined purchase price per share of Common Stock and Warrants (the "Offering").</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_CombinedPurchasePriceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount available to right holders to purchase common stock upon acquisition of minimum shareholding by acquiring person.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gross proceeds received from offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum acquisition percentage of outstanding common stock to exercise rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NetProceedsFromSaleOfWarrantsAndCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net proceeds from sale of Warrants and Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NetProceedsFromSaleOfWarrantsAndCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NumberOfCommonSharesForEachRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares upon exercise of each right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NumberOfCommonSharesForEachRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of One-Thousandth share of Series A Preferred stock Included In Right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of preferred share purchase right for each outstanding share of Common Stock by means of dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fees on offering based on aggregate exercise price paid to placement agents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_PercentageOfOfferingFeesInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fees on offering in cash to placement agents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_PercentageOfOfferingFeesInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_PercentageOfOfferingFeesInWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fees on offering in warrants to placement agents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_PercentageOfOfferingFeesInWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_PurchasePriceOfRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_PurchasePriceOfRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ThresholdPeriodForArrangingFutureFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period within which the future financing should be consummated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ThresholdPeriodForArrangingFutureFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=snpx_PlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=snpx_PlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_SecuritiesPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_SecuritiesPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_ShareholderRightsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_ShareholderRightsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_RightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_RightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=snpx_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesGWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesGWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesFWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesFWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342561991160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation: (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 13, 2021 </div>
<div>director </div>
<div>employee </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 06, 2021 </div>
<div>director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 12, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 13, 2021 </div>
<div>USD ($) </div>
<div>employee </div>
<div>director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 07, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 07, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of securities available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=snpx_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of securities available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock options expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,198,860<span></span>
</td>
<td class="nump">$ 387,928<span></span>
</td>
<td class="nump">$ 1,918,651<span></span>
</td>
<td class="nump">$ 1,449,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue', window );">Fair value of options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,054,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price of stock options | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfDirectors', window );">Number of director | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfEmployee', window );">Number of employee | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=snpx_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock options expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,528<span></span>
</td>
<td class="nump">153,025<span></span>
</td>
<td class="nump">424,993<span></span>
</td>
<td class="nump">551,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=snpx_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock options expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 983,332<span></span>
</td>
<td class="nump">$ 234,903<span></span>
</td>
<td class="nump">$ 1,493,658<span></span>
</td>
<td class="nump">$ 897,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=snpx_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,575<span></span>
</td>
<td class="nump">12,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">495,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfDirectors', window );">Number of director | director</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfExecutiveDirectors', window );">Number of executive directors | director</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU's | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfEmployee', window );">Number of employee | employee</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Director | RSU's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember', window );">Nonemployee directors | Director Compensation Policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of securities available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember', window );">Newly appointed director | Director Compensation Policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of securities available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors', window );">Stock option grant authorized for service on a committee of the Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Employee | RSU's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=srt_ChiefFinancialOfficerMember', window );">CFO | RSU's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">First anniversary from Start Date | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">First anniversary from Start Date | Newly appointed director | Director Compensation Policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Second anniversary from Start Date | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Second anniversary from Start Date | Newly appointed director | Director Compensation Policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Third anniversary from Start Date | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Third anniversary from Start Date | Newly appointed director | Director Compensation Policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=snpx_DateOfGrantMember', window );">Date of grant | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=snpx_FirstAnniversaryOfGrantDateMember', window );">First anniversary of grant date | RSU's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=snpx_SixMonthAnniversaryOfGrantDateMember', window );">Six month anniversary of grant date | RSU's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NumberOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of directors affected by the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NumberOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NumberOfEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of directors .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NumberOfEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NumberOfExecutiveDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of executive directors affected by the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NumberOfExecutiveDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement for service on a committee of the Board of Directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=snpx_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=snpx_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=snpx_DirectorCompensationPolicyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=snpx_DirectorCompensationPolicyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=snpx_DateOfGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=snpx_DateOfGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=snpx_FirstAnniversaryOfGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=snpx_FirstAnniversaryOfGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=snpx_SixMonthAnniversaryOfGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=snpx_SixMonthAnniversaryOfGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342569343112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation: - Stock option activity under the stock option plans (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at the beginning</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">123,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at the end</a></td>
<td class="nump">123,850<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at the end</a></td>
<td class="nump">89,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at the beginning (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">9.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at the end (in dollars per share)</a></td>
<td class="nump">9.84<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at the end (in dollars per share)</a></td>
<td class="nump">$ 9.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years) and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Options granted (in years)</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding at the end (in years)</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable at the end (in years)</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at the end (in dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable at the end (in dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No definition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards in granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342568822264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants: - Common stock warrant activity (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_CommonStockWarrants', window );"><strong>Common Stock Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding January 1, 2021</a></td>
<td class="nump">978,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants issued</a></td>
<td class="nump">6,908,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="num">(1,038,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding September 30, 2021</a></td>
<td class="nump">6,847,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_CommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_CommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342558220872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants: - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 16, 2021 </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 07, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 26, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,334<span></span>
</td>
<td class="nump">978,077<span></span>
</td>
<td class="nump">978,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,908,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants', window );">Exercise price to purchase shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SpinOffRatio', window );">Spin-Off Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Total expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,382,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises | $</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesWarrantsMember', window );">Series A Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment', window );">Exercise price of warrants before amendment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment', window );">Exercise price of warrants before amendment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesCWarrantsMember', window );">Series C Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment', window );">Exercise price of warrants before amendment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesDWarrantsMember', window );">Series D Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment', window );">Exercise price of warrants before amendment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesHWarrantsMember', window );">Series H Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants', window );">Exercise price to purchase shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesGWarrantsMember', window );">Series G Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,653,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants', window );">Exercise price to purchase shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesGWarrantsMember', window );">Series G Warrants | Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfWarrantHoldersWhoExercisedWarrants', window );">Number Of Warrant Holders Who Exercised Warrants | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesFWarrantsMember', window );">Series F Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants', window );">Exercise price to purchase shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,567,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfWarrantHoldersWhoExercisedWarrants', window );">Number Of Warrant Holders Who Exercised Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesFWarrantsMember', window );">Series F Warrants | Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">47,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">47,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfWarrantHoldersWhoExercisedWarrants', window );">Number Of Warrant Holders Who Exercised Warrants | item</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesEWarrantsMember', window );">Series E Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,333,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants', window );">Exercise price to purchase shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">754,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">754,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfWarrantHoldersWhoExercisedWarrants', window );">Number Of Warrant Holders Who Exercised Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesEWarrantsMember', window );">Series E Warrants | Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">425,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">425,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_NumberOfWarrantHoldersWhoExercisedWarrants', window );">Number Of Warrant Holders Who Exercised Warrants | item</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SpinOffRatio', window );">Spin-Off Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SpinOffRatio', window );">Spin-Off Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SpinOffRatio', window );">Spin-Off Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SpinOffRatio', window );">Spin-Off Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SpinOffRatio', window );">Spin-Off Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SpinOffRatio', window );">Spin-Off Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_SpinOffRatio', window );">Spin-Off Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_PlacementAgentAgreementMember', window );">Placement Agent Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=snpx_AdvisoryAgreementsMember', window );">Advisory Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.76<span></span>
</td>
<td class="nump">$ 11.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Total expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding, before amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator used to determine the initial exercise price of warrants in the event of spin-off.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_NumberOfWarrantHoldersWhoExercisedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrant holders who exercised their warrants during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_NumberOfWarrantHoldersWhoExercisedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_SpinOffRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of shares of spin-off company issued for shares of the Company's common stock owned by such stockholder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_SpinOffRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesHWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesHWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesGWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesGWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesFWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesFWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=snpx_SeriesEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_PlacementAgentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_PlacementAgentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=snpx_AdvisoryAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=snpx_AdvisoryAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140342569244184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Parent Company Investment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsAbstract', window );"><strong>Parent Company Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation', window );">Stock based compensation from Parent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 387,927<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,449,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold', window );">Consultant compensation paid with Parent equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">233,281<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_snpx_ContributionsFromParent', window );">Parent contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,519,988<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 621,208<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,469,751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ContributionsFromParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of contributions from Parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ContributionsFromParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for parent company employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>45
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MDTQ]#-0'I/B;/JQ [(P<I_H N27"R$VIMERP?ZH.:1JC/I<HFCUI_7D[G(S
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MHG4JG7&6ZYL".;K'%+,,T,)X270UQP*8*D"1#--K]!E]0BZ2A5Z5B:OTUL;
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M)[9/>Z9M5/H(!5S..$<O%$HUV@I&@KQ2KMTD;=V,#V+7[4G7 #W !78_VS5
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M0.K\:LSJ7S.G(M]06"N]8&_!01L;UWBZ:BP?]ME CB_6*&I(#YP83.CQ[]M
M),TOD/<@5!&A\!D>,DOP$-B%;9M,&B  -X\ A!D%X<7GC^]^&%2]_/QSKRLE
M@8>1R=[ GXA,Z5&B]0Z"@MS&W!<5@!OZ>N(F@8R?<'ZT[A9YR-%2@&E!X&*K
M<!0MS:,<KGQK%KXCQ#DY8U^>JB?!(+"HUCQ33V$3T>B:-%*_>J"X9N8E)>8]
M'T"V/!S--V!D@ /H>D>G+V$%&!\@*;2-+<\1.F+M#KS,"$H, Q4%((78GT-F
M*2?FSE MD1R$ERP<CVOJ03>V)J)F_$:M'#9)3+(GZ)IKVP+0XL88>4"NH=C5
MR]@GV50IH+YC<-BWZPXQ[#KL#L%$!%=E]<)6EI[->G^2$+>H[$H40-',<7X\
MC>(#H5#2$X-ZZK:&#FW,TI)HPOB*:'(',[1DT113POE)W3%<Z/N XDL93.='
M??^T#\9,Q\&;?;69E(#C??2!I%T;? CJ&K!6ZX)Q05?AOV%_2A'9G%&*4@W)
M^,'$#OG7[(I6[]]?SBC>N"L9L=M35,#GV+TB[^7AG->.#_Q\/!22(IF812&7
M])!QTZB[!AX0D,E^5?)ZS4B>$ZS)6?WB05(&"*$O1'-U'NA4UY167">9G!2=
M%'W=PMMW='!^P4?9STP*5U^YS7)IN*\BA-BM\+06.0DK/+$_,*DH=%@35@&9
MB$WBLM]AV=&1_$>TY@^(DR+Q!YH?,1?#VITMI;R,E\DI5LHG$DD+A)90O$O^
M\/,\/+$N,P01'V_(3>*U[)'=CT;)G *>Y'1A<N64C^VAFJ3($PM[)'9&FGB#
M<"YW=,H+^I1"HF\UGK N%7M([(,,N0%'$M2O=13EZ&Y[28I$6\X( <RLR!6!
M$I0R5H(#YE<PIQXI*T-8%/Q+](9\[!HCE(2^V$-9)B2%*#YE&>@B!=!(91XP
M@EJC^,_$> \>]'\>84/H]*(RJFL=.YY0(+47C[B -.L]^Y>;8:JCN3>^ /]@
M#IBB(-LY! 2K.$8%DL;&2N*52TYA6^'QTXAH.X_3FMC#"$I9S8S&&_(YL20!
M@ J5(<.-O.".'.N\H=Y 8(;:-[DK*]1JR^E-$"'T)4N0/1W.WI >P]^1YB#2
M,,RSV=G9C[/CYV=_PK8Y])U_K^OVY6?U>Q(Z8/R0&3^^>#$[.SW>?^QXV,/Q
MR1Z,3-5&+X:.F-'.X2G$'D_9A]TQ+-^]#'P"U*258Z3H.R.QN 5+2QYGRC4
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MMQ"S-7MJPS&:;J#Z>XD>?_"X\9ZO'3XIX6PB<:<"#!7@=I;G]>*$<9XSF-W
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MT]J?PX]RR>!Z8ZP@5KG,B%+GET[__Z+I Z"!J3]X/N5:9CY/=8?^V5N.!OC
M^/0&T7!!:+N2TA,/1"70#<,; /TX+\G%6-0C%PX#PGU\?)#Y%:+ UDM44ZF0
M%*-_]?P>&;$\;O2DHY#KJZ/3J7PM!L/18"^^(V3X-2,>Y]%GJ?I\*0+(^.DG
MM>9#[_7J/03,=+4TZW&"..:/FT8RJ9!+T"'N%0%$P8.3_I?7RA0RX^N ^73>
MWQOD=R6>3A+H55<5<!:Y^:^>>L1%&N#E8M9W*;]$=,9OD/QP/KAGT#?:5KW>
M:%56W/T;BOXJ([V?(A;@+IFX.-U3SB#D9(H@*J2/6P'C3OU2M&XP59SW>-H;
M&AB31G^8]=H8\LRF'[K:?5OGUH%IX[S/[&'X=GXDY&PK+64_Y:4J"#5T]?BT
M85O-@DWA^'2M-GI?TKO&T?4C[WA)R>NR6W>HQM3'2/[ZF#O]P<8%OW-($?[.
MX5]_XX26-4\"8\-V<-O7+5]#IWV7BZ]Y&QU].GLVR5,2B4%^3R /OP8OS=2H
M9I446V0&E.762@:CUUI8L(D4N)!'2WFBV8\R!T.E!VG)<*/BUT*X*M#TR/.=
M,.R7FA\B0%4;Z&A\FS1%0_\UB=B/UM-K6*,W=_@D>94AS=*69FT;]CH9:N:Q
M]_RI..A4?6"TJ4NW37<T6TJ0;;N?//!+O*#/,ZNT"0H>L#D]])KPV>#E;#30
M:WX%G4%IT\I[VOEI?LO]4E[N[I?+*_)P>DB%0FY6V#J;/G]Z(M<9Z4OKMORJ
M]]*UK:OYX\9H>#<MP.\KA_03O] !^=W_M_\#4$L#!!0    ( "6(;%/;0(<P
MS0P  #(D   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&ULY5IM<]LV$OXK
M&#?I.'.*+,OV)6E>9AP[N;B-74^<WMU7B(1$U"3  J!E]=??LPL2).677&^N
M<Q_NBRV)P&)WL?OLLRN]65MW[0NE@KBM2N/?[A0AU#_L[?FL4)7T4ULK@R=+
MZRH9\-:M]GSME,QY4U7NS6>SO^Y54IN==V_XLTOW[HUM0JF-NG3"-U4EW>:]
M*NWZ[<[^3O?!%[TJ GVP]^Y-+5?J2H5?ZDN'=WM)2JXK9;RV1CBU?+MSO/_#
M^T-:SPO^KM7:#UX+LF1A[36].<O?[LQ((56J+) $B7\WZD25)0F"&K^U,G?2
MD;1Q^+J3_I%MART+Z=6)+?^A\U"\W7FY(W*UE$T9OMCU)]7:<T3R,EMZ_BO6
M<>TA3LP:'VS5;L;[2IOX7]ZV?AAL>#E[8,.\W3!GO>-!K.6I#/+=&V?7PM%J
M2*,7;"KOAG+:T*5<!8>G&OO".UA3RH5UDIPCCE=.*;@\>"%-+DYL5>G []_L
M!9Q&>_:R5O+[*'G^@.17XMR:4'CQP>0J'^_?@Y9)U7FGZOOYHP*O5#T5![.)
MF,_F^X_(.TBF'["\@_^JZ:.C#M-1AWS4X9_@Y<<E7]B@Q,'WW[V<[^^_%O_N
M.3\(VC$[>"VN@C1([5Q\UAE2;;3I9R/.Y4;LS\GE^X<3$0I%4FII-@(KE%.Y
MT"98(479;I?==K%+J^F8^>QU.B5)YP?[KY\AW$,AOF+I>RNQP"[%5X>P5\KS
M:SSXK$I2/\GXL3':.O&+@8W.Z[ 1NUO'=,(GHFZ<;R2T@9+K0F=%+Z:07JP<
MGL$(/!W:)@$W-\HTZOE"2:?-:D+84N;/D9M*.$IT]JBZS<K&DZM;\R?1')(5
M5T$PGP'06[1KO-@%&F7*!4"FR*S)->&3A[8-,L6E1[4,Y$<6%&_0P1.LKLH*
M8TN[V@B8PL<U\#W\M7 ;ZP.NWP@?7).%QLD2*.7T#<>$GXAK8]= 0]_=#6V!
M*#]IO<8B21QDD.0 K.>H(?FP()!$H]R-;;SP&UQ5)7+MX5+<QD24&V^]K; &
MV.6 Z_10 3?Q#"K9:S@IPTUK*VJ'X&W!&=9!< .8U1FL(/NU^;5QFTDRL=1+
MMC&^9E_FK9/\E".ENS_MX:K?&NWBU9(Q&8)?N4S+LMS@H?36R$6IA%I"/-R+
M93GNO+3U!/!JFJ4DWRE6##6D)&5S^-.G8/O<J7#9/DDAW3HN+?BH5<F1_0L4
MV87G4360QODSD3<47='-RE5CZ^A)GTXQ>M5M#:N\:&IKTC9M)#NQVRU]$#>R
MU+G(2JE9*GEERV=MM(4"WDK'3,49+B./(3E.^ I9*2KB";Y6F5[BGG)=ZI4R
MF4)E*A7NV] MD\M8/UI,1O@&F@]75/):]5+2$RBVB<B#V^CR='RSK(0LO:6U
M?2X[NY%ET!$S#I[27T.*RI*.TVS_A#Z]<VGC^R#5[U$'&YN:E'IR,'U!"TIR
M=Z[ C'+V)%F+M%MQ?+:1TL53=.LQ2T$)0[HLX/:NCDV$L0/U#6+]'@4*"8Q9
M*&527$\)G7]$H())B?U7C- O'D/H_EIEB4Q4!#SWH#;C5^?7_S_\;'/[?0^C
M9).%X"CA7(7"YGR7ET[5,J7OE:Q40E#(]!MP'^7U[SBN!^7)H^!J5.-(*YT1
M9B?4S.S*:"[H^<8O&],C9NTW6:%E<)R+"8+_.&#64@\*[),7L\EL-HMAK6Y5
MUH3.S!0P.!VX87$I*]E& &7D*,S$D_TH2!K$*0$O0J:G"M0R0!=)^+%4:@MZ
MB&JW.-)=: \A;2QJ@_A!1-V3<:QA#_KZ=WD7T;;*!.D?TWS+BOET/R4]B5VH
ML*9<W)\>/>4/#NE%3.+- #5ZS=MT0,(H5$YVV&(STH5#D[ULQ_?5Q^KXRBC]
M*@GCX=C>C.CID6L[??X,##H'LEVA_.B[])'QJ<&=$W'\%GTTXD."@KN2ADSR
M'+D8VC,?().T^BR3A1%766'14<'H<Y7K#!@O9!!#$;MWQ7;"IN)R 'XD]-ZS
M)Z./$R .3-V5S_['B+AEW?Z+UYX<CPM -=7]UE\M/NT00A3$6K;"E#%PZ+_!
MU?S(NR_C[G0E"-,U\2?IAR?A9+3-$5-S]*TC0=3(0DYVC8+:R\'*W05YTECS
M_#_TT[UNFM#:[F-.-P9@;>+((Z*1A?#M',VU7!D@N\XF!$%UL2EIR)")B+].
MUJJAMX3WC,D$]K2_PW9:F'";W%.  !M"I7)#Z[JI1:)WE\28L>XG.!]"3\2'
MVNL2S[HXOOSIY/OO7AV^>MVW0".H].)"*YQAGE_J[%J<1D4>S+ A<^WSXNM#
MN4!89-=^%#'P%2X;09\5$S(VL^C:)D.R31T!@PO!V82\U;['*U 0C?KKD&8E
M:3IA,MX^][;,.2[L<CFL^RVUXTO)E&\=7;6E.Q3  .FH);AA"$*(#]@R8^2W
M$H8,'(4['0 4^]G5!?Z=NF8E3E']5RTS/ZYKQ&!\S<=V]708ZO>!T5W"NMUE
M/'1=3&R9>5.+X-GBEN?>MS7=X;-'6RFJD3WHWT^5G\Q3M>3R+6O< SS,?0A(
MSEKDY)_T<6?VQ>GQMG'H\0E-P4R"BF"Q33"F1^FP9;P#B.EEMW(^@%C5"@\A
MD#+)@3K#O$>ZG4?M'K0;IF\TR+Z>9K64!)_-I[.GD??%'F)^-$LZ#QL5MN^
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MA-N%;G O@*PHQQF75,YL6)!K%<U<Q&I!^2XCO'0)V)UW?'DVKF!II"!;LX?
MTI9DREILA/@-M<ODJ;%?%K3_FB<U8NUT"&V04IV 6OU%(\ZI]R1B ).\OA55
MG([7CH:9[4VU6V%(KDH:;VZ(':D[D&QLZ)R-NV@X:Q_P(9F@D27=W5P65/#G
M*'8Z\AQTC_A+%[P&ON#@.%)2B%48 \6 ,];5-%16K&1_$&<1?;0EK*V[#*\
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MKY/ =!;2G9!%H;2"!&&+)')5*IB_DG =4* &Q&(MYOP90=W8D9B*8*-YC$J
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M3LY9/^Y?/ZAKJX7RZYA%:C:W#YG(2E<[N::%,TD=G)VJBY5Z?G5P?QN@D_C
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MW_.+7X*=\[MU8QO M/GC3$DT/AJ YQ.+Q*J^T +-RY;G_P-02P,$%     @
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M.E=ECAF5IUG2.04_&2MF%7U<J+DLBCLA;Z0NY+10 M#'#E[).\ 13VJE2 ]
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M;G73I.O-+R->.\+V*/85#^=@3VR#=/B6],+H^TF#W7PVY($13N0J*R1%OV4
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M0"XK?0M2(V!$BW /T]L..@4=LO3:(5= KUD$RE2\;CZ]8SM'V)-+@L5QE/<
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MH+#D1CJ#>)2;U@]4S^+N+=T^]"9XW911VDB=3-03<ZCH?7LE06'P.[8<B1B
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M4+"V-M=R_1TV\0PL7R9K[;YDW?DF>&/6:B/Y!HPVKT3W9P^;/.P TG /@&X
MU.GN+G(JOS##9A,EUT19;V2S"Q>J0Z.X2MBB+(S"TPIQ9C9G"H0A%Y(W3#R2
M2W$/VG"[]>F&+6O0GR>!P7NL=Y!M.,\[3KJ'<TRNI#"E)E]%#OE3?(#Z>I%T
M*_*<'B1<0'-,XM G-*31 ;ZX#SIV?/%;@S[ G?3<B>-.]FG%MLG;&DB&[%(@
MJ2:R(*8$(K#'C&)"%Z#T2VD]S/SQ0TK#^)2\U_^F5 "$=Z4"6ZIG+IAX WP)
MRF7_WU-;C5TC) LCLUO7);F+'YN7N>8KE.1DD_8CAXGH*:[B=.2/Z0A+(33V
M$</C)[B&53EVA"FW8+AK*_/X1(IEZE7$L4_3:.N=87"J6K:62^\%;>T;:5C=
M[QX]\SLB0QKY-$S?K00_L,3_4P&7^==G_%!(D9\D8S^D\;O58!"&_B@)WU:#
M:.@/HK$_3M-7E"%*_60X]D>#%X=!L#,-.:B5F_D:=;3"=(.QW^V?E;-NFOYU
M[]ZD*Z96%:JNH4!H>#P:>$1U<[XSC&S<;%U*@Y/:+4M\&D%9!SPOI#1;PU[0
M/[:S/U!+ P04    "  EB&Q3&[2^BPP#  !G"0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6RU5FMOTS 4_2M7$1^&-)9'WZBMQ#80(+%-FP:?W?2F
ML>;8Q7;6CE_/M9.&3DM#$= /K5_G^)R3^CK3C=(/)D>TL"V$-+,@MW;]-@Q-
MFF/!S)E:HZ293.F"6>KJ56C6&MG2@PH1)E$T# O&93"?^K$;/9^JT@HN\4:#
M*8N"Z:=S%&HS"^)@-W#+5[EU ^%\NF8KO$-[O[[1U L;EB4O4!JN)&C,9L&[
M^.U%[ %^Q5>.&[/7!F=EH=2#ZWQ:SH+(*4*!J744C'X>\0*%<$RDXWM-&C1[
M.N!^>\?^P9LG,PMF\$*);WQI\UDP#F")&2N%O56;CU@;&CB^5 GCOV%3KXT"
M2$MC55&#24'!9?7+MG40>X"X?P"0U(#D6$"O!O2\T4J9MW7)+)M/M=J =JN)
MS35\-AY-;KATC_'.:IKEA+/S:[UBDO]@+M-3."\-S1MS"K?</!A@<@GW,D5M
MZ0]A.1HXN41J"_,:WL#]W26<O'H]#2T)<71A6F]Z7FV:'-CT$M,SB$:GD$1)
MU *_Z(9_9O(,>K&'Q\_A(=EO,DB:#!+/US_ =U46"]2@,C YTV0R94+@$NB0
MP.()-DQK)JUI\UD1#SRQ.S&/\T$R&?>FX6.+GEZCI]>IYUN](5C415L\W? !
M/"'3IB.8?B.DW\ETM^;RS7660:95 5=8:F4U59 .ZD%#/?BSS%W8^(CZ"3(Z
MU[O1',6R+??!B]SC]LR'C9[AO]!#\RZ&5!4%U2 ZG>D#<&-*MA (Y9K&4B4)
MY:L<+:;2FJ'6]&>JUA[R,SS6SZCQ,SK2SS.MG:ZJAPL=YG"+.N4&/6]5%?:1
MNY-RT.;H6)OCQN:XT^;[;4KERLMA)@>20SHT53.Y F8,DI9W5,,$9PLNN*M@
M;;*J/89[LN@6])]V=9-&W>1_%9;)BZ3ZX_$D'HS;%<71KWH?':FI:_N:9#^2
MR6@T[AUX7/'>=1/_56T[_PV^H[B%>[>@>P7YPO2*2P,",Z**SD:4IJYN]:IC
MU=I?C MEZ9KUS9S>A%"[!32?*65W'7?7-N]6\Y]02P,$%     @ )8AL4_S5
M5I:= P  J P  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULM5=M;^(X
M$/XK5G0?=J5>\P()L *D4JBVTNU>5=2[SR:9$*N)S=H.=$_WXV_LA$!+2+G;
M/3Z '<_S>.:9L3.,=T(^JPQ DY<BYVKB9%IO/KFNBC,HJ+H6&^"XD@I94(U3
MN7;51@)-+*C(W<#S(K>@C#O3L7WV(*=C4>J<<7B01)5%0>7W&>1B-W%\9__@
MD:TS;1ZXT_&&KF$)^FGS(''F-BP)*X K)CB1D$Z<&__3G1\8@+7X@\%.'8V)
M"64EQ+.9W"<3QS,>00ZQ-A04?[9P"WENF-"/;S6IT^QI@,?C/?N=#1Z#65$%
MMR+_DR4ZFSA#AR20TC+7CV+W&>J 0L,7BUS9;[*K;3V'Q*72HJC!Z$'!>/5+
M7VHAC@#(TPX(:D!P*:!7 WJ7 OHUH/\6$)T!A#4@? OHGP%$-2"RVE=B6:7G
M5-/I6(H=D<8:V<S ILNB46#&364MM<15AC@]_5VN*6=_49/F*S(K%:XK=44>
MF7I6A/*$//$8I,8:U0P4^97\QKZ5+&'Z^YN5#W/ <:X^HLW3<DX^_/)Q[&IT
MT6SDQK4[L\J=X(P[ ?DBN,X46? $DA;\;3>^]QY^WHT?O8=?O.._WT'@8FZ:
M! 7[!,V"3L:O8GM->MX5";S ;Q.D&[Z$32=\_F/PQ8_![[KA<X@1[ENXUZ%E
MKRGVGN7KG^&[I2JS-1V; 6 =;VD.7*LV72NJR%*9^WD[[?G!J!_UP[&[/5;P
M4L/%I89WIX;A8!1ZX<'N5?C])OS^?PN?P,L&;WI(""U$R36AFJ2,4QXSFN/[
M8R.D9GQ-$JJA3:IJV_ XL-"SGS=276JXN,#PE01A(T'8*<&#%#% HD@J18%A
M@XR9 B)2PO@6\+:59$>EI&=J(CQ)S+ MS!:SWC (_:C=^:AQ/NITWIP"L@2Y
M93'>MS=K"8#O>$W^)E_M_8VYNN=*,UUJ7,>8/@/-==9Q< ;-SH/.G1^!%:M2
MJFH_9-;25(8I&ZZ@3:K%X$2#(.I(X+#Q9-CIR;)<*:Q<XP9L3X_N*\Y1PSGJ
MY+SG*398)BQ[,)(2B!;[.C@4B3DYLE.(MO?=Z/0L=Q6R[QU>W-[_6,JSFOWX
MB/7#+L>..@K_WZ4("_3GEZX?'/P)?G+QSFK&5UGKM6CC'C5>!<BU;9$5B<TE
M6O5@S=.F#;^QS:=[,*]Z^"]4KAE7)(<4H=[U #,CJ[:XFFBQL6W<2FAL"NTP
MP[\2((T!KJ="Z/W$;-#\.9G^ U!+ P04    "  EB&Q3R/ 5!"$%  !4%P
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M2'U Y^C'9(#.?OO0=31P,)*<,-?W>:./'-$W8.$%<H./B+C$K8#W[?![L;I
MGGL4/K##OZ31!2+>4?AU?>VX CX\I3VQPF_JPZO(C^SP"5M:M8_KPZNT?_E_
MVK_:X7=4 AQG<%(!OZV1=3G\%7D'"J:H&E)4#<GD>2>JYMOIJOGS%K!HK%FL
M_K)H]@K-7J:Y>41SGZH%;#L134)FBI8G*I5LBH:#<1_1V*BO2HV-T%8FU&S,
MJY[7<LU?UUGM!O'TNCW6S8)U\TVLTV3+^SCEC41_APH)@BK.-1;ND?8+TOX)
MTDNN:<3_!IJ2*49EN$ TF<(FOX+I90FSB$:*R14/F:JRP#\@]IKZR16W_D%
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MP]K(E>T=V_O['4]..;GLB+C]WDXN.QVVM[JW.]DNSSOI8U)V+6+O6O?4G&/
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MRLT1[N9&BV5VC/8HM!9Q=KE@%.9#LP#>SX30VQMS,E<<I/?^!5!+ P04
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M_?V:<W4\,6_:J]]NIO\"4$L#!!0    ( "6(;%-X!_=66P(  +L&   9
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MCL""+'$6LH?D^8H4#ME"GY^$:?X7/!=CC2/@9RE+HD*86Q %\>Y__*-8B(J
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MM1GR\S2+-Z(R4[ )HO(G^2D&HE;!=#HJ&**"L5=!-SLJF**".;0%2U2PAE;
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MIHP78']?Q7'V]H&_@UF]_WS^?U!+ P04    "  FB&Q3B-I0,3P(  #/,P
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MQMY @M(H);8KY4O[N,L2K\_T&]7$]LY[9B*Q4P&,[N%P&)/M&GES^S;-/13
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MY5Y 5ZR'UU=U;]#SFQ^.&.D:R$0F3P4P&^M!>U_WACV_8<9"['?5-]+)^RZ
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M3MQ^NT5C)1=0W-6C^+=U<LLS]'V^[2U<I(L9SW+T\S[=]AEF[7"I.NY*%15
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  FB&Q3Q*+*J&L#  #6%@  #P
M 'AL+W=O<FMB;V]K+GAM;,686T_;,!2 _XJ5EW42+(T#Y2**Q&T;TS001>P1
MN<EI8]6QB^V4P:^?G:R:,^C17@Q/;6S7_7)\^8Y]]*CT8JK4@ORJA33CI+)V
M>9BFIJB@9N:36H)T-3.E:V;=HYZG9JF!E:8"L+5(Z7 X2FO&97)\M.[K6J?A
M@[)06*ZD*_0%=QP>S=]Z_TA6W/ I%]P^C9/VNX"$U%SRFC]#.4Z&"3&5>ORJ
M-']6TC(Q*;028IQD7<4=:,N+%\43#WG+IJ8ML6QZPQS(.!D-78<SKHUM6[3]
M,\>X M>X>VJL^LR%!7W.+'S1JEER.??=N+=(@]=HX[#^[()XJ/\GC&HVXP6<
MJZ*I0=HNCAJ$!Y2FXDN3$,EJ&"?K)H3)DEQ(ZX)$+F77E6OKW]3]]679O;5U
MN$$,]2%W%?JR;,'C09XI68(T4))3)I@L@+21-0$=1>CH^]"1P373$(8P1R#S
MMX*<> +?VA U(U=+T*YU +F#0.Z\#^19Q>0<PN'>12!WWPF2F8I\%@'D"($<
MQ86\TG,F^7-;L45.&\,E&+-%;KA9&,("R#T$<B\NY*2I:Z:??/ F?"ZY^QES
M.]%)4:A&]N;D/@*Y'WNXA6!3Y1?)"LC)7,.?(?<;YID*( \0R(.XD#>^T,U(
MM^&X_?M6,VE8:\4.,]S%A]@V/HP=R[KF-@R?&V:WLF7!>ZL[0UT36383JXI%
MI40)VGP@%P^-4^)]"(>I)HOLFA;.><9O/RZ:KB?3-NH!8IK)HGNFKI4D'>=/
MIMU4M*9'A_DEBRR85LBVC1R3/M%9@6GG8PB(N26++)=),S7PT'C(BY5?)R$8
MYI,LLE#0O?J>AIB84;+82MFT/LC )=^AG#/,*5ETJ;RV2CI&,!]#3,PJ662M
M;%PN+Z)),:W0R%I!DYW>W*286&ADL>"8>8B)GF9B*P9=Z3U,3#0TNFB0O*P_
MZ)AQ:&3CH)E9'Q/S#HU^J$$R,S((,3$+T=@6>BTW(X-SL(R+WKY),0O1M[#0
M"\QM\HW)QBVM$!.S$(UL(426/J(A)F8A&ME"FS&WO4'#^Q7,0OD;'&Y><?HV
MZ2I"3,Q">?2[M V8)V7)>X?N'+-0'ME"2.KQS]S,T5NUUD+I^AZUA)F3;OG#
M_85QY043Q;4F_J,[V>WL^GQKU@AQYLJNY'?%RO6U[/I*^?@W4$L#!!0    (
M ":(;%/@/0E7: $  $H4   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'/-V,V.@C 4AN%;(;T RSE5U(FXFHW;B3= L("1O]!.1N]^""[P([.8C>E9
MD4(X?1?D">GAR]:9OW:MJZZ]B^Y-W;I45=[W'UJ[O+)-YE9=;]OQ2=$-3>;'
MY5#J/LMO66DUQW&BA]<9ZGAXG1F='[W]S\2N**ZY_>SR[\:V_H_!^J<;;JZR
MUJOHG VE]:G2]WJ^[?1TH=4X646G2ZJ&TX64#AW$$,3A@PP$F?!!:PA:AP_:
M0- F?% "04GXH"T$;<,'[2!H%SYH#T'[\$$4HXRQ@*0%U@*T)N2:!'A-"#8)
M$)N0;!)@-B':)$!M0K9)@-N$<), N0GI)@%V$^)- O1FU)L%Z,VH-PO0FQ<_
MVP+T9M2;!>C-J#<+T)M1;Q:@-Z/>+$!O1KU9@-Z,>K, O1GU9@%Z&]3;"-#;
MH-Y&@-X&]38"]#:+PY)WZNW\H[9N[GFN<?]W4NW'=^V\_;1\WEQ\*A/.&HX.
MC[]02P,$%     @ )HAL4QR:"5V, 0  YQ0  !,   !;0V]N=&5N=%]4>7!E
M<UTN>&ULS9C-;L(P$(1?)<H5$6.GI3\"+FVO+8>^@)MLB$426[:A\/9UPH_4
MBD8@*G4NL1+OSHR]TG?(Y'UKR$6;NFK<-"Z]-X^,N:RD6KI$&VK"3J%M+7UX
MM0MF9+:4"V)B-!JS3#>>&C_TK48\FSQ3(5>5CUXVX;-3NIG&EBH71T^[PM9K
M&DMC*I5)'_;9NLE_N SW#DGH[&I<J8P;A(*8G71H=WXWV/>]K<E:E5,TE]:_
MRCI4L4W%G-]6Y))^B1,9=5&HC'*=K>K0DCAC2>:N)/)UE>Q$!_W./MPP[9[\
M:O].IL\P5,ZM-BY,S-+E=H>1M-U#$X3(>M5_Q*-CD+[Z?-1..Z?\3.]PO9_:
M+KMY.-8MU]_Q]QD?]2_,(4!RI" Y;D!RW(+D&(/DN /)<0^2XP$D!Q^A!$$A
M*D=!*D=A*D>!*D>A*D?!*D?A*D<!*T<AJT AJT AJT AJT AJT AJT AJT A
MJT AJT AJT A:XI"UA2%K"D*6=/_).N'ULN__O76KDDM57/P9]W_S=D74$L!
M A0#%     @ )8AL4P=!36*!    L0   !               ( !     &1O
M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  EB&Q3;,.CR.X    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  E
MB&Q3F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( "6(;%,F#*IL6P4  ,,6   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  E
MB&Q3I$/^<)8$  !,#P  &               @(&>#0  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ )8AL4S<8'!S  @  1PD  !@
M         ("!:A(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( "6(;%/QY.X+FP0  ,81   8              " @6 5  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  EB&Q3';^;U94(  "+-P
M&               @($Q&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ )8AL4P:MENF?!@  G1D  !@              ("!_"(  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( "6(;%-QX\W[S@X
M +TG   8              " @=$I  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    "  EB&Q3!]YDCA$1   ',   &               @('5
M.   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ )8AL4]M
MAS#-#   ,B0  !@              ("!'$H  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( "6(;%,4$['N708  * /   9
M  " @1]7  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M)8AL4_%WXLE&#0  >"D  !D              ("!LUT  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    "  EB&Q3KU60(HD-  #[+0  &0
M            @($P:P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( "6(;%/;P1_ST0H  /$@   9              " @?!X  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ )8AL4[KH9TRH"0
M920  !D              ("!^(,  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    "  EB&Q37<C6E-8"   +"   &0              @('7
MC0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "6(;%,[
MHRFC$0(  *T$   9              " @>20  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ )8AL4S-L].65$0  2C0  !D
M     ("!+),  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "6(;%/\U5:6G0,  *@,   9              "
M@4VQ  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ )8AL
M4\CP%00A!0  5!<  !D              ("!(;4  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    "  EB&Q3@/UB_"8%  #'&0  &0
M        @(%YN@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( "6(;%-X!_=66P(  +L&   9              " @=:_  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ )8AL4^L-C^*<"P  D3\
M !D              ("!:,(  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    "  FB&Q3CO,-#R0#  #/"@  &0              @($[S@
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ":(;%.R=A%X
MTPD   L]   9              " @9;1  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ )HAL4XC:4#$\"   SS,  !D
M ("!H-L  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  F
MB&Q3Z A;.<(#  "/#@  &0              @($3Y   >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ":(;%,:?Z367 (    &   9
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M  !X;"]S='EL97,N>&UL4$L! A0#%     @ )HAL4Y>*NQS     $P(   L
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64$L%!@     I "D %@L  ,L# 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>236</ContextCount>
  <ElementCount>304</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/StatementCondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/StatementCondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Condensed Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Condensed Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity</Role>
      <ShortName>Condensed Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization, Business, Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertainties</Role>
      <ShortName>Organization, Business, Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Collaborative Agreements and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitments</Role>
      <ShortName>Collaborative Agreements and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Related Party Transactions and Licensing / Research Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureRelatedPartyTransactionsAndLicensingResearchAgreements</Role>
      <ShortName>Related Party Transactions and Licensing / Research Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Stockholders' Equity:</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity:</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Stock Based Compensation:</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock Based Compensation:</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Common Stock Warrants:</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureCommonStockWarrants</Role>
      <ShortName>Common Stock Warrants:</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Parent Company Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureParentCompanyInvestment</Role>
      <ShortName>Parent Company Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Stock Based Compensation: (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation: (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.synaptogen.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Common Stock Warrants: (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureCommonStockWarrantsTables</Role>
      <ShortName>Common Stock Warrants: (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.synaptogen.com/role/DisclosureCommonStockWarrants</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Parent Company Investment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentTables</Role>
      <ShortName>Parent Company Investment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.synaptogen.com/role/DisclosureParentCompanyInvestment</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization, Business, Risks and Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails</Role>
      <ShortName>Organization, Business, Risks and Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertainties</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40102 - Disclosure - Organization, Business, Risks and Uncertainties - Liquidity Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails</Role>
      <ShortName>Organization, Business, Risks and Uncertainties - Liquidity Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Collaborative Agreements and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails</Role>
      <ShortName>Collaborative Agreements and Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Related Party Transactions and Licensing / Research Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureRelatedPartyTransactionsAndLicensingResearchAgreementsDetails</Role>
      <ShortName>Related Party Transactions and Licensing / Research Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.synaptogen.com/role/DisclosureRelatedPartyTransactionsAndLicensingResearchAgreements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.synaptogen.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Stockholders' Equity: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.synaptogen.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Stockholders' Equity: - January 2021 Private Placement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails</Role>
      <ShortName>Stockholders' Equity: - January 2021 Private Placement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Stock Based Compensation: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails</Role>
      <ShortName>Stock Based Compensation: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.synaptogen.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Stock Based Compensation: - Stock option activity under the stock option plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails</Role>
      <ShortName>Stock Based Compensation: - Stock option activity under the stock option plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Common Stock Warrants: - Common stock warrant activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureCommonStockWarrantsCommonStockWarrantActivityDetails</Role>
      <ShortName>Common Stock Warrants: - Common stock warrant activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Common Stock Warrants: - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails</Role>
      <ShortName>Common Stock Warrants: - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="snpx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Parent Company Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails</Role>
      <ShortName>Parent Company Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="snpx-20210930x10q.htm">snpx-20210930x10q.htm</File>
    <File>snpx-20210930.xsd</File>
    <File>snpx-20210930_cal.xml</File>
    <File>snpx-20210930_def.xml</File>
    <File>snpx-20210930_lab.xml</File>
    <File>snpx-20210930_pre.xml</File>
    <File>snpx-20210930xex31d1.htm</File>
    <File>snpx-20210930xex31d2.htm</File>
    <File>snpx-20210930xex32d1.htm</File>
    <File>snpx-20210930xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>51
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "snpx-20210930x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "contextCount": 236,
   "dts": {
    "calculationLink": {
     "local": [
      "snpx-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "snpx-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "snpx-20210930x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "snpx-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "snpx-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "snpx-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 383,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 22,
    "http://www.synaptogen.com/20210930": 2,
    "http://xbrl.sec.gov/dei/2021": 7,
    "total": 31
   },
   "keyCustom": 92,
   "keyStandard": 212,
   "memberCustom": 38,
   "memberStandard": 25,
   "nsprefix": "snpx",
   "nsuri": "http://www.synaptogen.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Related Party Transactions and Licensing / Research Agreements",
     "role": "http://www.synaptogen.com/role/DisclosureRelatedPartyTransactionsAndLicensingResearchAgreements",
     "shortName": "Related Party Transactions and Licensing / Research Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Commitments and Contingencies",
     "role": "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Stockholders' Equity:",
     "role": "http://www.synaptogen.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity:",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Stock Based Compensation:",
     "role": "http://www.synaptogen.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock Based Compensation:",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "snpx:StockOptionNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Common Stock Warrants:",
     "role": "http://www.synaptogen.com/role/DisclosureCommonStockWarrants",
     "shortName": "Common Stock Warrants:",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "snpx:StockOptionNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Parent Company Investment",
     "role": "http://www.synaptogen.com/role/DisclosureParentCompanyInvestment",
     "shortName": "Parent Company Investment",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Subsequent Events",
     "role": "http://www.synaptogen.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Stock Based Compensation: (Tables)",
     "role": "http://www.synaptogen.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock Based Compensation: (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Common Stock Warrants: (Tables)",
     "role": "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsTables",
     "shortName": "Common Stock Warrants: (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Condensed Balance Sheets",
     "role": "http://www.synaptogen.com/role/StatementCondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Parent Company Investment (Tables)",
     "role": "http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentTables",
     "shortName": "Parent Company Investment (Tables)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "snpx:StockOptionNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Organization, Business, Risks and Uncertainties (Details)",
     "role": "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails",
     "shortName": "Organization, Business, Risks and Uncertainties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_12_7_2020_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember_z7n6W5VrT0C_iRbgTEtdow",
      "decimals": "INF",
      "lang": null,
      "name": "snpx:NumberOfSharesForEveryFiveCommonSharesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40102 - Disclosure - Organization, Business, Risks and Uncertainties - Liquidity Uncertainties (Details)",
     "role": "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
     "shortName": "Organization, Business, Risks and Uncertainties - Liquidity Uncertainties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_10_1_2021_To_11_30_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eDY3684nJE-p7S0A8UmC-g",
      "decimals": "-6",
      "lang": null,
      "name": "snpx:ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "snpx:CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "snpx:CapitalizedResearchAndDevelopmentServices",
       "p",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ",
      "decimals": "0",
      "lang": null,
      "name": "snpx:CapitalizedResearchAndDevelopmentServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "snpx:CollaborativeAgreementsAndCommitmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_19_2017_To_1_19_2017_RyYqzdEgTkmLuudVtZapew",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "snpx:AnnualLicenseMaintenanceFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Collaborative Agreements and Commitments (Details)",
     "role": "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails",
     "shortName": "Collaborative Agreements and Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "snpx:CollaborativeAgreementsAndCommitmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_19_2017_To_1_19_2017_RyYqzdEgTkmLuudVtZapew",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "snpx:AnnualLicenseMaintenanceFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "snpx:NumberOfStatementsEnteredIntoAgreement",
       "snpx:NumberOfStatementsEnteredIntoAgreement",
       "snpx:NumberOfStatementsEnteredIntoAgreement",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "snpx:NumberOfStatementsEnteredIntoAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Related Party Transactions and Licensing / Research Agreements (Details)",
     "role": "http://www.synaptogen.com/role/DisclosureRelatedPartyTransactionsAndLicensingResearchAgreementsDetails",
     "shortName": "Related Party Transactions and Licensing / Research Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "snpx:NumberOfStatementsEnteredIntoAgreement",
       "snpx:NumberOfStatementsEnteredIntoAgreement",
       "snpx:NumberOfStatementsEnteredIntoAgreement",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "snpx:NumberOfStatementsEnteredIntoAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_2_1_2020_To_2_1_2020_nGp21D17LkONtLS4Ybajpg",
      "decimals": "0",
      "lang": null,
      "name": "snpx:ConsultingAgreementMonthlyInstallmentFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_12_7_2020_To_12_7_2020_sjyc_Q4Tz0y82heiYi_stA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "snpx:IssueOfSharesOnSpinOff",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Stockholders' Equity: (Details)",
     "role": "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails",
     "shortName": "Stockholders' Equity: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": "INF",
      "lang": null,
      "name": "snpx:NumberOfVotesPerShareOwned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Vote_DzbStCv5TEKWycjen-OBEA",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_21_2021_To_1_21_2021_HYTbWiKKQEKRtx7xP4_xwQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "snpx:AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Stockholders' Equity: - January 2021 Private Placement (Details)",
     "role": "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails",
     "shortName": "Stockholders' Equity: - January 2021 Private Placement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_21_2021_To_1_21_2021_HYTbWiKKQEKRtx7xP4_xwQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "snpx:AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Stock Based Compensation: (Details)",
     "role": "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails",
     "shortName": "Stock Based Compensation: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_12_7_2020_LkRF4tPIf02myH0afRIH_g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Condensed Balance Sheets (Parenthetical)",
     "role": "http://www.synaptogen.com/role/StatementCondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Stock Based Compensation: - Stock option activity under the stock option plans (Details)",
     "role": "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails",
     "shortName": "Stock Based Compensation: - Stock option activity under the stock option plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_8iEx3cY6mEyq2loGlwI0eQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Common Stock Warrants: - Common stock warrant activity (Details)",
     "role": "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsCommonStockWarrantActivityDetails",
     "shortName": "Common Stock Warrants: - Common stock warrant activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_ota3Ge_I8kyWy33ZCO--nQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_1_31_2021_e--_NbHbEE6MXeRdEtUWUQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Common Stock Warrants: - Additional Information (Details)",
     "role": "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
     "shortName": "Common Stock Warrants: - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_1_31_2021_e--_NbHbEE6MXeRdEtUWUQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_nIB16CTm9EGediwtzEbtaQ",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
       "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "snpx:ParentCompanyEmployeeBenefitsAndShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Parent Company Investment (Details)",
     "role": "http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails",
     "shortName": "Parent Company Investment (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
       "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Condensed Statements of Operations",
     "role": "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations",
     "shortName": "Condensed Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_iZw4i03bs0ivcBCcu9iBww",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_FMu0KxA6Dk2LDplFkct4jA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Condensed Statements of Changes in Shareholders' Equity",
     "role": "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity",
     "shortName": "Condensed Statements of Changes in Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_FMu0KxA6Dk2LDplFkct4jA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_2qFg8n1orkW-4PAzer2JOw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Condensed Statements of Cash Flows",
     "role": "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows",
     "shortName": "Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_qFfHpKrEIUqTK8bRrG_54A",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Organization, Business, Risks and Uncertainties",
     "role": "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertainties",
     "shortName": "Organization, Business, Risks and Uncertainties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "snpx:CollaborativeAgreementsAndCommitmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Collaborative Agreements and Commitments",
     "role": "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitments",
     "shortName": "Collaborative Agreements and Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snpx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_KMsyVkdk8kC2UGAUR5PmGw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "snpx:CollaborativeAgreementsAndCommitmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 63,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.synaptogen.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "snpx_AccountsPayableForServiceAgreementCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount payable under the service agreement, classified as current.",
        "label": "Accounts Payable For Service Agreement, Current",
        "terseLabel": "WCT payments included in accounts payable"
       }
      }
     },
     "localname": "AccountsPayableForServiceAgreementCurrent",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_AdditionalMilestonePaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional milestone payments payable by the company.",
        "label": "Additional Milestone Payments Payable",
        "terseLabel": "Additional milestone payments"
       }
      }
     },
     "localname": "AdditionalMilestonePaymentsPayable",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_AdvisoryAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to advisory agreements.",
        "label": "Advisory Agreements [Member]"
       }
      }
     },
     "localname": "AdvisoryAgreementsMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_AggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition.",
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueAbstract",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "snpx_AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of shares authorized to issue under purchase agreement.",
        "label": "Aggregate Number of Shares Authorized to Issue Under Purchase Agreement",
        "terseLabel": "Aggregate number of shares authorized to issue under purchase agreement"
       }
      }
     },
     "localname": "AggregateNumberOfSharesAuthorizedToIssueUnderPurchaseAgreement",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "snpx_AgreementsWithBryologyxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to agreements with BryoLogyx.",
        "label": "Agreements with BryoLogyx"
       }
      }
     },
     "localname": "AgreementsWithBryologyxMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_AmountFundedAgainstTotalTrialCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount stated the total trial cost.",
        "label": "Amount funded against the total trial cost",
        "terseLabel": "Amount funded against the total trial cost"
       }
      }
     },
     "localname": "AmountFundedAgainstTotalTrialCost",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_AmountOfAwardReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of award received to support an additional phase 2.",
        "label": "Amount of Award Received",
        "terseLabel": "Amount of award received",
        "verboseLabel": "Amount of award received"
       }
      }
     },
     "localname": "AmountOfAwardReceived",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_AmountOfFundingReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funding receivable by the company.",
        "label": "Amount Of Funding Receivable",
        "terseLabel": "Funding receivable in second year"
       }
      }
     },
     "localname": "AmountOfFundingReceivable",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_AmountOfFundingReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funding received by the company.",
        "label": "Amount Of Funding Received",
        "terseLabel": "Funding received in first year",
        "verboseLabel": "Reimbursement of trial expenses"
       }
      }
     },
     "localname": "AmountOfFundingReceived",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_AnnualConsultancyAgreementFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of annual consulting fee.",
        "label": "Annual Consultancy Agreement Fees",
        "terseLabel": "Annual consulting fee"
       }
      }
     },
     "localname": "AnnualConsultancyAgreementFees",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_AnnualDiscretionaryBonusPayableMaximumPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of base salary payable as annual discretionary bonus to the employee.",
        "label": "Annual Discretionary Bonus Payable, Maximum Percent",
        "terseLabel": "Annual discretionary bonus payable (as a percent)"
       }
      }
     },
     "localname": "AnnualDiscretionaryBonusPayableMaximumPercent",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snpx_AnnualLicenseMaintenanceFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of annual license maintenance fee paid during reporting period",
        "label": "Annual License Maintenance Fee",
        "verboseLabel": "Annual license maintenance fee"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFee",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_CapitalizedResearchAndDevelopmentServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized non-refundable advance payments for research and development services pursuant to contractual agreements.",
        "label": "Capitalized Research and Development Services",
        "terseLabel": "Capitalized research and development services"
       }
      }
     },
     "localname": "CapitalizedResearchAndDevelopmentServices",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for Cash and Cash Equivalents and Concentration of Credit Risk.",
        "label": "Cash and Cash Equivalents and Concentration Of credit Risk [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Concentration of Credit Risk"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "snpx_CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the expected amount of cash and cash equivalents at financial reporting date.",
        "label": "Cash and Cash Equivalents, Expected Amount at Financial Reporting Date",
        "terseLabel": "Cash and cash equivalents expected amount at financial reporting date"
       }
      }
     },
     "localname": "CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_CashBonusPayableUponSeparation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash bonus payable to the employee upon his separation.",
        "label": "Cash Bonus Payable Upon Separation",
        "terseLabel": "Cash bonus payable upon Separation"
       }
      }
     },
     "localname": "CashBonusPayableUponSeparation",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_CharlesRyanSeparationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Charles Ryan Separation Agreement.",
        "label": "Charles Ryan Separation Agreement"
       }
      }
     },
     "localname": "CharlesRyanSeparationAgreementMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercise period.",
        "label": "Class of Warrant or Right, Exercise Period of Warrants or Rights",
        "terseLabel": "Warrants exercise period"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snpx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding, before amendment.",
        "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Before Amendment",
        "terseLabel": "Exercise price of warrants before amendment"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsBeforeAmendment",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "snpx_ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator used to determine the initial exercise price of warrants in the event of spin-off.",
        "label": "Class Of Warrant Or Right, Numerator Used To Determine Initial Exercise Price Of Spin-Off Warrants",
        "terseLabel": "Exercise price to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumeratorUsedToDetermineInitialExercisePriceOfSpinOffWarrants",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Rights, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase shares of common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "snpx_CollaborativeAgreementsAndCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about collaborative agreements and commitments.",
        "label": "Collaborative Agreements and Commitments"
       }
      }
     },
     "localname": "CollaborativeAgreementsAndCommitmentsAbstract",
     "nsuri": "http://www.synaptogen.com/20210930",
     "xbrltype": "stringItemType"
    },
    "snpx_CollaborativeAgreementsAndCommitmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative agreements and commitments.",
        "label": "Collaborative Agreements and Commitments [Text Block]",
        "terseLabel": "Collaborative Agreements and Commitments"
       }
      }
     },
     "localname": "CollaborativeAgreementsAndCommitmentsTextBlock",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "snpx_CombinedPurchasePriceOfCommonStockAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined purchase price per share of Common Stock and Warrants (the \"Offering\").",
        "label": "Combined Purchase Price of Common Stock and Warrants",
        "terseLabel": "Combined purchase price of common stock and warrants"
       }
      }
     },
     "localname": "CombinedPurchasePriceOfCommonStockAndWarrants",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "snpx_CommitmentToPayFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of committed fees to be paid by the entity.",
        "label": "Commitment To Pay Fees"
       }
      }
     },
     "localname": "CommitmentToPayFees",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_CommonStockWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Common Stock Warrants:"
       }
      }
     },
     "localname": "CommonStockWarrants",
     "nsuri": "http://www.synaptogen.com/20210930",
     "xbrltype": "stringItemType"
    },
    "snpx_ConsultancyFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of consulting fees incurred during the period.",
        "label": "Consultancy Fees",
        "terseLabel": "Consultancy fees"
       }
      }
     },
     "localname": "ConsultancyFees",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_ConsultingAgreementMonthlyInstallmentFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the monthly installment of annual consulting fee.",
        "label": "Consulting Agreement, Monthly Installment, Fee",
        "terseLabel": "Monthly installment of annual consulting fee"
       }
      }
     },
     "localname": "ConsultingAgreementMonthlyInstallmentFee",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_ConsultingAgreementNoticeForCancellation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the notice term for cancellation.",
        "label": "Consulting Agreement, Notice for Cancellation",
        "verboseLabel": "Threshold period of prior written notice to terminate agreement"
       }
      }
     },
     "localname": "ConsultingAgreementNoticeForCancellation",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snpx_ConsultingAgreementWithGpNurmenkariIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for consulting agreement with GP Nurmenkari.",
        "label": "Consulting Agreement with GP Nurmenkari, Inc [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementWithGpNurmenkariIncMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_ConsultingAgreementWithKatalystSecuritiesLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for consulting agreement with Katalyst Securities LLC.",
        "label": "Consulting Agreement with Katalyst Securities LLC [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementWithKatalystSecuritiesLlcMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_ConsultingAgreementWithSmCapitalManagementLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for consulting agreement with SM Capital Management, LLC.",
        "label": "Consulting Agreement with SM Capital Management, LLC [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementWithSmCapitalManagementLlcMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting services paid by issuance of Parent company common stock.",
        "label": "Consulting services paid by issuance of Parent company common stock",
        "terseLabel": "Consulting services paid by issuance of Parent company common stock"
       }
      }
     },
     "localname": "ConsultingServicesPaidByIssuanceOfParentCompanyCommonStock",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting services paid by issuance of Parent company common stock warrants.",
        "label": "Consulting services paid by issuance of Parent company common stock warrants",
        "terseLabel": "Consulting services paid by issuance of Parent company common stock warrants"
       }
      }
     },
     "localname": "ConsultingServicesPaidByIssuanceOfParentCompanyCommonStockWarrants",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_ContractPaymentsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from commencement over which fixed contract payments are due per the terms of an agreement.",
        "label": "Contract Payments, Term"
       }
      }
     },
     "localname": "ContractPaymentsTerm",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snpx_ContributionsFromParent": {
     "auth_ref": [],
     "calculation": {
      "http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LaborAndRelatedExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of contributions from Parent.",
        "label": "Contributions from Parent",
        "terseLabel": "Parent contributions"
       }
      }
     },
     "localname": "ContributionsFromParent",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_CostOnTrailAndInvestigationNewDrugDocumentationExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount relates to cost on Trail and investigation new drug documentation expenses.",
        "label": "Cost on Trail and investigation new drug documentation expenses",
        "terseLabel": "Cost on Trail and investigation new drug documentation expenses"
       }
      }
     },
     "localname": "CostOnTrailAndInvestigationNewDrugDocumentationExpenses",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_CurrentShareholdersOfCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for current shareholders of the Company.",
        "label": "Current Neurotrope stockholders"
       }
      }
     },
     "localname": "CurrentShareholdersOfCompanyMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_DateOfGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to date of grant.",
        "label": "Date of grant"
       }
      }
     },
     "localname": "DateOfGrantMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_DirectorCompensationPolicyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to director compensation policy.",
        "label": "Director Compensation Policy"
       }
      }
     },
     "localname": "DirectorCompensationPolicyMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount available to right holders to purchase common stock upon acquisition of minimum shareholding by acquiring person.",
        "label": "Discount Available to Right Holders to Purchase Common Stock Upon Acquisition of Minimum Shareholding by Acquiring Person",
        "terseLabel": "Discount available to right holders to purchase common stock upon acquisition of minimum shareholding by acquiring person"
       }
      }
     },
     "localname": "DiscountAvailableToRightHoldersToPurchaseCommonStockUponAcquisitionOfMinimumShareholdingByAcquiringPerson",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snpx_EmploymentAgreementWithAlanJ.TuchmanM.dMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for employment agreement with Alan J. Tuchman, M.D.",
        "label": "Employment agreement with Alan J. Tuchman, M.D"
       }
      }
     },
     "localname": "EmploymentAgreementWithAlanJ.TuchmanM.dMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_EquityIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2020 Equity Incentive Plan.",
        "label": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2020Member",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_EstimatedBudgetForServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the estimated budget for services.",
        "label": "Estimated Budget For Services",
        "totalLabel": "Total estimated budget for the services"
       }
      }
     },
     "localname": "EstimatedBudgetForServices",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_ExcessOfCashInOperatingAssetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents Excess Of Cash In Operating Assets And Liabilities.",
        "label": "Excess Of Cash In Operating Assets And Liabilities",
        "verboseLabel": "Excess of cash in operating assets And liabilities"
       }
      }
     },
     "localname": "ExcessOfCashInOperatingAssetsAndLiabilities",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of accounting policy for expense reimbursement for grant award.",
        "label": "Expense Reimbursement For Grant Award, Policy [Policy Text Block]",
        "terseLabel": "Expense Reimbursement for Grant Award"
       }
      }
     },
     "localname": "ExpenseReimbursementForGrantAwardPolicyPolicyTextBlock",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "snpx_FirstAnniversaryOfGrantDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to First anniversary of grant date.",
        "label": "First anniversary of grant date"
       }
      }
     },
     "localname": "FirstAnniversaryOfGrantDateMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_GrossProceedsFromSaleOfWarrantsAndCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gross proceeds received from offering.",
        "label": "Gross Proceeds from Sale of Warrants and Common Stock",
        "terseLabel": "Gross proceeds in offering"
       }
      }
     },
     "localname": "GrossProceedsFromSaleOfWarrantsAndCommonStock",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the scenario, if the employee is terminated after six months but within one year from Start Date.",
        "label": "If employee is terminated after six months but within one year from Start Date"
       }
      }
     },
     "localname": "IfEmployeeIsTerminatedAfterSixMonthsButWithinOneYearFromStartDateMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_IncreaseDecreaseInGrantReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in grants receivable, classified as current.",
        "label": "Increase (Decrease) In Grant Receivable, Current",
        "negatedLabel": "Decrease (Increase) in grant receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInGrantReceivableCurrent",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_InitialAnnualBaseSalaryPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of initial annual base salary payable to the employee.",
        "label": "Initial Annual Base Salary Payable",
        "terseLabel": "Initial annual base salary"
       }
      }
     },
     "localname": "InitialAnnualBaseSalaryPayable",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_IssuanceOfStockAndWarrantsForServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered.",
        "label": "Issuance Of Stock And Warrants For Services",
        "terseLabel": "Consulting services paid by issuance of common stock warrants"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServices",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_IssueOfSharesOnSpinOff": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued at spin off.",
        "label": "Issue of Shares On Spin Off",
        "verboseLabel": "Issue of shares on spin off"
       }
      }
     },
     "localname": "IssueOfSharesOnSpinOff",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "snpx_LicenseAgreementsDevelopmentCostsAndPatentFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of development costs and patent fees paid by the company.",
        "label": "License Agreements, Development Costs And Patent Fees",
        "terseLabel": "Development costs and patent fees"
       }
      }
     },
     "localname": "LicenseAgreementsDevelopmentCostsAndPatentFees",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_LicenseAgreementsLicensingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of license fees paid by the company.",
        "label": "License Agreements, Licensing Fees",
        "terseLabel": "Licensing fees"
       }
      }
     },
     "localname": "LicenseAgreementsLicensingFees",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_MilestonePaymentsPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for milestone payments during the current period.",
        "label": "Milestone Payments Paid",
        "terseLabel": "Milestone payments made"
       }
      }
     },
     "localname": "MilestonePaymentsPaid",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_MilestonePaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments payable by the company.",
        "label": "Milestone Payments Payable",
        "verboseLabel": "Payable of milestone payments"
       }
      }
     },
     "localname": "MilestonePaymentsPayable",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum acquisition percentage of outstanding common stock to exercise rights.",
        "label": "Minimum Acquisition Percentage of Outstanding Common Stock to Exercise Rights",
        "terseLabel": "Minimum acquisition percentage of outstanding common stock to exercise rights"
       }
      }
     },
     "localname": "MinimumAcquisitionPercentageOfOutstandingCommonStockToExerciseRights",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "snpx_MinimumPercentageOfAnnualizedSalaryPayableUponTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of annualized salary payable as compensation upon termination of the employee within six months from Start Date of the employment.",
        "label": "Minimum Percentage Of Annualized Salary Payable Upon Termination",
        "terseLabel": "Minimum percentage of annualized salary payable if the employee is termination within six months from start date"
       }
      }
     },
     "localname": "MinimumPercentageOfAnnualizedSalaryPayableUponTermination",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snpx_Mt.SinaiLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Mt. Sinai License Agreement.",
        "label": "Mt. Sinai License Agreement"
       }
      }
     },
     "localname": "Mt.SinaiLicenseAgreementMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_NationalInstitutesOfHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to National Institutes of Health.",
        "label": "National Institutes of Health"
       }
      }
     },
     "localname": "NationalInstitutesOfHealthMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_NemoursAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Nemours Agreement",
        "label": "Nemours Agreement"
       }
      }
     },
     "localname": "NemoursAgreementMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_NetChangeInInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of investment in equity.",
        "label": "Net Change In Investment",
        "terseLabel": "Net change in Parent company investment"
       }
      }
     },
     "localname": "NetChangeInInvestment",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_NetProceedsFromSaleOfWarrantsAndCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net proceeds from sale of Warrants and Common Stock",
        "label": "Net Proceeds from Sale of Warrants and Common Stock",
        "terseLabel": "Net proceeds in offering"
       }
      }
     },
     "localname": "NetProceedsFromSaleOfWarrantsAndCommonStock",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_NetSalesOverDollarsMillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the scenario, net sales of over $250 million.",
        "label": "Net sales over $250 million"
       }
      }
     },
     "localname": "NetSalesOverDollarsMillionMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_NetSalesUpToDollars250MillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the scenario, net sales of up to $250 million.",
        "label": "Net sales up to $250 million"
       }
      }
     },
     "localname": "NetSalesUpToDollars250MillionMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_NetTransferFromToParent": {
     "auth_ref": [],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".",
        "label": "Net Transfer from (to) Parent",
        "terseLabel": "Net transfer from parent"
       }
      }
     },
     "localname": "NetTransferFromToParent",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_NumberOfCommonSharesForEachRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares upon exercise of each right.",
        "label": "Number of Common Shares for Each Right",
        "terseLabel": "Number of common shares for each right"
       }
      }
     },
     "localname": "NumberOfCommonSharesForEachRight",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "snpx_NumberOfDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of directors affected by the transaction.",
        "label": "Number of Directors",
        "verboseLabel": "Number of director"
       }
      }
     },
     "localname": "NumberOfDirectors",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snpx_NumberOfEmployee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of directors .",
        "label": "Number Of Employee",
        "terseLabel": "Number of employee"
       }
      }
     },
     "localname": "NumberOfEmployee",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snpx_NumberOfExecutiveDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of executive directors affected by the transaction.",
        "label": "Number Of Executive Directors",
        "terseLabel": "Number of executive directors"
       }
      }
     },
     "localname": "NumberOfExecutiveDirectors",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snpx_NumberOfMonthsBaseSalaryPayableUponSeparation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of months base salary payable to the employee upon his separation.",
        "label": "Number Of Months Base Salary Payable Upon Separation",
        "terseLabel": "Number of months base salary payable as of the Separation Date"
       }
      }
     },
     "localname": "NumberOfMonthsBaseSalaryPayableUponSeparation",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snpx_NumberOfMonthsBaseSalaryPayableUponTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of months base salary payable to the employee upon his termination.",
        "label": "Number Of Months Base Salary Payable Upon Termination",
        "terseLabel": "Number of months base salary payable if the employee is terminated"
       }
      }
     },
     "localname": "NumberOfMonthsBaseSalaryPayableUponTermination",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snpx_NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of One-Thousandth share of Series A Preferred stock Included In Right.",
        "label": "Number of One-Thousanth share of Series A Preferred stock Included In Right",
        "terseLabel": "Number of One-Thousandth share of Series A Preferred stock Issued In Right"
       }
      }
     },
     "localname": "NumberOfOneThousanthShareOfSeriesPreferredStockIncludedInRight",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "snpx_NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of preferred share purchase right for each outstanding share of Common Stock by means of dividend.",
        "label": "Number of Preferred Share Purchase Right for Each Outstanding Share of Common Stock, Dividend",
        "terseLabel": "Number of preferred share purchase right for each outstanding share of Common Stock by means of dividend"
       }
      }
     },
     "localname": "NumberOfPreferredSharePurchaseRightForEachOutstandingShareOfCommonStockDividend",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "snpx_NumberOfSharesForEveryFiveCommonSharesHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of Synaptogenix, Inc. . common stock for every five shares of Neurotrope common stock held.",
        "label": "Number of Shares for Every Five Common Shares Held",
        "terseLabel": "Number of shares for every five shares held"
       }
      }
     },
     "localname": "NumberOfSharesForEveryFiveCommonSharesHeld",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares of common stock for every five shares of Neurotrope common stock issuable upon conversion of Neurotrope preferred stock held.",
        "label": "Number of Shares For Every Five Shares of Common Stock Issuable Upon Conversion of Preferred Stock Held",
        "terseLabel": "Number of shares for every five shares of Neurcommon stock issuable upon conversion of preferred stock held"
       }
      }
     },
     "localname": "NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponConversionOfPreferredStockHeld",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "snpx_NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of common stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held.",
        "label": "Number of Shares for Every Five Shares of Common Stock Issuable Upon Exercise of Warrants Held",
        "terseLabel": "Number of common stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held"
       }
      }
     },
     "localname": "NumberOfSharesForEveryFiveSharesOfCommonStockIssuableUponExerciseOfWarrantsHeld",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "snpx_NumberOfStatementsEnteredIntoAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of statements entered into agreements",
        "label": "Number of Statements Entered Into Agreement",
        "terseLabel": "Number of statements"
       }
      }
     },
     "localname": "NumberOfStatementsEnteredIntoAgreement",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureRelatedPartyTransactionsAndLicensingResearchAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snpx_NumberOfVotesPerShareOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes entitled for each common share held.",
        "label": "Number of Votes Per Share Owned",
        "terseLabel": "Votes per share of common stock"
       }
      }
     },
     "localname": "NumberOfVotesPerShareOwned",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snpx_NumberOfWarrantHoldersWhoExercisedWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrant holders who exercised their warrants during the period.",
        "label": "Number Of Warrant Holders Who Exercised Warrants"
       }
      }
     },
     "localname": "NumberOfWarrantHoldersWhoExercisedWarrants",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snpx_OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options granted to the employee to purchase shares of common stock as a minimum percent of Company's outstanding shares of common stock immediately following the Spin-Off.",
        "label": "Options Granted As A Minimum Percent Of Company's Outstanding Shares Of Common Stock Immediately Following Spin Off",
        "terseLabel": "Options granted to purchase shares of common stock as a percent of Company's outstanding shares of common stock immediately following the Spin-Off"
       }
      }
     },
     "localname": "OptionsGrantedAsMinimumPercentOfCompanySOutstandingSharesOfCommonStockImmediatelyFollowingSpinOff",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snpx_ParentCompanyEmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LaborAndRelatedExpense",
       "weight": 1.0
      },
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for parent company employee benefit and equity-based compensation.",
        "label": "Parent Company Employee Benefits and Share-based Compensation",
        "terseLabel": "Parent company stock based compensation",
        "verboseLabel": "Stock based compensation from Parent"
       }
      }
     },
     "localname": "ParentCompanyEmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_PaymentsInLieuSharesForReverseStockSplit": {
     "auth_ref": [],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in lieu of shares for reverse stock split.",
        "label": "Payments In Lieu Shares For Reverse Stock Split",
        "negatedLabel": "Cash in lieu of shares for reverse stock split"
       }
      }
     },
     "localname": "PaymentsInLieuSharesForReverseStockSplit",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_PercentageOfGrossRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value represents percentage of gross revenue.",
        "label": "Percentage of Gross Revenue"
       }
      }
     },
     "localname": "PercentageOfGrossRevenue",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snpx_PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fees on offering based on aggregate exercise price paid to placement agents.",
        "label": "Percentage Of Offering Fees Based On Aggregate Exercise Price Of Warrant",
        "terseLabel": "Percentage of offering fees on aggregate price of warrant exercise"
       }
      }
     },
     "localname": "PercentageOfOfferingFeesBasedOnAggregateExercisePriceOfWarrant",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snpx_PercentageOfOfferingFeesInCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fees on offering in cash to placement agents.",
        "label": "Percentage of Offering Fees in Cash",
        "terseLabel": "Percentage of offering fees in cash"
       }
      }
     },
     "localname": "PercentageOfOfferingFeesInCash",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snpx_PercentageOfOfferingFeesInWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fees on offering in warrants to placement agents.",
        "label": "Percentage of Offering Fees in Warrants",
        "terseLabel": "Percentage of offering fees in warrants"
       }
      }
     },
     "localname": "PercentageOfOfferingFeesInWarrants",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snpx_PeriodFollowingSeparationDateToPayCobraPremiums": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period following the Separation Date to pay COBRA premiums, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period Following Separation Date To Pay COBRA Premiums",
        "terseLabel": "Period following the Separation Date to pay COBRA premiums"
       }
      }
     },
     "localname": "PeriodFollowingSeparationDateToPayCobraPremiums",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snpx_PlacementAgentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for placement agent agreement.",
        "label": "Placement Agent Agreement [Member]"
       }
      }
     },
     "localname": "PlacementAgentAgreementMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_PlacementAgentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about placement agents.",
        "label": "Placement Agents"
       }
      }
     },
     "localname": "PlacementAgentsMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_PrefundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents prefunded warrants.",
        "label": "Prefunded warrants"
       }
      }
     },
     "localname": "PrefundedWarrantsMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_PrepaymentsForServiceAgreementCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepayments under the service agreement, classified as current.",
        "label": "Prepayments For Service Agreement, Current",
        "terseLabel": "WCT prepayments included as a prepaid expense and other current assets"
       }
      }
     },
     "localname": "PrepaymentsForServiceAgreementCurrent",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_ProceedsFromGrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of proceeds from grants during the period.",
        "label": "Proceeds From Grants",
        "terseLabel": "Funding received"
       }
      }
     },
     "localname": "ProceedsFromGrants",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow due to warrant exercise and reimbursement of trial expenses.",
        "label": "Proceeds From Warrant Exercises And Reimbursement of Trial Expenses",
        "terseLabel": "Inflow of cash due to warrant exercise and reimbursement of trial expense"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercisesAndReimbursementOfTrialExpenses",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_PurchasePriceOfRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of right.",
        "label": "Purchase Price of Right",
        "terseLabel": "Purchase price of right"
       }
      }
     },
     "localname": "PurchasePriceOfRight",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "snpx_RightsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the Rights Agreement.",
        "label": "Rights Agreement"
       }
      }
     },
     "localname": "RightsAgreementMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_RoyaltyPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Payment Percentage .",
        "label": "Royalty Payment Percentage",
        "verboseLabel": "Royalty payment percentage"
       }
      }
     },
     "localname": "RoyaltyPaymentPercentage",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snpx_RoyaltyPaymentThresholdNetSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold amount of net sales to be considered for payment of royalty.",
        "label": "Royalty Payment, Threshold Net Sales",
        "terseLabel": "Threshold net sales"
       }
      }
     },
     "localname": "RoyaltyPaymentThresholdNetSales",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_SecuritiesPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents Securities Purchase Agreements.",
        "label": "Securities Purchase Agreements"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementsMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_SeparationBenefitsReimbursed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of separation benefits paid by the company, which has been reimbursed.",
        "label": "Separation Benefits Reimbursed",
        "terseLabel": "Separation benefits reimbursed by Metuchen pursuant to Merger"
       }
      }
     },
     "localname": "SeparationBenefitsReimbursed",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_SeriesBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series H Warrants.",
        "label": "Series B Warrants"
       }
      }
     },
     "localname": "SeriesBWarrantsMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_SeriesCWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series C Warrants.",
        "label": "Series C Warrants"
       }
      }
     },
     "localname": "SeriesCWarrantsMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_SeriesDWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series D Warrants.",
        "label": "Series D Warrants"
       }
      }
     },
     "localname": "SeriesDWarrantsMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_SeriesEWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series E Warrants.",
        "label": "Series E Warrants"
       }
      }
     },
     "localname": "SeriesEWarrantsMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_SeriesFWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series F Warrants.",
        "label": "Series F Warrants"
       }
      }
     },
     "localname": "SeriesFWarrantsMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_SeriesGWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series G Warrants.",
        "label": "Series G Warrants"
       }
      }
     },
     "localname": "SeriesGWarrantsMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_SeriesHWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series H Warrants.",
        "label": "Series H Warrants"
       }
      }
     },
     "localname": "SeriesHWarrantsMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_SeriesWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stand for Series A Warrants.",
        "label": "Series A Warrants"
       }
      }
     },
     "localname": "SeriesWarrantsMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_ServicesAgreement2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2020 Services Agreement.",
        "label": "2020 Services Agreement"
       }
      }
     },
     "localname": "ServicesAgreement2020Member",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement for service on a committee of the Board of Directors.",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized For Service On Committee Of The Board Of Directors",
        "terseLabel": "Stock option grant authorized for service on a committee of the Board of Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForServiceOnCommitteeOfBoardOfDirectors",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards in granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options granted (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options grant.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Value",
        "terseLabel": "Fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateValue",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_ShareBasedPaymentArrangementNewlyAppointedDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to newly appointed directors.",
        "label": "Newly appointed director"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNewlyAppointedDirectorsMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_ShareBasedPaymentArrangementNonemployeeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to nonemployee directors.",
        "label": "Nonemployee directors"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeDirectorsMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_ShareBasedPaymentArrangementTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Fourth anniversary from Start Date"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementTrancheFourMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_ShareholderRightsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents shareholders rights plan member.",
        "label": "Shareholder Rights Plan"
       }
      }
     },
     "localname": "ShareholderRightsPlanMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_SixMonthAnniversaryOfGrantDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to six month anniversary of grant date.",
        "label": "Six month anniversary of grant date"
       }
      }
     },
     "localname": "SixMonthAnniversaryOfGrantDateMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_SpinOffRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of shares of spin-off company issued for shares of the Company's common stock owned by such stockholder.",
        "label": "Spin Off Ratio",
        "terseLabel": "Spin-Off Ratio"
       }
      }
     },
     "localname": "SpinOffRatio",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "snpx_StandFordLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stand Ford License Agreement Member",
        "label": "Stand Ford License Agreement [Member]"
       }
      }
     },
     "localname": "StandFordLicenseAgreementMember",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snpx_StockIssuedDuringPeriodSharesWarrantExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of capital stock issued during the current period as a result of warrants exercised.",
        "label": "Stock Issued During Period Shares, Warrant Exercises",
        "verboseLabel": "Exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantExercises",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "snpx_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "verboseLabel": "Exercise of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_StockOptionNoteDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for stock option note disclosure.",
        "label": "Stock Option Note Disclosure [Text Block]",
        "verboseLabel": "Common Stock Warrants:"
       }
      }
     },
     "localname": "StockOptionNoteDisclosureTextBlock",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "snpx_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "snpx_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "snpx_TargetEnrollmentOfStudySubjects": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the target enrollment of study subjects.",
        "label": "Target Enrollment Of Study Subjects",
        "terseLabel": "Target enrollment of study subjects"
       }
      }
     },
     "localname": "TargetEnrollmentOfStudySubjects",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snpx_ThresholdPeriodForArrangingFutureFinancing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period within which the future financing should be consummated.",
        "label": "Threshold Period For Arranging Future Financing",
        "terseLabel": "Period within which future financing should be consummated"
       }
      }
     },
     "localname": "ThresholdPeriodForArrangingFutureFinancing",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snpx_TotalAmountOfBaseSalaryPayableUponSeparation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amounts of base salary payable to the employee upon his separation.",
        "label": "Total Amount Of Base Salary Payable Upon Separation",
        "terseLabel": "Total base salary payable upon Separation"
       }
      }
     },
     "localname": "TotalAmountOfBaseSalaryPayableUponSeparation",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_TotalSavings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of savings made by the company as of the balance sheet date.",
        "label": "Total Savings",
        "verboseLabel": "Total services fees"
       }
      }
     },
     "localname": "TotalSavings",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_TotalSeparationBenefitsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total benefits payable to the employee upon his separation.",
        "label": "Total Separation Benefits Payable",
        "terseLabel": "Total commitment"
       }
      }
     },
     "localname": "TotalSeparationBenefitsPayable",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_WarrantAmendmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of warrant amendment expense.",
        "label": "Warrant amendment expense",
        "negatedLabel": "Warrant amendment expense"
       }
      }
     },
     "localname": "WarrantAmendmentExpense",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snpx_WarrantsAndRightsOutstandingTermFollowingEffectiveDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants term following the effective date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants And Rights Outstanding, Term, Following Effective Date",
        "terseLabel": "Warrants term following the effective date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTermFollowingEffectiveDate",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snpx_WarrantsIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued for consulting service.",
        "label": "Warrants Issued During Period, Shares, Issued for Services",
        "verboseLabel": "Consulting services paid by issuance of Parent company common stock warrants (in Shares)"
       }
      }
     },
     "localname": "WarrantsIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "snpx_WarrantsIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Values of warrants issued for consulting service.",
        "label": "Warrants Issued During Period Value Issued For Services",
        "verboseLabel": "Consulting services paid by issuance of Parent company common stock warrants"
       }
      }
     },
     "localname": "WarrantsIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://www.synaptogen.com/20210930",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CFO"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r26",
      "r28",
      "r57",
      "r58",
      "r139",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r138",
      "r146",
      "r175",
      "r177",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r291",
      "r293",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails",
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r138",
      "r146",
      "r175",
      "r177",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r291",
      "r293",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails",
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r108",
      "r171",
      "r172",
      "r270",
      "r290",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r108",
      "r171",
      "r172",
      "r270",
      "r290",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r138",
      "r146",
      "r173",
      "r175",
      "r177",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r291",
      "r293",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails",
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r138",
      "r146",
      "r173",
      "r175",
      "r177",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r291",
      "r293",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails",
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r27",
      "r28",
      "r57",
      "r58",
      "r139",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r68",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r68",
      "r73",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails",
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r68",
      "r73",
      "r124",
      "r176",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails",
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r109",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r18",
      "r257"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r9",
      "r208",
      "r257"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r205",
      "r206",
      "r207",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r179",
      "r182",
      "r211",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "verboseLabel": "Parent company stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": {
     "auth_ref": [
      "r160",
      "r167"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.",
        "label": "Adjustments to Additional Paid in Capital, Stock Split",
        "negatedLabel": "Reverse stock split rounding"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r137",
      "r160",
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of warrants for consulting fees"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used by operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r182",
      "r203",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Stock options expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails",
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r55",
      "r101",
      "r103",
      "r106",
      "r111",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r229",
      "r231",
      "r238",
      "r255",
      "r257",
      "r272",
      "r280"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r25",
      "r55",
      "r111",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r229",
      "r231",
      "r238",
      "r255",
      "r257"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r183",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r16",
      "r50"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r44",
      "r50",
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "CASH AND EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "CASH AND EQUIVALENTS AT BEGINNING OF PERIOD"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r44",
      "r239"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "NET INCREASE IN CASH AND EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Cash balance of insured FDIC amount"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Cash balance of uninsured amount"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r169",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price",
        "verboseLabel": "Exercise price of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Common share issuable upon exercise of warrants",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase shares of common stock",
        "verboseLabel": "Number of shares called for by warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "verboseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r21",
      "r123",
      "r274",
      "r284"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r125",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r60",
      "r61",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, stated value (in dollars per share)",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails",
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails",
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails",
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r257"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock - 150,000,000 shares authorized as of September 30, 2021, $0.0001 par value; 6,136,967 shares issued and outstanding as of September 30, 2021 and 1,257,579 shares as of December 31, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LaborAndRelatedExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold.",
        "label": "Compensation Expense, Excluding Cost of Good and Service Sold",
        "verboseLabel": "Consultant compensation paid with Parent equity"
       }
      }
     },
     "localname": "CompensationExpenseExcludingCostOfGoodAndServiceSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r40",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Aggregate amount paid",
        "verboseLabel": "Aggregate amount paid"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails",
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r48",
      "r99"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Based Compensation:"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation:"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "PER SHARE DATA:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r37",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r74",
      "r77",
      "r80",
      "r81",
      "r82",
      "r85",
      "r86",
      "r234",
      "r235",
      "r277",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r37",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r77",
      "r80",
      "r81",
      "r82",
      "r85",
      "r86",
      "r234",
      "r235",
      "r277",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-based Compensation",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r32",
      "r33",
      "r34",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r87",
      "r112",
      "r160",
      "r167",
      "r205",
      "r206",
      "r207",
      "r224",
      "r225",
      "r233",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r294",
      "r295",
      "r296",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r48",
      "r140"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Total expense"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r178",
      "r180",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "verboseLabel": "Grants receivable"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantsReceivableCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Grants Receivable, Current",
        "terseLabel": "Grant receivable",
        "verboseLabel": "Funding receivable in year two"
       }
      }
     },
     "localname": "GrantsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r35",
      "r101",
      "r102",
      "r104",
      "r105",
      "r107",
      "r271",
      "r275",
      "r278",
      "r287"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedTotalLabel": "Net loss before income taxes",
        "verboseLabel": "Federal and state net operating loss carryforwards"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r114",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r56",
      "r71",
      "r72",
      "r100",
      "r219",
      "r226",
      "r227",
      "r288"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "(Decrease) increase in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "(Decrease) increase in accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Increase in prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.",
        "label": "Investment Holdings, Schedule of Investments [Table Text Block]",
        "verboseLabel": "Schedule components of the net transfers"
       }
      }
     },
     "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investment holdings.  This includes the information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.",
        "label": "Investment Holdings, Schedule of Investments [Text Block]",
        "terseLabel": "Parent Company Investment"
       }
      }
     },
     "localname": "InvestmentHoldingsScheduleOfInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureParentCompanyInvestment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "verboseLabel": "Consulting services paid by issuance of common stock"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureParentCompanyInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r55",
      "r111",
      "r238",
      "r257",
      "r273",
      "r282"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r20",
      "r55",
      "r111",
      "r126",
      "r127",
      "r128",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r230",
      "r231",
      "r232",
      "r238",
      "r255",
      "r256",
      "r257"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r90",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "verboseLabel": "Organization, Business, Risks and Uncertainties"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertainties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used in Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "CASH FLOWS USED IN INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r44",
      "r46",
      "r49"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOW USED IN OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r29",
      "r30",
      "r34",
      "r36",
      "r49",
      "r55",
      "r63",
      "r65",
      "r66",
      "r67",
      "r68",
      "r71",
      "r72",
      "r78",
      "r101",
      "r102",
      "r104",
      "r105",
      "r107",
      "r111",
      "r126",
      "r127",
      "r128",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r235",
      "r238",
      "r276",
      "r285"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTotalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r68",
      "r74",
      "r75",
      "r79",
      "r82",
      "r101",
      "r102",
      "r104",
      "r105",
      "r107"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "TOTAL OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Business, Risks and Uncertainties"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "verboseLabel": "OTHER INCOME (EXPENSE):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent Company Investment."
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r183",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails",
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails",
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r7",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r14",
      "r15"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Private placements of common stock and warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of investor warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r5",
      "r6",
      "r113",
      "r257",
      "r279",
      "r283"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Fixed assets, net of accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r113",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Fixed Assets and Leases"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life (years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r174",
      "r249",
      "r250",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions and Licensing / Research Agreements"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r247",
      "r248",
      "r250",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions and Licensing / Research Agreements"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureRelatedPartyTransactionsAndLicensingResearchAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r214",
      "r269",
      "r305"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Clinical trial expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "RSU's"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r115",
      "r116",
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r167",
      "r208",
      "r257",
      "r281",
      "r297",
      "r298"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r112",
      "r205",
      "r206",
      "r207",
      "r224",
      "r225",
      "r233",
      "r294",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company Investment"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r183",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule of stock outstanding under the plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r188",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock option activity",
        "verboseLabel": "Schedule of Common stock warrant activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsTables",
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r22",
      "r53",
      "r88",
      "r89",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r149",
      "r153",
      "r158",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsCommonStockWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted",
        "verboseLabel": "Warrants issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsCommonStockWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r189",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Warrants outstanding September 30, 2021",
        "periodStartLabel": "Warrants outstanding January 1, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsCommonStockWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of securities available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years) and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable at the end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable at the end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options granted",
        "verboseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails",
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Options outstanding at the end (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r190",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding at the end",
        "periodStartLabel": "Options outstanding at the beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding at the end (in dollars per share)",
        "periodStartLabel": "Options outstanding at the beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r181",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercise price of stock options",
        "verboseLabel": "Less options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails",
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercise price",
        "verboseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails",
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "First anniversary from Start Date"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Third anniversary from Start Date"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Second anniversary from Start Date"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r180",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r178",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Director"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Options granted, vesting percentage",
        "verboseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r198",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Options exercisable at the end (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable at the end (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options outstanding at the end (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationStockOptionActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Number of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r52",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SpinoffMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Creation of an independent entity from an existing entity through divestiture, for example, but not limited to, sale or distribution of new shares.",
        "label": "Spin-Off from Neurotrope"
       }
      }
     },
     "localname": "SpinoffMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r23",
      "r32",
      "r33",
      "r34",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r87",
      "r112",
      "r160",
      "r167",
      "r205",
      "r206",
      "r207",
      "r224",
      "r225",
      "r233",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r294",
      "r295",
      "r296",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statements of Changes in Shareholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r87",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Number of warrants"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r160",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Private placement of common stock and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "terseLabel": "Shares issued for reverse stock split rounding (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Consulting services paid by issuance of Parent company common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r160",
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Private placement of common stock and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r55",
      "r110",
      "r111",
      "r238",
      "r257"
     ],
     "calculation": {
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets",
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity:"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r54",
      "r145",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r167",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity:"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse Stock Split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r246",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r246",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r246",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r258",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCollaborativeAgreementsAndCommitmentsDetails",
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesLiquidityUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityJanuary2021PrivatePlacementDetails",
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r115",
      "r116",
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails",
      "http://www.synaptogen.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants, measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.synaptogen.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.synaptogen.com/role/DisclosureOrganizationBusinessRisksAndUncertaintiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r76",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r74",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Basic weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.synaptogen.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r306": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r307": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r308": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r309": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r310": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r311": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r312": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>52
<FILENAME>0001104659-21-138190-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-138190-xbrl.zip
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M=G:/U:0^2%5,5TCQ-POMZ_CM):UK7,U95%;<D[K=I4VR3P=WC[6N7^2E4OR
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MX%4TVE[;!Y5V'#O[YQ\*8Y#A$-2.M,Y'I891J7\P:A<QM%G2<O%(Y;OD0);
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M@?,J=2G4=*RB#8'K,]X9HE0L[C;&JT$'Y?W[9KQ78PZ!_0=_ZLP+^5$K>Q#
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M5W4@Q!Q%+T2(?+RV<['0!X2351>"S-/4RW%ICT(6DU*Z?. X7)&$&@Y0]3J
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M8KM+)</C%$HX".=E!ZTY!-LJJ>@_$EL.>^;*Y0H@A'-M?397R!B(S^>N?*X
M0CB"UN=SA8R!^'SARN<*((0#8GT^5\@8B,\_N_*Y @BA%D)]/E?(&(C/GUWY
M7 &$D-A?G\\5,@;B\Y4KGRN $%+3Z_.Y0L9 ?+YTY7,%$$)>=7T^5\@ =_T[
M3QX8^C/A1[3+1W%.,]_^:J$!E4"W'CFU1 "5A_G%(3T\D,.F1<,LDH%T[UM"
MS_Q>GAH6PNG4JF(&D4#RF!T*S=I*K"H 1RR9JD6[P/>2&7NQ=4R5B^8TB5GL
MX2#$RSINM$(S"!X(-UG::0&W+5"B7,A[W7]DV5>FJU_6L"\(GH\6\K43"$[H
MS0NH$)PF#^X>6F+<X,BPQ_2QS^YK#]L'A.#0<33U/7(!GHZ)C)%KQA(47"24
M&[\TQSE-,[U%3_*3?B%W:PS!R>2ZS+M1!$Z.^_0B'*0&+;>>B4@QC03MS2 X
MKMQD9Z>E=Z]*DY7G#"T(1:><O"#;*U9\,)UT"\$S9A9D=[2.(^A;;NRIZ.(K
M7QCNR06*N=8)0@6WO:A$Q'P3XNEB3XNSW%N. L%QUU0-6I+>OU,U'?%.;!B4
MOM3"=Q!E_^R2*"+]HA:^<LQF@T6PV@6,XG:M5\0J8>!$>RA4&OR>L%B@.M79
M2\<V,$K$.0G/0@DX:>DL=EJV!OE\.QV+4 0OBE!PMBVOX76<%75ZA5%8K;G?
MH@ZMXVQ[6&,A=]0GC*)E#?<TM2@=K)A(-O3/).)$LU]79+>W"DS[U3JM853\
ML@NM#DW@;/*,$A^A@%UQJC,T]\44-0;7W 1&B2PG:VHFI%%5F!^/4X[Q_XA"
M6?_Y/U!+ P04    "  FB&Q3.<AI5'1>  "S&@4 %0   '-N<'@M,C R,3 Y
M,S!?;&%B+GAM;-V]:W/D-I(H^OU&W/^ XW,B;$=4V]WVF=FU[\Z>*+W:VJ-6
M:26UO7,=-R:H*I3$,RRRAF2I5?/K+Q+@ R0!$'PA6?ZPLVU59B(3S$P B43F
MO_VOMUU 7FF<^%'XEZ\^?/?^*T+#=;3QP^>_?'5(WGG)VO>_^E___G__7__V
MW]Z]^Z^S^QNRB=:''0U3LHZIE](-^>*G+^0QVN^]D'RB<>P' 3F+_<TS)>2G
M[_[\W;_\]/Y?O_OAQP\__43>O<LHG7D)PXQ"PDG^\-V'XI?SC&H4_DP^?/C^
MPP_?__#^AP_D7W_^G__Z\Y]^)'>?"LA/C,VMKP/]GP5HX(=__QG^YXD-2IC
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M(!&+8\P\/(7%844+C>X1VHXI&E#\5=]X0%&M^+/)VK'GO[I"^M.QWV>9'TL
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M_VU!KL/U=^0[WLRJN+O@"3@P$ME"NZ02M53.*L(+X\!Q,LZ(4Y,%>4%J3H0
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MNF;[.KI19@JTP")H0AOCA3;H -UJA)D+K58LB(2!M93GS%Q%[(#L)>KBR"9
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M683M*?M\+\MP<T%?:1#M^?W^&YP(S*D95IAH(7Q;H6J!_#8TC'"^'4^*'93
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M)= ?Q0/>^\G?KV)*KT,V[31)7?D_];A_ .]GFM#)?)]JT-/V?'J)7/H]X((
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M^5YD!YT[+W(=_W^  ]E^-*RB[<%32H(<4IKIQ&I(<X>AK9AWZ"^TLP6C9'L
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MW,,2[.8TFFV<%*-;$K,1L3X.-[JD.HD)U;1F+I'7[ZZK6'UY-02+/TQ4HFW
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M-,<5T)LBEABH%Z&/1(EN_TS0I^4RPY[O9X8M-OFOO;31GPUGA-T7\VL85Z6
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M/AC&CL\>UM3]X-\_I)B@_\%)N/[C_P-02P,$%     @ )HAL4V,J*6B9Y@$
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MM9Y3F[;$SVZES$DC8(B8:CJN:$K/=\%GRN[VQMU71'^N?MPT51<NY@!I?]1
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M?TZK.#5P<'4FI=*2EU!3\_F/B PDU1!U**/XX: [0!V.H"U,0J,F#D'5,P;
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MPXYWAC6CR]3KO!]5&(R#0NXC2TD^D?$K&DO'=H6F: Y!<J$ZP55%-57#,RH
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M'Q-O-:@A84X R[&)^ECJ6+4L\_6\[$W*W AO)#L\QVM\TXZ.%XPR_Q@OSZV
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ME^<ULS_IEJUT:D!J*C[V:S1KZWSVH9F_G-L[.0I74<UNL235TS[P^<Y4\U1
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MO9_Q+P_]/KA/D'"VOY<5=$T;YI"FK<V(G,[7IN698,VQ@=K]1MS_=$N#HQ)
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M"X-Q!JHYF"0['BK(HJ(?)-&!#-&MN;-N@T:(.JOJNCKU5!DZ%'\&-$ 2"V]
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M-YZS$P*3$"08$.S%?3:X"="_*9N+#X2CG& \&]$CR_Q)Y@") 4165S850&(
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M'7Z<+*+Z'H!HLV2;7:S9.9[1NA.>H)>50GL==C4ZOHBA\'LZ>9@1_2L^2S)
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M]?B9[4;;AG\ZVESV])46/OO94R.M>/;B="IYD7Y0OQ7P7SDQ=4+D^]]./8,
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M,8#20>F@]/=&3OY@3S_T[VB]IEN@=%#Z<S% N()RBL&]5N+]I QN8#[[=??
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M2(%.X? B2)%/YK+S>M'M&;U*:^B0G:K73*="I @KD?Q]DN+O\>1;0074(I$
M.ZA%QBL?NA6[A'(EV"78)6HQ8.Q"/2A7@LW%"0JOI5S9<.QPV$$R%20?4*R\
M,IX22BLD0&@Z;K%SISFV*KO3UQ<:.O+F@=J=UBQMK'NOK TL','N:C5RB/?2
MDKX3'5UM==82P8:ER= R"/(_L(8(/$> A1@5-K\/"QFGLMHM?$W ]=%F+6>]
MM,8PS1 66( %X#0!IRF&1<SOHX);6I7Z%HZQ0GY5:@OFLCW:>!$J\( *@ J
M"C$L6'X?%3@:]QKX0)_AV^&NUTZ+/;'2CE A+"^^#PM07$0"V*"X"$4<%.T2
MBHM@EV"74.B!XB+87/QL[G:+B_MS4Q^ID+ *<,Z2 14DQ*KMC^;:9=8!_N_L
MY8(+C!B!-8!S<"8##_Z];_FM;<9<C5\4>HV>(69F;KO:KF5RTCPE$1RP' $9
M !EB64D\#C*05:R27:][:R$S8KIY=K0I3\5UB Q :D2E<G#MP'!8-;A-8#@'
M(_+#P%#M,CEU8K--@ZS7FD9+-B66BT(&X# ",  PQ+">>!Q@<,=<HT"44XRA
MKQL44>^E-R0V"8$!*(NP8@G5&R27+,$NP2[!+N-GEU#A ;,$LP2SC'?A,7AF
M0V@EVH542TAD4YW43U@F@/,3;S#( 1,'$P<3!Q./58AU/0?6H:9CL'"P<'0L
M');EK\5'XQQ/W6C8!'8)=@EV&1>[1"=TN:D(!<P2S!)!LXSKLOP+/E!:=G4E
M(5MJ0M7GOJ>I^XO2%IJ34&S3M /93&5'@Y3XED@!S\2#N9J"Z1ML+YN?A>@?
MR>$7\S6^K-6%3$K ZWI.*+6&S9=_^ZTN[7\,'Q1(S#'E^?Z3M19Z\>-'3[Q[
MKHT?]B<^*.WTNKLV?D-67^FJ%NU5C-S>E>C5SJ^4,I.QJ&%63MWDK>:<.C;]
MB?S$ED5!=JQ @&Y#<]IA%R, >V7'8CDC3Q@'3YN&WFD6=^,&,]H5UQ))ANPG
M_ >=A%W,@'%O8YQ?<H;NW*\6#'V:X0K%XGK0+DP XP#COD#D.@7&J1RU7:1V
MTRZ.37I]@FI9YF30##&.#3&.QP'C;IFI\0&(JS1-;;CJU@5#YC1!SS(:WY_<
M8!AW7:23;T+<5REIIX"X$BNVMW3><XU>6RHJH]5&U0>I$.+XN[^#J0E8J@!Q
M;T,<UYO4S3[;:(A;9LQB;;8XWU;6 '$ <5\@UYT"XF;T>&!5>*]G:"U[DW>H
M%MW1(X@+N77D#Y(#6MT-H#3426.R\@]V"78)=AD_NX1"*9@EF"68Y977[_=9
M9_"-''1;GFC/ZOANPO8]-SR3).@BK)3<4L'K0O>&Q7F1X=?A/0]+#%8Q3;"9
MCLD+>4W5U]Y.&'ER\X)G@?8>?#VU=_6:;XXTISZ.EAO<^F]/_]/2PZ3(3T<F
M86NBMEB*Q<%V(2G\6B+IL$C.WA,\>\_B4$4"X #@.#MPG/2HT.\"AS19Z+CI
M2UO<UZL560V^9A?-$#BB$T23#'-/ '#<=FWF0I>/W2QNG.,DT>_BQA3K57S9
M9 JXORZF\9K 3,1AA!M\B!LTB=^3@!N &X ;9\>-DQXT^EW<*"T7U0VE3X>B
M-LR5>WVV7%"9"#?"&BE]3R;I=X C6N_YMR<'^D7&IX]N18H6Z-=YT;'1L[<\
M;$H8V7,U^&5;TQ*RHMAFT*=M(/^$97O!RST[-!4UO&=238QU2[8479X'SY$]
MS0S>X?[X[[]'QQS#]^%1U5=__S?X\OAWRER3G1 )I@\/_^7GX4L>< #'_W$2
M;WZN!Y)^LFRW'R+]I-/1U__W/T\[?PAT#XCT9%33O2+)")PF&C9R--G Y''P
MXI_R?"UOW8=1<MP/DGY$NY^_4"V40X+YP7'_2/S^-I3&@2A->8,]$=@#%&+A
M+I:?^[]Z_"A"L<?/;%</??"GH\T#H%EIX;.?/372BF<O3J>2%\NFU&\%_%=.
M3)T0!O^W4\\@L!>H$P)3PAXG,B%$!Q[VR[CECQCX<P6])GDY@E*)H,?<>*QH
MDCSF"8G&95GB.!J7J%%25>D1P?(X>[=_ZYG1Z<'028)D2/X_KV'5UI(7GCW1
M+'USGRA:RF\0V@].6/H!3$@\35($HF/(_$+5]B\LC;0^E:U)T"?="GYA*\8T
M:*XY;G19;_(_B?W(CHRY[XWJJ4L\']CO&.UB<]F[DOZG:,F^&@2 ZK].+K?H
M$SW4K/?S[=GLH*//YR8B1/,/SG@/#LTG<95C.%:B>$J6:#[P94YF68ECE21)
M)AF-PM4'9Y ?HRE!5IB-J#@U0ZZ5Q5UG80YV0BH, U^VG&P&BI'=Y.=!2-A;
MU;C9HK+"4A(I$=3+IF8EB]%&FRR(^K+7DA=S;J9PS; I^[)IWB_.UU5SP(BZ
MJ/05"V^G2^.41!V^7Z$DK%C0=U/<GXGS[=8?,L)B$K1,OFQ94NR=:?8'6:%M
MI@;4;%$@K?PZ:'G84TK;5/F!6;0-N;"J:SR;6>+M9MCTH*?$F&782;%3QS-V
M<3?O-+(91@O?3_ '@_(*/3D[J9<-=JYGQOB6[E+-ID0?#FJUWG(KRV8V>";9
MMQ4KG[.RN4G0DG[9LH8YY6R]59S@,FZU9[E!72.*8<N#X4]Z8C,_#V(X7'<;
MNN[S;E<;ART)_&53C,0,7$R/:F*YNN9+&S*;; VBI@>24NN.DVYUIR3N^]HV
M+S5FWBX9CNE04CC>U;J]34[!>V:U;#EV/C-H1$\]D%1K4:\2J<ZJ;^0S^BB3
M7A23HALV)0]$U:'XAJ!@-">0C85:U.MXJSA+2:QT,*IUOF]Z:VS>$?S62M&'
MF:Z-\Y.@Y8%0#;RN$@Z5JXEU)C<U^#[5V%3"9QX(=497YC/6*++XDB3*<HT4
M/%H.GWDHU)38+4CY&M,1,]M)O>B5F\62U0R;'@AUM!GWB^)N(PO+<G)("J.E
M/V##]Q\*M>8,Y561%]IXWI6\';^NK)M6U($#H4Y*&Z%NU!9-,;]L%7999]%4
MA^%3#X6*F?55E2LM7=&?;?W2BJ&W124E<8="W;J&:NW415'LM4PJEU>XB4 V
M@^$?-JWO)LPXG<ILC79N5?&'GI7:!49-D(=-.WDKI8Q2BR"C7.:'2I9,EHQ!
M\%3ZL&F^39JF42ORHEX=C*7.6&D79^OP+ON#IJ2Y+#+JC*2,/&7,B&5I457,
MZ(J*@Z:%1:F&&SNKA6-$I94KKGE]5IX$>>]A4]PQ2K3&)WU<)T9>EM+6>K&^
M#IL>V-6J2E4']5:>Q)?#)>\N1H(8Y+IATP/#DNGE)K_LFDN\7B=7&Z*HY^Q,
MU/30LH9V:N8W)^F<2%8HEQ_10C*73$5M#TRKEYK/JD*_/C1\U\7]LMVNXXNH
MMX>V56]E++[=&4T%W9NX>27-3/IT,VI[T%]"E\AIA<'*AE^:,B1+VWELLW_N
M@2&FFIGD8JW+3<-,-TT\E^_GLT34]M 2\T2N..%3PP#>.<D=391RL3N*^D ^
MCBW*V'_E1?L5FV#RG\L+5_OY^,W3*3K<%_&0&X5QL;*/IQ\GVBAID7W/?OQ@
MG[)$GSQ+;)XL^CRT.4Q2/.>Q8P\O)/8S_L?V8I/)'Q3UULKCDV#_R?/MX)GC
MN;U^# X>?\;"!:Z?^RQP'<CIW03L(>:(7OS85!ZY=KB-Y!S9&/X#9W[G8P=1
MTO[O/AX//4FF3[SQ#/1R&;VP/W#P%P3U OZ"IE[P'SSX"X)Z87YP/.@%/;T
MCJ&IEP#'WJ04@5XNAF/@+PCJ!7 ,3;U /(:F7B >0U,O@&-HZ@5P#$V]0#R&
MIEX Q]#4"^25:.J%_T&]28H'O0".@5Z>X1@+>D%/+\P/'G ,0;T CJ&I%XC'
MT-0+Q&,GU<LGC_!\=]O8Q820_(00T#X9+/F. /;TA\.OS\:FV/-PP'_=D>3=
M%P>:)'X0W$NB*K'8) +KU]5S\%1#2;Q%RGC%.-[B&W:FCJ8EJL$OIFY"L-20
M"*,M/"VD@R8H_#X1<D]_\37 /=!T#^0E\-Y.P>N7 -C >U6*ZY? >W7-ZY<
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MCC M'$L8ES^/Y_]..;RS+ZL=#R#$=E9:YL:%1=D1BN*R4^9&+2<O,73JTNB
M?Q ;PH=.[;FJ.>Z^#Z^ PZRXZ/BYQL8W?&LQS*SS7'5AAN#  #B@  X7YO2<
M&AS.FS?%,'KXQ7I^"A%#KIY;SY/"2*R7Q$IV+O%4P9F<+(!8"$1&,ONR(RZ7
MVXTVZ$P)CTP%0^( (U# " @@D,2(\P007P2(8\800\%OD>N"510S25?$TJ-!
M<JN',01! $  0$ 0<5& ^'V89'B21M%Z((,\(,6@76SO6@X^,K;LK*3[/7'5
M'35/A13;#.XO99P<&&3#:^+B-%^E=F$D0=" %"@@Q36G&V=?FH\;4NS/(7T
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M21QNP7C3.$9_W'YQ]W=-M[1$-?A\ZB8$2]74UT^ &(%[H.P>R$L V?K1.6T
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M#\5,W6Q@E1-'"%.5;&338Q7/S =CEF$FI98>^CM)?C!" "H24)%0W]6"+FL
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MRY,W>=^O;KS^W (CN:A/6N:PC->U-9^BBK-.CH_0(Z1FL?<,P=_S' < @@J
M7'\J<^W\K*/BQQ_86CW-<+)]9[ 3VYM.O]4TR%9V\QFVUJ= 1+.S53%?R= X
MEL$-C"BENO5I!"+ UD(/02 $N78(R9:V="-3'^K&UAAU.:?7,<K,:>.(DJET
M)YRQRHGFCE(I=<@W5U$<$1&X/A)' ($+"%S7O)WLVI;GKZ0\'K>5=K!4('"!
MBH' =4-X=&VIW/5D;'&K,H&Q@K$BLXH !*XXFO?5Q U X+IZ6P4H1AV*KX?
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MVX0(1"ARX8"@FP\\[H G=U8(>ILVQ^:;.>$I(0%Q_FC4*YV8,FX5/ESQ?@%
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M7E]M9#6N)4E3W70&\P<A:J&[MA(^.93GDI$X3Y/T?3ARU#=H?PE!]*8(HK\
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M4T%TG.CXIP?EY]%QQQ;FV65N/I*4ZCBWJ3676GPC(!U/(!WG4XE(\L1]D;=
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MSW9J_N8=2FYOG;(K[C0C9JKIU9,V>GI*)@29BZ/=8(Z-,(EXA(F]Y3:3T)L
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MKE<<^,7\R@0^1W'],\>_[R["" M,:OKBYW_@7]OOJ1.@V @61L'#=TJ/7A*
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M(/O$)?B861*CLV2;%GAIFHD./[;P#53Y S0'78D:.,3;S3/LMP-]VO=L!Z>
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M^2XVZ'4(+I/H8B7#MAUD]<Y49#43@4C\J-,)^H"F0585<07!&4*J- TZK@!
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MY:]P:O_( .NW7G9_CC9XA<ET^^+X*[3 3VCK>X:V1)8J^0EMO<^?_,)RB9_
MP4WZG5^](CX[-/;5[_O7[X ?5?<36ON+5=QGA=Z^^J7_?_:^M#=Q95OT^Y7N
M?[#VO>>J6X(<8^;N\[;$#"',8_(%&6/ P=C& T-^_5NKRA-@,I.0WCG2Z=V=
MV*ZJ-<_UYX3F7MGAV!$U4\2^,'K**'NZR?'R>?J=??1]XHP"<4Y4:RR+ET"=
M']73Z%7YI*3"-BK<)I:%W8J3U9*\J;#B8RV-9RT[?4Y?X[B>N%X/Q7"OT)G+
M1:-J1+?E[0;+W[^K3M\I'/+I+'*FJ.FGG^LB^AE?POSO6JAZMI[&H29+B5E/
MO%_PE46E-C42.F?.4"1\5ZG^&9KPP\M8]XAZ_#11CU],U*>J63F7K+7[9*]:
M'8BE'G=G=H2LPFU%C6BZ[WK6;RWW3._KHMGZ/)V0+U%PE]@(F=FJTJIZ$^87
M5KU5SIO7+'==:2'?O[H3\I*S+\_U<>W\"X^D[/=QF<?<VR\<R_H'U/G]T_W=
M@D?2)_W=N%6*]0;<,+80[PTU-=02^64;K( H^KNI="@1B?[I SLN+JK[^9;!
M'UNS_<_S>WU"X(5^[Z";W:8'X>*";=Q?:P-Y-!=E=8:BX25^[Q<6#/\\%?EE
M'>'35'[*$8ZX=-ZJ+8?S]&(AL\O,NK9*1KFYD"$J\ 6.\!<F\V_]]^?V"GQM
MC_A]!,*^1QP)<(F;4KB^D<8/L<5J6)M$U9*R&S2(IGN!2_QO$Q?[^TA8G,V-
M)3^2%.!1\U<T\1Y<_4E;;2@'0W.CU.,.,9JE&Q:OF(RI,I)IX$]9IBGS2H@Q
MYR*#I,$K.V?*$>Q>%19N126\ ^\+<Z 0!D#!.U?#,^KTS -XHJZ"]/YA$_8(
M=U\'4L]L)6.$XPQ&A94%B*DH.&996HOX )ZS1L(/([6V&$0Z[&*P"/.;U7WC
M9E*_S5SRY)XZK^NC:VNW,%/%?*7'24*\.0W+>5/:_/5W))((10,RJ R%-*(&
M-K8$C'0(+@&'ST351-)%P53U43L3;T>[FX;(2NF;[*[=+H\'M<VE(*M2+QX;
M18"RC:I/#%'9FW-!G?;&-&\?+1C4R60GLRH\\ 4VL>;*D>OQ3-)KK;_^-J3M
M,9B79)\$SLA 8Q5 A_]PH&< ITR>"W)QJ<GJ3A1'W6IXMAS6U71A=1^K;D;1
M[&ZRO!C^> W("_;1 B'>JFGUNQ+?W_2JFT1KW,T_##AC]M??4]72CT'N0,D(
M,9(BR!:IHCFG_.%P"C,.ZD/XNO\P='/4E4Q9;$PKR@0=73"$*9#A-[FY)$Y!
M9PH6@K@QG8)+J-L0?BUF6AES5TI$:S(KE7I-HY3@Q/SBXB576!.YNPXWZO:6
MF7JT'-7#=\,62BXN%$_&C]&K[D_:0XGE4TW$=DC^-A@"8,:%,&.#>$_#S27#
MIA;</"@L720G8S:2.=]3>!,>E\J+@J\,*TF4)GO%=.'!?4TXY]=$!3H]!HR&
M+C_R_?^>>X#5Q[+ZATZ^<N(GKQI^16CM;C)/6-9\8"S"9BI1'%_+TV1Y=B*X
MPFA +@0+1$83=&H2A30A"* 0WF2 AI[IQ7\$:@+<_P.Q^V:#O^!"@6+!!]_5
MHC*O/XRNHP5^S=_=**F'OEG-_/6W*2H,1B&,0V.=F>KJDG#:Q#84)0/94Q"O
M_MDFXQL\L;YH $\XBI5>3Q7(#2E+OHD:R]H Q$UFO>TMRL5X"@R9"!L-)1\3
MO6M8X;GH 7DKC@9@H.0,$&&]1C/Z<*NTTLE!8O8QR''>0[" )>"]E@>*:TR)
MFK(?S:E#=5L:ID>+4G_SL$S'-UQYD'F3O'L-'LD?]G;;*.$,8#0\',@X%Y%A
MSH?)\;![W[V^C3PL.K'=HGS-S<K)&,BU ,/_7PS@RL]P1(^^Q J]2(PZ/SNA
M9!"B73BH,!<;BFA_IY&2C>%TS2;8%9NJ1:/53?%:?5O>X&/0G>[TQ.2T6+$6
M";#Y"OUXK-Q<;AY']U32#42S O#4#7#]'9>$XA^I@?KX'R]V/]Y23@^6LWIE
MEWQ86(N(LDW>R?T2G[ET2WDHIV=K)97=%E:;VT:O4TA)@]M76,J%QM>7X,_G
M]^Y&M;\SU@?#AI'6UXMP[H9;*HJVG@I?0KS/"N#Q1UB![:R2O+IEZYV1"685
M=XST?Q&K=67QN@G_5=?XAR(2XRODN342(%CBY7\*!<S!K[._Q"K;1'33V@T6
MNYEYF^\55I%HZBO(_.ZDD4_-A"%;",^*Y:*E9-)EZ10-K.F74?;7>%V8^QW6
MR!734)@,>*0RDPB*^P9YTTY$C/&?DVFJLB3LF!^&*#)C458W/R\O3$PS)K%1
MXFT4.-U&=K-*5;UEN4IWGDZ-M7QLV7HLZG4FG;%OUV<L<Z[JTH,X"=08]\U,
M61DV!WJOP^K1B=*)E7-YL/"3H3A[.3%A%SD@*]Z,**EQ6[N9U$:K7D=1C)O8
MH!TK<;/S1H2K7;XM:?>94:'1-V['_60_P\6 -Z>PO5>$A*\8RJ^7$U?Z8 Q]
ML:C2>%HJ),KY_@.[T@K%8F;,-FX*&1)5"F"RQZ)*+PDH?0A./C><5)Z7>QDN
M;RJ%U;8SWNC62.O-9J\,)V5D&7\#3+,7QGB^>W3UF2G;-V67CZLKIN1_OS_V
M#"C/LC+L)=P1YJH,BZUYV:*4OU0GHLQL>(.Q#.JJ )\)EDS#K( ?7M+)XZ*-
M&.-0-B*FX<U#2\;-8-,X_?YW K^ FT#[:4EB_L"0^V0 &T33BFQ*E<'HP7]M
M;)G!\%1H,#Q\:TF_^XNATA>X?2>)\M>)LSP=UHQ]A,53!)212I*,!U,0&J K
MQ8D#V38@)MAN+HZWC8I<21J+7"IBK?B[WO(F#S(D(%3RFW$^RX#SM+SPL/Z[
M5O4]!F-?\1XM-6"SN1T[NJOV<I/[\7UGLV;#?3 JX\>%>U1*_]XW\]<J<#61
M7@S9!V-IP 0\,Y:116RQBP<&1=F$S0+?';HC<PDX5\>Z,/_74)_.+* '60*7
M5["=D.!GG^]K? $VC'XV&_9=P)YF1'FE1=EDZKK=6VURQB[-%L9J98;1J_15
M.H@9$9UMR5B$I^"^,Q)>B8X*6T<:^G-P]VDB%$%;!,A6;,">QEQNJ.K-2OBF
MW O+,[5\T^4BU2&*T*MXY!AQ5,\>*42? MW7P8=12E2_O*;IZI9H8'GWE&_S
MXB+*RTX#OM^-.[Z0,OP+TUW[+8I^'^9VF@JW*_-A=Y'C'R(*WQ\^Q(O(G2$V
M'@NQ =&"KVL.?WBQI2\&%^&<D%MGI_":J<Y$1=HR_ 38 +F%46 G .:P4\7D
MA@6(0G-#;YH=>D-=B6?EV-^/Q>C((Y'?/RES/AK- \Y#FXK<_4)4,3A%%BA/
MWC(!0"880I25@75AGROXE325'@WR6=H+0D@O#NU%R:P8/]_2ZZ9$^*1I&1[S
M'C.,QTYU57$ [H9ZGLPQ.4_ZH4B!:+]:VO+U'<M-D[WPNG^;C/3%;":>N?2@
M8;FIMIO]CL;V5LEH(]RI;.M##LL"G@H:^BG:J\,ZB"2*O# _^;#BH<$?#NM8
M\ ZA.@.7 T=>%01+MRD3-(3KQ$_-.3-&!PTGO4YXL FGF >AOY1)2/S$TAE*
MY6U14W42%2@"5FR>9<-58HW0M?UA ]AO&&W<O<C!41"",HQAC>_A1(YCZIS/
MW0&2MJ2@!PJ29TWB>G21K!,A=$G3^8T3YR?AB:=9&TA.#>#O/YJQQ8V\RVB:
MBO;CY!UYVUC'NU-ANUL4<K7*J!WNYA?YQJ-QYDO@[5MMVLL.!]%AH5',1[>%
M72N72A+>YM[(VR%&DRWC9))G,I'P%\_/.7Z3RQFLPU.T K*N0V5.0T&D2B;
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M/.A3?354N[ ])]03;LAQHUFM%9:=8J>U?-@V'I*MXQ'@$TO'D;R'\LX1+AE
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M,7\;3:1BRG4AK"4[;";56^;"LX^+FB]N1#;5>NC?+2RI50F7YS?U=ASMRJL
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MRP7B)4T<_V^\7!I>ON789>+E6XY=)EY CG'?>#D;7OYMZF@ROYMY_&E 2+T
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MXY@S F<R= XG]V 0'0EC3O2\$JQ'<3J0?:+CW65L_0KG2,0]HB+R"[SS0,%
M 8/3('$=2K:F9XQ$.>\[TJ&N!K(\T,SDR]'HT3M[AI!K[1"%<]K.D);$P:4E
M3"C@W?W_B%VE;$OLI[,$@9E/2#D@LO/6S]O^#SBO\P+0U3ZV-.;_9/,W7G')
M)C&#%39YS*6YTVGW#@F?BOH_97I')@FOQ\[M&*5')M2)<](D_*G-1F(Q.E,$
MLYC^>CYGOW:\P* #;FGOWIJT;('4C%(Y@4-MS3D9X6/ZD0?;I@3G!ZO;OS<6
M%9$.-J+,?BP&;3ZG+.PS+(.-PR?,0K(I-$M.P_:']O_8*R[))7_:4T*G-.=
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M>0!YQH_1O9%>6-><,'"#$W3!Z&03VJ$(HR_05/( X':>U'R*%[2QJ=E;9:C
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MMV&N0 *SV$\24$R$K"(#M55FJ*>0]3FXSR?@-. @SV\3?U:D .WH1E7.DF"
MBE ,W;)=P+^U./2T+/(H9#)HY%9MB2V7/+%,,.JNMH8G;\EILUUGL4,8)<R,
MAMLM6QZJ0\]8TV[#=]H ,_*I4':*,;# TOO/_SS[<*)[I/G]"X040#T0\$)7
M1/( F!BGU[2%>X+S&IY$0>4PQB&,<:@MCC%*0'+@0 F'!MN3G*R&JUN.:GOF
MA@/&!"$VU(1IR'% +U*8=3<G&J^#08SR-,N5:23)18./_B+W^R0*X1=P;?B
M24\FK5P#0A9Z^\[(0J>@ ACBS%,MW5SD"&B]"<MS3@+Y>O-3P"^11(3Y!(0
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MX.3'#.O68F$$7MN3BN8]66 R9DPLUPQ&H64' $P#@>D&(\\,O- 9NZYC31:
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M=K^9N]_,?81WSSR&"I%E=8:6:82N/PH#0Q]9FN.,QO!O9'B!P?2AY=C#]KG
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MYG8 OLNJM1^@]56UL6IQ=]A5&H5W; ZKEV/':7@+_TV+R_CG_P]02P,$%
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ME=?OP:'^<7-)Y2")CN _XPNW4%7V\Q;<A^7Y2EI059I\?0O PF6]ZU:9\)Z
M/0-2_H*J!YD=KS.?#]C=P-->LZZ3W)N-Z'H WU'B55%4:0IO(\MMT)HK8]%.
M9U?092(HJ@\=O)J4FU4.)])Q0!2Q8V,W@9HI%]B]7HFLWN3>DF]]\YQ>P'>O
MVG7O.VP_W#%4O(1JZX8/B)Z:<+FA!B*6!R3R.U7?RC2.RL\J;5:YTS5 99Y+
M:X7X OF&"MF9WL<2]I&2ETW#5S8-1QEJ$'24"#_MMFC?%DF!>-69:E6\SP6_
MHM3C:Q*7?%PUY4Z_EB<-#T)!76?[O>X&#N$Q.AJQHI#/(J:NP= %84>IU/+Y
MSR#YF2J'*^ I-YF::S>>R;S0R[=6]4=(88G&<FTALL(Q#+#ASB-K$+5\0I'%
M3&4S05FEX-/Z6%77I"3R,E,+@;?S5'DFXFL0!:2^2X[LO 3[:Y1VC+CUFR$^
M@S/S$/[L;;<87;?XCL9\,YFZ&Q+6;=GJCB'(0.AVI+*,ET;TE_\TAZ:8I/X+
M.;KQ0*@!'@?-N/#*JF6#OTSA6M:N7)#9ZQ<NJ*5Q?V*+.4>_V_+?$=)E$(W?
M>#5)2L:HO>IX6%76O??0N>&;>I"EGQ[!]S[4SJ6!C;]@8ZBL57G#S-K?OKW?
MZQ#HW=D->]5U/T\[D< $;.-7F3=S"UP0?O1 _(4VOOCW<6W\S'?N+Q[^;C:^
MJ4_,4!N(E9OK_=#;6WX.7'I9WL9[)GG/&^,_4[W*?3RZFFI5%3'E/Z7[2PIN
M7/%;?U%GP6T8DLE"M.OG[EHN]-<(UY+A6M/JSF*)RJX=HK"_:O,$":_/9TK&
M=9#W]SO;NZM\X=NZ[IJCOPOI+E<>_@E02P,$%     @ )HAL4\SS@)(T"
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M6*S3;3"ZX/"]AOLC%.GN)%BWZ:H:AECH0C<CE::\,**W^E$?FJR>^/=@=,>
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M/5I'(5_6=O<5_:5&=TOR[+]02P,$%     @ )HAL4_V$??E1!0  GQ<  !@
M  !S;G!X+3(P,C$P.3,P>&5X,S)D,2YH=&WM6&U3&S<0_BM;9YK S+T;$N?L
M,./89D(G8(*/:?-1/NE\:N335:?#N+^^JWLQMIM.PC00/L P&$NK?7EVI7VD
MP2^V/<E2DL6,PH?H_"-0&9=+EFF(%2,:1U=<IQ#)/"<9G#.EN!#P7G&Z8 !O
M'=]W/*=W;-LG U0U:M;(+ 3?=_W #;S !Z\7'O7"X U<GL/!=30ZK,3'TU'T
M^7)2F[V\?O_Q; 0=VW5_[XY<=QR-ZXDCQ_,A4B0KN.8R(\)U)Q<=Z*1:YZ'K
MKE8K9]5UI%JXT96;ZJ4X<H64!7.HIIV3@1G!OXS0D\&2:0)Q2E3!]+O.=71J
M]U!"<RW8R<!M/VO9N:3KDP'E-U#HM6#O.DNB%CRSM<S#KI?K/JYT<7I/YM9>
M<:K3T/>\7_LYH91G"UNP1(?'3J]W-Z3X(MV,R3JT4#%!-+]A1O>6UE@PHL*Y
MU&E_W\#75N;MND1FVD[(DHMU^"KB2U; !5O!E5R2[)55C^!GP11/7O4KZ8+_
MS5 UAJ?9K;:)X M4;GRM!WA&L33"[FN4J $)&RSF.U97K(IO+@7%R<EMRN=<
M0S=P_($[1^#RG^6F6=X:ON$%NB6X7H<II[@"!5Z^Z 5>MS]PC> #.1JC;TS=
M [_1Y"HZ.ST;#:.SZ07NE*O9]? B@FCZ<&#>VT>_!]?.S!DY,)N,*C_][K%G
M/2$/AS,8CJ>7T63\)"&L5E(62T6J+5UB#2O!,[8_8\=22!6^\*H?5-H"_M9[
M#=-3B#Y,8#:\>C^\F,SLZ1\?)Y]A.(K,3.!YP2/'N[W?_A7RS]J ?Y:%YLGZ
M&V?%60:QS#(6&]#K+JA3!I]*HC!.L88KEDNE028P6V<DUW+!,GYKP5D6.W!@
M9$TP@=<?R24VSW7US>\?8G>$4ZF6X'OV)TBDJO3FZ+6DP#+3'V#&<LV6<Z:@
MZUE@FJ@%I("$B[8CFS4S%I<*.P "03(*DUML;AGV932XY$5A_,9?(TFQ+4/*
M%$-OMUVK8V@]0]\M& IL]+\Y$)5QBL!:<.Z,'0M&*6<)FD"3IM/ -$EXC/ZA
M0J.OB='"7!E3QAV<-3!;D)>J* D6@I9P=TZ\?.&_?M.OCPD3&Z$R-]QA6[J1
M,97=V)D1-2<9*^SIK6!K&,95 DQE6SA/=/@S2^9)M)?O<_7 /S3@>OT(06TJ
M.2D%EG6,F12FI#9EIMA?)5?,L,*B*O=F3_C= X+5K, _/J"'FPS=%>6F()LT
M^6^[1WU3&\])^KXD!5M)XAD>%<NJ!9B#21/L#11'*]#;#!)N3J9<L<(DRS+3
M!/DZ+D./B,!4%CEFK["J50G/D/F;<51(*RI9[5R4*D6=:XGG4F6SV-OIS@\$
MYG_GIR+BFLP%:Q?.I<+^:7JE('G!PO:?;=,&[[3N1X98&U 1M<:;FK634LMV
MH.;LU<@.LS=N[_)Z,[)%TSM0)1V9?-4BS9U#M7XV]OTZ=$TW@9O#,R:BJ1>\
M=C0:CU'A%EZ-X1:[K6O#EF:)VA(A5RV&[7=[I4@>SO'2]L5>(6#?O(ILYLF\
MD*+42$[P/K0?[L.7Q98@3GYGD=37M>:OIL]H/R[:KE:F\'\ [ \0[Q@/R! N
M,%45Z?*#FG35D=RC5IIC!R_K6BY#WT'M@+GC%%J^_JAAN87[=3YW%]B33DO=
M_>Z=A4?U\1G?A_7Q/RX>SPC_,!\/<L61!N;( ]D&9EG#?+B'LUNQK/9@?R+T
M;[O7I!MJ-2?QEX6294;WGDRV'E1W)YHF'J CYN7%;KY[.Y2P?K3=X80[0YL7
MXIPLF%VW>Y(@[PO)C>2T27*OYP1'FWY1CWG5HW+]\EP]99_\ U!+ P04
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M>A4MGUE/_P102P$"% ,4    "  FB&Q3ZK'MQ'T4  #4RP  $0
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M @!S;G!X+3(P,C$P.3,P>&5X,S%D,2YH=&U02P$"% ,4    "  FB&Q3S/.
MDC0(  #Z*0  &               @ &5V0( <VYP>"TR,#(Q,#DS,'AE>#,Q
M9#(N:'1M4$L! A0#%     @ )HAL4_V$??E1!0  GQ<  !@
M ( !_^$" '-N<'@M,C R,3 Y,S!X97@S,F0Q+FAT;5!+ 0(4 Q0    ( ":(
M;%,4YE2R304  #L6   8              "  8;G @!S;G!X+3(P,C$P.3,P
A>&5X,S)D,BYH=&U02P4&      H "@"F @  ">T"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
